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Recent years have seen the emergence of two serious coronavirus pathogens with the 
emergence of the MERS-CoV still an ongoing concern. In addition, the recent unprecedented 
Ebola outbreak has claimed more than 10,000 lives and affected the lives of countless more. All 
three of these viruses have been linked through differing strands of research to the second largest 
mammalian family, Chiroptera, the bats.  Bats are among the most diverse a widespread of all 
mammalian species and have become subject of intensive research in recent years as various 
bats species have been linked to a number of severe viral outbreaks.  
In the studies described in this thesis attempts were made to develop, pseudotyped 
viruses (PV) bearing the glycoprotein of a number of highly pathogenic viruses including MERS-
CoV, Ebolavirus, Marburgvirus and SARS-CoV coupled with envelope-defective Human 
Immunodeficiency Virus and envelope-defective Murine Leukemia Virus. These tools were then 
used to examine the potential for cross reactivity among related coronaviruses, and a number of 
computational tools were employed to investigate the phenomenon and attempt to develop a 
better understanding of the antigenic regions that are responsible for the observed cross 
reactivity.  
The next stage in the thesis involved attempts to develop a novel form of multiplex assay 
that made use of PV to attempt to make serological screening of bat specimens more feasible 
and efficient. The novel bat-borne influenza A haemagglutinin H17 was then successfully 
incorporated into the PV system, and screening of this PV against a number of cell lines led to 
improved understanding of the viral tropism and the role protease plays in this tropism.  
The final set of experiments carried out in this thesis involved a combination of 
computational biology and PV based protocols to both predict patterns of viral evolution through 
selection analysis and to then test these predictions in the PV framework. This study leads to the 
generation of a number of mutant MERS-CoV spike proteins and Ebolavirus glycoproteins. These 
were then incorporated into the PV system, and the effects of these mutations of PV production 
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Amp Pr   Ampicillin promoter 
ANOVA   Analysis of Variance 
ATP    Adenosine triphosphate 
BEAST  Bayesian evolutionary analysis by sampling trees 
BSA    Bovine serum albumin 
cat. #   Catalogue number 
CD4+    Cluster of differentiation 4 positive T lymphocyte 
CD26    Cluster of differentiation protein 26 
CDC    Centers for Disease Control and Prevention 
cDNA    Complementary DNA 
CPE    Cytopathic effect 
cPPT    Central polypurine tract cis-active sequence 
cRNA    Complementary RNA 
csv    Comma-separated value 
DC    Dendritic cell 
df    Degree of freedom 
DMEM   ฀D฀u฀l฀b฀e฀c฀c฀o฀’฀s฀ ฀M฀o฀d฀i฀f฀i฀e฀d฀ ฀E฀a฀g฀l฀e฀ ฀M฀e฀d฀i฀u฀m 
DMSO   Dimethyl sulfoxide 
DNA    Deoxyribonucleic acid 
dNTPs   deoxyribonucleotides 
DRC   Democratic Republic of Congo 
ECD    Extracellular domain 
EDTA   Ethylenediaminetetraacetic acid 
eGFP    enhanced Green Fluorescence Protein 
ELISA    Enzyme-Linked Immunosorbent Assay 
emGFP   emerald Green Flourescent Protein 
ER    Endoplasmic reticulum 
FAO    Food and Agricultural Organization of the United Nations 
FBS    Fetal Bovine Serum 
Fc    Fragment crystallizable 
FITC    Fluorescein isothiocyanate 
Fw    Forward (primer) 
G   Gravity 
GC-rich   Guanosine Cytosine rich 
GFP    Green Fluorescent Protein 
GISAID   Global Initiative on Sharing Avian Influenza Data 
HA    Haemagglutinin 
HAT    Human airway trypsin-like protease 
hCMV    Human cytomegalovirus 
hCMV IE Pr   Human cytomegalovirus immediate-early promoter 
HEF    Haemagglutinin฀–esterase-fusion 
HEK    Human Embryonic Kidney 
HI    Haemagglutination inhibition 
HIV-1    Human immunodeficiency virus type-1 
HKY    Hasegawa, Kishino and Yano 
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HPAI    Highly Pathogenic Avian Influenza 
HSV    Herpes Simplex Virus 
IC50    Half maximal inhibitory concentration 
IC90    90% inhibitory concentration 
ICH    International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for 
Human Use 
IE    Immediate-early 
IFN    Interferon 
IFTIM3   Interferon-induced transmembrane protein 3 
Ig    Immunoglobulins 
KSA   Kingdom of Saudi Arabia 
LB    Luria Bertani 
LPAI    Low Pathogenic Avian Influenza 
LTR    Long terminal repeat 
M1    Matrix proteins 1 
mAb    Monoclonal antibody 
MCMC   Metropolis-Hastings Markov chain Monte Carlo 
MCS    Multiple cloning site 
MDCK   Madin-Darby Canine Kidney 
MEGA   Molecular Evolutionary Genetics Analysis 
MHC    Major histocompatibility complex 
MLV    Murine leukaemia virus 
MN    Micro-neutralisation 
mRNA   Messenger RNA 
MVA    Modified Vaccinia Ankara 
NA    Neuraminidase 
NCBI    National Center for Biotechnology Information 
NEP    Nuclear export proteins 
NIBSC   National Institute for Biological Standards and Control 
NK    Natural Killer 
NP    Nucleoprotein 
NS1    Non-structural protein 1 
NS2    Non-structural protein 2 
Nls   Nuclear localisation signal 
OIE    World Organization for Animal Health 
ori    Origin of replication 
pA or poly   A polyadenylation 
PA    Polymerase acidic protein 
PB2    The polymerase basic protein 2 
PBS    ฀D฀u฀l฀b฀e฀c฀c฀o฀’฀s฀ ฀P฀h฀o฀s฀p฀h฀a฀t฀e฀ ฀B฀u฀f฀f฀e฀r฀ ฀S฀a฀l฀i฀n฀e 
PCR    Polymerase chain reaction 
PDB    Protein Data Bank 
PEI    Polyethylenimine 
pH    Potentia hydrogenii 
PV    Pseudotyped virus 
PV-NT   Pseudotype particle neutralization assay 
PRNT    Plaque-reduction neutralization test 
PVDF    Polyvinylidene fluoride membrane 
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RBC    Red blood cell 
RBD   Receptor binding domain 
RBS    Receptor binding site 
Rev    Reverse (primer) 
RLU    Relative luminescence unit 
RNA    Ribonucleic acid 
rpm    Revolutions per minute 
RT    Room temperature 
SCR    Seroconversion rate 
SDS    Sodium dodecyl sulphate 
SDS-PAGE   Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SEM    Standard error of the mean 
SFFV    Spleen Focus Forming virus 
SNARE   Soluble N-ethylmaleimide-sensitive factor Attachment 
Protein Receptors 
SOC    Super Optimal Broth with catabolite repression 
SRH    Single Radial Haemolysis 
SV40    Simian Vacuolating virus 40 
TAE    Tris-Acetate-Ethylenediaminetetraacetic acid buffer 
TCDI50   50% Tissue Culture Infectious Dose 
TMPRSS2   Type II Transmembrane Protease Serine 2 
TMPRSS3   Type II Transmembrane Protease Serine 3 
TMPRSS4   Type II Transmembrane Protease Serine 4 
TMPRSS6   Type II Transmembrane Protease Serine 6 
TNS    Trypsin Neutralizing Solution 
TPCK-Trypsin  L-tosylamido-2-phenyl ethyl chloromethyl ketone treated 
trypsin 
UK    United Kingdom 
UPGMA   Unweighted Pair Group Method with Arithmetic mean 
USA    United States of America 
v/v    Volume per volume 
VLP    Virus-like particle 
vRNA    Viral RNA 
vRNP    Viral ribonucleoprotein complex 
VSV    Vesicular Stomatitis Virus 
w/v    Weight per volume 
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Chapter 1 Introduction 
1.1. Zoonotic viruses  
Zoonotic viruses have repeatedly emerged over the course of human history and continue 
to cause significant threats to both human and animal health. These newly emerging infections 
are largely the result of the evolution of existing pathogens that are exploiting a new viral host. 
Virology has advanced significantly in recent years largely because of advances in both 
technology and study protocols, and these advances have enabled researchers to gain a greater 
understanding of the dynamics of viral infections and in particular understanding of the 
evolutionary history that allows such pathogens to make the host change. With their short 
generation times and relatively high mutation rates viruses are exceptionally complex pathogens 
and exist in a constant evolutionary arms race with their host's defence mechanisms, rapidly 
adapting to the changing environment of their hosts (Cann, 1994; Domingo et al., 1996; dos Reis 
et al., 2011). This constant adaptation has led to num฀e฀r฀o฀u฀s฀ ฀i฀n฀c฀i฀d฀e฀n฀t฀s฀ ฀o฀f฀ ฀“฀h฀o฀s฀t฀ ฀s฀w฀i฀t฀c฀h฀i฀n฀g฀”฀ ฀b฀y฀ ฀v฀i฀r฀u฀s฀e฀s฀ 
and of particular importance are the zoonotic viruses that switch from non-human hosts to human 
hosts often with severe consequences. Zoonotic viruses evolve in parallel with their primary host, 
but those viruses that establish themselves in multiple species are compelled to evolve the ability 
to infect and replicate within often quite disparate hosts. This further complicates studies involving 
zoonotic viruses as these viruses often exhibit different traits in different hosts. Members of the 
Lyssavirus, such as Rabies virus (a range of mammalian hosts) (Hung et al., 2004; Bale, 2012), 
the Coronaviridae such as MERS-CoV (Camels and Humans) (Abdel-Moneim, 2014; Jiang et al., 
2014; Sharmin and Islam, 2016) are good examples of viruses that have adapted to multiple 
hosts. Also, experimentally many viruses including vesicular stomatitis virus have been known to 
replicate in the vast majority of eukaryotic cells in laboratory cell culture (Hastie et al., 2013).  
While there still exists some variation in the estimates, conservative studies have 
speculated that as much as 64% of all human pathogens are zoonotic in origin (Woolhouse, 
2006). Analysis of recently emerging viral infections also indicates that novel viral spillovers are 
most likely to be zoonotic (Smith and Wang, 2013). Despite the increase in the available data 
concerning virus host-switching events in recent years, there remain significant shortfalls in our 
understanding of the critical transition stages, between a virus being endemic in a single species 
and becoming a multi-host pathogen. Wolfe et. al. (Wolfe, Dunavan and Diamond, 2007) sought 
to outline stages a viral pathogen went through during the process of becoming a zoonotic 
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disease.  This outline specified that the first stage of a pathogen's evolution towards becoming a 
zoonotic disease is that the pathogen is present in the animal host but has never been detected 
in the human population under normal conditions. Under opportune conditions, a viral pathogen 
may be transmitted from animals to humans (leading to what can be termed a ฀‘฀p฀r฀i฀m฀a฀r฀y฀ ฀i฀n฀f฀e฀c฀t฀i฀o฀n฀’฀Ψ฀ 
but is not at this stage capable of infection between humans, and this is considered the second 
฀s฀t฀a฀g฀e฀ ฀o฀f฀ ฀a฀ ฀z฀o฀o฀n฀o฀t฀i฀c฀ ฀v฀i฀r฀u฀s฀’฀s฀ ฀d฀e฀v฀e฀l฀o฀p฀m฀e฀n฀t฀.฀ Stages 3 and 4 in the criteria outlined by Wolfe et. al. 
(2007) specifies the range of phases that a zoonotic virus must go through from stage 3 where a 
virus gains sufficient foothold to cause a limited number of secondary transmission between 
humans. At this stage, the virus can cause significant numbers of infections but the lack of 
sustained transmission results in the epidemic rapidly dying out. As a virus evolves to become 
more established in the human population, it develops into a disease that exists in animals, but 
with a life cycle including infecting humans by primary transmission from the animal host and that 
also undergoes long sequences of secondary transmission between humans without the need for 
animal hosts. Viruses that have reached this stage regularly trigger epidemics that are often far-
reaching and persistent. Many of the influenza A viruses fall into this category, such as the H1N1 
strain commonly which has caused multiple major human outbreaks most recently through a 
strain originating in domestic pigs which caused the 2009 H1N1 outbreak that led to over 18,000 
deaths over a period of 14 months (Smith et al., 2009). Figure 1 highlights the different stages of 




Figure 1: Different phases of the evolution of a viral pathogen from an animal only pathogen to a fully developed zoonotic 
disease. 
 Solid lines indicate transmission with broken lines indicating limited primary infection spread. Images of bats are representative of 
wild animals with domestic animals of all types being represented by the image of a cow. Figure created using inkscape® with 
reference to (Wolfe, Dunavan and Diamond, 2007).  
 
For a virus to become a zoonotic pathogen, there are a number of criteria that are required 
to allow the spillover event. These criteria are a mix of extrinsic and intrinsic factors. The relevant 
extrinsic factors include environmental and anthropogenic factors that can have an effect on the 
spread of the virus in bats. Environmental factors can include climatic events such as hurricanes 
or droughts, but can also include less abrupt events such as climate change. These events can 
21 
 
alter or even destroy habitat and food resources, and so the behaviours of the original host may 
change, increasing the likelihood of contact between hosts and humans. In addition to climatic 
and environmental factors human actions can artificially drive increasing animal densities by 
changing the land use, and this is increasing the contact between humans, domesticated animals 
and wild animals (Daszak, 2008; Plowright et al., 2011; McFarlane, Sleigh and McMichael, 2012; 
Smith and Wang, 2013). As many viruses, including the significant zoonotic diseases Hendra and 
Nipah virus, infect humans through intermediate hosts in a process whereby the domestic animals 
are termed amplifying hosts of these zoonotic viruses (Philbey et al., 1998; Cotten, Watson, et 
al., 2013; Moratelli and Calisher, 2015) increased contact between wild animals and domestic 
livestock presents ample opportunity for zoonotic spillover.   
1.2. Bat-borne viral pathogens  
Despite being among the most abundant, diverse, and geographically dispersed orders of 
terrestrial mammals and including approximately 20% of extant mammals species (Teeling et al., 
2005), research on bats historically focused more on their habits and outward characteristics than 
on their role as pathogen carriers and disease vectors. Even in those cases where bats have long 
been known to carry particular pathogens, study of those pathogens often did not account for the 
role of the bat host species in shaping viral evolution. A large body of evidence has mounted in 
recent years demonstrating that bats are an increasingly important source of new viral pathogens 
(Calisher et al., 2008; Kurth et al., 2012; Baker, Schountz and Wang, 2013; Schountz, 2014). In 
part, the role of bats as pathogen vectors have been illuminated in recent years as improvements 
in research tools make it possible to study the relationship between bats and their pathogens 
more directly. Table 1 summarises the known host species for several recent disease outbreaks 
and gives a clear indication of the prominent role of bats in these outbreaks. However, in addition 
to these zoonotic ฀v฀i฀r฀u฀s฀’฀s st dies on bats have identified a range of other viruses in bats that have 
at least some potential for zoonosis. Modern research techniques coupled with the increasing 
awareness of the importance of bats as viral vectors has led to research making use of molecular 
biology based methods (Calisher et al., 2006, 2008; Kohl and Kurth, 2014; Moratelli and Calisher, 
2015). A more detailed overview of bat-borne viruses is given in table 2 which summarises the 
specific bat species that have been linked to some high-profile viral pathogen outbreaks. In 
addition to these viruses to date, more than 80 distinct virus species have been isolated from or 
detected in various species of bats (Halpin et al., 2000; Chu et al., 2008; Chu, Peiris and Poon, 
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2009; Drexler et al., 2009; A. S. Turmelle et al., 2010; Kurth et al., 2012; Smith and Wang, 2013; 
Tong et al., 2013; Yang et al., 2014; Jayme et al., 2015; Wacharapluesadee et al., 2015).  
Table 1: Examples of human pathogens with known zoonotic origins.  
Based on earliest published reporting of the identified pathogen. Table adapted from Woohouse (2006) (Woolhouse, 2006). Recent 
evidence for SARS-CoV resivoir host was added, and details of the recently emerged MERS-CoV were added.  
PATHOGEN RESERVOIR HOST YEAR 
EBOLA VIRUS Bats 1977 
ESCHERICHIA COLI O157: H7 Cattle 1982 
BORRELIA BURGDORFERI Ticks 1982 
HIV-1 Chimpanzees 1983 
HIV-2 Mangabeys 1986 
HENDRA VIRUS VCJD Bats 1994 
AUSTRALIAN BAT LYSSAVIRUS Cattle 1996 
H5N1 INFLUENZA A VIRUS Birds 1996 
NIPAH VIRUS Bats 1997 
SARS-COV Bats (Gouilh et al., 2011) 2003 
MERS-COV(ZAKI <I>ET AL.</I>, 
2012) Bats 2012 
 
The role bats play in the spread of viral pathogens is made particularly apparent by the 
spread in recent years of the coronaviruses, severe acute respiratory syndrome coronavirus 
(SARS-CoV) (Rota et al., 2003) and the still ongoing outbreak of Middle Eastern respiratory 
syndrome coronavirus (MERS-CoV) (Boheemen, Graaf, Lauber, Theo M Bestebroer, et al., 2012; 
Chan et al., 2012). Also, the recent discovery of yet another SARS-like virus designated SHC014- 
CoV, in Chinese horseshoe bats, shows the potential for human spill over (Menachery et al., 
2015). The spread of a number of non-coronaviruses are also inextricably linked to bats with 
significant research indicating bats may be the primary reservoir for Henipavirus (Field et al., 
2001; Drexler et al., 2009; Edson et al., 2015) as well as the Filoviridae species Ebola virus 
(EBOV) (Guyton and Brook, 2015; Jayme et al., 2015) and Marburg (Marv) virus (Dimitrov et al., 
2008; Towner et al., 2009), and for a number of Lyssavirus species (Johnson et al., 2010; 
Rupprecht, Turmelle and Kuzmin, 2011; Serra-Cobo et al., 2013; Weir et al., 2014). Recent 
studies have also uncovered two novel members of the Orthomyxoviridae family (Tong et al., 
2012, 2013; Hoffmann et al., 2013). These novel influenza A viruses have been designated 
H17N10 and H18N11. In addition to these viral groups, bats have been linked to a range of other 
viruses known to infect humans including members from the families Togaviridae, Flaviviridae, 
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Bunyaviridae, Reoviridae, Arenaviridae, Herpesviridae, Picornaviridae, Papillomaviridae, 
Adenoviridae, and Astroviridae. In fact, to date, approximately 80 distinct viruses have been 
isolated from bats (Calisher et al., 2008; Wang, 2009; Baker, Schountz and Wang, 2013; 
Schountz, 2014) with significant numbers of these diseases known to be capable of infection in 
humans (Jánoska et al., 2010; Kurth et al., 2012; Tao et al., 2013; Tong et al., 2013; Jayme et al., 
2015; Wacharapluesadee et al., 2015).   
Table 2: Significant zoonotic viruses in recent years and the bat species linked to these outbreaks. 
Virus Disease Reservoir Host Pathology in Bats 
Lyssavirus ( Turmelle et al., 
2010; Warrell, 2010) Rabies 
Several different species carry 
rabies, and other lyssaviruses are 
carried by still other species 
Yes, variation in severity 
depending on virus and 
bat species 
Marburg virus (Towner et al., 
2009) Marburg virus disease 
Egyptian fruit bat 
(Rousettus aegyptiacus) None documented 
Ebolaviruses (Smith and Wang, 
2013; Jayme et al., 2015) Ebola virus disease 
Hammer-headed bat 
(Hypsignathus monstrosus), 
฀F฀r฀a฀n฀q฀u฀e฀t฀’฀s฀ ฀e฀p฀a฀u฀l฀e฀t฀t฀e฀d฀ ฀f฀r฀u฀i฀t฀ ฀b฀a฀t฀ 
(Epomops franqueti), little-collared 
fruit bat (Myonycteris torquata) * 
None documented 
SARS-CoV (Gouilh et al., 2011) Severe acute respiratory 
syndrome 
Chinese horseshoe bat 
(Rhinolophus spp.) ** None documented 
MERS-CoV (Wang et al., 2014) Middle East respiratory syndrome Egyptian tomb bat (Taphozous 
perforatus) ** None documented 
Nipah and Hendra viruses 
(Halpin et al., 2011; Mahalingam 
et al., 2012) 
Encephalitis 
Certain flying foxes 
(Pteropus spp.) None documented 
Sosuga virus (Amman et al., 
2015) Severe Acute Febrile Disease Rousettus spp. 
1
  
* Suspected reservoirs; **Nucleotide sequences found with high similarity to SARS or MERS coronaviruses. 
 
Current research suggests that the bat lineage originated approximately 50 million years 
ago and the bat order has evolved into a globally distributed Order with species occupying a 
diverse range of niches (Teeling et al., 2005; Agnarsson et al., 2011). The bats are traditionally 
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grouped into two distinct suborders, the Megachiroptera (Megabat), consisting of a single family 
designated the Pteropodidae (42 genera, including 166 species), and Microchiroptera (Microbat), 
that consists of 16 unique bat families (135 genera, including 759 species) within the order 
Chiroptera (Adams and Pedersen, 2013). Species in the Megabat lineage are primarily 
frugivorous, in contrast, species of Microbats are primarily insectivorous, however, there are 
numerous species that have adapted to a range of ecological niches including species specialised 
to feed on birds, lizards, frogs, fish or blood (vampire bat) (Teeling et al., 2005; Almeida et al., 
2008). Bats have various habitats, including caves, trees, roof and discarded tunnels, with a large 
group from hundreds to thousands of individuals in the same habitat and often sharing the same 
roosting and feeding sites. While not all bats are so highly gregarious, the presence of this trait in 
numerous species makes transmission of viral pathogens highly probable and provides ample 
opportunity for the development of novel viral strains. Since the reproductive cycle of, in particular, 
RNA viruses produce a diverse viral population within a single host (quasispecies) (Domingo et 
al., 1998), this can lead to a range of diverse viruses within a host that are ready to exploit any 
new hosts that become available. The diversity and species richness of bats, when taken as a 
large phylogenetic group, may also lend itself to the formation of a more diverse and 
comprehensive range of innate immunity related genes with a consequent close evolution of 
significant numbers of pathogens and in particular the rapidly evolving RNA viruses (Calisher et 
al., 2008; Kurth et al., 2012; Bowen et al., 2013; Schountz, 2014; Escobar et al., 2015; Han et al., 
2015). The number of variant genomes that exist within a viral quasispecies complex can increase 
significantly with the population size (Domingo and Holland, 1997).  This may be demonstrated 
through a genome distribution with an observed average of five mutations per genome resulting 
in 26 genomes containing 20 mutant nucleotides or more within a population of 1x108 viral 
particles,  When the population of viral particles reaches 2x1011 the population of mutants jumps 
to 2,600 based on the Poisson distribution of mutation (Domingo et al., 1998). Studies have shown 
increasingly that quasispecies evolutionary patterns may result in the selection of more virulent 
viruses and viruses with a greater likelihood of spillover, thus the emergence of novel zoonotic 
viral pathogens (Domingo and Holland, 1997; Domingo et al., 1998; Gierer et al., 2013; Wang et 
al., 2014). With the comparatively high mutation rates of RNA viruses (figure 2) the potential for 
mutation increases even more and the likelihood of virulent mutants becoming fixed within 
population increases. Given the similarity between certain bat-borne coronaviruses and the 
recently emergent MERS-CoV, there is a strong possibility that this process has driven the 
evolution of bat coronaviruses such as HKU4-CoV that make use of the bat dipeptidyl peptidase 
-4 (DPP-4), towards the use of human DPP-4 as may have been the case with MERS-CoV (Wang 
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et al., 2014; Yang et al., 2014). Other examples of this, increasing virulence is the introduction of 
a single site mutation at the 5'- end of an untranslated genomic region of coxsackievirus B3 was 















































































Figure 2: Mutation rates by groups the mutation rate represents the number of mutations per site per replication cycle.  
This is distinct from the substitution rate which is an observed number of mutations fixed in the genome per site in a given period. 
Mutation rate and substitution rate differ due to selection pressure data accumulated from several sources (Domingo and Holland, 
1997; Beutler et al., 2007; Sanjuán et al., 2010; Goldstein, 2013; Regoes, Hamblin and Tanaka, 2013) Figure drawn with GraphPad® 
Prism 7.02. 
 
The quasispecies nature of RNA viral infections is likely particularly significant for bat-
borne zoonotic viruses since highly social bats species, such as the Mexican free-tailed bat 
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(Tadarida brasiliensis mexicana) can roost in colonies reaching densities of 3000 individuals per 
square meter and these roosts can have populations of up to a million bats (Russell et al., 2011; 
Luis et al., 2013). Furthermore many species of bats are known to cohabit with members of other 
species (Kuzmin et al., 2010, 2014; Streicker et al., 2010). In addition to population density, the 
highly tactile nature of the social interaction between many bat species supports high Intra- and 
interspecific contact and can facilitate rapid transmission of pathogens (A. S. Turmelle et al., 2010; 
Dunshea et al., 2011; Hayman et al., 2013; To et al., 2013; Johnson, Aréchiga-Ceballos and 
Aguilar-Setien, 2014; Moratelli and Calisher, 2015). The highly social nature of many bat species 
coupled with the constant exchange of viral pathogens between bats within a roost may act as an 
amplifying factor in the driving of viral evolution and the quasispecies nature of RNA viral infection 
may increase the likelihood that such roosts will drive the evolution of novel zoonotic viruses. 
These viruses evolve within a fitness framework where the environment and its selective 
pressures determine the make-up of the quasispecies population and the rate at which new 
mutations evolve (Lauring and Andino, 2010). The unit of selection in this system is the population 
as a whole, and the functional interactions among genetically distinct variants are therefore of 
critical importance to pathogenesis in infected hosts. Lauring et. al. (2010) described the 
quasispecies theory as the evolution of viruses within a fitness landscape wherein ฀t฀h฀e฀ ฀‘฀‘฀g฀r฀o฀u฀n฀d฀ 
฀l฀e฀v฀e฀l฀’฀’฀ state of a virus is representative of the range of genotypes in sequence space. In this 
framework, the ฀‘฀‘฀a฀l฀t฀i฀t฀u฀d฀e฀’฀’฀ ฀a฀t฀ ฀a฀n฀y฀ ฀g฀i฀v฀e฀n฀ ฀p฀o฀i฀n฀t฀ ฀i฀n฀ ฀t฀h฀i฀s฀ ฀l฀a฀n฀d฀s฀c฀a฀p฀e is the fitness associated with specific 
genotype (Lauring and Andino, 2010). The selective pressures acting on the population then 
determine the contours of the corresponding landscape and govern the adaptation to these 
pressures; the virus population then begins to evolve in a pattern referred to as a ฀‘mutational walk฀’ 
from one point in the fitness landscape to another (Figure 3A). Under this theory, a network of 
mutations will be developed and linked together spanning the corresponding peaks and valleys 
of the fitness landscape. Following this system as a population or subpopulation of the virus 
becomes more specialised, ฀i฀t฀s฀ ฀‘altitude฀’฀ will increase while populations of genetically diverse and 
non-specialised virus will appear as a broad and flat peak. As this framework can be applied to 
any virus population, it can be used to contrast several viruses and so it can be seen that fast 
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replicating populations well suited to a particular environment will inhabit a high but narrow peak 
in the landscape. 
 
 
Figure 3: Selective pressures acting on the population determine adaptation to these pressures  
(A) Population 1 (red peek) has high fitness but is trapped in an unchanging sequence configuration because mutation leads to a 
dramatic loss of fitness. Population 2 is more mutationally robust because mutation leads to minor fitness losses, this may be viewed 
as a less specailied population. The flatter population is ideally situated to move through the sequence and access other peaks through 
neighbouring mutational networks (indicated in different colours), i.e. this population gives rise to more variation and can give rise to 
multiple specialised populations exploiting new conditions. (B) At low mutation rates, variants will be genotypically stable and cluster 
at the top of the fitness peak. The variant with the highest fitness will easily outcompete all others. At high mutation rates, variants 
spread out over the corresponding peaks. Variants on the flatter peak (green) remain near their fitness optimum and have a higher 
mean fitness than the population located on the steeper peak (red). The flatter population will become predominant (from Lauring et. 




In general, the fitness of an organism is a measure of that ฀o฀r฀g฀a฀n฀i฀s฀m฀’฀s level of adaptation 
to the specific environment in which it currently resides. However, the quasispecies theory adds 
the further complexity of viewing the organisms not as individuals but rather as a mutant network. 
This requires that any analysis of the viral sequence must incorporate a population-based model, 
and so an RNA virus within a host population should be viewed not as a single species and more 
as the dynamic system under constant adaptive pressure. As an example of the complexities that 
exist in such a system studies on vesicular stomatitis virus (VSV) have determined that even 
highly fit mutants could be suppressed within a complex population by less highly specialised and 
less apparently fit mutants (de la Torre and Holland, 1990). In this study, it was demonstrated that 
although the highly fit mutant could rapidly reproduce and become established in lab cultures, this 
mutant would fail to completely overwhelm less well-adapted mutants unless the viral titre added 
initially was significantly in excess of the expected level required. In practice, this meant that while 
the specalised mutant would predominant less well adapted variants would continue to survive in 
the culture. This observation supports the contention of a viral quasispecies as a dynamic 
collection of genomes with mutations arising and becoming extinct in response to selective 
pressure exhibited by a complex set of conditions driven by the host's biology and also 
competition with other mutant genomes. In the case of a potential zoonotic disease, this means 
that at any time within a single host there is likely to be a range of mutations and upon exposure 
to a novel host the likelihood of spillover increases.  
 With the high rates of mutations and the easy spread of viral pathogens between bats 
within a roosting environment, a bat roost is clearly a high-risk location for the evolution of novel 
zoonotic viruses. However, as there are also other factors that are significant when investigating 
potential emergent zoonosis. The evolutionary selective pressure acting on a virus is ultimately 
the determining factor in fixing mutations within a population and giving rise to novel mutations. 
In turn, the diversity within this quasispecies population in part determines the likelihood that a 
virulent mutant with high potential for spillover will become fixed within the population. In order to 
examine the relative impact of these traits, it is necessary to examine the host organism in detail.  
1.3. Bat-borne virus research 
The number of identified bat viruses rapidly increased after the discovery of the henipavirus 
family members in Australia in 1994 and the subsequent SARS-CoV outbreak in China in 2002. 
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Despite this growing recognition data supporting the basic ecology of bat reservoirs for viral 
pathogens, especially in developing regions of the world, is limited and the study of bat-virus 
interaction is still in its infancy (Omatsu et al., 2007; Kohl and Kurth, 2014). As human populations 
continue to increase, and humans begin to move into previously unpopulated areas, contact 
between bats and humans, and contact between bats and domestic animals will continue to 
increase, thus providing ever greater opportunities for cross-species transmissions of potentially 
pathogenic viruses. The development of new technologies in recent years, in particular, the 
increasing use of parallel sequencing technology has made it possible to reveal viral assemblages 
within biological samples, and also allows the isolation of viral traces in environmental samples. 
These tools have been particularly important in bat-related studies due to the difficulty in obtaining 
samples from these organisms (Li et al., 2010, 2015; Tong et al., 2015). Although this technology 
and the accompanying tools have made it possible to determine the range of viruses that are 
carried by bats, there are limits to the insights that can be gained by this approach. As RNA 
viruses replicate as complex mutant distributions (Fig. 3), extraction of the viral sequence and 
determination of the consensus sequence provides only fragmentary information about the 
genetic composition and the spillover potential of a virus population (Hayman et al., 2013). As 
such large number of questions remain unanswered for example:  
(1) How many bats, and of which species, are likely to carry any given virus? 
(2) Can viruses move between bat species and if so which viruses and with what frequency? 
(3) What are the risk factors that determine the likelihood of transmission from bats to other 
mammals? 
(4) Are all RNA viruses equally likely to give rise to zoonotic strains? 
The basic questions outlined above are crucial to allow more accurate prediction and control 
of a viral outbreak often involve isolation and treatment of infected individuals and post control 
measures aimed at limiting future exposure of humans to the virus. In cases where a reservoirs 
population can be identified this may involve the population dynamics of a pathogen or its host. 
This population manipulation can be achieved either by reducing host numbers, inoculating host 
individuals, or moving host individuals (Mandl et al., 2014). The life cycles of all viruses require 
the persistence and propagation of viruses at multiple levels; a virus must replicate in the cells of 
a host, spread throughout an individual host and then propagate through a population of hosts. 
Individual hosts organisms are the primary habitat for a virus, however in order to persist viruses 
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must replicate, exit from and be transmitted between hosts. In order to survive through this 
multilevel cycle, a virus must evade or co-฀e฀x฀i฀s฀t฀ ฀i฀n฀ ฀s฀o฀m฀e฀ ฀w฀a฀y฀ ฀w฀i฀t฀h฀ ฀a฀ ฀h฀o฀s฀t฀’฀s฀ ฀i฀n฀n฀a฀t฀e฀ ฀a฀n฀d฀ ฀a฀d฀a฀p฀t฀i฀v฀e฀ 
immune responses in addition to passing intact through multiple highly variable environments.   
As already discussed, bats and the viral pathogens they have been discovered to transmit, 
share an evolutionary history that may accommodate an interaction between virus and host that 
results in little or no pathology (Kurth et al., 2012; Luis et al., 2013; Smith and Wang, 2013; 
Wacharapluesadee et al., 2015). Such co-evolution has allowed both host and virus survival and 
facilitates viral transmission within the host populations, this, in turn, ensures a stable population 
of viral pathogens that carries a constant potential to be a source of viral spillover events allowing 
the viruses to infect humans and other mammals. The lack of a coherent framework for research 
investigating bat-borne viruses means that serological studies and research into bats as viral 
vectors are often conducted in isolation and without historical context that can only be generated 
through long-term serological monitoring of host populations. Where such studies exist, it is often 
the case that serological tests and or viral screening are successful in extracting RNA from virus 
families such henipaviruses, filoviruses and coronaviruses. However, these studies rarely 
succeed in the recovery of actual viral particles (Marsh et al., 2012; Hayman et al., 2013; Brook 
and Dobson, 2015). Even with the recent significant disease outbreaks and the subsequent 
increase in available resources to combat these outbreaks viruses such as the Ebola virus have 
yet to be isolated from the host bats that are likely to form the reservoir population (Guyton and 
Brook, 2015; Jayme et al., 2015; Plowright et al., 2015).  
In the case of many bat-borne viruses, research is further compounded since the very 
virulence that makes them important research topics also means that work with such agents may 
require maximum biocontainment, at biosafety level 4 (BSL4). As such, even in cases where 
isolates exist, experiments are costly, confined to the limited number of highly secure laboratories 
and limited in sample size and duration. In addition, as many of these viruses have a long history 
of co-evolution with their species-specific bat hosts, viruses such as those of the henipavirus 
family have been difficult to establish in captive bats. An excellent example of this is seen when 
20 bats were inoculated with extremely high doses of Wildtype (WT) Hendra virus, and only a 
single bat was shown to shed infectious virus particles (Halpin et al., 2000; Edson et al., 2015). 
This unusually low level of viral shedding and the difficulty of experimentally infecting bats has led 
to suggestions that the relationship between bats and their viral pathogens is dependent on the 
distinct ecology of bats. Many bat species have densly populated, three-dimensional roost 
structures that may facilitate indirect transmission through droplets of viruses excreted in urine or 
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faeces; in addition, this is further compounded by the tactile nature of many bats within the roost 
which allows yet more paths for viral transfer between individuals. Although the probability of 
developing an infection from any given exposure to the virus may be low, continuous exposure 
through multiple pathways of infection may exponentially increase the probability of infection. 
Whether bat viruses are patchily or evenly distributed among roosting sites depends on the viral 
infectious period, and how this time period relates to the movement rates of the bat, many species 
are known to frequent a number of different roosts. Short infectious periods and/or low movement 
rates among the bat hosts are likely to create a patchy viral distribution across a population, in 
contrast, long periods of viral infectiousness and/or high levels of movement are likely to 
homogenise the distribution of a viral infection across a population (Halpin et al., 2007). For most 
bat-borne viruses infectious periods are unknown. However, it is known that many bat species 
have high movement rates (Daszak, 2010; Hayman et al., 2013; Kuzmin et al., 2014). This will 
tend to result in a wide distribution of antibodies (indicative of the cumulative distribution of 
viruses) across bat populations, however without systematic serological studies over significant 
geographic areas significant areas of this research remain conjecture. Also, studies examining 
viral shedding have observed that this often occurs in discrete pulses (Murrell et al., 2012; Volz 
and Pond, 2014; Plowright et al., 2015), and this is suggestive of short infectious periods leading 
to cycles of local extinction of a virus and subsequent recolonization.  
1.3.1. Coronavirus family overview 
Coronaviruses (CoVs) infect humans as well as a wide variety of other animals primarily 
causing respiratory, enteric, hepatic, and neurological diseases of various degrees of severity. In 
recent years there have been two coronavirus spillover rvents with significant human impact, the 
outbreak of the, then novel, SARS-CoV began in November of 2002 in Guandong Province of the 
People฀’฀s฀ ฀R฀e฀p฀u฀b฀l฀i฀c฀ ฀o฀f฀ ฀C฀h฀i฀n฀a฀ (Rota et al., 2003). Little more than ten years after the spread of the 
(SARS-CoV) caused more than 700 deaths in over 8000 infections the emergence of another 
Betacoronavirus has once again highlighted the potential dangers posed from emerging 
coronaviruses. The clinical symptoms of severe respiratory illness characterised by MERS 
infection are very similar to those related to SARS-CoV infection (Chan et al., 2012). Therefore, 
the outbreak and spread of the MERS-CoV has raised serious concerns of a potential global 
pandemic on a similar scale to the SARS-CoV, although to date the MERS-CoV has not spread 
as efficiently as SARS-CoV and to date there have been 1472 laboratory-confirmed cases of 




The more limited spread of the MERS-CoV indicates that this virus has not become easily 
spreadable between humans, to date person to person infection has been limited to cases of 
prolonged close contact, such as providing unprotected care to an infected patient (Garbati et al., 
2016). This means that MERS-CoV would be considered either a phase 2 or phase 3 virus as per 
figure 1, with the route of transmission from animals to humans involving dromedary camels as a 
major reservoir host for MERS-CoV and an animal source of infection in humans. Strains of 
MERS-CoV that are identical to human strains have been isolated from dromedary camels in 
several countries, including Egypt, Oman, Qatar, and Saudi Arabia (Azhar et al., 2014; Haagmans 
et al., 2014). The first human case of MERS-CoV was identified in a male patient with severe 
progressive and ultimately fatal pneumonia in Jeddah, Saudi Arabia in June 2012 (Zaki et al., 
2012). However, molecular clock analysis indicates that MERS-CoV strains from the earliest 
recorded cases may have their origins in spillover events that date to 2011 suggesting that these 
cases are descended from a single zoonotic event (Cotten, Lam, et al., 2013). This suggests that 
earlier MERs-CoV cases may have been undetected.  
Although many initial studies into the MERS-CoV focused on the similarity between this 
virus and the SARS-CoV it was quickly determined that the MERS-CoV was more closely related 
to the bat coronaviruses Tylonycteris bat coronavirus HKU4 (BtCoV-HKU4), Pipistrellus bat 
coronavirus HKU5 (BtCoV-HKU5) (Woo et al., 2012; Wang et al., 2014).  The MERS-CoV shares 
the same gene organisation as BatCoV-HKU4 and BatCoV-HKU5, emphasising the close 
evolutionary relationship between these three viruses (Wang et al., 2014).   
In general, the coronavirus family is divided into the alphacoronavirus, betacoronavirus, 
gammacoronavirus, and deltacoronavirus (Figure 4). These groups include phylogenetically 
compact genetic groups, all sharing traits such as being enveloped, positive-sense, single-
stranded RNA viruses with a nucleocapsid, displaying helical symmetry. The lineage C viruses 
Ty-BatCoV HKU4 and Pi-BatCoV HKU5 share approximately 90% sequence similarity with these 
viruses (Boheemen, Graaf, Lauber, Theo M Bestebroer, et al., 2012; Lau et al., 2013). As such, 
MERS-CoV has been assigned to lineage C and is the first lineage C coronavirus that is known 






Figure 4: Phylogenetic tree of MERS-CoV and other coronaviruses:  
Analysis is highlighting the primary groups within the coronavirus lineage. Betacoronavirus is divided into lineages A-D. Highlighted 
sections indicate coronavirus clades. Figure produced with inkscape with reference to (Corman et al., 2014) 
 
The MERS-CoV genome contains c. 30,000 nucleotide bases with ten identified open 
฀r฀e฀a฀d฀i฀n฀g฀ ฀f฀r฀a฀m฀e฀s฀ ฀(฀O฀R฀F฀s฀Ψ฀.฀ ฀I฀m฀m฀e฀d฀i฀a฀t฀e฀l฀y฀ ฀p฀o฀s฀t฀ ฀5ƍ-UTR the genome contains two large O฀R฀F ’฀s, ORF1a
and ORF1b, responsible for the production of the nonstructural polyproteins ฀(฀N฀S฀P฀’฀s฀Ψ PLpro which 
is post-translationally processed into pp1a and pp1ab, which occurs via ribosomal frameshifting 
at the junction between the two ORFs. These polyproteins contribute to RNA synthesis through 
the formation of replicase complexes with the endoplasmic reticulum membranes  (Báez-Santos, 
St John and Mesecar, 2015; Wang et al., 2016). Following the second of these open reading 
frames (ORF1b) the MERS-CoV genome consists of an additional eight ORFs encoding the spike 
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฀(฀S฀Ψ฀,฀ ฀e฀n฀v฀e฀l฀o฀p฀e฀ ฀(฀E฀Ψ฀,฀ ฀m฀e฀m฀b฀r฀a฀n฀e฀ ฀(฀M฀Ψ฀ ฀a฀n฀d฀ ฀n฀u฀c฀l฀e฀o฀c฀a฀p฀s฀i฀d฀ ฀(฀N฀Ψ฀ ฀s฀t฀r u c t u฀r฀a l฀ ฀p฀r฀o฀t฀e฀i n฀s  t e r m i n a t฀i฀n฀g  i฀n฀ ฀t฀h฀e฀ ฀3฀’-
UTR. Furthermore, between the S and E genes, there are four additional ORFs which are 
designated 3a, 3b, 3c, 3d and all encode for additional non-structural proteins (Boheemen, Graaf, 
Lauber, Theo M Bestebroer, et al., 2012; Reguera et al., 2014). 
As with other coronaviruses, the MERS-CoV viral particle relies on a glycoprotei฀n฀ ฀‘฀s฀p฀i฀k฀e฀’฀ 
to facilitate entry into host cells, this spike protein is generally designated as the S glycoprotein 
and is a key target for research into the treatment and prevention of coronavirus infection (Corti 
et al., 2015; Zumla et al., 2016). The Spike protein of the MERS-CoV, as with other coronaviruses, 
mediates the binding of the virus to the host receptor and the membrane fusion step that is 
essential for viral infectivity. The MERS-CoV S protein is a 1353 residue type I membrane 
glycoprotein. The S protein occurs in trimers that form the peplomers on the surface of the viral 
particles. The S protein of any coronavirus can, in general, be divided into two distinct domains, 
the S1 and S2 domains. At the N-terminal end of the S protein is designated as the S1 (residues 
1-751) and is responsible for the first step of the viral entry, i.e. the binding to the host receptor, 
while the C-terminal part, named S2 (residues 752-1353) (Millet and Whittaker, 2014), is 
responsible for the second step, i.e. the membrane fusion. In all coronaviruses, the binding to the 
host receptor is mediated by a ~150-300aa-long receptor binding domain (RBD), located in the 
S1 subunit (Qian, Dominguez and Holmes, 2013), figure 5. The RBD consists of a core 
subdomain, which is highly conserved between all coronaviruses and an external receptor binding 
motif that makes specific contacts to the cell receptor and is generally poorly conserved between 
coronaviruses (Lu et al., 2013). The RBD region is a well-known antigenic site that elicits 
neutralizing antibodies, which can block the binding of the spike protein to DPP-4 (Du et al., 2014; 




Figure 5: MERS-CoV genome structure identifying Open reading frames (ORF).  
Non-structural proteins (NSPs) are encoded by ORF 1 A and B with the second frame produced through ribosomal frame shifting, these reading frames encode elements highlighted 
including ubiquitin-like fold (UB1), ADP-ribose-1d-phosphatase (ADRP), SARS-unique domain (SUD) as well as the papain-like cysteine protease (PLpro) and the TM domain. Open 
reading frame 2 encodes the spike protein which includes the Signal peptide (SP), Receptor binding region (RBD), Fusion peptide (FP) the two Heptad repeat regions (Hep 1 and Hep 
2), the Transmembrane domain (T) as well as the structural proteins indicated, Envelope (E), Membrane (M) and nucleocapsid (N). Figure prepared by author using Inkscape® 
(https://inkscape.org/en/). With reference to (Zumla et al., 2016) 
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Similar to the MERS-CoV the SARS-CoV is a positive and single stranded RNA vi-
rus belonging with a slightly smaller genome of about 29.7kb compared to MERS-CoV. SARS-
CoV has 13 identified genes which encode 14 proteins ฀w฀i฀t฀h฀ ฀a฀ ฀5฀’฀ ฀U฀T฀R฀ ฀r฀e฀g฀i฀o฀n฀ ฀c฀o฀n฀s฀i฀s฀t฀i฀n฀g฀ ฀o฀f฀ ฀2฀6฀5฀ 
nucleotides and 342 nucleotides in a 3'UTR. SARS-CoV is structurally similar to the MERS-
CoV and expression starts with the translation of two large ORFs, 1a and 1b, both of which 
encode polyproteins. These polyproteins encode the viral replicase and the four major struc-
tural proteins: nucleocapsid, spike, membrane and envelope. During viral replication, the pol-
yproteins are then processed by enzymes that are encoded by ORF 1a. There are two different 
enzymes encoded by the SARS-CoV genome, 3CLpro and PL2pro; these enzymes cleave 
the large polyproteins into 16 smaller subunits encoded by 1a and 1b (Zhao, 2007). 
The SARS-CoV depends on a similar spike protein structure as other coronaviruses 
with the SARS-CoV RBD mapped to a ׽200-residue region in the C-terminal domain of the 
S1 region (Woo et al., 2006). The Angiotensin I converting enzyme 2 (ACE 2) was identified 
as the cell entry receptor of SARS-CoV (Li et al., 2003). ACE2 is a type I membrane 
glycoprotein with an N-terminal extracellular domain consisting o฀f฀ ฀t฀w฀o฀ Į-helical lobes (Hou et 
al., 2010). After binding of the ACE2 receptor to the SARS-CoV spike protein cell entry spike 
protein undergos a conformational change that exposes hydrophobic domains including a 
fusion peptide (FP). The FP then inserts into the target cell membrane, and the viral structure 
becomes intermixed with the membrane of the target cell. While the functional aspects of 
SARS-CoV cell entry are understood to a great extent there remain significant gaps in this 
knowledge (Bolles, Donaldson and Baric, 2011). Further studies on the role of individual viral 
spike protein regions are required in order to elucidate the mechanism of infection of SARS-
CoV more fully.  
As is the case with the MERS-CoV, the SARS-CoV transmission chain has been linked 
to at least one species of bat (Drexler et al., 2010; To et al., 2013). In 2003, serological studies 
identified SARS-CoV from samples taken from masked palm civets (Paguma sp.). However there 
was at the time no sign of clinical infection in the animals (Shi and Hu, 2008). Further testing also 
identified SARS-CoV positive samples from raccoon dogs (Nyctereuteus sp.), ferret 
badgers (Melogale spp.), and domestic cats (To et al., 2013). Later studies identified a number of 
SARS-like coronaviruses in Chinese bats (Table 2) (Ren et al., 2006; Lau et al., 
2007).  Phylogenetic analysis of these viruses indicated a high probability that SARS-CoV had, in 
fact, originated in bats and spread to humans and to other animals, this transmission was facilitated 
through the crowded conditions in which animals were kept in Chinese markets animals markets 




1.3.2.1. Coronavirus antiviral and vaccine development  
Until the outbreak of MERS-CoV only two receptors had been identified for human 
coronaviruses: CD13, used by hCoV-229E and ACE2, used by both hCoV-NL63 and SARS-
CoV. However soon after the first cases of MERS-CoV were reported, a number of 
researchers attempted to identify the cell receptor that is utilized by this novel virus. Studies 
were quickly able to demonstrate (Bestebroer et al., 2012; Gierer et al., 2013) that neither the 
ACE2 nor CD13 receptors were the primary receptors for the MERS-CoV. The rapid pace of 
research into the MERS-CoV outbreak identified the Dipeptidyl peptidase-4 (DPP-4) protein, 
also known cluster of differentiation 26 (CD26) as the primary receptor for the MERS-CoV 
spike (Raj et al., 2013).  DPP-4 is 766aa-long type II transmembrane glycoprotein that is 
expressed on a broad range of cell types, forming dimers on the cell surface. As part of normal 
metabolic processes, the DPP-4 glycoprotein has a range of roles including but not limited to 
a major role in glucose metabolism. It is responsible for the degradation of incretins such 
as GLP-1 and also plays a significant role in the suppression of tumors (DPP-4 inhibitors and 
their potential role in the management of type 2 diabetes).  Despite a number of 
comprehensive studies demonstrating the role of DPP-4 in MERS-CoV infection, it has also 
been shown that MERS-CoV retains high infectivity in cell lines with undetectable expression 
of the DPP-4 receptor. This implies that the infectivity of the virus might not be directly 
associated with the expression levels of DPP-4 or even that MERS-CoV might utilize 
alternative receptors, additionally to DPP-4, for cell entry (Chan et al., 2016). Figure 6 shows 
the crystal structure of MERS-CoV Spike protein RBD region complexed with the DPP-4 
receptor (Wang et al., 2013).  
The S protein of a coronavirus is part of the class I family of viral fusion proteins, which 
contain highly conserved elements in their transmembrane unit for facilitating membrane 
fusion (Belouzard et al., 2012). A fusion peptide and two heptad repeats (HRs) are located 
between the surface unit and the transmembrane domain (Liu et al., 2004; Wang et al., 2013). 
A mature class I membrane fusion protein may be triggered via any of several different stimuli. 
Among the most common of these are low pH or receptor binding, regardless of the stimulus 
the this will cause a conformation change and the fusion peptide to be projected towards the 
target cell, in practice, this facilitates viral fusion with the host cell. The peptide responsible for 
fusion is located at the N-terminus of the transmembrane subunit or internally of the 
transmembrane protein subunit (Lu et al., 2013; Millet and Whittaker, 2014). After the trigger 
event the HRs fold, forming a six-helix bundle structure. It is this conformational change that 
moves  the N-terminal fusion peptide and allows the target cell membrane to close around the 
transmembrane domain of S protein and thus the complete viral membrane, this process 
results in membrane fusion (Qian, Dominguez and Holmes, 2013; Yu et al., 2015). As the cell 
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entry processes in coronaviruses are wholly dependent on the activity of the S protein, the 
coronaviruses are, like the lyssaviruses, superbly suited to study within the frame of viral 
pseudotyping. The use of PV incorporating MERS-CoV have made perhaps the largest 
contribution to research conducted during an ongoing viral outbreak with research by Zhao et. 
al. (2013) investigating HIV entry inhibitors for their potential inhibitory activity on MERS-CoV, 
using a PV based assay (Zhao et al., 2013). At the same time, this study identified specific 
cell lines derived from human liver and mink lungs that were susceptible to the MERS-CoV 
PV and therefore useful for further research. The screening conducted during this study 
identified potential inhibition of MERS-CoV by the compounds ADS-J1, a small inhibitor 
targeting the HIV glycoprotein 41 (gp41) (Zhao et al., 2013) as well as the 3-hydroxyphthalic 
anhydride-modified human serum albumin (HP-HAS).  Both of these compounds have been 
previously determined to target the HIV-1 glycoprotein 120 (gp120) and the HIV-1 receptor, 
CD4 and in the case of the MERS-CoV pseudoparticle, both molecules were found to 
significantly inhibit infection of the cell lines by a MERS-CoV pseudo-virus. Although further 
studies are still ongoing to determine the effectiveness of these compounds in vivo this study 
provides an effective demonstration of the potential role pseudoparticles can play as part of 
the research response to viral outbreaks. In addition, the potential limitations of such tools are 
as yet still unknown as factors such as distribution and density of surface glycoproteins may 
play an as yet unclear role.  
 
Figure 6: Crystal structure of the MERS-CoV RBD-DPP-4 receptor complex.  
The RBD consists of a core subdomain (light blue) and a long-extended loop (purple). The extracellular domain of the DPP-4 
฀r฀e฀c฀e฀p฀t฀o฀r฀ ฀c฀o฀n฀t฀a฀i฀n฀s฀ ฀a฀ ȕ- p฀r o p e฀l l e r d o฀m฀a฀i฀n฀ ฀(฀g฀r฀e฀e฀n฀Ψ฀ ฀a฀n฀d฀ ฀a฀n฀ Į฀/ȕ฀ ฀h฀y฀d฀r฀o฀l฀a฀s฀e฀ ฀d฀o฀m฀a฀in  ฀(฀o฀r฀a฀n฀g฀e Ψ฀.฀ ฀T h e  R B D-receptor contact is mediated 
฀v฀i฀a฀ ฀t฀h฀e฀ ฀e฀x฀t฀e฀n฀d฀e฀d฀ ฀l฀o฀o฀p฀ ฀o฀f฀ ฀t฀h฀e฀ ฀R฀B฀D฀ ฀a฀n฀d฀ ฀t฀h฀e฀ ȕ-propeller domain of the receptor (adapted from Structure of MERS-CoV spike 
receptor-binding domain complexed with human receptor DPP-4). 
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Although the spike proteins are certainly a major determinant of host tropism, studies 
have also identified the potential for variation in the C-terminal region of spike protein, partic-
ularly in the dual heptad regions designated HR1 and HR2 to be another critical factor in host 
range expansion (Liu et al., 2004; Follis, York and Nunberg, 2005; Forni et al., 2015). A num-
ber of studies have also demonstrated the close association between MERS-CoV and the 
related bat coronavirus HKU4. Although both viruses utilise the DPP-4 receptor studies have 
clearly demonstrated that the MERS-CoV binds human DPP-4 with higher affinity than the bat 
originated HKU4, which conversely shows a preference for the bat receptor, the RBDs of the 
two viruses engage human DPP-4 via a similar method of binding and fusion  (Cui et al., 2013; 
Caì et al., 2014; Yang et al., 2014). The results of these studies indicate that MERS-CoV and 
related viruses may have the potential to shift hosts and make species jumps relatively with 
little adaptation of the RBD region. 
In addition to the pivotal role that pseudotype virus particles (PV) can play in 
preparedness and prediction for future outbreaks can be characterised by the use of viral 
pseudo particles in the ongoing research into previous the evolutionary patterns of 
coronaviruses. Phylogenetic studies strongly suggest that there have been three interspecies 
spill-over events of zoonotic beta-CoVs to humans and two of these are very clearly linked to 
bats (Jackson et al., 2008; Nadin-Davis et al., 2010; Johnson, Aréchiga-Ceballos and Aguilar-
Setien, 2014; Kohl and Kurth, 2014; Brook and Dobson, 2015; Ching et al., 2015) and are 
believed to have been circulating in bats before the species jump occurred to an intermediate 
host (likely civets for SARS-CoV and dromedary camels for MERS-CoV) and/or to the human 
hosts that are of greatest concern. Research using PV has demonstrated that the Bat CoV 
HKU4 circulates freely in Middle Eastern bats (Yang et al., 2014) and that this virus uses the 
same receptor as MERS-CoV  (Caì et al., 2014; Wang et al., 2014; Yang et al., 2014). Wang 
et. al. also demonstrated that mutations introduced into the HKU4 S protein could be coupled 
with the PV system to alter the tropism of viral vectors and thus create a highly effective model 
for viral evolution. A similar earlier study by Ren et.al. employed this system to demonstrate 
that species specificity of the SARS-CoV infection was dependent on species specific variation 
in the ACE2 receptor (Ren et al., 2006).  
Replication of coronaviruses depends on the proteolytic activation of the replicase 
polyprotein by the viral papain-like protease (PLpro) and the 3-chymotrypsin-like protease 
(3CLpro), also named main protease (Mpro) 1. Therefore, these proteases are another target 
for anti-viral intervention and, since they are present only in the virus and not in the host cell, 
this therapeutic strategy appears to be much safer than the one that targets host cell proteins 
(Báez-Santos, St John and Mesecar, 2015; St. John et al., 2015). Inhibitors of the viral 
proteases that block SARS-CoV infection have already been discovered and, since the 
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sequence and structure of the 3CLpro shows high similarity between SARS-CoV and MERS-
CoV, they could also be utilized as therapeutic agents against MERS-CoV infection (Shirato 
et al., 2013; Wang et al., 2016). Two independent studies have already investigated the 
possible beneficial effect of two of these inhibitors. Ren et al. (Ren et al., 2013) showed that 
the anti-coronavirus inhibitor N3 blocks the proteolytic activity of MERS-CoV 3CLpro, and they 
presented the crystal structure of the N3 in a complex with the protease, concluding that N3 
blocks the function of MERS-CoV 3CLpro in a similar way it does to the protease of other 
coronaviruses. Kilianski et al. (2014) (Kilianski and Baker, 2014) evaluated the ability of 
several antiviral drugs that were optimized for inhibition of SARS-CoV 3CLpro to block MERS-
CoV 3CLpro activity. This research opens the possibility of pan-coronavirus antivirals that 
target the ability of coronaviruses to replicate in host cells.  
While viral replication cannot be studied in the context of the PV system the interaction 
of the spike receptors with the cell membranes can be studied as can the effects of spike 
protein mutations. Given the potential danger of coronaviruses such as SARS-CoV and 
MERS-CoV the development of PV based tools such as those outlined within this thesis are 
potentially invaluable to the research into novel therapeutics. 
1.3.2. Filoviridae family overview 
The Filoviridae are negative-sense, single-stranded RNA viruses that have a 
filamentous morphology and are linked to outbreaks of viral haemorrhagic fever. Viruses in 
this family include Ebolavirus and Marburgvirus and  Lloviu virus (LLOV), of these all members 
of the Ebolavirus and Marburgvirus have been linked to infection of humans while LLOV has 
only been isolated from bat carcasses (Leroy, Gonzalez and Baize, 2011; Negredo et al., 
2011). Table 3 displays the known members of the Filoviridae family and highlights the virus 
species that have previously been responsible for human infections. The Filoviridae are 
characterized by a sudden epidemic occurrence, and well as a high lethality, both traits are 
often considered clear indications of spillover events (Mathews, 2009). Although the reservoir 
host for any species of Ebolavirus  has not been conclusivly determined, there is evidence of 
a bat origin for these viruses (Spengler et al., 2016). IgG-specific to the Zaire Ebolavirus strain 
(ZEBOV) antibodies have been detected in the fruit bats Hypsignathus monstrosus, Epomops 
franqueti, and Myonycteris torquata during the Ebolavirus of 2001 and 2005 in Gabon and the 









Table 3: List of currently accepted members of the Filoviridae family of viruses with details of the year of first 
identification, Reservoir host, if known, and recorded human outbreaks of the disease. 





CUEVAVIRUS Lloviu cuevavirus (Negredo 




(Towner et al., 2009) 
 
1967 1967, 1975, 1980, 1987, 1998, 2005, 2007, 2008 
Ravn virus  Rousettus aegypti (Towner 
et al., 2009) 1996 1987, 1998, 2007 
EBOLAVIRUS 
Reston ebolavirus Multiple Bat sp.(Jayme et 
al., 2015) 1990 n/a 
Sudan ebolavirus 
Unknown 
1998 1976, 1979,2000, 2004, 2011, 2014 
Ta¨I Forest ebolavirus 1995 1994 
Zaire ebolavirus 1976 
1976, 1977, 1994, 1995, 
1996, 2001, 2002, 2003, 
2004, 2007, 2008, 2014 
Bundibugyo ebolavirus 2008 2007, 2012 
 
The Filoviridae genome encodes seven structural proteins (Figure 7), and in addition, 
the Ebolavirus genome encodes a further two non-structural, soluble, glycoproteins (GP): 
usually designated a soluble GP (sGP) and small soluble GP. The Marburgvirus consists of 
two species  termed Lake Victoria Marburg Marburgvirus (MARV) (sometimes refered to as 
Lake Victoria Marburg virus) and Ravn virus (RAVV) (Burk et al., 2016). Ebolavirusis a more 
diverse group with five currently accepted different species: Zaire ebolavirus (ZEBOV), Sudan 
ebolavirus (SEBOV), Taï Forest virus (TAFV), Reston ebolavirus (REBOV) and Bundibugyo 
ebolavirus (BEBOV) (Towner et al., 2008). In addition, novel Filoviridae was identified in 
European bats in 2011; this novel Filoviridae designed Lloviu virus appears to be more 
distanctly related to either Marburgvirus or Ebolavirus then these viruses are to each other 
(Negredo et al., 2011), and is not known to cause disease in humans.  
As indicated in table 3 the majority of Filoviridae outbreaks have been linked to species 
of Ebolavirus; this includes the most recent 2014 outbreak which was linked ZEBOV and 
resulted in a greater number of human infections then recorded in all other Filoviridae 
outbreaks in total (Na et al., 2015). However, there is significant variation in the apparent 
pathogenicity of the Ebolavirus species in humans; ZEBOV is the most pathogenic (up to 90% 
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case fatality rate), followed by SEBOV (approximately 50% case fatality rate) and BEBOV 
(approximately 40% case fatality rate). TAFV and REBOV cause lethal infections in nonhuman 
primates but have not been associated with fatal infections in humans under natural 
conditions.   
 
Figure 7: Schematic representation of the seven structural proteins encoded by the Filoviridae genome.  
Proteins are nucleoprotein (NP), Polymerase cofactor vp35 (vp35), viral matric protein (vp40), glycoprotein (GP), transcription 
activator vp30 (vp30), matric protein vp24 (vp24) and the RNA polymerase (Poly). Figure produced in inkscape with reference to 
(Burk et al., 2016) 
 
Of particular importance in the study of Filoviridae is the role played by the glycoprotein 
(GP), this protein is responsible for cellular attachment and entry (Sanchez et al., 1996). The 
first step in viral replication is the viral attachment mediated by the GP which binds to cellular 
receptors is followed by endocytosis (Wool-lewis and Bates, 1998).  
The GP protein of the Ebolavirus is typical of the Filoviridae in terms of function, 
however, in Ebolavirus GP correct protein functioning requires post transcriptional editing, to 
express structural GP (Volchkov et al., 1998). In addition, to the strucutural GP, the Ebolavirus 
GP gene also encodes two non-structural GP proteins, sGP and ssGP that are not present in 
other Filoviruses (Khun, 2008). The three GP proteins which are encoded by the fourth gene 
of the Ebolavirus genome are the full-length 676-residue surface glycoprotein (GP), the 364-
residue secreted glycoprotein (sGP), and the 298-residue small secreted glycoprotein (ssGP). 
The GP is produced by ribosomal slippage or stuttering by the viral polymerase at the editing 
site (seven consecutive template uridines) in the GP gene (de La Vega et al., 2015). This 
slippage adds an eighth adenosine residue to the transcribed mRNA and allows for the fusion 
of the two separate ORFs of this gene, this in turns produces a structural GP composed of 
two subunits GP1 and GP2 (Sanchez et al., 1996). When transcribed without the ribosomal 
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slippage affect the unedited mRNA transcripts produce sGP. Furthermore the addition of two 
additional adenosine residues during this process (i.e. nine adenosines) produces ssGP 
(Dolnik et al., 2015). After the sGP RNA is translated, the immature sGP is cleaved by cellular 
furin protease to produce  the mature sGP (Lee and Saphire, 2009). The precise function of 
this non-structural GP is unknown, however, is has been observed that large amounts of sGP 
are produced and secreted into the blood of Ebolavirus patients (Sanchez et al., 1996). It has 
also been demonstrated that antibodies present in serum extracted from Ebolavirus 
convalescent patients show greater affinity for sGP over GP (Maruyama et al., 1999). It is, 
therefore, possible that the sGP has a role in immune evasion by binding to antibodies that 
would otherwise bind to the GP. The ssGP produced by the post transcriptional inserting of 
two adenosine bases is poorly understood at present. To date the role this protein plays in 
viral replication and pathogenesis is unknown (Volchkova et al., 2015). 
The GP of Ebolavirus facilitates cellular binding and fusion with the host cell; this 
protein is produced by the post transcription insertion  of an additional adenosine at  hairpin 
loop (Sanchez et al., 1996)  that results in a frameshift causing the production of protein 676-
residues in length (677 amino acids in REBOV).  This protein is type I transmembrane GP that 
is the immature form of the final Ebolavirus GP (Sanchez et al., 1996). Due to the encoding of 
both proteins by the same gene GP and sGP have an identical 295 amino acid N-terminus, 
but differ at C-termini (Lee and Saphire, 2009). The differences in the proteins C-termini 
change the disulphide bonding and yield different final structures for the proteins. The GP 
protein is a trimer while the sGP forms a dimer. The immature Ebolavirus GP is cleaved by 
furin at a multi-basic site, forming two subunits designated GP1 and GP2. These subunits are 
connected via a disulphide linkage between Cys53 of GP1 and Cys609 of GP2 (Lee and 
Saphire, 2009; Volchkova et al., 2015) (figure 8). The finished GP protein comprised of two 
linked subunits then forms trimers on the surface of the assembling virons. Virons then escape 
the cell via the cleavage of the GP through the action of a NF-Į-converting enzyme (TACE) 
allowing the virion to detach from the cell membrane, thus releasing the viron from the cell 
(Dolnik et al., 2004). Figure 8 describes the basic composition of the Ebolavirus GP gene and 








Figure 8: Structure of the Ebola virus Glycoprotein showing domains typical for the Filoviridae.   
GP1 domain is divided into head fragments indicated in blue, base fragments indicated in green. Glycan C indicates the glycan cap; Mucin D indicates the mucin-like domain; RBD is receptor 
binding domain; SP is a signal peptide. GP2 region highlights the following domains HR1 and HR2 are heptad repeats 1 and 2 respectively; MPER, membrane-proximal external region and TM, 




When an Ebolavirus viron comes into contact with a cell, the GP is the protein 
responsible for both binding and fusion to allow entry of virus into the cell. Initial binding of the 
GP to host cell receptors is mediated by the RBD region in the GP1 domain of the protein 
(figure 8). However, virus cell interaction in filoviruses  is thought to differ from many other 
enveloped viruses as in filoviruses amino acid residues do not appear to directly interact with 
a cell surface receptors (Moller-Tank and Maury, 2015). The initial binding of these viruses to 
cells are instead mediated through non-specific receptors: C-type lectins (CLECs) that interact 
with glycans on Ebolavirus GP and PtdSer receptors that interact with the viral envelope 
(Moller-Tank and Maury, 2015). The interaction between the virus and these relatively non-
specific cellular proteins leads to uptake of the viron by the cell via Macropinocytosis (Mingo 
et al., 2015). Macropinocytosis is a form of clathrin-independent endocytiosis (Lim and 
Gleeson, 2011). Viral entry is made more efficient by the activity of the mucin-like domain and 
glycan cap both of which mediate GP binding to several cell surface proteins (Simmons et al., 
2003; Martinez et al., 2011; Takada, 2012). After virus endocytosis, the GP is cleaved by 
intrinsic host proteases that remove 80% of the mass of the GP1 subunit, including the mucin-
like domain and glycan cap (Côté et al., 2011; Martinez et al., 2012). After cleavage of GP in 
the endosome, the receptor-binding sites on GP become exposed, and the GP1 head then is 
able to bind to its receptor, Niemann-Pick C1 (NPC1) protein (Carette et al., 2011; Chandran 
et al., 2005; Côté et al., 2011). Subsequent conformational changes in GP facilitate fusion 
between viral and endosomal membranes. 
In addition, to the role GP plays in cell entry, there is a growing number of studies that 
have linked this protein to pathogenic differences among viral species.  Studies comparing the 
pathogensis of different Ebolavirus species have shown evidence that ZEBOV GP causes 
endothelial cell damage in both human and monkey vessel explants, while REBOV appears 
asymptomatic in humans while being detrimental to monkey cells (Takada, 2012). ZEBOV and 
REBOV also significantly differ in their susceptibility to furin cleavage (Lee and Saphire, 2009; 
Dolnik et al., 2015) and amino acid sequence at the TACE cleavage site (Dolnik et al., 2004). 
Moreover, it has been reported overexpression of GP causes cytotoxicity and downregulation 
of a number of cellular surface proteins, ฀i฀n฀c฀l฀u฀d฀i฀n฀g฀ ฀s฀e฀v฀e฀r฀a฀l฀ ฀i฀n฀v฀o฀l฀v฀e฀d฀ ฀i฀n฀ ฀c฀e฀l฀l฀u฀l฀a฀r฀ ฀a฀d฀h฀e฀s฀i฀o฀n฀ ฀(ȕ1-
฀i฀n฀t฀e฀g฀r฀i฀n฀,฀ Į5-฀i n฀t฀e฀g฀r฀i฀n฀ ฀a฀n฀d฀ ĮV-integrin) nd immune surveillance (MHC class I), but that lower 




1.3.3.1. Filoviridae antiviral and vaccine development  
Ebolavirus is the most well studied of the Filoviridae; this is largely due to the increased 
frequency of human outbreaks of this virus compared to other filoviruses. Ebolavirus can be 
considered a stage 3 virus (Wolfe, Dunavan and Diamond, 2007) (Section1.1), although 
REBOV has not been recorded as a human infection other species of Ebolavirus do fall into 
this category. Sporadic outbreaks of this virus (Table 3) have been linked wild animals, and 
the virus has not proven capable of efficient human-human spread (Carroll et al., 2015; Na et 
al., 2015).  
The 2014 Zaire Ebola outbreak in West Africa and has resulted in an estimated 10,500 
laboratory confirmed Ebola cases, that resulted in more than 4,800 confirmed deaths (World 
Health Organization, 2016). Prior to this, Ebola outbreaks were reported on average every 1.5 
years since the viruses first discovery in 1976, with the largest previous outbreaks infecting 
425 people (Martinez et al., 2012).  The unprecedented scale of this latest outbreak has led 
to a rapid increase in the pace of research. Much of the research has, by necessity, focused 
on the development of effective treatments and vaccines.   
The GP of Ebolavirus as in other filoviruses is the only viral envelope protein and the 
only surface accessible protein on the Ebolavirus virion. Thus this protein constitutes the sole 
target for the neutralizing antibody response (Yu et al., 2015). As such, much of the research 
has focused on identifying the most antigenically active domains in GP and the generation of 
drugs targeting regions essential for cellular entry that can be targeted (Hofmann-Winkler, 
Kaup and Pöhlmann, 2012).  
1.3.3. Bat borne influenza 
Influenza viruses are a group of virus genera in the Orthomyxoviruses family of RNA 
viruses. This family includes three distinct influenza genera as well as a number of other virus 
genera. There are three distinct phylogenetic groupings of influenza viruses generally divided 
into influenza A, B and C. Of these influenza A viruses are the most significant regarding 
human health impact. Influenza A are the major source of numerous serious viral disease 
outbreaks including all known influenza pandemics that resulted in large numbers of human 
fatalities (Lam et al., 2008; Fukuyama and Kawaoka, 2011). In addition to occasional 
pandemics, influenza A causes annual epidemics which cause significant economic losses. 
Furthermore, the virus may also cause outbreaks in poultry and other domestic animals, 
requiring costly and laborious countermeasures. Therefore, influenza virus has a substantial 
impact on health and the global economy (Edinger, Pohl and Stertz, 2014). Although in most 
cases infection with influenza A causes a severe but non-fatal disease, in patients with 
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compromised immunity such as the elderly, young children and people suffering from chronic 
disease, influenza is associated with high mortality. In the United States, some estimates 
indicate that influenza infection is responsible for approximately 200,000 hospitalizations and 
36,000 deaths in a typical endemic season (Taubenberger and Morens, 2008).  
 Influenza A are negative-sense, single-stranded, segmented RNA viruses and can be 
characterised based on the antigenic properties of their two primary membrane expressed 
glycoproteins, hemagglutinin (HA) and neuraminidase (NA) (Tong et al., 2012). There are, at 
present, 18 different known H antigens (H1 to H18) and 11 different known N antigens (N1 to 
N11). HA is a protein that mediates binding of the virion to target cells and entry of the viral 
genome into the target cell, while NA facilitates the release of progeny virions from infected 
cells. Unlike the majority of other RNA viruses, influenza replicates within the nucleus of cells 
(Boulo et al., 2007; Hutchinson and Fodor, 2013; Martín-Benito and Ortín, 2013). Due to this 
method of replication, the virus must overcome or evade a number of additional barriers to 
replication when compared to RNA viruses that do not depend on entry to a cell nucleus. Viral 
entry is a dynamic process that requires the successful completion of several steps: 
attachment to target cells, internalization into cellular compartments, endosomal trafficking to 
฀t฀h฀e฀ ฀p฀e฀r฀i฀n฀u฀c฀l฀e฀a฀r฀ ฀r฀e฀g฀i฀o฀n฀,฀ ฀f฀u฀s฀i฀o฀n฀ ฀o฀f฀ ฀v฀i฀r฀a฀l฀ ฀a฀n฀d฀ ฀e฀n฀d฀o฀s฀o฀m฀a฀l฀ ฀m฀e฀m b r a n e s ,  “ u n฀c฀o฀a฀t฀i n g ”  a n d  t h฀e฀ 
subsequent import of the viral genome into the nucleus (Böttcher et al., 2006; Martín-Benito 
and Ortín, 2013). The influenza HA protein mediates both the attachment of the influenza virus 
to the target cell and the fusion process which allows the virus to pass its genetic material 
through the cell membrane. HA is a diverse protein and is the most significant factor in 
determining virus tropism (Sahini, Tempczyk-russell and Agarwal, 2010; dos Reis et al., 2011).  
In general, for influenza replication HA is synthesized as an initial precursor molecule 
designated as HA0, this molecule is then subsequently cleaved into HA1 and HA2 by serine 
proteases (trypsin-like enzymes) for activation. These proteases work by recognizing a 
conserved Q/E-X-R motif found at the HA cleavage site as part of the HA maturation process 
(Böttcher-Friebertshäuser, Klenk and Garten, 2013). The receptor binding region of the HA 
molecule is located in the head region of the molecule with the stalk region mediating cell 
fusion (Iba et al., 2014). It is this fusion process that requires the cleavage of the HA molecule 
as this process allows the formation of the mature HA structure.  Upon binding to the host cell 
the HA to undergo a low-pH-induced, irreversible conformational change in endosomes post-
endocytosis that drives fusion of the HA into the host cell (Scott et al., 2012).  
The discovery recently two novel influenza strains identified from bat hosts, have been 
designated H17N10 and H18N11 (Tong et al., 2012), has resulted in a rapid re-evaluation of 
many previously accepted theories. These novel viruses appear to have many unique traits 
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that are not present in other influenza A strains (X. Sun et al., 2013; Juozapaitis et al., 2014). 
The phylogenetic relationship between these different strains is displayed in figure 9. While 
the association between influenza viruses and wild birds has long been understood (J. F.-W. 
Chan et al., 2013) the discovery of novel influenza virus in bats has resulted in a significant 
shift in the influenza research field. The discovery of the H17 and H18 strains in new world 
bats has cast doubt on the accepted paradigm that aquatic birds are the primary historical 
hosts of influenza A (Tong et al., 2012, 2013; X. Sun et al., 2013). While sialic acid is the 
dominant receptor in mediating the interaction between cell and virus the process of viral cell 
binding and entry may also involve numerous other receptors (Edinger, Pohl and Stertz, 2014). 
While the exact mechanisms of these interactions are not yet fully understood and the relative 
roles are still matters for debate, the crystal structures of the newly discovered H17 and H18 
indicate that these proteins do not bind sialic acid (Tong et al., 2013). This finding may indicate 
that the binding and entry mechanisms of influenza A viruses are more complex than 




Figure 9: Influenza A phylogeny based on hemagglutinin subtype.  
Showing distinct grouping of group 1 and 2 HAs' and highlighting the H17 and H18 novel subtypes 
 
1.3.3. Bat borne influenza research 
The identification of two novel influenza viruses has led to a rapid series of studies 
examining the characteristics of these new viral strains. Initial studies demonstrated that these 
strains did not bind to sialic acid receptors, a trait common to all other influenza A strains (X. 
Sun et al., 2013) and the NA derivatives of these strains also do not demonstrate standard 
enzymatic activity common to other NA strains (Li et al., 2012). The unique features of the HA 
and NA of the H17 and H18 virus isolates indicate that these viruses do not bind to sialic acid 
as other influenza strains do (Tong et al., 2013) and to date, the receptor or receptors for these 
strains have not yet been identified. 
Although the receptor/s remain unknown, significant analysis of the HA proteins of H17 
and H18 viruses have been carried out both to determine the relationship these proteins have 
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to other HA sequences and the potential for these viruses to become zoonotic (Mänz, 
Schwemmle and Brunotte, 2013; Freidl et al., 2015). Initial studies made use of bat influenza 
virus sequences in a reverse genetics system. However, these approaches failed to generate 
infectious virus surrogates (Juozapaitis et al., 2014; Zhou et al., 2014) when infection studies 
relied on the novel HA proteins. More recently the reconstruction of bat chimeric influenza 
virus particles demonstrated that all genomic segments of at least the H17N10 are capable of 
infecting specific cell lines (Juozapaitis et al., 2014). However intial studies failed to 
demonstrate the ability of  HA and NA segments from H17 to produe functional products that 
allow viral entry and replication in mammalian cells (Juozapaitis et al., 2014). This study was 
however rapidly followed by a study demonstrated that the H17N10 proteins could, in fact, 
mediate cell entry (Hoffmann et al., 2016) but only within a limited number of cell lines. This 
study demonstrated only a single cell line identified as susceptible from the non-bat derived 
cell lines, and in fact, it was also determined that only 50% of tested cell lines derived from 
bats were, in fact, susceptible to the H17N10 expressing viral particles (Hoffmann et al., 2016).  
Particularly interesting in this data is the fact that while transduction appeared to be 
efficient in three of the bat cell lines, it was not universal in all cell lines derived from bats. 
Where infection did occur is was in two Miniopterus sp. and two Pteropus sp. derived cell line. 
This finding suggests that these viruses may be restricted to a particular set of closely aligned 
species as the Miniopteridae and Pteropidae bat families are closely related to the 
Phyllostomidae family from which the original H17 and H18 samples were isolated (Agnarsson 
et al., 2011; Tong et al., 2012). However, this also leads to further questions as the cell line 
derived from Pteropus dasymallus yayeyamae failed to facilitate transduction as did the cell 
line derived from Rousettus leschenaultii and as both of these bats species are also members 
of the Pteropus genus the pattern of susceptibility of species to these new influenza viruses 
are apparently not simplistic. Finally, as these cell lines are relatively newly derived and 
immortalised (Maeda et al., 2008; Maruyama et al., 2014) detailed characterisations of their 
surface proteins and proteases are not yet available, making conclusions drawn from H17 PV 








Table 4: Cell lines used in successful VSV based pseudotyping of H17 and H18 viruses. Underlined entries are cell lines 
originating from bats. Bold entries are those cell lines which were found to be permissive for viral transduction (Maruyama et al., 
2016). * Maruyama et.al. did not report the specific variety of MDCK cells used in this study, see section 6.4. for further details. ¥ 
indicates cells extracted from bats. 
CELL LINE SPECIES ORIGIN 
VERO E6 Chlorocebus sp. Kidney 
HEK293 Homo sapiens Kidney 
MDCK* Canis lupus familiaris Kidney 
SK-L Sus scrofa Kidney 
QT6 Coturnix japonica Muscle 
BKT1 Rhinolophus ferrumequinum¥ Kidney 
FBKT1 Pteropus dasymallus yayeyamae¥ Kidney 
YUBFKT1 Miniopterus fuliginosus¥ Kidney 
INDFSPT1 Pteropus giganteus¥ Spleen 
DEMKT1 Rousettus leschenaultii¥ Kidney 
ZFBK11-97 Epomophorus gambianus¥ Kidney 
SUBK12-08 Miniopterus schreibersii¥ Kidney 
ZFBS13-75A Eidolon helvum¥ Spleen 
 
The susceptibility of the MDCK cells is less clear and showed far lower levels of 
successful transduction (Maruyama et al., 2016), this also does not agree with a previous 
study that showed H17 HA failed to bind to MDCK cells (X. Sun et al., 2013). While the reasons 
for this are currently unclear, it has been hypothesized that low affinity of H17 HA for the MDCK 
cells may mean that the level of binding is below the threshold of detection for the assays used 
in this earlier study (Maruyama et al., 2016). However, another hypothesis that may resolve 
this discrepancy is that since the MDCK cell line is highly diverse. Many different strains of 
฀M฀D฀C฀K฀ ฀c฀e฀l฀l฀s฀ ฀a฀v฀a฀i฀l฀a฀b฀l฀e฀,฀ ฀i฀n฀c฀l฀u฀d฀i฀n฀g฀ ฀t฀h฀e฀ ฀p฀a฀r฀e฀n฀t฀a฀l฀ ฀l฀i฀n฀e฀ ฀(฀d฀e฀s฀i฀g฀n฀a t฀e d  ‘฀N B L-฀2฀’฀ ฀A฀T฀C฀C® cat # CL- 3฀4฀™ Ψ฀,฀ 
MDCK I (EEACC cat # 00062106), MDCK II (EEACC cat# 00062107), MDCK.1 (ATCC® cat# 
CRL-฀2฀9฀3฀5฀™฀Ψ฀,฀ ฀M฀D฀C฀K฀.฀2฀ ฀(฀A฀T฀C฀C฀®฀ ฀c฀a฀t฀#฀ ฀C฀R฀L- CRL- 2 9 3 6฀™ Ψ฀,฀ ฀s฀u฀p฀e r฀ ฀d฀o฀m฀e(ATCC® cat # CRL-2286฀™) 
and super tube (ATCC® cat# CRL-฀2฀2฀8฀5฀™฀Ψ cell lines as well as several other strains (Dukes 
et al., 2011). It is possible that studies such as those investigating cell susceptibility to the H17 
virus may, in fact, be comparing different variants of MDCK and so differences in the observed 
susceptibility of the respective MDCK cells would not be surprising.  
฀A฀l฀t฀h฀o฀u฀g฀h฀ ฀t฀h฀e฀ ฀‘฀l฀i฀v฀e฀’฀ H17N10 and H18N11 viruses have not been isolated and so their 
potential for future zoonosis is still unknown the development of the replication-incompetent 
VSV pseudotype system allows the tropism of these viruses to be studied. The further 
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development of such tools coupled with the potential generation of chimeric HA constructs 
may allow detailed study of the both the potential for zoonosis of these viruses and also the 
potential for the generation of antiviral interventions in particular to the well conserved stalk 
region (Krammer et al., 2014).   
 
1.4. Viral spillover and selection analysis  
As already discussed (Section 1.1.) newly emerging and re-emerging viral diseases 
are very frequently zoonotic in origin. When a viral spillover occurs, a virus adapted to one 
host has infected a novel host, and as such it undergoes significant change in the 
environmental conditions in which the virus reproduces. The need to monitor both wild animals 
and domestic animals for viral pathogens with the potential to become zoonotic is well known 
(Gilbert et al., 2013; Peel et al., 2013), however, the requirement that such studies must be 
conducted in a systematic manner over long time periods is a significant barrier that must be 
breached. PV offers the potential to conduct such studies in a safe and convenient manner, 
and through the adaptation of the PV system, it is possible to construct new more efficient 
protocols making use of multiple reporter genes to develop multiplex protocols that can 
dramatically improve the efficiency of serological assays (Wright et al., 2010; Molesti, Wright, 
et al., 2014).  
 In addition to the need to monitor potential host population for evidence of potential 
zoonosis, it is necessary to develop a system of metrics that will allow researchers to 
determine the likelihood of a particular virus switching hosts and becoming a zoonotic 
pathogen. When a virus switches host there will be significant shift in the evolutionary 
pressures that are acting upon the virus  (Regoes, Hamblin and Tanaka, 2013) through 
analysis of the regions of a virus genome that is under evolutionary pressure it may be possible 
to determine the degree to which a virus is adapting to the new host and therefore the 
likelihood that this virus will become a more serious disease in the human population. As the 
rates of mutation in viruses and in particular RNA viruses are unusually high (Section 1.1. and 
1.2.) (Drake, 1999), while most mutations have a negative impact on selective fitness pressure 
driving the evolution of the virus will lead to specific mutations becoming fixed. The quasi 
species model of viral studies means that in the event of an exposure of a virus to a novel 
host, there is likely to be a number of mutations of a virus within the host population with the 
ratio of these mutant strains dependent on the evolutionary pressure acting on the sequence 
(Section 1.1. and 1.2.).  
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The change in selective pressure that results from a virus infecting a new host can be 
measured via a number of methods, but among the most popular and efficient is the 
determination of the ratio of synonymous mutations (dS) to non-synonymous mutations (dN). 
Non- synonymous mutations (dN) are a measure of the number of mutations that have 
occurred within a sequence that results in a change in the translation of the sequence, i.e. 
they change the amino acid that a codon encodes, this measure may be considered a 
measurement the level of divergence between two homologous coding sequences in terms of 
the evolution of their amino-acid content. It is calculated from the average number of 
nucleotide differences between the sequences per non-synonymous site. Synonymous 
mutations are a complimentary measure that reflects the degree to which two homologous 
coding sequences differ with respect to nucleotide substitutions that do not result in a change 
in the amino acid encoded by a specific codon. Figure 10 summarises this situation with with 
ten nucleotide differences between the sequences but this only results in five amino acid 
changes, so in this example, there were five non-synonymous substitutions and five 
synonymous. 
 This measurement indicates the degree to which two sequences differ at synonymous 
sites and can be calculated as an average number of nucleotide differences between 
sequences per synonymous site. Non-synonymous substitutions can be the result of either 
positive (adaptive or diversifying) selective pressure or a relaxing of the negative (purifying) 
selection that causes mutations to be harmful to the ฀v฀i฀r฀u฀s฀’฀s fitnes , and so the nucleotides are 
฀m฀o฀r฀e฀ ฀‘฀f฀r฀e฀e฀’฀ ฀t฀o฀ ฀v฀a฀r฀y฀.฀ ฀ ฀This r laxation is occasionally termed genetic drift and is the changing of 
allele frequency in a population as a result of the natural mutations not being removed through 
disruption of the virus life cycle (Dzeverin, 2008; Akashi, Osada and Ohta, 2012). The value 
of dN/dS can be calculated in relatively straightforward manner, and this value will then 
indicate the form of selection that the sequence under analysis is undergoing (Pond et al., 
2010) the results of this form of analysis can be interpreted as: 
x ฀A฀ ฀d฀N฀/฀d฀S฀ ฀r฀a฀t฀i฀o฀ ฀≈ 1, in general, implies that there has been an approximately equal 
number of synonymous and non-synonymous changes since the sequences diverged. 
This is generally termed Neutral evolution or genetic drift.  
x A dN/dS ratio > 1, in general, implies that there have been more non-synonymous 
changes than synonymous changes. This means that, since the divergence of the 
sequences, there has been evolutionary pressure on the sequences to diversity and 
adapt , i.e. positive selective pressure. This aspect of viral evolution may drive the 
development of escape mutants and can be viewed as a powerful indicator of the 
spillover virus becoming better adapted to its new host.  
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x A dN/dS ratio < 1, in general, implies there have been more synonymous changes than 
non-synonymous changes. This indicates that the evolution of the sequences since 
divergence has been shaped by evolutionary pressure to conserve the ancestral state, 
i.e. negative selective pressure. This form of selection is likely to be to predominate 
across most protein coding regions of an organism as many mutations will cause 
disruption to protein functioning. Regions of a virus genome where negative selection 
predominates also make ideal targets for drug development as these regions are less 
likely to mutate over time. 
 
Figure 10: Two homologous aligned sequences  
(A) with their corresponding translation (B) From the protein sequence comparison, it is obvious that five of the nucleotide 
substitutions caused an amino acid change, meaning that these were non-synonymous substitutions the remaining five changes 
to the nucleotide sequence did not affect the protein and so were synonymous.  
 
There are many tools availbale to calculate dN/dS and thus provide an assessment of 
selective pressure that can be inferred from a Mulitple Sequence Alignment (MSA). Among 
the most popular of these are the Phylogenetic Analysis Using Maximum Likelihood (PAML) 
(Yang, 1997, 2007) and the hypothesis testing using phylogenies (HyPhy) package 
(Kosakovsky Pond, Frost and Muse, 2005). PAML is a package of programs that utilises max-
imum likelihood analysis of protein and DNA sequences to infer the ratio of dN/dS. The HyPhy 
package of programs uses a similar maximum likelihood based approach but also provides 
model selection and model fitting tools. The HyPhy package has been used as the basis for a 
comprehensive set of algorithms implemented through the webserver Datamonkey (Pond and 
Frost, 2005; Delport et al., 2010).  
Before the calculation of dN/dS can be performed a multiple sequences, alignment must 
be assessed for the potential presence of recombination breakpoints. This is particularly im-
portant for analysis of viral proteins that may have drug discovery applications as recombina-
tion may not have any apparent effect on analysis that is simply examining overall selective 
pressure acting on gene (Simon-Loriere and Holmes, 2011; Su et al., 2016) i.e. as may be 
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used in phylogenetic studies involving ancestral state reconstruction.  However, recombination 
is likely to have a more serious effect on analysis that relies on site-site, and branch-branch 
comparisons  (Lemey, Salemi and Vamdamme, 2009), i.e. overall selective pressure across 
all clades may not be changed, but analysis of specific sites or regions will become unreliable.   
While many tools that examine recombination in an MSA exist among the most popular is 
an algorithm applied within the HyPhy package, known as a genetic algorithm for recombina-
tion detection (GARD) (Kosakovsky Pond, Posada, et al., 2006). This algorithm uses a genetic 
algorithm to compare the phylogeny based on the alignment with alternative alignment centred 
around variable sites that are the presumed breakpoints that indicate recombination events 
(Pond et al., 2006). It is noteworthy that GARD cannot detect breakpoints that do not occur at 
variable sites. However such breakpoints cannot be detected through any phylogenetic meth-
ods and when compared to other methods making use of sequence phylogeny GARD outper-
forms other tools in speed and with a high degree of accuracy. Since genetic recombination 
is potentially a major component of viral evolution (Simon-Loriere and Holmes, 2011) any in-
vestigation into viral evolution, and in particular an analysis relying on sequence changes to 
infer information, must account for this and alternative phylogenies generate by GARD allow 
analysis to be conducted while taking recombination into account.  
After assessment of and accounting for, recombination within an MSA there are several 
tools that can be applied to determine the specific codons or regions of the MSA that are under 
some form of selective pressure.   
The last point to make concerning selection analysis is that this form of analysis is wholly 
dependent on the nature of the MSA that is input and is therefore highly susceptible to errors 
in this alignment (Fletcher and Yang, 2010; Privman, Penn and Pupko, 2012). However, sev-
eral tools have been developed to allow the evaluation of alignments and therefore provide 
insight into the reliability of any analysis that is taken from them. These tools most commonly 
rely on codon based methods, distance methods or an approach based on maximum likeli-
hood calculations. Codon based methods involve the application of a transition matrix to the 
MSA which is an attempt to quantify the rate of change with the MSA over time (Lemey, Salemi 
and Vamdamme, 2009). Distance methods which estimate the expected value for dN/dS if the 
neutral model of the evolution is applied, this is then compared to the value of dN/dS as cal-
culated from the data. Maximum likelihood methods are more complex than codon or distance 
methods, this technique involves the initial estimate of dN/dS value that is the same across all 
฀b฀r฀a฀n฀c฀h฀e฀s฀ ฀a฀n฀d฀ ฀c฀l฀a฀d฀e฀s฀ ฀o฀f฀ ฀t฀h฀e฀ ฀M฀S฀A฀.฀ ฀T฀h฀i฀s฀ ฀e฀s฀t฀i฀m฀a฀t฀e฀ ฀i฀s฀ ฀t฀h฀e฀n฀ ฀r฀e฀f฀i฀n e d  u s฀i฀n฀g฀ ฀a฀ ฀v฀a฀r฀i฀a฀n฀t฀ ฀o฀f  F e฀l฀s฀e฀n฀s฀t฀e฀i฀n฀’฀s฀ 
pruning algorithm to evaluate the probability of the actual data being derived from a set of 
evolutionary models that are calculated through modifications of the likelihood function, and 
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independent parameters are adjusted using a numerical optimization technique to obtain their 
maximum likelihood estimates. 
1.5. Epitope prediction 
Antiviral immunity is mediated by T and B-lymphocytes of the adaptive immune system 
these cells, express antigenǦspecific receptors which allow them to discriminate between 
components of the host organism (self) and a large number of non-self molecules as well as 
specific epitopes that may indicate damaged or malfunctioning proteins/cells (Turvey and 
Broide, 2010; Papenfuss et al., 2012). These receptors specifically recognize and bind 
subdomains of foreign macromolecules and damaged or otherwise compromised components 
of self, they specific domains that form the targets of these receptors, called epitopes. The 
key distinction between those epitopes that react with B cells and antibodies is that the 
antibodies generated by B cells can recognize the B -cell epitope (BCE) of an antigen in its 
non-native (unfolded) conformation. TǦcell receptors (TCRs) in contrast recognize the TǦcell 
epitopes (TCEs) only after intracellular processing of the antigen, and usually only when the 
antigen is in association with major histocompatibility complex (MHC) molecules (Cooper, 
2002). For neutralisation assays since these are conducted within a cell a monoculture and 
using heat de-activated serum to remove the potential compounding factor of complement, 
the only source of neutralisation is the presence of viable antibodies produced by the B cells 
of the host from which the sera were taken (Louis Du Pasquier, 2001).  
B cell epitopes are generally divided into two types: linear (continuous) epitopes and 
conformational (discontinuous) epitopes. Linear epitopes are short peptides, corresponding to 
a contiguous amino acid sequence fragment of a protein or similar antigenic determinant (El-
Manzalawy, Dobbs and Honavar, 2008; Ponomarenko and van Regenmortel, 2009). In 
contrast to these, conformational epitopes are composed of amino acids that are not 
contiguous in the linear sequence, but rather these are brought into proximity within the folded 
protein structure and so may be referred to as structural epitopes (Male et al., 2012). Although 
studies have demonstrated that discontinuous B-cell epitopes may compose the majority of 
epitopes targeted by B cells ฀(฀H฀a฀n฀c฀o฀c฀k฀ ฀a฀n฀d฀ ฀O฀’฀R฀e฀i฀l฀l฀y฀,฀ ฀2฀0฀0฀5฀;฀ ฀L฀i฀l฀j฀e฀r฀o฀o฀s฀ et al., 2015), computational 
epitope identification has primarily focused on linear epitopes (Yao et al.฀,฀ ฀2฀0฀1฀2฀;฀ ฀L฀u฀š฀t฀r฀e฀k฀ et al., 
2013; P. Sun et al., 2013) largely due to the difficulties inherent with the prediction of such 
epitopes dependent on protein folding. Even in the case of linear B-cell epitopes, however, 
antibody฀–antigen interactions are often conformation dependent as a linear epitope may not 
be accessible to antibodies and thus efficient epitope studies must account for the structure 
of the final protein. The conformation-dependent aspect of antibody binding complicates the 
problem of B-cell epitope prediction, making it less tractable than T-cell epitope prediction. 
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When a B-cell receptor binds its corresponding antigen, the B cell is stimulated to undergo 
proliferation, and it is this proliferation that provides the response to a viral infection. The 
proliferation of B cells in response to infection (i.e. the detection of a recognised antigen) 
results in the generation of two different types of cells, effector or plasma B cells, which 
produce and secrete soluble antibodies, and memory B cells, which remain in the organism 
and can proliferate rapidly, if re-exposed to antigen, this process is the basis of modern 
vaccination. Hence, understanding the sequence and structural features of B-cell epitopes is 
critical both for the design of effective vaccines and for the development of sensitive diagnostic 
tests. 
1.6. Thesis goals and research strategy  
Bats are significant sources of a large number of viral pathogens and have been linked to a 
number of historic and ongoing high-profile zoonotic virus outbreaks worldwide. Although 
apparently not pathogenic in bats, reinforcing the idea of bats as the reservoir hosts for these 
viruses, some of these viruses have been linked to catastrophic pathologies in other 
mammals, including humans. Recently the role of new tools including PV has gained greater 
acceptance, and this has led to rapid improvements in the speed and efficiency of research 
into new and ongoing viral outbreaks. Also, the role computational tools including phylogenetic 
analysis and analysis of evolutionary pressures offer further insights and when combined with 
tools such as viral pseudotyping offer exciting opportunities to make viral research on 
emerging and reemerging viruses more efficient through the combination of detailed data 
analysis and experimental testing. It is hoped that the outcome of the thesis will provide a 
workflow outline for greater efficiency in research towards future viral outbreaks. This project 
will seek to:  
x Develop plasmid vectors expressing the envelope glycoprotein(s) of MERS-CoV, 
SARS-CoV, Ebolavirus and H17 influenza viruses. After confirmation of high levels of 
cell surface expression of these glycoproteins, candidate constructs prepared with 
outbreak/vaccine strains will be used in transfection experiments with retroviral core 
constructs to produce PV retroviruses.  
x Carry out transduction experiments with PV on human/animal cell lines for the study 
of viral tropism (including host cellular receptor/co-receptor identification if applicable), 
and to identify optimal cell lines for use in downstream high-throughput reporter-based 
assays.  
x Use these PV to study the seroprevalence of these viruses in bats worldwide, and also 




x To investogate the potential of computational tools to inform experimental research to 




Chapter 2 Materials and Methods 
More detailed techniques and protocols will be recorded within the corresponding 
results chapters, while this chapter will provide details for the basic molecular biology, cell 
culture techniques, as well as a broad overview of the in-silico methodology employed for 
analysis, and materials will be described with references made the corresponding catalogue 
numbers. Furthermore, generalised pseudotype virus (PV) production protocols and reagents 
will be reported. 
2.1. Molecular biology protocols, reagents 
The original MERS-CoV S gene kindly provided by Dr Davide Corti (Institute for 
Research in Biomedicine & Humabs BioMed, Bellinzona) in the phCMV1 plasmid, figure 11. 
The phCMV1 vector is a 4.2 kb constitutive mammalian gene expression vector driven by a 
modified version of the hCMV immediate-early promoter and enhancer/intron. Additionally, it 
possesses kanamycin and neomycin resistance that allows selection of plasmid-positive 
prokaryotic and eukaryotic cells, respectively. However, prior to transfection, the spike gene 
was cloned into a pCAGGS (Hitoshi, Ken-ichi and Jun-ichi, 1991) vector following steps 




Figure 11: Plasmid map of the phCMV1 plasmid.  
Displaying the modified hCMV promoter and the Simian Vacuolating virus 40 (SV40) polyadenylation signal (pA) permit the 
expression of the gene that is cloned in the multicloning site. The restriction enzyme sites in the multicloning site are reported in 
red. In black highlighting the pUC ori necessary for plasmid amplification in bacterial cells as cloned into this vector from the 
original pBR322 plasmid. The resistance to kanamycin and neomycin is encoded by the respective genes (yellow) under control 





Figure 12: The pCAGGS plasmid showing unique restriction sites and presence of additional features.  
Expression of the inserted gene/s is mediated by the presence of the human cytomegalovirus immediate-early promoter (hCMV 
IE Pr). The terminator sequence permits polyadenylation of the mRNA enhancing stability. The restriction enzyme sites in the 
multiple cloning site (MCS), "-lactamase, which mediates the resistance to ampicillin, is encoded by the ampicillin gene (yellow) 
driven by its own promoter (Amp Prom). 
 
The gagpol expression plasmid p8.91 (originally named pCMV(R8.91 (Zufferey et al., 
1997)) is a second generation packaging plasmid construct that expresses HIV-1 gagpol under 
a human CMV promoter. This plasmid has been altered to remove the  HIV-1 accessory genes 
vif, vpr, vpu and nef and thereby rendered incapable of producing viable virus in its own right. 
This plasmid was kindly provided by Dr Nigel Temperton (Universities of Greenwich and Kent, 
Medway, UK) for use in this project. Dr Temperton also provided the reporter genes pCSFLW 
and pCSRLW. The pCSFLW (Zufferey et al., 1997) vector is a firefly luciferase expressing 
contsruct with ฀3ƍ฀ ฀L฀T฀R฀ ฀d฀e฀l฀e฀t฀i฀o฀n฀ ฀(฀U฀3฀ ฀p฀r฀o฀m฀o฀t฀e฀r฀ ฀r฀e฀g฀i฀o฀n฀Ψ฀,฀ ฀c฀r฀e฀a฀t฀i฀n฀g฀ ฀w฀h฀a฀t฀ ฀i฀s฀ ฀t฀e r฀m฀e฀d฀ ฀a฀ ฀s฀e฀l฀f-inactivating 
(SIN) vector. The pCSRLW is the same vector but with the firefly luciferase gene replaced with 
a renilla luciferase. 
Both reporter plasmids are self-฀i฀n฀a฀c฀t฀i฀v฀a฀t฀i฀n฀g฀ ฀l฀e฀n฀t฀i฀v฀i฀r฀a฀l฀ ฀v฀e฀c฀t฀o฀r฀ ฀t฀h฀a฀t฀ ฀i฀n฀c฀o฀r฀p฀o฀r฀a฀t฀e฀s฀ ฀a฀ Ȍ฀ 
packaging signal, a central polypurine tract cis-active sequence (cPPT), an internal promoter 
constituted by the U3 part of the Spleen Focus Forming Virus (SFFV) long terminal repeat 
sequence, and a Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) 
to enhance reporter gene expression. pCSFLW was originally modified from pCSGW 
฀(฀o฀r฀i฀g฀i฀n฀a฀l฀l฀y฀ ฀p฀H฀R฀’฀S฀I฀N-cPPT-SE (Demaison et al., 2002)) inserting firefly luciferase-encoding 
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gene as a reporter system instead of enhanced GFP (eGFP)-encoding gene. The pCSRLW 
was also modified from pCSGW but with a renilla luciferase-encoding gene instead of a firefly 
encoding gene. The emerald green fluorescent protein (emGFP), pCSemGW, was kindly 
provided by Prof. Greg Towers, University College London, UK. The last reporter gene used 
in this study was the tomato red fluorescent protein (tRFP), pCSdNTW and was provided by 
Dr Edward Wright. Both of these flourescent protein plasmids are further versions of the 
pCSGW (Demaison et al., 2002) with the emerald GFP  and the tomato RFP genes 
respectively, replacing the original enhanced GFP (eGFP) encoding gene. The pCSdNTW 
was a dual expression vector, expressing both the tRFP and a Nuclear localisation signal 
(NLS). The inclusion of the NLS component in this vector should facilitate localisation of the 
fluorescent signal in the nucleus (Kosugi et al., 2009) of the target cell and result in more 
punctuate expression of the fluorescence as the NLS causes the fluorescent protein to be 
tagged for import to the nucleus. 
2.1.2. Codon optimisation 
All viral envelopes used in this study with the exception of the final mutated product 
from the mutagenesis experiments were codon optimised version of the viral envelope gene 
of interest. Codon optimisation is used to increase the expression of protein in a cell by 
increasing the translational efficiency of this protein. A number of studies (Burgess-Brown et 
al., 2008) have demonstrated that genes making use of rare codons have lower expression 
levels (in terms of protein translation) when compared to genes, which use more frequently 
occurring codons. This is not the sole criteria in determining the efficiency of expression of the 
glycoprotein in the generation of a PV however. The choice of expression vectors and 
฀t฀r฀a฀n฀s฀c฀r฀i฀p฀t฀i฀o฀n฀a฀l฀ ฀p฀r฀o฀m฀o฀t฀e฀r฀s฀ ฀a฀r฀e฀ ฀a฀l฀s฀o฀ ฀o฀f฀ ฀g฀r฀e฀a฀t฀ ฀i฀m฀p฀o฀r฀t฀a฀n฀c฀e฀ ฀i฀m฀p฀o฀r฀t a฀n฀t฀, w i t h d i f฀f฀e฀r฀i฀n฀g฀ ฀p฀r฀o฀m฀o t฀o฀r฀’฀s฀ 
exhibiting a range of different promotion potencies (Jordan, Schallhorn and Wurm, 1996; 
Yamano, Dai and Moursi, 2010; Shintani, Sanchez and Kimbara, 2015). As the initial MERS-
CoV spike protein was inserted into the phCMV1 plasmid, this spike gene was sub cloned into 
a different plasmid vector to determine if variation in the plasmid sequence would influence 
pseudo virus production.  
2.2. Transformation and plasmid preparation 
2.2.1. Antibiotic stocks, liquid and solid media 
All plasmids used in this study made use of either ampicillin or kanamycin antibiotics 
as a selective agent. Ampicillin sodium salt (Fisher Scientific, cat. #BP1760) and kanamycin 
sulphate (Fisher Scientific, cat. #BP906) were each ฀d฀i฀s฀s฀o฀l฀v฀e฀d฀ ฀i฀n฀ ฀U฀l฀t฀r฀a฀P฀u฀r฀e฀™฀ ฀D฀N฀a฀s฀e฀/฀R฀N฀a฀s฀e฀ 
Free Distilled Water (฀G฀i฀b฀c฀o฀®฀,฀ ฀I฀n฀v฀i฀t฀r฀o฀g฀e฀n฀™฀,฀ ฀c฀a฀t฀.฀ ฀#฀ ฀0฀9฀7฀7-049) to produce stock concentrations 
of 100 mg/ml and 10 mg/ml respectively. These stocks were then filtered using a syringe 
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driven 0.22 µm filter (Merk Millipore®, cat. # SLGP033RS). Ampicillin working stocks were 
prepared at a concentration of 100 µg/ml in liquid medium, for use in Luria Bertani (LB) broth, 
and 200 µg/ml in solid medium for use in bacterial culture plate. Kanamycin was used at 50 
µg/ml in both liquid and solid media as this antibiotic is known to be less susceptible to 
breakdown over time and therefore may considered stable for storage in either media form. 
฀‘Ready-to-dissolve฀’ LB Agar (Fisher Scientific, cat # BP1425, or Sigma-Aldrich, cat. # L3147) 
and LB Broth (Fisher Scientific, cat# BP1426) were used for preparing bacterial liquid and 
฀s฀o฀l฀i฀d฀ ฀m฀e฀d฀i฀a฀,฀ ฀d฀i฀s฀s฀o฀l฀v฀e฀d฀ ฀i฀n฀ ฀d฀o฀u฀b฀l฀e฀ ฀d฀i฀s฀t฀i฀l฀l฀e฀d฀ ฀w฀a฀t฀e฀r฀ ฀f฀o฀l฀l฀o฀w฀i฀n฀g฀ ฀m a n u f a c t u r e฀r ’ s฀ ฀i฀n฀s฀t฀r u c t i o n฀ ( L฀B฀ ฀A฀g฀a฀r฀:฀ 
16 g in 400 ml water; LB Broth: 12.5 g in 500 ml water) and autoclaved. Super Optimal Broth 
with catabolite repression (SOC; In฀v฀i฀t฀r฀o฀g฀e฀n฀™฀,฀ ฀c฀a฀t฀#฀ ฀1฀5฀5฀4฀4-034) containing 2% tryptone (w/v), 
0.5% yeast extract (w/v), 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 
mM glucose was used as recovery medium in bacterial transformation to maximise the 
efficiency of the procedure. 
2.2.2. Transformation competent Escherichia coli cells 
Cells used for transformation were sub-cloning efficiency chemically induced 
competent Escherichia coli of the ฀D฀H฀5Į฀ ฀s฀t฀r฀a฀i฀n฀ ฀(฀I฀n฀v฀i฀t฀r฀o฀g฀e฀n฀™฀,฀ ฀c฀a฀t฀.฀ ฀#฀ ฀1฀8฀2฀6฀5-017). 
Transformations were carried out using the classic heat-shock protocol with cell aliquots of 
12.5 µl used for each transformation. The heat shock step was carried out in ฀a฀n฀ ฀A฀c฀c฀u฀B฀l฀o฀c฀k฀™฀ 
Digital Dry Bath (Labnet International, cat. # D1100-230 V) for 30 seconds with subsequent 
incubations carried out a laboratory incubator (Genlab, cat. # INC/75) overnight at 37°C (The 
amount of media plated was increased for low copy number plasmids).  
2.3. Isolation of plasmid DNA from bacterial culture 
Amplification and purification of plasmid DNA for further analysis, sequencing or 
transfection of eukaryotic cells was performed using the commercial kits QIAprep Spin 
Miniprep Kit (QIAGEN, cat. # 27106) that makes use of a modified version of the alkaline lysis 
with sodium dodecyl sulphate (SDS) method of plasmid purification from transformed bacterial 
฀c฀e฀l฀l฀s฀.฀ ฀I฀n฀ ฀a฀d฀d฀i฀t฀i฀o฀n฀,฀ ฀s฀e฀v฀e฀r฀a฀l฀ ฀p฀r฀e฀p฀a฀r฀a฀t฀i฀o฀n฀s฀ ฀w฀e฀r฀e฀ ฀p฀e฀r฀f฀o฀r฀m฀e฀d฀ ฀u฀s฀i฀n฀g฀ ฀t฀h฀e฀ ฀Z฀i฀p฀p฀y฀™  P฀l a m฀i d  M฀i n i p r e p฀ K i฀t฀ 
(Zymo, cat. # D4036) that makes use of a modified alkaline lysis method and this method 
bypasses bacterial culture centrifugation and resuspension steps that are used in the Qiagen 
protocols. 
For the plasmids purified using the Qiagen kit. Plasmid isolation was carried out as per 
the manufacturer provided protocol (QIAGEN 2012b; QIAGEN 2012a), briefly: 
For low copy number plasmids, a larger amount of bacterial growth was required, and so 
the volume of the LB broth was increased as was the time spent growing the bacteria during 
this stage. This method is henceforth referred to as the midiprep protocol to correspond to the 




2.3.1. Determination of nucleic acid concentration 
DNA concentration and purity (260 nm/280 nm absorbance ratio) were measured by 
฀u฀l฀t฀r฀a฀v฀i฀o฀l฀e฀t฀ ฀s฀p฀e฀c฀t฀r฀o฀p฀h฀o฀t฀o฀m฀e฀t฀r฀y฀ ฀u฀s฀i฀n฀g฀ ฀a฀ ฀N฀a฀n฀o฀D฀r฀o฀p฀™฀ ฀2฀0฀0฀0฀ ฀S฀pe c฀t฀r฀o฀p h o t฀o m฀e฀t e r  ฀(฀N฀a฀n฀o฀D r฀o฀p฀™฀ 
Products, Thermo Fisher Scientific cat # ND-2000฀Ψ฀ ฀f฀o฀l฀l฀o฀w฀i฀n฀g฀ ฀m฀a฀n฀u฀f฀a฀c฀t฀u฀r฀e฀r฀’฀s฀ ฀i฀n฀s฀t฀r฀u฀c฀t฀i฀o฀n฀ 
฀(฀‘฀N฀a฀n฀o฀D฀r฀o฀p฀ ฀2฀0฀0฀0฀ ฀/฀ ฀2฀0฀0฀0฀c฀ ฀S฀p฀e฀c฀t฀r฀o฀p฀h฀o฀t฀o฀m฀e฀t฀e฀r฀’฀,฀ ฀2฀0฀0฀0฀Ψ. 
2.4. Amplification, sequencing 
Prior to sub cloning, the gene of interest was amplified using a high-fidelity DNA 
฀p฀o฀l฀y฀m฀e฀r฀a฀s฀e฀ ฀w฀i฀t฀h฀ ฀p฀r฀o฀o฀f฀r฀e฀a฀d฀i฀n฀g฀ ฀a฀c฀t฀i฀v฀i฀t฀y฀ ฀(฀3฀’฀ ฀e฀n฀d฀ ฀t฀o฀ ฀5฀’฀ ฀e฀n฀d฀ ฀e฀x฀o฀n฀u฀c฀l฀e฀a฀s฀e  a c฀t i v฀i t y Ψ ,฀ ฀a฀ ฀p฀r o o f r e฀a฀d฀i฀n฀g฀ 
polymerase was required as changes to the glycoprotein gene of a virus may have unforeseen 
consequences on protein stability and function. The results of amplifications were sent for 
฀S฀a฀n฀g฀e฀r฀ ฀s฀e฀q฀u฀e฀n฀c฀i฀n฀g฀ ฀a฀t฀ ฀G฀A฀T฀C฀ ฀B฀i฀o฀t฀e฀c฀h฀ ฀A฀G฀ ฀u฀s฀i฀n฀g฀ ฀t฀h฀e฀ ฀L฀I฀G฀H฀T฀r฀u฀n฀™฀ ฀s฀e฀q฀u฀e฀n c i฀n฀g฀ ฀o฀p฀t฀i o n฀.  F o฀r 
฀L฀I฀G฀H฀T฀r฀u฀n฀™฀ ฀5฀ ฀µ฀l฀ ฀o฀f฀ 80 ng/µl plasmids were mixed with an equal volume of 5 pmol/µl forward 
(Fw) or reverse (Rev) primer. Resulting electropherograms were checked and edited using 
Bioedit and CodonCode Aligner; nucleotide and amino acid sequences were then aligned with 
the reference sequences using Jalview (Clamp et al., 2004; Waterhouse et al., 2009) and the 
MUSCLE algorithm (Edgar, 2004). 
2.4.1. Oligonucleotides for amplification and sequencing  
Primers were ordered from ฀T฀h฀e฀r฀m฀o฀f฀i฀s฀h฀e฀r฀™฀ ฀I฀n฀v฀i฀t฀r฀o฀g฀e฀n฀™฀ ฀u฀s฀i฀n฀g฀ ฀t฀h฀e฀ ฀c฀o฀m฀p฀a฀n฀i฀e฀s฀ 
Invitrogen Custom DNA Oligos Value Olgos service to produce primers that were desalted in 
a 25 nmol synthesis scale and were delivered lyophilised. Although the use of HPLC purified 
primers for certain applications is recommended by many suppliers, this method of purification 
was not employed during this study and primers were ordered without additional purification. 
Although this errors in primer production can result in attenuated oligonucleotide synthesis, 
many studies have successfully made use of non-purified primers even for applications such 
as mutagenesis, that are known to be highly vulnerable to variation in primer composition 
(Tyagi, Lai and Duggleby, 2004; Trehan et al., 2016). Prior to use, the primers were 
reconstituted in DNase/RNase free water to a stock concentration of 100 pmol/µl and from this 
working stock were prepared by dilution to 5pmol/µl. 
3RO\PHUDVHFKDLQUHDFWLRQXVLQJ$FFX3ULPH3I[6XSHU0L[ 
AccuP฀r฀i฀m฀e฀™฀ Pfx S฀u฀p฀e฀r฀M฀i฀x฀ ฀(฀I฀n฀v฀i฀t฀r฀o฀g฀e฀n฀™฀,฀ ฀c฀a฀t฀.฀ ฀#฀ ฀1฀2฀3฀4฀4-040) is a ready-to-use mixture 
of DNA polymerase, accessory proteins, salts, magnesium, and deoxyribonucleotides 
(dNTPs) with demonstrated fidelity greater than standard Taq DNA polymerase . This fidelity 
coupl฀e฀d฀ ฀w฀i฀t฀h฀ ฀t฀h฀e฀ ฀e฀a฀s฀e฀ ฀o฀f฀ ฀u฀s฀e฀ ฀o฀f฀ ฀t฀h฀e฀ ฀A฀c฀c฀u฀P฀r฀i฀m฀e฀™฀ Pfx SuperMix makes this polymerase 
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suitable for amplification of genes that need to be cloned and expressed for further studies. 
Amplification using the ฀A฀c฀c฀u฀P฀r฀i฀m฀e฀™฀ fx SuperMix was carried out with 25 µl of total combined 
reactant and consisted of: 22.4 µl of ฀A฀c฀c฀u฀P฀r฀i฀m฀e฀™฀ fx SuperMix,  2 µl of DNA template (Diluted 
to give a concentration of 60-80ng of DNA), 0.3 µl of each For. and Rev. primers (primer 
concentration of 200 nM). The reaction mix was aliquoted in 0.2 ml microtubes (VWR 
International Ltd, cat. # 732-0548) which were placed in a Master cycler ep Gradient S 
(Eppendorf) or to the Mastercycler ep Gradient (Eppendorf) thermal cycler, and the PCR 
program reported in Table 5 was run. 
Table 5: Thermocycler conditions for $FFX3ULPHPfx SuperMix 




 98oC 3:00 
DENATURATION 
 




 XXoC 0:15 
EXTENSION 
  
4 72oC 2 mins/Kb 
FINAL EXTENSION 
 
5 72oC 20:00 
2,3,4
 TO BE CYCLED X25 
3
 ANNEALING TEMPERATURE TO BE DEFINED ACCORDING TO PRIMER DESIGN. GRADIENT TEMPERATURE USED HERE  
4
 EXTENSION TIME TO BE DETERMINED BY LENGTH OF DNA: 2 MINUTES PER KB 
 
Primer melting temperatures were calculated based on primer sequence that anneals 
to the template, however other factors are more difficult to account for. However primers were 
analysed using NCBI primer design tools (https://www.ncbi.nlm.nih.gov/guide/howto/design-
pcr-primers/) and primers with high levels of primer dimer potential were rejected, with primer 
length modified when required to avoid this difficulty. To circumvent the difficulties of accurate 
primer melting calculations, gradient PCR was used to determine the optimal conditions for 
amplification.  
Sequencing primers were designed by identifying locations flanking the inserted gene 
in the plasmid and selecting these regions for primer attachment with the online NCBI primer 
design tools (https://www.ncbi.nlm.nih.gov/guide/howto/design-pcr-primers/) with the criteria 
customised as summarised in Table 6. Additional criteria were left at the default values. The 
฀s฀e฀l฀e฀c฀t฀e฀d฀ ฀p฀r฀i฀m฀e฀r฀s฀ ฀w฀e฀r฀e฀ ฀a฀l฀t฀e฀r฀e฀d฀ ฀w฀h฀e฀n฀ ฀n฀e฀c฀e฀s฀s฀a฀r฀y฀ ฀s฀o฀ ฀t฀h฀a฀t฀ ฀t฀h฀e฀ ฀3฀’ ฀e n฀d฀ ฀o f t฀h฀e฀ ฀p฀r฀i฀m฀e฀r฀ i n c l u d e d฀ ฀a฀ G฀C  
clamp (Li et al., 2008). 
 
Table 6: Modifications of the default conditions set for primer design for the use of the NCBI primer design tool. 
 
Primer Length 16-28 
Primer Melting Temperature ฀5฀9๦฀C฀ ฀– ฀6 4๦฀C 





All primer sequences were also aligned with the target sequence in MEGA 6.0 (Tamura 
et al., 2011) through the use of the MUSCLE alignment algorithm (Edgar, 2004), to insure that 
the primer binding occurred in a suitable area of the target plasmid without additional non-
specific binding occurring. This provided the added advantage of storing a fasta file with the 
primers of interest aligned to the complete plasmid and insert sequence.  
2.5. Site-directed mutagenesis of plasmid DNA 
2.5.1. Site-directed mutagenesis with in-house made protocol 
Previous work within the Viral Pseudotype Unit resulted in the development of an in-
house protocol, based on the similar a similar protocol to the commercially available 
QuikChange Lightning Site-direct mutagenesis kit.  This protocol makes use of the same 
primers design tool (QuikChange Primer Design web-tool) as the commercial quick change kit 
but departs from the protocol by not making use the Agilent patented QuickSolution to increase 
the reaction speed of the PfuUltra High Fidelity DNA polymerase and so this protocol results 
in a longer extension time (2mins/Kbp Vs 1min/kbp). The QuikSolution reagent acts to improve 
the efficiency of linear amplification, and so increases the speed of the overall reaction. As 
with the QuickChange protocol oligonucleotide primers, each complementary to opposite 
strands of the vector, are extended during temperature cycling by the action of the polymerase, 
in this case, ฀t฀h฀e฀ ฀A฀c฀c฀u฀P฀r฀i฀m฀e฀™฀ Pfx SuperMix.  Th  Pfx polymerase contains a similar chemical 
to the Pfu compound found in the PfuUltra High Fidelity DNA polymerase that is used in the 
QuickChange kit, and like this polymerase, this compound minimizes the potential for primer 
slip during cycling. During the temperature cycling, the polymerase mediates the extension of 
the oligonucleotide primers and so generates a mutated plasmid which due to the nature of 
the primer binding will include a number of nicked elements of sequence. The product of this 
mutagenic amplification is treated with Dpn I. The Dpn I restriction enzyme (target sequence: 
5´-Gm6ATC-3´) is specific for methylated and hemimethylated DNA and is used to digest the 
parental DNA template, and thus in theory, only the mutated product will remain. DNA isolated 
from almost all E. coli strains is dam methylated and therefore susceptible to Dpn I digestion. 
Mutagenic amplification was performed using the site-direct mutagenesis PCR protocol that 
is unchanged from that reported in table 5 and preparing an amplification reaction with 25 µl 
฀o฀f฀ ฀A฀C฀C฀U฀Z฀Y฀M฀E฀™฀ ฀M฀i฀x฀ ฀(฀B฀i฀o฀l฀i฀n฀e฀,฀ ฀c฀a฀t฀.฀ ฀#฀ ฀B฀I฀O-25028), 125 ng of each prim r, 140 ng of plasmid 
DNA to be mutated, and DNase/RNase free water to a final volume reaction of 50 µl. 
It should be noted that the intial starting concentration of the DNA is greater in this reaction 
when compared to a PCR reaction. The use of overlapping primers in this protocol does not 
facilitate exponential amplification of the type that can be expected during a PCR, this reaction 
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allows only the linear growth phase of the amplification to occur and so in order to generate 
significant output of mutated product it is necessary to increase the amount of DNA initially 
input. Although previous protocols of this type included a verification of amplification by 
analytical DNA gel electrophoresis any observed product on a Gel prior to DPN1 digestion 
would be likely only too be the initial parental DNA, further the linear nature of this reaction is 
likely to yield a quantity of product below the detection threshold of standard ethidium bromide 
based gel electrophoresis. As such gel electrophoresis was not run on the mutated product 
and the products were taken directly to the purification stages.  
The mutant amplicons were purified via Qiagen PCR purification kit before 80-100 ng were 
digested for 20 min at 37°C in a 10 µl reaction with 10 U of FastDigest® D pnI (Thermo Fisher 
Scientific, cat. # FD1703) in 1X FastDigest® Buffer (Thermo Fisher Scientific, cat. # B64). The 
DpnI reaction was heat-inactivated for 5 min at 80°C, before being used to transform E. coli 
฀D฀H฀5Į฀ ฀c฀e฀l฀l฀s฀.฀  
2.5.2. Site-directed mutagenesis with QuikChangeOLJKWQLQJVite-directed 
mutagenesis kit 
The second method of mutagenesis employed in this study was the use of the 
commercial QuikChange Lightning site-directed mutagenesis. This protocol was carried out 
฀a฀s฀ ฀p฀e฀r฀ ฀t฀h฀e฀ ฀m฀a฀n฀u฀f฀a฀c฀t฀u฀r฀e฀r฀’฀s฀ ฀p฀r฀o฀t฀o฀c฀o฀l฀ (Agilent, 2002) and is largly similar to the previously 
฀d฀e฀s฀c฀r฀i฀b฀e฀d฀ ฀‘฀i฀n- h o u s e฀’฀ ฀m฀u฀t฀a฀g฀e฀n฀e฀s฀i฀s฀ ฀p฀r฀o฀t฀o฀c฀o฀l฀.฀ ฀I฀n฀ ฀b฀r฀i฀e฀f฀,฀ ฀t฀w฀o฀ ฀o฀v฀e฀r฀l฀a฀p฀p฀i฀n฀g฀ ฀re v e฀r s e-complementary 
oligonucleotide primers containing the desired mutation were designed using the QuikChange 
Primer Design web-tool (Agilent Technologies). These primers (125 ng) were used in a 50 µl 
PCR reaction together with 140 ng of the plasmid DNA to be mutated, 5 µl of specific reaction 
buffer, 1.5 µl of QuikSolution reagent (an Agilent Technologies proprietary salt solution), and 
DNase/RNase free water. To this reaction mix, 1 µl of QuikChange Lightning Enzyme is also 
฀a฀d฀d฀e฀d฀.฀ ฀T฀h฀i฀s฀ ฀m฀i฀x฀ ฀w฀a฀s฀ ฀t฀h฀e฀n฀ ฀a฀l฀i฀q฀u฀o฀t฀e฀d฀ ฀i฀n฀ ฀t฀h฀e฀ ฀s฀a฀m฀e฀ ฀w฀a฀y฀ ฀a฀s฀ ฀t฀h฀e฀ ฀’฀i n- h o u s฀e฀’  protocol, and the 
thermocycling conditions were as described in table 5 with the exception that the extension 
step was 1 min/Kbp due to the improved efficiency of the commercial kit mediated by the 
QuickSolution additive.  
The commercial QuickChange Kit also contains a specifically formulated Dpn1 
mixture, as such before proceeding to the bacterial transformation  
2 µl of the provided DpnI restriction enzyme mix was added to the amplification reaction to 
digest the parental/template DNA.  
2.5.3. Gradient polymerase chaLQUHDFWLRQXVLQJ3KXVLRQ'1$
polymerase 
฀F฀o฀r฀ ฀a฀m฀p฀l฀i฀f฀i฀c฀a฀t฀i฀o฀n฀ ฀r฀e฀a฀c฀t฀i฀o฀n฀s฀ ฀w฀e฀r฀e฀ ฀t฀h฀e฀ ฀u฀s฀e฀ ฀o฀f฀ ฀t฀h฀e฀ ฀A฀c฀u฀z฀y฀m฀e฀™ based protocol fail d to 
amplify the desired sequence, in particular, this method was employed for mutagenesis 
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reactions. The acuzyme enzyme is recommended for sequences upto approximatly 5kb so 
this may be an issue. Therefore a simailar protocol, but optimised to make use of the 
฀P฀h฀u฀s฀i฀o฀n฀™฀ ฀p฀o฀l฀y฀m฀e฀r฀a฀s฀e฀ ฀w฀h฀i฀c฀h฀ ฀i฀n฀c฀l฀u฀d฀e฀s฀ ฀a฀ ฀p฀r฀o฀o฀f฀r฀e฀a฀d฀i฀n฀g฀ ฀e฀n฀z฀y฀m฀e฀ ฀w฀as  ฀d e฀v e฀l฀o฀p฀e฀d฀.฀ T฀h฀i฀s  p r o t o c฀o฀l  
as with the acuzyme based protocol makes use of  non-฀o฀v฀l฀a฀p฀p฀i฀n฀g฀ ฀p฀r฀i฀m฀e฀r฀s฀.฀ ฀T฀h฀e฀ ฀P฀h฀u฀s฀i฀o฀n฀™฀ 
polymerase will generate linear amplification, that is the sense strand cannot be used as a 
template for the reverse primers and vice versa. Therefore 160ng of template will be added to 
attempt to offset this reduced ampifcation. Will also run a prolonged DPN1 digestion to remove 
this excessive template.  
As with ฀t฀h฀e฀ ฀A฀c฀u฀z฀y฀m฀e฀™฀ ฀b฀a฀s฀e฀d฀ ฀m฀e฀t฀h฀o฀d฀ ฀p฀r฀i฀m฀e฀r฀s฀ ฀w฀e฀r฀e฀ ฀i฀n฀ ฀g฀e฀n฀e฀r฀a฀l฀ ฀d฀e฀s฀i฀g฀n฀e฀d฀ ฀u฀s฀i฀n฀g฀ ฀t h e฀ 




x 1 98oC  1:00 (denature) 
x 2 98oC  0:30 
x 3 XXoC  0:45  18 cycles  
x 4 72oC  XX 
x 5 72oC  10:00 
2,3,4
 To be cycled x18 (25-฀3฀5฀ ฀r฀e฀c฀o฀m฀m฀e฀n฀d฀e฀d฀ ฀a฀s฀ ฀p฀e฀r฀ ฀s฀t฀a฀n฀d฀a฀r฀d฀ ฀P฀h฀u฀s฀i฀o฀n฀™฀ ฀a฀m฀p฀l฀i฀f฀i฀c฀a฀t฀i฀o฀n฀ ฀p฀r฀o฀t฀o฀c฀o฀l฀ b฀u t  
reduced due to large amount of template) 
3
 Annealing temperature to be defined according to primer design. Gradient applied 
4
 Extension time to be determined by length of DNA: 1 minutes per kb 
 
2.5.4. Gradient polymerase chain reaction using 3KXVLRQ DNA 
polymerase 
For amplification reactions were the use of the Acuzyme฀™ based protocol failed to 
amplify the desired sequence, in particular, this method was employed for mutagenesis 
reactions.  
The acuzyme enzyme is recommended for sequences upto approximatly 5kb so this 
may be an issue. Therefore a simailar protocol฀,฀ ฀b฀u฀t฀ ฀o฀p฀t฀i฀m฀i฀s฀e฀d฀ ฀t฀o฀ ฀m฀a฀k฀e฀ ฀u฀s฀e฀ ฀o฀f฀ ฀t฀h฀e฀ ฀P฀h฀u฀s฀i฀o฀n฀™฀ 
polymerase which includes a proofreading enzyme was developed. This protocol as with the 
acuzyme based protocol makes use of  non-ovlapping primers. The Phusion฀™ polymerase 
will generate linear amplification, that is the sense strand cannot be used as a template for the 








x 1 98oC  1:00 (denature) 
x 2 98oC  0:30 
x 3 XXoC  0:45  18 cycles  
x 4 72oC  XX 
x 5 72oC  10:00 
2,3,4
 To be cycled x18 (25-35 recommended as per standard Phusion amplification protocol but 
reduced due to large amount of template) 
3
 Annealing temperature to be defined according to primer design. Gradient applied 
4
 Extension time to be determined by length of DNA: 1 minutes per kb 
2.5.5. Gradient polymerase chain reaction using PCR Supermix DNA 
polymerase 
PCR SuperMix is a platnum Taq based polymerase mix that combines reagents for the 
฀a฀m฀p฀l฀i฀ﬁ฀c฀a฀t฀i฀o฀n฀ n a single ready to use mix, in this way it is similar to Acuzyme Pfx. However 
while this mix combines similar levels of Mg++, dNTPs, and polymerase, it is the polymerase 
that is different. The recombinant Taq DNA Polymerase does not include a proofreading 
enzyme, and so mutagenesis mediated by this polymerase runs a high risk of introducing un-
intended mutations.   
Temperature Time (minutes: seconds) 
x 1 94oC  2:00 (denature) 
x 2 98oC  0:20 
x 3 XXo C 0:20  20  cycles  
x 4 68oC  XX 
x 5 72oC  20:00 
2,3,4
 To be cycled x20 
3
 Annealing temperature to be defined according to primer design. Gradient applied 
4
 Extension time to be determined by length of DNA: 1 minutes per kb 
2.6. Colony PCR for screening 
Colony PCR is a fast and high-throughput method that can be used to quickly determine 
if a bacterial colony has been successfully transformed and thus possesses the desired 
plasmid DNA. Although not widely employed in this study colony PCR was carried out for 




1. The bacterial colony of interest on a plate of transformed media was selected and 
฀‘฀p฀i฀c฀k฀e฀d฀’฀ ฀b฀y฀ ฀s฀c฀o฀o฀p฀i฀n฀g฀ ฀t฀h฀e฀ ฀c฀o฀l฀o฀n฀y฀ ฀w฀i฀t฀h฀ ฀t฀h฀e฀ ฀s฀t฀e฀r฀i฀l฀e฀ ฀t฀o฀o฀t฀h 
2. The toothpick was then washed repeatedly in a 0,2ml tube containing 25 µl of 
DNase/RNase-free water  
3. Part of this solution was then-then spread on a 10cm culture plate previously prepared 
with a suitable antibiotic selective agent and a grid drawn on the underside of the plate 
4. The remaining suspension was then lysed at 94°C for 3 min in a thermal cycler  
5. 5 µl of each colony suspension was transferred to a separate PCR microtube in which 
an aliquot of 20 µl of PCR mix had previously been added; this PCR mix is recorded 
below  
For the PCR mix, stock was prepared and aliquoted into PCR microtubes; the 
the stock mix was prepared to calculate the samples to be screened and for each reaction 
adding 12.5 µl of DreamTaq Green PCR Master Mix (Thermo Fisher Scientific, cat. # 
K1082), 0.1 µl of each For. and Rev. primers (final concentration 400 nM). As this procedure 
was only carried out with the pCAGGS plasmid primers annealing upstream and downstream 
of the MCS in which the gene of interest was cloned were used.  Successful amplification of 
the target sequence was confirmed via DNA gel electrophoresis after the colony PCR program 
had completed (Table 6).  
Table 4: Thermocycler conditions for Colony PCR. As used for screening colonies for the insert.  
CYCLES TEMPERATURE TIME STEP 
94°C 2 min Initial denaturation 
94°C 30 seconds Denaturation 
51°C 1 min Annealing 
72°C 2 min Extension 





2.7. Cell culture reagents, materials, and techniques 
Protocols used for cell culture including the maintenance of cell lines and the 
methodology used in culturing these lines are described below. All the procedures were 
performed in a MSC-Advantage฀™ Class II Biological Safety Cabinet (Thermo Fisher Scientific, 
cat. # 51025413฀Ψ฀ ฀a฀n฀d฀ ฀c฀e฀l฀l฀s฀ ฀w฀e฀r฀e฀ ฀i฀n฀c฀u฀b฀a฀t฀e฀d฀ ฀u฀s฀i฀n฀g฀ ฀a฀ ฀H฀e฀r฀a฀c฀e฀l฀l฀™฀ ฀1฀5฀0฀i฀ ฀h฀u฀m฀i฀d฀i฀f฀i฀e฀d฀ ฀C฀O2 Incubator 




2.7.1 Cell lines characteristics and maintenance 
The key cell line used in this research is the Human Embryonic Kidney (HEK) 
HEK293T/17(ATCC®: CRL-฀1฀1฀2฀6฀8฀™฀Ψ฀ ฀c฀e฀l฀l฀ ฀l฀i฀n฀e฀.฀ ฀T฀his is a highly transfectable cell line that was 
selected from a clone of HEK293T cells and is widely used to produce retroviral and lentiviral 
฀v฀e฀c฀t฀o฀r฀s฀ ฀d฀u฀e฀ ฀t฀o฀ ฀i฀t฀s฀ ฀e฀x฀c฀e฀p฀t฀i฀o฀n฀a฀l฀ ฀‘transfectability ’  a n d  ฀t฀h฀e  r฀e฀l฀a t฀i฀v฀e฀ ฀e฀a฀s฀e฀ ฀w฀i฀t฀h฀ ฀w฀h฀i฀c฀h฀ ฀t฀h฀i฀s฀ ฀c฀e฀l฀l฀ ฀l฀i฀n฀e฀ 
can be maintained in a laboratory. HEK293T/17฀c฀e฀l฀l฀s฀ ฀w฀e฀r฀e฀ ฀m฀a฀i฀n฀t฀a฀i฀n฀e฀d฀ ฀i฀n฀ ฀D฀u฀l฀b฀e฀c฀c฀o฀’฀s฀ ฀M฀o฀d฀i฀f฀i฀e฀d฀ 
฀E฀a฀g฀l฀e฀ ฀M฀e฀d฀i฀u฀m฀ ฀(฀D฀M฀E฀M฀Ψ฀ ฀w฀i฀t฀h฀ ฀h฀i฀g฀h฀ ฀g฀l฀u฀c฀o฀s฀e฀ ฀a฀n฀d฀ ฀G฀l฀u฀t฀a฀M฀A฀X฀™฀4฀ ฀(฀G฀i฀b฀c฀o฀® ,฀ ฀I฀n฀v฀i฀t r o g e n ™฀,฀ ฀c a฀t .  #  
31966-021). The medium was generally supplemented with 10% (v/v) European Union 
approved origin heat-฀i฀n฀a฀c฀t฀i฀v฀a฀t฀e฀d฀ ฀F฀e฀t฀a฀l฀ ฀B฀o฀v฀i฀n฀e฀ ฀S฀e฀r฀u฀m฀ ฀(฀F฀B฀S฀;฀ ฀G฀i฀b฀c฀o฀®฀,฀ ฀I฀n฀v฀i฀t฀r฀o฀g฀e฀n฀™ ,  ฀c฀a t฀.฀ #฀ 
10500-064) and 1% (v/v) penicillin/streptomycin (Sigma-Aldrich, cat.# P4333). However, in 
specific instances, this supplementation was altered or in some cases abandoned, and this 
will be discussed in greater detail in the corresponding chapters.  
HEK293T/17cells were cultured at a constant temperature of 37°C with 5% CO 2 in 10 cm 
sterile 'Nunclon® surface cell culture dishes (Thermo Fisher Scientific, cat. # 150350) using 
10% FBS-DMEM media three times a week, maintaining a constant subculture ratio of 1:6, 
1:6, and 1:12 respectively.  
The method of cell culture in brief was:  
1. Growth media was removed from the cells that were rinsed with 1.5 ml of 0.05% (w/v) 
Trypsin-0.53 mM EDTA solution (PAN-Biotech, cat. n° P10- 040100)   
2. After removal of rinse trypsin, the cells were incubated with 2 ml of fresh Trypsin-EDTA 
solution at 37°C 5% CO 2 until the cells were completely detached from the dish. 
3. ฀A฀f฀t฀e฀r฀ ฀c฀e฀l฀l฀ ฀d฀e฀t฀a฀c฀h฀m฀e฀n฀t฀,฀ ฀t฀h฀e฀ ฀t฀r฀y฀p฀s฀i฀n฀ ฀w฀a฀s฀ ฀‘฀q฀u฀e฀n฀c฀h฀e฀d฀’, a d he cells were resuspended 
through the addition of 4 ml of 10% FBS-DMEM medium. 
4. Finally, 1 ml (1:6 ratio) or 0.5 ml (1:12 ratio) of this cell suspension was added to 10 ml 
of fresh medium in a clean 10 cm dish. 
Madin-Darby Canine Kidney (MDCK) cells were kindly provided by Prof. Sarah 
Gilbert (Jenner Institute, University of Oxford, UK). These cells are canine kidney epithelial 
cells with a mutation converting L-alanine-L-glutamine, a more stable derivate of L-glutamine, 
which does not degrade to ammonia.  
MDCK cells are widely used for the propagation of several well studied virus families but are 
best known for their role in influenza virus research. MDCK cells were cultured in DMEM 
(Sigma-Aldrich, cat. # D6429) with 5% heat-inactivated FBS (PAN Biotech) and 1% penicillin-
streptomycin and sub-cultured twice a week to a ratio of 1:10 following the same basic protocol 
as HEK293T/17cells but with volumes adjusted to arrive at the 1:10 ration for sub culturing. 
The A549 cell line (ATCC®: CCL-฀1฀8฀5฀™฀Ψ฀,฀ ฀k฀i฀n฀d฀l฀y฀ ฀p฀r฀o฀v฀i฀ded by Prof. Paul Kellam 
(Wellcome Trust Sanger Institute, UK), is a human lung carcinoma epithelial cell line. A549 
cells were cultured in DMEM/F12 media (Hyclone, cat. # SH30023.02) with 10% FBS and 1% 
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penicillin-streptomycin. This cell line was maintained and cultured in a similar way to 
HEK293T/17.  
The HUH-7 cell line was kindly provided by Dr Ian Harmer (University of 
Westminster)and is a hepatocyte-derived cellular carcinoma cell line.  Huh-7 cells were 
cultured in DMEM with 10% heat-inactivated FBS (PAN Biotech) and 1% penicillin-
streptomycin and sub-cultured three times a week to a ratio of 1:5, 1:5 and 1:8 following the 
same basic protocol as HEK293T/17cells but with volumes adjusted to arrive at the 1:5 ration 
for subculturing. It was noted that high ratios of sub-culturing of this cell line result in poor 
growth and so the ratio of the did not follow the same progression as other cell lines. Huh-7 
cells were cultured in T75 cell culture flasks (ThermoFisher Cat. #156499).  
2.7.2 Freezing and thawing of cell lines 
Cells were frozen when they reached 80% confluence. Initially all cells were frozen in 
cryovial (Corning®, cat. # 430915), however, it was quickly determined that this was not 
required while the cells were to be stored at -80ႏ and so standa฀r฀d฀ ฀E฀p฀p฀e฀n฀d฀o฀r฀f฀’฀s฀ ฀w฀e฀r฀e฀ ฀u฀s฀e฀d฀ ฀i฀n฀ 
place of cryovials.  
 
For cells grown on a 100-mm dish one cryovial Eppendorf was prepared, and for a T75 
flask three vials were prepared according to the following steps:   
1. Cells were detached by trypsinization as per cell subculture protocols  
2. Cell suspension was centrifuged at 1200 g for 5 min using Rotor 6M of ELMI 
CM-6MT Centrifuge (Spectra Services) 
3. Cells were then re-suspended in freezing media, which is heat inactivated FBS 
with the addition of 10% (v/v) dimethyl sulfoxide (DMSO; VWR International Ltd, 
BDH Prolabo GPR RECTAPUR®, cat. # 282164K).  
4. ฀C฀e฀l฀l฀s฀ ฀w฀e฀r฀e฀ ฀t฀h฀e฀n฀ ฀t฀r฀a฀n฀s฀f฀e฀r฀r฀e฀d฀ ฀i฀n฀t฀o฀ ฀c฀r฀y฀o฀v฀i฀a฀l฀s฀/฀ ฀E฀p฀p฀e฀n฀d฀o฀r฀f฀’฀s฀ ฀(฀1฀ ฀ml฀/cryovial) that were 
฀p฀l฀a฀c฀e฀d฀ ฀i฀n฀ ฀a฀ ฀M฀r฀.฀ ฀F฀r฀o฀s฀t฀y฀™฀ ฀F฀r฀e฀e฀z฀i฀n฀g฀ ฀C฀o฀n฀t฀a฀i฀n฀e฀r฀ ฀(฀T฀h฀e฀r฀m฀o฀ Fisher Scientific, cat. # 
5100-0001) at -80°C (propanol in the container buffers the cells ag ainst rapid 
cooling that is likely to induce ice crystal formation and slows the cooling rate 
to approximately 1°C/min cooling rate)  
5. Subsequently, they were maintained at -80°C in a cryobox (Thermo Fisher  
Scientific, cat. # 1417563). 
Cells were thawed for use on an as-needed basis, and this procedure followed the following 
protocol:  
1. A tube of cells was thawed at in warm water until approximately 50% of the 
suspension had become liquid.  
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2. The still partially solid cell suspension was then transferred into 15 ml tubes 
(Greiner Bio-One, cat. # 188271) which contained 7 ml of appropriate medium 
at R.T. 
3. This falcon tube was then inverted 4-5 times to ensure all ice had melted and 
cells were well distributed in the media  
4. The cell suspension is then centrifuged at 1200 g for 5 min, and supernatant 
was removed, with care taken to avoid disturbing the cell pellet 
5. Cells were then re-suspended in 10 ml of appropriate medium and transferred 
to a 10 cm dish or were re-suspended in 12 ml and transferred to the T75 flask 
(Thermo Fisher Scientific cat. # 156367).  
6. Cells were inspected using a microscope at 24 hours, and if cells adhered to 
the culture vessel the media was changed  
Cells were subcultured when they were 70-80% confluent and then cultured as normal.  
 
2.8. Restriction endonuclease digestion, electrophoresis, and ligation 
DNA (plasmid and PCR product) digestions using restriction endonucleases were 
performed for preparative (cloning) and for diagnostic reasons. In addition, digestion was used 
as a screening procedure for the production of chimeric HA molecules in of H17 and H5. 
Specific details of restriction digests will be given in each chapter in which they were 
conducted however a generalized protocol, as used in this research will be given here.  
Cloning digestions were conducted as double digests with the two restriction enzymes 
(Fermentas/Thermo Fisher Scientific) to be used added to a common buffer. However, in the 
rare instances where less than 100% activity was expected in a common buffer 
(Fermentas/Thermo Fisher Scientific) a decision was made on an as needed basis as to the 
acceptable level of enzyme activity, where necessary a sequential digestion was performed 
enzyme appropriate buffer (Thermo Fisher Scientific), with reaction purification (Qiagen 
purification) carried out  between the first and the second reaction.  
Digestions were carried out with, 100-300 ng of plasmids or 80-400 ng of purified PCR 
products were digested. For these reactions, 10 U of each restriction enzyme was used; in 
sequential digestions, when the second reaction volume was bigger than 30 µl, 15 U of 
restriction enzyme was usually used. Due to the potential inhibitory effect of the glycerol in a 
glycerol-based buffer, the enzymes are suspended in, to maintain the percentage of glycerol 
less than or equal to 10% of the reaction volume, single digestions were usually set-up in a 
total volume of 10 µl and double digestion in 20 µl. In cases where this was not possible due 
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to low DNA concentration, this will be highlighted in the corresponding results chapter.  
Reactions were incubated at 37°C in a thermocycler pre-warmed to this temperature , with 
fastdigest protocols run for 15-30 mins, and slow digest enzymes run for 2 hours, in all cases, 
the enzymes were deactivated using the thermocycler immediately after the digestion period 
was completed. Digestion reactions performed for cloning procedures were then purified either 
via PCR purification (Qiagen) or through the use of gel extraction procedures from an 
electrophoresis gel. 
2.8.1 DNA gel electrophoresis 
DNA gel electrophoresis was performed both to confirm the presence of genetic 
material at a specific size and also to aid the isolation and purification of this material through 
the excision of the material from the gel. Gels run for diagnostic purposes were made to have 
an  agarose (Fisher Scientific, cat.# BP1356) gel concentration between 1% and 2% (w/v), 
which were made up in 0.5X Tris-Acetate-Ethylenediaminetetraacetic acid (EDTA) buffer 
(TAE; 50X stock solution, Alpha Laboratories, cat. # EL0077; or Fisher Scientific, cat. # 
BP1332) for use as a  matrix for the electrophoresis. In order to visualize the DNA on the gel 
Ethidium bromide (Sigma-Aldrich, cat. # 46067) was added, this dye intercalates with double-
strand DNA and fluoresces with a bright orange-red colour when exposed to ultraviolet light; 
this was added to the agarose gel to give a final concentration of 0.1µg/ml. 
Samples to be analysed on a gel were loaded together with a commercial loading dye mixture: 
for PCR products, in most cases, 4 µl to 8 µl of DNA was loaded after mixing this with of 1.5 
µl or 3 µl respectively of 6X DNA Loading Dye (Thermo Fisher Scientific, cat. # R0611).  
Colony PCRs were performed using DreamTaq Green PCR Master Mix which is premixed 
with several tracking dyes and can, therefore, be directly loaded onto the gel without. 
 All gels were run with GeneRuler 1 kb DNA Ladder Mix (Thermo Fisher Scientific, cat. # 
SM0311), a molecular weight marker/ladder which contains a number of fragments of genetic 
material with a fixed molecular weight that can be used to determine the size of the bands in 
a gel.  
Agarose gels prepared for DNA purification through gel extraction were prepared with 
a 1% concentration of low-melting point agarose (Melford Laboratories Ltd, cat. # L1204) or 
฀1฀%฀ ฀U฀l฀t฀r฀a฀P฀u฀r฀e฀™฀ ฀A฀g฀a฀r฀o฀s฀e฀ ฀(฀I฀n฀v฀i฀t฀r฀o฀g฀e฀n฀™฀,฀ ฀c฀a฀t฀.฀ ฀#฀ ฀6฀5฀0฀0-500) gels in 0.5X TAE were used. 
All agarose gels regardless of the purpose they were to be used for were run in 0.5X TAE 
buffer using a power supply (Consort, cat. # EV231) and electrophoretic chambers (SCIE-
PLAS, cat. # SVG-SYS Vari-gel MINI; or PEQLAB Biotechnologie GmbH, cat. # 40-124 or 40-
0911; or Sigma-Aldrich, cat. # EP1101); gels for use as diagnostic tools only were run with the 
current set to 90-120 V for 1-2 h depending the specific voltage used, the gel length and the 
required level of resolution. Throughout every gel run the progress of the DNA was monitored 
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by monitoring loading dye migration. Gels for use in gel extraction purification procedures run 
at 40 V, as larger current generated excessive heat and could result in the gel melting. 
Gels were visualized using a transilluminator (UVItec, cat. # BXT-26.MX) and GeneSnap 
software (Syngene) was used to acquire images. 
 
2.8.2. DNA fragment extraction from agarose gel 
To purifiy a DNA band of interest using gel extraction an agarose gel electrophoresis 
was performed, and the band of interest was excised from the gel using a sterile scalpel. The 
DNA was extracted from the agarose gel slice using the QIAquick Gel 
Extraction Kit (QIAGEN, cat. # 28704) or MinElute Gel Extraction Kit (QIAGEN, cat. # 28604).  
Fully details of the use of this kit may be found in the manufacturer manuals however details 
of the protocol as used in this study are recorded below: 
1. The gel slice was removed from the gel, and excess Agrose was removed, the 
remaining agrose fragment was then placed in a pre-weighed eppendorf tube 
2. The weight of the gel slice was then determined.   
3. 1.5 volumes of Buffer QG, were added for every 1 volume of gel slice  
4. This mix was then incubated at 50°C for 10 min with vortexing every 2- 3 mins 
until the gel slice was completely dissolved. Note: at this point, it was frequently 
necessary to adjust the solution pH to 7.5 using 3 M sodium acetate pH 5.0 
5.  To this mix one volume of isopropanol (Fisher Scientific, cat. # P/7500/17) was 
added.  
6. The mixture was then loaded into a QIAquick or MiniElute spin column for 1 min 
with 17000 g centrifugation. 
7. Two centrifugation-wash steps were performed with Buffer QG and Buffer PE 
to remove all traces of agarose and excessive salt.  
8. An additional centrifugation at 17000 g for 2 min was carried out to remove 
additional ethanol residue  
9. DNA was eluted in 30 µl DNase/RNase free water that had been previously 
heated to 70°C. This water was added to the QIAquick or MiniElute spin co lumn 
and was then incubated 1 min at RT before a final centrifugation step to elute 
DNA into a clean 1.5 ml microtube 
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2.8.3. PCR and digest purification 
Purification of PCR product and restriction digest reactions were carried out using a QIAquick 
฀P฀C฀R฀ ฀p฀u฀r฀i฀f฀i฀c฀a฀t฀i฀o฀n฀ ฀k฀i฀t฀ ฀(฀Q฀I฀A฀G฀E฀N฀,฀ ฀c฀a฀t฀.฀ ฀#฀ ฀2฀8฀1฀0฀4฀Ψ฀ ฀f฀o฀l฀l฀o฀w฀i฀n฀g฀ ฀t฀h฀e฀ ฀m฀a฀n฀u฀f฀a฀c฀t฀u฀r฀e r ’฀s฀ ฀i฀n฀s฀t฀r฀u฀c t฀i฀o฀n฀ 
(QIAGEN). This protocol in brief as followed in this study was: 
1. 5 volumes of Buffer PB were added to the reaction; pH was then balanced 
through the addition of 10 µl of 3 M sodium acetate pH 5.0  
2. The mixture was then centrifuged in a QIAquick column at 17000 g for 1 min to 
permit specific DNA adsorption to the silica membrane. Flow-through was dis-
carded  
3. 750 µl of ethanol-containing Buffer PE was used to remove salt contaminant 
through another centrifugation at the same speed 
4. An additional 2 min centrifugation to remove ethanol residue  
5. DNA was eluted from the column adding 30 µl of 70°C DNase/RNase free wa-
ter, incubating for 1 min, and centrifuging in a clean 1.5 ml microtube for 1 min 
at 17000 g. 
2.8.4. DNA ligation 
DNA ligation was not generally required during the plasmid amplification protocols due 
to the use of overlapping primers. However, ligation was required to both specific plasmid 
vectors to the genes of interest and in the use of mutagenesis protocols that did not make use 
of overlapping primers. In these cases, the T4 DNA 
Ligase system was used (Thermo Fisher Scientific, cat. # EL0011) and the protocol was 
implemented as follows:  
1. Reactions were set-up in the lowest volume possible, in general, this was ap-
proximatly 8-10 µl, using 5 U of T4 DNA Ligase in the provided buffer (Thermo 
Fisher Scientific, cat. # B69).  A vector to insert ratio of 1:3 was maintained.  
2. A ligation control reaction (no insert) was also set-up to determine if undigested 
or re-ligated vector were present.  
3. Reactions were incubated for 68-72hrs at RT before being transformed into 
chemically ฀c฀o฀m฀p฀e฀t฀e฀n฀t฀ ฀D฀H฀5Į E. coli. 
2.9. PV production protocol using PEI 
A transfection protocol developed by (Ferrara et al., 2013) for routine pp production 
developed by Dr Edward Wright (University of Westminster) and Dr Nigel Temperton was 
kindly provided by Dr  Francesca Ferrara and was adapted to produce initially influenza PV. 
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This protocol was the initial basis for all PV production in this study and formed the basis of 
significant further adaptation and optimization.  Firstly, branched 25 kDa PEI (Sigma-Aldrich, 
cat # 408727)) was dissolved in water to 50 mg/ml and then diluted to 1 mg/ml adjusting the 
pH to 7 with hydrochloric acid (Fisher Scientific, cat. n° H/1200/PB17). The sol ution was 
sterilised by filtration with a 0.22 µm filter, aliquoted, and conserved at -20°C. The working 
aliquot once thawed and opened was stored at 4°C for a maximum duration of two months. 




Figure 13: PV production protocol visual representation (Grehan, Ferrara, et al., 2015)  
Figure displays the steps in the production of PV including time line  
 
Timeline: Transfection ± 24h 
1. HEK293T/17cells were subcultured into 100mm Petri dishes at a ratio (1:4) that 
will yield 70฀–90% confluence at the time of transfection.  
Timeline: Day of transfection 
2. DMEM/10% FBS/1% P/S and Opti-฀M฀E฀M฀™฀ was pre-warmed to 37C using a water 
bath or similar. 
3. Two sterile 1.5ml microcentrifuge tubes (tube 1 and tube 2) per transfection were 
prepared and prelabeled.  
4. Plasmids expressing the envelope: core: vector with a ratio to be determined via 
experimentation were added to transfection to tube 1. 
5. 200µl Opti-฀M฀E฀M฀™฀ ฀w฀a฀s฀ ฀a฀d฀d฀e฀d to the plasmi  DNA mix (tube 1). 
6. 200µl Opti-฀M฀E฀M฀™ and 35µl of 1mg/ml PEI to tube 2. 
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7. Incubation: Both tubes were mixed by gently flicking and incubated for 5min at 
room temperature (RT). 
8. After incubation, the Opti-฀M฀E฀M฀™/PEI solution was pipetted from tube 2 into the 
Opti-฀M฀E฀M฀™/DNA solution in tube 1. 
9. Incubation: The tube containing plasmid DNA and transfection reagent mix was 
incubated at RT for 20min with gentle flicking to mix every 3฀–4min. 
10. While transfection mix was incubating, the culture media on the HEK293T/17 cells 
was removed and 7ml of fresh DMEM/10% FBS/1% P/S added. 
11. After 20min incubation, the DNA/Opti-฀M฀E฀M฀™/PEI solution was added onto the 
HEK293T/17 producer cells by the slow ฀‘dropwise฀’฀ ฀a฀d฀d฀i฀t฀i฀o฀n฀ ฀o฀f฀ ฀m฀i฀x over the com-
plete area of the plate.  
12. Incubation: The plate was then incubated at 37Ԩ, 5% CO2 overnight (o/n).  
Timeline: 12±16h post transfection 
13. Post o/n incubation the media on the cells was be changed and 7ml fresh 
DMEM/10% FBS/1% P/S added.  
14. Incubation: The plates were then incubated at 37Ԩ 5% CO2 o/n for 32฀–36h. 
Timeline: 44±52h post transfection 
15. The supernatant containing the PV was harvested using a 10ml sterile syringe and 
then filtered into falcon tubes via a syringe driven Millex HA-0.45mm filter. 
16. All filtered supernatant was stored at -80Ԩॶ.  
 
2.9.1. PV production using (QGRIHFWLQ Lenti Transfection Reagent 
To produce a renilla luciferase expressing MERS-CoV PV the transfection was 
฀a฀t฀t฀e฀m฀p฀t฀e฀d฀ ฀w฀i฀t฀h฀ ฀E฀n฀d฀o฀f฀e฀c฀t฀i฀n฀™฀ ฀L฀e฀n฀t฀i฀ ฀T฀r฀a฀n฀s฀f฀e฀c฀t฀i฀o฀n฀ ฀R฀e฀a฀g฀e฀n฀t฀ ฀(฀G฀e e฀C o p o e i฀a฀ C฀a฀t฀.  #  E฀F฀L฀1฀0฀0฀1-
01/02), using the following protocol:  
1. Plating of cells prior to transfection 
48 hours prior to transfection HEK293T/17cells were trypsinized and sub-cultured in new 
plates in a 1:8 ratio. This gave an expected confluence of 70-80% on the day of transfection.   
2. Preparation of DNA/EndoFectin complex  
DNA, EndoFectin Lenti reagent, and diluents were first acclimated to room temperature prior 
to the following steps.  
x DNA was diluted with 500ul Opti-฀M฀E฀M฀™฀ ฀.฀  
x EndoFectin Lenti reagent was diluted with an additional 500ul of Opti-฀M฀E฀M฀™฀  
x As per ฀E฀n฀d฀o฀F฀e฀c฀t฀i฀n฀™฀ ฀L฀e฀n฀t฀i฀ ฀T฀r฀a฀n฀s฀f฀e฀c฀t฀i฀o฀n฀ ฀R฀e฀a฀gent pro ocol, 3.0 ȝ l  ฀o฀f฀ ฀E฀n d F e฀c฀t i฀n฀ 
฀r฀e฀a฀g฀e฀n฀t฀ ฀w฀a฀s฀ ฀a฀d฀d฀e฀d฀ ฀p฀e฀r฀ ฀1฀ ȝ฀g฀ ฀o฀f฀ ฀D฀N฀A฀ ฀g฀i฀v฀i฀n฀g฀:฀  
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o DNA Added ฀– 3.5 ug  
o Endofectin Added -10ul 
x Dilutions were prepared in separate 15ml falcon tubes and vortexed to insure 
homogenous mixing 
x The diluted EndoFectin฀™ Lenti reagent was added drop-wise to the DNA solution 
while the mix was gently vortexed 
x The mixture was then incubated for 20 minutes at room temperature to allow the 
DNA-EndoFectin complexes to form 
3. Transfection of producer cells  
x After incubation, the DNA-EndoFectin complex containing mixture was added directly 
to each plate after which the plates were gently swirled to distribute the mixture 
through the media evenly.  
x The plates were incubated for 48 hours at 37Ԩ and 5% CO2 in a Genlab incubator 
(Genlab, cat. # INC/75) 
4. Harvesting of lentivirus bearing supernatant  
x ฀P฀V฀ ฀c฀o฀n฀t฀a฀i฀n฀i฀n฀g฀ ฀s฀u฀p฀e฀r฀n฀a฀t฀a฀n฀t฀ ฀w฀a฀s฀ ฀c฀o฀l฀l฀e฀c฀t฀e฀d฀ ฀a฀f฀t฀e฀r฀ ฀4฀8฀ ฀h฀o฀u฀r฀s฀ ฀a฀n฀d฀ ฀f฀i l t e฀r฀e฀d  ฀t฀h฀r o u g h  0 . 4 5฀ ȝ฀M  
polyethersulfone (PES) low protein-binding filters. The filtered supernatant was then 
stored at -80Ԩ in 15ml falcon tubes 
2.10. PV titration  
฀T฀i฀t฀r฀a฀t฀i฀o฀n฀ ฀e฀x฀p฀e฀r฀i฀m฀e฀n฀t฀s฀ ฀w฀e฀r฀e฀ ฀c฀a฀r฀r฀i฀e฀d฀ ฀o฀u฀t฀ ฀i฀n฀ ฀N฀u฀n฀c฀™฀ ฀F฀9฀6฀ ฀Mi฀c฀r฀o฀W e l l฀™  w฀h฀i฀t฀e฀ p฀o฀l฀y฀s฀t y r e n฀e  
plates (Thermo Fisher Scientific, cat. # 136101), with media prepared using reagent reservoirs 
(Corning®, cat. # 4870, or Dutscher Scientific, cat. # 006793) and 8 or 12-channel pipettes 
(PZ HTL, cat. # 5123 and 5127) to perform dilutions. The PV titre was then determined via 
transduction of the target cell line of interest with 2-fold serial dilutions of neat PV supernatants 
performed in a total mixing volume of 100 µl, discarding 50 µl from the final dilution stage. 
Following this, a cell suspension was added to each well (details below).  
The cell suspension prepared to be added to the titration plates were taken from either a plate 
or flask of confluent target cells.  This vessel was washed with 1.5 ml of Trypsin-EDTA solution 
before 2 ml of fresh trypsin was added, and the vessel was incubated at 37°C 5% CO 2 until 
complete cell detachment; after this 4ml of 10% FBS-DMEM was added to quench and 
resuspend the cells for counting using an IC20 BioRad cell counter (BioRad cat. #145-0101). 
The cell suspension was then diluted to a concentration of 1X104 cells/50 µl suspension with 
10% FBS-DMEM, and from this suspension, 50 µl (1X104 cells) were added to each well of 
the plate that was then incubated at 37°C 5% CO 2 to allow PV transduction of cells and 
expression of the desired reporter gene. 
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The commonly used firefly luciferase reporter gene was evaluated using the Bright-฀G฀l฀o฀™฀ 
assay system (Promega, cat. # E2650,) and GloMax Multi detection system luminometer 
(Promega, cat. # E7041) and quantified after 48 h by luminometry. In this protocol 50 µl of 
Bright-฀G฀l฀o฀™฀ ฀L฀u฀c฀i฀f฀e฀r฀a฀s฀e฀ ฀A฀s฀s฀a฀y฀ ฀S฀y฀s฀t฀e฀m฀ ฀s฀o฀l฀u฀t฀i฀o฀n฀ ฀w฀a฀s฀ ฀a฀d฀d฀e฀d฀ ฀t฀o฀ ฀e฀ach well and, af er incubation 
for 5 min at RT, the plate was read using the standard Bright-฀G฀l฀o฀™฀ ฀p฀r฀o฀t฀o฀c฀o฀l฀ ฀p฀r฀e-installed on 
the luminometer. However, this protocol was found to be wasteful, and it was quickly 
determined that 25ul of Bright-฀G฀l฀o฀™฀ ฀L฀u฀c฀i฀f฀e฀r฀a฀s฀e฀ ฀A฀ssay System solution would yield simailr 
results and this was eventually reduced to 12.5ul of solution mixed with 12.5 ul of DMEM 
฀g฀r฀o฀w฀t฀h฀ ฀m฀e฀d฀i฀a฀.฀ ฀I฀n฀ ฀t฀h฀i฀s฀ ฀u฀p฀d฀a฀t฀e฀d฀ ฀p฀r฀o฀t฀o฀c฀o฀l฀ ฀a฀ ฀V฀a฀c฀u฀s฀i฀p฀™฀ ฀(฀I฀N฀T฀E฀G฀R฀A  ฀c฀a t฀.฀ #฀ 159000) is first used to 
remove media present in the wells taking care not to disturb the cell layer. The Bright-฀G฀l฀o฀™฀ 
Luciferase Assay System solution is then mixed with DMEM growth media in a reservoir in a 
1:1 ratio, 25ul of this mixture is then added to each well, and the plate is centrifuged in an 
ELMI CM-6MT Centrifuge at 500 rpm for 1 min to ensure that all cellular material is moved 
towards the solution at the bottom of the well. The plate is then quantified after by luminometry 
as per the standard protocol.  
Using Microsoft® Excel 2011 (Microsoft®) each relative luminescence unit (RLU) value 
obtained at a different PV dilution stages were transformed into RLU/ml; the arithmetic mean 
of these concentrations was considered as the PV titre (expressed as RLU/ml). Titres were 
also displayed graphically using GraphPad Prism® version 7.02 (GraphPad Software) and 
were possible the standard error of the mean (SEM) was calculated. 
2.11 PV  micro-neutralization assay 
The PV based neutralization assay (pv-฀N฀T฀Ψ฀ ฀w฀a฀s฀ ฀c฀a฀r฀r฀i฀e฀d฀ ฀o฀u฀t฀ ฀i฀n฀ ฀t฀h฀e฀ ฀s฀a฀m฀e฀ ฀N฀u฀n฀c฀™฀ ฀F฀9฀6฀ 
฀M฀i฀c฀r฀o฀W฀e฀l฀l฀™฀ ฀w฀h฀i฀t฀e฀ ฀p฀o฀l฀y฀s฀t฀y฀r฀e฀ne plates and using the same reagent reservoirs as the titration; 
human sera used in these experiments was always handled using 200 µl MultiGuard NX 
Barrier tips (Sorenson BioScience, cat. # 30550T), 20 µl MultiGuard Barrier tips (Sorenson 
BioScience, cat. # 35220), or 10 µl MultiGuard E Barrier tips (Sorenson BioScience, cat. # 
15020T) and dilutions were performed using 8 or 12-channel pipettes. For the pv-NT, the 
following protocol was used  
1. 2-fold serial dilutions of (in general) 5 µl serum samples and both positive and 
negative controls were performed in a total mixing volume of 100 µl with 50 µl 
from the final dilution step discarded 
2. The plate was centrifuged for 1 min at 500 g using an ELMI CM-6MT Centrifuge  
3. 50 µl of a PV solution with a previously calculated concentration based on ex-
pected RLU values added to each well 
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4. Either four or eight wells were designated as viral input control, in which no 
sera was present, but the same viral volume added as to other wells  
5. An additional four or eight wells were designated as cell only, and no antibody 
or virus was added to these wells.  
6. The plate was centrifuged for 1 min at 500 g  
7. The plate was then incubated for 1h at 37°C 5% CO 2.  
8. After incubation 1X104 of the designated target cells were added, prepared as 
described in the previous section 
9. The plate is then incubated at 37°C 5% CO 2 for 48 h   
10. The plate is then read as per the previous section concerning titration 
Data analysis was performed using Microsoft® Excel 2011 and GraphPad Prism® version 
7.02  (GraphPad Software). To measure neutralization activity, RLU results were first 
normalized and expressed as the percentage of neutralization (inhibition of PV entry into cells 
as indicated by a reduction in luminescence) using the arithmetic mean of the RLU values of 
viral input control and of the cell control as 0% and 100% neutralization values respectively. 
The 50% inhibitory concentration (IC50), as expressed as the dilution factor in which the 
sample shows 50% neutralization activity, was calculated using a non-linear regression 
฀m฀e฀t฀h฀o฀d฀ ฀(฀G฀r฀a฀p฀h฀P฀a฀d฀ ฀P฀r฀i฀s฀m฀®฀ ฀“฀l฀o฀g฀a฀r฀i฀t฀h฀m฀ ฀o฀f฀ ฀i฀n฀h฀i฀b฀i฀t฀o฀r฀ ฀v฀e฀r฀s฀u฀s฀ ฀n฀o r฀m a฀l฀i z e d  ฀r฀e฀s p n฀s฀e฀ ฀– variable 
฀s฀l฀o฀p฀e฀”฀Ψ฀ ฀i฀n฀ ฀w฀h฀i฀c฀h฀ ฀t฀h฀e฀ ฀e฀q฀u฀a฀t฀i฀o฀n฀ ฀c฀o฀r฀r฀e฀s฀p฀o฀n฀d฀i฀n฀g฀ ฀t฀o฀ ฀t฀h฀e฀ ฀s฀l฀o฀p฀e฀ ฀v฀a฀r i a b฀l e  w฀a฀s฀ ฀c฀o฀n฀s฀t r a฀i n e d฀ ฀t o฀ ฀b฀e฀ ฀l฀e฀s฀s  




Immunofluorescence was performed in a limited number of instances in this study and 
was primarily used to evaluate the expression of receptors in the target cells and to investigate 
the localization of the chimeric HA proteins post transfection in to HEK293T/17cells. In all 
cases, the cells to be transfected were seeded in a 9-well plate within which a poly-lysine 
coated glass coverslip (VitroCam, cat. # 1290-P01) had been positioned under 1 ml of 10% 
FBS-DMEM.  
This plate was incubated overnight at 37°C 5% CO 2 to allow cells to become adherent. 
After this 200-400ng of the plasmid expressing the gene of interest were transfected using 4.5 
µl of the 1 mg/ml PEI solution following a protocol similar to the one described in Section 2.9. 
for PV production but with OptiMEM® I volumes reduced to 75 µL in each DNA and PEI 
microtube. After 24 h, medium was changed with 1 ml of fresh 10% FBS-DMEM. 48 h post-
transfection media was removed, and the cells were washed with PBS (Sigma-Aldrich, cat. # 
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D8537). The cells were then fixed and permeabilised for 10 min using 1 ml of methanol 
(Sigma-Aldrich, cat. # 32213) that had previously been stored overnight at -20°C. 
These fixed cells were maintained at 4°C overnight before staining was carried out. C ontrols 
of non-transfected cells were also kept under similar conditions and were exposed to the same 
antibodies for use as negative controls. After overnight incubation, the cells were washed 
using PBS, and then 200 µl of solutions containing the primary antibody was incubated with 
the cells for 1 h at 37°C. At the end of the incubation, cells were w ashed with 1 ml of PBS five 
times: with the initial wash for 1 min, the successive washes for 3 min each. Subsequently, 
400 µl of a secondary antibody solution was incubated for 1 h at 37°C. Cells were washed 
again using the previously described washing protocol, and then incubated for 20 min at RT 
with 500 µl of 1 drop/ml NucBlue® Live ReadyProbes® reagent (Molecular Probes®, cat. # 
R37605) in PBS to permit nuclear staining with a Hoechst 33342. Cells were again washed 
with PBS for 5 min immediately prior to the mounting of coverslips using an RT Mowiol® 
solution. These slides were then imaged using an epifluorescence microscope Eclipse 50i 
(Nikon) with a charge-coupled device digital camera QICAM Fast 1394 (QImaging).  
2.13. Viral phylogeny and selection analysis 
Virus sequences were retrieved from the NCBI GenBank database, and a complete 
list of the downloaded accession numbers is provided in the corresponding chapters. Studies 
have demonstrated that errors in an inferred multiple sequence alignment (MSA) can be 
common when divergent sequences are analysed, and these errors can inflate estimates of 
positive selection acting on the genes of interest. In an effort to circumvent this difficulty 
GUIDANCE2 (Privman, Penn and Pupko, 2012) was used for filtering unreliably aligned 
codons (i.e. codons that had and an alignment score of < 0.90) were masked for subsequent 
analysis (Privman, Penn and Pupko, 2012). Alignments were carried out initially with MEGA 
7.02 and the MUSCLE algorithm. However alignments for the final input into the selection 
analysis software were realigned using Probabilistic Alignment Kit (PRANK) (Fletcher and 
Yang, 2010).  
PRANK is a probabilistic multiple alignment programs that can be used to align 
nucleotide, codon and amino-acid sequences. PRANK is based on a novel algorithm that 
treats insertions and deletions as distinct entities and thus can avoid the common alignment 
problem of assigning multiple penalties to single deletion event (Löytynoja and Goldman, 
2005). This trait, in theory, means that the PRANK algorithm will create a more evolutionarily 
correct alignment, as selection analysis is fundamentally a study of the evolutionary patterns 
at work on a sequence this factor may be crucial to improving analysis results. 
 83 
 
2.13.1. Selection analysis 
To test for positive selection in individual codons of the viral glycol proteins of interest 
in this study, the ratio of Non-synonymous(dN) to synonymous (dS) changes were compared 
using several distinct methods. The analysis was implemented using the Datamonkey (Pond 
and Frost, 2005; Delport et al., 2010) webserver to apply a number of different algorithms to 
the datasets.  The use of Datamonkey has several advantages over other methods for 
detection of selection, i.e. PAML (Yang, 1997, 2007), the most significant of which for this 
study is that complex model are quickly fitted using the remote servers on which the tools run. 
This allows an analysis that would otherwise take hours or days to run on a conventional PC 
to be completed in minutes (Pond and Frost, 2005). The Datamonkey tools require an MSA 
and an initial phylogenetic reconstruction or in the case that recombination has occurred in 
the dataset, multiple phylogenetic trees (one for each non-recombinant segment). To avoid 
frameshift errors etc. the sequence alignment was conducted on translated protein 
sequences, and then back translated in nucleotides. This MSA was then used to perform an 
initial phylogenetic reconstruction to form the frame work for comparison of selective pressure 
within the MSA when the observed phylogeny inferred from available sequence data did not 
match published phylogenetic information the tree was manually edited to reflect the most 
recent and robust phylogeny prior to selective analysis. 
Due to the well-known difficulties in performing this form of analysis in the presence of 
recombination (Fletcher and Yang, 2010; Brieuc and Naish, 2011) all MSA datasets were pre-
screened for the presence of recombination using the genetic algorithm for recombination 
detection (GARD) tool in the Datamonkey web based selection detection tools (Delport et al., 
2010). Recombination, in general, has a minor impact on estimates of global dN/dS rates but 
can have a profound effect on estimates of site-to-site and branch-to-branch variation in 
selection pressure. To perform selection analysis in the presence of recombination in a 
phylogenetic reconstruction, it is necessary to split the alignment into non-recombinant 
sequence fragments first. The GARD algorithm uses a genetic algorithm to identify 
breakpoints in an MSA that separates non-recombinant fragments. Once these separate non-
recombinant fragments have been identified, selection analyses was run separately on each 
fragment.  
After analysis looking for evidence of recombination in the assembled MSA, several 
algorithms were implemented to search for sites under positive selection. internal fixed effects 
likelihood (IFEL) uses the entire alignment to infer model parameters shared by all sites (e.g., 
branch lengths) and then fits dS and dN rates individually at every site. Neutrality of an 
individual site is tested using the likelihood ratio test. This method is useful for inferring 
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selective pressure that is acting on internal branches of the phylogeny being tested (Delport 
et al., 2010) 
 The Single likelihood ancestor counting (SLAC), the SLAC analysis involves a 
maximum likelihood reconstruction of ancestral codon states using a phylogenetic tree input 
together with the MSA.  This is then compared to the observed ratio of nonsynonymous and 
synonymous substitutions with the approximate estimate of the expected ratio assuming 
neutral evolution (Kosakovsky Pond and Frost, 2005; Sorhannus and Kosakovsky Pond, 
2006). Therefore, if the algorithm counts more nonsynonymous mutations than synonymous 
it can be expected that the selective pressure acting on the gene/domain is not adequately 
explained by the neutral model of evolution. For SLAC, analysis sites identified with a p value 
> 0.2 were considered under positive selection.  
Internal fixed effect likelihood (IFEL), In the IFEL analysis, every codon is assigned a 
single rate of synonymous substitution and two nonsynonymous rates. These two 
nonsynonymous rates are assigned to account for differences in potential codon selection that 
is driven as the codon evolves along a terminal branch (i.e. usually indicating recent bouts of 
evolutionary pressure) and the potentially different rate of evolution of the codon for internal 
branches (i.e. episodic or historical evolution) . This manner of testing has been demonstrated 
to be effective in cases were strong diversifying selection is in effect, and so codons are likely 
to be highly divergent (Kosakovsky Pond, Frost, et al., 2006). For the IFEL algorithm sites with 
a significance level of 0.1 were considered under positive selection. 
Fast Unconstrained Bayesian Approximation for Inferring Selection (FUBAR), is a 
hierarchical Bayesian method that makes extensive use of a Markov chain Monte Carlo 
(MCMC) algorithm to return robust results even in cases were the fitted model is a poor fit for 
the data. This is achieved by averaging over a large number of predefined site classes. This 
differs from the SLAC and IFELmethods  which both use a small number of discrete categories 
which are combined with probability distributions to estimate the likelihood of selective 
pressure acting on a region/site. By employing a large number of categories, the FUBAR 
algorithm does not require a re-assessment and re-sorting of the maximum likelihood function 
of the dataset. In effect, this means that the a-priori categories of the FUBAR algorithm deliver 
much faster analysis when compared the maximum likelihood approaches of the SLAC or 
IFEL (Murrell et al., 2013). 
For FUBAR analysis sites with a posterior probability of positive selection > 0.8 were 
taken as under positive selective pressure.   
 85 
 
The MEME algorithm allows the distribution of dN/dS to vary from site to site (the fixed 
effect) and also from branch to branch at a specific site (the random effect) (Murrell et al., 
2012).  This method uses phylogenetic models to describe the evolution of codon characters 
along a given branch of a phylogenetic tree by a continuous-time stationary Markov process. 
For MEME analysis codon-specific positive selection was admitted at p-value < 0.1, and the 
inference of the lineages in which diversifying selection occurred at a given codon was 
performed using a Bayes empirical Bayes approach. Codons in which the Bayes factor was 
greater than 1 were considered as targets of episodic diversifying selection.  
For GARD, MEME, IFEL, Fubar and SLAC the best fit nucleotide substitution models 
















Chapter 3 Coronavirus PV Production and Optimisation of MERS-
CoV PV Production Protcol 
3.1. Introduction 
This chapter outlines the protocols and procedures adapted and tested during the 
optimisation of production of the PV-expressing the spike protein the MERS coronavirus and 
the SARS coronavirus 
As the cell entry processes in coronaviruses are primarily dependent on the activity of 
the S protein (Chapter 1), coronaviruses are well suited to study within the framework of viral 
pseudotyping. The use of PV incorporating MERS-CoV has made significant contributions to 
research conducted during this ongoing viral outbreak. The first published accounts of 
successful MERS-CoV PV  production were produced by Zhao et. al. (2013) and this study 
used PV to investigate HIV entry inhibitors for their inhibitory activity on MERS-CoV (Du, Kou, 
et al., 2013; Zhao et al., 2013). The study also identified specific cell lines derived from human 
liver and mink lungs that were susceptible to the MERS-CoV PV and therefore critical tools to 
make use of PV for further research. The screening conducted during that study identified 
potential inhibition of MERS-CoV by the compounds ADS-J1, a small inhibitor targeting the 
HIV glycoprotein 41 (gp41) (Zhao et al., 2013) and the 3-hydroxyphthalic anhydride-modified 
human serum albumin (HP-HAS).  Both of these compounds have been previously determined 
to target the HIV-1 glycoprotein 120 (gp120) and the HIV-1 receptor, CD4 and in the case of 
the MERS-CoV PV particle both molecules were found to significantly inhibit infection of 
susceptible cell lines by a MERS-CoV PV (Kido et al., 1996; Zhao et al., 2013).  Although 
further studies are still ongoing to determine the effectiveness of these compounds in vivo, this 
study provides an effective demonstration of the role PV can play as part of the research 
response to viral outbreaks.  
The significant role that PV can play in preparedness for, and prediction of, future 
outbreaks can be characterised by the use of viral PV particles in the ongoing research into 
the evolutionary patterns of coronaviruses. Phylogenetic studies strongly suggest that there 
have been three interspecies spillover events of zoonotic beta-CoVs to humans and two of 
these are very clearly linked to bats (Gouilh et al., 2011; Li et al., 2011; Jc et al., 2014; Wang 
et al., 2014; Han et al., 2015). These viruses are believed to have been circulating in bats 
before a species jump occurred, that resulted in infection of an intermediate host (likely civets 
for SARS-CoV and dromedary camels for MERS-CoV), before the viruses became zoonotic 
and began to infect human hosts (Josset et al., 2013; Cotten, Watson and Zumla, 2014; 
Haagmans et al., 2014; White, 2014; Forni et al., 2015). Research using PVs has 
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demonstrated that the Bat-CoV HKU4 circulates freely in Middle Eastern bats (Wang et al., 
2014) and that this virus uses the same receptor as MERS-CoV (Wang et al., 2014; Yang et 
al., 2014). Wang et. al. (2014) also demonstrated that mutations introduced into the HKU4 S 
protein within the PV system to alter the tropism of viral vectors could be used to create a 
highly effective model for viral evolution (Wang et al., 2014). An earlier study by Ren et.al. 
(2006) also employed PV to demonstrate that species specificity of the SARS-CoV infection 
was dependent on species-specific variation in the ACE2 receptor (Li et al., 2005; Ren et al., 
2006).  
Studies on inhibition and viral cell entry are often subject to variation driven by a range 
of factors. As assays investigating the inhibition or neutralisation of viruses depends on the 
measurable reduction in viral activity as assay results, it is essential that PV used in such 
assays can be produced in a consistent manner. The production of PV for a virus such as 
MERS-CoV using an optimised protocol that generates consistently high viral titres is essential 
if PV is to continue to be valuable tool for use in research (Balasuriya et al., 1997; Sanders, 
2002; Temperton et al., 2005; Zhou et al., 2011; Tang et al., 2012; Perera et al., 2013; 
Verschoor et al., 2015). 
3.1.1 Differential cell line susceptibility to CoV PV transduction  
As obligate cellular parasites, it is vital to determine which cell types are susceptible to 
infection with a virus before most research begin. As such, determining an appropriate cell 
line for MERS-CoV transduction is an essential first step in the production process and must 
be conducted prior to any further optimisation of the process. MERS-CoV has been shown to 
replicate successfully in cells of the lower respiratory tract, while cells from the upper 
respiratory tract did not support viral replication (Hoffmann et al., 2013). In addition, previous 
research making use of viral PV particles (Zhao et al., 2013) has demonstrated that a range 
of cell lines available in the lab are susceptible to MERS-CoV infection/transduction.  A number 
of additional studies have also confirmed that the target of MERS-CoV in the respiratory tract 
was the non-ciliated cells of the epithelium, in contrast to the majority of the other respiratory 
viruses, which mainly infect the ciliated cells-, and type II pneumocytes of the lung tissue (R. 
W. Y. Chan et al., 2013; Raj et al., 2013). SARS-CoV is known to replicate in cells of both the 
upper and lower respiratory tract. This difference in virus tropism has significant implications 
for the spread of the disease with MERS-CoV seemingly unable to infect the relatively easily 
accessible cells of the upper respiratory tract. Although Zhao et. al. (2013) (Zhao et al., 2013) 
identified a number of cell lines that were susceptible to MERS-CoV PV this chapter will 
attempt to both confirm the results of this study and identify other potential cell lines that may 
be susceptible and thus available for use in further research.  
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3.1.2. PV production methods 
PV production was carried out with a general protocol as outlined in Chapter 2. 
However, this protocol was modified in a number of ways in order to optimise the production 
process and produce high titre PV. Any transfection protocol requires an optimisation process, 
there is a significant degree of variability in the transfection conditions that work for different 
virus envelopes, in particular, discerning the concentration of envelope expression plasmid 
that is required, is an essential first step. There are a wide variety of different transfection 
methods currently in widespread use and utilising a number of commercially available 
transfection reagents and techniques (Nefkens et al., 2007; Carnell et al., 2015). Although 
there is variation in the precise mechanism through which different transfection reagents 
facilitate transfection the different reagents generally fall into a small number of categories:  
1) Cationic polymers  
2) Calcium phosphate 
3) Cationic lipid 
Chemical reagents that fall into these categories have been developed and optimised 
by a range of companies with, generally, proprietary formulations to improve efficacy and ease 
of use (Yamano, Dai and Moursi, 2010). Although significant variation does exist in the 
mechanism that these materials use to transfect cells, in general, they all induce cellular 
uptake of DNA through complexing of nucleic acids and generating positively charged particles 
which then bind to the negatively charged cell membrane.  Cell entry is then facilitated by 
spontaneous endocytosis, and with most commercially available reagents cytotoxicity is 
negligible (Yamano et al. 2010). For any transfection method, the efficiency of genetic material 
uptake is dependent upon the cell type, health and phase of growth, the size of the genetic 
material to be transfected and medium conditions including temperature and pH (Jordan, 
Schallhorn and Wurm, 1996; Kim and Eberwine, 2010). For this study PEI and ฀F฀u฀g฀e฀n฀e฀ ฀6฀™฀ 
were used to facilitate transfection, in attempts to optimise the production process.  
Viral envelope concentration is poorly understood factor in the production of PV, 
however the ratio of viral envelope to viral GAG core and reporter gene appears to interact 
with the transfection reagent to play a significant role in the final PV yield (Wool-lewis and 
Bates, 1998; Jordan and Wurm, 2004; Claus and Klaus, 2006; Hu et al., 2007; Carnell et al., 
2015). It is, therefore, essential that a range of different envelope concentrations be compared 
in with each transfection reagent to optimise the yield derived. As both transfection reagents 
used in this study have previously been shown to work equally well with similar ratios of 
expression plasmids only the viral envelope was varied as previous work demonstrated that a 
number of viruses yield optimal results with a set concentration of viral GAG and reporter gene 
(Scott et al., 2012; Ferrara et al., 2013; Molesti, Ferrara, et al., 2014; Carnell et al., 2015).  
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3.1.3. Protease and MERS-CoV PV 
Previous coronavirus PV production methods have suggested that the overexpression 
of specific proteases are likely required for efficient production of mature coronavirus PV 
(Follis, York and Nunberg, 2006; Glowacka et al., 2011). Although a number of proteases are 
expressed in the cell line HEK293T/17, it may be necessary to induce expression of additional 
proteases through co-transfection of a protease containing expression plasmid. This protocol 
has been widely used in the production of PV for influenza viruses and other viruses that 
require specific proteases to mediate viral maturation (Wang et al., 2008; Ferrara et al., 2013).  
As with many other viral families, coronavirus maturation is dependent upon the activity of a 
specific set of proteases that recognise and cleave the S protein in order allow protein refolding 
into the mature state that allows cell entry (Shulla et al., 2011). Determining the factors that 
mediate the maturation of the coronavirus S protein is crucial in order to gain any 
understanding of the pathogenesis, epidemiology, and tropism of these viruses. Previous 
studies making use of PV have demonstrated the necessity of proteases such as 
Transmembrane protease, serine 2 for the production of certain  PV (Böttcher et al., 2006; 
Ferrara et al., 2013) (Chapter 1 Introduction). TMPRSS2 or similar proteases are required in 
order to facilitate cleavage and subsequent activation of hemagglutinin of Group-2 human 
influenza and low pathogenicity avian influenza (LPAI) virus strains (Böttcher et al., 2006; 
Böttcher-Friebertshäuser, Klenk and Garten, 2013). In the case of the MERS-CoV the virus 
may utilize host proteases for virus entry into lung cells (Shirato et al., 2013) either through 
cleavage in the cell surface as has been demonstrated with the TMPRSS2 protease, or 
through the action of cathepsin L within the cell endosome, to facilitate spike protein cleavage 
(Shirato et al., 2013).  
MERS-CoV reportedly enters cells by a cathepsin-mediated endosomal pathway 
(Section 1.3.1). However, the presence of proteases on the cell surface may also facilitate 
MERS-CoV entry, and this may allow cathepsin independent infection of cells (Gierer et al., 
2013; Simmons et al., 2013; El Najjar et al., 2015).  The precise mechanism of the responsible 
proteolytic activity and the true biological relevance of cleavage has not as yet been fully 
studied. Gierer et. al. (2013) demonstrated that TMPRSS2 could be used to generate 
maturation and subsequent cathepsin B/L-independent entry of the MERS-CoV (Gierer et al., 
2013). The activation of MERS-CoV by TMPRSS2 in transfected cells raised the question of 
which of the possible S protein maturation pathway is dominant in target cells which are 
susceptible to MERS-CoV mediated transduction. In order to further investigate the role of 
proteases the same protease expressing plasmids transfected during the PV production 
process were transfected into cells targeted for transduction. Millet et. al. (2015) determined 
coronaviruses can enter cells via fusion either directly at the cell surface or can be internalised 
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through the endosomal compartment (Millet and Whittaker, 2015). This was further elucidated 
by Yang et. al. (2014) in a study of cross-species transmissibility of bat coronavirus HKU4, 
which is the most closely related virus to MERS-CoV, and determined that human cellular 
proteases act at different stages of MERS-CoV-spike-mediated cell entry (Yang et al., 2015). 
These studies determined that viral entry could be facilitated via several protease-dependent 
actions human endogenous proteases (e.g. proprotein convertases) can act during virus 
packaging and release, human TMPRSS2 can act during viral attachment to the cell surface, 
and human endosomal cathepsins can act during viral endocytosis. In contrast to the intrinsic 
proteases, exogenous proteases contribute to but were determined to not be essential for, 
MERS-CoV entry into human cells that exogenously expressed DPP-4. Although MERS-CoV 
spike protein is cleaved in transfected cells and is then incorporated into virions, further 
processing by host cell proteases during viral entry may be required or may enhance 
infectivity, in the current study this hypothesis was investigated by the co-transfection of 
protease expression plasmids at differing concentrations during the production stage. In 
addition, in order to investigate the potential for post binding cleavage with cell protease target 
cells were further transfected with protease expression plasmid in order to induce enhanced 
expression of protease in these cells and thereby investigate the potential for this mode of 
entry to be enhanced. As host cell protease expression is well known to be a critical 
determinant of coronavirus tropism (Qian, Dominguez and Holmes, 2013; Millet and Whittaker, 
2015), these experiments offer insights into the potential significance  different proteases play 
in mediating coronavirus expression  
3.1.4. The use of different viral cores in the production of corona PV 
Previous studies have demonstrated the utility of incorporating different viral cores to 
improve final PV titre (Liu, Halbert and Miller, 2004; Temperton et al., 2005; Provine et al., 
2009). In particular, previous studies of pseudotyping coronaviruses have made extensive use 
of murine leukaemia virus (MLV) viral cores (Yang et al., 2004; Temperton et al., 2005; Ratia 
et al., 2014). Consequently, transfections were carried out with the MLV core in parallel with 
the lentiviral (HIV) core and results were compared. 
3.1.5 The role of serum variation in the production of PV 
Growth media used in cell culture is composed of commercially available DMEM, 
antibiotic and serum which provides a nutrient source for growing cells. Although the presence 
of serum provides optimal conditions for cell growth, it is also a complex mix of proteins with 
a highly variable composition and so may represent an important and undesirable confounding 
factor in experiments (Pirkmajer and Chibalin, 2011). In addition, some studies have shown 
that transfection efficiency may be reduced by the presence of serum (Wallenstein et al., 
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2010). Although the specific mechanisms through which the serum interacts with the 
transfection process are unclear, it is likely that the presence of serum reduces basal cellular 
activity. As serum has been shown to affect colony stimulating factor-1 expression in Astrocyte 
cells (Codeluppi et al., 2011) and serum starvation has been demonstrated to result in 
upregulation of several transcription pathways (Levin et al., 2010). Furthermore given the 
importance that cell proliferation plays in the efficient transfection of eukaryotic cells (Jordan 
and Wurm, 2004; Invitrogen, 2015) control of the concentration of serum may enable greater 
degrees of control over the phase of cell growth that predominates in a cell culture during 
transfection. Transfection has been demonstrated to be most efficient when the transfected 
cells are at the S growth phase (Jordan and Wurm, 2004) this is because cells that are at this 
phase when transfected will incorporate the transfected DNA into their nucleus during their 
next cycle of mitosis. 
3.2. Materials and methods 
3.2.1. Plasmids origin and sub-cloning 
A codon optimised gene expressing full-length S protein of MERS-CoV (AFS88936.1) 
(Boheemen, Graaf, Lauber, Theo M. Bestebroer, et al., 2012), was kindly provided by Dr 
Davide Corti (Humabs, Biomed). Codon optimised SARS-CoV (Urbani strain) was a kind gift 
from Dr Graham Simmons (University of California).  As previous attempts to produce viral PV 
particles making use of the available MERS-CoV plasmids had failed the MERS-CoV spike 
was sub-cloned from the phCMV vector to the pCAGGS vector.  Sub-cloning was carried out 
as outlined in Section 2.8. with restriction enzyme sites identified from the sequence data 
฀u฀s฀i฀n฀g฀ ฀D฀N฀A฀D฀y฀n฀a฀m฀o฀™฀ ฀v฀e฀r฀s฀i฀o฀n฀ ฀1฀.฀4฀6฀9฀.฀ D i฀g฀e฀s฀t฀i o n฀s฀ ฀w฀e฀r฀e฀ ฀p฀e฀r฀f฀o฀r฀m฀e฀d฀ ฀u฀s฀i฀n฀g฀ ฀F฀a฀s฀t฀D฀i฀g฀e฀s฀t฀™฀ ฀e฀n฀z฀y฀m฀e฀s฀ 
(Thermo Fisher Scientific) with 400-700 ng of plasmid DNA digested in a total volume of 20 µl 
฀f฀o฀r฀ ฀e฀a฀c฀h฀ ฀d฀o฀u฀b฀l฀e฀ ฀d฀i฀g฀e฀s฀t฀i฀o฀n฀.฀ ฀T฀h฀e฀ ฀u฀n฀i฀v฀e฀r฀s฀a฀l฀ ฀F฀a฀s฀t฀D฀i฀g฀e฀s฀t฀™฀ ฀b฀u฀ff e฀r  ( T h e r m฀o฀ F฀i฀s h฀e฀r฀ ฀S฀c฀i฀e฀n฀t i f i฀c฀,฀ ฀c a฀t .  ฀n฀°฀ 
B72) and 10 U of FastDigest® enzymes were used as per Section 2.8.3. Digestion reactions 
were then incubated at 37°C for 20 minutes using Mastercycler ep Gradient S therm ocycler, 
and subsequently, the digestion products were purified using gel electrophoresis and the 
Qiagen Gel Extraction Kit (Section 2.8.2). Post extraction DNA purity and concentration were 
assessed using a ฀N฀a฀n฀o฀D฀r฀o฀p฀™฀ ฀2฀0฀0฀0฀ ฀S฀p฀e฀c฀t฀r฀o฀p฀h฀o฀t฀o฀m฀e฀t฀e฀r (Section 2.3.1.) 
After the gel extraction step, the DNA ligation was performed, and the ligation product was 
฀t฀r฀a฀n฀s฀f฀o฀r฀m฀e฀d฀ ฀i฀n฀t฀o฀ ฀D฀H฀5Į฀ ฀c฀e฀l฀l฀s฀ ฀f฀o฀l฀l฀o฀w฀i฀n฀g฀ ฀t฀h฀e฀ ฀p฀r฀o฀t฀o฀c฀o฀l฀ ฀a฀s฀ ฀o฀u฀t฀l i n e฀d฀ ฀i฀n฀ ฀C฀h฀a p t฀e r  ฀2฀.฀  
3.2.2 Cell culture and cell lines 
Huh-7, BHK, Caco-2, 293T, ACE2/293T/17, MDCK, Vero, QT6 and DPP-
4/HEK293T/17฀c฀e฀l฀l฀s฀ ฀w฀e฀r฀e฀ ฀a฀l฀l฀ ฀u฀s฀e฀d฀ ฀a฀s฀ ฀“฀t฀a฀r฀g฀e฀t฀”฀ ฀c฀e฀l฀l฀s฀ ฀f฀o฀r฀ ฀i฀n฀f฀e฀c฀t฀i฀o฀n฀ ฀i฀n฀ ฀o฀r฀d฀e฀r฀ t o฀ d฀e฀t฀e฀r m฀i฀n฀e฀ ฀t฀h e  p฀t฀i฀m฀a฀l฀ 
cell line for use in further study of MERS-CoV and SARS-CoV. All cell lines were maintained 
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in DMEM supplemented with10% FBS and 1% penicillin-streptomycin and cell maintenance 
was carried out as per Section 2.7.  
3.2.3. PV production methods 
PV production was carried out with a protocol as outlined in Chapter 2. However, a 
number of modifications were carried out there including modification of the envelope 
expressing plasmid concentration, the addition of various protease expression plasmids at 
differing concentrations and alteration of the conditions in which the cells were grown through 
changes in the serum concentration.  
PV produced bearing a Vesicular Stomatitis Virus glycoprotein (VSV-G) was used as 
a positive control in assays of PV production. VSV-G PV is particularly suited to this task as 
the broad tropism of VSV means that PV with the VSV-G is capable of transducing a large 
number of cell lines (Hastie et al., 2013).  
3.2.3.1. Optimisation of MERS-CoV Spike protein expressing plasmid concentration 
To test the variation in yield of PV that is attributable to the concentration of envelope 
expression plasmid concentrations of between 200ng and 1200ng were added and the 
protocol described in chapter 2 adapted to a 35mm cell culture plate. Plasmids were combined 
in 100µl Opti-MEM® for PEI transfection and in molecular grade water for transfection with 
฀F฀u฀g฀e฀n฀e฀ ฀6฀™฀. 
3.2.3.2. The role of serum variation in the production of PV 
Two distinct criteria were tested through the alteration of Serum content. A reduced serum 
concentration was used, cells were cultured 5% FBS for 48 hours prior to transfection. This 
experiment then followed the transfection protocol as outlined in Section 2.9 with the following 
exceptions: 
x 48 hours prior to transfection. HEK293T/17cells were subcultured into a 100mm petri 
dish.  
x Day of transfection. DMEM+5%FBS + 1%P/S was replaced 1 hour prior to transfection 
with DMEM+10%FBS + 1% P/S  
After these initial steps, the protocol was carried out as per section 2.9 with 900ng of pCAGGS-
MERS-CoV S added to 1000ng of p8.91 lentiviral core and 1500ng of luciferase reporter 
expression plasmid (pCSFLW).  
3.2.3.3. Effects of protease on the production and titration of PV  
Proteolytic  processing of the S protein is required in order produce mature S protein 
that can mediate cellular fusion (Millet and Whittaker, 2014). Several studies have now 
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demonstrated that MERS-CoV is capable of using different proteases to facilitate S protein 
maturation and subsequent cell entry (Section 1.4.3.) (Shirato et al., 2013; Simmons et al., 
2013). Recent studies have also determined that the tropism of MERS-CoV is determined by 
this protease action (Park et al., 2016). As MERS-CoV appears to be capable of making use 
of several proteases at different stages of its life cycle and at different locations within hosts 
cells (Park et al., 2016) (Section 1.4.3.), the effects of protease on production and use of PV 
must be better understood. The cellular localisation of the proteases has important 
implications for the processing of the S protein. MERS-CoV S protein can utilise proteases 
expressed in endosomal compartments, to facilitate S maturation during the protein synthesis, 
or the S protein can interact with proteases expressed on the plasma membrane, allowing 
activation to occur either during the latter stages of production or during viral entry (Böttcher-
Friebertshäuser, Klenk and Garten, 2013; Simmons et al., 2013; Zmora et al., 2014; Hoffmann 
et al., 2016). 
In order to further investigate the role of proteases in the production of MERS-CoV PV, 
protease expression plasmids were used to transfect cells that were subsequently employed 
as target cells for transduction.  
For both proteases expressed in the producer cells and protease expressed in target 
cells, ฀a฀ ฀‘฀n฀o฀ ฀p฀r฀o฀t฀e฀a฀s฀e฀’฀ ฀P฀V฀ ฀p฀r฀e฀p฀a฀r฀a฀t฀i฀o฀n฀ ฀w฀a฀s฀ ฀u฀s฀e฀d฀ ฀a฀s฀ ฀a฀ ฀c฀o฀n฀t฀r฀o฀l฀.฀ ฀N฀o฀ ฀p฀r o t e a฀s฀e฀ ฀c฀o฀r r e s p o n d฀s฀ t o a  
titration completed with no additional protease expression vectors added at any stage in the 
process. 
3.2.3.4 Use of different viral cores and alternate expression vectors 
To assess the potential of variation of the viral core used in PV production to affect 
efficiency, a murine leukaemia virus (MLV) viral core is a commonly used core in PV 
production (Chapter 1). In addition, the availability of multiple viral cores offers alternative 
research tools that may allow PV to be used in a wider variety of applications. Of particular 
importance is the potential for intrinsic cell restriction factors to inhibit the activity the 
lentiviruses (Besnier, Takeuchi and Towers, 2002; Ikeda et al., 2002), although the potential 
impact these factors have on PV use is not clear the availability of effective alternatives to 
lentiviral core PV offers a method to circumvent any limitations before they occur.  
3.3.6 Production consistency in the titre of PV  
A critical factor in determining the utility of a tool such as PV for research use is efficient 
and consistent production. In order to assess the consistency of the PV production, the 
protocol derived from the experiments described in this chapter was repeated with 
transfections labelled MERS-T194, MERS-T195, MERS-T196, MERS-T197 and MERS-T198. 
These transfections were carried out approximately 48 hours from each other with MERS-
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T194 being conducted first followed 48 hours later by MERS-T195, the remaining transfections 
were conducted sequentially following this pattern with a transfection every 48hours. 
Harvesting of the PV was conducted as per protocol outlined in Section 2.9.  All titrations were 
conducted using Huh-7 cells maintained in DMEM supplemented with 10% FBS and 1% 
penicillin-streptomycin, as target cells.  
3.3. Results 
3.3.1. Subcloning of MERS-CoV S protein 
The phCMV plasmid is cleaved before and after the MCS site by KpnI and NotI 
respectively (Figure 14) to release the S protein open reading frame (ORF) fragment. 
Following purification (Section 3.2.) this fragment was ligated (Section 2.8.4.) into these same 
sites in the linearised pCAGGS plasmid.   
 
Figure 14: phCMV construct with MCS site identified and restriction sites highlighted.  




Figure 15: Novel plasmid with the MERS-CoV S protein  
MERS-CoV was sub-cloned from the phCMV plasmid to the pCAGGS.plasmid. Figure produced using Plasmapper 
(Dong et al., 2004).  
3.3.2. MERS-CoV PV production 
3.3.2.1 Cell line susceptibility  
VSV-G positive control PV was found to be highly infectious in all tested cell types, 
(figure 16) most likely due to the broad host range of VSV-G which has the capability of 
infecting multiple tissues in various hosts. The delta envelope PV (Delta env-) negative control 
was unable to infect tested cell lines via specific receptor binding and gave consistently low 
results in all lines as indicated be the orange speckled bars, figure 16. Detection of DPP-4 
receptor expression in different cell lines has already been well documented (Zhao et al., 
2013), and Huh-7 is known to express this receptor ubiquitously. The results of these titrations 
indicated that Huh-7 cells are more susceptible to MERS-CoV than HEK293T/17cells that 
have been transfected with the DPP-4 receptor (figure 16). Based on these results the Huh-7 












































































































































































































293/D PP-4 2 9 3 T /1 7 H u h -7 Q T -6 V e ro CaCo BHK
P V  a n d  C e ll lin e s
M D C K
(T y p e 1 )
T ra n s d u c tio n  o f M E R S -C o V  P V
 
Figure 16: Cell tropism of MERS-CoV PV in a variety of target cells from human and non-human hosts.  
VSV-G and Delta Envelope pseudotyped virus were used as positive and negative controls, respectively. Data reported as mean 
relative luminescence units (RLU) per ml. 293/DPP-4 cells were transiently transfected 24 hours prior to assay. All PV production 
฀w฀a฀s฀ ฀c฀a฀r฀r฀i฀e฀d฀ ฀o฀u฀t฀ ฀u฀s฀i฀n฀g฀ ฀l฀e฀n฀t฀i฀v฀i฀r฀a฀l฀ ฀c฀o฀r฀e฀s฀ ฀a฀n฀d฀ ฀f฀u฀g฀e฀n฀e฀™฀ ฀t฀r฀a฀n฀f฀e฀c฀t฀i฀o฀n  r฀e a฀g฀e฀n฀t฀.    
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3.3.2.2. Effect of different plasmid vectors 
The Huh7 line was then used to assess whether pCAGGS or phCMV vectors resulted 































P la s m id s  E x p re s s in g  M E R S -C o V  S  p ro te in
M E R S -C o V  S  e x p re s s io n  p la s m id s  c o m p a ris io n
 
Figure 17: Comparison of different plasmid vectors yields produced when transduced into HEK293T/17cells transfected 
with the DPP-4.  
Figure displays yield based on serial dilution with eight data points with results multiplied to derive RLU per ML as per Section 
2.10.  
3.3.2.3. Variation of the MERS-CoV Spike expression plasmid concentration 
Production of PV bearing the MERS-CoV S was attempted with concentrations of 
pCAGGS-MERS-CoV ranging from 300ng to 1500ng (1.5µg) the concentration of p8.91 and 
pCSFLW remained the same for all transfections with 1000ng and 1500ng of each added 
respectively. Results of these titrations are shown in figure 18. As indicated in the figure there 
is a specific amount of MERS-CoV Spike gene that is required is order to ensure that the 


























































C o n c e n tra tio n  o f p C A G G S -M E R S -C o V  S
C o m p a r is io n  o f d if fe re n t M E R S -C o V  c o n c e n tra tio n s
 
Figure 18: Showing variation in the RLU values obtained of MERS-CoV PV produced using a variety of different MERS-
CoV spike pCAGGS containing plasmid concentrations.  
Data recorded as mean relative luciferase units (RLU) for 8 parallel wells in 96-well culture plates with 10,000 Huh-7 cells per 
well as target cells. Values for each concentration are calculated based on eight serial dilutions and processed to RLU per ML 
based on Section 2.10. 
 
The optimal concentration of pCAGGS MERS-CoV S expressing plasmid was 
identified as 0.9µg, although similar levels were observed with 0.8µg and 1µg. However, it 
was also observed that larger concentrations of plasmid yielded increasingly lower titrations 
with increasing concentrations seemingly have a suppressive effect on the RLU values.    
3.3.2.4. The role of protease in MERS-CoV PV production 
Protease expression plasmids were co-transfected with 900ng of pCAGGS MERS-
CoV, 1000ng of p8.91 (HIV-Gag) and 1500ng of pCSFLW (Firefly Luciferase Reporter). Three 
concentrations each of TMPRSS2, HAT and Furin were transfected, and results of 
transduction with PV produced in this way is recorded in Figure 19.  
To further investigate the role of proteases in the production of MERS-CoV PV, 
protease expression plasmids were used to transfect cells that were subsequently employed 



















































T M P R S S 2 H A T F u r in
P ro te a s e  e x p re s s io n  ve c to r  v o lu m e
P V  p ro d u c t io n  w ith  c o -tra n s fe c tio n  o f p ro te a s e
Figure 19: Showing variation in the PV titres (RLU/ml) obtained of MERS-CoV PV produced using co-transfection of 
protease. Expressing plasmids at varying concentrations. RLU per ML calculated as per Section 2.10. Huh-7 cells used as target 
cells. There was no statistical difference between different protease preparations as per ANOVA multiple comparisons testing in 
GraphPad 7.02. The no protease preparation showed significant difference to the remaining groups with the next highest value 

























































T M P R S S 2 H AT F u r in
P ro te a s e  c o n c e n tra tio n  tra n s fe c te d  in to  ta rg e t c e lls
4 8 h o u rs  p r io r  to  tra n s d u c t io n
P V  tra n s d u c tio n  in to  ta rg e t c e lls  tra n s fe c te d  w ith  p ro te a s e  e x p re s s io n
p la sm id s
 
Figure 20: Showing variation in the PV titres (RLU/ml) obtained of MERS-CoV PV produced using target cells transfected 
with protease. Protease is expressing plasmids at varying concentrations 48hours prior to transduction with PV. R RLU per ML 
calculated as per Section 2.10. Huh-7 cells used as target cells. 
 
Even in the absence of protease MERS-CoV appears to be efficiently cleaved in 
transfected cells, as evidenced by the high titres obtained in Huh-7 cells (figure 19 and figure 
20). The addition of protease appears to consistently result in reduced PV titre when compared 
to PV titration with no additional protease added.  
3.3.2.5. Use of different viral cores and alternate expression vectors 
In order to assess the potential of a different viral core to impact production of MERS-
CoV S bearing PV, production of PV was attempted using the MLV core and with pCAGGS 
MERS-CoV S in the concentrations determined to yield the highest titres with HIV cores 
(Section 3.3.4.). The concentration of the MLV core and of the MLV-Luc reporter gene was 
kept constant at 1000ng and 1500ng respectively.  Results of transduction using PV produced 






























































R e tro v ira l (M L V )  a n d  L e n t iv ir a l (H IV )  g a g -p o l P V
p re p a ra t io n s
P V  p ro d u c tio n  u s in g  re tro v ira l a n d  le n tiv ira l v ira l g a g -c o re s
 
Figure 21: Showing variation in the RLU values obtained of MERS-CoV PV produced using a variety of different MERS-
CoV spike pCAGGS.  
PV production with either an MLV viral core or a lentiviral core. Values for 1, 2 and 3 correspond to different preparations using 
these cores with each preparation completed on a separate day. RLU per ML calculated as per Section 2.10. Huh-7 cells used 
as target cells. 
 
The results of the use of differing viral cores display consistent results with MLV cores 
showing significantly lower titres than the HIV cores. This low titre is consistent with results 
from other studies (Buchschacher et al., 1999; Wright et al., 2008). Viable PV was produced 
with the MLV core with MLV-MERS (2) and (3) yielding significantly higher RLU values 
compared to delta env- (t=3.94 df=6.014, p=0.0076; t=3.178 df=6.031 P=0.019, respectively). 
However, although the MLV-MERS (1) clearly did give a higher RLU/ML value than the delta 
env-, it did not yield statistically significant values higher (t=2.423 df=6.03, p=0.0514). 
Although close to the significance level required (p=0.05) this result means that assays making 
use of this preparation may face difficulties in interpreting results as values so close to Delta 
env- will make interpretation difficult.   
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3.3.2.6. The role of serum variation in the production of PV 
DMEM was prepared and supplemented with 5% FBS in a place of the 10% FBS that 
used at all other times in this study all other variables remained as standard (Section 2.7.). 
This 5% DMEM preparation was then used in place of standard (10%) growth media in the 
standard protocol for PV production (900ng of pCAGGS MERS-CoV S). The results of PV 
produced following identical protocols, but with the different concentrations of FBS added to 




























1 0 %  F B S 5 %  F B S
T ra n s fe c t io n  re a g e n t  a n d  s e ru m  c o n c e n tra t io n  b y  v o lu m e
P V  p ro d u c t io n  w ith  d if fe re n t tra n s fe c tio n  re a g e n ts  a n d  F B S
c o n c e n tra t io n s
Figure 22: Showing variation in the RLU values obtained of MERS-CoV PV produced using different concentrations of 
FBS. RLU per ML calculated as per Section 2.10. Huh-7 cells used as target cells. 
 
Results in figure 22 indicate no statistical ฀d฀i฀f฀f฀e฀r฀e฀n฀c฀e฀ ฀b฀e฀t฀w฀e฀e฀n฀ ฀t฀h฀e฀ ฀P฀E฀I฀ ฀a฀n฀d฀ ฀F฀u฀g฀e฀n฀e฀™฀ 
preparations with 10% FBS supplemented media (t=0.1446 df=13.24, p=0.8). Also, no 
฀s฀t฀a฀t฀i฀s฀t฀i฀c฀a฀l฀l฀y฀ ฀s฀i฀g฀n฀i฀f฀i฀c฀a฀n฀t฀ ฀d฀i฀f฀f฀e฀r฀e฀n฀c฀e฀s฀ ฀c฀o฀u฀l฀d฀ ฀b฀e฀ ฀f฀o฀u฀n฀d฀ ฀b฀e฀t฀w฀e฀e฀n฀ ฀P฀E I  a n฀d฀ ฀F฀u฀g฀e฀n฀e฀™  a t  ฀5 %฀ ฀F฀B฀S฀ 
(t=1.509 df=7.393, p=0.17) and there did not appear to be any significant differences between 
the same reagents used in the presence of more or less serum with PEI differing between 5 
and 10% (t=0.1446 df=13.24, p=0.8872) an฀d฀ ฀F฀u฀g฀e฀n฀e฀™฀ ฀(฀t฀=฀1฀.฀3฀4฀7฀ ฀d฀f฀=฀7฀.฀9฀2฀2฀,฀ ฀p฀=฀0฀.฀2฀Ψ. 
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 The results of PV produced following identical protocols but with target cells grown in 






























T ra n s d u c tio n  re s u lts  w ith  P V  p ro d u c e d  in  c e lls  g ro w n  w ith
re s tr ic te d  s e ru m
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Figure 23: Transduction results of PV produced in cells grown under conditions of serum restriction  
compared with cells grown under standard conditions (10% FBS).  
 
Serum restriction did not yield the expected improvements in PV production efficiency. 
Figure 23 shows similar results for PV produced in FBS restricted cells when compared to 
cells grown under standard conditions of 10% FBS. No statistical significance could be 
determined from this data (t=0.7503 df=11.34, p= 0.4683). 
3.3.3. SARS-CoV PV production 
3.3.3.1 Cell line susceptibility  
Just as DPP-4 transfected HEK293T/17cells showed similar levels of transduction 
when used as target cells for MERS-CoV PV as Huh-7 cells, so too did SARS-CoV PV, show 
similar results with HEK293T/17cells transfected with the ACE2 receptor and Huh-7 cells. 
































































































































































































2 9 3 -A C E 2 2 9 3 T /1 7 H u h -7 Q T - 6 V e r o M D C K
(T y p e 1 )
C a C o B H K
P V  a n d  C e ll lin e s
T ra n s d u c tio n  o f S A R S -C o V  P V
Figure 24: SARS-CoV PV transduced into a variety of different cells lines.  
Results showing variation in the transduction efficiency based on cell line and the transient transfection of the ACE2 SARS 
receptor. It is noteworthy that the HUH-7 cell line is optimal for SARS-CoV PV.  
 
Mean titre obtained for SARS-CoV PV transduced into HEK293T/17cells transfected 
with the ACE2 receptor was 26,162,500 RLU/ML, and for Huh-7 cells, the mean titre per ML 
was 27,112,500. In contrast, the HEK293T/17cells that had not been previously transfected 
with the ACE2 receptor resulted in an RLU value of 985,479. It is worth noting that while the 
non-transfected (naïve) HEK293 cells yielded far lower RLU values then the same cell line 
transfected with the SARS-CoV receptor, the RLU value was still significantly greater than the 
delta env- control t=3.928 df=7.332, p=0.0052). Although the transfected HEK293 cells proved 
to be adequate target cells the advantages of using the Huh-7 cell line in its naïve form meant 
that this was selected as the target cell of choice for further studies.  
3.3.3.2. The Role of protease on production of SARS-CoV PV  
Protease expression plasmids were co-transfected with 900ng of pCAGGS MERS-
CoV, 1000ng of p8.91 (HIV-Gag) and 1500ng of pCSFLW (Firefly Luciferase Reporter). Three 
concentrations each of TMPRSS2, HAT and Furin were transfected, and results of 
transduction with PV produced in this way is recorded in figure 25. 
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T M P R S S 2 H A T F u r in
P ro te a s e  e x p re s s io n  v e c to r  c o n c e n tra tio n
P V  p ro d u c tio n  w ith  th e  c o tra n s fe c tio n  o f p ro te a s e  e x p re s s io n  p la s m id s
Figure 25: Showing variation in the RLU values obtained of SARS-COV PV produced using co-transfection of protease  
expressing plasmids at varying concentrations. Data recorded as mean relative luciferase units (RLU) for 8 parallel wells in 96-
well culture plates with 10,000 Huh-7 cells per well as target cells. 
 
Transfection with protease did not appear to enhance SARS-CoV PV production 
efficiency when producer cells were transfected with protease the resulting PV yielded a 
reduced RLU. These results suggest that as with MERS-CoV PV, the SARS-CoV S protein is 
cleaved efficiently by the endogenously expressed proteases of the HEK293T/17cells used 
as producers. Increased protease expression does not yield improvement in PV production.  
3.3.4. Consistency of production in the titre of PV  
Multiple transfections were carried out on different days with different aliquots of 
HEK293T/17 in order to assess the consistency of the results yielded by the methods derived 
from this chapter i.e. T194 was carried out on day 1, T195 carried on day 2 etc.Results of 
these transfections as assessed via transduction of MERS-CoV PV in Huh-7 cells are 
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Figure 26: Transduction results of MERS-CoV PV produced from multiple transfections, conducted at different times.  
The consistency of results is clear with very limited variation between preparations. Data is normalised as outlined in Section 
2.10 
Figure 26 clearly indicates that the derived protocol yields consistent results across 
multiple replications. However, despite the apparent homogeneity of the results, there was a 
statistically significant difference between groups as determined by one-way ANOVA (F (4 
,35) = 19, p = <0.0001). Although the results do indicate variation within the results over time, 
the consistently high results (lowest mean MERS-T198 = 135,125,000 RLU/ML) coupled with 
the normalisation method outlined in Section 2.11, mean that this variation should have 
minimal the impact on the use of PV for further research.  
3.4. Discussion 
3.4.1. Optimisation of the MERS-CoV PV production 
Based on the optimization steps outlined above the greatest impact on final 
pseudotype titre from the methodological changes was observed when the amount of 
pCAGGS plasmid expressing the MERS-CoV S protein was varied.  Optimal results appear 
to be obtained for 900ng of this plasmid. It is noteworthy that leve฀l฀s฀ ฀o฀f฀ ฀t฀h฀i฀s฀ ฀p฀l฀a฀s฀m฀i฀d฀ ฀a฀b฀o฀v฀e฀ ฀1ȝ฀g฀ 
led to a reduction in the mean titre. The reasons for this are unclear, recent studies have 
demonstrated that high levels of Ebola glycoprotein expression can impair production and 
release of Ebola virus-like particles (VLPs) and may inhibit the ability of PV to transduce target 
cells (Mohan et al., 2015). Mohan et. al. (2015) demonstrate that high levels of Ebola 
glycoprotein expression can reduce the synthesis of other proteins needed for virus assembly, 
and also demonstrated that PV-containing high levels of glycoprotein are significantly less 
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able to transduce target cells. It was hypothesised that this lower ability to transduce cells may 
be due to impaired receptor binding or inefficient endosomal processing.  
Lentiviral (HIV) cores were found to give significantly higher titres than MLV cores. 
However, while the mean titres are low, the MLV cores did generate viable PV. This fact may 
be of use in overcoming potential cell restriction factors that may impact either the lentiviral or 
retroviral-based PV (Besnier, Takeuchi and Towers, 2002; Huang et al., 2011; Kelly et al., 
2011). It has been demonstrated that intrinsic host cell restriction factors, in particular, ฀T฀R฀I฀M฀5Į฀ 
can have an inhibitory effect on lentiviral-based PV (Stremlau, Owens and Perron, 2004) with 
฀t฀h฀e฀ ฀T฀R฀I฀M฀5Į฀ affecting the HIV capsid, this study found that MLV based PV were unaffected by 
the restriction factors. Therefore, the demonstration that MERS-CoV PV is generated with 
either HIV or MLV viral Gag core constructs using the protocol derived in this chapter expands 
the potential for the use of these PVs in combination with different cell lines.  
Testing of protease expression plasmid concentrations determined that the addition of 
a protease expressing plasmid was not required to produce high titre viral particles; indeed, 
the addition of these plasmids had a negative effect on the viral titre. While the reason for this 
is unclear, it may be hypothesised that expression of these proteases has a negative on the 
฀p฀r฀o฀d฀u฀c฀e฀r฀’฀s฀ ฀c฀e฀l฀l฀s฀.฀ ฀I฀t฀ ฀i฀s฀ ฀a฀l฀s฀o฀ ฀p฀o฀s฀s฀i฀b฀l฀e฀ ฀t฀h฀a฀t฀ ฀o฀v฀e฀r฀e฀x฀p฀r฀e฀s฀s฀i฀o฀n฀ ฀o฀f฀ prote ses within the producer cell 
may have a negative effect on the produced PV. Over the course of this study, it was not 
possible to test these theories as a cell viability experiment could not be completed within the 
available time. These results support the findings of other studies that have demonstrated the 
ability to generate coronavirus PV without the need for additional proteases (Temperton et al., 
2005; Zhao et al., 2013). However, it has also (Gierer et al., 2013) been demonstrated that PV 
MERS-CoV can utilise TMPRSS2 to enter colon-derived Caco-2 cells but can also use 
Cathepsin related proteases. This means that MERS-CoV spike protein can be proteolytically 
cleaved by two independent pathways. As the results in this chapter demonstrate no 
improvement in PV when co-transfected with protease expressing plasmids it may be inferred 
that proteolytic maturation of the MERS-CoV spike protein in PV production is efficiently 
carried out by ubiquitously expressed proteases found in the HEK293T/17cell line. While 
specific reasons for the apparent protease caused a reduction in titre when protease 
expression plasmids are cotransfected during the production of PV remains unclear, it is clear 
that the protocol derived in this chapter does not benefit from the addition of the protease. 
In addition, the failure of protease expression within target cells during transduction to 
enhance reporter gene expression may indicate that in the case of the PV one or more of the 
following is likely responsible for proteolytic processing: 
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1) Viral entry is efficiently facilitated through Cathepsin related proteases natively 
expressed within the target cell endosome. 
2) Viral pseudotype particles are pre-processed into the mature form by host cell 
proteases within the producer cells. 
3) The exogenous protease may not be expressed in a usable form by the viral particles 
i.e. expression may be limited to specific regions of the target cells or expression may 
be so transient that the protease is not available to the viral particles. 
As protease inhibition studies were not possible at the time of this study further exploration of 
this issue was not possible.  
For MERS-CoV PV production modifications to the protocol based on limiting the 
concentration of FBS in the media, observable differences could be determined with cells 
grown in serum-restricted conditions. Figure 23 , shows that although the media change 1 
hour prior to transfection was anticipated to lead to an increase in PV production through 
compelling cells to enter a more rapid growth phase triggered by increased nutrient supply, 
no increase in PV yield was observed. While further experimentation is required in order to 
investigate this phenomenon in more detail a number of hypotheses are feasible:  
1. Cell starvation may not have been sufficiently severe to have a significant effect on cell 
growth/physiology  
2. The protocol of growing cells in media supplemented with 10% FBS may already result 
in an optimised transfection efficiency, and further improvements may not be possible 
at this stage of the process 
3. Physiological responses of the cells to starvation may not result in appreciable 
improvement in transfection efficiency 
Serum limitation during the transfection process similarly did not yield appreciable gains in PV 
titre; this suggests that serum presence during the transfection process is of limited impact. 
3.4.2 Optimised protocol for MERS-CoV PV production 
Within this chapter, it was determined that the optimal protocol for the generation of 
MERS-CoV bearing PV was following the protocol outlined in Section 2. But with the 
concentration of the MERS-CoV S protein expressing pCAGGS plasmid fixed at 900ng. This 
protocol, in brief, is:  
Timeline: transfection -24 hours 
1. HEK293T/17cells were subcultured into a 100mm petri dish with a ratio of 1:4 to 
yield 70-90% confluent cells at the time of transfection. 
Timeline: day of transfection 
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2. DMEM+10%FBS + 1% P/S and Opti-MEM® were pre-warmed to 37°C using a water 
bath.   
3. DNA-containing plasmids for the transfection were added to one microcentrifuge 
tube in the following concentrations:  
pCAGGS-MERS-CoV spike ฀– 0.9 ȝ฀g 
p8.91-lentiviral vector ฀– ฀1฀ ȝ฀g 
pCSFLW  - ฀1฀.฀5฀ ȝ฀g 
4. Opti-MEM® was added ฀t฀o฀ ฀t฀h฀e฀ ฀p฀l฀a฀s฀m฀i฀d฀ ฀D฀N฀A฀ ฀m฀i฀x฀ ฀(฀2฀0฀0ȝ฀l฀Ψ฀. 
5. Opti-MEM® was added ฀t฀o฀ ฀t฀h฀e฀ ฀e฀m฀p฀t฀y฀ ฀t฀u฀b฀e฀ ฀(฀2฀0฀0ȝ฀l฀Ψ฀ ฀w฀i฀t฀h฀ ฀P฀E฀I฀ ฀(฀3฀5฀ ȝ฀l฀Ψ฀. 
6. Both tubes were mixed by gently flicking while incubated for 5 minutes at RT. 
7. After incubation, the Opti-MEM®/PEI solution was added to the Opti-MEM®/DNA 
solution 
8. Incubation Step. The tube was incubated at RT for 20 minutes with the tube flicked 
to mix every 4 mins. 
9. While transfection mix was incubating the media on the HEK293T/17producer cells 
was changed, and 7ml of fresh DMEM + 10% FBS + 1% P/S was added. 
10. After incubation the DNA/Opti-MEM®/PEI  has added the solution to the 
HEK293T/17cells by adding dropwise around the complete plate. 
11. Incubation Step. The plates were then Incubated at 37°C, 5% CO 2 overnight   
Timeline: 12-16 hours post-transfection  
12. Post incubation the media on the cells was changed, and 7ml fresh DMEM +10% 
FBS +1% P/S was added. 
13. The plates were then incubated 37°C 5% CO 2 for 32-36 hours.   
Timeline: 44-52 hours post transfection  
14. Supernatant containing the viral pseudotype particles was harvested using a sterile 
syringe and then filtered into Falcon tubes via Millex HA-฀0฀.฀4฀5ȝ฀m฀ ฀f฀i฀l฀t฀e฀r฀. 
Production with this protocol yields consistent and reproducible results as displayed in 
Section 3.3.4. figure 26 with multiple transfections conducted at different times following the 
same protocol yielding statistically similar results.   
3.4.3 Production and optimisation of SARS-CoV PV 
While the studies in this chapter did not as comprehensively investigate the potential 
optimisation of SARS-CoV, the experiments that were attempted failed to yield significant 
improvements in the production of SARS-CoV PV. The addition of protease during the 
production process failed to improve titre yield and may indicate: 
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1. Cleavage of the SARS-CoV PV spike protein is achieved is efficiently achieved by 
proteases natively expressed in HEK293T/17cells used during PV production, 
2. The proteases utilised in this study were not available to provide additional cleavage 
activity to the SARS-CoV PV. This may be due to localisation or poor expression 
levels 
While it cannot be discounted based on this research, that alternative proteases 
included in the production of PV may result in improvements in yield, the proteases used in 
this chapter have been previously demonstrated to be capable of cleavage of SARS-CoV 
(Kam et al., 2009; Matsuyama et al., 2010). As such it would be expected that overexpression 
of these proteases in producer cells would yield improvements in PV titre, however since this 
was not the case it appears more likely that additional factors not related to the proteases are 


















Chapter 4 Cross Reactivity of MERS-CoV PV with Serum Obtained 
from Convalescent SARS Patients 
4.1. Introduction  
The outbreak and rapid spread of two betacoronaviruses in recent years has 
highlighted the potential threat to humans of the traditionally zoonotic coronavirus family. The 
SARS-CoV outbreak occurred in November 2002 in southern China and this disease has 
resulted in more than 8000 cases with more than 800 deaths reported in 37 countries. First 
identified in 2012 (Zaki et al., 2012), within a relatively short time frame from the MERS-CoV 
outbreak has so far caused more than 1472 laboratory confirmed cases of MERS-CoV 
resulting in 615 deaths (reported case fatality rate 41.8 percent)  (As of September 2016) (Kim 
et al., 2016). Both SARS-CoV and MERS-CoV are zoonotic in origin and detailed serological 
studies have been required in both cases in order to identify the reservoir species of these 
viruses (Lau et al., 2010; Li et al., 2011; Zaki et al., 2012; Perera et al., 2013; Abdel-Moneim, 
2014; Raj et al., 2014; Bahah et al., 2015) and thus the potential for route for human infection. 
As limited historic data has previously been available for coronaviruses in both human or non-
human hosts there is very little information on the potential for cross-reaction between differing 
coronavirus infections, although some evidence for the potential for cross neutralisation has 
been identified (Che et al., 2005; Patrick et al., 2006).   
Most recently  there has been some evidence that sera from convalescent SARS 
patients shows evidence of cross neutralisation with MERS-CoV (K. H. Chan et al., 2013). 
Cross reactivity between antigenically distinct viruses can occur because of prior vaccination 
or exposure, resulting in a more complicated interpretation of the serological findings. Chan et 
al. (2013), made use of neutralisation assays where inactivated patient serum mixed with the 
replication-competent virus was used to investigate the potential for patients previously 
exposed to the SARS-CoV epidemic to have retained antibodies that may display cross-
reactive potential with the more recent MERS-CoV (K. H. Chan et al., 2013). This study made 
use of replication competent virus and used target cells that were inoculated with a dilution of 
this virus and subsequently examined for cytopathic effects (K. H. Chan et al., 2013). This 
assay is believed to be, highly specific and it was, therefore, surprising that high levels of 
MERS-CoV neutralizing antibodies were detected in the sera from SARS patients (K. H. Chan 
et al., 2013). Prior to this cross reactivity had previously been reported only for closely related 
coronaviruses (Che et al., 2005; Vlasova et al., 2007) and is due to sequence and structural 
homologies between the respective coronavirus spike proteins. However, since the homology 
between MERS-CoV and SARS-CoV on amino acid level is low, the authors of this study 
 112 
 
suggest that structural homologies are responsible for the cross reactivity, however further 
bioinformatics studies were not conducted as part of this study. 
In the examination of the spike protein of MERS and SARS, sequence analysis 
indicates that significant similarity exists between these viruses particularly within the 
homologous S2 domain of the Spike glycoprotein (c. 71% residue identity). This region 
displays a high level of similarity between all Betacoronaviruses with significant overlap in 
terms of structure and sequence identity between MERS-CoV, SARS-CoV, HCoV-OC43 and 
HCoV-HKU1 (K. H. Chan et al., 2013). This domain specific similarity raises the prospect of 
research to focus on this region as a target for coronavirus antivirals due to the potential for 
broad-spectrum antiviral compounds with the potential to effect multiple coronaviruses.   
As previously discussed (Section 1.1.1), a large number of studies have sought to 
unravel the crystal structure of the MERS-CoV RBD region. Jiang et al. (Jiang et al., 2013) 
presented a homology model of the crystal structure of the MERS-CoV RBD domain, based 
on the structure of the RBD domain of SARS-CoV, using a number of Swiss-Model Workplace 
tools for homologous protein modelling. Subsequently, this group presented a putative 
conformation model of this domain in complex with the DPP-4 receptor, the structure of which 
was previously characterised (Lu et al., 2013). The results of this study were later supported 
by similar findings from other groups and suggests that, like SARS-CoV, the MERS-CoV RBD 
shares a similar RBD structure with other coronavirus. More detailed analysis and 
comparisons between coronavirus spike proteins (Lei et al., 2014; Sharmin and Islam, 2016) 
indicates that although the RBD regions share broadly similar structures and are universally 
the primary mediator of cell entry, there exists significant divergence in the overall sequence 
of these proteins and in particular the RBD regions differ markedly between different viral 
species (Wang et al., 2014) with structural variation in these regions likely responsible for 
variation in receptor binding between HKU4 and MERS-CoV (Wang et al., 2014). It is likely 
therefore, that cross-reactivity between coronaviruses may be mediated by an alternative yet 
uncharacterised region that is more conserved between coronavirus species.   
Several studies have reported correlations between certain physicochemical 
properties of amino acids and the locations of linear B-cell epitopes within protein sequences 
(Emini et al., 1985; Gough et al., 2001; Haste Andersen, Nielsen and Lund, 2006; Parker et 
al., 2013), and several epitope prediction methods based on physicochemical properties of 
amino acids have been proposed. For example, hydrophilicity, flexibility, turns, or solvent 
accessibility propensity scales were used in the methods of Parker. After the production of 
MERS-CoV based PVs was optimised it became possible to make use of these PVs in 
experiments investigating the potential for cross neutralisation of MERS-CoV pseudotyped 
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virus with convalescent sera from SARS patients (Grehan, Scott, et al., 2015). The use of PVs 
for these cross neutralisation studies allows the focus of the study to remain on the antigenic 
potential of the Spike protein, without the confounding effects of other viral proteins, in addition 
the use of PVs allows assays to be carried out in low level biosafety laboratory. This makes 
these ideal tools for cross reactivity studies (Sanders, 2002; Molesti, Wright, et al., 2014). The 
relative ease with which the viral spike proteins can be modified via mutagenesis and the 
simplicity with which these modified glycoproteins can be incorporated into a viral pseudotype 
particle offers the potential for rapid characterisation of potential antigenically active sites. Viral 
vectors pseudotyped with the spike proteins of interest, mimic cellular entry of coronaviruses 
and can be used for the detection of neutralizing antibodies and as such are the ideal tools 
when combined with in-silico analysis methods to determine the extent and source of the cross 
reactive antibodies (Simmons et al., 2004; Du, Zhao, et al., 2013; Perera et al., 2013; Zhao et 
al., 2013). The methods employed to produce MERS-CoV PV and SARS-CoV PV have been 
described in Section 3.4, further analysis of the MERS-CoV spike protein was carried out to 
determine the potential source of the observed cross reactivity.  
Sequence-based methods utilise the notion that sequence dictates structure and 
identical structure in turn suggests identical functions, this is not a new field (Emini et al., 1985; 
Kohl et al., 1988; Kolaskar and Tongaonkar, 1990), however recent advances in technological 
tools have allowed this field to develop rapidly in recent years. Although this method is limited 
as sequence similarity is not a guarantee of conserved function, sequence based methods 
offer the potential to gain rapid insights into viral evolution. The ongoing development of 
various bioinformatics methods making use of experimental data has allowed databases of 
conformational B-cell epitopes to grow rapidly and aid in the identification of new epitopes. 
The development of epitope-related databases promotes conformational B-cell epitopes 
prediction and makes even linear epitope prediction more accurate. Anitgenically active 
regions may be identified in the IEDB (Zhang et al., 2008) database which provides not only 
a more comprehensive collection of characterised epitopes but also provides a range of tools 
to allow this database to be used to make predictions about novel proteins based on 
physiochemical properties thought to be common among epitopes. Although tools such as 
Emini Surface Accessibility Prediction and Bepipred Linear Epitope Prediction are limited only 
to linear epitopes the use of these tools to gain rapid data to inform experimental work may 
be valuable in planning further experiments. In addition these forms of analysis can be carried 
out without the need for structural characterisation of viral proteins and so are valuable tools 
in the face of newly emerged viral pathogens.  
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4.2. Materials and methods 
4.2.1. Serum samples  
Three distinct panels of sera were available for this study. The first available serum 
panel (designated serum panel 1) consisted of a total of 73 blood samples previously obtained 
from 24 patients (c. 67% female) 11฀–80 years of age who were admitted to the Prince of Wales 
Hospital, Hong Kong, from March to May 2003 (Temperton et al., 2005). These patient sera 
fulfilled the WHO criteria for a probable SARS diagnosis, none of these patients died of the 
infection although one patient did require intensive care treatment. For most patients, multiple 
samples were obtained at sequential times covering the acute, convalescent, and recovered 
phase of the disease, all available patient details for this serum panel has been recorded in 
Appendix 1 (a).  
The second sera panel was kindly provided through a collaboration with Dr Michael 
Liu and limited patient information was available at the time of this study. The sera in this 
cohort was sourced from patients from three different cities within the Republic of China; 
Bejing, Guangzhou, Hong Kong. As such should represent several different SARS-CoV 
strains, thereby presenting the possibility of identifying strain specific variation in cross 
reactivity.  This panel consisted of 208 samples with a mix of sera from SARS positive and 
SARS negative patients. The samples comprising this serum panel designated serum panel 
2 are recorded in Appendix 1 (b). The final sera panel was composed of a subset of sera 
samples taken from volunteers as described in (Jones et al., 2014). This subset consisted of 
eight samples from eight individuals all of whom were healthy at the time of sampling and were 
resident in the UK. None of the volunteers reported clinical symptoms prior to sampling. As 
this panel had previously been used in influenza A serology the IC50 values previously 
calculated for these samples when assayed against influenza PVs expressing the 
hemagglutinin of H1 Brisbane, H5 1194 Vietnam, H3 Udorn and H7 Shanghai.  
All sera were inactivated at 56 C° for 30 min before micro-neutralisation assays w ere 
performed. Patient sera was originally numbered according to clinical barcoding practices, this 
was replaced with a identifier that includes both a patient identifier and an indicator of the 
number of days after fever onset that the serum was extracted from the patient, in this system 
the first number in the code is a patient identifier followed by an underscore, the middle number 
followed by the letter d indicates the number of days after fever onset the serum was taken 
and the final character in the code is a letter indicated if the sampled was a serum or plasma 
sample, i.e. 1_1d_S indicates a sample from patient 1, taken 1 day after fever onset and is a 
serum sample.   
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4.2.2. Cell lines and culture 
Both Huh-7 and HEK293T/17฀c฀e฀l฀l฀s฀ ฀w฀e฀r฀e฀ ฀c฀u฀l฀t฀u฀r฀e฀d฀ ฀i฀n฀ ฀D฀u฀l฀b฀e฀c฀c฀o฀’฀s฀ ฀M฀o฀d฀i฀f฀i฀e฀d฀ ฀E฀a฀g฀l฀e฀ ฀M฀e฀d฀i฀u฀m฀ 
(DMEM) with Glutamax and high glucose (Gibco, Invitrogen, UK) supplemented with 10% (v/v) 
฀f฀e฀t฀a฀l฀ ฀b฀o฀v฀i฀n฀e฀ ฀s฀e฀r฀u฀m฀ ฀(฀S฀i฀g฀m฀a฀Ψ฀ ฀(฀F฀B฀S฀Ψ฀ ฀a฀n฀d฀ ฀1฀%฀ ฀(฀v฀/฀v฀Ψ฀ ฀p฀e฀n฀i฀c฀i฀l฀l฀i฀n฀⁄฀s฀t r e p t o m฀y c฀i n  (฀F i฀s฀h฀e฀r฀ ฀B i฀o r฀e฀a฀g e n฀t฀s฀Ψ฀.฀ 
Cell culture procedures were as previously described (Section 2.7.).  
4.2.3. Pseudotype production and titration of MER-CoVS/SARS-CoV PVs 
A HIV gag pol plasmid (p8.91) (Zufferey et al., 1998), a luciferase expressing plasmid 
(pCSFLW) (Zufferey et al., 1998) and a plasmid expressing the glycoprotein of interest 
(pCAGGS-MERS-CoV-S) were co-transfected into human kidney HEK293T/17cells using 
Fugene 6฀™฀ ฀a฀s฀ ฀t฀h฀e฀ ฀t฀r฀a฀n฀s฀f฀e฀c฀t฀i฀o฀n฀ ฀a฀g฀e฀n฀t. All MERS-CoV PV supernatant used for eutralisation 
tests was produced at the same time in three 100mm cell culture plates, titration results for 
these viral preps is recorded in figure 27. Plasmids expressing the SARS-CoV spike protein 
were kindly provided by Prof Stefan Pöhlmann and Dr Graham Simmons.  The production of 
the SARS-CoV virus was carried out following the protocol for this PV outlined in Chapter 3, 
briefly, ฀1฀ ȝ฀g฀ ฀o฀f฀ ฀S฀A฀R฀S-CoV envelope in a pCAGGS ฀e฀x฀p฀r฀e฀s฀s฀i฀o฀n฀ ฀v฀e฀c฀t฀o฀r฀,฀ ฀1ȝ฀g฀ ฀o฀f฀ ฀p฀8฀.฀9฀1฀ ฀l฀e฀n฀t฀i฀v฀i฀r฀a฀l฀ 
vector and 1.5 ȝ฀g฀ ฀o฀f฀ ฀l฀u฀c฀i฀f฀e฀r฀a฀s฀e฀ ฀e฀x฀p฀r฀e฀s฀s฀i฀n฀g฀ ฀p฀C฀S฀F฀L฀W฀ ฀p฀l฀a฀s฀m฀i฀d฀.฀ ฀A฀l฀l฀ ฀S฀A฀R฀S-CoV PV was produced 
in a single 100 ฀m฀m฀ ฀p฀l฀a฀t฀e฀ ฀w฀i฀t฀h฀ ฀t฀w฀o฀ ฀s฀e฀q฀u฀e฀n฀t฀i฀a฀l฀ ฀h฀a฀r฀v฀e฀s฀t฀s฀’฀ ฀p฀r฀o฀d฀u฀c฀i฀n฀g฀ ฀1฀4 ml of viral supernat nt 
titrations result for these viral preps is recorded in figure 27.   
For both MERS-PV and SARS-PV, PV containing supernatant was harvested 48hours 
post tr฀a฀n฀s฀f฀e฀c฀t฀i฀o฀n฀ ฀b฀y฀ ฀f฀i฀l฀t฀e฀r฀i฀n฀g฀ ฀t฀h฀r฀o฀u฀g฀h฀ ฀a฀ ฀0฀.฀4฀5฀ ȝ฀m฀ ฀f฀i฀l฀t฀e฀r฀.฀ ฀T฀h฀e฀ ฀h฀a฀r฀v฀e s t e d  ฀v฀i฀r฀u฀s฀ ฀w฀a฀s฀ ฀t h e฀n฀ ฀s฀t฀o r e d  ฀a฀t฀ -
80°C. Titrations of both MERS-CoV and SARS-CoV PVs were carried out using Huh-7 cells 
as a target cell line which has previously been found to be susceptible to both viruses (Nie et 
al., 2004; Zhao et al., 2013). From these initial titrations, mean titres per ml were calculated 
and used to calculate the input volume of viral particles required for micro-neutralization as-
says. All viral titres were quantified by luminescence expression, expressed as relative lumi-


















Figure 27: Results of titres from three replicates of optimised transfection protocol using codon optimised MERS-CoV 
Spike expressed in a pCAGGS expression plasmid.  
Also shown are results from two replicates of improved SARS-CoV transfection showing markedly lower titre within the Huh-7 
cell line. All values are recorded in RLU per ml as calculated using multiplication method outlined in chapter 2. Titre displayed is 
for dilution beginning with 50µl of viral supernatant transduced into 1x104 cells suspended in 50µl of DMEM as outlined in 
Section 2.10. 
4.2.4. PV-neutralisation assay 
Serum samples (5 ߤL) were twofold serially diluted in culture medium (DMEM 
GlutaMAX supplemented with 10% FBS and 1% Penicillin/Streptomycin) and mixed with a 
volume of viral pseudotype particles calculated to yield 500,000 RLU at a ratio 1: 1 v/v ratio. 
After incubation of this serum/virus mix at 37ႏ for 1 hour, 1 × 104 Huh-7 cells were added to 
each well of a white 96-well flat-bottomed tissue culture plate. These plates are then incubated 
at 37ͼC and 5% CO2 for 48 hours before the transduction titres were measured by 
luminometer. For each serum sample, a complete range of eight dilution points were 
measured with the resultant RLU values used to calculate the IC50 for each serum sample. 
For each sample, RLU values were normalized and compared with the RLU value detected in 
the absence of pseudotype virus (equivalent to 100% neutralization) and the signal of the 
negative control (equivalent to 0% neutralization). The 50% inhibitory doses (IC50) were 
determined as the reciprocal of serum dilution resulting in a 50% reduction of a single round 
of infection (reporter gene mediated signal). 
4.2.5. Bioinformatic analysis  
Complete CDS nucleotide sequences of the MERS-CoV and SARS-CoV S proteins 
were downloaded from NCBI GenBank and alignments were performed using MEGA 6.0 
(Tamura et al., 2011) and the Muscle algorithm (Edgar, 2004). Epitopes that may elicit a  
human B-cell response were predicted using SVMTrip (Yao et al., 2012). The SVMTrip 
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employs an algorithm previously tested using a dataset constructed by extracting non-
redundant linear B-cell epitopes from the  IEDB dataset. 
In addition, the IEDB web tools were employed to assess both the potential of the 
SVMTrip identified linear epitopes and to identify additional epitopes (Yao et al., 2012). The 
IEDB tools were used to identify the potential of the identified epitopes to be available for 
antibody interaction via the Emini Surface Accessibility Prediction and Bepipred Linear 
Epitope Prediction. 
Table 5: The relationship between selected thresholds and the sensitivity/specificity of the bepipred prediction method, calculated 
on basis of the epitope/non-epitope predictions. The table is based on a large benchmark calculation containing 85 B-cell epitopes 
(Larsen, Lund and Nielsen, 2006) 
Threshold Sensitivity Specificity 
-0.20 0.75 0.50 
0.20 0.56 0.68 
0.35 0.49 0.75 
0.90 0.25 0.91 
1.30 0.13 0.96 
 
4.3. Results 
4.3.1. Serum panel 1 
Neutralisation assays indicated that 6 study patients out of the 24 patients comprising 
sera panel 1 tested positive for neutralising antibody titres for MERS-CoV PV. Results of 
neutralisation are recorded in figure 28.  It should be noted that there is significant variation in 
the % neutralisation between samples. In addition, due to lack of availability serum was not 
available for all patients at all time points and as such, it was impossible to assess whether 
the time of sampling was significant in determining the neutralisation potential of the serum 
sample. Table 8 displays the mean IC50 val฀u฀e฀s฀ ฀a฀s฀ ฀c฀a฀l฀c฀u฀l฀a฀t฀e฀d฀ ฀b฀y฀ ฀G฀r฀a฀p฀h฀P฀a฀d฀™฀ ฀P฀r฀i฀s฀m 7.02, this 
mean is based on two neutralisation assays, except in the case of patient 1 which was based 
on a single assay due to lack of serum. Additional assays were not possible due to lack of 
serum availability. Statistical analysis of the MERS-CoV and SARS-CoV indicate that there is 
not a significant correlation between the IC50 values (Pearson correlation 0.03, p<0.05) for 
the sera panel 1. This lack of correlation suggests that large IC50 values for the serum when 





Figure 28: Sera panel 1 neutralisation assay results.  
All assays include the commercially produced MERS-Ab as a control.  All data shown are normalised based on cell only and virus 
only controls assayed at the same time as the serum. X axis corresponds to log dilution factor with a value of 1.6 correponding 
to a 1:40 dilution of the serum.   
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Table 6: Indicating summary of the IC50 calculations based on results of neutralisation assays recorded on figure 28.  
Each sample was assayed twice for each of the MERS-CoV and SARS-CoV PV. Underlined samples are those considered to 
be positive for MERS-฀C฀o฀V฀ ฀n฀e฀u฀t฀r฀a฀l฀i฀s฀a฀t฀i฀o฀n฀.฀ ฀A฀l฀l฀ ฀c฀a฀l฀c฀u฀l฀a฀t฀i฀o฀n฀s฀ ฀w฀e฀r฀e฀ ฀c฀a฀r฀r฀i฀e฀d฀ ฀ou฀t฀ i n฀ ฀i n  G฀r฀a฀p฀h p a d p r฀i฀s฀m ™฀ 7.02  
SERUM# SAMPLE CODE MERS IC50 MERS MEAN SARS IC50 SARS MEAN 
5 1_1d_S 0 0 0 0 4.9 2.45 
28 10_3d_P 0 0 0 0 8.1 4.05 
29 11_2d_P 154 264 209 47.69 67 57.345 
75 12_10d_P 0 0 0 1 0 0.5 
36 12_1d_P 0 0 0 0 0 0 
39 12_2d_P 0 0 0 0 0 0 
43 12_3d_P 38 N/a 38 39 23 31 
25703 12_5d_S 0 0 0 93 
 
93 
25753 12_5d_S 0 0 0 734 411 572.5 
65 12_8d_P 0 0 0 0 0 0 
25780 14_3d_S 0 0 0 81 
 
81 
25820 14_3d_S 19 35 27 834 689.2 761.6 
24 15_2d_S 38 N/a 38.2 72 51 61.5 
25749 16_3d_S 0 0 0 0 0 0 
38 17_3d_P 0 0 0 55 44.3 49.65 
44 17_4d_P 0 1 0.5 47 29.1 38.05 
55 17_6d_P 0 0 0 52 
 
52 
25701 17_6d_S 0 0 0 0 0 0 
25773 17_9d_S 0 1 0.5 69 
 
69 
30233 18_0d_P 0 6 3 0 0 0 
71 18_4d_P 82 119 100.5 1421 
 
1421 
25796 18_4d_S 0 0 0 15 9 12 
30272 19_2d_P 26.2 41 33.6 3 0 1.5 
30397 2_3d_P 0 0 0 156 
 
156 
30398 20_4d_P 0 0 0 266 194 230 
30572 21_32d_P 0 0 0 1623 890 1256.5 
61 22_1d_P 0 0 0 7.1 0 3.55 
30195 23_2d_P 16.7 32 24.35 0 0 0 
58 23_3d_P 298.2 486 442.1 451 234 342.5 
25715 23_3d_S 0 0 0 0 0 0 
30369 23_7d_P 69.5 81.776 75.638 216 
 
216 
35 24_1d_P 0 0 0 0 0 0 
40 24_1d_P 0 0 0 0 0 0 
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19 24_3d_S 0 0 0 191 139.2 165.1 
50 24_4d_P 8 24 16 105 87.3 96.15 
30246 24_5d_P 0 0 0 0 0 0 
25698 24_5d_S 0 0 0 0 0 0 
64 24_7d_P 0 0 0 933 0 466.5 
25748 24_7d_S 0 0 0 0 0 0 
73 24_9d_P 0 0 0 212 
 
212 
25799 24_9d_S 0 0 0 104 56,6 104 
25797 3_10d_S 0 0 0 17 11 14 
34 3_2d_P 0 0 0 3.8 1 2.4 
41 3_3d_P 30 41 35.5 123 90 106.5 
47 3_4d_P 0 0 0 73 61 67 
51 3_5d_P 0 0 0 8 0 4 
25677 3_5d_S 0 1.3 0.65 17.7 1 9.35 
25697 3_6d_S 0 0 0 15 9 12 
62 3_8d_P 0 0 0 39.6 0 19.8 
30303 4_10d_P 17.8 41 29.4 274 216 245 
30363 4_10d_P 78 138.2 108.1 110 
 
110 
30085 4_1d_P 47.4 68.3 57.85 80 0 40 
10 4_2d_S 18.9 24.9 21.9 80 60 70 
42 4_3d_P 0 13.5 6.75 0 0 0 
45 4_4d_P 67 94.1 80.55 503 407.2 455.1 
49 4_5d_p 0 0 0 0 0 0 
25665 4_5d_s 0 5.6 2.8 56 
 
56 
25692 4_6d_s 0 0 0 212 
 
212 
32 5_3d_P 38 N/a 16 32 46.3 39.15 
30317 6_33d_P 0 0 0 692 278 485 
57 7_4d_P 0 1 0.5 66 
 
66 
25747 7_6d_S 2 14 8 19 7 13 
25792 7_8d_S 0 0 0 0 0 0 
69 8_4d_P 0 0 0 288 
 
288 
30194 9_1d_P 0 9 4.5 26 14.4 20.2 
59 9_2d_P 4 29 16.5 27 0 13.5 
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Figure 29: Graphical plot displaying mean IC50 values calculated based on two neutralisation tests sera panel 1.  
Although statistical analysis failed to determine a significant correlation the graph demonstrating the trend in IC50 values indicating that although specific samples do not show a clear link between SARS and MERS 
IC50 the general trend shows a clear link.
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4.3.2. Serum panel 2 
The second batch of patient sera gave a greater number of patient serum samples 
positive for MERS-CoV neutralisation. Of 208 serum samples 30 tested positive for MERS-
฀C฀o฀V฀ ฀n฀e฀u฀t฀r฀a฀l฀i฀s฀a฀t฀i฀o฀n฀ ฀(฀d฀e฀f฀i฀n฀e฀d฀ ฀a฀s฀ ฀a฀n฀ ฀I฀C฀5฀0฀ ฀v฀a฀l฀u฀e฀ ฀a฀s฀ ฀≥฀5฀0฀Ψ฀ t h e  I C 5 0฀ v a฀lues for these amples are 
recorded in table 9. This data is displayed graphically in figure 30, due to the large numbers 
of samples the complete set of figures from neutralisation assays from this dataset are 
recorded in Appendix 1(c).  
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Figure 30: Percentage neutralisation of convalescent SARS sera from multiple samples.  
Showing reduction in viral titre driven by serum neutralisation. All data shown are normalised based on cell only and virus only 
controls assayed at the same time as the serum. X axis corresponds to log dilution factor with a value of 1.6 correponding to a 
1:40 dilution of the serum.   
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Table 7: IC50 values for Sera panel 2 with positive neutralisation against the MERS-CoV PV. Each sample scored as positive for 
MERS-CoV neutralisation was assayed twice for the MERS-CoV. As all samples had previously been assessed for SARS-CoV 
by non-PV methods a limited number of samples were selected for SARS-CoV PV screening, these values are also listed  
SUBJECT 
ID 







BJ005 SARS 51.0 61.02317 56.0 88.4 
BJ006 SARS 54.6 85.6 70.1   
BJ033 SARS 72.2 74.9213 73.6   
BJ034 SARS 55.2 79.3 67.3   
BJ035 SARS 61.7 64.7 63.2   
BJ038 SARS 87.7 97.612 92.6 108.4 
BJ039 SARS 70.0 61.24 65.6   
BJ040 SARS 57.2 52.176 54.7   
BJ041 SARS 75.0 59.7 67.4   
BJ043 SARS 57.6 92.76434 75.2 116.71 
BJ044 SARS 63.4 51.03874 57.2   
BJ045 SARS 89.0 54.043 71.5   
BJ049 SARS 53.9 61.1 57.5   
BJ050 SARS 58.3 52.647 55.5   
BJ051 SARS 53.8 71.23 62.5   
BJ052 SARS 73.1 85.4641 79.3   
BJ054 SARS 60.6 88.39 74.5   
BJ060 SARS 96.8 67.92172 82.4   
BJ072 SARS 85.6 66.6 76.1   
BJ073 SARS 55.0 103.8268 79.4 99.2 
BJ077 SARS 110.0 69.16844 89.6   
BJ080 SARS 73.8 66.48972 70.2   
BJ084 SARS 56.0 64.99007 60.5   
BJ096 SARS 420.0 117.648 268.8 243.21 
BJ098 SARS 271.9 98.6 185.3 389.4 
BJ099 SARS 79.0 54.07 66.5   
BJ100 SARS 93.4 78.65 86.0   
BJ102 SARS 63.9 51.9 57.9   
GZ 042 Non-SARS 83.1 45.7 64.4 23.8 



































IC 5 0  va lu e s  ca lcu a lte d  fo r S A R S -C o V  P V  a n d  M E R S -C o V  P V
 
Figure 31: Graphical plot displaying mean IC50 values calculated based on two neutralisation tests sera panel 2.  
Trend between MERS-PV (recorded in blue) and SARS-PV (recorded in red) IC50 values is apparent.  













%  N e u tra lis a t io n  fo r  S A R S -C O V  P V  w ith  S e ru m  p a n e l 2  s u b s e t
B J 0 5 2
B J 0 5 6
B J 0 9 6
B J 0 0 4
B J 0 4 3
B J 0 7 7
B J 0 3 2
G Z023
F B S













Figure 32: Percentage Neutralisation of convalescent SARS sera from serum panel 2 with increased initial starting 




4.3.3. Serum panel 3 
Sera Panel 3 consisted of healthy volunteers with no history of clinical respiratory 
disease. This panel was assayed against the MERS-CoV PV with results recorded in figure 
33. Specific IC50 values calculated for these samples are recorded in table 10.  
Table 8: IC50 values for Serum Panel 3 as calculated in Graph Pad Prism 7.02 for MERS-CoV PV.  
Note IC50 values for influenza A PVs calulated separtly with Graph Pad Prism 6.0 
 
MERS IC50 H1 IC50 H5 IC50 H3 IC50 H7 IC50 
46_12V 0 5213 763 2417 424 
51_12V 0 9298 109 1491 637 
53_12V 0 4478 6 21139 1070 
54_12V 36 32973 3 7856 260 
37_12V 0 3011 828 3538 299 
42_12V 0 3528 25 5599 391 
60_12V 0 10518 1782 2292 159 
56_12V 0 3747 670 2836 412 
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Figure 33: Percentage neutralisation of sera drawn from healthy volunteers  
from multiple samples showing reduction in viral titre driven by serum neutralisation. All data shown are normalised based on cell 
only and virus only controls assayed at the same time as the serum. X axis corresponds to log dilution factor with a value of 1.6 
correponding to a 1:40 dilution of the serum.   
 
Results of PV neutralisation assays with Serum Panel 3 as displayed in table 10 clearly 
indicate no serum samples attaining the specified level for neutralisation of the MERS-CoV 
PV. In addition, figure 33 shows that only single sample, 54-12v, displayed any neutralisation 
potential based on serum concentration.  
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4.3.4. Bioinformatics analysis  
Amino acid alignment showed generally limited sequence conservation between the 
SARS-CoV and MERS-CoV spike proteins (<20%). The S1 section showed significant 
divergence (<17%), in contrast the S2 amino acid regions showed an amino acid sequence 
identity of c. 40%. As observed by Chan et. al. (K. H. Chan et al., 2013) this low level of 
similarity reduces the probability that cross-neutralization by antibodies produced in response 
to the S1 region could be responsible for cross reactivity between these viruses, due to the 
low sequence identity in these regions. Although an antibody response may be elictited by a 
small region of similarity, the well conserved regions between coronaviruses are in the 
absence of additional information more likely to contain regions of shared antigenic activity 
and are therefore likely good targets for further study. Table 11 displays the results of analysis 
of the sequences showing the predicted linear epitopes produced by the SVMTrip program.  
Table 9: Epitopes predicted based on SARS-CoV and MERS-CoV spike protein sequences. Epitopes underlined are located 
within the more highly conserved S2 domain 
SARS-COV MERS-COV 
LOCATION Epitope Score Location Epitope Score 
1168 - 1187 LNEVAKNLNESLIDLQELGK 1 662 - 681 IYDKETKTHATLFGSVACEH 1 
943 - 962 TLVKQLSSNFGAISSVLNDI 0.987 1077 - 1096 TLNAFVAQQLVRSESAALSA 0.82 
284 - 303 AELKCSVKSFEIDKGIYQTS 0.978 890 - 909 IEDLLFDKVTIADPGYMQGY 0.77 
84 - 103 KDGIYFAATEKSNVVRGWVF 0.971 345 - 364 SQLHCSYESFDVESGVYSVS 0.668 
701 - 720 SISITTEVMPVSMAKTSVDC 0.971 136 - 155 TSATIRKIYPAFMLGSSVGN 0.637 
328 - 347 VFNATKFPSVYAWERKKISN 0.968 1039 - 1058 ELSNTFGAISASIGDIIQRL 0.53 
154 - 173 DNAFNCTFEYISDAFSLDVS 0.968 585 - 604 CPKLEFANDTKIASQLGNCV 0.504 
1076 - 1095 VFVFNGTSWFITQRNFFSPQ 0.967 1292 - 1311 YNKWPWYIWLGFIAGLVALA 0.428 
1210 - 1229 VMVTILLCCMTSCCSCLKGA 0.966 255 - 274 GITQTAQGVHLFSSRYVDLY 0.397 
580 ± 599 GVSVITPGTNASSEVAVLYQ 0.966 1317 - 1336 ILCCTGCGTNCMGKLKCNRC 0.384 
 
Figure 34 displays the results of Emini Surface Accessibility Prediction and Bepipred 
Linear Epitope Prediction as implement  through the IEDB web based tools, performed on the 
MERS-CoV Spike protein. This figure also highlights the principle features of the spike protein 
to make locations of accessible residues or predicted epitopes apparent. Figure 35 displays 
the results of these same tools as applied to the the SARS-CoV Spike protein, again key 
domains of this protein are highlighted. Figure 36 is an overlay of the Emini Surface 
Accessibility Prediction and Bepipred Linear Epitope Prediction data obtained for the SARS-
CoV with an alignment of the MERS-CoV and SARS-CoV Spike proteins. This figure 
demonstrates where regions of conservation are found and so the likelihood that predicted 
antigenically significant regions may have a role in the observed cross reactivity.   Complete 
output for the Emini Surface Accessibility Prediction and Bepipred Linear Epitope Prediction 
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Figure 34: 2-Dimensional linear structure of the MERS-CoV spike protein with the Surface accessibility scores  
displayed on the bar grap in black. SVTPM predicted epitopes are indicated with brown boxes. Furthermore the graph indicates that a number of potnetial antigenically active sites can be located on the S2 region and in 
particualr the well conserved Hep 2 region may be associated with at least one potential epitope. The threshold for epitope prediction in this figure is induicated by the red line, the values above this line (indicated in 
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Figure 35: 2-Dimensional linear structure of the SARS spike protein with the Surface accessibility scores  
displayed on the bar grap in black. SVTPM predicted epitopes are indicated with brown boxes. Furthermore the graph indicates that a number of potnetial antigenically active sites can be located on the S2 region and in 
particualr the well conserved Hep 2 region may be associated with at least one potential epitope. The threshold for epitope prediction in this figure is induicated by the red line, the values above this line (indicated in 








Figure 36: Epitope predictions based on MERS-CoV Spike protein, including alignment of MERS -CoV S with SARS -CoV S proteins.  
Figure highlighting key structures demonstrating increased conservation in the S2 domain and in particular the high degree of conservation in the Heptad regions. These regions are also the site of several predicted 





Figure 37: Showing the MERS-CoV phylogeny.  
Calculated from (A) the S1 domain indicating the low likelihood values at the nodes and the non-monophyletic grouping of the 
SARS-CoV when compared with other coronaviruses. (B) Shows greater levels of support for the phylogenetic relationships 
between taxa and demonstrates a closer relationship between SARS and MERS indicating that based on the S2 domain these 
are sister taxa. 
 
4.4. Discussion  
Previous studies have showed the potential for cross reactivity among viruses of  the 
coronavirus lineage (He et al., 2006; Vlasova et al., 2007; Zhu et al., 2007; K. H. Chan et al., 
2013). Chan et. al. (2013) demonstrated that among the 28 SARS patients, 17 (60.7%) had 
positive anti-MERS-CoV IgG detected by indirect immunofluorescence (IF) with titres ranging 
from 1:20 to 1:320 based on dilution. All of these MERS antibody positive patients were also 
found to have HCoV-OC43 neutralizing antibodies. Anti-SARS-CoV IF and neutralizing 
antibodies were found in the most (96.4%) of the SARS patients with the majority of these 
having high titres of 1:80 or greater. This study also demonstrated that for a small number of 
patients (4) for which sera was available prior to SARS-CoV infection the anti-MERS and anti-
HCOV43 was significantly lower in the pre-infection sera. Although pre-and post-exposure 
serum samples were not available for this study the available samples did demonstrate that 
positive neutralisation of the MERS-CoV only occurred in patient sera that showed high IC50 
values for SARS-CoV, statistical correlation indicated that there was no direct correlation 
between the SARS-CoV neutralisation and the MERS-CoV neutralisation. Furthermore, the 
Pearson correlation only measures linear relationships between X and Y and for the statistical 
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test to determine a relationship exists between the two datasets, any change in one dataset 
has to have a constant proportional change in the other dataset. If the actual relationship 
between the two datasets is not linear then the result may not accurately reflect the 
relationship between the datasets (Mukaka, 2012).  
Figure 30 provides strong evidence that although the statistical correlation may be 
weak there is a clear link between the high titre for SARS-CoV neutralisation and the 
probability of this sample showing positive neutralisation for MERS-CoV. However, as the 
Pearson correlation indicate that there is no linear relationship between the SARS-CoV IC50 
and MERS-CoV IC50 It is unlikely that a more robust immune response to SARS-CoV will be 
predictive of neutralisation of the MERS-CoV by that same serum. However, figures 28 and 
30 indicate that for both datasets there did appear to be a trend wherein the highest titre 
SARS-CoV did appear more likely to demonstrate positive neutralisation for the MERS-CoV 
PV. The lack of patient specific data concerning past exposure and symptom severity makes 
determination of the role these factors play in the presence of MERS-CoV neutralising 
antibodies in patient sera.  
The results of Serum Panel 3 also clearly indicate that despite high IC50 values 
calculated for several samples when assayed with influenza A PV no samples could be 
considered to have successfully neutralised the MERS-CoV PV. Table 10 shows the 
interesting observation that sample 54_12v indicate a minor drop in infectivity, however this 
drop fell well below the acceptable range at which the serum could be considered as 
neutralising the PV.  In addition, there does not appear to be a link between the IC50 values 
obtained for these samples assayed against different influenza PV and the ability of the 
samples to neutralise MERS-CoV PV. However, the relatively small size contained in this 
dataset mean that this potential cannot be discounted entirely based on this data.   
It was not possible in this study to determine if co-infection with additional viruses was 
a critical factor in determining the likelihood of patient sera showing positive neutralisation for 
MERS-CoV. Detailed patient information will be required in order to investigate this 
phenomenon and form a framework to interpret statistical analysis. It is likely that concomitant 
infection with additional coronaviruses will play at least some role in the further studies of 
coronavirus cross reactivity. Coronaviruses such as OC43, 229E and increasingly NL63 are 
responsible for infections globally and have been linked to 10฀–15% of common cold cases. 
The relatively minor symptoms associated with most coronavirus infections make positive 
association between the two difficult as many infections with these viruses are unlikely to be 
reported and therefore will often not be included in patient notes. Patient details (Appendix 1 
(a)) for serum panel 1 demonstrated that the time from onset of fever did not appear to be 
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diagnostic of high IC50 titres for either SARS-CoV or MERS-CoV. Table 9 and figure 28 both 
show that patient IC50 values vary between sampling times but that there does not appear to 
be a trend towards increasing values as date from fever onset increases. However, 
conclusions on this point could not be reached, as it was unclear from this data due to the 
small dataset and the lack of consistency in the timelines of sampling. This highlights the 
complexity of studies investigating cross-reactivity and the necessity for gathering as much 
information as possible from patient medical records to ensure that data trends can be 
analysed in-detail and statistical analysis can be performed.   
In addition to the impact of the severity of SARS-CoV or concomitant infection on the 
odds of convalescent SARS patient sera displaying MERS-CoV neutralisation the potential 
source of cross-reactive antibodies is a critical factor in understanding the observed data. 
Chan et. al. (2013) already demonstrated the MERS-CoV antibodies in SARS convalescent 
patient sera.  However, this study made limited use of further bioinformatics analysis and 
hypothesised the potential for antigenic activity stimulated by the well-conserved S2 regions 
of the spike protein figures 34-36-42 summarise the potential for epitopes to be in this area 
with five distinct epitopes identified as potentially in this area. This figure also demonstrates 
that a significant portion of this region is accessible for antibody binding. As previously stated 
the MERS-CoV RBD is likely to have therapeutic implications, however as this region is widely 
dissimilar, likely to be highly adaptive and therefore unlikely to be a source of the observed 
antigenic cross reactivity.  A major goal of epitope prediction is to aid the design of compounds 
which can mimic the structure and function of a genuine epitope and provide targets for 
compounds that may inhibit or block viral activity. The most reliable methods for identification 
of an epitope are X-ray crystallography and NMR techniques, however as these procedures 
are complex and require significant commitments in terms of time and expense computational 
methods and tools, are a useful alternative. In silica analysis tools are particularly useful during 
zoonotic spillover viral outbreaks such as the MERS-CoV, where disease spread is often rapid 
and case fatalities are high.  
Studies have identified the potential ectodomains of S (spike) and Orf3a as sources of 
antigenic activity that could elicit a neutralizing antibody response and may therefore be the 
source of observed cross reactivity (Buchholz et al., 2004; Kam et al., 2009; Du, Zhao, et al., 
2013; K. H. Chan et al., 2013).  While previously the potential of other structural proteins 
separate from the S protein could not be ascertained, an advantage of the PV in this form of 
assay is that only the spike protein is present and as such any cross-reactive antibodies are 
by necessity targeting this protein. Since all betacoronaviruses use a broadly similar S protein 
for attachment and fusion of the viron with the host cell membrane the potential for antibodies 
that can be raised against, well-conserved regions of this protein are significant and may show 
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potential for neutralisation against a broad range of coronaviruses. Furthermore, analysis of 
the SARS-CoV and MERS-CoV spike proteins successfully identified a number of potential 
epitopes that are located within this domain. Analysis using the IEDM tools also demonstrated 
that these epitopes were at least partially available on the surface of the protein structure. 
Making use of this analysis as summarised in figure 36, we can clearly demonstrate 
that a number of predicted epitopes lie within several well preserved regions of the spike 
protein. In particular, the S2 domain has yielded a number of potentially previously unknown 
epitopes that are apparently readily accessible on the surface of the folded spike protein. In 
particular, although the SVTPM linear eptiope prediction tool did not indicate the presence of 
antigenically active regions in the well conserved Heptad 2 region towards the C terminal of 
the S2 domain the IEDB tools, Bepipred Linear Epitope Prediction and Kolaskar & Tongaonkar 
Antigenicity did indicate epitopes in this region. It is also suggestive that this region is at least 
partially accessible to antibodies; there are no less than 5 potential antigenically active sites 
identified between 1210 and 1236 by the Kalkaska and Tongaonkar Antigen predication 
algorithm. Further analysis of this phenomenon should be conducted with both alanine 
scanning and the use of yeast based immunology protocols to determine if these regions can 













 Chapter 5 Development of a PV Based Multiplex Assay 
5.1. Introduction  
As previously discussed, the last decade has seen the rise of two major coronavirus 
outbreaks that have had significant costs in both economic and human terms. SARS-CoV 
struck between November 2002 and July 2003 in southern China that spread globally causing 
widespread economic and social disruption and more than 600 deaths (Chan and Chan, 
2013). Today the ongoing outbreak of MERS-CoV has been recorded in more than 20 
countries globally (Banik, Khandaker and Rashid, 2015). In addition, the recent 
unprecedented size and scope of the Ebola outbreak which has been estimated to have begun 
in December 2013 (Carroll et al., 2015) has demonstrated the need for more efficient and 
effective assays and tools for further research into highly pathogenic zoonotic viruses. In the 
case of Ebola since the first published description of the disease in 1976 in Zaire, outbreaks 
have tended to cluster in central and east Africa (Pourrut et al., 2009; Pigott et al., 2014; Volz 
and Pond, 2014; Guyton and Brook, 2015), however this most recent and devastating 
outbreak occurred in west Africa. In all of these cases the spillover events have been traced 
to bat borne RNA viruses  (Woo et al., 2006; Caì et al., 2014; Jayme et al., 2015) and the 
sudden nature of these outbreaks highlighted the gaps in knowledge that exist in 
understanding the ecology and prevalence of viral pathogens within bat hosts.  
Intermittent studies monitoring viral infections in wild bat populations have identified 
serologic evidence for infection of bats with many viruses (Calisher et al., 2006; Moratelli and 
Calisher, 2015) (Chapter 1). But despite this continual emergence of novel pathogens, large 
scale systematic monitoring of bats has not been carried out.  The potential for so many viral 
spillover events originating from bats and due to the difficulty in obtaining serum from such 
small and highly mobile host animals means that protocols that minimise the amount of serum 
used in serological studies are a high priority for any future research.  
The development of a significant panel of PV based on bat borne viruses has 
presented the opportunity to develop safe and efficient multiplex assay systems for the study 
of neutralising antibodies that are indicative of historical infection with the specific virus. A 
multiplex assay makes use of diverse reporter genes expressed by PV bearing the 
glycoproteins of different viruses. Using this system it is possible to use a single serum sample 
to perform a serological assay with multiple different viruses. As each PV will express a 
different reporter gene the transduction of each may be measured independently. 
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In recent years PV has been used in a small number of multiplexing assays for 
detection of different strains of HA in sera panels derived from avian sources (Molesti, Wright, 
et al., 2014) and for the detection of different lyssavirus strains in bat derived serum (Wright 
et al., 2010). This format has also been used to increase the accuracy of screening studies 
examining inhibition of  viruses by various compounds (Zhou et al., 2011). Protocols of this 
type allow the testing of sera against multiple PV at the same time and thus offer the potential 
to reduce the quantity of sera required to conduct screening of multiple viruses. Despite this 
obvious advantage any studies making use of this form of protocol must be aware of and 
control for the potential for cross reactivity which as identified in Chapter 4 can have a 
significant impact on results of micro-neutralisation assays and can be a significance 
confounding factor even in cases such as SARS-CoV and MERS-CoV where the viruses differ 
quite significantly in many respects (Section 4.1).   
The previous studies that have developed these multiplex protocols have used 
different luciferase reporters (Wright et al., 2010; Molesti, Wright, et al., 2014), however the 
reagents required to make use of these reporters can be costly in addition to the requirements 
for specialised equipment in order to read titre signal. The flexibility and adaptability of the PV 
system allow the incorporation of alternative reporter genes with well-established protocols 
making use of PV incorporating LacZ (Wright et al., 2009) and a range of fluorescent proteins 
(Nefkens et al., 2007; Kaku et al., 2009). Although fluorescent proteins do require expensive 
equipment to, accurately gauge the results of neutralisation assays, this equipment often has 
a broad range of functions and so may be available to research groups that lack the more 
specialised luciferase reading equipment. Furthermore, the need to establish large scale and 
long-term surveillance studies in order to identify novel emerging diseases may require the 
acquisition of a range of specialised equipment. In such cases the cost of such equipment 
may limit the scale of such studies . The cost and complexity of such studies means that serum 
obtained during the course of them must be used to best effect and in particular the additional 
complexity caused by the legal framework that governs the management of bats makes this 
need even more acute. In these situations, the multiplex format increases the potential return 
of data from a single serum sample.  
Studies of this kind are increasingly needed as ongoing human development and 
expansion of human settlements increases the interaction between humans and their 
domesticated animals and bats, thus driving increasing rates of infections. Previously, there 
has been passive surveillance on dead animals and limited sporadic surveys of live bat 
populations (Woodall and Baer, 1966; Li et al., 2010; Zhang et al., 2013), however the growing 
awareness that more comprehensive and systematic studies are needed is driving the need 
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to develop new and more fit for purpose tools to conduct such studies (Smith and Wang, 
2013).  
This chapter will investigate the potential for the development of a multiplex assay 
incorporating viruses from three different viral families, the Coronaviridae, the Filoviridae and 
the Rhabdoviridae. The successful development of an assay of this type offers the potential 
for significant improvements in the efficiency and cost effectiveness of serological studies into 
disease prevalence.  
The use of three socially and economically important viruses with limited epidemiological 
distribution information offers an effective and timely solution to ongoing research needs. In 
addition, at the time of writing there are no published accounts of the use of three viruses in 
an assay of this type.    
5.2. Materials and methods 
The construction of PV was performed as outlined in Chapter 2 and, in the case of the 
MERS-CoV PV, using the optimised protocol as described in Chapter 3. Some modifications 
of this protocol were attempted in the case of the renilla luciferase reporter containing PV as 
improvements of the production efficiency from this reporter were attempted. 
5.2.1. Cell line preparation and plasmids  
Due to the differences in cell line susceptibility it was necessary to make use of 
HEK293T/17 cells that had been transfected prior to the multiplex assays with the DPP-4 
(CD26) cellular receptor, that facilitates MERS-CoV PV entry into these cells (Chapter 3). The 
DPP-4 receptor as described in Chapter 2 was previously cloned into the mammalian 
expression vector pcDNA3.1 which utilises the cytomegalovirus (CMV) enhancer-promoter for 
high-level expression of the inserted protein. Transfection of this plasmid into the HEK293T/17 
target cells for assay was conducted using a PEI transfection as described in Chapter 2, with 
500ng of pcDNA3.1-DPP-4 transfected into target cells 48 hours prior to conducting the assay. 
This step was required in order to create a cell line in which all three PV could be transduced, 
although the HUH7 cell line was proven in chapter 3 to be optimal for MERS-CoV PV 
transduction this cell line did not prove susceptible to the Rabies PV used in this study (CVS-
11).  
 PV was produced bearing the MERS-CoV spike, the Ebola/Mayinga glycoprotein and 
the rabies (CVS-11) glycoprotein for incorporation in the multiplex assay. These glycoproteins 
were incorporated into PV with the firefly luciferase reporter (pCSFLW) in order to test the 
expected titre and to accurately calculate the IC50 values of the serum samples to be used in 
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the assay. This is due to the difficulties that may arise when IC50 values are assessed using 
the more difficult to quantify microscopic evaluation methods. MERS-CoV PV was prepared 
with a firefly luciferase reporter, Ebola PV was produced using emerald (em) GFP 
(pCSemGW) and Rabies CVS-11 was produced using the tomato red fluorescent protein 
(tRFP) which was previously cloned into a an expression vector in which  a nuclear localisation 
signal sequence was used as a linker sequence between two copies of the tRFP gene 
(pCSdNTW).  
5.2.2. Construction of MERS-CoV with firefly and renilla luciferase reporter 
Lentiviral vector (carrying the Renilla luciferase reporter gene, pCSRLW) pseudotyped 
with the MERS-CoV S codon optimised glycoprotein. Transfections with this reporter gene 
฀w฀a฀s฀ ฀a฀t฀t฀e฀m฀p฀t฀e฀d฀ ฀w฀i฀t฀h฀ ฀P฀E฀I฀ ฀a฀n฀d฀ ฀F฀u฀g฀e฀n฀e฀ ฀6฀™฀ ฀a฀s฀ ฀o฀u฀t฀l฀i฀n฀e฀d฀ ฀i฀n฀ ฀S฀e฀c฀t฀i฀o฀n฀ ฀2฀. 9฀. 2 ,฀ ฀i฀n฀ ฀a d d i t i฀o฀n  t o  ฀t฀h฀e  M฀E฀R฀S-
CoV PV production was also carried out with VSV-G to provide an additional control virus. In 
฀a฀d฀d฀i฀t฀i฀o฀n฀,฀ ฀t฀h฀e฀ ฀t฀r฀a฀n฀s฀f฀e฀c฀t฀i฀o฀n฀ ฀w฀a฀s฀ ฀a฀t฀t฀e฀m฀p฀t฀e฀d฀ ฀w฀i฀t฀h฀ ฀E฀n฀d฀o฀f฀e฀c฀t฀i฀n฀™  L e n t i฀ ฀T r a n฀s฀f฀e฀c฀t฀i o n฀ ฀R฀e฀a฀g฀e฀n฀t฀ 
(GeneCopoeia Cat. # EFL1001-01/02) using the following protocol outlined in Section 2.9.3 
5.2.3. Production of Ebola/Mayinga PV with firefly luciferase and emGFP 
reporter genes 
Separate lentiviral PV preparations bearing the Ebola/Mayinga glycoprotein, were 
produced incorporating either the pCSFLW or the emerald green fluorescent protein (emGFP) 
reporter gene (pCSemGFP). Transfection was carried out as per production protocol outlined 
in Section 2.9 for PEI production of PV with quantities of plasmid DNA as outlined in tables 12 
and 13  
Table 10: Production of Ebola/Mayinga PV with the firefly luciferase reporter gene 
Plasmid Target Conc. ng/µl 
Ebola glycoprotein-pCAGGS 1000 
HIV Gag Vector- P8.91 1000 
F. luciferase Reporter ± pCsFLW 1500 
 
 
Table 11: Production of Ebola/Mayinga PV with the emerald GFP reporter gene 
Plasmid Target Conc. ng/µl 
Ebola glycoprotein-pCAGGS 1000 
HIV Gag Vector- P8.91 1000 
GFP Reporter ± pCsemGFP 1500 
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5.2.4. Production of Rabies glycoprotein expressing firefly luciferase and tRFP 
reporter genes 
Production of PV bearing the rabies CVS-11 glycoprotein and expressing either the 
firefly luciferase reporter gene encoded by pCSFLW or the tomato red fluorescent protein 
(tRFP) encoded by pCSdNTW followed the same protocol as described in Section 2.10 for 
PEI transfection based production of PV. Plasmid quantities for these transfections were 1000 
ng of Rabies (CVS-11) expression plasmid in a ratio of 1:1:1.5 with lentiviral gag core and 
reporter gene expression plasmid. Both CVS-11 and Ebola/Mayinga PV were also produced 
with the firefly luciferase following this same procedure. This enabled simple and rapid testing 
for cross reactivity and allowed the initial IC50 values of the serum samples against their target 
viruses to be determined, a task that is functionally impossible through microscopy.   
5.2.5. Serum samples   
To neutralise RABV PV, serum was used from a human subject vaccinated on days 0, 
7 and 21 with the inactivated Rabipur vaccine (Novartis Vaccines, Germany) which was 
provided by Dr Edward Wright (University of Westminster). To neutralise the Ebola/Mayinga 
PV commercially prepared serum produced by NIBSC was purchased, this is a standardised 
reference serum for Ebola neutralisation (NIBSC cat.# 15/220). To neutralise the MERS-CoV 
PV serum samples from serum panel 2 (Section 4.2) were used. Due to lack of serum MERS-
CoV serum from serum numbers BJ96, BJ55 and BJ74 were pooled to provide sufficient 
serum for duplication of the multiplex micro-neutralisation.  
5.2.5.1. Calculation of IC50 values for serum samples  
Prior to conducting the multiplex assay the IC50 of each sera sample was calculated 
฀t฀o฀ ฀a฀s฀s฀e฀s฀s฀ ฀t฀h฀e฀ ฀a฀b฀i฀l฀i฀t฀y฀ ฀o฀f฀ ฀t฀h฀e฀s฀e฀ ฀s฀e฀r฀a฀ ฀s฀a฀m฀p฀l฀e฀s฀ ฀t฀o฀ ฀n฀e฀u฀t฀r฀a฀l฀i฀s฀e฀ ฀t฀h฀e฀ P฀V ’฀s฀ ฀a฀g฀a฀i฀n฀s฀t฀ ฀w฀h฀i c h฀ t h e฀y฀ ฀w฀o฀u฀l฀d฀ ฀b e  
tested. This calculation was performed using the firefly luciferase expressing PV of each virus 
฀a฀n฀d฀ ฀t฀h฀e฀ ฀c฀a฀l฀c฀u฀l฀a฀t฀i฀o฀n฀s฀ ฀w฀e฀r฀e฀ ฀p฀e฀r฀f฀o฀r฀m฀e฀d฀ ฀i฀n฀ ฀G฀r฀a฀p฀h฀p฀a฀d฀™฀ ฀P฀r฀i฀s฀m฀ 7 . 0 2  following the procedures as 
outlined in Section 2.11. Cross reactivity of the serum samples between each of the viruses 
used in the multiplex was also assessed to determine the degree of any cross-reactivity 
between viruses. Cross reactivity was also carried out with VSV-G PV and Marburg/Lake 
Victoria PV.  
Serum samples were prepared by a colleague, and blinded to avoid any potential bias 
in the identification of neutralisation as determined using the fluorescence of cells transduced 
with fluorescent reporter expressing PV. Serum preparations with pre-blinding designations 
are recorded in table 14 after preparation these sera mixes were re-labelled with numerical 
values 1-4 with number values assigned to each preparation at random. The relabeling was 
 139 
 
conducted by researcher George Carnel and after this relabeling Keith Grehan had no access 
to the label assignment details and so was blinded to the content of tubes, now labelled 1-4. 
 
Table 12: Serum composition as prepared with prior to relabelling and blinding of primary researcher 
 
A B C D 
SARS-COV 
SERUM 
10ul 5ul 5ul 20ul 
RABIES SERUM 10ul 20ul 5ul 5ul 
EBOLA SERUM 10ul 5ul 20ul 5ul 
  
5.2.6. Multiplex assay 
Multiplex assay plates were laid out as per figure 38, when assessing the fluorescence 
of the cells four views were taken for each well with the X10 objective lens in place (giving 
X400 magnification in total). The diameter of single well of a 96 well plate is 7 mm (direct 
measurement)  (Scientifi, 2011) and the field of view under X10 objective lens was calculated 
to be 2 mm, therefore four independent cell counts taken from each well represents an efficient 
and effective method to assess the overall rates of successful transduction in a particular well. 
After fluorescent cell data had been acquired the firefly luciferase reporter gene was evaluated 
using the Bright-฀G฀l฀o฀™฀ ฀a฀s฀s฀a฀y฀ ฀s฀y฀s฀t฀e฀m฀ ฀(฀P฀r฀o฀m฀e฀g฀a฀,฀ ฀c฀a฀t฀.฀ ฀#฀ ฀E฀2฀6฀5฀0฀,฀Ψ฀ ฀a฀n฀d฀ ฀G฀l฀o฀M฀a฀x฀™ Multi detection 
system luminometer (Promega, cat. # E7041), following the protocol as outlined in chapter 2 
with some modification. After addition of the Bright-฀G฀l฀o฀™฀ ฀L฀u฀c฀i฀f฀e฀r฀a฀s฀e฀ ฀A฀s฀s฀a฀y฀ ฀S฀y฀s฀t฀e฀m฀ ฀s฀o฀l฀u฀t฀i฀o฀n 
and DMEM mix the plate was centrifuged at 500 rpm for 1 min and incubated at room 
temperature for 5 minutes, as per protocol outlined in chapter 2, however the clear plastic 
plates required for the microscopic evaluation of the fluorescent gene expression are not 
suitable for use in GloMax Multi detection system luminometer (Promega, cat. # E7041) for 
reading luciferase expression. Therefore, after incubation with the Bright-฀G฀l฀o฀™ s lution the 
Figure 38: Plan of multiplex plate showing positioning of controls and the locations of each of 
the serum samples. As per the labelling assigned during the blinding process the well indicated as 12A 
also shows the plan for four distinct counts within the well and this was followed for all wells in the plate. 
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cells were examined under a microscope to insure cell lysis had completed and the solution 
was then transferred to a pre-฀p฀r฀e฀p฀a฀r฀e฀d฀ ฀n฀u฀n฀c฀™฀ ฀w฀h฀i฀t฀e฀ ฀9฀6฀ ฀w฀e฀l฀l฀ ฀p฀l฀a฀t฀e฀,฀ ฀l฀a฀b฀e฀l฀e฀d฀ ฀t฀o฀ ฀c฀o฀r฀r฀e฀s฀p฀on฀d฀ t o  
the clear plate in which the assay was initially carried out. This allowed the luciferase 
expression to be measured and the pre-preparing of the white plate insured that the plate plan 
was preserved during the transfer.  
The micro-฀n฀e฀u฀t฀r฀a฀l฀i฀z฀a฀t฀i฀o฀n฀ ฀a฀s฀s฀a฀y฀ ฀w฀a฀s฀ ฀c฀a฀r฀r฀i฀e฀d฀ ฀o฀u฀t฀ ฀i฀n฀ ฀N฀u฀n฀c฀™฀ ฀9฀6- w฀e฀l l฀ ฀M i฀c฀r฀o W฀e฀l฀l ™฀ ฀w฀h i฀t฀e฀ 
polystyrene plates and reagent reservoirs were used; as all serum used in these assays were 
of human origin all serum handling was done using either MultiGuard NX Barrier tips The 
assay was then carried out as per micro-neutralization assay protocol described in Section 
2.11. However, viral input was modified, due to the need for three distinct viruses to be added 
each with different titration values. ฀A฀l฀l฀ ฀v฀i฀r฀u฀s฀e฀s฀ ฀w฀e฀r฀e฀ ฀‘฀s฀c฀o฀r฀e฀d฀’฀ ฀p฀r฀i฀o฀r฀ ฀t฀o฀ ฀t฀h฀e฀ ฀b฀e฀g฀i฀n฀n฀i฀n฀g฀ ฀o฀f฀ ฀t฀h฀e฀ ฀as s a y ,  ฀ 
with a simple numerical RLU per mL used for the MERS-CoV firefly luciferase PV, following 
the protocol as set out in Section 2.11. For fluorescent protein reporters, a scoring sheet was 
printed with the number of green fluorescent and red fluorescent cells to be recorded in each 
well (Table 15). 
Table 13: Example of scoring sheet created to identify the number the number of green and red fluorescent cells in each well of 
the 96-well plate  
  
Col 1  
Dilution Well # GFP # RFP # 
1:40 1     
1:80 2     
1:160 3     
1:320 4     
1:640 5     
1:1280 6     
1:2560 7     
1:5120 8     
 
5.3. Results  
5.3.1. Production of MERS-CoV and VSV-G expressing PV with a renilla 
luciferase reporter gene 
 MERS-CoV PV production with the renilla luciferase reporter gene was conducted 
using a VSV-G bearing PV as a control. Results of these experiments are recorded in figure 
39 (A-C), in this figure (A) displays the results of MERS-CoV PV and VSV-G PV with renilla 
compared to firefly luciferase reporter expressing PV produced on the same day with producer 
cells sub-cultured from the same plate 24 hours prior to transfection. Figure 39 (B) displays 
the results of all three different transfection reagents that were used for production of renilla 
expressing PV in an effort to increase the production efficiency. Figure 39 (C) displays the 
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results of variation in titre based on changing concentration of renilla reporter gene expressing 
plasmid during the PV production process 
Figure 39: Comparisons between renilla and firefly reporter genes demonstrating lower titres for renilla containing PV.   
Figure (A) displays the results of MERS-CoV PV and VSV-G PV with renilla compared to firefly luciferase reporter expressing PV 
produced on the same day with producer cells from the same culture, Figure (B) displays the results of different transfection 
reagents used for production of renilla expressing PV. Figure (C) displays the results of variation in titre based on changing 
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5.3.2. Production of tRFP and emGFP PV expressing Rabies CVS-11 and 
Ebola/Mayinga glycoproteins 
 PV supernatant was titrated against HEK293T/17 previously transfected with DPP-4 
as per Section 5.2. Figure 40 displays images taken from first two wells of titration, these 
wells correspond to the highest levels of virus used in the titration. Table 16 displays more 
detailed results of these titrations with wells scored to allow calculation of approximate viral 
input into multiplex assay.  
  
Figure 40: Results of titration of fluorescent protein expressing PV.  
From left to right Ebola/Mayinga emGFP PV FITC filtered microscopic image, brightfield image of same area of well, Rabies 
CVS-11 tRFP PV with TRITC filter engaged, same view under brightfield, Cell only control with FITC filter engaged, same view 
under brighfield. Only the two highest concentrations of virus are show in image with the topmost image corresponding to a 1:2 
dilution and the lower image a 1:4 dilution. ฀I฀m฀a฀g฀e฀ ฀i฀s฀ ฀b฀r฀i฀g฀h฀t฀e฀n฀e฀d฀ ฀u฀s฀i฀n฀g฀ ฀i฀n฀k฀s฀c฀a฀p฀e฀™฀ ฀p฀r฀i฀o฀r฀ ฀t฀o฀ ฀p฀u฀b฀l฀i฀c฀a฀t฀i฀o฀n฀. Mag. X10.  
 
Table 14: Results of Titrations of emerald GFP and tomato RFP titrations against a cell 293 cell line transfected with 
DPP-4 receptor 48 hours previously. Values are based in based on four counts per well with results averaged. 
  
EBOLA-
EMGFP CVS-11 TRFP 
DILUTION Well # GFP % RFP % 
1:2 1 30% 80% 
1:4 2 20% 75% 
1:8 3 15% 50% 
1:16 4 15% 30% 
1:32 5 15% 20% 
1:64 6 10% 20% 
1:128 7 5% 20% 
1:256 8 >2%* 15% 
 
5.3.2. Serum cross reactivity analysis  
Figures 41 and 42 display the results of serum neutralisation against, figure 41 other 
viruses used in the multiplex and figure 42 related two viruses not used in the multiplex but 
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Figure 41: Results of neutralisation assays of serum Vs different PV preparations  
Assay conducted with rabies serum assayed against (A) Rabies PV (B) Ebola PV (C) MERS-CoV PV, Ebola serum assayed against (D) Rabies PV (E) Ebola PV (F) MERS-CoV PV and MERS-CoV 
serum assayed against (G) Rabies PV (H) Ebola PV (I) MERS-CoV PV 
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S e ru m  s a m p le s  a s s a y e d  a g a in s t P V
 
Figure 42: Multiplex sera assayed against VSV-G PV  
This testing is to indicate non-specific neutralisation with results against (A) Rabies serum showing positive neutralisation curve 
(B) Ebola serum showing no neutralisation and (C) MERS-CoV serum showing no neutralisation  
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5.3.3. Multiplex assay results 
Figure 43 displays results of Bright-฀G฀l฀o฀™฀ ฀a฀s฀s฀a฀y฀ ฀c฀o฀n฀d฀u฀c฀t฀e฀d฀ ฀p฀o฀s฀t฀ ฀m฀i฀c฀r฀o฀s฀c฀o฀p฀y฀ ฀r฀e฀s฀u฀l฀t฀s฀.฀ 




































S e ru m  1
S e ru m  2
S e ru m  3




































S e ru m  1
S e ru m  2
S e ru m  3
S e ru m  4
 
Figure 43: Results of luciferase reporter neutralisation assay showing evidence of neutralisation  
only in the serum samples marked as serum 1. 
Fluorescent cells were observed for each plate as per tables 17 and 18 with the mean 
values rounded to the nearest whole number reported here and the complete scoring for 
counts reported in Appendix 2 (a). Images taken from plate 1 displaying brightfield images of 
each of the first four wells for each serum column (i.e. the four wells with the largest 
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concentration of serum) and corresponding TRIC and FITC filtered image is recorded in 
Appendix 2 (b).  
Table 15: Mean values of counts emGFP expressing cells after four counts taken from each well of the 96 well plate.  
Dilution indicates the serum dilution in the well. Ebola Ctl. is an assay using NIBSC Ebola serum in an unblended fashion as a 
control for the assay, MERS Ctl is the same un-blinded control with the MERS-CoV pooled serum. At the time of the assay Serum 
tubes were labelled 1-4 with the researcher conducting the assay blind to the contents and this labelling has been preserved 
here. Virus only is a control of only the mixed virus with no serum added to the wells  
Dilutution Log Dilution Ebola Ctl MERS Ctl Serum 1 Serum 2 Serum 3 Serum 4 Virus Only 
40 1.60206 1 13 26 7 7 7 15 
80 1.90309 4 11 6 6 9 4 14 
160 2.20412 9 15 11 7 6 4 17 
320 2.50515 9 15 9 9 6 7 13 
640 2.80618 15 14 9 6 6 9 6 
1280 3.10721 12 17 11 9 10 9 14 
2560 3.40824 11 11 6.5 5 12 13 15 
5120 3.70927 17 15 6.5 9 8 1 6 
 
Table 16 : Mean values of four counts of tRFP expressing cells.  
Dilution indicates the serum dilution in the well. Ebola Ctl. is an assay using NIBSC Ebola serum in an unblended fashion as a 
control for the assay, MERS Ctl is the same un-blinded control with the MERS-CoV pooled serum. At the time of the assay Serum 
tubes were labelled 1-4 with the researcher conducting the assay blind to the contents and this labelling has been preserved 
here. Virus only is a control of only the mixed virus with no serum added to the wells 
Dilution Log Dilution Ebola Ctl MERS Ctl Serum 1 Serum 2 Serum 3 Serum 4 Virus Only 
40 1.60206 31 49 28 3 0 20 50 
80 1.90309 31 44 5 15 2 10 46 
160 2.20412 26 31 27 40 7 20 34 
320 2.50515 37 36 30 40 14 9 34 
640 2.80618 34 55 41 36 25 39 38 
1280 3.10721 42 33 49 39 27 36 24 
2560 3.40824 42 39 65 54 37 49 47 
5120 3.70927 38 29 64 62 18 4 7 
 
5.3.4. Un-blinded data 
Table 19 provides a translation of numerical serum labels as used in the multiplex 
assay in a blinded fashion, to the unblinded data as recorded in table 14. This data w used in 
the unblinding which occurred after all data have been gathered and serum samples scored, 
data and analysis was then circultated to lab collegues at which time the primary researcher 
was unblended and the results of the assay compared to the serum make-up.  
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Table 17: Unblinded data provided after the multiplex plates had been read and all data shared with lab colleagues.  In this 
schematic alphabetical value correspond to data recorded in table 14 numerical values are the corresponding blinded labels. 
Serum 4 = A, Serum 3 = B, Serum 2 = C and Serum 1 = D. 
 
A B C D 
SARS-COV SERUM 10 5 5 20 
RABIES SERUM 10 20 5 5 
EBOLA SERUM 10 5 20 5 
BLINDED LABEL Serum 4 Serum 3 Serum 2 Serum 1 
 
5.4. Discussion 
Based on the results of both the luciferase and fluorescent assays it was determined 
that serum 1 was the serum with greatest MERS-CoV antibodies, serum 3 was determined to 
have the highest concentration of rabies serum as data compiled in table 18 show a clear 
relationship between the concentration of this serum and the count of fluorescent red cells. 
However, the most potent mix of Ebola serum could not be determined, as indicated in table 
17 no serum matched the counts of cells in the Ebola control column. This is likely due to the 
comparatively low number of cells successfully transduced by this PV preparation. 
Furthermore, the high IC50 of the rabies serum meant that even the trace amounts of this 
serum in Serum 2 and 4 resulted in a reduction in the number of cells successfully transduced 
at the highest levels of serum concentration. Despite these limitations the successful 
determination of the most potent serum samples for two of the three viruses represents a 
significant milestone in the development of this assay.  
The use of PV as surrogate viruses in serological assays is increasing in popularity 
and application, in this chapter a number of novel applications have been adapted to make 
improved use of the flexibility of the PV system. The ability to identify the MERS-CoV positive 
serum in a dilution of other sera in a blinded fashion and with the compounding factor of 
additional sera added in a mixture demonstrates that the theoretical framework of such an 
assay is sound and presents an opportunity to develop more efficient assays in the future that 
may with refinement make the sort of long term systematic studies of wildlife serology cost 
effective and feasible. It has previously been demonstrated that multiplexing of HA based PV 
using avian sera was also described was an effective method of improving the power and 
efficiency of the micro-neutralisation assay (Molesti, Wright, et al., 2014). Multiplex serology 
in one form or another already plays an important role in clinical differential diagnosis in the 
field of veterinary medicine where Luminex technologies provide multiplex assays (Lin et al., 
2011; Sehr et al., 2013) that improve the cost effectiveness of viral monitoring in livestock. 
However the cost of this analysis per assay means that while it is well suited to livestock 
management where the monitoring of livestock herds relies on statistics-based sampling of a 
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small proportion of the total population to minimize cost (Mortensen et al., 2001; Anderson et 
al., 2011).  
For wildlife serology multiplex assays making use of the PV system offer a number of 
advantages, as previously demonstrated there are well established protocols making use of 
multiple luciferase expressing PVs, in this study we demonstrate that even lacking the 
specialised equipment traditionally used to assess the levels of fluorescence in a cell culture 
it is possible to assess the presence of antibodies in patient serum with a significant degree 
of accuracy.  Although the production of renilla expressing PV was not successful this was 
likely linked to renilla reporter assay reagents that were found to be significantly out of date 
and so the failure of these PV is not indicative of a failure of this system. When combined 
together the potential to use dual luciferase reporters combined with fluorescent proteins open 
the potential to use single serum samples to detect several viruses, among the well-
established reporter genes are there are a large number that have non-overlapping emission 
spectra (Kremers et al., 2011; Chu et al., 2016) (figure 44). With proven techniques 
establishing the use of both different luciferase and fluorescent reporter genes offers the 
potential for expanding on this triplex virus assay to develop assays that can detect potentially 
many viruses assuming the availability of viable PV expressing suitable reporters.  
 
Figure 44: Emission and excitation wavelength of some of the commonly used fluorescent proteins (Chu et al., 2016). 
Values of excitation and emission wavelengths may be of use in planning of future multiplexing assays. Proteins that do not 
overlap in emission spectrum may be used in conjuction with each other. 
 
 Furthermore, the stability of PV has been demonstrated (Mather et al., 2013; Bentley, 
Mather and Temperton, 2015) and the ability to lyophilize and transport PV makes these ideal 
tools when used in the context of the multiplex assay the potential improvement in the amount 
of data that can be generated from small amounts of sera.  
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Chapter 6 Generation of PV with H17 Haemagglutinin  
6.1. Background 
Influenza A virus is the causative agent of influenza disease which is a large burden to 
the economy of countries worldwide and represents a significant public health risk world-wide 
(Ma et al., 2009; Reperant, Kuiken and Osterhaus, 2012). Influenza A virus belongs to the 
family Orthomyxoviridae alongside influenzas B, C and the recently identified D, these viruses 
all possess a segmented, negative-sense RNA genome. As discussed in Chapter 1 both the 
first and second stages of the viral replication process is mediated by the influenza 
glycoprotein HA which is expressed on the outer coat of the influenza virus. This protein 
mediates both the attachment of the influenza virus to the target cell and the fusion process 
which allows the virus to pass its genetic material through the cell membrane. The specific HA 
expressed by a virus is used as a method for distinguishing different viral strains (Tong et al., 
2012) as the HA is a key determinant of virus tropism (Sahini, Tempczyk-russell and Agarwal, 
2010; dos Reis et al., 2011). While the association between influenza viruses and wild birds 
has long been appreciated (J. F.-W. Chan et al., 2013) the discovery of novel influenza virus 
in bats has resulted in a significant shift in the influenza research field (Tong et al., 2012, 2013; 
X. Sun et al., 2013).  
The H17N10 influenza virus was isolated, followed by H18N11, from bat species in 
Guatemala and appears to have diverged significantly from previously known influenza strains 
with all eight of the viral gene segments differing markedly from any influenza A gene 
segments (Tong et al., 2012). As both the HA and NA display unique characteristics (chapter 
1) and given the critical role that the NA proteins play in the reproductive cycle of other 
influenza A viruses the unusual properties of the N10 and N11 proteins may indicate an 
alternative replication method (Li et al., 2012). As such this chapter will also include an attempt 
to incorporate the N10 protein into the production of the H17 PV.  
At present the degree to which the H17 and H18 isolates are capable of infecting non-
bat hosts is unknown, however sequence analysis indicates that there is significant potential 
of spillover occurrence and further research is required to assess the true potential of these 
virus strains as potential pandemic threats (Juozapaitis et al., 2014; Freidl et al., 2015). This 
chapter will outline the a study the H17 virus, through the attempted generation of H17 bearing 
PV with lentivirus Gag-Pol promotor cores and a reporter gene, all combined via the co-
transfection of expression plasmids (Ferrara et al., 2013). PV were generated incorporating 
either green fluorescent protein reporters or a firefly luciferase reporter. In addition taking 
advantage of the structure of the HA protein it was possible to generate chimeric 
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haemagglutinin structures incorporating the head region of one HA with the stalk region of 
another (Hai et al., 2012) and this chapter will outline the methods involved in using this 
technique to produce chimeric HA with components of  H5 and H17. The successful production 
of PV of this type would offer a potential tool in the study of antibody response to the H17 
novel influenza and may be particularly informative for studies investigating antibody cross 
reactivity.  
6.2. Materials and methods 
The H17 HA was previously sub-cloned into a PI.18 vector, by Dr Francesca Ferrara, 
this plasmid includes the additional polyadenylation signals required to facilitate gene 
transcription into mRNA as well as allowing its nuclear export, and improving the inserts 
stability. This plasmid also includes a CMV based promotor (Section 2.1.2.). In addition, the 
pI.18-H17 construct also includes a Kozak consensus sequence which has been determined 
to improve the yields of protein from inserted genetic materials (Section 2.1.2).  
6.2.2. Cell lines and reagents 
Multiple cell lines were used in titrations, with initial attempts using the cell lines 
discussed in Chapter 2, MDCK (type 1),  HEK293T/17,  Huh-7,  Caco-2,  Vero, DF-1, BHK, 
QT-6 and A549. In addition a single titration was conducted using the U87-MG cell line by a 
colleague (Stuart Mather) prior to the commencment of this research. However later attempts 
to resuscitate U87-MG frozen stocks were not successful within the time of this research. In 
addition, upon completion of this research two additional cell lines MDCK (Type II) and 
RIE1495 were kindly provided by Dr  Gert Zimmer (Division of Virology at the Institute of 
Virology and Immunology in Switzerland). Titrations with these cell lines occurred after the 
primary research program had been completed and were conducted by a colleague (George 
Carnell) within the Viral Pseudotype Unit. 
6.2.1. Phylogenetic reconstruction of the H17N10 and H18N11 viruses (within 
the influenza A genus  
Viral sequences were retrieved from the GenBank NCBI database and a list of 
accession numbers is recorded in table 20. Multiple Sequence Alignment (MSA) was 
performed using the MUSCLE alignment algorithm (Edgar, 2004) implemented in the MEGA 
6.0 (Tamura et al., 2011) program. Phylogenetic reconstruction was performed using ML 
methods implemented through MEGA. Reconstruction of the phylogeny of the HA sequences 
of the influenza A viruses was conducted to determine the closest HA sequences to the H17 
from those available at the time of the study. This step was conducted to improve the likelihood 
of successful chimeric HA production.  
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Table 18: Details of sequences downloaded for inclusion in H17 phylogeny. List is a mixture of nucleotide and amino acid 
sequences as only translated sequences were used so nucleotides were translated prior to alignment 
ACCESSION NO. STRAIN ISOLATE DETAILS HOST 
CY053627.1 H1N1 A/Russia/165/2009 Human 
CY117389.1 H2N3 A/mallard/Alberta/242/2004 Mallard 
EU045371.1 H3N2 A/swine/Italy/297576/2004 Swine 
CY187095.1 H4N8 A/blue winged-teal/Wisconsin/12OS4304/2012 Teal 
HM006759.1 H5N1 A/Viet Nam/1203/2004 Human 
CY116633.1 H6N1 A/ruddyturnstone/Delaware/892/2002 Ruddy turnstone 
EU258943.1 H7N7 A/swine/Missouri/4296424/2006 Swine 
ABI84519.1 H8N4 A/turkey/Ontario/6118/1968 Turkey 
AGO17970.1 H9N2 A/turkey/Pavia/141/1983 Turkey 
ABI84469.1 H10N9 A/duck/Hong Kong/562/1979 Duck 
AAV91221.1 H11N2 A/mallard/Netherlands/7/99 Mallard 
ABB87249.1 H12N5 A/mallard/Alberta/52/1997 Mallard 
AAV91213.1 H13N6 A/black-headed gull/Sweden/1/1999 Black-headed Gull 
GQ247868.1 H14N5 A/mallard/Gurjev/263/1982 Mallard 
AAA92247.1 H15N8 A/duck/Australia/341/1983 Duck 
ACV86820.1 H16N3 A/black headed gull/Mongolia/1756/2006 Black-headed Gull 
AFC35438.1 H17N10 A/little yellow-shouldered bat/Guatemala/060/2010 Bat 
AGX84934.1 H18N11 A/flat-faced bat/Peru/033/2010 Bat 
 
6.2.2. H17N10 bat influenza PV production with firefly luciferase reporter 
To produce influenza A HA PV, it is necessary to activate the HA via proteolytic 
cleavage causing HA maturation. Without protease maturation HA is not capable of initiating 
virus/cell fusion (Chapter 1) (Galloway et al., 2013). Ubiquitously expressed proteases, in 
particular furin-like proteases that are expressed in the HEK293T/17 producer cell line used 
in this study for transfection (Böttcher-Friebertshäuser, Klenk and Garten, 2013) and these 
proteases are sufficient to result in cleavage of highly pathogenic influenza HA such as the 
H5 strains, during the production of PV. However, for other HA strains that are either cleaved 
very inefficiently or not cleaved at all by these HEK intrinsic proteases, the specific protease 
required to induce successful cleavage must be added to the HEK293 cells, this is usually 
done via co-transfection of an expression plasmid containing the desired protease coding 
region (Ferrara et al., 2013; Carnell et al., 2015). As the nature of protease cleavage in the 
H17 HA protein is yet unknown it was decided to test several in-house proteases during the 
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production process to determine the optimal protease for H17 cleavage. Figure 45 
summarises the protocol used for generation of influenza PV including both the protease 
expression vector and the addition of neuraminidase to facilitate cell exit. 
In order to test the effects of different proteases in the production of H17 PV the 
protocol described in Section 2.9 for reduced volume transfection in 35mm cell culture plates 
was used: transfection reactions were performed in the wells of 6-well plates in 2 ml media 
volume and all other reagents including the Opti-MEM® volumes, plasmids quantities halved 
relative to 100mm culture plates while maintaining a fixed plasmid ratio of 1:1.5:1. The 
employed protocol did not differ markedly from the protocol outlined in chapter 2, however the 
protocol in brief was, a DNA mix containing 500 ng of p8.91, 750 ng of pCSFLW or pCSeGW, 
and 500 ng of HA-expressing plasmid was prepared and then a protease-encoding plasmid 
(Chapter 2: pCAGGS-HAT, pCAGGS-TMPRSS2 or pCAGGS-Furin) was added to permit HA 
cleavage/maturation and test the activity of HAT, TMPRSS2 and Furin. 
For this testing, three quantities of protease-encoding plasmids were tested (125ng, 
250 ng and 500ng ng). A transfection in the absence of protease-฀e฀n฀c฀o฀d฀i฀n฀g฀ ฀p฀l฀a฀s฀m฀i฀d฀ ฀(ǻ฀ 
protease) was also included in all experiments as a control. 
 
 
Figure 45: Production of influenza A HA PV by four-plasmid co-transfection including the protease expression plasmid.  
Highly pathogenic influenza does not require the addition of a protease expression plasmid, however this is required for low 
pathogenic strains (Ferrara et al., 2013). In addition, the production of PV bearing an influenza HA requires the addition of 
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Neuraminidase to facilitate the PV exit from the cell. Figure displays the components required to produce viable influenza A 
bearing PV 
 
6.2.3. H17N10 bat influenza PV titration enhanced green fluorescent protein 
reporter 
As the receptor for H17 is unknown, multiple cell lines were used in transduction 
experiments with both the firefly luciferase reporter (pCSFLW) and the enhanced green 
florescent protein (pCSeGFW) reporter genes. To determine the susceptibility of different cell 
lines to the H17 PV, the following cell lines were transduced: Huh-7, Caco-2, HEK-293T, A549, 
MDCK.1, Vero, BHK, U87, DF-1, MDCK II and RIE1495.  
In addition, as the N10 protein sequence departs markedly from the NA proteins of 
other HA strains PV production was also attempted with the addition of a plasmid expressing 
฀t฀h฀e฀ ฀N฀1฀0฀ ฀p฀r฀o฀t฀e฀i฀n฀ ฀p฀u฀r฀c฀h฀a฀s฀e฀d฀ ฀f฀r฀o฀m฀ ฀G฀e฀n฀e฀s฀c฀r฀i฀p฀t฀™฀.฀ ฀T฀i฀t฀r฀a฀t฀i฀o฀n฀s฀ ฀w e r฀e฀ ฀c a r r฀i฀e฀d฀ o u t  a s฀ p฀e r  S e฀c฀t฀i o฀n฀ ฀2฀. 9฀,฀ 
briefly; different target cells (104/well in 96-well plates) from various sources were respectively 
฀t฀r฀a฀n฀s฀d฀u฀c฀e฀d฀ ฀w฀i฀t฀h฀ ฀H฀1฀7฀ ฀P฀V฀.฀ ฀V฀i฀r฀u฀s฀ ฀t฀e฀s฀t฀i฀n฀g฀ ฀w฀a฀s฀ ฀c฀a฀r฀r฀i฀e฀d฀ ฀o฀u฀t฀ ฀i฀n ฀a฀ ฀9 6฀ ฀w e l l  c฀l฀e฀a r  ฀N u n c ™฀ ฀p฀l a฀t฀e฀ f o r  e฀G฀F฀P฀ 
titrations and ฀i฀n฀ ฀a฀ ฀9฀6฀ ฀w฀e฀l฀l฀ ฀w฀h฀i฀t฀e฀ ฀N฀u฀n฀c฀™฀ ฀p฀l฀a฀t฀e฀ ฀f฀o฀r฀ ฀f฀i฀r฀e฀f฀l฀y฀ ฀l฀u฀c฀i฀f฀e฀r฀a฀s฀e฀ ฀b฀a฀s฀e฀d฀ t i t r฀a t฀i฀o n s .  
6.2.4. Production of a chimeric HA construct incorporating H17 and H5 
components 
The selection of the additional HA sequence to be combined with the H17 construct 
was guided on the basis of that the highly pathogenic H5 A/Vietnam/1194/2004 influenza 
strain PV had previously demonstrated a high transduction titre and as a highly pathogenic 
influenza did not require the addition of protease in order to generate viable PV (Ferrara et al., 
2013; Molesti, Ferrara, et al., 2014; Carnell et al., 2015) . This meant that the selection of this 
HA for inclusion meant that unforeseen factors related to cleavage or fusion efficiency would 
be unlikely to have an impact on results and that the H5 components of the chimeric construct 
would have a high likelihood of functioning correctly. Based on this criterion the 
A/Vietnam/1203/2004 HA construct was selected.   The phylogenetic relationship between 
the two HAs, is shown in figure 47, both of these viruses are likely to be compatible as although 
the exact relationship of the H17 virus to the other influenza viruses in still a matter of debate 
(Lu et al., 2012; X. Sun et al., 2013) the phylogeny of the H17 HA protein places it within group 
1 of the influenza virus family. The incorporation of the H17 stalk with the H5 head allows 
determination of the viability of the H17 stalk to mediate cell fusion and offers the potential to 
investigate the potential for stalk specific antibodies to bind to the H17 stalk region thus 
informing stalk based investigations of cross-reactive antibodies (Steel, Lowen and Wang, 
2010; Hai et al., 2012; Margine et al., 2013). In addition, the inverse of this construct with the 
incorporation of the H5 stalk with the H17 head allows the potential to investigate the ability of 
the H17 head to bind to receptors and removes the compounding factor of fusion.   
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Previous studies constructing HA chimeric proteins required the amplification of the 
desired region of each of the parental HA sequences using primers that included specific 
restriction sites, followed by multi-segment ligation (Hai et al., 2012). However, the multiple 
cycles of amplification and ligation make this a relatively inefficient process and the availability 
of enhanced ligation tools such as the Gibson Assembly (NEB, cat. # E5510) allows the 
combination of multiple sequences in an efficient and non-direction-sensitive method to create 
novel sequences. The Gibson Assembly protocol allows multiple overlapping DNA fragments 
to be assembled through a reaction mediated by three different enzymes simultaneously: an 
฀e฀x฀o฀n฀u฀c฀l฀e฀a฀s฀e฀ ฀w฀h฀i฀c฀h฀ ฀c฀r฀e฀a฀t฀e฀s฀ ฀3฀’฀ ฀o฀v฀e฀r฀h฀a฀n฀g฀s฀,฀ ฀a฀ ฀p฀o฀l฀y฀merase which  fills sequence gaps, and DNA 
ligase which acts to close the final assembled DNA (Gibson et al., 2009). The intial step in the 
generation of a chimeric HA is the identification of the two cysteines Cys52 and Cys277 that 
form the dividing region between the head and the stalk of the HA protein. These residues 
were identified through an alignment of HA sequences of CY103892.1 (A/little_yellow-
shouldered_bat/Guatemala/060/2010(H17N10)) and HM006759.1 (A/Viet 
Nam/1203/2004(H5N1)). ฀D฀N฀A฀ ฀D฀y฀n฀a฀m฀o฀™฀ ฀(฀B฀l฀u฀e฀ ฀T฀r฀a฀c฀t฀o฀r฀ ฀S฀o฀f฀t฀w฀a฀r฀e฀ ฀L฀t฀d฀Ψ฀ ฀a฀n฀d฀ ฀the complete 
plasmid DNA sequences were then used to identify the nucleotide sequence corresponding 
to the regions of interest: the N-terminus and C-terminus of both the stalk and head regions of 
the sequences for A/little yellow shouldered bat/Guatemala/060/2010 and A/Viet 
Nam/1203/2004(H5N1). Based on this analysis the desired chimeric HA sequence was 
assembled and primers, summarised in Table 21, were designed using the NEBuilder® online 
tool (New England Biolabs). 
Attempts were then made to generate the proposed HA constructs using a Gibson 
assembly and the NEBuilder HighFidelity DNA Assembly Cloning tool to create primers. 
Primers were designed to amplify the respective stalk regions within the expression vector 
which allowed the respective head region to be ligated into the plasmid.  
Table 19:Primer sequences and annealing temperatures for cloning of the chimeric HA proteins. Regions of primers highlighted 
in red indicate primer sequence annealing to the corresponding to a region of the stalk/plasmid which is used during the 
incorporation process of the two amplicons during the final amplification, the black regions of these primers anneal to the 
respective head region. The shorter primers correspond to their respective stalk regions and are designed to amplify both the 
stalk region and plasmid in which this resides.  
Primer Name Sequence Annealing Temp 
H5_Head_Fw CACAACGGAAAATTATGCGATCTAGATGGAGTGAAGC 59.7 Ԩ 
H5_Head_Rv GGCATTTGGTTGAGCAGTTACCATATTCCAATTCACTTTTC 59.7 Ԩ 
H17_Head_Fw CAATGGGAAGCTCTGCAGCCTAAATGGAGTCCCAC 61.6 Ԩ 
H17_Head_Rv GACACTTGGTGTTGCAGTCACTAATTGGCAGCTTAC 61.6 Ԩ 
H5_Stalk_Fw TGCAACACCAAGTGTCAAA 64.5 Ԩ 
H5_Stalk_Rv GCAGAGCTTCCCATTGTG 64.5 Ԩ 
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H17_Stalk_Fw TGCTCAACCAAATGCCAAAC 61.1 Ԩ 
H17_Stalk_Rv GCATAATTTTCCGTTGTGATTG 61.1 Ԩ 
 
Figure 46: Schematic summary of generalised protocol for generation of chimeric HA cloning using Gibson Assembly. 
Red border regions on head amplicons indicate the region of non-head sequence amplified to facilitate reassembly of the 
complete hybrid. This process was repeated with both a H5 head and H17 stalk and again with a H5 stalk and H17 head region. 
NEBuilder® designs primers that are suitable for amplification using the Q5® High-
Fidelity DNA Polymerase and for this reason 25 µl PCR reactions were set-up as follows: 
dNTPs at a final concentration of 200 µM, 0.5 µM of each primers, 1X Q5® Reaction Buffer, 
0.005 U of Q5® High-Fidelity DNA Polymerase, and 1 ng of plasmid DNA (pI.18- 
A/little_yellow-shouldered_bat/Guatemala/060/2010(H17N10) or the pI.18- A/Viet 
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Nam/1203/2004(H5N1)) used as the template sequence.  Amplification was performed using 
a Mastercycler ep Gradient S and in the Mastercycler ep Gradient thermal cyclers using the 
programs reported in tables 22 and 23.  
 
Table 20: PCR program for the amplification of the H5 and H17 stalk-encoding sequence combined with the pI.18 plasmid 
vector 
Cycles Temperature Time Step 
 
98°C 3 min Initial denaturation 
30 cycles 
98°C 15 sec Denaturation 
59.6 - 62°C 30 sec Annealing 
72°C 1 min Extension 
 
72°C 2 min Final extension 
 




Table 21: PCR program for the amplification of the H5 and H17 head-encoding sequence 
Cycles Temperature Time Step 
 





61.2 - 65 °C 30 
sec 
Annealing 
72°C 6 min Extension 
 
72°C 8 min Final extension 
 
4°C ฀฀ Stabile holding temperature of 
amplicons 
 
Amplification of the stalk in the pI.18 backbone (~5.5 kb total) and of the head (680 bp) 
regions were verified by gel electrophoresis using a 1% agarose gel (Section 2.8). Amplicons 
were purified with the QIAquick PCR purification kit (Chapter 2), and the amplification products 
฀a฀s฀s฀e฀s฀s฀e฀d฀ ฀f฀o฀r฀ ฀c฀o฀n฀c฀e฀n฀t฀r฀a฀t฀i฀o฀n฀ ฀a฀n฀d฀ ฀p฀u฀r฀i฀t฀y฀ ฀b฀y฀ ฀N฀a฀n฀o฀D฀r฀o฀p฀™฀.฀ ฀F฀r฀o฀m฀ ฀t฀h฀e  ฀p฀u r฀i฀f฀i e฀d฀ p r฀o฀d฀u฀c฀t฀ ฀~฀5฀0฀0฀ n฀g฀ D฀N A฀ 
was digested in a total volume of 20 µl using 10 U of FastDigest® DpnI in 1X FastDigest® 
buffer and molecular grade water (Section 2.1). This digestion destroyed remaining parental 
DNA and is necessary to improve the efficiency of subsequent Gibson Assembly protocol. 
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After digestion, purification to remove buffer salts and enzyme was carried out, then samples 
฀w฀e฀r฀e฀ ฀m฀e฀a฀s฀u฀r฀e฀d฀ ฀b฀y฀ ฀N฀a฀n฀o฀D฀r฀o฀p฀™฀ ฀a฀n฀d฀,฀ ฀t฀o฀ ฀j฀o฀i฀n฀ ฀t฀h฀e฀ ฀t฀w฀o฀ ฀o฀v฀e฀r฀l฀a฀p฀p฀i n฀g฀ f฀r฀a฀g฀m฀e n t s ,  a  ฀2฀0฀ ฀µ฀l  G฀i b s฀o฀n฀ 
Assembly reaction was set up in DNase/RNase free water using 10 µl of 2X Gibson Assembly 
mix, 80 ng of the stalk fragment, and 28 ng of the head fragment to produce a vector to insert 
ratio of approximately 1:3. The mix was incubated for 15 min at 50°C in the Mastercy cler ep 
฀G฀r฀a฀d฀i฀e฀n฀t฀ ฀S฀ ฀t฀h฀e฀r฀m฀o฀c฀y฀c฀l฀e฀r฀,฀ ฀2฀ ȝ฀l฀ ฀o฀f฀ ฀t฀h฀i฀s฀ ฀a฀s฀s฀e฀m฀b฀l฀e฀d฀ ฀p฀r฀o฀d฀u฀c฀t฀ ฀w฀as  a฀d฀d e d฀ t o฀ ฀2฀5฀ ฀µ฀l฀ ฀D฀H฀5-Į E. coli 
(New England Biolabs, cat.# C2987) for transformation according to the protocol presented in 
Chapter 2.  The transformation mixture was inoculated onto an ampicillin -LB Agar plate and 
incubated for 16 hours at 37°C. Several colonies present on the plates were screened using 
T7 and pI.18 Forward primers in a colony PCR reaction (Chapter 2) to confirm the presence 
of a 1.7 kb band corresponding to the assembled chimeric HA product.  
After PCR amplification and purification of plasmid DNA, some of the positive clones 
were then additionally screened via restriction enzyme digestion (Chapter 2) with FastDigest®  
BGlII: this enzyme linearises the two parental sequences but cleaves the H17 sequence in the 
stalk only and the H5 sequence in the head only, therefore the digestion patterns of this 
enzyme will yield distinct bands during electrophoresis that allow confirmation that the correct 
HA constructs have been produced. In addition, post transformation and mini-prep two plasmid 
preparations were sent for to GATC (Section 2.4) for Sanger sequencing to confirm the pI.18-
H17/H5 or pI.18-H5/H17 constructs had been successfully produced. After the amino acid 
sequence of the HA construct was confirmed through alignment using MUSCLE algorithm 
(Edgar, 2004) in MEGA 6.0 (Tamura et al., 2011), the chimeric HA was used for PV production 
as using protocols as outlined in Section 2.9.   
6.3. Results 
6.3.1. H17 phylogeny 
Phylogenetic analysis indicates that the HA molecules can be divided into two groups, 
designated group 1 and group 2. The bat-derived H17 and H18 belong to group 1 (figure 47), 
displaying the typical set of sequence features for HA molecules in this group. The best fit 
model was determined by MEGA (Tamura et al., 2011) to be the Tamura Nei model referred 
to the MEGA software as TN93 (Tamura and Nei, 1993). The TN93 model distinguishes 
between two different types of transition meaning that nucleotide changes from A <-> G may 




Figure 47: Phylogeny of Influenza A inferred using the maximum-likelihood method  
with bootstrapping support under the TN93+G mode. H17 and H18 influenza viruses form a single clade with the remaining group 
1 Influenza A strains indicated in red. The evolutionary history was inferred by using the Maximum Likelihood method based on 
the Tamura-Nei model. The tree with the highest log likelihood (-8026.2835) is shown. Initial tree (for the heuristic search were 
obtained automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated using the 
Maximum Composite Likelihood (MCL) approach, and then selecting the topology with superior log likelihood value. The tree is 




6.3.2. H17 expressing PV transduced carrying luciferase reporter genes in different 























































































































































































































































































































































































































































































































































































(A ) (B )
(C ) (D )
(E ) (F )
 
Figure 48: Results of H17 bearing PV transduction of firefly luciferase containing particles in various cell lines. (A) MDCK 
(type 1) (B) HEK293T/17 (C) Huh-7 (D) Caco-2 (E) A549 (F) Vero. All results are based on a single titration using a serial dilution 
to generate 8 datapoints. This data is then multiplied in order to give a project per ML value for each datapint as outlined in 
chapter 2. Graphs display complete range of values for each datapoint. Each graph shows the results of this process for non-
envelope PV (Delta Env) in the first coloumn, the results of production of the H17 PV with no additional protease in the second 
coloumn and the results of this same H17 produced in the absence of protease but in this case treated with TPCK trypsin prior 
to titration in the third coloumn. The reamining coloumns display the reults of titrations of PV produced with proteases in this 
order: 125ng, 250ng and 500ng of TMPRSS2,  125ng, 250ng and 500ng of HAT, 125ng, 250ng and 500ng of Furin.    
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The results summarised in figure 48 display data for cell lines (A) MDCK (type 1) (B) 
HEK293T/17 (C) Huh-7 (D) Caco-2 (E) A549 (F) Vero with titrations conducted as per Section 
2.9 and section 6.2. All results are based on a single titration using a serial dilution to generate 
eight datapoints. This data is then multiplied in order to give a project per mL value for each 
datapoint as outlined in Section 2.10. Graphs display complete range of values for each 
datapoint with RLU/ml calculated as per Section 2.10. In order to accurately compare data the 
delta envelope preparation was treated in the same way as viable PV, in this way inflation 
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Figure 49: Displaying results of H17 bearing PV transduction of firefly luciferase containing particles in various cell 
lines.  
(A) BHK (B) DF-1 (C) QT-6. Results are based on a single titration using a serial dilution to generate 8 datapoints. This data is 
then multiplied in order to give a project per mL value for each datapint as outlined in chapter 2. Graphs display complete range 
of values for each datapoint. Each graph shows the results of this process for non-envelope PV (Delta Env) in the first coloumn, 
the results of production of the H17 PV with no additional protease in the second coloumn and the results of this same H17 
produced in the absence of protease but in this case treated with TPCK trypsin prior to titration in the third coloumn. The reamining 
coloumns display the reults of titrations of PV produced with proteases in this order: 125ng, 250ng and 500ng of TMPRSS2,  
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Figure 50: Results of H17 bearing PV that also express the N10 protein, transduction of firefly luciferase containing 
particles in various cell lines.  
(A)HEK293T/17 (B) MDCK (C) Huh-7 (D) A549 (E) BHK (F) DF-1. Results are based on a single titration using a serial dilution 
to generate 8 datapoints. This data is then multiplied in order to give a project per mL value for each datapint as outlined in 
chapter 2. Graphs display complete range of values for each datapoint. Each graph shows the results of this process for non-
envelope PV (Delta Env) in the first coloumn, the results of production of the H17N10 PV with no additional protease in the second 
coloumn and the results of this same H17N10 produced in the absence of protease but in this case treated with TPCK trypsin 
prior to titration in the third coloumn. The reamining coloumns display the reults of titrations of PV produced with proteases in this 
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Figure 51: Results of H17 bearing PV that also express the N10 protein,  
Transduction of firefly luciferase containing particles in various cell lines. (A)Vero (B) Caco-2 (C) BHK. Results are based on a 
single titration using a serial dilution to generate 8 datapoints. This data is then multiplied in order to give a project per ML value 
for each datapint as outlined in chapter 2. Graphs display complete range of values for each datapoint. Each graph shows the 
results of this process for non-envelope PV (Delta Env) in the first coloumn, the results of production of the H17N10 PV with no 
additional protease in the second coloumn and the results of this same H17N10 produced in the absence of protease but in this 
case treated with TPCK trypsin prior to titration in the third coloumn. The reamining coloumns display the reults of titrations of PV 
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P V p re p a r a t io n
 
Figure 52: H17 expressing PV preparations titrated against (A) MDCK type 2 cells and (B) RIE1495 cells. Results are 
based on a single titration using a serial dilution to generate 8 datapoints. This data is then multiplied in order to give a project 
per ML value for each datapint as outlined in chapter 2. Graphs display complete range of values for each datapoint. Graphs 
display results of H17 preparation with 125ng of HAT plasmid, a H17N10 with the same concentration of HAT, a H17 produced 
with 125ng of Furin and a H17N10 produced with 125ng of TMPRSS2. In addition these titrations include PV produced expressing 
a highly pathogenic H5 strain HA  and a VSV-G expressing PV for use as controls. 
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6.3.3. H17 expressing PV eGFP reporter genes transduced in different cell lines  
Although transduction of all cells lines was attempted no fluorescence was detected at 
any cells except for a small number of cells of DF-1 (Figure 53). A repeat of this titration failed 
to repeat these results and no transduced cells could be discerned in the repeat or in wells 
with concentrations of PV below.  
 
 
Figure 53:DF-1 cells transduced with the H17N10 PV showing positive cells fluorescing green cells under X20 
magnifying objective lens. Bright Field image of the same view is displayed alongside the FITC filtered image. Fluorescent cells 
are indicated by red circle.  
6.3.3. Chimeric HA construct production  
Amplification of head and stalk regions of H17 and H5 was successful as shown in 
figure 54. The chimeric HA constructs, comprising the head region of H17 A/little yellow-
shouldered bat/Guatemala/060/2010 and stalk region of a H5 A/Vietnam/1203/2004 as well 
as the stalk region of H17 A/little yellow-shouldered bat/Guatemala/060/2010 and head region 
of a H5 A/Viet Nam/1203/2004 were both successfully cloned using the Gibson Assembly.  
After cloning was complete the novel constructs were confirmed through Sanger 
sequencing and were then incorporated into a PV production transfection as outlined in 




Figure 54: Results of gel electrophoresis showing successful amplification of the stalk-vector amplicon and the head 
amplicon. Rows 1 and 5 of this gel is a GeneRuler 1kb ruler both used as a reference, row two contains the stalk and plasmid 
amplicon for the H5 HA and is approximately and row four contains the stalk and plasmid amplicon of H17 these are at the 
expected size of approximately 8000bp. Row six contains the head region of the H5 and row eight contains the head region of 
H17 these rows are both at the expected size of approximately 700bp. 
6.3.4. Chimeric HA PV transduced into HEK293T/17 cells 
 With the chimeric HA sequence confirmed, (Appendix3 (a)) production of the 
corresponding PVs was carried out as outlined in Section 2.9. As the inclusion of protease did 
not result in any increase in transduction efficiency in the wild type (WT) H17 figures 50-52 
and the H5 as a highly pathogenic strain with a multibasic cleavage site does not require the 
addition of protease, no additional protease was co-transfected during the production of the 
chimeric PV. Attempts to produce viable PV with these chimeric constructs focused on the 
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Figure 55:Results of PV production incorporating chimeric HA PV with chimeric construct concentration varied 
between preparations 
Results for PV production using concentrations of chimeric HA constructs from 400 ng to 
600ng are recorded in figure 55.  
6.4. Discussion 
The receptor for H17 is currently unknown, studies examining the susceptibility of 
different cell lines to transduction with H17 PV can potentially offer a valuable tool in the 
determination of this receptor. The H17 PV appeared to show positive transduction 
considerably in excess of the delta envelope when transduced against MDCK type 2 cells and 
RIE1495 cells, figure 52. However, it is particularly interesting that the MDCK type II cells 
appear to be permissive to transduction whereas the original MDCK cells were not as indicated 
in figure 50 (B). Although the data was not available on the origin of the MDCK cells originally 
in the lab it is assumed that these are MDCK 2 (which are distinct from MDCK type II) cells 
which are widely used in flu research (Dukes et al., 2011). the MDCK cell line is a crucial 
component in virology studies however the difficulties observed in this research demonstrate 
the importance of accurate identification of the cell line for use for a research program. This is 
particularly important when dealing with a highly diverse cell line such as MDCK which has 
numerous derivatives in use (Dukes et al., 2011).  
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The original parental MDCK cell line, from which subsequent strains have been 
derived, is designated as the ฀“฀N฀B฀L- 2 ” strain and this strain was observed to display obvious 
heterogeneity early in its use in features including cell size and presence of an apical cilium 
(Valentich, 1981). The observed heterogeneity in this cell line has proven an important 
component for ongoing experimental manipulation that has given rise to the large number of 
cell lines labelled MDCK in use today. MDCK type II cells were isolated from high passage 
MDCK (NBL-2) cells and display  lower transepithelial resistance (TER) ฀v฀a฀l฀u฀e฀s฀ ฀(฀<฀ ฀3฀0฀0฀ ȍ฀•฀c฀m฀2฀Ψ 
when compared to the standard MDCK cells which are noted to have unusually high values 
(>2000 ȍ฀•฀c฀m฀2) as measured in fixed cells (Valentich, 1981; Hansson, Simons and Meer, 
1986). Although this trait is unlikely to change the susceptibility of these cells to PV mediated 
transduction this value is indicative of marked differences in cell physiology including traits 
such as unusually permeable tight junctions between cells in culture (Barker and Simmons, 
1981; Valentich, 1981)฀.฀ ฀T฀h฀e฀s฀e฀ ฀‘฀l฀e฀a฀k฀y฀’฀ ฀j฀u฀n฀c฀t฀i฀o฀n฀s฀ ฀h฀a฀v฀e฀ ฀b฀e฀e฀n฀ ฀l฀i฀n฀k฀e฀d฀ ฀t฀o฀ ฀v฀a฀r฀i฀a฀b฀i฀l฀i฀t฀y฀ ฀t h฀e฀ ฀e฀x฀p฀r฀e฀ssion 
of claudin-2 a junction pore-forming protein which may lower the TER of MDCK II cells when 
compared to MDCK (NBL-2) which do not express the protein (Furuse et al., 2001). While the 
variation in junctions between the cell lines are unlikely to fully explain the differences in 
susceptibility between these cell lines some studies have found significant variation between 
closely related MDCK strains in the phospholipid composition and this seems a more likely 
direction for research into the H17 receptor to take (Hansson, Simons and Meer, 1986). The 
marked differences between different MDCK cell types physiology make it difficult to determine 
the factors that make the H17N10 PV successfully transduce the MDCK type II but not the 
MDCK 1 cell line. However, the finding that closely related MDCK cell lines show different 
susceptibility offer the potential for the use of these cells in receptor identification studies as 
the similarities between cell lines may remove many confounding factors.    
The second cell line found to be susceptible to H17 PV transduction was the RIE1495 
which is a recently isolated and poorly characterised cell line. This cell line  is derived from the 
RIE-1 cell line derived from rat small intestine (Blay and Brown, 1984). However there has to 
date been no characterisation of the RIE-1495 cell lines physiology of glycoprotein expression, 
as such it is unclear what significance the susceptibility of this cell line to the H17 PV will have. 
Nevertheless, the susceptibility of a rat derived cell line to a bat borne influenza virus may 
have consequences for the potential zoonosis of this virus. Despite the well demonstrated 
functional complementarity of many of the proteins of H17N10 with other influenza A viruses, 
the HA envelope proteins of the bat viruses seems to contain significantly greater differences 
when compared to other HA proteins, as both H17 and H18 lack a sialic-acid-binding site (X. 
Sun et al., 2013) and the N10 and N11 proteins lack the well characterized NA activity (Li et 
al., 2012). Given these observations, coupled with the recent evidence that H17 mediated cell 
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entry was not dependent on sialic acid receptors (Hoffmann et al., 2016), make it very likely 
that the bat influenza viruses make use of cellular receptors that are specific for certain bat 
species and/or tissues.  
It is interesting to note that previous studies have demonstrated that the TMPRSS2 
protease was capable of inducing HA maturation of the H17 HA (Hoffmann et al., 2016) 
however in this study we demonstrated that the HAT protease was also capable of inducing 
HA maturation. Therefore, it is likely that any observed species specificity of the H17 virus is 
influenced by the presence of an as yet unidentified receptor and is less limited by the 
expression of proteases in the host cells. This is potentially a significant finding as the 
expression of specific proteases is a known limiting factor in viral tropism (Bottcher-
Frietertshauser et al., 2010; Ferrara et al., 2013; Millet and Whittaker, 2015). It has been widely 
demonstrated that a number of TMPRSS proteases can cleave and activate HA in cell culture 
and recent studies demonstrated that TMPRSS2 is essential for influenza A viral spread in 
mice (Maisner et al., 2000). This ability of multiple proteases to cleave the H17 HA coupled 
with the observed susceptibility of a rat derived cell line to the H17 PV will suggest that at least 
some non-bat mammalian species will prove to be susceptible to H17 infection. 
The construction of a bat derived chimera influenza virus harbouring the entry 
machinery of an alternative influenza A virus failed in generating viable PV, although this 
failure to generate chimeric PV has yet to be confirmed via transduction with the identified 
susceptible cell line. Furthermore, the apparent production of viable H17 will largely supersede 
the chimeric production as future investigations into the zoonotic potential of H17N10 and 
H18N11 as well as the investigation of neutralizing antibodies that affect these viruses should 









Chapter 7 Analysis of Selective Pressure Acting on the MERS-CoV 
Spike Protein and Mutagenesis of Identified Codons 
7.1. Introduction 
When a virus moves from one host to another such as during a zoonotic spillover, it 
undergoes significant change in the environmental conditions in which the virus reproduces 
(Section 1.1) (Mänz, Schwemmle and Brunotte, 2013). Outbreaks of RNA viruses due to host 
switching have been highlighted by the recent SARS-CoV, MERS-CoV, and Ebola epidemics 
that have caused such significant loss of life (Temperton et al., 2005; White, 2014; Na et al., 
2015). However, zoonotic viruses are a far larger and more widespread problem than isolated 
high impact outbreaks; they encompass a number of the most prevalent and damaging 
infections including pandemic influenza (Fukuyama and Kawaoka, 2011) and the Human 
Immunodeficiency Virus (HIV) (Wood et al., 2009). The long-term viability of a virus to remain 
persistent in a population after a host switching event depends on upon the ability of that virus 
to adapt to the new conditions and challenges that are prevalent in the new host.   
RNA virus polymerase lacks a proofreading component and so is well suited to rapid 
evolution and this trait increases the likelihood that viruses of this type will become established 
in a novel host. As previously discussed the phenomenon of quasispecies population 
dynamics also ensures that the likelihood of that a ฀‘spillover฀’ will occur as there is likely to be 
a range of mutant viral strains circulating within a population (Chapter 1). However, as most 
฀m฀u฀t฀a฀t฀i฀o฀n฀s฀ ฀a฀r฀e฀ ฀d฀e฀t฀r฀i฀m฀e฀n฀t฀a฀l฀ ฀t฀o฀ ฀t฀h฀e฀ ฀v฀i฀r฀u฀s฀’฀s฀ ฀s฀u฀r฀v฀i฀v฀a฀l฀ ฀a฀n฀d฀ ฀a฀b฀i฀l฀i t y  t o  r฀e฀p฀r฀o฀d฀u฀c฀e  ฀a n  u n d฀e฀r฀s฀t฀a฀n฀d฀i฀n฀g฀ ฀o฀f฀ 
the pressures that are driving their evolution and particularly when the viruses begin to infect 
a novel host. With technological developments in recent years, it has become possible to 
isolate and sequence viral nucleotides from emerging viral outbreaks rapidly, and this data 
can then be used to analyse the pattern of evolution of a virus as it adapts to a new host. 
Bioinformatics tools allow the comparison of viral sequences to identify evolutionary patterns 
to assist in public health decisions and to provide insights into potential drug targets. Middle 
East respiratory syndrome coronavirus was first identified in Saudi Arabia in 2011 (Boheemen, 
Graaf, Lauber, Theo M Bestebroer, et al., 2012) and genetic comparison to other 
coronaviruses was rapidly conducted (Gierer et al., 2013). As of 29-Oct-16, there were 1,471 
laboratory confirmed cases spread across 26 countries and confirmed by the World Health 
Organization (WHO), 615 (42%) cases in humans proving fatal (ProMED-mail, 2016).  
As a coronavirus, the MERS-CoV uses an S protein to bind a host receptor and to 
initiate membrane fusion (Wang et al., 2013). These spike proteins are class I fusion proteins 
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and are similar to glycoproteins found in many other virus families including the retroviruses, 
orthomyxoviruses, paramyxoviruses, and filoviruses and these proteins all share broadly 
similar domain structural organization, as well as common functional properties (Hoffmann et 
al., 2013) (Section 1.4.3 and 3.1). Although the receptor binding domain (RBD) of spike 
proteins is undoubtedly the most significant component in the determination of viral tropism, 
the data presented in Chapter 4 indicates the potential for other regions of this protein to play 
a significant role in host interaction. It is, therefore, essential to determine which regions of the 
MERS-CoV spike protein are undergoing rapid evolutionary change, as these regions may 
present unique opportunities, or may indicate adaptation of the pathogen to more efficent 
human transmission. A number of studies have indicated that MERS-CoV and the bat 
coronavirus HKU4 both bind DPP-4 (Cui et al., 2013; Caì et al., 2014; Wang et al., 2014; Yang 
et al., 2014).  However, the affinity of these viruses to either human or bat DPP-4 differs, with 
the MERS-CoV displaying a greater affinity for the human DPP-4 receptor and HKU4 spike 
showing a greater affinity for the bat-derived DPP-4. The RBDs of these viruses appear to 
engage with the human DPP-4 via a similar mode of action and so the difference in affinity is 
likely linked to differences in the spike proteins not related to the RBD sequences (Wang et 
al., 2014). These observations may suggest that coronaviruses such as MERS-CoV may have 
the potential to switch host species with a little adaptation of the RBD regions. As such 
selection analysis may yield insights into the variation that underlies host shifts in these viruses 
and may provide further insights into commonalities more generally, host-pathogen 
interactions (Longdon et al., 2014). 
This chapter outlines the use of several computational tools to determine the nature 
and the degree of evolutionary selection that is driving the evolution of the MERS-CoV spike 
protein. This analysis was used to identify sites that may contribute to the adaptation of this 
virus to humans. To test for positive selection in individual codons of the spike protein 
sequences, the ratio of Non-synonymous (dN) to synonymous (dS) changes was assessed 
using the algorithms of the HyPhy software package as implemented in the Datamonkey 
webserver (Pond and Frost, 2005; Delport et al., 2010). Through the Datamonkey server, the 
MSA was screened for evidence of recombination before the SLAC, the IFEL, and the MEME 
methods were implemented to search for evidence of natural selection implemented. 
Datamonkey based analysis were all conducted using an evolutionary model based on the 
LRT algorithm available in the Datamonkey web tools (Delport et al., 2010).  
After the identification of codons under positive selection several mutagenesis 
reactions were attempted to induce mutations at these sites. This process generated novel S 
sequences which were subsequently incorporated into the PV assay system. The effects of 
these mutations was then inferred using PV titrations (Section 2.10) and PV based micro-
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neutralisation assays (Section 2.11) making use of serum samples (Section 4.2) to determine 
if mutated S proteins affect the degree of antibody interaction with the S bearing PV. Through 
this integration of in-silico and wet lab tools, it is hoped to develop novel insights into the 
evolution of the MERS-CoV within the human host.  
7.2. Materials and methods  
7.2.1. Dataset and phylogeny 
Viral sequences were retrieved from the GenBank NCBI database, and a list of 
accession numbers is recorded in Appendix 4(a), in total 140 sequences were added to this 
dataset. Due to the scale of the dataset used in the initial phylogenetic reconstruction, the 
MAFFT (Katoh and Standley, 2013) alignment algorithm was employed to build the MSA. This 
dataset consisted of 125 MERS-CoV sequences, five sequences each of HKU4 and HKU5, 
four sequences novel coronavirus isolates from bats and a single sequence of SARS-CoV. In 
this dataset MERS-CoV, HKU4, HKU5 and the bat isolates are closely related and so the 
SARS- CoV which is a more distantly related sequence can provide an outgroup for the 
analysis.  
To create a dataset that was more computationally feasible for the analysis of selective 
pressure a second dataset was extracted from dataset 1, this second dataset was named 
dataset 2 and consisted of 60 sequences, table 24.  This dataset was selected by eliminating 
MERS-CoV sequences where genetic distances were less than 0.01 as calculated with MEGA 
7.0 (Kumar et al., 2016). This reduction in dataset size has the added benefit of enabling a 
greater range of analytical tools to be applied as the larger dataset was too large to be 
accurately analysed within Datamonkey. The use of offline versions of the HyPhy (Pond, Poon 
and Frost, 2009) program to perform the analysis, without the constraint on dataset size was 
computationally prohibitive. Also, to the introduction of false diversity through the inclusion of 
many distantly related sequences the SARS-CoV sequence AY278741.1 was also removed 
as was the DQ648794_1_BTCOV_133_2005 bat coronavirus sequence.  
The model of nucleotide substitution was identified using the model selection tool in 
MEGA 7.02 (Kumar et al., 2016). This tool assesses the potential fit of 24 different nucleotide 
substitution models and provides calculations for the fit of these models based on Bayesian 
Information Criterion (BIC), Akaike Information Criterion, corrected (AICc) and the Maximum 
Likelihood value (lnL) of the model fitting the data. For each model, the above scores are 
calculated and displayed along with the number of parameters (including branch lengths) in 
the model. Non-uniform evolutionary rates among sites can also be modelled by using a 
discrete Gamma distribution (+G) with five different rate categories, and the MEGA program 
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can also include the assumption that a certain fraction of sites are evolutionarily invariable 
(+I). The program will also assume or estimate from the data, values for transition/transversion 
bias rate and this is displayed for each model indicated by the variable (R). The final data 
points calculated by the MEGA 7.0 model selection tool are the nucleotide frequencies (f) and 
rates of base substitutions (r) for each nucleotide pair.  
The phylogenetic tree used in the analysis was first generated with the Maximum 
likelihood calculations supported within the MEGA 7.0 (Kumar et al., 2016) program, figure 
58. This phylogeny was then modified based on published phylogenies of the coronaviruses 
(Huynh et al., 2012; Abdel-Moneim, 2014; Wernery et al., 2015), this step is required as the 
complete phylogeny of the large dataset is based complete or nearly complete genome 
sequences and as such manual editing based on published sequences corrects for the bias 
introduced through the variation in sequence lengths.  
Table 22: Reduced dataset, designated dataset 2 with the remaining 60 spike sequences after exceptionally well conserved and 
exceptionally diverse sequences were removed. This dataset formed the basis of further selective pressure analysis and was 
used for upload to Datamonkey webserver tools.   
Accession Number Virus Strain/isolate Host Location of Isolate Year of Isolation 
JX869059.2 MERS-CoV HCoV-EMC Human England 2012 
KC667074.1 MERS-CoV HCoV-EMC Human England/Qatar 2012 
KJ477102.1 MERS-CoV NRCE-HKU205 Camel Egypt 2013 
KT156560.1 MERS-CoV Hu/Oman Human Oman 2013 
KT036373.1 MERS-CoV ChinaGD01 (V1) Human China 2015 
KT026454.1 MERS-CoV Hu/Riyadh Human KSA 2015 
KT026453.1 MERS-CoV Hu/Riyadh Human KSA 2015 
KR011265.1 MERS-CoV Hu/Riyadh Human KSA 2015 
KP719933.1 MERS-CoV D1209 Camel UAE 2014 





Human UAE 2013 
KP223131.1 MERS-CoV USA-2_Saudi Arabia Human USA 2014 
KP209313.1 MERS-CoV UAE_26 Human UAE 2014 
KP209307.1 MERS-CoV UAE_18 Human UAE 2014 
KM210278.1 MERS-CoV England/3/2013 Human UK 2013 
KM210277.1 MERS-CoV England/4/2013 Human UK 2013 
KM027288.1 MERS-CoV KSA_551 Human KSA 2014 
KM027286.1 MERS-CoV KSA_351 Human KSA 2014 
KM027284.1 MERS-CoV KSA_345 Human KSA 2014 
KM027281.1 MERS-CoV KSA_158 Human KSA 2014 
KM027279.1 MERS-CoV KSA_059 Human KSA 2014 
KM027278.1 MERS-CoV KSA_057 Human KSA 2014 
KM027277.1 MERS-CoV KSA_042 Human KSA 2014 
KM027276.1 MERS-CoV Jeddah_C9313 Human KSA 2014 
KM027275.1 MERS-CoV Jeddah_C9282 Human KSA 2014 
KM027263.1 MERS-CoV Jeddah_C7058 Human KSA 2014 
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KM027258.1 MERS-CoV Jeddah_C8826 Human KSA 2014 
KJ713299.1 MERS-CoV KSA_376 Camel KSA 2013 
KJ650098.1 MERS-CoV Qatar_2 Camel Qatar 2014 
KJ361500.1 MERS-CoV FRA1_1627-2013_BAL Human France 2013 
KJ156952.1 MERS-CoV Riyadh_4 Human KSA 2013 
KJ156949.1 MERS-CoV Taif_1 Human KSA 2013 
KJ156942.1 MERS-CoV Riyadh_8b Human KSA 2013 
KJ156939.1 MERS-CoV Al-Hasa_27b Human KSA 2013 
KJ156934.1 MERS-CoV Riyadh_14 Human KSA 2013 
KJ156920.1 MERS-CoV Riyadh_17b Human KSA 2013 
KJ156916.1 MERS-CoV Madinah_3b Human KSA 2013 
KJ156910.1 MERS-CoV Hafr-Al-Batin_2 Human KSA 2013 
KJ156876.1 MERS-CoV Taif_2b Human KSA 2013 
KJ156873.1 MERS-CoV Riyadh_13b Human KSA 2013 
KF961222.1 MERS-CoV Qatar4 Human KSA 2013 
KF811036.1 MERS-CoV Tunisia-Qatar_2013 Human Tunisia 2013 
KF745068.1 MERS-CoV FRA/UAE Human France 2013 
KF600652.1 MERS-CoV Riyadh_2 Human KSA 2012 
KF600645.1 MERS-CoV AlHasa_15 Human KSA 2013 
KF600643.1 MERS-CoV AlHasa_14b Human KSA 2013 
KF600630.1 MERS-CoV Buraidah_1 Human KSA 2013 
KF600628.1 MERS-CoV HafrAlBatin_1 Human KSA 2013 
KF600620.1 MERS-CoV Bisha_1 Human KSA 2012 
KT868867.1 MERS-CoV CNUH_SNU/024_06 Human Korea 2015 
KX034097.1 MERS-CoV Seoul/080-3 Human Korea 2015 
KT374050.1 MERS-CoV Seoul/163-2 Human Korea 2015 
KT868871.1 MERS-CoV CNUH_SNU/054 Human Korea 2015 
KT374057.1 MERS-CoV Seoul/168-2 Human Korea 2015 
KT868870.1 MERS-CoV CNUH_SNU/038_06 Human Korea 2015 
EF065505.1 HKU4 B04f Bat China 2007 
KC522051.1 HKU4 4S Tylonycteris bat China (Hong Kong) 2010 
KJ473822.1 BtTp-BetaCoV/GX2012 BtTp-GX2012 
Tylonycteris 
pachypus (Bat) China 2012 
KJ473820.1 BtPa-BetaCoV/GD2013 BtPa-GD2013 
Pipistrellus abramus 
(bat) China 2013 
EF065509.1 HKU5 LMH03f bat China 2006 
 
7.2.2. In-silico analysis of the MERS-CoV spike protein 
After identification of codons under positive selection, IEDB web tools were employed 
to assess the proximity of these sites to identified potential antigenic regions (Yao et al., 2012) 
and the accessibility of these sites on the surface on the protein. The IEDB tools were used to 
identify the potential of these sites to be available for antibody interaction via the Emini Surface 
Accessibility Prediction and Bepipred Linear Epitope Prediction both of which employ heuristic 
algorithms based on experimental data to infer structural data about proteins for which 
complete, reliable structural information was not available. 
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7.2.3. Selection analysis and recombinant screening of the MERS-CoV spike 
After the assembly of the MERS-CoV phylogeny, this was used as the basis for the 
implementation of the initial analysis of recombination and selection using the Datamonkey 
server (Pond and Frost, 2005). Before additional analysis, the MSA was screened for evidence 
of recombination events using the GARD (Pond et al., 2006) (Chapter 2) algorithm. The GARD 
algorithm works by performing statistical probability calculations to determine sites at which 
breakpoints have occurred, these breakpoints may have created chimeras or putative 
recombinants and so will affect selection analysis. The likelihood of any breakpoint identified 
by the GARD algorithm is assessed using the Kishino-Hasegawa (KH) test. This test is a 
maximum likelihood method that estimates the variance of the difference of log likelihood 
between trees and can be used to compare the breakpoints within the trees to assess their 
credibility. Recombination breakpoints identified through this analysis were considered 
significant if the KH value was < 0.01.  
After assessment of the potential recombination within the dataset the following 
methods: SLAC, Single likelihood ancestor counting; IFEL, internal fixed effect likelihood; 
FUBAR, Fast Unconstrained Bayesian Approximation for Inferring Selection and finally the 
MEME algorithm. The SLAC analysis involves the analysis of MSA through the interpretation 
of a phylogenetic tree and a model of nucleotide substitution, both of which are recalculated. 
The SLAC then simply counts the number of nonsynonymous and synonymous changes, and 
these are compared for each site in the MSA (Kosakovsky Pond and Frost, 2005). In the IFEL 
analysis, every codon is assigned a single rate of synonymous substitution and two 
nonsynonymous rates. These two nonsynonymous rates are assigned to account for 
differences in potential codon selection that is driven as the codon evolves along a terminal 
branch (i.e. usually indicating recent bouts of evolutionary pressure) and the potentially 
different rate of evolution of the codon for internal branches (i.e. episodic or historical 
evolution) . This manner of testing has been demonstrated to be effective in cases were strong 
diversifying selection is in effect, and so codons are likely to be highly divergent (Chapter 2) 
(Kosakovsky Pond, Frost, et al., 2006). The MEME algorithm allows the distribution of dN/dS 
to vary from site to site (the fixed effect) and also from branch to branch at a specific site (the 
random effect) (Chapter 2) (Murrell et al., 2012).  This method uses phylogenetic models to 
describe the evolution of codon characters along a given branch of a phylogenetic tree by a 
continuous-time stationary Markov process. 
These analyses were conducted using an evolutionary model based on the LRT 
algorithm available in Datamonkey. For MEME analysis codon-specific positive selection was 
admitted at p-value < 0.1, and the inference of the lineages in which diversifying selection 
 176 
 
occurred at a given codon was performed using a Bayes empirical Bayes approach. Codons 
in which the Bayes factor was greater than 1 were considered as targets of episodic 
diversifying selection. Complete output for all codons with all methods is recorded in Appendix 
4(c). For FUBAR analysis sites with a posterior probability of positive selection > 0.8 were 
taken as under positive selective pressure. For SLAC, analysis sites identified with a p value 
> 0.2 were considered under positive selection. Finally, for the IFEL algorithm sites with a 
significance level of 0.1 were considered under positive selection. 
7.2.4. Mutagenesis protocols 
Mutagenesis was carried out as outlined in Chapter 2, however in brief, initial attempts 
to induce the mutations using the crossover PCR protocol for site-directed mutagenesis 
(Sukdeo and Charles, 2003; Heckman and Pease, 2007). In this method, synthetic 
oligonucleotide DNA primers, both sense, and antisense, containing the mutation to be 
introduced are used in PCR reactions with sequence flanking primers. This generates two 
fragments which can then be combined using a further cycle of amplification, with additional 
primers, which generates the final product which can then be ligated into an expression 
plasmid. In addition to this method, both additional protocols outlined in Chapter 2 were 
attempted. The first of these techniques was the commercially available QuikChange 
Lightning II Site-direct mutagenesis kit protocol (Agilent Technologies, cat. # 210518); the 
second was an in-house protocol originally developed by Dr Francesca Ferrara, although 
modified here to adapt to the increased length of the coronavirus spike compared to the HA 
sequence for which the protocol was originally devised, table 25. For all protocols, 
concentrations of primers and reagents were as recorded in Chapter 2.  
Table 23฀:฀ ฀ ฀R฀e฀a฀g฀e฀n฀t฀s฀ ฀r฀e฀q฀u฀i฀r฀e฀d฀ ฀f฀o฀r฀ ฀A฀c฀u฀z฀y฀m฀e฀™฀ ฀m฀u฀t฀a฀g฀e฀n฀e฀s฀i฀s฀ ฀p฀r฀o฀t฀o฀c฀o฀l  or reaction in the 50 µl total reaction volume.  
REAGENT CONC. VOLUME 
ACCUZYMETM MIX N/a 25 µl 
MERS-COV S (pCAGGS) 140 ng X* 
FWD PRIMER 125 ng 1.5 µl 
REV PRIMER 125 ng 1.5 µl 
H2O 
 
Total reaction volume of 50 µl 
*CALCULATED ON A PER REACTION BASIS 
 
In instances where the Acuzyme฀™ based protocol failed to amplify the MERS-CoV 
mutagenesis, ฀a฀ ฀m฀o฀d฀i฀f฀i฀e฀d฀ ฀p฀r฀o฀t฀o฀c฀o฀l฀ ฀u฀s฀i฀n฀g฀ ฀t฀h฀e฀ ฀P฀h฀u฀s฀i฀o฀n฀™฀ ฀p฀o฀l฀y฀m฀e฀r฀a฀s฀e฀s฀ ฀w฀a฀s฀ employed. T e 
Acuzyme฀™ enzyme is recommended for sequences up to approximately 5 kb while the overall 
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length of pCAGGS plasmid and the MERS-CoV spike insert is c. 8.5 kbp and so an additional 
฀p฀r฀o฀t฀o฀c฀o฀l฀ ฀m฀a฀k฀i฀n฀g฀ ฀u฀s฀e฀ ฀o฀f฀ ฀t฀h฀e฀ ฀P฀h฀u฀s฀i฀o฀n฀™฀ ฀p฀o฀l฀y฀m฀e฀r฀a฀s฀e฀ ฀w฀a฀s฀ ฀e฀m฀p฀l฀o฀y฀e฀d฀ a s o u t฀l฀i฀n฀e฀d฀ i n  ฀C h a p t e r฀ ฀2 with 
reagent concentrations as per table 26. 
Table 24: Reagents required for Phusion฀™฀ ฀m฀u฀t฀a฀g฀e฀n฀e฀s฀i฀s฀ ฀p฀r฀o฀t฀o฀c฀o฀l฀ for r action in 20µl total reaction volume. DMSO was added 
only when initial amplification was unsuccessful.  
Reagent Conc. Volume 




Forward Primer 1.25ng 1 
Reverse Primer 1.25ng 1 
Template 80ng 1 
DMSO N/a 0.6* 
Phusion Polymerase N/a 0.25 
Water Volume to 20ul 11.75 
 
Amplification of the mutant product was verified by analytical DNA gel electrophoresis 
post digestion with DpnI (Thermo Fisher Scientific, cat. # FD1703) fast digest enzyme as per 
Chapter 2. ฀A฀s฀ ฀t฀h฀e฀ ฀A฀c฀u฀z฀y฀m฀e฀™฀ ฀b฀a฀s฀e฀d฀ ฀p฀r฀o฀t฀o฀c฀o฀l฀ ฀i฀s฀ ฀a฀ ฀n฀o฀n-PCR amplification and p oduces only 
linear amplification it is likely that a significant amount of the product contained in the final 
volume is parental DNA. To reduce the risk that the subsequent transformation would only 
yield parental sequence the digest was carried out for 30 min at 37ႏ in a 10 µl reaction with 
DpnI enzyme in 1X FastDigest® Buffer (Thermo Fisher Scientific, cat. # B64). The DpnI 
reaction was heat-inactivated for 5 min at 80ႏ, prior to transformation E. coli ฀D฀H฀5Į cells. 
After transformation and purification via Qiagen miniprep kit, the mutant sequences 
were sent ฀f฀o฀r฀ ฀s฀e฀q฀u฀e฀n฀c฀i฀n฀g฀ ฀u฀s฀i฀n฀g฀ ฀t฀h฀e฀ ฀G฀A฀T฀C฀™฀ ฀L฀i฀g฀h฀t฀r฀u฀n฀™฀ ฀s฀e฀r฀v฀i฀c฀e฀ ฀t฀o฀ ฀c฀o฀n฀f฀i฀rm  t฀h฀a฀t฀ t฀h฀e฀ d e s i r฀e d฀ 
mutant was present through Sanger sequencing reaction. 
Primers designed to introduce the primary mutations are listed in table 27, in addition 
to sites identified by selection analysis attempts were made to induce mutations at sites where 
residue differences had already been observed, even in cases where such sites were not 
identified in the selection analysis conducted here. All primer sequences were designed based 
on a codon optimised version of the MERS-CoV spike sequence from KC164505 inserted into 
the pCAGGS expression plasmid. After the identification of codons of interest through the 
analysis a decision was taken to induce mutations at these positions that reflected already 
circulating MERS-CoV variants. In the case of codon 1193 there did not appear too be 
significant variation in the circulating strains at this position, and so it was decided that the 
Alanine at this position would be mutated into a Serine to explore the role this codon plays in 
viral binding and entry. Furthermore, the 1020 codon site is particularly variable and so in 
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addition to mutations to this site corresponding to already identified viral isolates an additional 
mutagenesis was attempted to replace the residue at this site with an Alanine to investigate 
the effect such a significant change would have on the resulting spike protein functions.  
Table 25: Primers used to induce mutation at selected codon positions within the codon optimised MERS-CoV Spike sequence 
sites 26, 506, 509, 1020 and 1208 primers were all designed to introduce residues that are present in circulating strains of the 
MERS-CoV. At sites 1020 and 1193 primers were also designed to introduce an Alanine at these positions to investigate the role 
these positions in viral infection after the identification of the sites by selection analysis. All primer sequences were designed 
based on a codon optimised version of the MERS-CoV spike sequence from KC164505.01 inserted into the pCAGGS expression 
plasmid.  
  
Cross-Over PCR Primers (P1) Lightning Quick change II Primers (P2) 
V26I 
F CCCTGATTCTATCAAAAGCGC GATGTCGGCCCTGATTCTCTCAAAAGCGCCTG 
R GCGCTTTTGATAGAATCAGGG CAGGCGCTTTTGAGAGAATCAGGGCCGACATC 
F506L 
F GCAGTAGATTGCTGTCAGACG CTCCTATATTAACAAGTGCAGTAGACTCCTGTCAGACGA 
R CGTCTGACAGCAATCTACTGC TCGTCTGACAGGAGTCTACTGCACTTGTTAATATAGGAG 
D509G 
F TCCTGTCAGGCGATAGGAC CAGTAGATTCCTGTCAGGCGATAGGACCGAAGTGC 
R GTCCTATCGCCTGACAGG GCACTTCGGTCCTATCGCCTGACAGGAATCTACTG 
H1020Q 
F GAAGCTTTCCAGAAAGTGCAGG ACTAACGAAGCTTTCCAGAAAGTGCAGGATGCAGT 
R CCTGCACTTTCTGGAAAGCTTC ACTGCATCCTGCACTTTCTGGAAAGCTTCGTTAGT 
H1020R 
F GAAGCTTTCCGCAAAGTGCAGG AACTAACGAAGCTTTCCGCAAAGTGCAGGATGCAG 
R CCTGCACTTTGCGGAAAGCTTC CTGCATCCTGCACTTTGCGGAAAGCTTCGTTAGTT 
H1020A 
F X GACTGCATCCTGCACTTTGGCGAAAGCTTCGTTAGTTGTG 
R X CACAACTAACGAAGCTTTCGCCAAAGTGCAGGATGCAGTC 
Q1208H 
F TACGTGGCCCCTCACGTCACATATC AGATATTCTGATATGTGACATGAGGGGCCACGTACTTA 
R GATATGTGACGTGAGGGGCCACGTA TAAGTACGTGGCCCCTCATGTCACATATCAGAATATCT 
A1193S 
F X ACACCGGCTCAAGCTTTTATGCACCCGAGCCT 











Figure 56: Primer names and sequences used for MERS-CoV mutagenesis showing the location of annealing of individual primers 
with sites to be mutated highlighted ฀A฀l฀l฀ ฀p฀r฀i฀m฀e฀r฀s฀ ฀a฀r฀e฀ ฀d฀i฀s฀p฀l฀a฀y฀e฀d฀ ฀i฀n฀ ฀5฀’฀ ฀t฀o฀ ฀3฀’฀ ฀d฀i฀r฀e฀c฀t฀i฀o฀n฀.฀ ฀N฀o฀t฀e฀ ฀t฀h฀a฀t฀ f o฀r  m฀u฀t฀a฀t฀i฀o฀n s  a t  ฀p o฀s฀i t i o฀n฀s฀ ฀5฀0฀6฀ ฀a฀n฀d฀ 
1020 two mutations are required to modify the desired residues. 
 
7.2.5. Production of PV with mutant spike sequence 
Post mutagenesis MERS-CoV PV was produced in HEK293T/17 cells using the novel 
mutated MERS-CoV spike sequences inserted into a pCAGGS vector. These PV preparations 
were prepared following the optimised protocol developed in Chapter 3.  
In order to investigate the changes in folding and maturation efficiency that may be 
linked to these mutations, this protocol was also attempted with the addition of pCAGGS 
expressing TMPRSS2 and Furin proteases. In these cases, 125 ng of protease expressing 
plasmids were added to each transfection during the production stage. 
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7.2.6. Screening of mutant MERS-CoV S bearing PV against SARS-CoV 
convalescent serum 
To neutralise the MERS-CoV PV serum samples were selected from serum panel 2 
as described in Section 4.2.1. with data analysis performed using Microsoft® Excel 2011 and 
GraphPad Prism® version 7.02 (Section 2.11).  
7.2.7. The Role of protease in the production of mutated spike bearing PV  
Expression of protease in the producer cell line through the co-transfection of the 
pCAGGS expression vector with protease gene inserts has been discussed in Section 3.1.3. 
To investigate the potential, impact these mutations could have on the cleavage of the spike 
protein protease was introduced during the production phase 125ng. The introduction of 
protease expression plasmids into the production process was carried out as described in 
Section 3.1.3. 
7.3. Results 
7.3.1. Phylogenetic reconstruction  
The nucleotide substitution model was determined through model selection tool 
implemented in MEGA 7.02 (Kumar et al., 2016). This selection tool determined that the 
optimal nucleotide substitution model was the GTR+G, which is the Generalised Time 
Reversible model (Tavare, 1986) with a Gamma shaped probability curve applied to among 
sites variation. The GTR model is among the most complex models that can be fitted to a 
nucleotide alignment as the large number of parameters permit this model to closely match a 
diverse range of alignments. The complete results of the MEGA model selection tool are 
recorded in Appendix 4(b). The phylogenetic relationships inferred from dataset 1 are recorded 
in figure 58; this phylogeny was used as a basis for subsequent analysis and trimmed to 
account for the reduced size of dataset 2.  The maximum likelihood method of reconstruction 
was then implemented through the MEGA7.02 (Kumar et al., 2016) with 100 bootstraps 
applied as a test of phylogeny. The complete list of sequences included in this analysis is 






Figure 57: Phylogentic tree of MERS-CoV based on 140 sequences. The evolutionary history was inferred by using the Maximum 
Likelihood method based on the Kimura 2-parameter model (Kimura, 1980). The tree with the highest log likelihood (-3568.4067) 
is shown. Initial trees for the heuristic search were obtained automatically by applying Neighbor-Join and BioNJ algorithms to a 
matrix of pairwise distances estimated using the Maximum Composite Likelihood (MCL) approach, and then selecting the 
topology with superior log likelihood value. A discrete Gamma distribution was used to model evolutionary rate differences among 
sites (2 categories (+G, parameter = 0.6911)). The rate variation model allowed for some sites to be evolutionarily invariable ([+I], 
30.4661% sites). The tree is drawn to scale, with branch lengths measured in the number of substitutions per site. The analysis 
involved 140 nucleotide sequences. All positions containing gaps and missing data were eliminated.  
The short branch length of the MERS-CoV clade indicates relatively little divergence 
between MERS-CoV sequences, and this appears true even with the inclusion of sequences 
isolated from the Korean MERS-CoV outbreak which had previously been demonstrated to be 
a more divergent strain if the virus (Kim et al., 2016) with apparently reduced affinity for human 
DPP-4.  
7.3.2. Results selection analysis of the MERS-CoV spike 
Several sites were identified as under positive selective pressure. Sites 26 and 1020 
as identified in the analysis are sites of significant variation across the currently available list 
of published MERS-CoV sequences. In addition, sites 506 and 509 while not identified in the 
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analysis do display significant variability in the circulating viral strains. Therefore, it was 
decided to in induce mutations at these sites based on residues matching known distinct 
isolates. The last sites identified were sites 1193, 1202 and 1208. Site 1202 had a surface 
accessibility score of 1.4 and was therefore below the threshold accepted as likely to be a 
good candidate for surface expression. Therefore this site was not included in the initial 
mutagenesis attempts.   
Table 26: Summary of the results of selection analysis of the MERS-CoV indicating the codons assessed as under positive or 
negative selection pressure by each of the four methods employed within the Datamonkey webserver to Dataset 2. 
 
SLAC IFEL MEME FUBAR 
POSTIVE 1020, 1193, 1208 26, 94, 158, 194, 301, 312, 744, 810, 1020, 1202 
424, 506, 509, 833, 
914, 1020, 1193, 
1202, 1208 
26, 424, 509 833, 
1020, 1193, 1202, 
1208, 1314 
NEGATIVE 38, 86, 112 Multiple N/A Multiple 
   
Making use of the IEDB analysis as implemented in Section 4.2.5 it can be 
demonstrated that several predicted epitopes lie within several well-preserved regions of the 
spike protein. In addition, the surface accessibility calculations indicate that codon 509 scores 
high and is likely to near the outer surface of the folded protein. Codons at positions 1020 and 
1208 also show values above the threshold of 1.4 that indicates a high probability of surface 
accessibility.  At the time of writing a complete crystallographic structure for the spike protein 
was not available. However, the results of surface accessibility predictions indicate that a 
number of these codons may be surface accessible and therefore may play a role in the virus-
host interaction. 
 Based on these results six sites were selected for mutagenesis with sites 424, 833 and 
1202 not considered for further analysis. Codon 26 was selected despite this site being 
unlikely to be involved in host-virus interaction. This site was selected as it lay some distance 
from the other identified sites and as such this site less likely to be connected to the other 
sites, based on the theory that closely clustered sites would have cumulative effect on protein 
folding while more distant sites may correspond to regions of the protein under different levels 
of selection.  
Table 27:Surface Accessibility scores as calculated by the Emini surface accessibility prediction algorithm. Sites selected for 














7.3.3. Generation of MERS-CoV spike mutations 
Attempts to generate the mutant sequences failed repeatedly with only the F506L, 
H1020R and A1193S mutations being successfully integrated into the S sequence. Numerous 
attempts to induce the mutation showed repeated failure of both sets of designed primers to 
amplify mutant sequence. Following attempts to generate mutant sequences following the 
standard protocol as outlined 7.2.4. DMSO was added to the reagent mixture in an attempt to 
increase amplification efficiency, furthermore annealing temperatures were reduced by 2ႏ in 
a further attempt to produce. However, from this method only parental (WT) sequence data 
was obtained after transformation and sequencing.   
7.3.4. Production of PV with mutant spike sequence 
Results of attempts to generate MERS PV using the newly generated MERS-CoV S 
proteins with introduced mutations are recorded in figure 59 with attempts to increase viral 
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Figure 58: RLU values recorded for PV produced using novel spike proteins generated with crossover PCR. Indicating relatively 
minor differences between the original sequence and the mutated strains. However, the use of unpaired T-tests to compare the 
means of these data indicates that significant differences do occur.  
Statistical analysis of the means of these mutant spike proteins, when compared to the 
original strain, show that the both F506L (unpaired t-test, t=4.438 df=14, R2= 0.5846, p=0.006) 
and H1020R (unpaired t-test, t=4.958 df=14, R2= 0.6372, p=0.0002) differed from the codon 
optimised MERS-CoV spike protein. In addition, the A1193S also differed significantly (t=5.286 
df=13.88, R2= 0.6681, p=0.0001), all analysis was conducted in GraphPad® Prism 7.02. 
However, the repeat assay did not support these findings with F506L (the unpaired t-test, 
t=0.2801, df=12.8, p=0.7839) and H1020R (the unpaired t-test, t=1.27, df=7.736, p=0.2409) 
and A1193S (the unpaired t-test, t=0.4893, df=11.71, p=0.636). These duplicated titrations are 
recorded in figure 60 (A) and (B) alongside the results of experiments with using protease 
during the production phase.  
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Figure 59: Values of comparison of different proteases introduced during the production stage of transfection of the 
expression plasmid on the production of Mutant MERS-CoV displayed in (A) titration carried out on day of viral harvesting and 
titration displayed in (B) was carried out 12 days later with PV preparations stored at -80ႏ in the interim. Note that as the 1193 
is so far distant from any potential cleavage site this mutant was not produced with protease.  
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Figure 60 displays the results of PV production incorporating the mutant spike DNA in 
the presence of protease expression plasmids during the production phase. In addition, the 
inclusion of PV bearing the respective mutant spikes allowed replication of the comparison 
between the MERS-CoV (codon optimised) original sequence and the mutant bearing PVs. It 
is interesting to note that the observed statistical different apparent in figure 59 was not 
replicated.  
7.3.4. Screening of mutant MERS-CoV S bearing PV against SARS-CoV 
convalescent serum 
The impact if any of the different residues on the potential for the MERS-CoV PV to be 
neutralised with convalescent serum from SARS patients was next assessed through the 
neutralisation assay described in Section 2.11.  For these assays serum was selected from 
Serum Panel 2 as identified in Section 4.2.1,  this the serum selected was chosen on the basis 
of representing the range of potential responses as with positive neutralising serum samples, 
negative samples and three additional samples which were below the accepted threshold 
(IC50 = 50) for positive neutralisation but were nevertheless only slightly below this cut off, it 
was expected that if the induced mutants altered the antigenic profile of the viral spike protein 
then this would be revealed through this range of serum. BJ38, BJ96, and BJ100 which had 
all been deemed positive for MERS-CoV PV neutralisation. The specific serum samples 
selected were BJ85, BJ90, and GZ013 which had all been deemed negative previously, and 
the final trio of serum samples were BJ58, GZ65, and GZ128 which although had been 
deemed negative for cross-reactivity all showed low levels of neutralisation of the MERS-CoV 
PV and so it was possible that these serum samples may have had a greater impact on the 
mutated MERS-COV strains than they had on the original PV.   In addition to the mutant spike 
PV, PV bearing the original codon optimised spike sequence was used as a control in each 
assay.  
Table 28: IC50 values for mutant MERS-CoV spike proteins as calculated with GraphPad Prism 7.02. Calculations performed as 
outlined in Section 2.11.  
 
ORIGINAL MERS F506L H1020R A1193S 
BJ38 302.3 88.6 79 77.3 
BJ96 167.7 341 359.2 300.6 
BJ100 511.1 91.1 108.1 75.2 
BJ85 0 26 37.8 15.1 
BJ90 38.3 44 39.8 44.1 
GZ13 0 13.6 14.1 31.6 
BJ58 0 11.1 45.1 53 
GZ65 0 0 8.9 0.2 
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Figure 60: Results of neutralisation assays of mutant MERS-CoV spike proteins assayed against Serum from SARS convalescent patients  
from Serum Panel 2 Chapter 4. Figure (A) shows results for MERS-CoV PV with the original codon optimised UK2 sequence, Figure B shows results of the same assay conducted with F506L mutation, Figure (C) shows these 
results for H1020R mutation and (D) shows the results for A1193S mutation. The serum selected for this batch of testing consisted of BJ38, BJ96, and BJ100 which had all been deemed positive for MERS-CoV PV neutralisation, 
BJ85, BJ90 and GZ013 which had all been deemed negative previously, and the final trio of serum samples were BJ58, GZ65 and GZ128 which although had been deemed negative for cross-reactivity all showed low levels of 





Figure 61: Relative positions of successfully mutated codons on the MERS-CoV Spike displayed with  overlay indicated the surface accessibility (black line) and with RBD and Heptad repeat regions 




Since the 2002-2003 SARS epidemic became the first, there has been a significant 
increase in the numbers of coronaviruses isolated and identified (Woo et al., 2010). However, 
the outbreak of MERS-CoV marked yet another previously unknown coronavirus that posed a 
threat to humans and domestic animals. Studies rapidly linked the MERS-CoV to the bat 
coronavirus HKU4 (Wang et al., 2014; Yang et al., 2014) however there remains a large 
number of unresolved questions surrounding pattern of evolution that led to a, most likely bat-
borne virus to begin to infect humans (Mackay and Arden, 2015). There have been several 
studies in recent years analysing the selective pressure acting on viral proteins (Voloch et al., 
2014; Azarian et al., 2015; Forni et al., 2015). These studies offer crucial insights into the 
evolution of viruses and are particularly beneficial when applied to viruses that have recently 
shifted hosts and so are exposed to novel evolutionary pressure to adapt to their new host. In 
the case of coronavirus spike proteins, they are ideal candidates for this form of analysis as 
they are highly exposed on the virus surface and represent a major target for antibody 
response (Ying et al., 2015). Therefore, adaptive evolution of the S protein is most likely driven 
by the host immune system, and diversification of this region may have consequences for drug 
development. This idea has also been discussed in contemporaneous research also analysing 
the spike protein through similar methods to those used here (Lau et al., 2013; Forni et al., 
2015). Studies of this nature have the potential to help identify novel drug targets as well as 
inform public health planners and epidemiologists, by assessing the risk of viruses such as 
MERS-CoV becoming better adapted to human hosts and developing the ability to escape 
existing and developing treatments, a trait already of concern with other members of the 
coronavirus lineage (Yoo and Deregt, 2001).  
The results outlined here, summarised in table 30 indicate that several adaptive 
changes, within the MERS-CoV clade, appear to be more common in the S2 region of the 
spike protein, with a smaller number in the S1 region. This closely matches the 
contemporaneous findings of Forni et. al. (2015) (Forni et al., 2015) although there is some 
variation in the precise codons identified by each analysis. It is interesting to note that there 
are far fewer identified sites located within not just the S1 domain and but in contrast to Forni 
et. al. (2015) this analysis did indicate a pair of sites, 506 and 509 that lie within the RBD 
domain. However, the identification of these sites as under positive selection did not meet the 
criteria applied as these sites were identified only by the MEME method which is by necessity 
more sensitive to selection and less conservative than other tools (Murrell et al., 2012). It is 
interesting to note that the detection of these sites occurred using a tool that is optimised for 
the detection of episodic periods of positive selection. The MEME algorithm can identify 
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positive selective pressure that is acting on only some of the branches of the phylogenetic 
reconstruction under study. This form of selection would be masked to other analysis types of 
analysis as transient periods of adaptive evolution such as those occurring after a virus 
spillover can be masked by the prevalence of purifying or neutral selection on other branches 
(Murrell et al., 2012). As such it is possible that the results of the MEME analysis should be 
given greater weight in studies of this nature, although given the potential for selective 
pressure to be overestimated it is essential that studies continue to make use of multiple 
testing (Anisimova and Yang, 2007; Privman, Penn and Pupko, 2012). The identification of 
these sites by the MEME method but not the other algorithm employed may indicate that these 
codons underwent a period of rapid diversification but that this is no longer the case, such 
evolutionary patterns are to be expected during viral spillover events (Plowright et al., 2015). 
PV production as outlined in figure 59, showed a minimal but statistically significant difference 
in the RLU/ml values between the preparations.  
As this dataset included a variety of HKU4 and HKU5 sequences for comparison these 
results may be interpreted to indicate that the MERS-CoV virus spillover from the original bat 
hosts occurred with minimal changes to the RBD domain and when coupled with affinity of 
HKU4 for the bat DPP-4 receptor this both provides yet more evidence this (Yang et al., 2014). 
It must, however, be acknowledged that the methods employed here are conservative and the 
requirement for sites to be identified by two different methods to declare a site as under 
positive selection makes this approach even more conservative. While this methodology limits 
the potential for false positive results it may have also have had the effect of increasing the 
number of false negative results, nevertheless this approach has rapidly become the standard 
method in this form of analysis (Areal, Abrantes and Esteves, 2011; Volz and Pond, 2014; 
Forni et al., 2015).  Although the identification of site 1193 represents a novel indication of the 
power of this form of analysis when combined with PV, this analysis was unable to identify 
evidence of changes in the evolutionary rate of MERS-CoV when compared to other CoV and 
no compelling data to suggesting a domain is undergoing adaptive changes in the spike 
protein driven by the MERS-CoV spillover event.  
Further studies of the MERS-CoV should seek to explore the sites identified in this 
chapter in more detail in particular, more successful mutagenesis may be employed to 
introduce mutants at all positions identified. In addition, as the methods use here rely on PV 
transducing target cells the use of assays capable of detecting binding and fusion of a spike 
protein separately may provide more information on the role these sites play (Matsuyama and 
Taguchi, 2009). The lack of available monoclonal antibodies also acted as a confounding 
factor in elucidating the role the identified codons played. As the micro-neutralisation assays 
conducted made use of patient serum, which is a complex mix of proteins and antibodies 
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(Nissum and Foucher, 2008). This complexity makes it difficult to divine specific effects of the 
mutations although it is clear from the data displayed in figure 59 that these mutations do not 
have a significant effect on the neutralisation potential of the serum when used neutralising 
PV. Although variation in the calculated IC50 scores did occur this variation did not cause any 
sufficient change to the values to alter the findings of Chapter 4 i.e. serum positive for 
neutralisation of MERS-CoV WT was also positive for the mutant strains, a serum that failed 





















Chapter 8 Analysis of Selective Pressure Acting on the Ebola 
Glycoprotein and Mutagenesis of Identified Codons 
8.1. Introduction 
The 2014 Ebola virus outbreak localised primarily in Western Africa is the largest Ebola 
epidemic in recorded history and highlighted the significant gaps in our knowledge of the 
disease. Despite the relatively high profile of the Ebola outbreak, in both scientific terms and 
in popular culture many basic questions about the virus remain unanswered. As previous 
outbreaks of the Zaire ebolavirus (ZEBOV)  were highly localised epidemics, it was initially 
expected that this outbreak would rapidly diminish as viable hosts died and so the virus would 
฀“฀b฀u฀r฀n฀ ฀o฀u฀t฀”฀ ฀a฀f฀t฀e฀r฀ ฀a฀ ฀s฀h฀ort period (Pourrut et al., 2005; Brown, Arkell and Rokadiya, 2015; Na et 
al., 2015). However, the unprecedented scale of this outbreak has led to increased interest in 
the potential for an Ebolavirus species to become better adapted to human hosts. This latest 
outbreak has resulted in excess of 10,500 laboratory confirmed Ebola cases, causing more 
than 4,800 deaths, in addition when coupled with suspected cases these figures rise to some 
28,638 cases and 11,316 (World Health Organization, 2016). The disparity in these figures 
highlights the complexity that outbreaks of this nature involve with large numbers of cases 
spread of multiple countries making the tracking of cases a difficult task. Furthermore, there 
is a high likelihood that cases have been unreported (Kuehne et al., 2016). Like the MERS-
CoV, the rapid spread of the  after this most recent spillover makes studies of the selective 
pressure acting on the viral glycoproteins informative. 
The role of viral host reservoirs is well known, but the details of viral spillover are not 
as well characterised. As is the case with the MERS-CoV the traits that allow the EBOV to 
become a zoonotic disease are poorly understood and this hinders the ability of 
epidemiologists to predict future outbreaks. Although human outbreaks have been 
uncommon, there have also been a number of large-scale die-offs in wild animals that have 
been attributed to ZEBOV. Between 2001 and 2005 18 gorillas and five chimpanzees, were 
discovered in Gabon and DRC and these deaths have been attributed to Ebola (Rouquet et 
al., 2005; Leroy, Gonzalez and Baize, 2011). With animal carcasses testing positive via both 
PCR and antigen detection for ZEBOV (Rouquet et al., 2005). In addition, much larger scale 
die-offs have also been linked to ZEBOV in the non-human great apes with evidence 
suggesting that large-scale die-offs of the gorilla populations in Democratic Republic of Congo 
(DRC) and Gabon are linked to ZEBOV (Bermejo et al., 2006). However, the difficulties in 
locating and sampling animal carcasses in situations like this mean that only a small number 
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of animal remains could be tested although several did show positive PCR tests for ZEBOV 
(Rouquet et al., 2005; Bermejo et al., 2006; Wittmann et al., 2007).  
A number of specific fruit bat species have been implicated as potential primary hosts 
of the virus (Pigott et al., 2014; Guyton and Brook, 2015; Han et al., 2015).  However, the 
complex patterns of spread and epidemiology of the Ebola virus mean that there is a high 
likelihood that the spread of Ebola will be linked to several animal species through a complex 
chain of infection (Carroll et al., 2015).  
The Ebola virus is a highly virulent pathogen that causes considerable human 
morbidity and mortality that has traditionally caused high levels of localised morbidity. 
However, the unprecedented scale of the most recent Ebola outbreak has emphasised the 
gaps in our knowledge about this virus and focused efforts on understanding the changing 
evolutionary patterns of the virus. With humans infected in numbers that were previously 
unheard of in the most recent outbreak, significant concern arose among healthcare providers 
that the Ebola virus may have become better adapted to the human hosts and numerous 
incidents of human to human transmission seemed to justify these concerns (Na et al., 2015).   
As with the MERS-CoV, the rapid pace of research into the Ebola outbreak has led to 
huge amounts of sequenced data becoming available very rapidly.  The use to which this data 
is put is crucial to develop a greater understanding of the Ebola virus and determine the 
likelihood of future outbreaks and the potential for the generation of escape mutant strains that 
could potentially circumvent the recently developed vaccines which have proven effective thus 
far (Davey et al., 2016; Pavot, 2016). As is the case with MERS-CoV the combination of recent 
viral spillover and highly virulent nature make the Ebola virus an excellent candidate for the 
development of a research pipeline that makes use of both in-silico tools to analyse the 
sequence and the use of PV in order to develop an effective workflow. 
In this chapter, the Ebola glycoprotein was analysed via several computational tools 
searching for evidence of natural selection acting to drive diversification of the Ebola envelope 
glycoprotein (GP).  Upon identification of sites undergoing high levels of selective pressure, 
mutagenesis experiments were attempted to generate mutations at these codons. As was the 
case for the MERS-CoV spike protein, identified sites were mutated both to mimic the diversity 
seen at these sites in the circulating strains (i.e. residues were altered to introduce residues 
in ZEBOV sequences previously isolated) and also mutated to a novel amino acid (when 
possible this was a mutation to alanine). Alanine is the most frequently used residue for 
exploratory mutagenesis as its introduction eliminates the amino acid side chain beyond the 
ȕ฀ ฀c฀a฀r฀b฀o฀n฀.฀ ฀ ฀H฀o฀w฀e฀v฀e฀r฀,฀ ฀u฀n฀l฀i฀k฀e฀ ฀t฀h฀e฀ ฀o฀t฀h฀e฀r฀ ฀a฀m฀i฀n฀o฀ ฀a฀c฀i฀d฀s฀ ฀t฀h฀a฀t฀ ฀s฀h฀a฀r฀e  t฀h฀i฀s฀ ฀p฀r฀o฀p e r฀t฀y  ฀(฀G฀l฀y฀c฀i฀n฀e฀ ฀a฀n฀d  ฀p฀r฀o l฀i฀n฀e฀Ψ฀ 
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of lacking a large side chain Alanine does not alter the main-chain conformation and does not 
possess extreme electrostatic or steric properties (Lefèvre, Rémy and Masson, 1997).  
The effects of these mutations were then assessed through the production of PV 
฀b฀e฀a฀r฀i฀n฀g฀ ฀t฀h฀e฀ ฀n฀o฀v฀e฀l฀ ฀g฀l฀y฀c฀o฀p฀r฀o฀t฀e฀i฀n฀s฀.฀ ฀T฀h฀e฀s฀e฀ ฀n฀o฀v฀e฀l฀ ฀P฀V฀’฀s฀ ฀w฀e฀r฀e฀ ฀t฀i฀t฀r a฀t e฀d฀ ฀a฀l฀o฀n฀g฀s฀i d฀e฀ ฀t h e  o฀r i฀g฀i฀n฀a฀l฀ 
Ebola/Mayinga (Wild Type, WT) glycoprotein bearing PV and the titres (in RLU/ml) attained 
for these PVs were compared. The novel PVs were also utilised into neutralisation tests with 
human-derived cells (HEK293T/17) where the ability of specific antisera to effectively 
neutralise these mutants was compared to WT. This study will in part, therefore, determine if 
the recent outbreak has resulted in the adaptation of the Ebola glycoprotein to the human host. 
Studies of this nature are required as the scale of the outbreak has provided an unprecedented 
opportunity for Ebola to evolve into a more infectious variant within humans. By examining the 
selective pressure acting on the Ebola glycoprotein and producing PV bearing mutations 
representing the identified residues will provide an experimental framework for testing a 
hypothesis about the evolution of a virus during an ongoing or recent outbreak. In addition, by 
developing tools of this nature and demonstrating the effectiveness of these protocols it is 
possible to demonstrate the neutralisation efficacy of the newly developed Ebola vaccine 
(Davey et al., 2016) against potential novel Ebolavirus glycoproteins that are likely to evolve.  
8.2. Materials and methods 
8.2.1. Datasets and phylogeny 
Viral sequences were retrieved from the GenBank NCBI database, and a list of 
accession numbers recorded in the Appendix 5(a) for a dataset comprising 128 Filovirus 
sequences, including Ebolavirus and sequences of Marburg virus (MARV) and the more 
distantly related a single representative of Lloviu virus, in this case, used as an outgroup.  This 
dataset was designated as Dataset_1 and was used to assemble the phylogeny of Ebolavirus. 
An additional smaller dataset was compiled of 46 glycoprotein sequences for use in further 
selection analysis; this smaller dataset was designated Dataset_2, table 31. Dataset_2 was 
assembled from a subset of the larger due to the large degree of conservation present among 
the Ebola glycoproteins isolated in the latest outbreak, and so many of these sequences were 
removed by eliminating sequences where genetic distances were less than 0.01. In this 
instance, the genetic distance is defined as an estimate of evolutionary divergence between 
sequences and calculated as the number of base substitutions per site between two 
sequences. In effect, if the distance between two sequences were less than 0.01 the analysis 
would be unlikely to yield informative results, and so one of this pair of sequences was 
removed from the dataset (Voloch et al., 2014). Duplicate (or near duplicate) sequences do 
not contribute any additional information to the analysis, and since HyPhy tools such as 
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Datamonkey use likelihood inference procedure, the computational complexity grows rapidly 
with the size of the dataset to be analysed.  informative results, and so one of each pair of 
such sequences was removed from the dataset (Voloch et al., 2014). Duplicate (or near 
duplicate) sequences do not contribute any additional information to the analysis, and since 
HyPhy tools such as Datamonkey use likelihood inference procedure, the computational 
complexity grows rapidly with the size of the dataset to be analysed.  
In order to reduce the potential impacts of errors in the calculated Multiple Sequence 
Alignment (MSA), the initial phylogeny was based on an alignment performed using the 
PRANK (Löytynoja and Goldman, 2005) algorithm to calculate the MSA, and GUIDANCE2 
(Sela et al., 2015) was employed to filter poorly aligned codons (i.e. codons with a score of < 
0.95 were masked). GUIDANCE2 (Sela et al., 2015) (Chapter 2)  makes use of bootstrapped 
phylogenetic trees, to generate alternative MSAs from the input MSA generated by the linked 
alignment program (PRANK). These alternative MSAs are generated by varying the alignment 
gap penalty score and realigning the sequence data. Comparing the initial alignment to the 
set of novel alternative alignments results in scores between 0-1 for each residue, residue-
pair, column 
Table 29: List of sequences downloaded from GenBank database for use in the analysis as Dataset_2. This dataset was reduced 
to 46 sequences by selective removal of closely related sequences. Note in instances where the year of isolation is not recorded 
then either year of publication, or year of upload to GenBank was recorded with the earliest of these two dates taken. Strain data 
is recorded ฀“฀a฀s฀ ฀i฀s฀”฀ ฀f฀r฀o฀m฀ ฀t฀h฀e฀ ฀G฀e฀n฀B฀a฀n฀k฀ database, with the information recorded here as it is recorded in the database and is used 
only for entry identification.  
Accession 





AY358025.2 Marburg Ozolin 1975 Human SA 
AF086833.2 Ebola Zaire 1976 Human DRC 
KC242801.1 Ebola Zaire 1976 Human DRC 
KM655246.1 Ebola Zaire 1976 Human DRC 
KC242791.1 Ebola Congo 1977 Human DRC 
U23152.1 Ebola Reston 1995 Human  
AY354458.1 Ebola Zaire 1995 Human DRC 
KC242799.1 Ebola Congo 1995 Human DRC 
U23069.1 Ebola Maleo 1995 Human Sudan 
KC242794.1 Ebola Congo 1996 Human DRC 
KC242795.1 Ebola Gabon 1996 Human Gabon 
KC242797.1 Ebola Gabon 1996 Human Gabon 
KC242798.1 Ebola Gabon 1996 Human Gabon 
DQ447651.1 Marburg 05DRC99 1999 Human DRC 
AF272001.1 Ebola Mayinga 1999 Guinea pig Germany 
EU051630.1 Ebola Zaire 2002 Gorilla DRC 
KC242785.1 Ebola Congo 2007 Human DRC 
KC242786.1 Ebola Congo 2007 Human DRC 
KC242787.1 Ebola Congo 2007 Human DRC 
KC242788.1 Ebola Congo 2007 Human DRC 
KC242790.1 Ebola Leubo 2007 Human DRC 
EU224440.2 Ebola Mayinga 2007 Guinea pig Russia 
KU182911.1 Ebola Zaire 2007 Human Uganda 
KC545388.1 Marburg Mbg-423 2012 Human Uganda 
KP271020.1 Ebola Zaire 2014 Human DRC 
KJ660346.2 Ebola Zaire 2014 Human Guinea 
KJ660347.2 Ebola Zaire 2014 Human Guinea 
KJ660348.2 Ebola Zaire 2014 Human Guinea 
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KR817192.1 Ebola Zaire 2014 Human Guinea 
KR817114.1 Ebola Zaire 2014 Human Liberia 
KR013754.3 Ebola Zaire 2014 Human SierraLeone 
KM034558.1 Ebola Zaire 2014 Human SierraLeone 
KM233041.1 Ebola Zaire 2014 Human SierraLeone 
KM233052.1 Ebola Zaire 2014 Human SierraLeone 
KM233063.1 Ebola Zaire 2014 Human SierraLeone 
KM233074.1 Ebola Zaire 2014 Human SierraLeone 
KM233085.1 Ebola Zaire 2014 Human SierraLeone 
KM233096.1 Ebola Zaire 2014 Human SierraLeone 
KM233107.1 Ebola Zaire 2014 Human SierraLeone 
KM233113.1 Ebola Zaire 2014 Human SierraLeone 
KM233118.1 Ebola Zaire 2014 Human SierraLeone 
KR074998.1 Ebola Zaire 2015 Human Liberia 
KU220269.1 Ebola Zaire 2015 Human Liberia 
KU220276.1 Ebola Zaire 2015 Human Liberia 
KU220284.1 Ebola Zaire 2015 Human Liberia 
KR781608.1 Ebola Zaire 2015 Human Liberia 
 
In order to reduce the potential impacts of errors in the calculated Multiple Sequence 
Alignment (MSA), the initial phylogeny was based on an alignment performed using the 
PRANK (Löytynoja and Goldman, 2005) algorithm to calculate the MSA, and GUIDANCE2 
(Sela et al., 2015) was employed to filter poorly aligned codons (i.e. codons with a score of < 
0.95 were masked). It is not generally feasible to completely remove a codon/residue from an 
MSA, to avoid loss of data GUIDANCE2 was used to mask unreliably aligned codons by 
replacing them with a missing data character, ฀‘฀n' It has been demonstrated that this method 
leads to more accurate results in the analysis of selective pressure (Privman, Penn and Pupko, 
2012).  
GUIDANCE2 (Sela et al., 2015) (Chapter 2)  makes use of bootstrapped phylogenetic 
trees, to generate alternative MSAs from the input MSA generated by the linked alignment 
program (PRANK). These alternative MSAs are generated by varying the alignment gap 
penalty score and realigning the sequence data. Comparing the initial alignment to the set of 
novel alternative alignments results in scores between 0-1 for each residue, residue-pair, 
column (alignment of a nucleotide or amino acid position across multiple sequences) and 
฀s฀e฀q฀u฀e฀n฀c฀e฀ ฀o฀f฀ ฀t฀h฀e฀ ฀M฀S฀A฀,฀ ฀t฀h฀i฀s฀ ฀s฀c฀o฀r฀e฀ ฀r฀e฀f฀l฀e฀c฀t฀s฀ ฀t฀h฀e฀ ฀d฀e฀g฀r฀e฀e฀ ฀o฀f฀ ฀‘฀r฀e฀l฀i a b฀i฀l i t฀y฀’฀ ฀f฀o฀r฀ ฀t฀h฀a฀t฀ ฀a฀l฀i฀g฀n฀m฀e฀n฀t฀ ฀o฀f฀ ฀t h฀a฀t฀ 
residue-pair, column or sequence. When combined with a PRANK alignment the GUIDANCE2 
algorithm is a computationally intensive process but yields an MSA better suited to selection 
analysis  (Privman, Penn and Pupko, 2012; Sela et al., 2015). As with the MERS-CoV 
(Chapter 7), PRANK was performed with 100 bootstraps to ensure accurate results were 
obtained.  (alignment of a nucleotide or amino acid position across multiple sequences) and 
฀s฀e฀q฀u฀e฀n฀c฀e฀ ฀o฀f฀ ฀t฀h฀e฀ ฀M฀S฀A฀,฀ ฀t฀h฀i฀s฀ ฀s฀c฀o฀r฀e฀ ฀r฀e฀f฀l฀e฀c฀t฀s฀ ฀t฀h฀e฀ ฀d฀e฀g฀r฀e฀e฀ ฀o฀f฀ ฀‘฀r฀e฀l฀i a b฀i฀l i t฀y฀’฀ ฀f฀o฀r฀ ฀t฀h฀a฀t฀ ฀a฀l฀i฀g฀n฀m฀e฀n฀t฀ ฀o฀f฀ ฀t h฀a฀t฀ 
residue-pair, column or sequence. When combined with a PRANK alignment the GUIDANCE2 
algorithm is a computationally intensive process but yields an MSA better suited to selection 
analysis  (Privman, Penn and Pupko, 2012; Sela et al., 2015). As with the MERS-CoV 
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(Chapter 7), PRANK was performed with 100 bootstraps to improve the accuracy of the 
phylogenetic inference.  
8.2.2. In-silico analysis of the Ebola glycoprotein 
After identification of codons under positive selection, IEDB web tools were employed 
to assess the proximity of these sites to identified potential antigenic regions (Yao et al., 2012) 
and the accessibility of these sites on the surface on the protein. The IEDB tools were used to 
identify the potential of these sites to be available for antibody interaction via the Emini Surface 
Accessibility Prediction and Bepipred Linear Epitope Prediction both of which employ heuristic 
algorithms based on experimental data to infer structural data about proteins for which 
complete, reliable structural information is not yet available. 
8.2.3. Selection analysis and recombinant screening of the Ebola glycoprotein 
After the assembly of the large dataset 1 phylogeny, this reconstruction was used as 
the basis for the initial of selection analysis implementation. Prior to performing any additional 
analysis the MSA was screened for evidence of recombination events using the GARD (Pond 
et al., 2006) (Chapter 2) algorithm. The GARD algorithm works by performing statistical 
probability calculations to determine sites at which breakpoints have occurred, these 
breakpoints may have created chimeras or putative recombinants and so will affect selection 
analysis. The likelihood of any breakpoint identified by the GARD algorithm is assessed using 
the Kishino-Hasegawa (KH) test. This test is a maximum likelihood method that estimates the 
variance of the difference of log likelihood between trees and can be used to compare the 
breakpoints within the trees to assess their credibility. Recombination breakpoints identified 
through this analysis were considered significant if the KH value was < 0.01.  
After assessment of the potential recombination within the dataset the following 
methods: Single Likelihood Ancestor Counting (SLAC); Internal Fixed Effect Likelihood (IFEL), 
Fast Unconstrained Bayesian Approximation for Inferring Selection (FUBAR) and finally the 
Mixed Effects Model of Episodic Diversifying Selection (MEME) algorithm. The SLAC analysis 
involves the analysis of MSA through the interpretation of a phylogenetic tree and a model of 
nucleotide substitution, both of which are recalculated. The SLAC then simply counts the 
number of nonsynonymous and synonymous changes, and these are compared for each site 
in the MSA (Kosakovsky Pond and Frost, 2005). In the IFEL analysis, every codon is assigned 
a single rate of synonymous substitution and two nonsynonymous rates. These two 
nonsynonymous rates are assigned to account for differences in potential codon selection that 
is driven as the codon evolves along a terminal branch (i.e. usually indicating recent bouts of 
evolutionary pressure) and the potentially different rate of evolution of the codon for internal 
branches (i.e. episodic or historical evolution) . This manner of testing has been demonstrated 
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to be effective in cases were strong diversifying selection is in effect, and so codons are likely 
to be highly divergent (Kosakovsky Pond, Frost, et al., 2006). The MEME algorithm allows the 
distribution of dN/dS to vary from site to site (the fixed effect) and also from branch to branch 
at a specific site (the random effect) (Murrell et al., 2012).  This method uses phylogenetic 
models to describe the evolution of codon characters along a given branch of a phylogenetic 
tree by a continuous-time stationary Markov process. 
These analyses were conducted using an evolutionary model based on the LRT 
algorithm available in Datamonkey. For MEME analysis codon-specific positive selection was 
admitted at p-value < 0.1, and the inference of the lineages in which diversifying selection 
occurred at a given codon was performed using a Bayes empirical Bayes approach. Codons 
in which the Bayes factor was greater than 1 were considered as targets of episodic 
diversifying selection. Complete output for all codons with all methods is recorded in Appendix 
5(d). For FUBAR analysis sites with a posterior probability of positive selection > 0.8 were 
taken as under positive selective pressure. For SLAC, analysis sites identified with a p value 
> 0.2 were considered under positive selection. Finally, for the IFEL algorithm sites with a 
significance level of 0.1 were considered under positive selection. 
8.2.4. Mutagenesis protocols  
Mutagenesis was carried initially using the in the Q5® mutagenesis kit (NEB cat # 
E0554S) with oligonucleotide DNA primers, designed using the NEBaseChanger 
(http://nebasechanger.neb.com/) tool; this online service also provides a complete protocol for 
use with the primers and kit (Figure 63).  
  The Q5® kit, in theory, allows rapid generation of, site-specific substitutions in 
plasmid DNA. The kit utilizes the Q5® Hot Start High-Fidelity DNA Polymerase coupled with 
non-overlapping mutagenic primers to create the desired mutation in the target plasmid. As 
these primers are non-overlapping, the reaction offers the potential for a true PCR reaction 
with the forward strand acting as a template for the reverse strand to allow exponential 
amplification to occur.  The post-PCR processing is performed using the supplied Kinase-
Ligase-DpnI (KLD) enzyme mixture which allows rapid (c. 5 minutes), room temperature re-
circularization of product and digestion of parental template.  Based on manufacturer 
instructions this kit should allow rapid generation of mutant sequences for plasmids even 
exceeding 20kbp in length, as the combined plasmid and insert for pCAGGS-EBOV is c. 
6.5kbp in length this amplification should be within the expected range of the kit.  
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Synthetic oligonucleotide DNA primers were designed using the NEBaseChanger 
(http://nebasechanger.neb.com/) tool and this tool also provides a complete protocol for use 
with the primers and kit (Figure 63).  
 
Figure 62: Protocol provided by NEB for the use of NEB Q5® mutagenesis kit. The figure indicates rapid and efficient incorporation 
of insertions, deletions, and substitutions into double stranded plasmid DNA. The first step is amplification using non-overlapping 
primers and the provided Q5 Hot Start High-Fidelity DNA Polymerase. The second step is the incubation of the PCR product with 
a proprietary enzyme mixture containing a kinase, a ligase, and a DpnI restriction enzyme. These three enzymes facilitate rapid 
re-circularization of the PCR product and removal of the template DNA. The final step is a transformation into chemically 
competent cells. Figure is taken from NEB protocol (https://www.protocols.io/view/Q5-Site-Directed-Mutagenesis-Kit-Quick-
Protocol-E0-imsvpv) 
However, as the in-house protocol described in Chapter 2 and again in Chapter 7 
requires that overlap primers designed for use in the Q5® mutagenesis kit cannot be used 
effectively to produce amplicons in this reaction. As such, further mutagenesis was carried out 
using the Phusion® polymerase which can be used with non-overlapping primers (Xia et al., 
2015) and will generate an exponential amplification of the desired product.  As the in-house 
protocol described in Chapter 2 and again in Chapter 7 requires that overlap primers designed 
for use in the Q5® mutagenesis kit cannot be used effectively to produce amplicons in this 
reaction. As such, further mutagenesis was carried out using the Phusion® polymerase which 
can be used with non-overlapping primers (Xia et al., 2015) and will generate an exponential 
amplification of the desired product.   
 
Table 30: Phusion® mutagenesis reagents for use in the standard protocol as outlined below. * DMSO was not added to initial 
reactions but was added to subsequent reactions were initial attempts at amplification were unsuccessful. 
REAGENT CONC. VOLUME 
5X PHUSION® BUFFER N/a 4 
10MM DNTPS 200µm 0.4 
FORWARD PRIMER 1.25ng 1 
REVERSE PRIMER 1.25ng 1 
TEMPLATE 80ng 1 
DMSO N/a 0.6* 
PHUSION POLYMERASE N/a 0.25 




The mixture of reagents recorded in table 32 was then placed in a thermocycler, and the 
following program was initiated;  
Temperature Time (minutes: seconds) 
x 1 98oC  1:00 (denature) 
x 2 98oC  0:30 
x 3 59-65oC 0:45   18 cycles  
x 4 72oC  9:30 
x 5 72oC  10:00 
2,3,4
 To be cycled x18 (cycle number reduced due to large input of DNA)  
3
 Annealing temperature was defined per primer design. Gradient applied 
4
 Extension time was determined by length of DNA: 1 minutes per kb 
Amplification of the mutant product was verified by analytical DNA gel electrophoresis post 
digestion with DpnI (Thermo Fisher Scientific, cat. # FD1703) Fast Digest enzyme as per 
Chapter 2. ฀A฀s฀ ฀t฀h฀e฀ ฀A฀c฀u฀z฀y฀m฀e฀™฀ ฀based protocol is a non-PCR amplification and produces only 
linear amplification it is likely that a significant amount of the product contained in the final 
volume is parental DNA.  To reduce the risk that the subsequent transformation would only 
yield parental sequence the digest was carried out for 30 min at 37°C in a 10 µl reaction with 
DpnI enzyme in 1X FastDigest® Buffer (Thermo Fisher Scientific, cat. # B64). As the DpnI 
enzyme only digests methylated DNA and so will digest parental template but not PCR 
product, it was hoped that the additional digestion time would completely remove parental 
DNA. The DpnI reaction was heat-inactivated for 5 min at 80°C, before transformation E. coli 
฀D฀H฀5Į cells. 
After transformation and purification via Qiagen miniprep kit, the mutant sequences were 
sent ฀f฀o฀r฀ ฀s฀e฀q฀u฀e฀n฀c฀i฀n฀g฀ ฀u฀s฀i฀n฀g฀ ฀t฀h฀e฀ ฀G฀A฀T฀C฀™฀ ฀L฀i฀g฀h฀t฀r฀u฀n฀™฀ ฀s฀e฀r฀v฀i฀c฀e฀ ฀t฀o฀ ฀c฀o฀n฀f฀i฀r฀m฀ t h a t฀ ฀t h฀e  ฀d e s i e d  ฀m฀u t฀a฀n t  
was present via Sanger sequencing. Primers designed to introduce the primary mutations are 
listed in table 33 with these primers aligned to the parental sequences recorded in, figures 63 
and 64. In addition to sites identified by selection analysis, attempts were made to induce 
mutations at sites where residue differences had already been observed, even in cases where 





Table 31: Mutagenic primers designed with the use of NEBaseChanger primer design tool to create non-overlapping primer 
pairs.  Ta indicates the recommended annealing temperature based on individual primer requirements as calculated by 
NEBaseChanger tool.  
Name (F/R) Oligo (Uppercase = target-specific primer) Len % GC Tm Ta * 
P429A_For CGCAGCCGGAgccCCAAAAGCAG 23 70 74°C 
72°C 
P429A_Rev GTCGTGGCAGAGGGAGTGTCG 21 67 70°C 
P429H_For CGCAGCCGGAcacCCAAAAGCAG 23 65 73°C 
72°C 
P429H_Rev GTCGTGGCAGAGGGAGTGTCG 21 67 70°C 
P430A_For AGCCGGACCCgcaAAAGCAGAGAAC 25 60 70°C 
72°C 
P430A_Rev GCGGTCGTGGCAGAGGGA 18 72 71°C 
P430L_For AGCCGGACCCctaAAAGCAGAGAAC 25 56 70°C 
72°C 
P430L_Rev GCGGTCGTGGCAGAGGGA 18 72 71°C 
P429A_P430A_For AGCCGGAGCCgcaAAAGCAGAGAAC 25 60 70°C 
72°C 
P429A_P430A_Rev GCGGTCGTGGCAGAGGGA 18 72 71°C 
P429H_P430L_For AGCCGGACACctaAAAGCAGAGAAC 25 52 68°C 
71°C 
P429H_P430L_For GCGGTCGTGGCAGAGGGA 18 72 71°C 
 
 
Figure 63: Primers designed to induce single point mutations in the Ebola/Mayinga optimised sequence shown aligned with the parental 
sequence (Ebola/May) codons to be altered highlighted in blue 
 
Figure 64: Primers designed to induce dual point mutations in the Ebola/Mayinga optimised sequence shown aligned with the parental 
sequence (Ebola/May) codons to be altered highlighted in blue. These primers are designed to anneal to the glycol protein sequence after 
mutation of the 429 codon to either and Proline (P) or an Alanine (A) by one of the single change primers displayed in Figure 64.  However, since 
the desired mutations are near the centre of the primer sequences these primers are also capable of introducing dual mutations in the parental 
sequence.  
8.2.5. Production of PV bearing Ebola/Mayinga glycoprotein and with Ebola 
mutant glycoproteins 
PV bearing the Ebola/Mayinga produced using the codon optimised gene and PV 
bearing the respective mutant glycoproteins were prepared in an identical fashion on the same 
day and with the HEK293T/17 cells at the same passage number.  PV was prepared as per 
Chapter 2 with lentiviral GAG core expressing plasmids p8.91 prepared with luciferase 
reporter gene expressing plasmids (pCSFLW) combined with the pCAGGS expression vector 
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that contained the relevant inserted glycoprotein. These plasmids were combined in a ratio of 
1:1.5:1 with a single 100mm plate of HEK293T/17 transfected with PEI and this expression 
plasmid mix.  
As PV bearing Ebola glycoproteins are often of poor titre the supernatant harvested as 
per protocol outlined in Chapter 2, was subsequently concentrated via Low-speed 
centrifugation. The concentration of the Ebola PV was conducted with Thermo Scientific 
Sorvall Legend Micro 21 (ThermoFisher Cat. # 75002493) centrifuge, PV was prepared by 
pipetting 1ml into a 1.5ml centrifuge tube at the time of PV harvesting. Tubes were clearly 
labelled, and their orientation in the centrifuge noted. This step is required as the concentrated 
PV pellet is likely to be invisible and additional PV particles will have a high likelihood to 
adhering to the side of the tube facing downwards. The tubes were then centrifuged for 24 
hours at 4.2 x G after 24 hours 900µl of PV supernatant was removed and stored for later 
testing. The remaining 100µl of PV was then used to resuspend the non-visible, viral pellet. 
During the resuspension step, ฀t฀h฀e฀ ฀r฀e฀m฀a฀i฀n฀i฀n฀g฀ ฀s฀u฀p฀e฀r฀n฀a฀t฀a฀n฀t฀ ฀w฀a฀s฀ ฀u฀s฀e฀d฀ ฀t฀o฀ ฀‘฀w฀a฀s฀h฀ ฀d฀o฀w฀n฀’฀ ฀t฀h฀e฀ ฀s i d e  o฀f  
the tube that had been facing downwards during the centrifuge stage. This method of 
resuspension yielded significant gains (figure 67) in the RLU values obtained for the 
concentrated PV and allowed further use of the Ebola PV as inputs in PV micro-neutralisation 
assays.   
8.2.6. Screening of mutant Ebola bearing PV against serum 
To neutralise the Ebola/Mayinga PV a sample of serum was purchased from NIBSC, 
this serum was a standardised reference serum for Ebola neutralisation (NIBSC cat. # 15/220). 
Neutralisation was carried out as per protocol outlined in Section 2.11 with 5µl of NIBSC serum 
added as an input. 
8.3 Results 
8.3.1. Filoviridae phylogenetic reconstruction 
The nucleotide substitution model was determined through the model selection tool 
implemented in MEGA 7.02 (Kumar et al., 2016). This selection tool determined that the 
optimal nucleotide substitution model was the GTR+G, the Generalised Time Reversible 
model (Tavare, 1986) with a Gamma shaped probability curve applied to among sites 
variation. The GTR model is a parameter-rich model and is the most general neutral, 
independent, finite-sites, time-reversible model that can be fitted to a nucleotide alignment. In 
this instance the GTR model describes the rate of change from one nucleotide to another, the 
Gamma shaped probability curve describes the rate variation among sites in a sequence and 
describes the non-uniformity nature of these changes may be modelled by using a discrete 
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Gamma shaped distribution with five rate categories. This model was used in the 
reconstruction of the Ebola phylogeny, and this (Figure 65) was used as the basis for the initial 
implementation of HyPhy (Yang and Rannala, 2012) algorithms through the Datamonkey 
server. Complete output of model selection tool is recorded in Appendix 5(b). 
The phylogeny derived here indicates exceptionally short branch lengths for the latest 
Ebolavirus outbreak (2014-2015 sequences), suggesting no periods of rapid evolution have 
occurred along these lineages. However, it should also be noted that U23152.1, U23069.1, 
and KU182911.1 all display longer branch lengths although still forming a monophyletic 
grouping with the remaining Ebolavirus. These Ebolavirus sequences are not the same 
Ebolavirus species U23152.1 is a representative of Reston Ebolavirus; U23069.1 is a Sudan 
Ebolavirus, and KU182911.1 is a Bundibugyo Ebolavirus.  
 
 
Figure 65 Ebola virus phylogeny of 128 publicly available Ebola sequences derived from PRANK (Löytynoja and Goldman, 2005) 
The evolutionary history was inferred by using the Maximum Likelihood method based on the General Time Reversible model . 
The tree with the highest log likelihood (-3936.7) is shown. Initial tree for the heuristic search was obtained automatically by 
applying Neighbor-Joining and BioNJ algorithms to a matrix of pairwise distances estimated using the Maximum Composite 
Likelihood approach, and then selecting the topology with superior log likelihood value. A discrete Gamma distribution was used 
to model evolutionary rate differences among sites (2 categories (+G, parameter = 2.1305)). The tree is drawn to scale, with 
branch lengths measured in the number of substitutions per site, however, note that tips have been aligned i.e. dashed lines do 
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not indicate branch length. The analysis involved 128 nucleotide sequences. Positions containing gaps and missing data were 
eliminated. There was a total of 859 positions in the final dataset. Evolutionary analyses were conducted in MEGA7 (Kumar et 
al., 2016) . Colours indicate different viruses with Ebola highlighted in red, and Marburg highlighted in yellow in addition and the 
Lloviu virus highlighted in blue. It is interesting to note the increased branch length of U23152.1, U23069.1, and KU182911.1. 
 
8.3.2. Results of selection analysis on the Ebola glycoprotein and in-silico 
analysis 
GARD analysis of dataset 2 identified no evidence of recombination within this dataset.  
These analyses were conducted using an evolutionary model based on the LRT algorithm 
available in Datamonkey. Complete output of all Datamonkey tools applied is recorded in 
Appendix 5 (d).  
Table 32: Sites indicated as under pervasive purifying selection as indicated by the Datamonkey webserver tools. Underlined 
codon sites are sites identified by two different methods, and these were taken as positive results for these sites to be mutated 
for further study 
 SLAC IFEL MEME FUBAR 





46,73, 82, 217, 248, 271, 
308, 326, 360, 382, 
400,425, 429, 430, 449, 
453, 475, 511, 512, 577, 
584, 592, 602 611, 613, 
647 
322, 323, 326, 
379, 417,425, 
429, 430, 
NEGATIVE Multiple Multiple N/A Multiple 
 
Based on this analysis seven sites were identified as under positive selection with sites 
325, 326, 360, 379, 425, 429 and 430 all identified by at least two different algorithms. 
However, given the complexity of mutagenesis at a large number of sites, it did not prove 
possible to induce mutations at all of these sites. To determine which of the identified sites 
would be most likely to affect GP function the Ebola/Mayinga sequence was submitted to the 
IEDB web server tools for evaluation of the potential antigenic activity and surface 
accessibility. Based on these results it was determined that the codons located at sites 429 
and 430 displayed the highest values for potential antigenic activity and surface accessibility 
and were therefore selected for further analysis. Figure 66 displays the results of IEDB 
analysis and the location of the two sites identified by selection analysis. Complete output of 





Figure 66: Domain schematic of the Ebola GP with overlay depicting Bepipred Epitope prediction results in Green and Surface 
accessibility results in orange. As is shown both sites lie within the mucin-like domain and this region appears to be both highly 
antigenic and accessible for antibodies given the high scores obtained for this region for both Bepipred and Surface accessibility 
tests. Also indicated are the heptad repeat 1 (Hep 1) and heptad repeat 2 (Hep 2). The diagram also indicates the cleavage site 
at residue 501 which is cleaved by furin-like proteases during the glycoprotein maturation process. 
 
8.3.4. Generation of PV bearing the mutated Ebola glycoproteins 
Initial attempts to generate PV using the EBOV/Mayinga glycoprotein resulted in a low 
RLU values and inconsistent results. Figure 67 (A) indicates the results of PV production prior 
to concentration and post concentration steps as outlined in Section 8.2.5.  This figure also 






































































































Figure 67: Results of titrations of Ebola/Mayinga bearing PV. 
Figure (A) shows a significant effect of overnight concentration of the harvested PV supernatant with Pre-and post-
concentration PV supernatant displayed and the additional supernatant removed after concentration, also indicated here is 
unconcentrated MERS-CoV Spike bearing PV results here used as a control. Figure (B) indicates results of titrations of Ebola 
mutants successfully generated and indicates no statistical difference in the mutant sequences compared to Wild-type original 
sequence. 
 
Results of production of PV making use of the mutated glycoproteins as PV envelope 
are recorded in figure 67 (B). The modification of the EBOV glycoprotein did not result in a 
change in RLU value obtained with no statistically significant different between the WT PV and 
the P429H (t=0.9484 df=12.32, p= 0.3612) and the P429A (t=1.181 df=10.19, p= 0.2645).  
 Attempts to induce mutations at site 430 were not successful despite several attempts 
using different conditions, including lowering of annealing temperatures and the addition of 
DMSO (Section 8.2.5.).  
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8.3.5. Screening of PV bearing the mutated Ebola glycoproteins with commercial 
anti-EBOV serum 
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Figure 68: Results of neutralisation assays of codon optimised Mayinga strain Ebola glycoprotein bearing PV when assayed against 
commercially available standardised NIBSC produced serum (A) and the results of this same serum assayed against PV produced 
bearing a P429H mutation (B) and a P429A mutation (C). To make comparisons easier normalised data from these assays are 
displayed on figure (D) 
Figure 68 displays the results of PV based micro-neutralisation assays of the NIBSC 
(15/220) standardised EBOV serum against WT and mutant glycoproteins. The calculated IC50 
values recorded for these PV preparations are recorded in table 35.  
Table 33:IC50 values for mutant and Wild-type EBOV PV assayed against NIBSC standard serum (15220). Values are calculated 
as recorded in Section 2. 
 
LOGIC50 IC50 
EBOV/MAY (WT) 2.2847162 192.62659 
EBOV-P429H 1.7925136 62.017405 
EBOV-P429A 1.9221927 83.59739 
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8.4. Discussion  
A high proportion of amino acids can be largely invariable in any given organism; this is 
because amino acid substitutions are frequently detrimental to the functioning of the protein. In 
this chapter, a number ML and Bayesian methods were employed and succeeded in identifying 
seven sites that were under positive selective pressure in the Ebola glycoprotein. All seven of 
these sites were located in the Mucin-like domain of the glycoprotein, and two were selected as 
candidates for further analysis through mutagenesis. These results indicate that although in the 
Ebola glycoproteins most of the residues are well conserved, and the glycoprotein is overall under 
negative selective pressure (Appendix 5(d)), there are specific regions and codons that are under 
positive selection  either through direct adaptive evolution or the relaxation of negative selection 
pressure. A greater knowledge of the viral protein structure evolution and the modifications that 
derive from this evolution offer the potential to be a key target for future drug development and 
offer insights into predicting future outbreaks based on the likelihood that certain traits may evolve 
to make Ebola better suited to human infection.  
Both sites selected for mutagenesis experiments in this chapter were in the Mucin-like 
domain and as indicated in figure 66 had a high likelihood of being accessible on the surface of 
the folded protein. Changes to these codons are likely to have minimal effect on protein structure, 
as changes to this region are likely to neither have a stabilizing nor destabilizing effect of the 
protein. Studies have demonstrated that the Mucin-like domain is not required for viral cell 
infection and even removal of this domain can still yield viable viral particles, although the affinity 
for these particles to cells appeared reduced (Takada, 2012). This may be linked to studies 
showing that interactions between the Ebola GP and human T cell Ig mucin 1 (TIM-1) may 
contribute to filovirus infection of mucosal epithelial cells and therefore the presence of this 
domain is likely to increase viral infection of human cells (Hofmann-Winkler, Kaup and Pöhlmann, 
2012). Furthermore, given the unusual cell binding method of the Filoviridae (Section 1.4.3) 
(Moller-Tank and Maury, 2015) it is difficult to predict the effects that change to the Mucin-like 
domain will have on the infectivity of EBOV or on the response of EBOV to antibodies. However, 
it is clear from the data recorded in figure 68 and table 35, that these mutations do not enable 
escape of EBOV from neutralisation with the standard NIBSC serum. The variation observed in 
the IC50 values raises several questions that could not be answered in the duration of this 
research. In particular, due to the variability that exists in serological assays, as those used to 
assess antibody activities in this chapter it is unclear is the variation in IC50 values is normal 
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variation between tests or the result of the modification of the glycoprotein (Wood et al., 2012; 
Kalliokoski et al., 2013).  
The data recorded in figures 67 and 68 support the hypothesis that changes to the Mucin-
like domain are unlikely to lead to a significant increase in the infection rates of humans. The 
findings in this chapter support previous studies which found no evidence that the difference 
between the current outbreak and previous ones has been caused by adaptation of the EBOV to 
human hosts. Therefore, it is likely that the rapid spread and persistence of the latest Ebola 
outbreak are linked to factors unrelated to evolution or adaptation of the EBOV GP, a number of 
studies have linked the spread of the viruses to patient behavior, with improved transport in the 
area of infection leading to more rapid spread to large population centres (Carroll et al., 2015; 
Ricketson, 2015; Tong et al., 2015).  
While changes to this region of the Mucin-like domain may not result in changes that can 
be easily detected in using the PV model, ongoing research into the role of this region in play in 
Ebola infection is revealing that this domain may play a more significant role than previously 
suspected. While the mucin-like domain of Ebola is not essential to the successful infection of 
host cells (Kaletsky, Simmons and Bates, 2007; Côté et al., 2011) this region may have a role in 
immune evasion (Martinez et al., 2011). In addition, this domain has been implicated in the 
recently identified post-Ebola syndrome (Ricketson, 2015) with specific mutations in this region 
potentially linked to ongoing pathologies affecting survivors of the recent Ebola outbreak. As such 
it is possible that future studies into the identified codons will yield additional insights that were 
not apparent in the assays conducted here. In fact in addition to the particular codons identified 
in this study,  the mucin-like domain of the Ebola isolates in the most recent outbreak are 
significantly different to older isolates (Hofmann-Winkler et al., 2015). Given the known role that 
the mucin-like domain plays in glycan interaction (Khun, 2008) with the host cell, it is possible that 
the rapid pace of change that this region in undergoing is linked to selective pressure in response 
to the human immune system. It has been demonstrated that Ebola constructs generated with a 
glycoprotein with the mucin-like domain removed elicited a lower immune response in mice that 
had been inoculated with the mutant Ebola (Khun, 2008). Even before the latest outbreak the 
mucin-like domain had already been implicated in direct cytotoxic effects, demonstrated as cell 
rounding and detachment of cells in vitro after overexpression of the glycoprotein in target cells 
(Sullivan et al., 2005).  
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Overall the findings in this chapter represent a broad agreement with the 
contemporaneous publications examining diversity and selective pressure acting on the Ebola 
glycoprotein in the latest outbreak.  The observation that the mucin-like domain of the latest Ebola 
isolates is subject to positive selective pressure is supported by studies demonstrating that this 
region is more highly diverse in the latest outbreak than in previous outbreaks (Stadler et al., 
2014). The recent isolates contain 16 amino acid substitutions relative to the mucin-like domain 
of 1976 isolate, and this suggests that this domain may be a region of more rapid evolution than 
the remainder of the Ebola glycoprotein. However, due to the nature of the Ebola virus previous 
outbreaks, the comparison between isolates from different times are complicated by the relative 
paucity of historical cases when compared to the recent outbreak.  The comparison of sequence 
data between outbreaks when one outbreak contains more cases than all historical outbreaks 
combined must be carefully examined as the rapid evolution and high mutation rates of RNA 
viruses lead to increasing diverse pools of sequence data that are made exponentially more 


















Chapter 9 Discussion 
Viral pathogens and in particular RNA viruses are among the most common form of 
infectious diseases that threaten human and domestic animals (Woolhouse, 2006; Bale, 2012). 
Newly emerging and re-emerging viral diseases are majors causes for public health concern and 
in recent years these concerns have been exacerbated by factors including a dramatic increase 
in international travel, climactic changes and the expansion of human populations into previously 
un-exploited areas. Many of the viral pathogens that humans and domestic animals are exposed 
to are zoonotic and recent years has seen several major outbreaks of zoonotic viruses that have 
been linked to bats (Hayman et al., 2013; Han et al., 2015; Plowright et al., 2015). As an unusually 
diverse and geographically widespread group it is not surprising that bats would play host to many 
pathogens that could be of significant danger to other species should the pathogens be given the 
opportunity to switch hosts. Many of the viruses that have been linked to bats have proven to be 
exceptionally virulent with viruses such as Ebola (EBOV) (Groseth, Feldmann and Strong, 2007; 
Jayme et al., 2015), Hendra (Halpin et al., 2000), Nipah (Luby, 2013), SARS-CoV (Gouilh et al., 
2011), MERS-CoV (Caì et al., 2014; Yang et al., 2014) and various lyssaviruses (Klug et al., 2011; 
Rupprecht, Turmelle and Kuzmin, 2011; Kuzmin et al., 2012; Banyard et al., 2014), being among 
the most highly virulent and dangerous pathogens currently known. The development of the use 
of pseudotyped virus (PV) as tools for research into these diseases is therefore a significant 
potential boon to research. The series of experiments presented in this thesis detail the generation 
of a range of PVs that are linked through various strands of research to one or more bat species. 
This thesis also outlines the use of these PVs in experiments involving titrations of the PV under 
various conditions and micro-neutralization assays to study the ability of these PVs to mimic wild 
type virus. The use of PV to study such dangerous pathogens relieves many of the difficulties that 
such research faces (Bentley, Mather and Temperton, 2015) and basic research into the 
development and maintenance of PV informs future studies where PV may be rapidly generated 
to provide safe and effective research tools to respond to deadly viruses outbreaks.  
Chapter 3 outlined a series of steps that were required to generate and subsequently 
optimise the production of PV expressing the MERS-CoV spike protein. The development of PV 
bearing the MERS-CoV spike occurred contemporaneously with the beginning of this research 
(Zhao et al., 2013), however the work contained in the Chapter 3 represents many different 
techniques not applied in research published by other groups. In addition, the optimisation 
 212 
 
process yielded significant improvements in both the titre and the consistency. Section 3.3.2. with 
PV remaining stable even after storage for several days at 4Ԩ or several weeks at -80Ԩ Section 
3.3.8. This chapter also demonstrates the consistency in the productions of PV using the methods 
derived within the chapter (Section 3.3.9). Given the virulent nature of the MERS-CoV a detailed 
understanding of the limits of a MERS-CoV spike bearing PV are essential for researchers to 
make best use of the PV as a research tool. In addition, to the optimisation of the production 
method for this PV this chapter also outlines several experiments investigating the potential for 
long and short-term storage of the PV. The consistency of the derived protocol is also 
demonstrated; it is this consistency that makes PV a useful tool when studying highly pathogenic 
viruses such as MERS-CoV. However, this chapter also highlighted the variation that can exist 
between different viruses, the SARS-CoV spike protein is structurally and functionally very similar 
to the MERS-CoV and yet SARS-CoV spike protein displays significantly lower RLU values when 
produced in the same way as MERS-CoV PV. The reasons for this disparity were beyond the 
scope of this work but highlighted the importance of greater emphasis being place on the 
characterisation of PV particles and the variation that exists between these particles.  
The PV generated in chapter 3 were applied as tools to the study of cross reactivity in 
chapter 4. Chapter 4 presented data demonstrating cross reactive antibodies present in serum 
extracted from SARS-CoV convalescent patients has capable of neutralising the MERS-CoV PV. 
This finding supports the study by Chan et. al. (2013) (K. H. Chan et al., 2013) which found similar 
results with convalescent SARS-CoV patient serum neutralising MERS-CoV. However, the actual 
source of this cross reactivity remains to be elucidated. In chapter 4 tools were applied to examine 
the SARS-CoV and MERS-CoV spike protein for antigenically active regions, based on the 
hypothesis that if such regions displayed high levels of conservation between the two viruses they 
may be responsible for cross reactive antibodies. Figure 36 is particularly informative and displays 
the high degree of conservation in the S2 domain between these viruses, this figure also shows 
that there are a number of regions with a combination of high probability of epitope/antigenic 
activity and surface accessibility. Although it was not possible to investigate this phenomenon in 
greater detail the findings within this chapter offer original and significant data that can be 
incorporated into future research seeking to identify potential antibody targets and may contribute 
to the development of vaccines based on these regions with potential pan-corona activity. In this 
study, it was only possible to study the problem in the terms of IC50 values of both PVs. As such, 
the potential role of concomitant infection could not be studied due to the lack availability of patient 
data for the serum samples used. In addition, no further coronavirus cross reactivity as spike 
proteins for additional viruses were not available during this study.  Given the importance of 
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coronaviruses such as OC43, 229E and increasingly NL63 cross reactivity triggered by these 
viruses are likely to have significant importance in serological studies of coronavirus. The 
relatively minor symptoms associated with most coronavirus infections make positive association 
between the two difficult as many infections with these viruses are unlikely to be reported and 
therefore will often not be included in patient notes. The findings of this study indicated that based 
on the microneutralization assay approximately 20% of SARS positive patients showed cross 
reactive antibodies to the MERS-CoV PV. This number is different to the results of Chan et. al. 
(2013), which resulted in 60.7% of SARS-CoV positive patients had positive anti-MERS-CoV IgG 
detected by IF with titres ranging from 1:20 to 1:320 based on dilution (K. H. Chan et al., 2013). 
However, neutralization assays conducted by Chan et. al. (2013) indicated that 25% of SARS-
CoV patients in this study had neutralizing antibodies for MERS-CoV, this data is surprisingly 
closely aligned with the findings in chapter 4 of this thesis. This broad agreement in proportion of 
SARS patients with MERS-CoV neutralizing antibodies between studies suggests that this 
approximate proportion may be consistent between all SARS-CoV positive patients, however this 
assertion will require further testing of larger datasets.  
A number of important viruses including both MERS-CoV and SARS-CoV (Section 1.4.1) 
as well  EBOV (Section 1.4.2) have been linked to bats. However, despite the virulence of these 
and other bat borne viruses (Section 1.4.5.) there have been few large scale serological programs 
to monitor bat viruses. Although the need for such studies is well accepted (Simons et al., 2014), 
the cost and complexity of such studies is often prohibitive. In Chapter 5, the development of a 
PV based multiplex assay was carried out, this assay sought to exploit the flexibility of PV through 
the incorporation of different reporter genes to develop a more efficient method of conducting 
serological screening. Although multiple assays using PV have been developed before (Wright et 
al., 2010; Molesti, Wright, et al., 2014) at the time of writing no published studies had attempted 
to make use of two different fluorescent proteins as a component of the assay. Although as 
indicated in Section 5.4. this attempt was not completely successful the ability to correctly 
ascertain the most potent concentration of serum for two of the three viruses used demonstrates 
the promise of such an assay for further development. In addition, the use of three viruses each 
from a different viral family represents an important step towards more effective cross-family 
assays. The development of assays of this nature have importance in the study of bat-borne 
viruses as the difficulties inherent in obtaining serum from such small and mobile animals, means 
that serum extracted from bats must be used in the most efficient manner possible.  
The multiplex assay demonstrated in this study while not completely effective did show 
significant potential of this protocol with two of the three viruses being successfully detected within 
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the prepared serum. The inability to accurately detect the Ebola positive serum was compounded 
by the low titre values of this virus preparation, as indicated in table 16 the highest concentration 
of Ebola PV with the GFP reporter still only resulted in 30% of cells expressing the reporter. This 
low titre coupled with the low neutralization potential of the available serum as indicated in figure 
41 made the assay of this PV extremely complex. This difficulty also highlighted the importance 
of PV production optimization as outlined for the MERS-CoV PV in chapter 3.  
The discovery of H17N10 and H18N11 influenza viruses in South American bats in 2012 
(Tong et al., 2012) represented a significant discovery. As these viruses appeared to be so 
divergent from other influenza A strains that the divergence point between the viruses was likely 
to be a significant time ago. Initial studies into these viruses quickly determined that they did not 
use the sialic acid receptors that were common among other influenza A strains. Furthermore, 
the N10 and N11 molecules did not appear to possess the enzymatic activity that was common 
to other NA molecules (Li et al., 2012). Chapter 6 demonstrated the successful generation of H17 
expressing PV with a lentiviral gag core. While H17 has been recently successfully incorporated 
into the PV system (Maruyama et al., 2016; Moreira et al., 2016) these studies made use of VSV 
based PV cores. The work presented in chapter 6 represents the first demonstration of H17 
expressing PV using a lentiviral core. As such this research represents a potentially significant 
development of a research tool to investigate a novel influenza.  
Although the H17 and H18 lack sialic acid-binding activity, they do possess a similar 
structure the HA of other influenza A viruses. This study demonstrated that lentiviral core PV can 
be used in place of the proven VSV based production (Moreira et al., 2016). Lentiviral cores are 
less prone to regulatory difficulties than VSV based PV and so can be more readily shared 
between working groups.  
The need to develop improved models for the prediction of viral evolution and therefore 
potentially predict the outbreak of zoonotic virus, is well understood. In chapters 7 and 8 the use 
of tools to analysis selective pressure highlights several sites in both the MERS-CoV and 
Ebolavirus glycoproteins that may be under selective pressure to diversify. The incorporation of 
this form of analysis with the PV system offers a potentially effective tool to make predictions 
about viral evolution and to test these predictions through experimentation. With the growing 
number of bat related zoonotic events in recent years (Section 1.4.) the development of improved 
methods for predicting the likelihood of zoonosis offers significant benefits. While this form of 
analysis has many limitations, it does represent a rapid method to provide data can be 
incorporated into PV based lab techniques. The selection analysis employed in this study relies 
on model selection which may not be a realistic reflection of the actual evolution of an emerging 
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viral pathogen. The methods employed in this study detects positive selection only if this 
evolutionary pressure generates excessive nonsynonymous substitutions. These techniques lack 
power in detecting one-off directional selection or when the sequences are highly similar or highly 
divergent. In addition, these methods do not detect alternative traits that may affect virus 
propagation such as changes in mRNA secondary structure or changes to co-translational folding.  
The research presented in this thesis developed a number of tools and protocols that are 
of particular use in the study of bat-borne viruses. The use of PV as tools to study such viruses is 
exploited throughout. The thesis offers a pattern of potential development for PV based tools, 
beginning with the optimisation of production before making use of PV to study cross reactivity. 
Next the flexibility of the PV system was exploited to develop a novel assay method that offers 
benefit to researchers studying zoonotic viruses. The development of viable PV incorporating a 
novel influenza demonstrated that PV may be used to study virus in the absence of detailed 
฀k฀n฀o฀w฀l฀e฀d฀g฀e฀ ฀a฀b฀o฀u฀t฀ ฀t฀h฀e฀ ฀v฀i฀r฀u฀s฀e฀s฀’฀ ฀r฀e฀c฀e฀p฀t฀o฀r฀ ฀o฀r฀ ฀t฀r฀o฀p฀i฀s฀m฀.฀ ฀L฀a฀s฀t฀l฀y฀ ฀t฀h฀e฀ ฀s฀y฀n t฀h฀e฀s฀i฀s฀ ฀o f฀ ฀c฀o m฀p฀u฀t฀a฀t i o n l  ฀b฀i฀o฀l฀o฀g฀y฀ 
and PV was examined and a workflow was developed to exploit the PV system to make best use 
of computational biology tools and predictions.  
However, a number of shortcomings in this work were also identified. Optimisation of the 
production of other relevant PV is essential as the results of chapter 5 multiplexing study 
demonstrate that the input of each can have a significant effect on utility of a PV. A more detailed 
analysis of the coronavirus cross-reactivity detected in chapter 4 will also require the production 
of additional PV expressing other coronaviruses of interest. The ability to compare different levels 
of neutralization titres between serum samples may provide additional insights into the factors 
driving the production of MERS-CoV neutralizing antibodies. The analysis of larger serum panels 
may also be useful to determine if the observed proportion of SARS-CoV patients testing positive 
for neutralizing MERS-CoV remains constant. While the research conducted in this thesis relied 
heavily on the use of microneutralization assays to detect antibodies it is also possible that an 
ELISA based assay could be incorporated in order to provide an additional source of antibody 
titres. A sandwich ELISA with an antibody directed against the specific glycoprotein may be 
coated in each well of a 96 well plate. This may then be used to capture each viral strain for a 
specific PV permitting the use of sera, monoclonal or polyclonal antibody preparations. In the 
development of an assay of this type attention must be paid to the origin of the antibodies used 
during the coating of the plates with different species used to avoid cross-reactivity. 
The development of optimised mutagenesis protocols will also open the possibility for more 
rapid production of novel PV which is essential for analysis methods that are targeted at emerging 
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and ongoing viral outbreaks. The limitations of the computational analysis employed in these 
studies may also be addressed with the incorporation of structural analysis required to make this 
form of analysis more accurate and insightful. The incorporation of structural data will also open 
the possibility of examination of conformational antibodies which are likely to have relevance to 
cross-reactivity studies as conducted in chapter 4. Future studies of the kind conducted during 
this thesis should focus on a more limited selection of viruses with a more detailed exploration of 
the evolutionary patterns of these viruses. In the conduct of these studies it also likely that a 
greater number of mutations can be introduced to the more limited range of viruses under 
investigation.  
Computational analysis conducted within this thesis was also limited in both scope and 
application. Computational analysis of the viral proteins under study relied on tools examining 
only linear epitopes and thus did not account for conformational based antigenicity which may be 
significant to emerging viral pathogens (Du et al., 2014). Furthermore, analysis of the epitope 
regions was limited to relatively large regions while in reality much shorter sequences of amino 
acids can function as epitopes with many epitopes consisting of sequences of between 15-22 
residues but in which as few as 2-5 residues can be considered to contribute to the majority of 
antibody binding (Rahman et al., 2016). The analysis conducted in this study would fail to detect 
such small regions of antigenic activity and as such are likely to not be an ideal method to detect 
regions of cross reactivity between viruses. The methods employed to detect selective pressure 
acting on the viral proteins failed to account for the impact of structural changes of the mutations 
identified would have on the viral protein. Further studies of this type should focus on the impact 
of changes in regions identified and impact of different amino acids at these positions should be 
studied. Future studies of this nature are likely to yield improved results through a focus on a 
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Appendix 1 (a) Chapter 4 Serum Panel 2  
Serum Panel 2 IC50 values as calculated with GraphPadΡ Prism 7 calculations performed as per section 2.11. SARS status indicates results of prior ELISA conducted on the serum to determine the presence of 
SARS-CoV antibodies. N/a indicates that assay was not attempted. Repeat assays were conducted for serum samples with intial IC50 values > 100 and for a selection of other samples chosen at random to assess 
the variability in the calculated IC50 value of the samples.  
SUBJECT ID SARS STATUS MERS IC50 A MERS IC50 B MEAN MERS IC50 SARS IC50 
** ** 1293.16 N/a N/a N/a 
BJ004 Anti-SARS IgG ELISA -ve 43.8 45.53 N/a N/a 
BJ005 SARS 51.0 61.02317 56.0 88.4 
BJ006 SARS 54.6 85.6 70.1 N/a 
BJ031 SARS 22.6 12.4 N/a N/a 
BJ032 SARS 45.6 34.30163 N/a N/a 
BJ033 SARS 72.2 74.9213 73.6 N/a 
BJ034 SARS 55.2 79.3 67.3 N/a 
BJ035 SARS 61.7 64.7 63.2 N/a 
BJ036 SARS 49.1 N/a N/a N/a 
BJ037 SARS 4.1 N/a N/a N/a 
BJ038 SARS 87.7 97.612 92.6 108.4 
BJ039 SARS 70.0 61.24 65.6 N/a 
BJ040 SARS 57.2 52.176 54.7 N/a 
BJ041 SARS 75.0 59.7 67.4 N/a 
BJ042 SARS 39.9 N/a N/a N/a 
BJ043 SARS 57.6 92.76434 75.2 116.71 
BJ044 SARS 63.4 51.03874 57.2 N/a 
BJ045 SARS 89.0 54.043 71.5 N/a 
BJ046 SARS 42.5 N/a N/a N/a 
BJ047 SARS 11.2 N/a N/a N/a 
BJ048 SARS 28.8 N/a N/a N/a 
BJ049 SARS 53.9 61.1 57.5 N/a 
BJ050 SARS 58.3 52.647 55.5 N/a 
BJ051 SARS 53.8 71.23 62.5 N/a 
BJ052 SARS 73.1 85.4641 79.3 N/a 
BJ053 SARS 41.4 N/a N/a N/a 
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BJ054 SARS 60.6 88.39 74.5 N/a 
BJ055 SARS 45.0 N/a N/a N/a 
BJ056 SARS 42.1 N/a N/a N/a 
BJ057 SARS 47.2 N/a N/a N/a 
BJ058 SARS 43.1 N/a N/a N/a 
BJ059 SARS 45.8 N/a N/a N/a 
BJ060 SARS 96.8 67.92172 82.4 N/a 
BJ071 SARS 29.9 N/a N/a N/a 
BJ072 SARS 85.6 66.6 76.1 N/a 
BJ073 SARS 55.0 103.8268 79.4 99.2 
BJ074 SARS 0.0 N/a N/a N/a 
BJ075 SARS 0.0 N/a N/a N/a 
BJ076 SARS 0.0 N/a N/a N/a 
BJ077 SARS 110.0 69.16844 89.6 N/a 
BJ078 SARS 12.7 N/a N/a N/a 
BJ079 SARS 44.2 N/a N/a N/a 
BJ080 SARS 73.8 66.48972 70.2 N/a 
BJ082 SARS 37.0 N/a N/a N/a 
BJ083 Anti-SARS IgG ELISA -ve 44.3 N/a N/a N/a 
BJ084 SARS 56.0 64.99007 60.5 N/a 
BJ085 Anti-SARS IgG ELISA -ve 0.0 N/a N/a N/a 
BJ086 Anti-SARS IgG ELISA -ve 0.0 N/a N/a N/a 
BJ087 SARS 0.0 N/a N/a N/a 
BJ088 SARS 25.2 N/a N/a N/a 
BJ089 SARS 37.4 N/a N/a N/a 
BJ090 SARS 0.0 N/a N/a N/a 
BJ091 SARS 17.7 N/a N/a N/a 
BJ092 SARS 21.2 N/a N/a N/a 
BJ093 SARS 34.4 N/a N/a N/a 
BJ094 SARS 9.4 N/a N/a N/a 
BJ095 SARS 30.3 N/a N/a N/a 
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BJ096 SARS 420.0 117.648 268.8 243.21 
BJ097 SARS 9.0 N/a N/a N/a 
BJ098 SARS 271.9 98.6 185.3 389.4 
BJ099 SARS 79.0 54.07 66.5 N/a 
BJ100 SARS 93.4 78.65 86.0 N/a 
BJ101 SARS 27.6 N/a N/a N/a 
BJ102 SARS 63.9 51.9 57.9 N/a 
BJ103 SARS 45.7 N/a N/a N/a 
BJ104 SARS 22.8 N/a N/a N/a 
BJ105 SARS 44.5 N/a N/a N/a 
BJ106 SARS 19.3 N/a N/a N/a 
BJ107 SARS 21.9 N/a N/a N/a 
BJ108 SARS 7.5 N/a N/a N/a 
BJ109 SARS 0.0 N/a N/a N/a 
BJ110 SARS 2.4 N/a N/a N/a 
BJ111 SARS 0.0 N/a N/a N/a 
BJ112 Anti-SARS IgG ELISA -ve 1.2 N/a N/a N/a 
BJ113 SARS 2.3 N/a N/a N/a 
BJ114 SARS 23.0 N/a N/a N/a 
BJ115 SARS 25.2 N/a N/a N/a 
BJ129 SARS 10.6 N/a N/a N/a 
GZ 001 Non-SARS 19.3 N/a N/a N/a 
GZ 002 Non-SARS 12.1 N/a N/a N/a 
GZ 003 Non-SARS 7.5 N/a N/a N/a 
GZ 004 Non-SARS 0.0 N/a N/a N/a 
GZ 005 Non-SARS 0.0 N/a N/a N/a 
GZ 006 SARS 0.0 N/a N/a N/a 
GZ 007 SARS 9.8 N/a N/a N/a 
GZ 008 Non-SARS 0.0 N/a N/a N/a 
GZ 009 SARS 0.1 N/a N/a N/a 
GZ 010 SARS 15.9 N/a N/a N/a 
GZ 011 Non-SARS 0.7 N/a N/a N/a 
GZ 012 Non-SARS 12.3 N/a N/a N/a 
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GZ 013 Non-SARS 0.0 N/a N/a N/a 
GZ 014 Non-SARS 37.2 N/a N/a N/a 
GZ 015 Non-SARS 41.8 N/a N/a N/a 
GZ 016 SARS 19.7 N/a N/a N/a 
GZ 017 SARS 11.1 N/a N/a N/a 
GZ 018 SARS 0.3 N/a N/a N/a 
GZ 019 Anti-SARS IgG ELISA -ve 3.8 N/a N/a N/a 
GZ 020 SARS 0.0 N/a N/a N/a 
GZ 021 SARS 12.6 N/a N/a N/a 
GZ 022 SARS 8.4 N/a N/a N/a 
GZ 023 Non-SARS 18.0 N/a N/a N/a 
GZ 024 Non-SARS 20.1 N/a N/a N/a 
GZ 025 Non-SARS 1.5 N/a N/a N/a 
GZ 026 Non-SARS 33.8 N/a N/a N/a 
GZ 027 Non-SARS 16.4 N/a N/a N/a 
GZ 028 Non-SARS 18.6 N/a N/a N/a 
GZ 029 Non-SARS 18.3 N/a N/a N/a 
GZ 030 Non-SARS 7.5 N/a N/a N/a 
GZ 031 Non-SARS 5.2 N/a N/a N/a 
GZ 032 Non-SARS 1.1 N/a N/a N/a 
GZ 033 Non-SARS 0.0 N/a N/a N/a 
GZ 034 Non-SARS 22.0 N/a N/a N/a 
GZ 035 Non-SARS 37.1 N/a N/a N/a 
GZ 036 Non-SARS 34.0 N/a N/a N/a 
GZ 037 Non-SARS 39.8 N/a N/a N/a 
GZ 038 Non-SARS 40.2 N/a N/a N/a 
GZ 039 Non-SARS 0.0 N/a N/a N/a 
GZ 040 Non-SARS 44.4 N/a N/a N/a 
GZ 041 Non-SARS 0.0 N/a N/a N/a 
GZ 042 Non-SARS 83.1 45.7 64.4 23.8 
GZ 043 Non-SARS 11.3 N/a N/a N/a 
GZ 044 Non-SARS 27 N/a N/a N/a 
GZ 045 Non-SARS 0.0 N/a N/a N/a 
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GZ 046 Non-SARS 0.0 N/a N/a N/a 
GZ 047 Non-SARS 29.1 N/a N/a N/a 
GZ 048 Non-SARS 39.9 N/a N/a N/a 
GZ 049 Non-SARS 0.0 N/a N/a N/a 
GZ 050 SARS 0.0 N/a N/a N/a 
GZ 051 SARS 0.0 N/a N/a N/a 
GZ 052 SARS 0.0 N/a N/a N/a 
GZ 053 SARS 0.0 N/a N/a N/a 
GZ 054 Anti-SARS IgG ELISA -ve 0.0 N/a N/a N/a 
GZ 055 SARS 0.0 N/a N/a N/a 
GZ 056 Non-SARS 36.3 N/a N/a N/a 
GZ 057 Anti-SARS IgG ELISA -ve 9.5 N/a N/a N/a 
GZ 058 SARS 2.1 N/a N/a N/a 
GZ 059 SARS 8.3 N/a N/a N/a 
GZ 060 SARS 7.5 N/a N/a N/a 
GZ 061 SARS 20.1 N/a N/a N/a 
GZ 063 Non-SARS 7.5 N/a N/a N/a 
GZ 065 Non-SARS 42.1 N/a N/a N/a 
GZ 066 Non-SARS 39.5 N/a N/a N/a 
GZ 067 Non-SARS 36.6 N/a N/a N/a 
GZ 068 Non-SARS 17.8 N/a N/a N/a 
GZ 069 Non-SARS 4.8 N/a N/a N/a 
GZ 070 Non-SARS 3.9 N/a N/a N/a 
GZ 071 Non-SARS 9.7 N/a N/a N/a 
GZ 072 Non-SARS 31.4 N/a N/a N/a 
GZ 073 Non-SARS 29.8 N/a N/a N/a 
GZ 074 SARS 33.9 N/a N/a N/a 
GZ 075 Non-SARS 30.3 N/a N/a N/a 
GZ 076 Non-SARS 34.4 N/a N/a N/a 
GZ 077 Non-SARS 27.1 N/a N/a N/a 
GZ 078 Non-SARS 35.2 N/a N/a N/a 
GZ 079 Non-SARS 30.8 N/a N/a N/a 
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GZ 080 Non-SARS 16.9 N/a N/a N/a 
GZ 081 Non-SARS 30.5 N/a N/a N/a 
GZ 082 Non-SARS 10.8 N/a N/a N/a 
GZ 083 Non-SARS 19.2 N/a N/a N/a 
GZ 084 SARS 0.8 N/a N/a N/a 
GZ 085 SARS 1.8 N/a N/a N/a 
GZ 086 SARS 26.1 N/a N/a N/a 
GZ 087 SARS 26.8 N/a N/a N/a 
GZ 088 SARS 29.2 N/a N/a N/a 
GZ 089 SARS 6.7 N/a N/a N/a 
GZ 090 SARS 1.5 N/a N/a N/a 
GZ 091 SARS 1.7 N/a N/a N/a 
GZ 092 SARS 3.2 N/a N/a N/a 
GZ 093 SARS 4.3 N/a N/a N/a 
GZ 094 SARS 5.9 N/a N/a N/a 
GZ 095 SARS 12.5 N/a N/a N/a 
GZ 096 SARS 0.0 N/a N/a N/a 
GZ 097 SARS 0.2 N/a N/a N/a 
GZ 098 SARS 3.4 N/a N/a N/a 
GZ 099 SARS 0.0 N/a N/a N/a 
GZ 100 SARS 8.8 N/a N/a N/a 
GZ 101 SARS 27.6 N/a N/a N/a 
GZ 102 SARS 3.2 N/a N/a N/a 
GZ 103 SARS 28.4 N/a N/a N/a 
GZ 104 SARS 3.0 N/a N/a N/a 
GZ 105 SARS 0.1 N/a N/a N/a 
GZ 106 SARS 10.1 N/a N/a N/a 
GZ 107 SARS 22.5 N/a N/a N/a 
GZ 108 SARS 0.0 N/a N/a N/a 
GZ 109 Non-SARS 6.9 N/a N/a N/a 
GZ 110 Non-SARS 1.5 N/a N/a N/a 
GZ 111 Non-SARS 1.1 N/a N/a N/a 
GZ 112 Non-SARS 17.1 N/a N/a N/a 
GZ 113 Non-SARS 0.0 N/a N/a N/a 
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GZ 114 Non-SARS 42.1 N/a N/a N/a 
GZ 115 Non-SARS 7.7 N/a N/a N/a 
GZ 116 Non-SARS 41.8 N/a N/a N/a 
GZ 117 Non-SARS 3.4 N/a N/a N/a 
GZ 118 Non-SARS 13.4 N/a N/a N/a 
GZ 119 Non-SARS 48.0 N/a N/a N/a 
GZ 120 Non-SARS 30.3 N/a N/a N/a 
GZ 121 Non-SARS 34 N/a N/a N/a 
GZ 122 Non-SARS 38 N/a N/a N/a 
GZ 123 Non-SARS 38 N/a N/a N/a 
GZ 124 Non-SARS 34 N/a N/a N/a 
GZ 125 Non-SARS 39 N/a N/a N/a 
GZ 128 Non-SARS 38 N/a N/a N/a 
HK001 SARS 66 53.1 59.6 N/a 
HK002 SARS 31 N/a N/a N/a 
HK003 SARS 33 N/a N/a N/a 
HK005 SARS 37 N/a N/a N/a 
HK007 SARS 23 N/a N/a N/a 
HK009 SARS 0.0 N/a N/a N/a 
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Images taken of plate 1 serum preparations 1-4 with first for rows photographed under 
brightfield and then with FTIC-TRCI filter in place, all images are taken of the centre of the 
well. 
Figure 1: Photographs of single view for each of first four wells of multiplex plate  1. FITC-TRIC filtered images  on left with 
same images under brightfield only on right. All images taken with X10 objective lens in place.  All images are taken from the 
centre of the well  
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Accession Number Virus Strain Host Location of Isolate Year of Isolation 
JX869059.2 MERS-CoV HCoV-EMC Human England 2012 
KC667074.1 MERS-CoV HCoV-EMC Human England/Qatar 2012 
KJ477102.1 MERS-CoV NRCE-HKU205 Camel Egypt 2013 
KT156560.1 MERS-CoV Hu/Oman Human Oman 2013 
KT036374.1 MERS-CoV ChinaGD01 (V2) Human China 2015 
KT036373.1 MERS-CoV ChinaGD01 (V1) Human China 2015 
KT026456.1 MERS-CoV Hu/Riyadh Human KSA 2015 
KT026454.1 MERS-CoV Hu/Riyadh Human KSA 2015 
KT026453.1 MERS-CoV Hu/Riyadh Human KSA 2015 
KR011266.1 MERS-CoV Hu/Riyadh Human KSA 2015 
KR011265.1 MERS-CoV Hu/Riyadh Human KSA 2015 
KR011264.1 MERS-CoV Hu/Riyadh Human KSA 2015 
KR011263.1 MERS-CoV KSA-2345 Human KSA 2015 
KP966104.1 MERS-CoV AlAhsa Camel KSA 2014 
KP719933.1 MERS-CoV D1209 Camel UAE 2014 
KP719932.1 MERS-CoV D1243.12 Camel UAE 2014 
KP719931.1 MERS-CoV D1339.2 Camel UAE 2014 
KP719930.1 MERS-CoV D1164.14 Camel UAE 2014 
KP405227.1 MERS-CoV AlAhsa C9 Camel KSA 2013 
KP405226.1 MERS-CoV AlAhsa C7 Camel KSA 2013 
KP405225.1 MERS-CoV AlAhsa C8 Camel KSA 2013 
KP236092.1 MERS-CoV Abu Dhabi/Oman_UAE_7_2013 Human UAE 2013 
KP223131.1 MERS-CoV USA-2_Saudi Arabia Human USA 2014 
KP209313.1 MERS-CoV UAE_26 Human UAE 2014 
KP209310.1 MERS-CoV UAE_2 Human UAE 2014 
KP209309.1 MERS-CoV UAE_30 Human UAE 2014 
KP209308.1 MERS-CoV UAE_16 Human UAE 2014 
KP209307.1 MERS-CoV UAE_18 Human UAE 2014 
KP209306.1 MERS-CoV UAE_8 Human UAE 2014 
KM210278.1 MERS-CoV England/3/2013 Human UK 2013 
KM210277.1 MERS-CoV England/4/2013 Human UK 2013 
KM027288.1 MERS-CoV KSA_551 Human KSA 2014 
KM027286.1 MERS-CoV KSA_351 Human KSA 2014 
KM027285.1 MERS-CoV KSA_349 Human KSA 2014 
KM027284.1 MERS-CoV KSA_345 Human KSA 2014 
KM027281.1 MERS-CoV KSA_158 Human KSA 2014 
KM027279.1 MERS-CoV KSA_059 Human KSA 2014 
KM027278.1 MERS-CoV KSA_057 Human KSA 2014 
KM027277.1 MERS-CoV KSA_042 Human KSA 2014 
KM027276.1 MERS-CoV Jeddah_C9313 Human KSA 2014 
KM027275.1 MERS-CoV Jeddah_C9282 Human KSA 2014 
KM027263.1 MERS-CoV Jeddah_C7058 Human KSA 2014 
KM027262.1 MERS-CoV KSA_683 Human KSA 2014 
KM027261.1 MERS-CoV Makkah_C9355 Human KSA 2014 
KM027260.1 MERS-CoV Jeddah_C10306 Human KSA 2014 
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KM027259.1 MERS-CoV Jeddah_C9055 Human KSA 2014 
KM027258.1 MERS-CoV Jeddah_C8826 Human KSA 2014 
KM027257.1 MERS-CoV Jeddah_C7770 Human KSA 2014 
KM027256.1 MERS-CoV Jeddah_C7569 Human KSA 2014 
KM027255.1 MERS-CoV Jeddah_C7149 Human KSA 2014 
KM015348.1 MERS-CoV England/2 Human UK 2013 
KJ813439.1 MERS-CoV Indiana/USA1 Human USA 2014 
KJ713299.1 MERS-CoV KSA_376 Camel KSA 2013 
KJ713296.1 MERS-CoV KSA_378 Camel KSA 2013 
KJ713295.1 MERS-CoV KSA_505 Camel KSA 2013 
KJ650098.1 MERS-CoV Qatar_2 Camel Qatar 2014 
KJ361500.1 MERS-CoV FRA1_1627-2013_BAL Human France 2013 
KJ156952.1 MERS-CoV Riyadh_4 Human KSA 2013 
KJ156949.1 MERS-CoV Taif_1 Human KSA 2013 
KJ156942.1 MERS-CoV Riyadh_8b Human KSA 2013 
KJ156939.1 MERS-CoV Al-Hasa_27b Human KSA 2013 
KJ156936.1 MERS-CoV Riyadh_10b Human KSA 2013 
KJ156934.1 MERS-CoV Riyadh_14 Human KSA 2013 
KJ156920.1 MERS-CoV Riyadh_17b Human KSA 2013 
KJ156916.1 MERS-CoV Madinah_3b Human KSA 2013 
KJ156911.1 MERS-CoV Riyadh_11b Human KSA 2013 
KJ156910.1 MERS-CoV Hafr-Al-Batin_2 Human KSA 2013 
KJ156905.1 MERS-CoV Riyadh_7b Human KSA 2013 
KJ156901.1 MERS-CoV Riyadh_12b Human KSA 2013 
KJ156876.1 MERS-CoV Taif_2b Human KSA 2013 
KJ156874.1 MERS-CoV Hafr-Al-Batin_6 Human KSA 2013 
KJ156873.1 MERS-CoV Riyadh_13b Human KSA 2013 
KJ156872.1 MERS-CoV AlHasa_26c Human KSA 2013 
KJ156869.1 MERS-CoV Riyadh_9 Human KSA 2013 
KJ156866.1 MERS-CoV AlHasa_25 Human KSA 2013 
KF961222.1 MERS-CoV Qatar4 Human KSA 2013 
KF961221.1 MERS-CoV Qatar3 Human KSA 2013 
KF811036.1 MERS-CoV Tunisia-Qatar_2013 Human Tunisia 2013 
KF745068.1 MERS-CoV FRA/UAE Human France 2013 
KF600652.1 MERS-CoV Riyadh_2 Human KSA 2012 
KF600651.1 MERS-CoV AlHasa_18 Human KSA 2013 
KF600647.1 MERS-CoV AlHasa_17 Human KSA 2013 
KF600645.1 MERS-CoV AlHasa_15 Human KSA 2013 
KF600644.1 MERS-CoV AlHasa_16 Human KSA 2013 
KF600643.1 MERS-CoV AlHasa_14b Human KSA 2013 
KF600636.1 MERS-CoV AlHasa_11c Human KSA 2013 
KF600634.1 MERS-CoV AlHasa_21 Human KSA 2013 
KF600632.1 MERS-CoV AlHasa_19 Human KSA 2013 
KF600630.1 MERS-CoV Buraidah_1 Human KSA 2013 
KF600628.1 MERS-CoV HafrAlBatin_1 Human KSA 2013 
KF600627.1 MERS-CoV AlHasa_12 Human KSA 2013 
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KF600623.1 MERS-CoV AlHasa_7b Human KSA 2012 
KF600620.1 MERS-CoV Bisha_1 Human KSA 2012 
KF600612.1 MERS-CoV Riyadh_1 Human KSA 2013 
KF186567.1 MERS-CoV AlHasa_1 Human KSA 2013 
KF186566.1 MERS-CoV AlHasa_2 Human KSA 2013 
KF186565.1 MERS-CoV AlHasa_3 Human KSA 2013 
KF186564.1 MERS-CoV AlHasa_4 Human KSA 2013 
KX034095.1 MERS-CoV Seoul_066 Human Korea 2015 
KX034094.1 MERS-CoV Seoul_050 Human Korea 2015 
KT868875.1 MERS-CoV CNUH_SNU/122_06 Human Korea 2015 
KT868873.1 MERS-CoV CNUH_SNU/085_06 Human Korea 2015 
KT868868.1 MERS-CoV CNUH_SNU/030_06 Human Korea 2015 
KT868866.1 MERS-CoV CNUH_SNU/023_06 Human Korea 2015 
KT868865.1 MERS-CoV KOR/CNUH_SNU/016_06 Human Korea 2015 
KT868877.1 MERS-CoV CNUH_SNU/172_06 Human Korea 2015 
KT868869.1 MERS-CoV CNUH_SNU/031_06 Human Korea 2015 
KT868867.1 MERS-CoV CNUH_SNU/024_06 Human Korea 2015 
KX034100.1 MERS-CoV KOR/Seoul/177-3 Human Korea 2015 
KX034098.1 MERS-CoV KOR/Seoul/162-1 Human Korea 2015 
KX034097.1 MERS-CoV Seoul/080-3 Human Korea 2015 
KX034096.1 MERS-CoV Seoul/077-2 Human Korea 2015 
KT868876.1 MERS-CoV CNUH_SNU/148_06 Human Korea 2015 
KT868874.1 MERS-CoV CNUH_SNU/110_06 Human Korea 2015 
KT868872.1 MERS-CoV CNUH_SNU/082_06 Human Korea 2015 
KT374052.1 MERS-CoV Seoul/014-1 Human Korea 2015 
KT374050.1 MERS-CoV Seoul/163-2 Human Korea 2015 
KT868871.1 MERS-CoV CNUH_SNU/054 Human Korea 2015 
KX034099.1 MERS-CoV Seoul/169-2015 Human Korea 2015 
KU308549.1 MERS-CoV Seoul/SNU1-035 Human Korea 2015 
KT374056.1 MERS-CoV Seoul/168-1 Human Korea 2015 
KT374054.1 MERS-CoV Seoul/035-1 Human Korea 2015 
KT374057.1 MERS-CoV Seoul/168-2 Human Korea 2015 
KT868870.1 MERS-CoV CNUH_SNU/038_06 Human Korea 2015 
KT029139.1 MERS-CoV KNIH/002_05 Human Korea 2015 
AY278741.1 SARS Urbani Human China 2003 
EF065505.1 HKU4 B04f Bat China 2007 
EF065507.1 HKU4 B07f Bat China 2007 
EF065506.1 HKU4 B05f Bat China 2007 
KC522050.1 HKU4 3S Tylonycteris bat China (Hong Kong) 2010 
KC522051.1 HKU4 4S Tylonycteris bat China (Hong Kong) 2010 
DQ648794.1 Bat coronavirus BtCoV/133/2005 Bat China 2006 
KJ473822.1 BtTp-BetaCoV/GX2012 BtTp-GX2012 Tylonycteris pachypus (Bat) China 2012 
KC522093.1 HKU5 19S Pipistrellus bat China (Hong Kong) 2007 
KC522101.1 HKU5 30S Pipistrellus bat China (Hong Kong) 2010 
KJ473820.1 BtPa-BetaCoV/GD2013 BtPa-GD2013 Pipistrellus abramus (bat) China 2013 
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EF065510.1 HKU5 TT03f bat China 2006 
EF065509.1 HKU5 LMH03f bat China 2006 
KC522097.1 HKU5 24S Pipistrellus bat China (Hong Kong) 2009 
KU182965.1 Bat JPDB144 Myotis daubentonii (bat) China 2012 
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Appendix 4 Chapter 7 Analysis of Selective Pressure  
 
Accession Number Virus Strain/isolate Host Location of Isolate Year of Isolation 
JX869059.2 MERS-CoV HCoV-EMC Human England 2012 
KC667074.1 MERS-CoV HCoV-EMC Human England/Qatar 2012 
KJ477102.1 MERS-CoV NRCE-HKU205 Camel Egypt 2013 
KT156560.1 MERS-CoV Hu/Oman Human Oman 2013 
KT036373.1 MERS-CoV ChinaGD01 (V1) Human China 2015 
KT026454.1 MERS-CoV Hu/Riyadh Human KSA 2015 
KT026453.1 MERS-CoV Hu/Riyadh Human KSA 2015 
KR011265.1 MERS-CoV Hu/Riyadh Human KSA 2015 
KP719933.1 MERS-CoV D1209 Camel UAE 2014 
KP719930.1 MERS-CoV D1164.14 Camel UAE 2014 
KP236092.1 MERS-CoV Abu Dhabi/Oman_UAE_7_2013 Human UAE 2013 
KP223131.1 MERS-CoV USA-2_Saudi Arabia Human USA 2014 
KP209313.1 MERS-CoV UAE_26 Human UAE 2014 
KP209307.1 MERS-CoV UAE_18 Human UAE 2014 
KM210278.1 MERS-CoV England/3/2013 Human UK 2013 
KM210277.1 MERS-CoV England/4/2013 Human UK 2013 
KM027288.1 MERS-CoV KSA_551 Human KSA 2014 
KM027286.1 MERS-CoV KSA_351 Human KSA 2014 
KM027284.1 MERS-CoV KSA_345 Human KSA 2014 
KM027281.1 MERS-CoV KSA_158 Human KSA 2014 
KM027279.1 MERS-CoV KSA_059 Human KSA 2014 
KM027278.1 MERS-CoV KSA_057 Human KSA 2014 
KM027277.1 MERS-CoV KSA_042 Human KSA 2014 
KM027276.1 MERS-CoV Jeddah_C9313 Human KSA 2014 
KM027275.1 MERS-CoV Jeddah_C9282 Human KSA 2014 
KM027263.1 MERS-CoV Jeddah_C7058 Human KSA 2014 
KM027258.1 MERS-CoV Jeddah_C8826 Human KSA 2014 
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KJ713299.1 MERS-CoV KSA_376 Camel KSA 2013 
KJ650098.1 MERS-CoV Qatar_2 Camel Qatar 2014 
KJ361500.1 MERS-CoV FRA1_1627-2013_BAL Human France 2013 
KJ156952.1 MERS-CoV Riyadh_4 Human KSA 2013 
KJ156949.1 MERS-CoV Taif_1 Human KSA 2013 
KJ156942.1 MERS-CoV Riyadh_8b Human KSA 2013 
KJ156939.1 MERS-CoV Al-Hasa_27b Human KSA 2013 
KJ156934.1 MERS-CoV Riyadh_14 Human KSA 2013 
KJ156920.1 MERS-CoV Riyadh_17b Human KSA 2013 
KJ156916.1 MERS-CoV Madinah_3b Human KSA 2013 
KJ156910.1 MERS-CoV Hafr-Al-Batin_2 Human KSA 2013 
KJ156876.1 MERS-CoV Taif_2b Human KSA 2013 
KJ156873.1 MERS-CoV Riyadh_13b Human KSA 2013 
KF961222.1 MERS-CoV Qatar4 Human KSA 2013 
KF811036.1 MERS-CoV Tunisia-Qatar_2013 Human Tunisia 2013 
KF745068.1 MERS-CoV FRA/UAE Human France 2013 
KF600652.1 MERS-CoV Riyadh_2 Human KSA 2012 
KF600645.1 MERS-CoV AlHasa_15 Human KSA 2013 
KF600643.1 MERS-CoV AlHasa_14b Human KSA 2013 
KF600630.1 MERS-CoV Buraidah_1 Human KSA 2013 
KF600628.1 MERS-CoV HafrAlBatin_1 Human KSA 2013 
KF600620.1 MERS-CoV Bisha_1 Human KSA 2012 
KT868867.1 MERS-CoV CNUH_SNU/024_06 Human Korea 2015 
KX034097.1 MERS-CoV Seoul/080-3 Human Korea 2015 
KT374050.1 MERS-CoV Seoul/163-2 Human Korea 2015 
KT868871.1 MERS-CoV CNUH_SNU/054 Human Korea 2015 
KT374057.1 MERS-CoV Seoul/168-2 Human Korea 2015 
KT868870.1 MERS-CoV CNUH_SNU/038_06 Human Korea 2015 
EF065505.1 HKU4 B04f Bat China 2007 
KC522051.1 HKU4 4S Tylonycteris bat China (Hong Kong) 2010 
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KJ473822.1 BtTp-BetaCoV/GX2012 BtTp-GX2012 Tylonycteris pachypus (Bat) China 2012 
KJ473820.1 BtPa-BetaCoV/GD2013 BtPa-GD2013 Pipistrellus abramus (bat) China 2013 
EF065509.1 HKU5 LMH03f bat China 2006 
 
GARD Results 
Site Support for BP Tree length (subs/site) 
1 0 1.18364 
2 0 1.18364 
3 0 1.18364 
4 0 1.18364 
5 0 1.18364 
6 0 1.18364 
7 0 1.18364 
8 0 1.18364 
9 0 1.18364 
10 0 1.18364 
11 0 1.18364 
12 0 1.18364 
13 0 1.18364 
14 0 1.18364 
15 0 1.18364 
16 0 1.18364 
17 0 1.18364 
18 0 1.18364 
19 0 1.18364 
20 0 1.18364 
21 0 1.18364 
22 0 1.18364 
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23 0 1.18364 
24 0 1.18364 
25 0 1.18364 
26 0 1.18364 
27 0 1.18364 
28 0 1.18364 
29 0 1.18364 
30 0 1.18364 
31 0 1.18364 
32 0 1.18364 
33 0 1.18364 
34 0 1.18364 
35 0 1.18364 
36 0 1.18364 
37 0 1.18364 
38 0 1.18364 
39 0 1.18364 
40 0 1.18364 
41 0 1.18364 
42 0 1.18364 
43 0 1.18364 
44 0 1.18364 
45 0 1.18364 
46 0 1.18364 
47 0 1.18364 
48 0 1.18364 
49 0 1.18364 
50 0 1.18364 
51 0 1.18364 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
52 0 1.18364 
53 0 1.18364 
54 0 1.18364 
55 0 1.18364 
56 0 1.18364 
57 0 1.18364 
58 0 1.18364 
59 0 1.18364 
60 0 1.18364 
61 0 1.18364 
62 0 1.18364 
63 0 1.18364 
64 0 1.18364 
65 0 1.18364 
66 0 1.18364 
67 0 1.18364 
68 0 1.18364 
69 0 1.18364 
70 0 1.18364 
71 0 1.18364 
72 0 1.18364 
73 0 1.18364 
74 0 1.18364 
75 0 1.18364 
76 0 1.18364 
77 0 1.18364 
78 0 1.18364 
79 0 1.18364 
80 0 1.18364 
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81 0 1.18364 
82 0 1.18364 
83 0 1.18364 
84 0 1.18364 
85 0 1.18364 
86 0 1.18364 
87 0 1.18364 
88 0 1.18364 
89 0 1.18364 
90 0 1.18364 
91 0 1.18364 
92 0 1.18364 
93 0 1.18364 
94 0 1.18364 
95 0 1.18364 
96 0 1.18364 
97 0 1.18364 
98 0 1.18364 
99 0 1.18364 
100 0 1.18364 
101 0 1.18364 
102 0 1.18364 
103 0 1.18364 
104 0 1.18364 
105 0 1.18364 
106 0 1.18364 
107 0 1.18364 
108 0 1.18364 
109 0 1.18364 
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110 0 1.18364 
111 0 1.18364 
112 0 1.18364 
113 0 1.18364 
114 0 1.18364 
115 0 1.18364 
116 0 1.18364 
117 0 1.18364 
118 0 1.18364 
119 0 1.18364 
120 0 1.18364 
121 0 1.18364 
122 0 1.18364 
123 0 1.18364 
124 0 1.18364 
125 0 1.18364 
126 0 1.18364 
127 0 1.18364 
128 0 1.18364 
129 0 1.18364 
130 0 1.18364 
131 0 1.18364 
132 0 1.18364 
133 0 1.18364 
134 0 1.18364 
135 0 1.18364 
136 0 1.18364 
137 0 1.18364 
138 0 1.18364 
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139 0 1.18364 
140 0 1.18364 
141 0 1.18364 
142 0 1.18364 
143 0 1.18364 
144 0 1.18364 
145 0 1.18364 
146 0 1.18364 
147 0 1.18364 
148 0 1.18364 
149 0 1.18364 
150 0 1.18364 
151 0 1.18364 
152 0 1.18364 
153 0 1.18364 
154 0 1.18364 
155 0 1.18364 
156 0 1.18364 
157 0 1.18364 
158 0 1.18364 
159 0 1.18364 
160 0 1.18364 
161 0 1.18364 
162 0 1.18364 
163 0 1.18364 
164 0 1.18364 
165 0 1.18364 
166 0 1.18364 
167 0 1.18364 
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168 0 1.18364 
169 0 1.18364 
170 0 1.18364 
171 0 1.18364 
172 0 1.18364 
173 0 1.18364 
174 0 1.18364 
175 0 1.18364 
176 0 1.18364 
177 0 1.18364 
178 0 1.18364 
179 0 1.18364 
180 0 1.18364 
181 0 1.18364 
182 0 1.18364 
183 0 1.18364 
184 0 1.18364 
185 0 1.18364 
186 0 1.18364 
187 0 1.18364 
188 0 1.18364 
189 0 1.18364 
190 0 1.18364 
191 0 1.18364 
192 0 1.18364 
193 0 1.18364 
194 0 1.18364 
195 0 1.18364 
196 0 1.18364 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
197 0 1.18364 
198 0 1.18364 
199 0 1.18364 
200 0 1.18364 
201 0 1.18364 
202 0 1.18364 
203 0 1.18364 
204 0 1.18364 
205 0 1.18364 
206 0 1.18364 
207 0 1.18364 
208 0 1.18364 
209 0 1.18364 
210 0 1.18364 
211 0 1.18364 
212 0 1.18364 
213 0 1.18364 
214 0 1.18364 
215 0 1.18364 
216 0 1.18364 
217 0 1.18364 
218 0 1.18364 
219 0 1.18364 
220 0 1.18364 
221 0 1.18364 
222 0 1.18364 
223 0 1.18364 
224 0 1.18364 
225 0 1.18364 
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226 0 1.18364 
227 0 1.18364 
228 0 1.18364 
229 0 1.18364 
230 0 1.18364 
231 0 1.18364 
232 0 1.18364 
233 0 1.18364 
234 0 1.18364 
235 0 1.18364 
236 0 1.18364 
237 0 1.18364 
238 0 1.18364 
239 0 1.18364 
240 0 1.18364 
241 0 1.18364 
242 0 1.18364 
243 0 1.18364 
244 0 1.18364 
245 0 1.18364 
246 0 1.18364 
247 0 1.18364 
248 0 1.18364 
249 0 1.18364 
250 0 1.18364 
251 0 1.18364 
252 0 1.18364 
253 0 1.18364 
254 0 1.18364 
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255 0 1.18364 
256 0 1.18364 
257 0 1.18364 
258 0 1.18364 
259 0 1.18364 
260 0 1.18364 
261 0 1.18364 
262 0 1.18364 
263 0 1.18364 
264 0 1.18364 
265 0 1.18364 
266 0 1.18364 
267 0 1.18364 
268 0 1.18364 
269 0 1.18364 
270 0 1.18364 
271 0 1.18364 
272 0 1.18364 
273 0 1.18364 
274 0 1.18364 
275 0 1.18364 
276 0 1.18364 
277 0 1.18364 
278 0 1.18364 
279 0 1.18364 
280 0 1.18364 
281 0 1.18364 
282 0 1.18364 
283 0 1.18364 
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284 0 1.18364 
285 0 1.18364 
286 0 1.18364 
287 0 1.18364 
288 0 1.18364 
289 0 1.18364 
290 0 1.18364 
291 0 1.18364 
292 0 1.18364 
293 0 1.18364 
294 0 1.18364 
295 0 1.18364 
296 0 1.18364 
297 0 1.18364 
298 0 1.18364 
299 0 1.18364 
300 0 1.18364 
301 0 1.18364 
302 0 1.18364 
303 0 1.18364 
304 0 1.18364 
305 0 1.18364 
306 0 1.18364 
307 0 1.18364 
308 0 1.18364 
309 0 1.18364 
310 0 1.18364 
311 0 1.18364 
312 0 1.18364 
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313 0 1.18364 
314 0 1.18364 
315 0 1.18364 
316 0 1.18364 
317 0 1.18364 
318 0 1.18364 
319 0 1.18364 
320 0 1.18364 
321 0 1.18364 
322 0 1.18364 
323 0 1.18364 
324 0 1.18364 
325 0 1.18364 
326 0 1.18364 
327 0 1.18364 
328 0 1.18364 
329 0 1.18364 
330 0 1.18364 
331 0 1.18364 
332 0 1.18364 
333 0 1.18364 
334 0 1.18364 
335 0 1.18364 
336 0 1.18364 
337 0 1.18364 
338 0 1.18364 
339 0 1.18364 
340 0 1.18364 
341 0 1.18364 
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342 0 1.18364 
343 0 1.18364 
344 0 1.18364 
345 0 1.18364 
346 0 1.18364 
347 0 1.18364 
348 0 1.18364 
349 0 1.18364 
350 0 1.18364 
351 0 1.18364 
352 0 1.18364 
353 0 1.18364 
354 0 1.18364 
355 0 1.18364 
356 0 1.18364 
357 0 1.18364 
358 0 1.18364 
359 0 1.18364 
360 0 1.18364 
361 0 1.18364 
362 0 1.18364 
363 0 1.18364 
364 0 1.18364 
365 0 1.18364 
366 0 1.18364 
367 0 1.18364 
368 0 1.18364 
369 0 1.18364 
370 0 1.18364 
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371 0 1.18364 
372 0 1.18364 
373 0 1.18364 
374 0 1.18364 
375 0 1.18364 
376 0 1.18364 
377 0 1.18364 
378 0 1.18364 
379 0 1.18364 
380 0 1.18364 
381 0 1.18364 
382 0 1.18364 
383 0 1.18364 
384 0 1.18364 
385 0 1.18364 
386 0 1.18364 
387 0 1.18364 
388 0 1.18364 
389 0 1.18364 
390 0 1.18364 
391 0 1.18364 
392 0 1.18364 
393 0 1.18364 
394 0 1.18364 
395 0 1.18364 
396 0 1.18364 
397 0 1.18364 
398 0 1.18364 
399 0 1.18364 
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400 0 1.18364 
401 0 1.18364 
402 0 1.18364 
403 0 1.18364 
404 0 1.18364 
405 0 1.18364 
406 0 1.18364 
407 0 1.18364 
408 0 1.18364 
409 0 1.18364 
410 0 1.18364 
411 0 1.18364 
412 0 1.18364 
413 0 1.18364 
414 0 1.18364 
415 0 1.18364 
416 0 1.18364 
417 0 1.18364 
418 0 1.18364 
419 0 1.18364 
420 0 1.18364 
421 0 1.18364 
422 0 1.18364 
423 0 1.18364 
424 0 1.18364 
425 0 1.18364 
426 0 1.18364 
427 0 1.18364 
428 0 1.18364 
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429 0 1.18364 
430 0 1.18364 
431 0 1.18364 
432 0 1.18364 
433 0 1.18364 
434 0 1.18364 
435 0 1.18364 
436 0 1.18364 
437 0 1.18364 
438 0 1.18364 
439 0 1.18364 
440 0 1.18364 
441 0 1.18364 
442 0 1.18364 
443 0 1.18364 
444 0 1.18364 
445 0 1.18364 
446 0 1.18364 
447 0 1.18364 
448 0 1.18364 
449 0 1.18364 
450 0 1.18364 
451 0 1.18364 
452 0 1.18364 
453 0 1.18364 
454 0 1.18364 
455 0 1.18364 
456 0 1.18364 
457 0 1.18364 
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458 0 1.18364 
459 0 1.18364 
460 0 1.18364 
461 0 1.18364 
462 0 1.18364 
463 0 1.18364 
464 0 1.18364 
465 0 1.18364 
466 0 1.18364 
467 0 1.18364 
468 0 1.18364 
469 0 1.18364 
470 0 1.18364 
471 0 1.18364 
472 0 1.18364 
473 0 1.18364 
474 0 1.18364 
475 0 1.18364 
476 0 1.18364 
477 0 1.18364 
478 0 1.18364 
479 0 1.18364 
480 0 1.18364 
481 0 1.18364 
482 0 1.18364 
483 0 1.18364 
484 0 1.18364 
485 0 1.18364 
486 0 1.18364 
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487 0 1.18364 
488 0 1.18364 
489 0 1.18364 
490 0 1.18364 
491 0 1.18364 
492 0 1.18364 
493 0 1.18364 
494 0 1.18364 
495 0 1.18364 
496 0 1.18364 
497 0 1.18364 
498 0 1.18364 
499 0 1.18364 
500 0 1.18364 
501 0 1.18364 
502 0 1.18364 
503 0 1.18364 
504 0 1.18364 
505 0 1.18364 
506 0 1.18364 
507 0 1.18364 
508 0 1.18364 
509 0 1.18364 
510 0 1.18364 
511 0 1.18364 
512 0 1.18364 
513 0 1.18364 
514 0 1.18364 
515 0 1.18364 
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516 0 1.18364 
517 0 1.18364 
518 0 1.18364 
519 0 1.18364 
520 0 1.18364 
521 0 1.18364 
522 0 1.18364 
523 0 1.18364 
524 0 1.18364 
525 0 1.18364 
526 0 1.18364 
527 0 1.18364 
528 0 1.18364 
529 0 1.18364 
530 0 1.18364 
531 0 1.18364 
532 0 1.18364 
533 0 1.18364 
534 0 1.18364 
535 0 1.18364 
536 0 1.18364 
537 0 1.18364 
538 0 1.18364 
539 0 1.18364 
540 0 1.18364 
541 0 1.18364 
542 0 1.18364 
543 0 1.18364 
544 0 1.18364 
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545 0 1.18364 
546 0 1.18364 
547 0 1.18364 
548 0 1.18364 
549 0 1.18364 
550 0 1.18364 
551 0 1.18364 
552 0 1.18364 
553 0 1.18364 
554 0 1.18364 
555 0 1.18364 
556 0 1.18364 
557 0 1.18364 
558 0 1.18364 
559 0 1.18364 
560 0 1.18364 
561 0 1.18364 
562 0 1.18364 
563 0 1.18364 
564 0 1.18364 
565 0 1.18364 
566 0 1.18364 
567 0 1.18364 
568 0 1.18364 
569 0 1.18364 
570 0 1.18364 
571 0 1.18364 
572 0 1.18364 
573 0 1.18364 
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574 0 1.18364 
575 0 1.18364 
576 0 1.18364 
577 0 1.18364 
578 0 1.18364 
579 0 1.18364 
580 0 1.18364 
581 0 1.18364 
582 0 1.18364 
583 0 1.18364 
584 0 1.18364 
585 0 1.18364 
586 0 1.18364 
587 0 1.18364 
588 0 1.18364 
589 0 1.18364 
590 0 1.18364 
591 0 1.18364 
592 0 1.18364 
593 0 1.18364 
594 0 1.18364 
595 0 1.18364 
596 0 1.18364 
597 0 1.18364 
598 0 1.18364 
599 0 1.18364 
600 0 1.18364 
601 0 1.18364 
602 0 1.18364 
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603 0 1.18364 
604 0 1.18364 
605 0 1.18364 
606 0 1.18364 
607 0 1.18364 
608 0 1.18364 
609 0 1.18364 
610 0 1.18364 
611 0 1.18364 
612 0 1.18364 
613 0 1.18364 
614 0 1.18364 
615 0 1.18364 
616 0 1.18364 
617 0 1.18364 
618 0 1.18364 
619 0 1.18364 
620 0 1.18364 
621 0 1.18364 
622 0 1.18364 
623 0 1.18364 
624 0 1.18364 
625 0 1.18364 
626 0 1.18364 
627 0 1.18364 
628 0 1.18364 
629 0 1.18364 
630 0 1.18364 
631 0 1.18364 
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632 0 1.18364 
633 0 1.18364 
634 0 1.18364 
635 0 1.18364 
636 0 1.18364 
637 0 1.18364 
638 0 1.18364 
639 0 1.18364 
640 0 1.18364 
641 0 1.18364 
642 0 1.18364 
643 0 1.18364 
644 0 1.18364 
645 0 1.18364 
646 0 1.18364 
647 0 1.18364 
648 0 1.18364 
649 0 1.18364 
650 0 1.18364 
651 0 1.18364 
652 0 1.18364 
653 0 1.18364 
654 0 1.18364 
655 0 1.18364 
656 0 1.18364 
657 0 1.18364 
658 0 1.18364 
659 0 1.18364 
660 0 1.18364 
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661 0 1.18364 
662 0 1.18364 
663 0 1.18364 
664 0 1.18364 
665 0 1.18364 
666 0 1.18364 
667 0 1.18364 
668 0 1.18364 
669 0 1.18364 
670 0 1.18364 
671 0 1.18364 
672 0 1.18364 
673 0 1.18364 
674 0 1.18364 
675 0 1.18364 
676 0 1.18364 
677 0 1.18364 
678 0 1.18364 
679 0 1.18364 
680 0 1.18364 
681 0 1.18364 
682 0 1.18364 
683 0 1.18364 
684 0 1.18364 
685 0 1.18364 
686 0 1.18364 
687 0 1.18364 
688 0 1.18364 
689 0 1.18364 
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690 0 1.18364 
691 0 1.18364 
692 0 1.18364 
693 0 1.18364 
694 0 1.18364 
695 0 1.18364 
696 0 1.18364 
697 0 1.18364 
698 0 1.18364 
699 0 1.18364 
700 0 1.18364 
701 0 1.18364 
702 0 1.18364 
703 0 1.18364 
704 0 1.18364 
705 0 1.18364 
706 1.92E-05 1.18363 
707 0 1.18363 
708 0 1.18363 
709 0 1.18363 
710 0 1.18363 
711 0 1.18363 
712 0 1.18363 
713 0 1.18363 
714 0 1.18363 
715 0.00864719 1.18 
716 0 1.18 
717 0 1.18 
718 0 1.18 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
719 0 1.18 
720 0 1.18 
721 0 1.18 
722 0 1.18 
723 0 1.18 
724 0 1.18 
725 0.000172993 1.17993 
726 0 1.17993 
727 0 1.17993 
728 0 1.17993 
729 0.0113876 1.17527 
730 0.0440959 1.15718 
731 0 1.15718 
732 0 1.15718 
733 0 1.15718 
734 0.015908 1.15076 
735 0 1.15076 
736 0 1.15076 
737 0 1.15076 
738 0 1.15076 
739 0 1.15076 
740 0 1.15076 
741 0.000385919 1.15059 
742 0.0564216 1.1268 
743 0 1.1268 
744 0 1.1268 
745 0.0212432 1.11797 
746 0 1.11797 
747 0 1.11797 
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748 0.00973098 1.11398 
749 0 1.11398 
750 0 1.11398 
751 0 1.11398 
752 0 1.11398 
753 0 1.11398 
754 0 1.11398 
755 0 1.11398 
756 0.0023707 1.11302 
757 0.00286481 1.11185 
758 0.00393979 1.11023 
759 0 1.11023 
760 0.00318567 1.10893 
761 0 1.10893 
762 0.00537664 1.10673 
763 0 1.10673 
764 0 1.10673 
765 0 1.10673 
766 0.00496265 1.10471 
767 0.00622744 1.10218 
768 0.00475992 1.10024 
769 0.00379589 1.09869 
770 0 1.09869 
771 0 1.09869 
772 0.00210855 1.09783 
773 0 1.09783 
774 0 1.09783 
775 0.0010755 1.09739 
776 0 1.09739 
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777 0.00103197 1.09698 
778 0.00130423 1.09645 
779 0 1.09645 
780 0 1.09645 
781 0 1.09645 
782 0 1.09645 
783 0 1.09645 
784 0.000235746 1.09636 
785 0 1.09636 
786 0.000181572 1.09629 
787 0 1.09629 
788 0 1.09629 
789 0 1.09629 
790 0 1.09629 
791 0 1.09629 
792 0 1.09629 
793 0 1.09629 
794 0 1.09629 
795 0 1.09629 
796 0 1.09629 
797 0 1.09629 
798 0 1.09629 
799 0 1.09629 
800 0 1.09629 
801 0 1.09629 
802 0 1.09629 
803 0 1.09629 
804 0 1.09629 
805 0 1.09629 
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806 0 1.09629 
807 0 1.09629 
808 0 1.09629 
809 0 1.09629 
810 0 1.09629 
811 0 1.09629 
812 0 1.09629 
813 0 1.09629 
814 0 1.09629 
815 0 1.09629 
816 0 1.09629 
817 0 1.09629 
818 0 1.09629 
819 0 1.09629 
820 0 1.09629 
821 0 1.09629 
822 0 1.09629 
823 0 1.09629 
824 0 1.09629 
825 0 1.09629 
826 0 1.09629 
827 0 1.09629 
828 0 1.09629 
829 0 1.09629 
830 0 1.09629 
831 0 1.09629 
832 0 1.09629 
833 0 1.09629 
834 0 1.09629 
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835 0 1.09629 
836 0 1.09629 
837 0 1.09629 
838 0 1.09629 
839 0 1.09629 
840 0 1.09629 
841 0 1.09629 
842 0 1.09629 
843 0 1.09629 
844 0 1.09629 
845 0 1.09629 
846 0 1.09629 
847 0 1.09629 
848 0 1.09629 
849 0 1.09629 
850 0 1.09629 
851 0 1.09629 
852 0 1.09629 
853 0 1.09629 
854 0 1.09629 
855 0 1.09629 
856 0 1.09629 
857 0 1.09629 
858 0 1.09629 
859 0 1.09629 
860 0 1.09629 
861 0 1.09629 
862 0 1.09629 
863 0 1.09629 
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864 0 1.09629 
865 0 1.09629 
866 0 1.09629 
867 0 1.09629 
868 0 1.09629 
869 0 1.09629 
870 0 1.09629 
871 0 1.09629 
872 0 1.09629 
873 0 1.09629 
874 0 1.09629 
875 0 1.09629 
876 0 1.09629 
877 0 1.09629 
878 0 1.09629 
879 0 1.09629 
880 0 1.09629 
881 0 1.09629 
882 0 1.09629 
883 0 1.09629 
884 0 1.09629 
885 0 1.09629 
886 0 1.09629 
887 0 1.09629 
888 0 1.09629 
889 0 1.09629 
890 0 1.09629 
891 0 1.09629 
892 0 1.09629 
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893 0 1.09629 
894 0 1.09629 
895 0 1.09629 
896 0 1.09629 
897 0 1.09629 
898 0 1.09629 
899 0 1.09629 
900 0 1.09629 
901 0 1.09629 
902 0 1.09629 
903 0 1.09629 
904 0 1.09629 
905 0 1.09629 
906 0 1.09629 
907 0 1.09629 
908 0 1.09629 
909 0 1.09629 
910 0 1.09629 
911 0 1.09629 
912 0 1.09629 
913 0 1.09629 
914 0 1.09629 
915 0 1.09629 
916 0 1.09629 
917 0 1.09629 
918 0 1.09629 
919 0 1.09629 
920 0 1.09629 
921 0 1.09629 
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922 0 1.09629 
923 0 1.09629 
924 0 1.09629 
925 0 1.09629 
926 0 1.09629 
927 0 1.09629 
928 0 1.09629 
929 0 1.09629 
930 0 1.09629 
931 0 1.09629 
932 0 1.09629 
933 0 1.09629 
934 0 1.09629 
935 0 1.09629 
936 0 1.09629 
937 0 1.09629 
938 0 1.09629 
939 0 1.09629 
940 0 1.09629 
941 0 1.09629 
942 0 1.09629 
943 0 1.09629 
944 0 1.09629 
945 0 1.09629 
946 0 1.09629 
947 0 1.09629 
948 0 1.09629 
949 0 1.09629 
950 0 1.09629 
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951 0 1.09629 
952 0 1.09629 
953 0 1.09629 
954 0 1.09629 
955 0 1.09629 
956 0 1.09629 
957 0 1.09629 
958 0 1.09629 
959 0 1.09629 
960 0 1.09629 
961 0 1.09629 
962 0 1.09629 
963 0 1.09629 
964 0 1.09629 
965 0 1.09629 
966 0 1.09629 
967 0 1.09629 
968 0 1.09629 
969 0 1.09629 
970 0 1.09629 
971 0 1.09629 
972 0 1.09629 
973 0 1.09629 
974 0 1.09629 
975 0 1.09629 
976 0 1.09629 
977 0 1.09629 
978 0 1.09629 
979 0 1.09629 
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980 0 1.09629 
981 0 1.09629 
982 0 1.09629 
983 0 1.09629 
984 0 1.09629 
985 0 1.09629 
986 0 1.09629 
987 0 1.09629 
988 0 1.09629 
989 0 1.09629 
990 0 1.09629 
991 0 1.09629 
992 0 1.09629 
993 0 1.09629 
994 0 1.09629 
995 0 1.09629 
996 0 1.09629 
997 0 1.09629 
998 0 1.09629 
999 0 1.09629 
1000 0 1.09629 
1001 0 1.09629 
1002 0 1.09629 
1003 0 1.09629 
1004 0 1.09629 
1005 0 1.09629 
1006 0 1.09629 
1007 0 1.09629 
1008 0 1.09629 
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1009 0 1.09629 
1010 0 1.09629 
1011 0 1.09629 
1012 0 1.09629 
1013 0 1.09629 
1014 0 1.09629 
1015 0 1.09629 
1016 0 1.09629 
1017 0 1.09629 
1018 0 1.09629 
1019 0 1.09629 
1020 0 1.09629 
1021 0 1.09629 
1022 0 1.09629 
1023 0 1.09629 
1024 0 1.09629 
1025 0 1.09629 
1026 0 1.09629 
1027 0 1.09629 
1028 0 1.09629 
1029 0 1.09629 
1030 0 1.09629 
1031 0 1.09629 
1032 0 1.09629 
1033 0 1.09629 
1034 0 1.09629 
1035 0 1.09629 
1036 0 1.09629 
1037 0 1.09629 
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1038 0 1.09629 
1039 0 1.09629 
1040 0 1.09629 
1041 0 1.09629 
1042 0 1.09629 
1043 0 1.09629 
1044 0 1.09629 
1045 0 1.09629 
1046 0 1.09629 
1047 0 1.09629 
1048 0 1.09629 
1049 0 1.09629 
1050 0 1.09629 
1051 0 1.09629 
1052 0 1.09629 
1053 0 1.09629 
1054 0 1.09629 
1055 0 1.09629 
1056 0 1.09629 
1057 0 1.09629 
1058 0 1.09629 
1059 0 1.09629 
1060 0 1.09629 
1061 0 1.09629 
1062 0 1.09629 
1063 0 1.09629 
1064 0 1.09629 
1065 0 1.09629 
1066 0 1.09629 
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1067 0 1.09629 
1068 0 1.09629 
1069 0 1.09629 
1070 0 1.09629 
1071 0 1.09629 
1072 0 1.09629 
1073 0 1.09629 
1074 0 1.09629 
1075 0 1.09629 
1076 0 1.09629 
1077 0 1.09629 
1078 0 1.09629 
1079 0 1.09629 
1080 0 1.09629 
1081 0 1.09629 
1082 0 1.09629 
1083 0 1.09629 
1084 0 1.09629 
1085 0 1.09629 
1086 0 1.09629 
1087 0 1.09629 
1088 0 1.09629 
1089 0 1.09629 
1090 0 1.09629 
1091 0 1.09629 
1092 0 1.09629 
1093 0 1.09629 
1094 0 1.09629 
1095 0 1.09629 
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1096 0 1.09629 
1097 0 1.09629 
1098 0 1.09629 
1099 0 1.09629 
1100 0 1.09629 
1101 0 1.09629 
1102 0 1.09629 
1103 0 1.09629 
1104 0 1.09629 
1105 0 1.09629 
1106 0 1.09629 
1107 0 1.09629 
1108 0 1.09629 
1109 0 1.09629 
1110 0 1.09629 
1111 0 1.09629 
1112 0 1.09629 
1113 0 1.09629 
1114 0 1.09629 
1115 0 1.09629 
1116 0 1.09629 
1117 0 1.09629 
1118 0 1.09629 
1119 0 1.09629 
1120 0 1.09629 
1121 0 1.09629 
1122 0 1.09629 
1123 0 1.09629 
1124 0 1.09629 
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1125 0 1.09629 
1126 0 1.09629 
1127 0 1.09629 
1128 0 1.09629 
1129 0 1.09629 
1130 0 1.09629 
1131 0 1.09629 
1132 0 1.09629 
1133 0 1.09629 
1134 0 1.09629 
1135 0 1.09629 
1136 0 1.09629 
1137 0 1.09629 
1138 0 1.09629 
1139 0 1.09629 
1140 0 1.09629 
1141 0 1.09629 
1142 0 1.09629 
1143 0 1.09629 
1144 0 1.09629 
1145 0 1.09629 
1146 0 1.09629 
1147 0 1.09629 
1148 0 1.09629 
1149 0 1.09629 
1150 0 1.09629 
1151 0 1.09629 
1152 0 1.09629 
1153 0 1.09629 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
1154 0 1.09629 
1155 0 1.09629 
1156 0 1.09629 
1157 0 1.09629 
1158 0 1.09629 
1159 0 1.09629 
1160 0 1.09629 
1161 0 1.09629 
1162 0 1.09629 
1163 0 1.09629 
1164 0 1.09629 
1165 0 1.09629 
1166 0 1.09629 
1167 0 1.09629 
1168 0 1.09629 
1169 0 1.09629 
1170 0 1.09629 
1171 0 1.09629 
1172 0 1.09629 
1173 0 1.09629 
1174 0 1.09629 
1175 0 1.09629 
1176 0 1.09629 
1177 0 1.09629 
1178 0 1.09629 
1179 0 1.09629 
1180 0 1.09629 
1181 0 1.09629 
1182 0 1.09629 
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1183 0 1.09629 
1184 0 1.09629 
1185 0 1.09629 
1186 0 1.09629 
1187 0 1.09629 
1188 0 1.09629 
1189 0 1.09629 
1190 0 1.09629 
1191 0 1.09629 
1192 0 1.09629 
1193 0 1.09629 
1194 0 1.09629 
1195 0 1.09629 
1196 0 1.09629 
1197 0 1.09629 
1198 0 1.09629 
1199 0 1.09629 
1200 0 1.09629 
1201 0 1.09629 
1202 0 1.09629 
1203 0 1.09629 
1204 0 1.09629 
1205 0 1.09629 
1206 0 1.09629 
1207 0 1.09629 
1208 0 1.09629 
1209 0 1.09629 
1210 0 1.09629 
1211 0 1.09629 
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1212 0 1.09629 
1213 0 1.09629 
1214 0 1.09629 
1215 0 1.09629 
1216 0 1.09629 
1217 0 1.09629 
1218 0 1.09629 
1219 0 1.09629 
1220 0 1.09629 
1221 0 1.09629 
1222 0 1.09629 
1223 0 1.09629 
1224 0 1.09629 
1225 0 1.09629 
1226 0 1.09629 
1227 0 1.09629 
1228 0 1.09629 
1229 0 1.09629 
1230 0 1.09629 
1231 0 1.09629 
1232 0 1.09629 
1233 0 1.09629 
1234 0 1.09629 
1235 0 1.09629 
1236 0 1.09629 
1237 0 1.09629 
1238 0 1.09629 
1239 0 1.09629 
1240 0 1.09629 
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1241 0 1.09629 
1242 0 1.09629 
1243 0 1.09629 
1244 0 1.09629 
1245 0 1.09629 
1246 0 1.09629 
1247 0 1.09629 
1248 0 1.09629 
1249 0 1.09629 
1250 0 1.09629 
1251 0 1.09629 
1252 0 1.09629 
1253 0 1.09629 
1254 0 1.09629 
1255 0 1.09629 
1256 0 1.09629 
1257 0 1.09629 
1258 0 1.09629 
1259 0 1.09629 
1260 0 1.09629 
1261 0 1.09629 
1262 0 1.09629 
1263 0 1.09629 
1264 0 1.09629 
1265 0 1.09629 
1266 0 1.09629 
1267 0 1.09629 
1268 0 1.09629 
1269 0 1.09629 
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1270 0 1.09629 
1271 0 1.09629 
1272 0 1.09629 
1273 0 1.09629 
1274 0 1.09629 
1275 0 1.09629 
1276 0 1.09629 
1277 0 1.09629 
1278 0 1.09629 
1279 0 1.09629 
1280 0 1.09629 
1281 0 1.09629 
1282 0 1.09629 
1283 0 1.09629 
1284 0 1.09629 
1285 0 1.09629 
1286 0 1.09629 
1287 0 1.09629 
1288 0 1.09629 
1289 0 1.09629 
1290 0 1.09629 
1291 0 1.09629 
1292 0 1.09629 
1293 0 1.09629 
1294 0 1.09629 
1295 0 1.09629 
1296 0 1.09629 
1297 0 1.09629 
1298 0 1.09629 
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1299 0 1.09629 
1300 0 1.09629 
1301 0 1.09629 
1302 0 1.09629 
1303 0 1.09629 
1304 0 1.09629 
1305 0 1.09629 
1306 0 1.09629 
1307 0 1.09629 
1308 0 1.09629 
1309 0 1.09629 
1310 0 1.09629 
1311 0 1.09629 
1312 0 1.09629 
1313 0 1.09629 
1314 0 1.09629 
1315 0 1.09629 
1316 0 1.09629 
1317 0 1.09629 
1318 0 1.09629 
1319 0 1.09629 
1320 0 1.09629 
1321 0 1.09629 
1322 0 1.09629 
1323 0 1.09629 
1324 0 1.09629 
1325 0 1.09629 
1326 0 1.09629 
1327 0 1.09629 
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1328 0 1.09629 
1329 0 1.09629 
1330 0 1.09629 
1331 0 1.09629 
1332 0 1.09629 
1333 0 1.09629 
1334 0 1.09629 
1335 0 1.09629 
1336 0 1.09629 
1337 0 1.09629 
1338 0 1.09629 
1339 0 1.09629 
1340 0 1.09629 
1341 0 1.09629 
1342 0 1.09629 
1343 0 1.09629 
1344 0 1.09629 
1345 0 1.09629 
1346 0 1.09629 
1347 0 1.09629 
1348 0 1.09629 
1349 0 1.09629 
1350 0 1.09629 
1351 0 1.09629 
1352 0 1.09629 
1353 0 1.09629 
1354 0 1.09629 
1355 0 1.09629 
1356 0 1.09629 
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1357 0 1.09629 
1358 0 1.09629 
1359 0 1.09629 
1360 0 1.09629 
1361 0 1.09629 
1362 0 1.09629 
1363 0 1.09629 
1364 0 1.09629 
1365 0 1.09629 
1366 0 1.09629 
1367 0 1.09629 
1368 0 1.09629 
1369 0 1.09629 
1370 0 1.09629 
1371 0 1.09629 
1372 0 1.09629 
1373 0 1.09629 
1374 0 1.09629 
1375 0 1.09629 
1376 0 1.09629 
1377 0 1.09629 
1378 0 1.09629 
1379 0 1.09629 
1380 0 1.09629 
1381 0 1.09629 
1382 0 1.09629 
1383 0 1.09629 
1384 0 1.09629 
1385 0 1.09629 
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1386 0 1.09629 
1387 0 1.09629 
1388 0 1.09629 
1389 0 1.09629 
1390 0 1.09629 
1391 0 1.09629 
1392 0 1.09629 
1393 0 1.09629 
1394 0 1.09629 
1395 0 1.09629 
1396 0 1.09629 
1397 0 1.09629 
1398 0 1.09629 
1399 0 1.09629 
1400 0 1.09629 
1401 0 1.09629 
1402 0 1.09629 
1403 0 1.09629 
1404 0 1.09629 
1405 0 1.09629 
1406 0 1.09629 
1407 0 1.09629 
1408 0 1.09629 
1409 0 1.09629 
1410 0 1.09629 
1411 0 1.09629 
1412 0 1.09629 
1413 0 1.09629 
1414 0 1.09629 
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1415 0 1.09629 
1416 0 1.09629 
1417 0 1.09629 
1418 0 1.09629 
1419 0 1.09629 
1420 0 1.09629 
1421 0 1.09629 
1422 0 1.09629 
1423 0 1.09629 
1424 0 1.09629 
1425 0 1.09629 
1426 0 1.09629 
1427 0 1.09629 
1428 0 1.09629 
1429 0 1.09629 
1430 0 1.09629 
1431 0 1.09629 
1432 0 1.09629 
1433 0 1.09629 
1434 0 1.09629 
1435 0 1.09629 
1436 0 1.09629 
1437 0 1.09629 
1438 0 1.09629 
1439 0 1.09629 
1440 0 1.09629 
1441 0 1.09629 
1442 0 1.09629 
1443 0 1.09629 
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1444 0 1.09629 
1445 0 1.09629 
1446 0 1.09629 
1447 0 1.09629 
1448 0 1.09629 
1449 0 1.09629 
1450 0 1.09629 
1451 0 1.09629 
1452 0 1.09629 
1453 0 1.09629 
1454 0 1.09629 
1455 0 1.09629 
1456 0 1.09629 
1457 0 1.09629 
1458 0 1.09629 
1459 0 1.09629 
1460 0 1.09629 
1461 0 1.09629 
1462 0 1.09629 
1463 0 1.09629 
1464 0 1.09629 
1465 0 1.09629 
1466 0 1.09629 
1467 0 1.09629 
1468 0 1.09629 
1469 0 1.09629 
1470 0 1.09629 
1471 0 1.09629 
1472 0 1.09629 
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1473 0 1.09629 
1474 0 1.09629 
1475 0 1.09629 
1476 0 1.09629 
1477 0 1.09629 
1478 0 1.09629 
1479 0 1.09629 
1480 0 1.09629 
1481 0 1.09629 
1482 0 1.09629 
1483 0 1.09629 
1484 0 1.09629 
1485 0 1.09629 
1486 0 1.09629 
1487 0 1.09629 
1488 0 1.09629 
1489 0 1.09629 
1490 0 1.09629 
1491 0 1.09629 
1492 0 1.09629 
1493 0 1.09629 
1494 0 1.09629 
1495 0 1.09629 
1496 0 1.09629 
1497 0 1.09629 
1498 0 1.09629 
1499 0 1.09629 
1500 0 1.09629 
1501 0 1.09629 
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1502 0 1.09629 
1503 0 1.09629 
1504 0 1.09629 
1505 0 1.09629 
1506 0 1.09629 
1507 0 1.09629 
1508 0 1.09629 
1509 0 1.09629 
1510 0 1.09629 
1511 0 1.09629 
1512 0 1.09629 
1513 0 1.09629 
1514 0 1.09629 
1515 0 1.09629 
1516 0 1.09629 
1517 0 1.09629 
1518 0 1.09629 
1519 0 1.09629 
1520 0 1.09629 
1521 0 1.09629 
1522 0 1.09629 
1523 0 1.09629 
1524 0 1.09629 
1525 0 1.09629 
1526 0 1.09629 
1527 0 1.09629 
1528 0 1.09629 
1529 0 1.09629 
1530 0 1.09629 
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1531 0 1.09629 
1532 0 1.09629 
1533 0 1.09629 
1534 0 1.09629 
1535 0 1.09629 
1536 0 1.09629 
1537 0 1.09629 
1538 0 1.09629 
1539 0 1.09629 
1540 0 1.09629 
1541 0 1.09629 
1542 0 1.09629 
1543 0 1.09629 
1544 0 1.09629 
1545 0 1.09629 
1546 0 1.09629 
1547 0 1.09629 
1548 0 1.09629 
1549 0 1.09629 
1550 0 1.09629 
1551 0 1.09629 
1552 0 1.09629 
1553 0 1.09629 
1554 0 1.09629 
1555 0 1.09629 
1556 0 1.09629 
1557 0 1.09629 
1558 0 1.09629 
1559 0 1.09629 
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1560 0 1.09629 
1561 0 1.09629 
1562 0 1.09629 
1563 0 1.09629 
1564 0 1.09629 
1565 0 1.09629 
1566 0 1.09629 
1567 0 1.09629 
1568 0 1.09629 
1569 0 1.09629 
1570 0 1.09629 
1571 0 1.09629 
1572 0 1.09629 
1573 0 1.09629 
1574 0 1.09629 
1575 0 1.09629 
1576 0 1.09629 
1577 0 1.09629 
1578 0 1.09629 
1579 0 1.09629 
1580 0 1.09629 
1581 0 1.09629 
1582 0 1.09629 
1583 0 1.09629 
1584 0 1.09629 
1585 0 1.09629 
1586 0 1.09629 
1587 0 1.09629 
1588 0 1.09629 
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1589 0 1.09629 
1590 0 1.09629 
1591 0 1.09629 
1592 0 1.09629 
1593 0 1.09629 
1594 0 1.09629 
1595 0 1.09629 
1596 0 1.09629 
1597 0 1.09629 
1598 0 1.09629 
1599 0 1.09629 
1600 0 1.09629 
1601 0 1.09629 
1602 0 1.09629 
1603 0 1.09629 
1604 0 1.09629 
1605 0 1.09629 
1606 0 1.09629 
1607 0 1.09629 
1608 0 1.09629 
1609 0 1.09629 
1610 0 1.09629 
1611 0 1.09629 
1612 0 1.09629 
1613 0 1.09629 
1614 0 1.09629 
1615 0 1.09629 
1616 0 1.09629 
1617 0 1.09629 
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1618 0 1.09629 
1619 0 1.09629 
1620 0 1.09629 
1621 0 1.09629 
1622 0 1.09629 
1623 0 1.09629 
1624 0 1.09629 
1625 0 1.09629 
1626 0 1.09629 
1627 0 1.09629 
1628 0 1.09629 
1629 0 1.09629 
1630 0 1.09629 
1631 0 1.09629 
1632 0 1.09629 
1633 0 1.09629 
1634 0 1.09629 
1635 0 1.09629 
1636 0 1.09629 
1637 0 1.09629 
1638 0 1.09629 
1639 0 1.09629 
1640 0 1.09629 
1641 0 1.09629 
1642 0 1.09629 
1643 0 1.09629 
1644 0 1.09629 
1645 0 1.09629 
1646 0 1.09629 
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1647 0 1.09629 
1648 0 1.09629 
1649 0 1.09629 
1650 0 1.09629 
1651 0 1.09629 
1652 0 1.09629 
1653 0 1.09629 
1654 0 1.09629 
1655 0 1.09629 
1656 0 1.09629 
1657 0 1.09629 
1658 0 1.09629 
1659 0 1.09629 
1660 0 1.09629 
1661 0 1.09629 
1662 0 1.09629 
1663 0 1.09629 
1664 0 1.09629 
1665 0 1.09629 
1666 0 1.09629 
1667 0 1.09629 
1668 0 1.09629 
1669 0 1.09629 
1670 0 1.09629 
1671 0 1.09629 
1672 0 1.09629 
1673 0 1.09629 
1674 0 1.09629 
1675 0 1.09629 
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1676 0 1.09629 
1677 0 1.09629 
1678 0 1.09629 
1679 0 1.09629 
1680 0 1.09629 
1681 0 1.09629 
1682 0 1.09629 
1683 0 1.09629 
1684 0 1.09629 
1685 0 1.09629 
1686 0 1.09629 
1687 0 1.09629 
1688 0 1.09629 
1689 0 1.09629 
1690 0 1.09629 
1691 0 1.09629 
1692 0 1.09629 
1693 0 1.09629 
1694 0 1.09629 
1695 0 1.09629 
1696 0 1.09629 
1697 0 1.09629 
1698 0 1.09629 
1699 0 1.09629 
1700 0 1.09629 
1701 0 1.09629 
1702 0 1.09629 
1703 0 1.09629 
1704 0 1.09629 
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1705 0 1.09629 
1706 0 1.09629 
1707 0 1.09629 
1708 0 1.09629 
1709 0 1.09629 
1710 0 1.09629 
1711 0 1.09629 
1712 0 1.09629 
1713 0 1.09629 
1714 0 1.09629 
1715 0 1.09629 
1716 0 1.09629 
1717 0 1.09629 
1718 0 1.09629 
1719 0 1.09629 
1720 0 1.09629 
1721 0 1.09629 
1722 0 1.09629 
1723 0 1.09629 
1724 0 1.09629 
1725 0 1.09629 
1726 0 1.09629 
1727 0 1.09629 
1728 0 1.09629 
1729 0 1.09629 
1730 0 1.09629 
1731 0 1.09629 
1732 0 1.09629 
1733 0 1.09629 
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1734 0 1.09629 
1735 0 1.09629 
1736 0 1.09629 
1737 0 1.09629 
1738 0 1.09629 
1739 0 1.09629 
1740 0 1.09629 
1741 0 1.09629 
1742 0 1.09629 
1743 0 1.09629 
1744 0 1.09629 
1745 0 1.09629 
1746 0 1.09629 
1747 0 1.09629 
1748 0 1.09629 
1749 0 1.09629 
1750 0 1.09629 
1751 0 1.09629 
1752 0 1.09629 
1753 0 1.09629 
1754 0 1.09629 
1755 0 1.09629 
1756 0 1.09629 
1757 0 1.09629 
1758 0 1.09629 
1759 0 1.09629 
1760 0 1.09629 
1761 0 1.09629 
1762 0 1.09629 
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1763 0 1.09629 
1764 0 1.09629 
1765 0 1.09629 
1766 0 1.09629 
1767 0 1.09629 
1768 0 1.09629 
1769 0 1.09629 
1770 0 1.09629 
1771 0 1.09629 
1772 0 1.09629 
1773 0 1.09629 
1774 0 1.09629 
1775 0 1.09629 
1776 0 1.09629 
1777 0 1.09629 
1778 0 1.09629 
1779 0 1.09629 
1780 0 1.09629 
1781 0 1.09629 
1782 0 1.09629 
1783 0 1.09629 
1784 0 1.09629 
1785 0 1.09629 
1786 0 1.09629 
1787 0 1.09629 
1788 0 1.09629 
1789 0 1.09629 
1790 0 1.09629 
1791 0 1.09629 
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1792 0 1.09629 
1793 0 1.09629 
1794 0 1.09629 
1795 0 1.09629 
1796 0 1.09629 
1797 0 1.09629 
1798 0 1.09629 
1799 0 1.09629 
1800 0 1.09629 
1801 0 1.09629 
1802 0 1.09629 
1803 0 1.09629 
1804 0 1.09629 
1805 0 1.09629 
1806 0 1.09629 
1807 0 1.09629 
1808 0 1.09629 
1809 0 1.09629 
1810 0 1.09629 
1811 0 1.09629 
1812 0 1.09629 
1813 0 1.09629 
1814 0 1.09629 
1815 0 1.09629 
1816 0 1.09629 
1817 0 1.09629 
1818 0 1.09629 
1819 0 1.09629 
1820 0 1.09629 
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1821 0 1.09629 
1822 0 1.09629 
1823 0 1.09629 
1824 0 1.09629 
1825 0 1.09629 
1826 0 1.09629 
1827 0 1.09629 
1828 0 1.09629 
1829 0 1.09629 
1830 0 1.09629 
1831 0 1.09629 
1832 0 1.09629 
1833 0 1.09629 
1834 0 1.09629 
1835 0 1.09629 
1836 0 1.09629 
1837 0 1.09629 
1838 0 1.09629 
1839 0 1.09629 
1840 0 1.09629 
1841 0 1.09629 
1842 0 1.09629 
1843 0 1.09629 
1844 0 1.09629 
1845 0 1.09629 
1846 0 1.09629 
1847 0 1.09629 
1848 0 1.09629 
1849 0 1.09629 
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1850 0 1.09629 
1851 0 1.09629 
1852 0 1.09629 
1853 0 1.09629 
1854 0 1.09629 
1855 0 1.09629 
1856 0 1.09629 
1857 0 1.09629 
1858 0 1.09629 
1859 0 1.09629 
1860 0 1.09629 
1861 0 1.09629 
1862 0 1.09629 
1863 0 1.09629 
1864 0 1.09629 
1865 0 1.09629 
1866 0 1.09629 
1867 0 1.09629 
1868 0 1.09629 
1869 0 1.09629 
1870 0 1.09629 
1871 0 1.09629 
1872 0 1.09629 
1873 0 1.09629 
1874 0 1.09629 
1875 0 1.09629 
1876 0 1.09629 
1877 0 1.09629 
1878 0 1.09629 
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1879 0 1.09629 
1880 0 1.09629 
1881 0 1.09629 
1882 0 1.09629 
1883 0 1.09629 
1884 0 1.09629 
1885 0 1.09629 
1886 0 1.09629 
1887 0 1.09629 
1888 0 1.09629 
1889 0 1.09629 
1890 0 1.09629 
1891 0 1.09629 
1892 0 1.09629 
1893 0 1.09629 
1894 0 1.09629 
1895 0 1.09629 
1896 0 1.09629 
1897 0 1.09629 
1898 0 1.09629 
1899 0 1.09629 
1900 0 1.09629 
1901 0 1.09629 
1902 0 1.09629 
1903 0 1.09629 
1904 0 1.09629 
1905 0 1.09629 
1906 0 1.09629 
1907 0 1.09629 
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1908 0 1.09629 
1909 0 1.09629 
1910 0 1.09629 
1911 0 1.09629 
1912 0 1.09629 
1913 0 1.09629 
1914 0 1.09629 
1915 0 1.09629 
1916 0 1.09629 
1917 0 1.09629 
1918 0 1.09629 
1919 0 1.09629 
1920 0 1.09629 
1921 0 1.09629 
1922 0 1.09629 
1923 0 1.09629 
1924 0 1.09629 
1925 0 1.09629 
1926 0 1.09629 
1927 0 1.09629 
1928 0 1.09629 
1929 0 1.09629 
1930 0 1.09629 
1931 0 1.09629 
1932 0 1.09629 
1933 0 1.09629 
1934 0 1.09629 
1935 0 1.09629 
1936 0 1.09629 
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1937 0 1.09629 
1938 0 1.09629 
1939 0 1.09629 
1940 0 1.09629 
1941 0 1.09629 
1942 0 1.09629 
1943 0 1.09629 
1944 0 1.09629 
1945 0 1.09629 
1946 0 1.09629 
1947 0 1.09629 
1948 0 1.09629 
1949 0 1.09629 
1950 0 1.09629 
1951 0 1.09629 
1952 0 1.09629 
1953 0 1.09629 
1954 0 1.09629 
1955 0 1.09629 
1956 0 1.09629 
1957 0 1.09629 
1958 0 1.09629 
1959 0 1.09629 
1960 0 1.09629 
1961 0 1.09629 
1962 0 1.09629 
1963 0 1.09629 
1964 0 1.09629 
1965 0 1.09629 
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1966 0 1.09629 
1967 0 1.09629 
1968 0 1.09629 
1969 0 1.09629 
1970 0 1.09629 
1971 0 1.09629 
1972 0 1.09629 
1973 0 1.09629 
1974 0 1.09629 
1975 0 1.09629 
1976 0 1.09629 
1977 0 1.09629 
1978 0 1.09629 
1979 0 1.09629 
1980 0 1.09629 
1981 0 1.09629 
1982 0 1.09629 
1983 0 1.09629 
1984 0 1.09629 
1985 0 1.09629 
1986 0 1.09629 
1987 0 1.09629 
1988 0 1.09629 
1989 0 1.09629 
1990 0 1.09629 
1991 0 1.09629 
1992 0 1.09629 
1993 0 1.09629 
1994 0 1.09629 
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1995 0 1.09629 
1996 0 1.09629 
1997 0 1.09629 
1998 0 1.09629 
1999 0 1.09629 
2000 0 1.09629 
2001 0 1.09629 
2002 0 1.09629 
2003 0 1.09629 
2004 0 1.09629 
2005 0 1.09629 
2006 0 1.09629 
2007 0 1.09629 
2008 0 1.09629 
2009 0 1.09629 
2010 0 1.09629 
2011 0 1.09629 
2012 0 1.09629 
2013 0 1.09629 
2014 0 1.09629 
2015 0 1.09629 
2016 0 1.09629 
2017 0 1.09629 
2018 0 1.09629 
2019 0 1.09629 
2020 0 1.09629 
2021 0 1.09629 
2022 0 1.09629 
2023 0 1.09629 
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2024 0 1.09629 
2025 0 1.09629 
2026 0 1.09629 
2027 0 1.09629 
2028 0 1.09629 
2029 0 1.09629 
2030 0 1.09629 
2031 0 1.09629 
2032 0 1.09629 
2033 0 1.09629 
2034 0 1.09629 
2035 0 1.09629 
2036 0 1.09629 
2037 0 1.09629 
2038 0 1.09629 
2039 0 1.09629 
2040 0 1.09629 
2041 0 1.09629 
2042 0 1.09629 
2043 0 1.09629 
2044 0 1.09629 
2045 0 1.09629 
2046 0 1.09629 
2047 0 1.09629 
2048 0 1.09629 
2049 0 1.09629 
2050 0 1.09629 
2051 0 1.09629 
2052 0 1.09629 
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2053 0 1.09629 
2054 0 1.09629 
2055 0 1.09629 
2056 0 1.09629 
2057 0 1.09629 
2058 0 1.09629 
2059 0 1.09629 
2060 0 1.09629 
2061 0 1.09629 
2062 0 1.09629 
2063 0 1.09629 
2064 0 1.09629 
2065 0 1.09629 
2066 0 1.09629 
2067 0 1.09629 
2068 0 1.09629 
2069 0 1.09629 
2070 0 1.09629 
2071 0 1.09629 
2072 0 1.09629 
2073 0 1.09629 
2074 0 1.09629 
2075 0 1.09629 
2076 0 1.09629 
2077 0 1.09629 
2078 0 1.09629 
2079 0 1.09629 
2080 0 1.09629 
2081 0 1.09629 
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2082 0 1.09629 
2083 0 1.09629 
2084 0 1.09629 
2085 0 1.09629 
2086 0 1.09629 
2087 0 1.09629 
2088 0 1.09629 
2089 0 1.09629 
2090 0 1.09629 
2091 0 1.09629 
2092 0 1.09629 
2093 0 1.09629 
2094 0 1.09629 
2095 0 1.09629 
2096 0 1.09629 
2097 0 1.09629 
2098 0 1.09629 
2099 0 1.09629 
2100 0 1.09629 
2101 0 1.09629 
2102 0 1.09629 
2103 0 1.09629 
2104 0 1.09629 
2105 0 1.09629 
2106 0 1.09629 
2107 0 1.09629 
2108 0 1.09629 
2109 0 1.09629 
2110 0 1.09629 
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2111 0 1.09629 
2112 0 1.09629 
2113 0 1.09629 
2114 0 1.09629 
2115 0 1.09629 
2116 0 1.09629 
2117 0 1.09629 
2118 0 1.09629 
2119 0 1.09629 
2120 0 1.09629 
2121 0 1.09629 
2122 0 1.09629 
2123 0 1.09629 
2124 0 1.09629 
2125 0 1.09629 
2126 0 1.09629 
2127 0 1.09629 
2128 0 1.09629 
2129 0 1.09629 
2130 0 1.09629 
2131 0 1.09629 
2132 0 1.09629 
2133 0 1.09629 
2134 0 1.09629 
2135 0 1.09629 
2136 0 1.09629 
2137 0 1.09629 
2138 0 1.09629 
2139 0 1.09629 
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2140 0 1.09629 
2141 0 1.09629 
2142 0 1.09629 
2143 0 1.09629 
2144 0 1.09629 
2145 0 1.09629 
2146 0 1.09629 
2147 0 1.09629 
2148 0 1.09629 
2149 0 1.09629 
2150 0 1.09629 
2151 0 1.09629 
2152 0 1.09629 
2153 0 1.09629 
2154 0 1.09629 
2155 0 1.09629 
2156 0 1.09629 
2157 0 1.09629 
2158 0 1.09629 
2159 0 1.09629 
2160 0 1.09629 
2161 0 1.09629 
2162 0 1.09629 
2163 0 1.09629 
2164 0 1.09629 
2165 0 1.09629 
2166 0 1.09629 
2167 0 1.09629 
2168 0 1.09629 
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2169 0 1.09629 
2170 0 1.09629 
2171 0 1.09629 
2172 0 1.09629 
2173 0 1.09629 
2174 0 1.09629 
2175 0 1.09629 
2176 0 1.09629 
2177 0 1.09629 
2178 0 1.09629 
2179 0 1.09629 
2180 0 1.09629 
2181 0 1.09629 
2182 0 1.09629 
2183 0 1.09629 
2184 0 1.09629 
2185 0 1.09629 
2186 0 1.09629 
2187 0 1.09629 
2188 0 1.09629 
2189 0 1.09629 
2190 0 1.09629 
2191 0 1.09629 
2192 0 1.09629 
2193 0 1.09629 
2194 0 1.09629 
2195 0 1.09629 
2196 0 1.09629 
2197 0 1.09629 
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2198 0 1.09629 
2199 0 1.09629 
2200 0 1.09629 
2201 0 1.09629 
2202 0 1.09629 
2203 0 1.09629 
2204 0 1.09629 
2205 0 1.09629 
2206 0 1.09629 
2207 0 1.09629 
2208 0 1.09629 
2209 0 1.09629 
2210 0 1.09629 
2211 0 1.09629 
2212 0 1.09629 
2213 0 1.09629 
2214 0 1.09629 
2215 0 1.09629 
2216 0 1.09629 
2217 0 1.09629 
2218 0 1.09629 
2219 0 1.09629 
2220 0 1.09629 
2221 0 1.09629 
2222 0 1.09629 
2223 0 1.09629 
2224 0 1.09629 
2225 0 1.09629 
2226 0 1.09629 
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2227 0 1.09629 
2228 0 1.09629 
2229 0 1.09629 
2230 0 1.09629 
2231 0 1.09629 
2232 0 1.09629 
2233 0 1.09629 
2234 0 1.09629 
2235 0 1.09629 
2236 0 1.09629 
2237 0 1.09629 
2238 0 1.09629 
2239 0 1.09629 
2240 0 1.09629 
2241 0 1.09629 
2242 0 1.09629 
2243 0 1.09629 
2244 0 1.09629 
2245 0 1.09629 
2246 0 1.09629 
2247 0 1.09629 
2248 0 1.09629 
2249 0 1.09629 
2250 0 1.09629 
2251 0 1.09629 
2252 0 1.09629 
2253 0 1.09629 
2254 0 1.09629 
2255 0 1.09629 
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2256 0 1.09629 
2257 0 1.09629 
2258 0 1.09629 
2259 0 1.09629 
2260 0 1.09629 
2261 0 1.09629 
2262 0 1.09629 
2263 0 1.09629 
2264 0 1.09629 
2265 0 1.09629 
2266 0 1.09629 
2267 0 1.09629 
2268 0 1.09629 
2269 0 1.09629 
2270 0 1.09629 
2271 0 1.09629 
2272 0 1.09629 
2273 0 1.09629 
2274 0 1.09629 
2275 0 1.09629 
2276 0 1.09629 
2277 0 1.09629 
2278 0 1.09629 
2279 0 1.09629 
2280 0 1.09629 
2281 0 1.09629 
2282 0 1.09629 
2283 0 1.09629 
2284 0 1.09629 
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2285 0 1.09629 
2286 0 1.09629 
2287 0 1.09629 
2288 0 1.09629 
2289 0 1.09629 
2290 0 1.09629 
2291 0 1.09629 
2292 0 1.09629 
2293 0 1.09629 
2294 0 1.09629 
2295 0 1.09629 
2296 0 1.09629 
2297 0 1.09629 
2298 0 1.09629 
2299 0 1.09629 
2300 0 1.09629 
2301 0 1.09629 
2302 0 1.09629 
2303 0 1.09629 
2304 0 1.09629 
2305 0 1.09629 
2306 0 1.09629 
2307 0 1.09629 
2308 0 1.09629 
2309 0 1.09629 
2310 0 1.09629 
2311 0 1.09629 
2312 0 1.09629 
2313 0 1.09629 
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2314 0 1.09629 
2315 0 1.09629 
2316 0 1.09629 
2317 0 1.09629 
2318 0 1.09629 
2319 0 1.09629 
2320 0 1.09629 
2321 0 1.09629 
2322 0 1.09629 
2323 0 1.09629 
2324 0 1.09629 
2325 0 1.09629 
2326 0 1.09629 
2327 0 1.09629 
2328 0 1.09629 
2329 0 1.09629 
2330 0 1.09629 
2331 0 1.09629 
2332 0 1.09629 
2333 0 1.09629 
2334 0 1.09629 
2335 0 1.09629 
2336 0 1.09629 
2337 0 1.09629 
2338 0 1.09629 
2339 0 1.09629 
2340 0 1.09629 
2341 0.000938912 1.09593 
2342 0.001921 1.0952 
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2343 0 1.0952 
2344 0.00201159 1.09442 
2345 0.00287649 1.0933 
2346 0.00401691 1.09174 
2347 0.00675255 1.08909 
2348 0.00943024 1.08537 
2349 0 1.08537 
2350 0.000823832 1.08505 
2351 0.00100223 1.08465 
2352 0.000676623 1.08438 
2353 0.00102986 1.08398 
2354 0 1.08398 
2355 0.000449959 1.0838 
2356 0.000595446 1.08356 
2357 0.000440678 1.08339 
2358 0 1.08339 
2359 0.000480787 1.0832 
2360 0 1.0832 
2361 0 1.0832 
2362 0 1.0832 
2363 0.00013199 1.08315 
2364 9.06E-05 1.08311 
2365 0.000404401 1.08295 
2366 0 1.08295 
2367 0.000408148 1.08279 
2368 0 1.08279 
2369 0.000208021 1.0827 
2370 0.000151283 1.08264 
2371 0.000231022 1.08255 
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2372 0 1.08255 
2373 0 1.08255 
2374 0 1.08255 
2375 0.000120222 1.0825 
2376 0.000179295 1.08243 
2377 0.00026926 1.08233 
2378 0.000201279 1.08225 
2379 0.000244497 1.08215 
2380 0.000203846 1.08207 
2381 0.000144286 1.08201 
2382 0.000102904 1.08197 
2383 0.000593528 1.08173 
2384 0.000823504 1.08139 
2385 0 1.08139 
2386 0.00104019 1.08097 
2387 0 1.08097 
2388 0 1.08097 
2389 0.90806 0.736388 
2390 0 0.736388 
2391 0 0.736388 
2392 0 0.736388 
2393 0 0.736388 
2394 0 0.736388 
2395 0 0.736388 
2396 0 0.736388 
2397 0 0.736388 
2398 0.00524403 0.734285 
2399 0.0106824 0.730329 
2400 0 0.730329 
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2401 0.00949545 0.726519 
2402 0 0.726519 
2403 0 0.726519 
2404 0 0.726519 
2405 0.00538511 0.724501 
2406 0.00542818 0.722326 
2407 0.00351173 0.720923 
2408 0 0.720923 
2409 0 0.720923 
2410 0.00571052 0.718627 
2411 0 0.718627 
2412 0 0.718627 
2413 0.00344267 0.717248 
2414 0 0.717248 
2415 0 0.717248 
2416 0.00215575 0.716389 
2417 0 0.716389 
2418 0 0.716389 
2419 0.00140859 0.715831 
2420 0 0.715831 
2421 0.000274923 0.715722 
2422 0 0.715722 
2423 0 0.715722 
2424 0 0.715722 
2425 0 0.715722 
2426 4.66E-05 0.715704 
2427 0 0.715704 
2428 3.97E-05 0.715688 
2429 0 0.715688 
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2430 0 0.715688 
2431 2.80E-05 0.715677 
2432 3.69E-05 0.715663 
2433 0 0.715663 
2434 4.37E-05 0.715646 
2435 0 0.715646 
2436 0 0.715646 
2437 0 0.715646 
2438 0 0.715646 
2439 0 0.715646 
2440 1.06E-05 0.715642 
2441 0 0.715642 
2442 0 0.715642 
2443 0 0.715642 
2444 0 0.715642 
2445 0 0.715642 
2446 0 0.715642 
2447 0 0.715642 
2448 0 0.715642 
2449 0 0.715642 
2450 0 0.715642 
2451 0 0.715642 
2452 0 0.715642 
2453 0 0.715642 
2454 0 0.715642 
2455 0 0.715642 
2456 0 0.715642 
2457 0 0.715642 
2458 0 0.715642 
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2459 0 0.715642 
2460 0 0.715642 
2461 0 0.715642 
2462 0 0.715642 
2463 0 0.715642 
2464 0 0.715642 
2465 0 0.715642 
2466 0 0.715642 
2467 0 0.715642 
2468 0 0.715642 
2469 0 0.715642 
2470 0 0.715642 
2471 0 0.715642 
2472 0 0.715642 
2473 0 0.715642 
2474 0 0.715642 
2475 0 0.715642 
2476 0 0.715642 
2477 0 0.715642 
2478 0 0.715642 
2479 0 0.715642 
2480 0 0.715642 
2481 0 0.715642 
2482 0 0.715642 
2483 0 0.715642 
2484 0 0.715642 
2485 0 0.715642 
2486 0 0.715642 
2487 0 0.715642 
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2488 0 0.715642 
2489 0 0.715642 
2490 0 0.715642 
2491 0 0.715642 
2492 0 0.715642 
2493 0 0.715642 
2494 0 0.715642 
2495 0 0.715642 
2496 0 0.715642 
2497 0 0.715642 
2498 0 0.715642 
2499 0 0.715642 
2500 0 0.715642 
2501 0 0.715642 
2502 0 0.715642 
2503 0 0.715642 
2504 0 0.715642 
2505 0 0.715642 
2506 0 0.715642 
2507 0 0.715642 
2508 0 0.715642 
2509 0 0.715642 
2510 0 0.715642 
2511 0 0.715642 
2512 0 0.715642 
2513 0 0.715642 
2514 0 0.715642 
2515 0 0.715642 
2516 0 0.715642 
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2517 0 0.715642 
2518 0 0.715642 
2519 0 0.715642 
2520 0 0.715642 
2521 0 0.715642 
2522 0 0.715642 
2523 0 0.715642 
2524 0 0.715642 
2525 0 0.715642 
2526 0 0.715642 
2527 0 0.715642 
2528 0 0.715642 
2529 0 0.715642 
2530 0 0.715642 
2531 0 0.715642 
2532 0 0.715642 
2533 0 0.715642 
2534 0 0.715642 
2535 0 0.715642 
2536 0 0.715642 
2537 0 0.715642 
2538 0 0.715642 
2539 0 0.715642 
2540 0 0.715642 
2541 0 0.715642 
2542 0 0.715642 
2543 0 0.715642 
2544 0 0.715642 
2545 0 0.715642 
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2546 0 0.715642 
2547 0 0.715642 
2548 0 0.715642 
2549 0 0.715642 
2550 0 0.715642 
2551 0 0.715642 
2552 0 0.715642 
2553 0 0.715642 
2554 0 0.715642 
2555 0 0.715642 
2556 0 0.715642 
2557 0 0.715642 
2558 0 0.715642 
2559 0 0.715642 
2560 0 0.715642 
2561 0 0.715642 
2562 0 0.715642 
2563 0 0.715642 
2564 0 0.715642 
2565 0 0.715642 
2566 0 0.715642 
2567 0 0.715642 
2568 0 0.715642 
2569 0 0.715642 
2570 0 0.715642 
2571 0 0.715642 
2572 0 0.715642 
2573 0 0.715642 
2574 0 0.715642 
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2575 0 0.715642 
2576 0 0.715642 
2577 0 0.715642 
2578 0 0.715642 
2579 0 0.715642 
2580 0 0.715642 
2581 0 0.715642 
2582 0 0.715642 
2583 0 0.715642 
2584 0 0.715642 
2585 0 0.715642 
2586 0 0.715642 
2587 0 0.715642 
2588 0 0.715642 
2589 0 0.715642 
2590 0 0.715642 
2591 0 0.715642 
2592 0 0.715642 
2593 0 0.715642 
2594 0 0.715642 
2595 0 0.715642 
2596 0 0.715642 
2597 0 0.715642 
2598 0 0.715642 
2599 0 0.715642 
2600 0 0.715642 
2601 0 0.715642 
2602 0 0.715642 
2603 0 0.715642 
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2604 0 0.715642 
2605 0 0.715642 
2606 0 0.715642 
2607 0 0.715642 
2608 0 0.715642 
2609 0 0.715642 
2610 0 0.715642 
2611 0 0.715642 
2612 0 0.715642 
2613 0 0.715642 
2614 0 0.715642 
2615 0 0.715642 
2616 0 0.715642 
2617 0 0.715642 
2618 0 0.715642 
2619 0 0.715642 
2620 0 0.715642 
2621 0 0.715642 
2622 0 0.715642 
2623 0 0.715642 
2624 0 0.715642 
2625 0 0.715642 
2626 0 0.715642 
2627 0 0.715642 
2628 0 0.715642 
2629 0 0.715642 
2630 0 0.715642 
2631 0 0.715642 
2632 0 0.715642 
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2633 0 0.715642 
2634 0 0.715642 
2635 0 0.715642 
2636 0 0.715642 
2637 0 0.715642 
2638 0 0.715642 
2639 0 0.715642 
2640 0 0.715642 
2641 0 0.715642 
2642 0 0.715642 
2643 0 0.715642 
2644 0 0.715642 
2645 0 0.715642 
2646 0 0.715642 
2647 0 0.715642 
2648 0 0.715642 
2649 0 0.715642 
2650 0 0.715642 
2651 0 0.715642 
2652 0 0.715642 
2653 0 0.715642 
2654 0 0.715642 
2655 0 0.715642 
2656 0 0.715642 
2657 0 0.715642 
2658 0 0.715642 
2659 0 0.715642 
2660 0 0.715642 
2661 0 0.715642 
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2662 0 0.715642 
2663 0 0.715642 
2664 0 0.715642 
2665 0 0.715642 
2666 0 0.715642 
2667 0 0.715642 
2668 0 0.715642 
2669 0 0.715642 
2670 0 0.715642 
2671 0 0.715642 
2672 0 0.715642 
2673 0 0.715642 
2674 0 0.715642 
2675 0 0.715642 
2676 0 0.715642 
2677 0 0.715642 
2678 0 0.715642 
2679 0 0.715642 
2680 0 0.715642 
2681 0 0.715642 
2682 0 0.715642 
2683 0 0.715642 
2684 0 0.715642 
2685 0 0.715642 
2686 0 0.715642 
2687 0 0.715642 
2688 0 0.715642 
2689 0 0.715642 
2690 0 0.715642 
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2691 0 0.715642 
2692 0 0.715642 
2693 0 0.715642 
2694 0 0.715642 
2695 0 0.715642 
2696 0 0.715642 
2697 0 0.715642 
2698 0 0.715642 
2699 0 0.715642 
2700 0 0.715642 
2701 0 0.715642 
2702 0 0.715642 
2703 0 0.715642 
2704 0 0.715642 
2705 0 0.715642 
2706 0 0.715642 
2707 0 0.715642 
2708 0 0.715642 
2709 0 0.715642 
2710 0 0.715642 
2711 0 0.715642 
2712 0 0.715642 
2713 0 0.715642 
2714 0 0.715642 
2715 0 0.715642 
2716 0 0.715642 
2717 0 0.715642 
2718 0 0.715642 
2719 0 0.715642 
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2720 0 0.715642 
2721 0 0.715642 
2722 0 0.715642 
2723 0 0.715642 
2724 0 0.715642 
2725 0 0.715642 
2726 0 0.715642 
2727 0 0.715642 
2728 0 0.715642 
2729 0 0.715642 
2730 0 0.715642 
2731 0 0.715642 
2732 0 0.715642 
2733 0 0.715642 
2734 0 0.715642 
2735 0 0.715642 
2736 0 0.715642 
2737 0 0.715642 
2738 0 0.715642 
2739 0 0.715642 
2740 0 0.715642 
2741 0 0.715642 
2742 0 0.715642 
2743 0 0.715642 
2744 0 0.715642 
2745 0 0.715642 
2746 0 0.715642 
2747 0 0.715642 
2748 0 0.715642 
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2749 0 0.715642 
2750 0 0.715642 
2751 0 0.715642 
2752 0 0.715642 
2753 0 0.715642 
2754 0 0.715642 
2755 0 0.715642 
2756 0 0.715642 
2757 0 0.715642 
2758 0 0.715642 
2759 0 0.715642 
2760 0 0.715642 
2761 0 0.715642 
2762 0 0.715642 
2763 0 0.715642 
2764 0 0.715642 
2765 0 0.715642 
2766 0 0.715642 
2767 0 0.715642 
2768 0 0.715642 
2769 0 0.715642 
2770 0 0.715642 
2771 0 0.715642 
2772 0 0.715642 
2773 0 0.715642 
2774 0 0.715642 
2775 0 0.715642 
2776 0 0.715642 
2777 0 0.715642 
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2778 0 0.715642 
2779 0 0.715642 
2780 0 0.715642 
2781 0 0.715642 
2782 0 0.715642 
2783 0 0.715642 
2784 0 0.715642 
2785 0 0.715642 
2786 0 0.715642 
2787 0 0.715642 
2788 0 0.715642 
2789 0 0.715642 
2790 0 0.715642 
2791 0 0.715642 
2792 0 0.715642 
2793 0 0.715642 
2794 0 0.715642 
2795 0 0.715642 
2796 0 0.715642 
2797 0 0.715642 
2798 0 0.715642 
2799 0 0.715642 
2800 0 0.715642 
2801 0 0.715642 
2802 0 0.715642 
2803 0 0.715642 
2804 0 0.715642 
2805 0 0.715642 
2806 0 0.715642 
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2807 0 0.715642 
2808 0 0.715642 
2809 0 0.715642 
2810 0 0.715642 
2811 0 0.715642 
2812 0 0.715642 
2813 0 0.715642 
2814 0 0.715642 
2815 0 0.715642 
2816 0 0.715642 
2817 0 0.715642 
2818 0 0.715642 
2819 0 0.715642 
2820 0 0.715642 
2821 0 0.715642 
2822 0 0.715642 
2823 0 0.715642 
2824 0 0.715642 
2825 0 0.715642 
2826 0 0.715642 
2827 0 0.715642 
2828 0 0.715642 
2829 0 0.715642 
2830 0 0.715642 
2831 0 0.715642 
2832 0 0.715642 
2833 0 0.715642 
2834 0 0.715642 
2835 0 0.715642 
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2836 0 0.715642 
2837 0 0.715642 
2838 0 0.715642 
2839 0 0.715642 
2840 0 0.715642 
2841 0 0.715642 
2842 0 0.715642 
2843 0 0.715642 
2844 0 0.715642 
2845 0 0.715642 
2846 0 0.715642 
2847 0 0.715642 
2848 0 0.715642 
2849 0 0.715642 
2850 0 0.715642 
2851 0 0.715642 
2852 0 0.715642 
2853 0 0.715642 
2854 0 0.715642 
2855 0 0.715642 
2856 0 0.715642 
2857 0 0.715642 
2858 0 0.715642 
2859 0 0.715642 
2860 0 0.715642 
2861 0 0.715642 
2862 0 0.715642 
2863 0 0.715642 
2864 0 0.715642 
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2865 0 0.715642 
2866 0 0.715642 
2867 0 0.715642 
2868 0 0.715642 
2869 0 0.715642 
2870 0 0.715642 
2871 0 0.715642 
2872 0 0.715642 
2873 0 0.715642 
2874 0 0.715642 
2875 0 0.715642 
2876 0 0.715642 
2877 0 0.715642 
2878 0 0.715642 
2879 0 0.715642 
2880 0 0.715642 
2881 0 0.715642 
2882 0 0.715642 
2883 0 0.715642 
2884 0 0.715642 
2885 0 0.715642 
2886 0 0.715642 
2887 0 0.715642 
2888 0 0.715642 
2889 0 0.715642 
2890 0 0.715642 
2891 0 0.715642 
2892 0 0.715642 
2893 0 0.715642 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
2894 0 0.715642 
2895 0 0.715642 
2896 0 0.715642 
2897 0 0.715642 
2898 0 0.715642 
2899 0 0.715642 
2900 0 0.715642 
2901 0 0.715642 
2902 0 0.715642 
2903 0 0.715642 
2904 0 0.715642 
2905 0 0.715642 
2906 0 0.715642 
2907 0 0.715642 
2908 0 0.715642 
2909 0 0.715642 
2910 0 0.715642 
2911 0 0.715642 
2912 0 0.715642 
2913 0 0.715642 
2914 0 0.715642 
2915 0 0.715642 
2916 0 0.715642 
2917 0 0.715642 
2918 0 0.715642 
2919 0 0.715642 
2920 0 0.715642 
2921 0 0.715642 
2922 0 0.715642 
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2923 0 0.715642 
2924 0 0.715642 
2925 0 0.715642 
2926 0 0.715642 
2927 0 0.715642 
2928 0 0.715642 
2929 0 0.715642 
2930 0 0.715642 
2931 0 0.715642 
2932 0 0.715642 
2933 0 0.715642 
2934 0 0.715642 
2935 0 0.715642 
2936 0 0.715642 
2937 0 0.715642 
2938 0 0.715642 
2939 0 0.715642 
2940 0 0.715642 
2941 0 0.715642 
2942 0 0.715642 
2943 0 0.715642 
2944 0 0.715642 
2945 0 0.715642 
2946 0 0.715642 
2947 0 0.715642 
2948 0 0.715642 
2949 0 0.715642 
2950 0 0.715642 
2951 0 0.715642 
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3796 0 0.715642 
3797 0 0.715642 
3798 0 0.715642 
3799 0 0.715642 
3800 0 0.715642 
3801 0 0.715642 
3802 0 0.715642 
3803 0 0.715642 
3804 0 0.715642 
3805 0 0.715642 
3806 0 0.715642 
3807 0 0.715642 
3808 0 0.715642 
3809 0 0.715642 
3810 0 0.715642 
3811 0 0.715642 
3812 0 0.715642 
3813 0 0.715642 
3814 0 0.715642 
3815 0 0.715642 
3816 0 0.715642 
3817 0 0.715642 
3818 0 0.715642 
3819 0 0.715642 
3820 0 0.715642 
3821 0 0.715642 
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3822 0 0.715642 
3823 0 0.715642 
3824 0 0.715642 
3825 0 0.715642 
3826 0 0.715642 
3827 0 0.715642 
3828 0 0.715642 
3829 0 0.715642 
3830 0 0.715642 
3831 0 0.715642 
3832 0 0.715642 
3833 0 0.715642 
3834 0 0.715642 
3835 0 0.715642 
3836 0 0.715642 
3837 0 0.715642 
3838 0 0.715642 
3839 0 0.715642 
3840 0 0.715642 
3841 0 0.715642 
3842 0 0.715642 
3843 0 0.715642 
3844 0 0.715642 
3845 0 0.715642 
3846 0 0.715642 
3847 0 0.715642 
3848 0 0.715642 
3849 0 0.715642 
3850 0 0.715642 
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3851 0 0.715642 
3852 0 0.715642 
3853 0 0.715642 
3854 0 0.715642 
3855 0 0.715642 
3856 0 0.715642 
3857 0 0.715642 
3858 0 0.715642 
3859 0 0.715642 
3860 0 0.715642 
3861 0 0.715642 
3862 0 0.715642 
3863 0 0.715642 
3864 0 0.715642 
3865 0 0.715642 
3866 0 0.715642 
3867 0 0.715642 
3868 0 0.715642 
3869 0 0.715642 
3870 0 0.715642 
3871 0 0.715642 
3872 0 0.715642 
3873 0 0.715642 
3874 0 0.715642 
3875 0 0.715642 
3876 0 0.715642 
3877 0 0.715642 
3878 0 0.715642 
3879 0 0.715642 
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3880 0 0.715642 
3881 0 0.715642 
3882 0 0.715642 
3883 0 0.715642 
3884 0 0.715642 
3885 0 0.715642 
3886 0 0.715642 
3887 0 0.715642 
3888 0 0.715642 
3889 0 0.715642 
3890 0 0.715642 
3891 0 0.715642 
3892 0 0.715642 
3893 0 0.715642 
3894 0 0.715642 
3895 0 0.715642 
3896 0 0.715642 
3897 0 0.715642 
3898 0 0.715642 
3899 0 0.715642 
3900 0 0.715642 
3901 0 0.715642 
3902 0 0.715642 
3903 0 0.715642 
3904 0 0.715642 
3905 0 0.715642 
3906 0 0.715642 
3907 0 0.715642 
3908 0 0.715642 
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3909 0 0.715642 
3910 0 0.715642 
3911 0 0.715642 
3912 0 0.715642 
3913 0 0.715642 
3914 0 0.715642 
3915 0 0.715642 
3916 0 0.715642 
3917 0 0.715642 
3918 0 0.715642 
3919 0 0.715642 
3920 0 0.715642 
3921 0 0.715642 
3922 0 0.715642 
3923 0 0.715642 
3924 0 0.715642 
3925 0 0.715642 
3926 0 0.715642 
3927 0 0.715642 
3928 0 0.715642 
3929 0 0.715642 
3930 0 0.715642 
3931 0 0.715642 
3932 0 0.715642 
3933 0 0.715642 
3934 0 0.715642 
3935 0 0.715642 
3936 0 0.715642 
3937 0 0.715642 
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3938 0 0.715642 
3939 0 0.715642 
3940 0 0.715642 
3941 0 0.715642 
3942 0 0.715642 
3943 0 0.715642 
3944 0 0.715642 
3945 0 0.715642 
3946 0 0.715642 
3947 0 0.715642 
3948 0 0.715642 
3949 0 0.715642 
3950 0 0.715642 
3951 0 0.715642 
3952 0 0.715642 
3953 0 0.715642 
3954 0 0.715642 
3955 0 0.715642 
3956 0 0.715642 
3957 0 0.715642 
3958 0 0.715642 
3959 0 0.715642 
3960 0 0.715642 
3961 0 0.715642 
3962 0 0.715642 
3963 0 0.715642 
3964 0 0.715642 
3965 0 0.715642 
3966 0 0.715642 
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3967 0 0.715642 
3968 0 0.715642 
3969 0 0.715642 
3970 0 0.715642 
3971 0 0.715642 
3972 0 0.715642 
3973 0 0.715642 
3974 0 0.715642 
3975 0 0.715642 
3976 0 0.715642 
3977 0 0.715642 
3978 0 0.715642 
3979 0 0.715642 
3980 0 0.715642 
3981 0 0.715642 
3982 0 0.715642 
3983 0 0.715642 
3984 0 0.715642 
3985 0 0.715642 
3986 0 0.715642 
3987 0 0.715642 
3988 0 0.715642 
3989 0 0.715642 
3990 0 0.715642 
3991 0 0.715642 
3992 0 0.715642 
3993 0 0.715642 
3994 0 0.715642 
3995 0 0.715642 
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3996 0 0.715642 
3997 0 0.715642 
3998 0 0.715642 
3999 0 0.715642 
4000 0 0.715642 
4001 0 0.715642 
4002 0 0.715642 
4003 0 0.715642 
4004 0 0.715642 
4005 0 0.715642 
4006 0 0.715642 
4007 0 0.715642 
4008 0 0.715642 
4009 0 0.715642 
4010 0 0.715642 
4011 0 0.715642 
4012 0 0.715642 
4013 0 0.715642 
4014 0 0.715642 
4015 0 0.715642 
4016 0 0.715642 
4017 0 0.715642 
4018 0 0.715642 
4019 0 0.715642 
4020 0 0.715642 
4021 0 0.715642 
4022 0 0.715642 
4023 0 0.715642 
4024 0 0.715642 
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4025 0 0.715642 
4026 0 0.715642 
4027 0 0.715642 
4028 0 0.715642 
4029 0 0.715642 
4030 0 0.715642 
4031 0 0.715642 
4032 0 0.715642 
4033 0 0.715642 
4034 0 0.715642 
4035 0 0.715642 
4036 0 0.715642 
4037 0 0.715642 
4038 0 0.715642 
4039 0 0.715642 
4040 0 0.715642 
4041 0 0.715642 
4042 0 0.715642 
4043 0 0.715642 
4044 0 0.715642 
4045 0 0.715642 
4046 0 0.715642 
4047 0 0.715642 
4048 0 0.715642 
4049 0 0.715642 
4050 0 0.715642 
4051 0 0.715642 
4052 0 0.715642 
4053 0 0.715642 
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4054 0 0.715642 
4055 0 0.715642 
4056 0 0.715642 
4057 0 0.715642 
4058 0 0.715642 
4059 0 0.715642 
4060 0 0.715642 
4061 0 0.715642 
4062 0 0.715642 
4063 0 0.715642 
4064 0 0.715642 
4065 0 0.715642 
4066 0 0.715642 
4067 0 0.715642 
4068 0 0.715642 
4069 0 0.715642 
4070 0 0.715642 
4071 0 0.715642 
4072 0 0.715642 
4073 0 0.715642 
4074 0 0.715642 
4075 0 0.715642 
4076 0 0.715642 
4077 0 0.715642 
4078 0 0.715642 
4079 0 0.715642 
4080 0 0.715642 
4081 0 0.715642 
4082 0 0.715642 
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4083 0 0.715642 
4084 0 0.715642 
4085 0 0.715642 
4086 0 0.715642 
4087 0 0.715642 
4088 0 0.715642 
4089 0 0.715642 
4090 0 0.715642 
4091 0 0.715642 
4092 0 0.715642 
4093 0 0.715642 
4094 0 0.715642 
4095 0 0.715642 
4096 0 0.715642 
4097 0 0.715642 
4098 0 0.715642 
4099 0 0.715642 
4100 0 0.715642 
4101 0 0.715642 
4102 0 0.715642 
4103 0 0.715642 
4104 0 0.715642 
4105 0 0.715642 
4106 0 0.715642 
4107 0 0.715642 
4108 0 0.715642 
4109 0 0.715642 
4110 0 0.715642 
4111 0 0.715642 
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4112 0 0.715642 
4113 0 0.715642 
 












d S. Prop. 








1 0 0 0 5.99481 0 0 0 0 0 0 0 0 




0 0 0 0 0 0 
3 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
4 0 0 1.47385 2.82253 0 0.34304
5 
0 0 0 0 0 0 
5 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
6 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
7 0 0 2.82253 1.59903 0 0.63835
6 
0 0 0 0 0 0 
8 0 0 2.82253 1.59903 0 0.63835
6 
0 0 0 0 0 0 
9 0 0 0 4.42155 0 0 0 0 0 0 0 0 
10 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
11 0 0 1.74491 2.65697 0 0.3964 0 0 0 0 0 0 
12 0 0 2.39158 1.9048 0 0.55665
1 
0 0 0 0 0 0 
13 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
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14 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
15 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
16 0 0 1.04291 2.83984 0 0.2686 0 0 0 0 0 0 
17 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
18 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
19 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
20 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
21 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
22 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






0.661731 0.338269 2.62196 
24 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
25 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
26 0 3 1.47104 2.95051 0 0.33269
8 
0 1.01677 1.01677 0.297144 0.702856 7.80022 




0 0 0 0 0 0 
28 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
29 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
30 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
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31 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
33 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
34 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
36 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 




0 0 0 0 0 0 
38 3 0 1.47385 2.9477 1 0.33333
3 
2.03548 0 -2.03548 1 0.037037 -15.6153 






0.99899 0.00101 0.006935 
40 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
41 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
42 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 
43 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
44 0 0 0 3.62909 0 0 0 0 0 0 0 0 
45 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
47 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
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48 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
49 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
50 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
51 0 1 1.47353 2.94802 0 0.33326
1 
0 0.33921 0.33921 0.666739 0.333261 2.60227 




0 0 0 0 0 0 
53 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
54 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
55 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
56 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
58 0 1 1.34868 2.94907 0 0.31381 0 0.33909 0.33909 0.68619 0.31381 2.60134 
59 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
60 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 




0 -0.67849 1 0.333333 -5.2051 
62 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
63 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
64 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
65 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
66 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
68 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
69 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
70 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
71 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
72 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
73 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
74 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
75 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
76 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
77 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 




0 0 0 0 0 0 
79 0 0 1.47385 2.40889 0 0.37959 0 0 0 0 0 0 
80 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
81 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
82 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
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83 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
84 0 0 0 4.42155 0 0 0 0 0 0 0 0 
85 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
86 5 0 1.47385 2.9477 1 0.33333
3 
3.39247 0 -3.39247 1 0.004115 -26.0255 
87 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
88 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
89 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
90 0 0 1.47385 2.40889 0 0.37959 0 0 0 0 0 0 






0.99899 0.00101 0.006935 
92 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
93 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






0.444444 0.555556 5.2051 
95 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
96 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






0.442618 0.557382 5.21583 






0.660516 0.339484 3.77967 




0 0 0 0 0 0 
100 0 0 1.74491 2.65697 0 0.3964 0 0 0 0 0 0 
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101 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
102 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
103 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
104 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
105 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 






0.666721 0.333279 2.60234 




0 0 0 0 0 0 






0.694977 0.305023 2.49653 
109 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
110 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 




0 0 0 0 0 0 
112 6 0 1.34868 3.07288 1 0.30502
3 
4.44881 0 -4.44881 1 0.000805 -34.1293 
113 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
114 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
115 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
116 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
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117 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
118 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
119 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
121 0 0 1.47385 2.40889 0 0.37959 0 0 0 0 0 0 
122 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
123 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
124 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
125 0 1.00833 1.34868 3.07175 0 0.30510
1 
0 0.32826 0.32826 0.692795 0.307205 2.51826 




0 -0.67849 1 0.333333 -5.2051 
127 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
128 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
129 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
130 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
131 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
132 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
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0.694977 0.305023 2.49653 
134 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






0.666685 0.333315 2.60248 
136 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






0.694904 0.305096 2.4968 
138 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






0.666745 0.333255 2.60225 




0 0 0 0 0 0 
141 0 0 1.49353 1.57935 0 0.48603
5 
0 0 0 0 0 0 
142 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 
143 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
144 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
145 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
146 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
147 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
148 0 0 0 4.42155 0 0 0 0 0 0 0 0 
149 0 0 2.82253 1.59903 0 0.63835
6 
0 0 0 0 0 0 
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150 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
151 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
152 0 0 1.47385 2.82253 0 0.34304
5 
0 0 0 0 0 0 
153 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
154 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
155 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
156 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
157 0 0 1.47385 2.82253 0 0.34304
5 
0 0 0 0 0 0 






0.694644 0.305356 2.50046 
159 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
160 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 




1 1.65E-09 0.00482 
162 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
163 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
164 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
165 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
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0.694972 0.305028 2.4966 






0.694905 0.305095 2.49738 
168 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
169 0 0 2.82253 1.59903 0 0.63835
6 
0 0 0 0 0 0 
170 7.04167 0 1.47385 2.9477 1 0.33333
3 
4.77773 0 -4.77773 1 0.000481 -36.6526 
171 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
172 0 0 1.74491 2.65697 0 0.3964 0 0 0 0 0 0 
173 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
174 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
175 0 0 1.47385 2.40889 0 0.37959 0 0 0 0 0 0 
176 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
177 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
178 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
179 0 0 2.39158 1.9048 0 0.55665
1 
0 0 0 0 0 0 
180 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
181 0 0 1.20934 2.9477 0 0.29091
4 
0 0 0 0 0 0 
182 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
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183 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
184 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
185 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
186 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
187 0 0 2.82253 1.59903 0 0.63835
6 
0 0 0 0 0 0 




0 0 0 0 0 0 
189 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
190 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
191 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
192 0 0 1.47385 2.40889 0 0.37959 0 0 0 0 0 0 




0 -0.74147 1 0.305023 -5.68821 




0.69462 0.30538 2.50075 
195 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
196 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
197 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






0.666721 0.333279 2.60234 
199 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
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200 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






0.686098 0.313902 2.60245 
202 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
203 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
204 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
205 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
206 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
207 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
208 4 0 1.34868 3.07288 1 0.30502
3 
2.96587 0 -2.96587 1 0.008656 -22.7528 
209 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
210 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
211 2 0 1.47385 2.9477 1 0.33333
3 
1.35699 0 -1.35699 1 0.111111 -10.4102 
212 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
213 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
214 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
215 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
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216 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
217 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
218 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
219 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
220 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
221 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
222 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
223 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
224 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 




0 -0.35429 1 0.638356 -2.71797 
226 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
227 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
228 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 




0 0 0 0 0 0 




0 0 0 0 0 0 
231 1 0 1.34868 2.9477 1 0.31391 0.74146
8 
0 -0.74147 1 0.31391 -5.68821 
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232 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
233 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
234 0 0 2.39158 1.9048 0 0.55665
1 
0 0 0 0 0 0 
235 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
236 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 




0 -0.74147 1 0.306386 -5.68821 
238 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
239 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
240 0 0 0 4.42155 0 0 0 0 0 0 0 0 
241 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 






0.666728 0.333272 2.60231 
243 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
244 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
245 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
246 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
247 0 0 1.04291 2.83984 0 0.2686 0 0 0 0 0 0 
248 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
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250 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
251 0 0 2.39158 1.9048 0 0.55665
1 
0 0 0 0 0 0 




0 0 0 0 0 0 
253 0 0 0 3.62909 0 0 0 0 0 0 0 0 
254 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
255 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
256 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
257 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
258 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
259 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
260 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
261 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
262 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
263 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
264 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
265 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
266 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
Appendix 4 Chapter 7 Analysis of Selective Pressure  




0 -0.67849 1 0.342883 -5.2051 
268 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
269 0 0 1.49353 2.92803 0 0.33778
4 
0 0 0 0 0 0 
270 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
271 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
272 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
273 0 0 1.74491 2.65697 0 0.3964 0 0 0 0 0 0 
274 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 




0 -0.67849 1 0.333333 -5.2051 
276 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
277 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
278 0 0 0 4.42155 0 0 0 0 0 0 0 0 
279 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
280 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
281 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
282 2 0 1.47385 2.9477 1 0.33333
3 
1.35699 0 -1.35699 1 0.111111 -10.4102 
283 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
284 0 0 1.74491 2.65697 0 0.3964 0 0 0 0 0 0 






0.998874 0.001126 0.007229 
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286 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
287 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
288 5 0 1.34868 3.07288 1 0.30502
3 
3.70734 0 -3.70734 1 0.00264 -28.441 






-0.00094 0.998875 0.00225 -0.00723 
290 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
292 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
293 20 0 1.34868 2.9477 1 0.31391 14.8294 0 -14.8294 1 8.63E-11 -113.764 
294 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
295 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
296 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
297 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 -0.74147 1 0.305023 -5.68821 
299 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
300 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
301 0 3 1.47369 2.94784 0 0.33329
9 
0 1.01769 1.01769 0.296342 0.703658 7.80729 
302 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
303 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 






0.660686 0.339314 3.77784 
305 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
306 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
307 0 0 1.20934 2.9477 0 0.29091
4 
0 0 0 0 0 0 
308 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 
309 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
310 0 0 0 3.62909 0 0 0 0 0 0 0 0 
311 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






0.666667 0.333333 2.60255 




0 -0.74147 1 0.305023 -5.68821 
314 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
315 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
316 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
317 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 
318 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
319 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
320 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
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321 0 0 2.39158 1.9048 0 0.55665
1 
0 0 0 0 0 0 
322 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
323 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
324 0 0 2.82253 1.59903 0 0.63835
6 
0 0 0 0 0 0 
325 0 0 1.74491 2.65697 0 0.3964 0 0 0 0 0 0 
326 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
327 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
328 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
329 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
330 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
331 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
332 1 0 1.34868 2.9477 1 0.31391 0.74146
8 
0 -0.74147 1 0.31391 -5.68821 




0 0 0 0 0 0 
334 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
335 0 0 1.20934 2.9477 0 0.29091
4 
0 0 0 0 0 0 






0.666667 0.333333 2.60255 
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0 0 0 0 0 0 
338 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
339 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
340 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
341 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
342 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
343 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
344 0 0 1.74491 2.65697 0 0.3964 0 0 0 0 0 0 
345 0 0 1.47385 2.82253 0 0.34304
5 
0 0 0 0 0 0 
346 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
347 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






0.99899 0.00101 0.006935 
349 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
350 0 0 1.47385 2.82253 0 0.34304
5 
0 0 0 0 0 0 
351 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
352 0 0 1.04291 2.83984 0 0.2686 0 0 0 0 0 0 
353 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
354 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
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355 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
356 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
357 0 0 1.04291 2.83984 0 0.2686 0 0 0 0 0 0 
358 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
359 0 0 1.47385 2.40889 0 0.37959 0 0 0 0 0 0 
360 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
361 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
362 0 0 1.47385 2.82253 0 0.34304
5 
0 0 0 0 0 0 
363 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
364 0 0 1.47385 2.92803 0 0.33482
3 
0 0 0 0 0 0 
365 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
366 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
367 0 0 1.04291 2.83984 0 0.2686 0 0 0 0 0 0 
368 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
369 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 
370 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
371 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
372 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
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373 0 0 1.47385 2.82253 0 0.34304
5 
0 0 0 0 0 0 






0.666903 0.333097 2.60163 
375 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
376 0 0 1.04291 2.83984 0 0.2686 0 0 0 0 0 0 




0 0 0 0 0 0 
378 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
379 0 0 1.04291 2.83984 0 0.2686 0 0 0 0 0 0 
380 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
381 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
382 0 0 1.04291 2.83984 0 0.2686 0 0 0 0 0 0 
383 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
384 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
385 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
386 0 0 1.47385 2.82253 0 0.34304
5 
0 0 0 0 0 0 
387 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
388 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
389 0 0 2.82253 1.59903 0 0.63835
6 
0 0 0 0 0 0 
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390 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
391 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
392 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
393 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
394 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
396 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
397 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
398 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
399 4 0 1.34868 3.07288 1 0.30502
3 
2.96587 0 -2.96587 1 0.008656 -22.7528 








0.903682 0.096319 2.04154 
401 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
402 0 0 1.74491 2.65697 0 0.3964 0 0 0 0 0 0 
403 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
404 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
405 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
406 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
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407 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
408 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
409 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
410 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 






0.666721 0.333279 2.60234 
412 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
413 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 
414 0 0 1.74491 2.65697 0 0.3964 0 0 0 0 0 0 
415 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
416 0 0 1.47385 2.82253 0 0.34304
5 
0 0 0 0 0 0 
417 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
418 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
419 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
420 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
421 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
422 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 




0 -0.74147 1 0.305023 -5.68821 
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424 0 4 1.47283 2.94872 0 0.33310
3 
0 1.35652 1.35652 0.197803 0.802197 10.4066 
425 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
426 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
427 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 




0 0 0 0 0 0 
429 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
430 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




-1.01774 0.962963 0.259259 -7.80765 
432 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
433 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 






0.444444 0.555556 5.2051 
435 2.01389 0 1.34868 3.07288 1 0.30502
3 
1.49323 0 -1.49323 1 0.093369 -11.4554 
436 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
437 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
438 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
439 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
440 0 0 1.47385 2.82253 0 0.34304
5 
0 0 0 0 0 0 
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441 0 0 2.82253 1.59903 0 0.63835
6 
0 0 0 0 0 0 
442 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
443 0 0 1.74491 2.65697 0 0.3964 0 0 0 0 0 0 
444 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
445 20 0 1.34868 2.9477 1 0.31391 14.8294 0 -14.8294 1 8.63E-11 -113.764 
446 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
447 0 0 1.47385 2.82253 0 0.34304
5 
0 0 0 0 0 0 
448 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
449 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
450 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
451 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
452 0 0 0 4.42155 0 0 0 0 0 0 0 0 
453 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 
454 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
455 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
456 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






0.694941 0.305059 2.49666 
458 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
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459 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 






0.666721 0.333279 2.60234 
461 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
462 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
463 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
465 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
467 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
468 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
469 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
470 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 




0 0 0 0 0 0 
472 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
473 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
474 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
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475 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
476 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
477 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
478 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
479 0 0 1.74491 2.65697 0 0.3964 0 0 0 0 0 0 
480 3 0 1.36835 3.0532 1 0.30947
3 
2.19242 0 -2.19242 1 0.029639 -16.8192 
481 0 0 2.39158 1.9048 0 0.55665
1 
0 0 0 0 0 0 






0.666667 0.333333 2.60255 
483 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
484 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






0.666667 0.333333 2.60255 




0 -0.74147 1 0.305023 -5.68821 
487 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
488 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
489 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
490 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
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491 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
492 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
494 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
495 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
497 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
498 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
499 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
500 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
501 3 0 1.34868 3.07288 1 0.30502
3 
2.22441 0 -2.22441 1 0.028379 -17.0646 




0 0 0 0 0 0 
503 0 0.002778 1.34868 3.0532 0 0.30638
6 
0 0.00091 0.00091 0.998984 0.001016 0.00698 
504 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
505 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






0.666776 0.333224 2.60212 
507 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
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508 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






0.694813 0.305187 2.49712 
510 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 






0.998874 0.001126 0.007229 
512 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
513 0 0 1.04291 2.83984 0 0.2686 0 0 0 0 0 0 






0.666109 0.333891 2.60492 
515 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
517 0 0 2.39158 1.9048 0 0.55665
1 
0 0 0 0 0 0 
518 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
519 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 






0.666667 0.333333 2.60255 
521 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 






0.660673 0.339327 3.77665 
523 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
524 0 0 1.47385 2.82253 0 0.34304
5 
0 0 0 0 0 0 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
525 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
526 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
527 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
528 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
529 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 






0.666667 0.333333 2.60255 
531 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
532 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
533 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






0.666667 0.333333 2.60255 
535 0 0 0 3.62909 0 0 0 0 0 0 0 0 
536 0 0 1.04291 2.83984 0 0.2686 0 0 0 0 0 0 
537 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
538 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
539 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
540 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
541 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 




0 0 0 0 0 0 
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543 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 
544 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
545 0 0 2.82253 1.59903 0 0.63835
6 
0 0 0 0 0 0 




0 -0.67849 1 0.333333 -5.2051 
547 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
548 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
549 0 0 1.04291 2.83984 0 0.2686 0 0 0 0 0 0 
550 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
551 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
552 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
553 0 0 0 3.62909 0 0 0 0 0 0 0 0 
554 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
555 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






0.998874 0.001126 0.007229 
557 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
558 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
559 0 0 1.47385 2.82253 0 0.34304
5 
0 0 0 0 0 0 
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560 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
561 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
562 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
563 0 0 0 4.42155 0 0 0 0 0 0 0 0 
564 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
566 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
567 0 0 2.39158 1.9048 0 0.55665
1 
0 0 0 0 0 0 




0 0 0 0 0 0 
569 0 0 0 4.42155 0 0 0 0 0 0 0 0 
570 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
571 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
572 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
573 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
574 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






0.666685 0.333315 2.60248 
576 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
577 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
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578 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
579 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
580 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
581 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






0.694954 0.305046 2.49662 
583 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
584 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
585 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
586 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
588 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
589 0 0 1.04291 2.83984 0 0.2686 0 0 0 0 0 0 
590 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
591 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
592 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
593 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
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594 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
595 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 
596 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
597 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
598 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
599 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
600 0 0 2.39158 1.9048 0 0.55665
1 
0 0 0 0 0 0 
601 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
602 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
603 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
604 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
605 0 0 1.04291 2.83984 0 0.2686 0 0 0 0 0 0 
606 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
607 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
608 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
609 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
610 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
611 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
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612 0 0 1.47385 2.92803 0 0.33482
3 
0 0 0 0 0 0 
613 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
614 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
615 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
616 2 0 1.47385 2.9477 1 0.33333
3 
1.35699 0 -1.35699 1 0.111111 -10.4102 
617 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
619 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
620 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
621 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
622 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
623 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
624 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
625 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
626 0 0 1.49353 1.57935 0 0.48603
5 
0 0 0 0 0 0 




0 0 0 0 0 0 
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0 0 0 0 0 0 
629 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
630 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
631 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
632 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
633 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
634 5 0 1.47385 2.9477 1 0.33333
3 
3.39247 0 -3.39247 1 0.004115 -26.0255 
635 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 




0 0 0 0 0 0 
637 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
638 0 0 2.39158 1.9048 0 0.55665
1 
0 0 0 0 0 0 
639 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
640 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
641 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
642 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
643 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
644 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
645 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
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646 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
647 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
648 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
649 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
650 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 




0 -0.52943 1 0.428836 -4.06158 
652 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
653 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
654 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
655 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
656 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
657 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






-0.00106 0.998173 0.003373 -0.00813 
659 0 0 1.46809 2.93619 0 0.33333
3 
0 0 0 0 0 0 
660 0 0 1.46809 2.93619 0 0.33333
3 
0 0 0 0 0 0 
661 0 0 1.46809 2.93619 0 0.33333
3 
0 0 0 0 0 0 
662 0 0 1.36301 3.04128 0 0.30947
3 
0 0 0 0 0 0 
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663 0 0 1.34341 2.93619 0 0.31391 0 0 0 0 0 0 




0 -0.74438 1 0.305023 -5.71051 
665 0 0 1.03883 3.10198 0 0.25087
7 
0 0 0 0 0 0 
666 0 1 1.03883 2.83318 0 0.26829
2 
0 0.35296 0.35296 0.731708 0.268292 2.70775 
667 0 0 1.46809 2.93619 0 0.33333
3 
0 0 0 0 0 0 
668 0 0 1.03883 3.10198 0 0.25087
7 
0 0 0 0 0 0 
669 0 0 1.46809 2.93619 0 0.33333
3 
0 0 0 0 0 0 
670 0 0 1.34341 3.06088 0 0.30502
3 
0 0 0 0 0 0 
671 0 0 1.46809 2.93619 0 0.33333
3 
0 0 0 0 0 0 
672 0 0 1.46809 2.93619 0 0.33333
3 
0 0 0 0 0 0 
673 0 0 2.8115 1.59278 0 0.63835
6 
0 0 0 0 0 0 
674 0 0 1.34341 3.06088 0 0.30502
3 
0 0 0 0 0 0 
675 0 0 1.46809 2.93619 0 0.33333
3 
0 0 0 0 0 0 
676 0 0 1.34341 3.06088 0 0.30502
3 
0 0 0 0 0 0 
677 0 0 1.46809 2.93619 0 0.33333
3 
0 0 0 0 0 0 






0.998312 0.001688 0.010844 
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679 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
680 0 0 1.04291 2.83984 0 0.2686 0 0 0 0 0 0 
681 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
682 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
683 21 1 1.47366 2.94789 0.954545 0.33329 14.2502 0.33922
5 
-13.911 1 1.43E-09 -106.719 
684 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
685 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0.22634 0.22634 0.999226 0.000774 1.73638 






0.666705 0.333295 2.6024 
688 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
689 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
690 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
691 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
692 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
693 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
694 0 0 1.49353 1.57935 0 0.48603
5 
0 0 0 0 0 0 
695 0 0 1.47385 2.82253 0 0.34304
5 
0 0 0 0 0 0 
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0.994606 0.005394 1.74444 
697 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
698 2 0 1.02294 3.13411 1 0.24607
3 
1.95515 0 -1.95515 1 0.060552 -14.9991 
699 0 0 1.49353 2.92803 0 0.33778
4 
0 0 0 0 0 0 
700 0 0 1.49353 1.57935 0 0.48603
5 
0 0 0 0 0 0 
701 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
702 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
703 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
704 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
705 23 0 1.47385 2.9477 1 0.33333
3 
15.6054 0 -15.6054 1 1.06E-11 -119.717 
706 2 0 1.47385 2.9477 1 0.33333
3 
1.35699 0 -1.35699 1 0.111111 -10.4102 
707 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
709 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
710 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
711 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
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712 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
713 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
714 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
715 0 0 2.82253 1.59903 0 0.63835
6 
0 0 0 0 0 0 
716 0 0 1.47385 2.40889 0 0.37959 0 0 0 0 0 0 
717 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
718 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
719 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
720 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
721 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
722 0 0 1.74491 2.65697 0 0.3964 0 0 0 0 0 0 
723 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
724 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
726 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
727 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 




0 0 0 0 0 0 
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729 0 0 1.74491 2.65697 0 0.3964 0 0 0 0 0 0 
730 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
731 23 0 1.47385 2.9477 1 0.33333
3 
15.6054 0 -15.6054 1 1.06E-11 -119.717 
732 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
733 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
734 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
735 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
736 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
737 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
738 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
739 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
740 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
741 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






0.666776 0.333224 2.60212 
743 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 






0.666667 0.333333 2.60255 
745 3 0 1.47385 2.9477 1 0.33333
3 
2.03548 0 -2.03548 1 0.037037 -15.6153 
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746 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
747 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
748 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
749 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
750 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
751 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
752 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
753 2 0 1.47385 2.9477 1 0.33333
3 
1.35699 0 -1.35699 1 0.111111 -10.4102 
754 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
755 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0.73049 0.26951 2.71393 
757 0 0 0 4.42155 0 0 0 0 0 0 0 0 
758 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
759 0 0 1.74491 2.65697 0 0.3964 0 0 0 0 0 0 
760 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 -0.67849 1 0.333333 -5.2051 
762 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
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763 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
764 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
765 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
766 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
767 23 0 1.47385 2.9477 1 0.33333
3 
15.6054 0 -15.6054 1 1.06E-11 -119.717 
768 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
770 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
771 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
772 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 






0.666703 0.333297 2.60241 
774 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
775 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
776 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
777 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
778 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
779 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 
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780 0 0 2.39158 1.9048 0 0.55665
1 
0 0 0 0 0 0 
781 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
783 20 0 1.47385 2.9477 1 0.33333
3 
13.5699 0 -13.5699 1 2.87E-10 -104.102 
784 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
785 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
786 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
787 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
788 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
789 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
790 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
791 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 




0 0 0 0 0 0 
794 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
795 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
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0 0 0 0 0 0 
797 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 -0.67849 1 0.333333 -5.2051 
799 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
801 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 
802 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
803 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
804 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
805 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
806 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
807 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 




0 0 0 0 0 0 
809 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 






0.667831 0.332169 2.59801 
811 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
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812 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
813 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
814 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 




0 0 0 0 0 0 




0 0 0 0 0 0 
817 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 




0 0 0 0 0 0 
819 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
820 0 0 2.39158 1.9048 0 0.55665
1 
0 0 0 0 0 0 
821 0 0 2.82253 1.59903 0 0.63835
6 
0 0 0 0 0 0 
822 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
824 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
825 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0.00701 0 -0.00701 1 0.000383 -0.05378 
827 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
828 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
829 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
830 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 




0 0 0 0 0 0 
832 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 




2.25355 4.09375 1.8402 0.476337 0.840248 14.1172 
834 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
835 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
836 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
837 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
838 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
839 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
840 0 0 2.39158 1.9048 0 0.55665
1 
0 0 0 0 0 0 
841 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
843 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
844 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
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845 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
846 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
847 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
848 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
849 0 0 1.74491 2.65697 0 0.3964 0 0 0 0 0 0 
850 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
851 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
852 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
853 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
854 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 
855 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
856 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
857 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
858 0 0 1.47385 2.82253 0 0.34304
5 
0 0 0 0 0 0 
859 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
860 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
861 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
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0 0 0 0 0 0 
863 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
864 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
865 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
866 0 0 1.47385 2.40889 0 0.37959 0 0 0 0 0 0 
867 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
868 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
869 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
870 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
871 0 0 1.74491 2.65697 0 0.3964 0 0 0 0 0 0 
872 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
873 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
874 0 0 2.82253 1.59903 0 0.63835
6 
0 0 0 0 0 0 
875 0 0 1.04291 2.83984 0 0.2686 0 0 0 0 0 0 
876 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
877 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
878 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
Appendix 4 Chapter 7 Analysis of Selective Pressure  




0 0.25063 0.25063 0.902384 0.097616 1.92272 
880 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
881 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
882 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
883 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
884 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
885 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
886 0 1 1.47385 2.94568 0 0.33348
6 
0 0.33948 0.33948 0.666514 0.333486 2.60434 
887 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 






0.694905 0.305095 2.49679 
889 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
890 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
892 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
893 0 0 1.74491 2.65697 0 0.3964 0 0 0 0 0 0 
894 0 0 2.82253 1.59903 0 0.63835
6 
0 0 0 0 0 0 
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895 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
896 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
897 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 
898 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
899 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
901 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
902 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
903 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
904 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
905 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
906 0 0 0 4.42155 0 0 0 0 0 0 0 0 
907 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
908 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
909 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
910 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
911 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
912 20 0 1.34868 3.0532 1 0.30638
6 
14.8294 0 -14.8294 1 5.31E-11 -113.764 
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913 0 0 0 4.42155 0 0 0 0 0 0 0 0 
914 0 5 0.41236 2.68336 0 0.13320
3 
0 1.86334 1.86334 0.489313 0.510687 14.2947 
915 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
916 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
917 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
918 0 1 1.47385 2.94568 0 0.33348
6 
0 0.33948 0.33948 0.666514 0.333486 2.60434 
919 0 0 1.47385 2.82253 0 0.34304
5 
0 0 0 0 0 0 
920 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
921 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
922 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
923 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
924 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
925 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
926 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
927 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
928 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
929 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
930 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
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931 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
932 20 0 1.34868 2.9477 1 0.31391 14.8294 0 -14.8294 1 8.63E-11 -113.764 
933 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 
934 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
935 0 0 2.39158 1.9048 0 0.55665
1 
0 0 0 0 0 0 
936 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
937 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
938 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
939 0 0 0 4.42155 0 0 0 0 0 0 0 0 
940 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
941 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
942 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
943 0 0 0 4.42155 0 0 0 0 0 0 0 0 
944 0 0 1.04291 2.83984 0 0.2686 0 0 0 0 0 0 
945 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
946 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
947 6 0 1.34868 2.9477 1 0.31391 4.44881 0 -4.44881 1 0.000957 -34.1293 
948 18 0 1.47385 2.9477 1 0.33333
3 
12.2129 0 -12.2129 1 2.58E-09 -93.6918 
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949 0 0 1.47385 2.82253 0 0.34304
5 
0 0 0 0 0 0 
950 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
951 0 0 1.74491 2.65697 0 0.3964 0 0 0 0 0 0 






0.666667 0.333333 2.60255 
953 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
954 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
956 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
957 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
958 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
959 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
960 0 0 0 3.62909 0 0 0 0 0 0 0 0 
961 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
962 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
963 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
964 0 0 2.39158 1.9048 0 0.55665
1 
0 0 0 0 0 0 
965 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
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-0.00024 0.998594 0.00225 -0.00181 
967 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
968 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
969 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
970 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
971 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
972 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
973 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
975 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
976 12.3333 0 1.36835 3.0532 1 0.30947
3 
9.01328 0 -9.01328 1 1.21E-06 -69.1458 
977 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
978 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 




0 0 0 0 0 0 
980 0 0 2.39158 1.9048 0 0.55665
1 
0 0 0 0 0 0 
981 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
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982 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
983 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
984 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
985 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
986 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
987 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 




0 0 0 0 0 0 
989 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
990 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
991 0 0 1.47385 2.82253 0 0.34304
5 
0 0 0 0 0 0 




0 0 0 0 0 0 
993 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
994 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 




0 0 0 0 0 0 
996 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 -0.73081 1 0.309473 -5.60641 
998 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
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999 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
1001 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1002 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
1004 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1005 1 0 2.8208 1.60076 1 0.63796
5 
0.35451 0 -0.35451 1 0.637965 -2.71964 
1006 0 0 1.47385 2.40889 0 0.37959 0 0 0 0 0 0 
1007 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1008 0 0 0 4.42155 0 0 0 0 0 0 0 0 
1009 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
1010 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1011 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1012 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1013 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1014 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1015 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
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1016 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1017 0 0 1.04291 2.83984 0 0.2686 0 0 0 0 0 0 
1018 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1019 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1020 4 14 1.42598 2.91702 0.222222 0.32833
9 
2.8051 4.79941 1.99432 0.244898 0.890344 15.2995 
1021 1 0 0.39706 3.75999 1 0.09551
5 
2.51851 0 -2.51851 1 0.095515 -19.3209 
1022 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
1024 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1025 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1026 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1027 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1028 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1029 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1030 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
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1032 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1033 0 0 2.82253 1.59903 0 0.63835
6 
0 0 0 0 0 0 
1034 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 -0.96154 1 0.250176 -7.37653 
1036 0 0 2.39158 1.9048 0 0.55665
1 
0 0 0 0 0 0 
1037 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1038 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
1040 0 0 2.82253 1.59903 0 0.63835
6 
0 0 0 0 0 0 
1041 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1042 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1043 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1044 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1045 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1046 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1047 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
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1048 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 -0.67849 1 0.333333 -5.2051 
1050 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1051 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 






0.620681 0.379319 3.18102 
1053 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1054 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
1056 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
1057 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1058 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1059 3 0 1.34868 3.07288 1 0.30502
3 
2.22441 0 -2.22441 1 0.028379 -17.0646 






0.666667 0.333333 2.60255 
1061 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1062 0 0 1.04291 2.83984 0 0.2686 0 0 0 0 0 0 




0 0 0 0 0 0 




0 -0.74147 1 0.305023 -5.68821 
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0 -0.67849 1 0.333333 -5.2051 
1066 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 




0 0 0 0 0 0 




0 -0.74147 1 0.305023 -5.68821 
1069 0 0 1.20934 2.9477 0 0.29091
4 
0 0 0 0 0 0 
1070 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1071 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
1072 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1073 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1074 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1075 0 0 1.74491 2.65697 0 0.3964 0 0 0 0 0 0 
1076 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1077 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 -0.35611 1 0.635704 -2.73189 
1079 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1080 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1081 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
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0 -0.00188 1 0.001126 -0.01446 




-1.01759 0.962929 0.259395 -7.80646 




0 0 0 0 0 0 




0 0 0 0 0 0 
1086 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1087 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1088 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1089 3 0 1.47385 2.9477 1 0.33333
3 
2.03548 0 -2.03548 1 0.037037 -15.6153 
1090 0 0 1.04291 2.83984 0 0.2686 0 0 0 0 0 0 
1091 0 0 1.47385 2.82253 0 0.34304
5 
0 0 0 0 0 0 
1092 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1093 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 -0.00188 1 0.001126 -0.01446 
1095 9 0 1.47385 2.9462 1 0.33344
7 
6.10645 0 -6.10645 1 5.10E-05 -46.8459 
1096 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1097 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
1098 0 0 1.74491 2.65697 0 0.3964 0 0 0 0 0 0 
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1099 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1100 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 
1101 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1102 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 
1103 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1104 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
1106 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 
1107 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
1109 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1110 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
1111 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
1113 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1114 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1115 0 0 1.47385 2.40889 0 0.37959 0 0 0 0 0 0 
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1116 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1117 6 0 1.34868 3.0532 1 0.30638
6 
4.44881 0 -4.44881 1 0.000827 -34.1293 
1118 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1119 0 0 1.04291 2.02997 0 0.33939 0 0 0 0 0 0 
1120 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1121 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1122 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
1124 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1125 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1126 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1127 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1128 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1129 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1130 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1131 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
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1132 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1133 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1134 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1135 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
1136 10 0 1.34868 3.07288 1 0.30502
3 
7.41468 0 -7.41468 1 6.97E-06 -56.8821 
1137 0 0 0 4.42155 0 0 0 0 0 0 0 0 
1138 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1139 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1140 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1141 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
1142 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
1143 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1144 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1145 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1146 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1147 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
1149 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
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1150 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1151 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1152 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1153 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
1154 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1155 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1156 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 




0 -0.74147 1 0.305023 -5.68821 






0.443924 0.556076 5.21426 






0.666667 0.333333 2.60255 
1160 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1161 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1162 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1163 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1164 0 0 1.34868 3.0532 0 0.30638
6 
0 0 0 0 0 0 




0 0 0 0 0 0 
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1166 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1167 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1168 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1169 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1170 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1171 0 0 1.34868 2.9477 0 0.31391 0 0 0 0 0 0 
1172 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1173 0 0 1.36835 3.0532 0 0.30947
3 
0 0 0 0 0 0 
1174 0 0 1.04291 3.11414 0 0.25087
7 
0 0 0 0 0 0 
1175 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 
1176 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1177 0 0 1.34868 3.07288 0 0.30502
3 
0 0 0 0 0 0 
1178 0 0 1.47385 2.9477 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
1180 0 0 1.3623 3.03969 0 0.30947
3 
0 0 0 0 0 0 
1181 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
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1182 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
1184 0 0 0 3.61303 0 0 0 0 0 0 0 0 
1185 0 0 1.46733 2.81004 0 0.34304
5 
0 0 0 0 0 0 
1186 0 0 1.34271 2.93466 0 0.31391 0 0 0 0 0 0 
1187 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1188 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1189 0 0 1.46733 2.91507 0 0.33482
3 
0 0 0 0 0 0 
1190 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1191 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 
1192 0 0 1.34271 2.93466 0 0.31391 0 0 0 0 0 0 
1193 0 10 1.46733 2.91983 0 0.33446 0 3.42486 3.42486 0.017051 0.982949 26.2739 
1194 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 






-0.00291 0.999681 0.000479 -0.02229 
1196 1 0 1.46733 2.93466 1 0.33333
3 
0.68151 0 -0.68151 1 0.333333 -5.22824 
1197 2 0 1.3623 3.03969 1 0.30947
3 
1.46811 0 -1.46811 1 0.095774 -11.2627 
1198 1 0 1.46733 2.93466 1 0.33333
3 
0.68151 0 -0.68151 1 0.333333 -5.22824 




-12.6136 1 1.17E-08 -96.766 
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1200 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1201 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 






0.444957 0.555043 5.22522 




0 0 0 0 0 0 
1204 0 0 1.34271 2.93466 0 0.31391 0 0 0 0 0 0 
1205 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1206 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1207 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 




0 2.23985 2.23985 0.410906 0.589094 17.1831 
1209 1 0 1.46733 2.93466 1 0.33333
3 
0.68151 0 -0.68151 1 0.333333 -5.22824 
1210 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1211 0 0 1.34271 2.93466 0 0.31391 0 0 0 0 0 0 
1212 0 0 1.03829 2.02099 0 0.33939 0 0 0 0 0 0 




0 -0.74476 1 0.305023 -5.71349 
1214 0 0 1.3623 3.03969 0 0.30947
3 
0 0 0 0 0 0 
1215 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1216 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
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1217 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 
1218 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1219 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1220 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1221 1 0 1.46733 2.93466 1 0.33333
3 
0.68151 0 -0.68151 1 0.333333 -5.22824 
1222 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1223 3 0 1.46733 2.93466 1 0.33333
3 
2.04453 0 -2.04453 1 0.037037 -15.6847 
1224 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1225 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 
1226 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 




-1.70398 0.987659 0.111084 -13.0722 
1228 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1229 0 0 1.3623 3.03969 0 0.30947
3 
0 0 0 0 0 0 
1230 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 
1231 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 
1232 0 0 1.03829 2.02099 0 0.33939 0 0 0 0 0 0 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
1233 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
1235 0 0 1.73718 2.64521 0 0.3964 0 0 0 0 0 0 
1236 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
1238 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 
1239 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 
1240 0 0 1.03829 3.10036 0 0.25087
7 
0 0 0 0 0 0 
1241 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 




0.66674 0.33326 2.61383 
1243 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 
1244 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1245 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
1247 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1248 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 
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1249 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 
1250 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1251 3 0 1.46733 2.93466 1 0.33333
3 
2.04453 0 -2.04453 1 0.037037 -15.6847 
1252 0 0 2.81004 1.59195 0 0.63835
6 
0 0 0 0 0 0 
1253 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
1255 0 0 1.3623 3.03969 0 0.30947
3 
0 0 0 0 0 0 
1256 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 
1257 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1258 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1259 0 0 2.381 1.89637 0 0.55665
1 
0 0 0 0 0 0 
1260 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1261 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 
1262 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1263 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1264 2 0 1.34271 2.93466 1 0.31391 1.48953 0 -1.48953 1 0.098539 -11.427 
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0 0 0 0 0 0 
1266 0 0 0 4.40199 0 0 0 0 0 0 0 0 
1267 0 0 1.73718 2.64521 0 0.3964 0 0 0 0 0 0 
1268 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1269 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1270 0 0 1.03829 2.02099 0 0.33939 0 0 0 0 0 0 
1271 0 0 1.03829 2.02099 0 0.33939 0 0 0 0 0 0 
1272 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1273 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1274 0 0 1.03829 3.10036 0 0.25087
7 
0 0 0 0 0 0 
1275 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1276 1 0 1.46733 2.93466 1 0.33333
3 
0.68151 0 -0.68151 1 0.333333 -5.22824 
1277 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
1279 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1280 0 0 1.34271 2.93466 0 0.31391 0 0 0 0 0 0 




0 0 0 0 0 0 
1282 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 
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1283 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1284 0 0 1.03829 3.10036 0 0.25087
7 
0 0 0 0 0 0 




0 0 0 0 0 0 
1286 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1287 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1288 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 
1289 0 0 1.34271 2.93466 0 0.31391 0 0 0 0 0 0 
1290 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1291 0 0 1.34271 2.93466 0 0.31391 0 0 0 0 0 0 
1292 0 0 1.34271 2.93466 0 0.31391 0 0 0 0 0 0 
1293 0 0 1.29906 2.95984 0 0.30502
3 
0 0 0 0 0 0 
1294 0 0 1.03829 3.10036 0 0.25087
7 
0 0 0 0 0 0 
1295 0 0 0 3.61303 0 0 0 0 0 0 0 0 
1296 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1297 0 0 0 3.61303 0 0 0 0 0 0 0 0 
1298 0 0 1.34271 2.93466 0 0.31391 0 0 0 0 0 0 
1299 0 0 1.3623 3.03969 0 0.30947
3 
0 0 0 0 0 0 
1300 0 0 0 3.61303 0 0 0 0 0 0 0 0 
1301 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
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1302 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 




0 -0.74476 1 0.305023 -5.71349 
1304 0 0 1.3623 3.03969 0 0.30947
3 
0 0 0 0 0 0 
1305 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1306 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1307 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1308 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1309 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1310 0 0 2.381 1.89637 0 0.55665
1 
0 0 0 0 0 0 
1311 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1312 0 0 2.81004 1.59195 0 0.63835
6 
0 0 0 0 0 0 






0.693617 0.306383 2.52375 
1314 0 2 1.46733 2.93466 0 0.33333
3 
0 0.68151 0.68151 0.444444 0.555556 5.22824 
1315 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 
1316 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
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1318 0 0 2.81004 1.59195 0 0.63835
6 
0 0 0 0 0 0 
1319 0 0 1.34271 3.03969 0 0.30638
6 
0 0 0 0 0 0 
1320 0 0 1.34271 3.03969 0 0.30638
6 
0 0 0 0 0 0 
1321 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1322 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1323 0 0 1.34271 3.03969 0 0.30638
6 
0 0 0 0 0 0 
1324 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1325 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1326 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 
1327 0 0 1.34271 3.03969 0 0.30638
6 
0 0 0 0 0 0 
1328 0 0 0 4.40199 0 0 0 0 0 0 0 0 
1329 0 0 1.46733 2.39823 0 0.37959 0 0 0 0 0 0 
1330 0 0 1.03829 3.10036 0 0.25087
7 
0 0 0 0 0 0 
1331 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 




0 0 0 0 0 0 






0.693174 0.306826 2.52521 
1334 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 
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1335 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1336 0 0 1.34271 3.03969 0 0.30638
6 
0 0 0 0 0 0 
1337 0 0 1.34271 3.03969 0 0.30638
6 
0 0 0 0 0 0 




0 -0.74476 1 0.305023 -5.71349 
1339 0 0 1.20399 2.93466 0 0.29091
4 
0 0 0 0 0 0 
1340 1 0 1.34271 2.93466 1 0.31391 0.74476
4 
0 -0.74476 1 0.31391 -5.71349 




0 0 0 0 0 0 
1342 0 0 1.03829 2.82727 0 0.2686 0 0 0 0 0 0 
1343 0 0 1.34271 2.93466 0 0.31391 0 0 0 0 0 0 
1344 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 
1345 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 








0.897896 0.102104 2.21145 
1347 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1348 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 




0 0 0 0 0 0 
1350 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1351 0 0 1.34271 3.05928 0 0.30502
3 
0 0 0 0 0 0 
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1352 0 0 1.46733 2.93466 0 0.33333
3 
0 0 0 0 0 0 
1353 0 0 0 0 0 0 0 0 0 0 0 0 
1354 0 0 1.29906 2.95984 0 0.30502
3 










dN=dS) Log(L) LRT  Selection 
1 0 0 0 Undefined 0 0 0 0 1  
2 0 0 0 Undefined 0 0 0 0 1  
3 0 0 0 Undefined 0 0 0 0 1  
4 0 0 0 Undefined 0 0 0 0 1  
5 0 0 0 Undefined 0 0 0 0 1  
6 0 0 0 Undefined 0 0 0 0 1  
7 0 0 0 Undefined 0 0 0 0 1  
8 0 0 0 Undefined 0 0 0 0 1  
9 0 0 0 Undefined 0 0 0 0 1  
10 0 0 0 Undefined 0 0 0 0 1  
11 0 0 0 Undefined 0 0 0 0 1  
12 0 0 0 Undefined 0 0 0 0 1  
13 0 0 0 Undefined 0 0 0 0 1  
14 0 0 0 Undefined 0 0 0 0 1  
15 0 0 0 Undefined 0 0 0 0 1  
16 0 0 0 Undefined 0 0 0 0 1  
17 0 0 0 Undefined 0 0 0 0 1  
18 0 0 0 Undefined 0 0 0 0 1  
19 0 0 0 Undefined 0 0 0 0 1  
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20 0 0 0 Undefined 0 0 0 0 1  
21 0 0 0 Undefined 0 0 0 0 1  
22 0 0 0 Undefined 0 0 0 0 1  
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24 0 0 0 Undefined 0 0 0 0 1  
25 0 0 0 Undefined 0 0 0 0 1  
26 5.26E-06 10.6722 4.99094 2028060 81.8694 2.68378 
-
20.7771 2.74562 0.097521 pos 
27 0 0 0 Undefined 0 0 0 0 1  
28 0 0 0 Undefined 0 0 0 0 1  
29 0 0 0 Undefined 0 0 0 0 1  
30 0 0 0 Undefined 0 0 0 0 1  
31 0 0 0 Undefined 0 0 0 0 1  
32 0 0 0 Undefined 0 0 0 0 1  
33 0 0 0 Undefined 0 0 0 0 1  
34 0 0 0 Undefined 0 0 0 0 1  
35 0 0 0 Undefined 0 0 0 0 1  
36 0 0 0 Undefined 0 0 0 0 1  
37 0 0 0 Undefined 0 0 0 0 1  
38 10.4021 0 0 0 -79.7975 7.80293 
-
16.9216 1.61869 0.203274  
39 0 0 0 Undefined 0 0 
-
4.25509 0 1  
40 0 0 0 Undefined 0 0 0 0 1  
41 0 0 0 Undefined 0 0 0 0 1  
42 0 0 0 Undefined 0 0 0 0 1  
43 0 0 0 Undefined 0 0 0 0 1  
44 0 0 0 Undefined 0 0 0 0 1  
45 0 0 0 Undefined 0 0 0 0 1  
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46 0 0 0 Undefined 0 0 0 0 1  
47 0 0 0 Undefined 0 0 0 0 1  
48 0 0 0 Undefined 0 0 0 0 1  
49 0 0 0 Undefined 0 0 0 0 1  
50 0 0 0 Undefined 0 0 0 0 1  
51 0 0 1.70134 Undefined 0 5.26E-06 
-
9.76387 4.48E-06 0.998311  
52 0 0 0 Undefined 0 0 0 0 1  
53 0 0 0 Undefined 0 0 0 0 1  
54 0 0 0 Undefined 0 0 0 0 1  
55 0 0 0 Undefined 0 0 0 0 1  
56 0 0 0 Undefined 0 0 0 0 1  
57 0 0 0 Undefined 0 0 0 0 1  
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59 0 0 0 Undefined 0 0 0 0 1  
60 0 0 0 Undefined 0 0 0 0 1  
61 1.52283 0 0 0 -11.682 1.40563 
-
12.5579 0.159245 0.689853  
62 0 0 0 Undefined 0 0 0 0 1  
63 0 0 0 Undefined 0 0 0 0 1  
64 0 0 0 Undefined 0 0 0 0 1  
65 0 0 0 Undefined 0 0 0 0 1  
66 0 0 0 Undefined 0 0 0 0 1  
67 0 0 0 Undefined 0 0 0 0 1  
68 0 0 0 Undefined 0 0 0 0 1  
69 0 0 0 Undefined 0 0 0 0 1  
70 0 0 0 Undefined 0 0 0 0 1  
71 0 0 0 Undefined 0 0 0 0 1  
72 0 0 0 Undefined 0 0 0 0 1  
Appendix 4 Chapter 7 Analysis of Selective Pressure  
73 0 0 0 Undefined 0 0 0 0 1  
74 0 0 0 Undefined 0 0 0 0 1  
75 0 0 0 Undefined 0 0 0 0 1  
76 0 0 0 Undefined 0 0 0 0 1  
77 0 0 0 Undefined 0 0 0 0 1  
78 0 0 0 Undefined 0 0 0 0 1  
79 0 0 0 Undefined 0 0 0 0 1  
80 0 0 0 Undefined 0 0 0 0 1  
81 0 0 0 Undefined 0 0 0 0 1  
82 0 0 0 Undefined 0 0 0 0 1  
83 0 0 0 Undefined 0 0 0 0 1  
84 0 0 0 Undefined 0 0 0 0 1  
85 0 0 0 Undefined 0 0 0 0 1  
86 20.218 0 0 0 -155.098 14.1673 
-
20.6563 3.17663 0.074699 neg 
87 0 0 0 Undefined 0 0 0 0 1  
88 0 0 0 Undefined 0 0 0 0 1  
89 0 0 0 Undefined 0 0 0 0 1  
90 0 0 0 Undefined 0 0 0 0 1  
91 0 0 0 Undefined 0 0 
-
3.50904 0 1  
92 0 0 0 Undefined 0 0 0 0 1  
93 0 0 0 Undefined 0 0 0 0 1  
94 5.03E-16 19.0244 4.43563 3.78E+16 145.941 1.37633 
-
15.5813 5.24808 0.021971 pos 
95 0 0 0 Undefined 0 0 0 0 1  
96 0 0 0 Undefined 0 0 0 0 1  
97 4.21E-14 0 3.11982 0 -3.23E-13 0 
-
16.3807 0 1  
98 5.59E-14 0 10.2772 0 -4.29E-13 9.87E-15 -12.91 0 1  
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99 0 0 0 Undefined 0 0 0 0 1  
100 0 0 0 Undefined 0 0 0 0 1  
101 0 0 0 Undefined 0 0 0 0 1  
102 0 0 0 Undefined 0 0 0 0 1  
103 0 0 0 Undefined 0 0 0 0 1  
104 0 0 0 Undefined 0 0 0 0 1  
105 0 0 0 Undefined 0 0 0 0 1  
106 0 0 1.70132 Undefined 0 5.26E-06 
-
10.0533 4.48E-06 0.998311  
107 0 0 0 Undefined 0 0 0 0 1  
108 0 0 6.12433 Undefined 0 3.64E-16 
-
12.5697 0 1  
109 0 0 0 Undefined 0 0 0 0 1  
110 0 0 0 Undefined 0 0 0 0 1  
111 0 0 0 Undefined 0 0 0 0 1  
112 28.6869 0 0 0 -220.066 16.3633 
-
23.3947 5.68564 0.017104 neg 
113 0 0 0 Undefined 0 0 0 0 1  
114 0 0 0 Undefined 0 0 0 0 1  
115 0 0 0 Undefined 0 0 0 0 1  
116 0 0 0 Undefined 0 0 0 0 1  
117 0 0 0 Undefined 0 0 0 0 1  
118 0 0 0 Undefined 0 0 0 0 1  
119 0 0 0 Undefined 0 0 0 0 1  
120 0 0 0 Undefined 0 0 0 0 1  
121 0 0 0 Undefined 0 0 0 0 1  
122 0 0 0 Undefined 0 0 0 0 1  
123 0 0 0 Undefined 0 0 0 0 1  
124 0 0 0 Undefined 0 0 0 0 1  
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125 4.86E-15 0 9.5399 0 -3.73E-14 1.00E-06 
-
10.6078 5.64E-07 0.999401  
126 1.49127 0 0 0 -11.44 1.23162 
-
9.71818 0.381356 0.536878  
127 0 0 0 Undefined 0 0 0 0 1  
128 0 0 0 Undefined 0 0 0 0 1  
129 0 0 0 Undefined 0 0 0 0 1  
130 0 0 0 Undefined 0 0 0 0 1  
131 0 0 0 Undefined 0 0 0 0 1  
132 0 0 0 Undefined 0 0 0 0 1  
133 1.00E-06 0 5.09065 0 -7.67E-06 1.00E-06 
-
10.6987 9.46E-08 0.999755  
134 0 0 0 Undefined 0 0 0 0 1  
135 0 0 1.70126 Undefined 0 0 
-
11.1518 0 1  
136 0 0 0 Undefined 0 0 0 0 1  
137 1.00E-06 0 5.0883 0 -7.67E-06 1.00E-06 
-
14.2794 9.45E-08 0.999755  
138 0 0 0 Undefined 0 0 0 0 1  
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140 0 0 0 Undefined 0 0 0 0 1  
141 0 0 0 Undefined 0 0 0 0 1  
142 0 0 0 Undefined 0 0 0 0 1  
143 0 0 0 Undefined 0 0 0 0 1  
144 0 0 0 Undefined 0 0 0 0 1  
145 0 0 0 Undefined 0 0 0 0 1  
146 0 0 0 Undefined 0 0 0 0 1  
147 0 0 0 Undefined 0 0 0 0 1  
148 0 0 0 Undefined 0 0 0 0 1  
149 0 0 0 Undefined 0 0 0 0 1  
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150 0 0 0 Undefined 0 0 0 0 1  
151 0 0 0 Undefined 0 0 0 0 1  
152 0 0 0 Undefined 0 0 0 0 1  
153 0 0 0 Undefined 0 0 0 0 1  
154 0 0 0 Undefined 0 0 0 0 1  
155 0 0 0 Undefined 0 0 0 0 1  
156 0 0 0 Undefined 0 0 0 0 1  
157 0 0 0 Undefined 0 0 0 0 1  
158 7.29E-15 25.3826 0 3.48E+15 194.717 3.50243 
-
9.56125 3.97779 0.046104 pos 
159 0 0 0 Undefined 0 0 0 0 1  
160 0 0 0 Undefined 0 0 0 0 1  
161 0.922886 0 0 0 -7.07971 0 
-
4.60369 0 1  
162 0 0 0 Undefined 0 0 0 0 1  
163 0 0 0 Undefined 0 0 0 0 1  
164 0 0 0 Undefined 0 0 0 0 1  
165 0 0 0 Undefined 0 0 0 0 1  
166 7.23E-15 0 9.13318 0 -5.55E-14 5.97E-15 
-
13.2951 0 1  
167 6.93E-15 0 2.67036 0 -5.32E-14 0 
-
8.32652 0 1  
168 0 0 0 Undefined 0 0 0 0 1  
169 0 0 0 Undefined 0 0 0 0 1  
170 29.0918 0 0 0 -223.171 19.9598 
-
25.8623 4.45717 0.034755 neg 
171 0 0 0 Undefined 0 0 0 0 1  
172 0 0 0 Undefined 0 0 0 0 1  
173 0 0 0 Undefined 0 0 0 0 1  
174 0 0 0 Undefined 0 0 0 0 1  
175 0 0 0 Undefined 0 0 0 0 1  
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176 0 0 0 Undefined 0 0 0 0 1  
177 0 0 0 Undefined 0 0 0 0 1  
178 0 0 0 Undefined 0 0 0 0 1  
179 0 0 0 Undefined 0 0 0 0 1  
180 0 0 0 Undefined 0 0 0 0 1  
181 0 0 0 Undefined 0 0 0 0 1  
182 0 0 0 Undefined 0 0 0 0 1  
183 0 0 0 Undefined 0 0 0 0 1  
184 0 0 0 Undefined 0 0 0 0 1  
185 0 0 0 Undefined 0 0 0 0 1  
186 0 0 0 Undefined 0 0 0 0 1  
187 0 0 0 Undefined 0 0 0 0 1  
188 0 0 0 Undefined 0 0 0 0 1  
189 0 0 0 Undefined 0 0 0 0 1  
190 0 0 0 Undefined 0 0 0 0 1  
191 0 0 0 Undefined 0 0 0 0 1  
192 0 0 0 Undefined 0 0 0 0 1  
193 4.07888 0 0 0 -31.2902 3.66799 
-
9.23983 0.203632 0.651805  
194 6.06E-15 11.532 0 1.9E+15 88.4655 2.98088 
-
6.97278 2.70501 0.100034 pos 
195 0 0 0 Undefined 0 0 0 0 1  
196 0 0 0 Undefined 0 0 0 0 1  
197 0 0 0 Undefined 0 0 0 0 1  
198 0 0 4.39157 Undefined 0 1.00E-06 
-
12.2752 1.46E-06 0.999035  
199 0 0 0 Undefined 0 0 0 0 1  
200 0 0 0 Undefined 0 0 0 0 1  
201 1.00E-06 0 3.43605 0 -7.67E-06 0 -10.314 
-5.11E-
07 1  
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202 0 0 0 Undefined 0 0 0 0 1  
203 0 0 0 Undefined 0 0 0 0 1  
204 0 0 0 Undefined 0 0 0 0 1  
205 0 0 0 Undefined 0 0 0 0 1  
206 0 0 0 Undefined 0 0 0 0 1  
207 0 0 0 Undefined 0 0 0 0 1  
208 6.48325 0 0 0 -49.7348 5.64531 
-
20.8445 1.08389 0.297828  
209 0 0 0 Undefined 0 0 0 0 1  
210 0 0 0 Undefined 0 0 0 0 1  
211 48.236 0 0 0 -370.032 14.1203 
-
20.0209 4.94727 0.026132 neg 
212 0 0 0 Undefined 0 0 0 0 1  
213 0 0 0 Undefined 0 0 0 0 1  
214 0 0 0 Undefined 0 0 0 0 1  
215 0 0 0 Undefined 0 0 0 0 1  
216 0 0 0 Undefined 0 0 0 0 1  
217 0 0 0 Undefined 0 0 0 0 1  
218 0 0 0 Undefined 0 0 0 0 1  
219 0 0 0 Undefined 0 0 0 0 1  
220 0 0 0 Undefined 0 0 0 0 1  
221 0 0 0 Undefined 0 0 0 0 1  
222 0 0 0 Undefined 0 0 0 0 1  
223 0 0 0 Undefined 0 0 0 0 1  
224 0 0 0 Undefined 0 0 0 0 1  
225 2.02971 0 0 0 -15.5704 1.73528 
-
13.4298 0.312607 0.576085  
226 0 0 0 Undefined 0 0 0 0 1  
227 0 0 0 Undefined 0 0 0 0 1  
228 0 0 0 Undefined 0 0 0 0 1  
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229 0 0 0 Undefined 0 0 0 0 1  
230 0 0 0 Undefined 0 0 0 0 1  
231 4.02843 0 0 0 -30.9032 3.12053 
-
9.82911 0.494792 0.481797  
232 0 0 0 Undefined 0 0 0 0 1  
233 0 0 0 Undefined 0 0 0 0 1  
234 0 0 0 Undefined 0 0 0 0 1  
235 0 0 0 Undefined 0 0 0 0 1  
236 0 0 0 Undefined 0 0 0 0 1  
237 1.57484 0 0 0 -12.081 1.36774 
-
8.82435 0.280821 0.596163  
238 0 0 0 Undefined 0 0 0 0 1  
239 0 0 0 Undefined 0 0 0 0 1  
240 0 0 0 Undefined 0 0 0 0 1  
241 0 0 0 Undefined 0 0 0 0 1  
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243 0 0 0 Undefined 0 0 0 0 1  
244 0 0 0 Undefined 0 0 0 0 1  
245 0 0 0 Undefined 0 0 0 0 1  
246 0 0 0 Undefined 0 0 0 0 1  
247 0 0 0 Undefined 0 0 0 0 1  
248 0 0 0 Undefined 0 0 0 0 1  
249 0 0 0 Undefined 0 0 0 0 1  
250 0 0 0 Undefined 0 0 0 0 1  
251 0 0 0 Undefined 0 0 0 0 1  
252 0 0 0 Undefined 0 0 0 0 1  
253 0 0 0 Undefined 0 0 0 0 1  
254 0 0 0 Undefined 0 0 0 0 1  
255 0 0 0 Undefined 0 0 0 0 1  
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256 0 0 0 Undefined 0 0 0 0 1  
257 0 0 0 Undefined 0 0 0 0 1  
258 0 0 0 Undefined 0 0 0 0 1  
259 0 0 0 Undefined 0 0 0 0 1  
260 0 0 0 Undefined 0 0 0 0 1  
261 0 0 0 Undefined 0 0 0 0 1  
262 0 0 0 Undefined 0 0 0 0 1  
263 0 0 0 Undefined 0 0 0 0 1  
264 0 0 0 Undefined 0 0 0 0 1  
265 0 0 0 Undefined 0 0 0 0 1  
266 0 0 0 Undefined 0 0 0 0 1  
267 26.4001 0 0 0 -202.523 5.93627 
-
9.49301 3.00985 0.08276 neg 
268 0 0 0 Undefined 0 0 0 0 1  
269 0 0 0 Undefined 0 0 0 0 1  
270 0 0 0 Undefined 0 0 0 0 1  
271 0 0 0 Undefined 0 0 0 0 1  
272 0 0 0 Undefined 0 0 0 0 1  
273 0 0 0 Undefined 0 0 0 0 1  
274 0 0 0 Undefined 0 0 0 0 1  
275 1.49258 0 0 0 -11.45 1.37981 
-
10.3559 0.156203 0.692676  
276 0 0 0 Undefined 0 0 0 0 1  
277 0 0 0 Undefined 0 0 0 0 1  
278 0 0 0 Undefined 0 0 0 0 1  
279 0 0 0 Undefined 0 0 0 0 1  
280 0 0 0 Undefined 0 0 0 0 1  
281 0 0 0 Undefined 0 0 0 0 1  
282 3.02033 0 0 0 -23.1698 2.60775 
-
13.4465 0.582892 0.445181  
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283 0 0 0 Undefined 0 0 0 0 1  
284 0 0 0 Undefined 0 0 0 0 1  
285 0 0 0 Undefined 0 0 
-
3.67712 0 1  
286 0 0 0 Undefined 0 0 0 0 1  
287 0 0 0 Undefined 0 0 0 0 1  
288 24.6399 0 0 0 -189.02 19.806 
-
23.8814 1.70749 0.191312 neg 
289 0 0 0 Undefined 0 0 
-
3.39368 0 1  
290 0 0 0 Undefined 0 0 0 0 1  
291 0 0 0 Undefined 0 0 0 0 1  
292 0 0 0 Undefined 0 0 0 0 1  
293 64.8798 0 0 0 -497.711 51.861 
-
38.6753 7.38992 0.006559 neg 
294 0 0 0 Undefined 0 0 0 0 1  
295 0 0 0 Undefined 0 0 0 0 1  
296 0 0 0 Undefined 0 0 0 0 1  
297 0 0 0 Undefined 0 0 0 0 1  
298 1.55534 0 0 0 -11.9314 1.36324 
-
10.6078 0.262484 0.608419  
299 0 0 0 Undefined 0 0 0 0 1  
300 0 0 0 Undefined 0 0 0 0 1  
301 2.60E-15 9.80244 4.59931 3.76E+15 75.1972 2.6283 
-
21.8028 2.63121 0.104782 pos 
302 0 0 0 Undefined 0 0 0 0 1  
303 0 0 0 Undefined 0 0 0 0 1  
304 4.38E-14 0 10.3208 0 -3.36E-13 1.08E-14 
-
14.3683 0 1  
305 0 0 0 Undefined 0 0 0 0 1  
306 0 0 0 Undefined 0 0 0 0 1  
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307 0 0 0 Undefined 0 0 0 0 1  
308 0 0 0 Undefined 0 0 0 0 1  
309 0 0 0 Undefined 0 0 0 0 1  
310 0 0 0 Undefined 0 0 0 0 1  
311 0 0 0 Undefined 0 0 0 0 1  
312 4.90E-15 9.90268 0 2.02E+15 75.9662 1.28586 
-
12.2987 4.05486 0.044045 pos 
313 1.55503 0 0 0 -11.9291 1.27719 -10.827 0.392292 0.531097  
314 0 0 0 Undefined 0 0 0 0 1  
315 0 0 0 Undefined 0 0 0 0 1  
316 0 0 0 Undefined 0 0 0 0 1  
317 0 0 0 Undefined 0 0 0 0 1  
318 0 0 0 Undefined 0 0 0 0 1  
319 0 0 0 Undefined 0 0 0 0 1  
320 0 0 0 Undefined 0 0 0 0 1  
321 0 0 0 Undefined 0 0 0 0 1  
322 0 0 0 Undefined 0 0 0 0 1  
323 0 0 0 Undefined 0 0 0 0 1  
324 0 0 0 Undefined 0 0 0 0 1  
325 0 0 0 Undefined 0 0 0 0 1  
326 0 0 0 Undefined 0 0 0 0 1  
327 0 0 0 Undefined 0 0 0 0 1  
328 0 0 0 Undefined 0 0 0 0 1  
329 0 0 0 Undefined 0 0 0 0 1  
330 0 0 0 Undefined 0 0 0 0 1  
331 0 0 0 Undefined 0 0 0 0 1  
332 3.92971 0 0 0 -30.1459 3.06346 
-
7.31789 0.484348 0.48646  
333 0 0 0 Undefined 0 0 0 0 1  
334 0 0 0 Undefined 0 0 0 0 1  
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335 0 0 0 Undefined 0 0 0 0 1  
336 4.90E-15 0 2.30985 0 -3.76E-14 0 
-
10.2476 0 1  
337 0 0 0 Undefined 0 0 0 0 1  
338 0 0 0 Undefined 0 0 0 0 1  
339 0 0 0 Undefined 0 0 0 0 1  
340 0 0 0 Undefined 0 0 0 0 1  
341 0 0 0 Undefined 0 0 0 0 1  
342 0 0 0 Undefined 0 0 0 0 1  
343 0 0 0 Undefined 0 0 0 0 1  
344 0 0 0 Undefined 0 0 0 0 1  
345 0 0 0 Undefined 0 0 0 0 1  
346 0 0 0 Undefined 0 0 0 0 1  
347 0 0 0 Undefined 0 0 0 0 1  
348 0 0 0 Undefined 0 5.55E-17 
-
4.44066 0 1  
349 0 0 0 Undefined 0 0 0 0 1  
350 0 0 0 Undefined 0 0 0 0 1  
351 0 0 0 Undefined 0 0 0 0 1  
352 0 0 0 Undefined 0 0 0 0 1  
353 0 0 0 Undefined 0 0 0 0 1  
354 0 0 0 Undefined 0 0 0 0 1  
355 0 0 0 Undefined 0 0 0 0 1  
356 0 0 0 Undefined 0 0 0 0 1  
357 0 0 0 Undefined 0 0 0 0 1  
358 0 0 0 Undefined 0 0 0 0 1  
359 0 0 0 Undefined 0 0 0 0 1  
360 0 0 0 Undefined 0 0 0 0 1  
361 0 0 0 Undefined 0 0 0 0 1  
362 0 0 0 Undefined 0 0 0 0 1  
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363 0 0 0 Undefined 0 0 0 0 1  
364 0 0 0 Undefined 0 0 0 0 1  
365 0 0 0 Undefined 0 0 0 0 1  
366 0 0 0 Undefined 0 0 0 0 1  
367 0 0 0 Undefined 0 0 0 0 1  
368 0 0 0 Undefined 0 0 0 0 1  
369 0 0 0 Undefined 0 0 0 0 1  
370 0 0 0 Undefined 0 0 0 0 1  
371 0 0 0 Undefined 0 0 0 0 1  
372 0 0 0 Undefined 0 0 0 0 1  
373 0 0 0 Undefined 0 0 0 0 1  
374 2.35E-15 0 2.47944 0 -1.80E-14 0 
-
10.0751 0 1  
375 0 0 0 Undefined 0 0 0 0 1  
376 0 0 0 Undefined 0 0 0 0 1  
377 0 0 0 Undefined 0 0 0 0 1  
378 0 0 0 Undefined 0 0 0 0 1  
379 0 0 0 Undefined 0 0 0 0 1  
380 0 0 0 Undefined 0 0 0 0 1  
381 0 0 0 Undefined 0 0 0 0 1  
382 0 0 0 Undefined 0 0 0 0 1  
383 0 0 0 Undefined 0 0 0 0 1  
384 0 0 0 Undefined 0 0 0 0 1  
385 0 0 0 Undefined 0 0 0 0 1  
386 0 0 0 Undefined 0 0 0 0 1  
387 0 0 0 Undefined 0 0 0 0 1  
388 0 0 0 Undefined 0 0 0 0 1  
389 0 0 0 Undefined 0 0 0 0 1  
390 0 0 0 Undefined 0 0 0 0 1  
391 0 0 0 Undefined 0 0 0 0 1  
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392 0 0 0 Undefined 0 0 0 0 1  
393 0 0 0 Undefined 0 0 0 0 1  
394 0 0 0 Undefined 0 0 0 0 1  
395 0 0 0 Undefined 0 0 0 0 1  
396 0 0 0 Undefined 0 0 0 0 1  
397 0 0 0 Undefined 0 0 0 0 1  
398 0 0 0 Undefined 0 0 0 0 1  
399 6.41048 0 0 0 -49.1766 5.23237 
-
22.7252 1.59793 0.206196  
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401 0 0 0 Undefined 0 0 0 0 1  
402 0 0 0 Undefined 0 0 0 0 1  
403 0 0 0 Undefined 0 0 0 0 1  
404 0 0 0 Undefined 0 0 0 0 1  
405 0 0 0 Undefined 0 0 0 0 1  
406 0 0 0 Undefined 0 0 0 0 1  
407 0 0 0 Undefined 0 0 0 0 1  
408 0 0 0 Undefined 0 0 0 0 1  
409 0 0 0 Undefined 0 0 0 0 1  
410 0 0 0 Undefined 0 0 0 0 1  
411 0 0 1.61599 Undefined 0 0 
-
10.3567 0 1  
412 0 0 0 Undefined 0 0 0 0 1  
413 0 0 0 Undefined 0 0 0 0 1  
414 0 0 0 Undefined 0 0 0 0 1  
415 0 0 0 Undefined 0 0 0 0 1  
416 0 0 0 Undefined 0 0 0 0 1  
417 0 0 0 Undefined 0 0 0 0 1  
418 0 0 0 Undefined 0 0 0 0 1  
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419 0 0 0 Undefined 0 0 0 0 1  
420 0 0 0 Undefined 0 0 0 0 1  
421 0 0 0 Undefined 0 0 0 0 1  
422 0 0 0 Undefined 0 0 0 0 1  
423 3.92971 0 0 0 -30.1459 2.52167 
-
7.38298 0.866994 0.351789  
424 2.54E-16 0 11.0051 0 -1.95E-15 5.10E-15 
-
21.9517 0 1  
425 0 0 0 Undefined 0 0 0 0 1  
426 0 0 0 Undefined 0 0 0 0 1  
427 0 0 0 Undefined 0 0 0 0 1  
428 0 0 0 Undefined 0 0 0 0 1  
429 0 0 0 Undefined 0 0 0 0 1  
430 0 0 0 Undefined 0 0 0 0 1  
431 47.2488 0 2.30707 0 -362.459 14.0347 
-
22.7915 4.89043 0.027006 neg 
432 0 0 0 Undefined 0 0 0 0 1  
433 0 0 0 Undefined 0 0 0 0 1  
434 4.90E-15 0 4.68249 0 -3.76E-14 0 
-
14.3686 0 1  
435 3.18277 0 0 0 -24.4159 2.95751 
-
12.8512 0.289934 0.590263  
436 0 0 0 Undefined 0 0 0 0 1  
437 0 0 0 Undefined 0 0 0 0 1  
438 0 0 0 Undefined 0 0 0 0 1  
439 0 0 0 Undefined 0 0 0 0 1  
440 0 0 0 Undefined 0 0 0 0 1  
441 0 0 0 Undefined 0 0 0 0 1  
442 0 0 0 Undefined 0 0 0 0 1  
443 0 0 0 Undefined 0 0 0 0 1  
444 0 0 0 Undefined 0 0 0 0 1  
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445 65.8379 0 0 0 -505.06 52.4519 
-
39.4924 7.475 0.006256 neg 
446 0 0 0 Undefined 0 0 0 0 1  
447 0 0 0 Undefined 0 0 0 0 1  
448 0 0 0 Undefined 0 0 0 0 1  
449 0 0 0 Undefined 0 0 0 0 1  
450 0 0 0 Undefined 0 0 0 0 1  
451 0 0 0 Undefined 0 0 0 0 1  
452 0 0 0 Undefined 0 0 0 0 1  
453 0 0 0 Undefined 0 0 0 0 1  
454 0 0 0 Undefined 0 0 0 0 1  
455 0 0 0 Undefined 0 0 0 0 1  
456 0 0 0 Undefined 0 0 0 0 1  
457 8.79E-15 0 5.05121 0 -6.75E-14 0 
-
11.7444 0 1  
458 0 0 0 Undefined 0 0 0 0 1  
459 0 0 0 Undefined 0 0 0 0 1  
460 0 0 1.70132 Undefined 0 0 -10.052 0 1  
461 0 0 0 Undefined 0 0 0 0 1  
462 0 0 0 Undefined 0 0 0 0 1  
463 0 0 0 Undefined 0 0 0 0 1  
464 0 0 0 Undefined 0 0 0 0 1  
465 0 0 0 Undefined 0 0 0 0 1  
466 0 0 0 Undefined 0 0 0 0 1  
467 0 0 0 Undefined 0 0 0 0 1  
468 0 0 0 Undefined 0 0 0 0 1  
469 0 0 0 Undefined 0 0 0 0 1  
470 0 0 0 Undefined 0 0 0 0 1  
471 0 0 0 Undefined 0 0 0 0 1  
472 0 0 0 Undefined 0 0 0 0 1  
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473 0 0 0 Undefined 0 0 0 0 1  
474 0 0 0 Undefined 0 0 0 0 1  
475 0 0 0 Undefined 0 0 0 0 1  
476 0 0 0 Undefined 0 0 0 0 1  
477 0 0 0 Undefined 0 0 0 0 1  
478 0 0 0 Undefined 0 0 0 0 1  
479 0 0 0 Undefined 0 0 0 0 1  
480 11.4798 0 0 0 -88.0649 8.46018 
-
15.7666 1.71813 0.189933 neg 
481 0 0 0 Undefined 0 0 0 0 1  
482 0 0 2.30581 Undefined 0 0 
-
10.2523 0 1  
483 0 0 0 Undefined 0 0 0 0 1  
484 0 0 0 Undefined 0 0 0 0 1  
485 0 0 1.54194 Undefined 0 0 
-
10.2432 0 1  
486 4.09511 0 0 0 -31.4147 2.96719 
-
10.7586 0.624102 0.429527  
487 0 0 0 Undefined 0 0 0 0 1  
488 0 0 0 Undefined 0 0 0 0 1  
489 0 0 0 Undefined 0 0 0 0 1  
490 0 0 0 Undefined 0 0 0 0 1  
491 0 0 0 Undefined 0 0 0 0 1  
492 0 0 0 Undefined 0 0 0 0 1  
493 0 0 0 Undefined 0 0 0 0 1  
494 0 0 0 Undefined 0 0 0 0 1  
495 0 0 0 Undefined 0 0 0 0 1  
496 0 0 0 Undefined 0 0 0 0 1  
497 0 0 0 Undefined 0 0 0 0 1  
498 0 0 0 Undefined 0 0 0 0 1  
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499 0 0 0 Undefined 0 0 0 0 1  
500 0 0 0 Undefined 0 0 0 0 1  
501 4.778 0 0 0 -36.6534 4.58173 
-
17.2522 0.246448 0.619588  
502 0 0 0 Undefined 0 0 0 0 1  
503 0 0 0 Undefined 0 0 
-
4.79902 0 1  
504 0 0 0 Undefined 0 0 0 0 1  
505 0 0 0 Undefined 0 0 0 0 1  
506 0 0 1.61636 Undefined 0 0 
-
9.66114 0 1  
507 0 0 0 Undefined 0 0 0 0 1  
508 0 0 0 Undefined 0 0 0 0 1  
509 3.12E-15 0 6.105 0 -2.40E-14 1.00E-06 
-
9.91443 5.90E-07 0.999387  
510 0 0 0 Undefined 0 0 0 0 1  
511 2.78E-17 0 0 0 -2.13E-16 7.62E-16 
-
4.11807 0 1  
512 0 0 0 Undefined 0 0 0 0 1  
513 0 0 0 Undefined 0 0 0 0 1  
514 1.02E-14 0 2.47805 0 -7.82E-14 0 -12.202 
-7.88E-
10 1  
515 0 0 0 Undefined 0 0 0 0 1  
516 0 0 0 Undefined 0 0 0 0 1  
517 0 0 0 Undefined 0 0 0 0 1  
518 0 0 0 Undefined 0 0 0 0 1  
519 0 0 0 Undefined 0 0 0 0 1  
520 2.35E-15 0 2.30981 0 -1.80E-14 0 
-
10.2552 0 1  
521 0 0 0 Undefined 0 0 0 0 1  
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522 3.35E-14 0 10.215 0 -2.57E-13 5.85E-15 
-
13.0645 0 1  
523 0 0 0 Undefined 0 0 0 0 1  
524 0 0 0 Undefined 0 0 0 0 1  
525 0 0 0 Undefined 0 0 0 0 1  
526 0 0 0 Undefined 0 0 0 0 1  
527 0 0 0 Undefined 0 0 0 0 1  
528 0 0 0 Undefined 0 0 0 0 1  
529 0 0 0 Undefined 0 0 0 0 1  
530 0 0 2.47751 Undefined 0 0 -12.437 0 1  
531 0 0 0 Undefined 0 0 0 0 1  
532 0 0 0 Undefined 0 0 0 0 1  
533 0 0 0 Undefined 0 0 0 0 1  
534 8.79E-15 0 2.47542 0 -6.75E-14 0 
-
11.7062 0 1  
535 0 0 0 Undefined 0 0 0 0 1  
536 0 0 0 Undefined 0 0 0 0 1  
537 0 0 0 Undefined 0 0 0 0 1  
538 0 0 0 Undefined 0 0 0 0 1  
539 0 0 0 Undefined 0 0 0 0 1  
540 0 0 0 Undefined 0 0 0 0 1  
541 0 0 0 Undefined 0 0 0 0 1  
542 0 0 0 Undefined 0 0 0 0 1  
543 0 0 0 Undefined 0 0 0 0 1  
544 0 0 0 Undefined 0 0 0 0 1  
545 0 0 0 Undefined 0 0 0 0 1  
546 3.61526 0 0 0 -27.7336 2.38037 
-
8.84937 0.817826 0.365817  
547 0 0 0 Undefined 0 0 0 0 1  
548 0 0 0 Undefined 0 0 0 0 1  
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549 0 0 0 Undefined 0 0 0 0 1  
550 0 0 0 Undefined 0 0 0 0 1  
551 0 0 0 Undefined 0 0 0 0 1  
552 0 0 0 Undefined 0 0 0 0 1  
553 0 0 0 Undefined 0 0 0 0 1  
554 0 0 0 Undefined 0 0 0 0 1  
555 0 0 0 Undefined 0 0 0 0 1  
556 0 0 0 Undefined 0 0 
-
3.30659 0 1  
557 0 0 0 Undefined 0 0 0 0 1  
558 0 0 0 Undefined 0 0 0 0 1  
559 0 0 0 Undefined 0 0 0 0 1  
560 0 0 0 Undefined 0 0 0 0 1  
561 0 0 0 Undefined 0 0 0 0 1  
562 0 0 0 Undefined 0 0 0 0 1  
563 0 0 0 Undefined 0 0 0 0 1  
564 0 0 0 Undefined 0 0 0 0 1  
565 0 0 0 Undefined 0 0 0 0 1  
566 0 0 0 Undefined 0 0 0 0 1  
567 0 0 0 Undefined 0 0 0 0 1  
568 0 0 0 Undefined 0 0 0 0 1  
569 0 0 0 Undefined 0 0 0 0 1  
570 0 0 0 Undefined 0 0 0 0 1  
571 0 0 0 Undefined 0 0 0 0 1  
572 0 0 0 Undefined 0 0 0 0 1  
573 0 0 0 Undefined 0 0 0 0 1  
574 0 0 0 Undefined 0 0 0 0 1  
575 4.90E-15 0 2.47597 0 -3.76E-14 0 
-
12.6447 0 1  
576 0 0 0 Undefined 0 0 0 0 1  
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577 0 0 0 Undefined 0 0 0 0 1  
578 0 0 0 Undefined 0 0 0 0 1  
579 0 0 0 Undefined 0 0 0 0 1  
580 0 0 0 Undefined 0 0 0 0 1  
581 0 0 0 Undefined 0 0 0 0 1  
582 9.63E-16 0 9.23921 0 -7.39E-15 1.37E-15 
-
11.0983 0 1  
583 0 0 0 Undefined 0 0 0 0 1  
584 0 0 0 Undefined 0 0 0 0 1  
585 0 0 0 Undefined 0 0 0 0 1  
586 0 0 0 Undefined 0 0 0 0 1  
587 0 0 0 Undefined 0 0 0 0 1  
588 0 0 0 Undefined 0 0 0 0 1  
589 0 0 0 Undefined 0 0 0 0 1  
590 0 0 0 Undefined 0 0 0 0 1  
591 0 0 0 Undefined 0 0 0 0 1  
592 0 0 0 Undefined 0 0 0 0 1  
593 0 0 0 Undefined 0 0 0 0 1  
594 0 0 0 Undefined 0 0 0 0 1  
595 0 0 0 Undefined 0 0 0 0 1  
596 0 0 0 Undefined 0 0 0 0 1  
597 0 0 0 Undefined 0 0 0 0 1  
598 0 0 0 Undefined 0 0 0 0 1  
599 0 0 0 Undefined 0 0 0 0 1  
600 0 0 0 Undefined 0 0 0 0 1  
601 0 0 0 Undefined 0 0 0 0 1  
602 0 0 0 Undefined 0 0 0 0 1  
603 0 0 0 Undefined 0 0 0 0 1  
604 0 0 0 Undefined 0 0 0 0 1  
605 0 0 0 Undefined 0 0 0 0 1  
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606 0 0 0 Undefined 0 0 0 0 1  
607 0 0 0 Undefined 0 0 0 0 1  
608 0 0 0 Undefined 0 0 0 0 1  
609 0 0 0 Undefined 0 0 0 0 1  
610 0 0 0 Undefined 0 0 0 0 1  
611 0 0 0 Undefined 0 0 0 0 1  
612 0 0 0 Undefined 0 0 0 0 1  
613 0 0 0 Undefined 0 0 0 0 1  
614 0 0 0 Undefined 0 0 0 0 1  
615 0 0 0 Undefined 0 0 0 0 1  
616 7.25254 0 0 0 -55.6362 5.31262 
-
11.1638 1.19021 0.275288  
617 0 0 0 Undefined 0 0 0 0 1  
618 0 0 0 Undefined 0 0 0 0 1  
619 0 0 0 Undefined 0 0 0 0 1  
620 0 0 0 Undefined 0 0 0 0 1  
621 0 0 0 Undefined 0 0 0 0 1  
622 0 0 0 Undefined 0 0 0 0 1  
623 0 0 0 Undefined 0 0 0 0 1  
624 0 0 0 Undefined 0 0 0 0 1  
625 0 0 0 Undefined 0 0 0 0 1  
626 0 0 0 Undefined 0 0 0 0 1  
627 0 0 0 Undefined 0 0 0 0 1  
628 0 0 0 Undefined 0 0 0 0 1  
629 0 0 0 Undefined 0 0 0 0 1  
630 0 0 0 Undefined 0 0 0 0 1  
631 0 0 0 Undefined 0 0 0 0 1  
632 0 0 0 Undefined 0 0 0 0 1  
633 0 0 0 Undefined 0 0 0 0 1  
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634 33.3366 0 0 0 -255.735 20.1221 
-
29.5619 5.13699 0.023421 neg 
635 0 0 0 Undefined 0 0 0 0 1  
636 0 0 0 Undefined 0 0 0 0 1  
637 0 0 0 Undefined 0 0 0 0 1  
638 0 0 0 Undefined 0 0 0 0 1  
639 0 0 0 Undefined 0 0 0 0 1  
640 0 0 0 Undefined 0 0 0 0 1  
641 0 0 0 Undefined 0 0 0 0 1  
642 0 0 0 Undefined 0 0 0 0 1  
643 0 0 0 Undefined 0 0 0 0 1  
644 0 0 0 Undefined 0 0 0 0 1  
645 0 0 0 Undefined 0 0 0 0 1  
646 0 0 0 Undefined 0 0 0 0 1  
647 0 0 0 Undefined 0 0 0 0 1  
648 0 0 0 Undefined 0 0 0 0 1  
649 0 0 0 Undefined 0 0 0 0 1  
650 0 0 0 Undefined 0 0 0 0 1  
651 3.23371 0 0 0 -24.8067 2.42 
-
9.99493 0.574645 0.448419  
652 0 0 0 Undefined 0 0 0 0 1  
653 0 0 0 Undefined 0 0 0 0 1  
654 0 0 0 Undefined 0 0 0 0 1  
655 0 0 0 Undefined 0 0 0 0 1  
656 0 0 0 Undefined 0 0 0 0 1  
657 0 0 0 Undefined 0 0 0 0 1  
658 0 0 0 Undefined 0 0 
-
3.67712 0 1  
659 0 0 0 Undefined 0 0 
-
3.20361 0 1 
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660 0 0 0 Undefined 0 0 
-
3.42645 0 1  
661 0 0 0 Undefined 0 5.55E-17 
-
4.13522 0 1  
662 0 0 0 Undefined 0 0 
-
4.22232 0 1  
663 0 0 0 Undefined 0 5.55E-17 
-
3.25838 0 1  
664 3.95315 0 0 0 -30.3257 3.40836 
-
7.19228 0.286386 0.592546  
665 1.78E-14 0 0 0 -1.37E-13 0 
-
4.17123 0 1  
666 1.07E-14 0 8.6572 0 -8.19E-14 4.01E-14 
-
9.01042 3.55E-15 1  
667 0 0 0 Undefined 0 0 
-
3.39368 0 1  
668 1.78E-14 0 0 0 -1.37E-13 0 
-
4.17123 0 1  
669 0 0 0 Undefined 0 0 -4.3253 0 1  
670 0 0 0 Undefined 0 0 
-
4.44066 0 1  
671 0 0 0 Undefined 0 6.94E-18 
-
3.30659 0 1  
672 0 0 0 Undefined 0 0 
-
3.39368 0 1  
673 0 0 0 Undefined 0 0 
-
4.51976 0 1  
674 0 0 0 Undefined 0 0 
-
3.32347 0 1  
675 0 0 0 Undefined 0 0 
-
3.74754 0 1  
676 0 0 0 Undefined 0 0 
-
3.83464 0 1  
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677 0 0 0 Undefined 0 0 
-
3.20361 0 1  
678 4.62E-14 0 0 0 -3.54E-13 0 
-
4.25221 0 1  
679 0 0 0 Undefined 0 0 0 0 1  
680 0 0 0 Undefined 0 0 0 0 1  
681 0 0 0 Undefined 0 0 0 0 1  
682 0 0 0 Undefined 0 0 0 0 1  
683 65.8577 0 1.70146 0 -505.213 45.3912 
-
46.7475 13.7307 0.000211 neg 
684 0 0 0 Undefined 0 0 0 0 1  
685 0 0 0 Undefined 0 0 0 0 1  
686 0 0 2.08795 Undefined 0 0 
-
12.2004 0 1  
687 0 0 1.70129 Undefined 0 5.26E-06 
-
10.4065 4.48E-06 0.998311  
688 0 0 0 Undefined 0 0 0 0 1  
689 0 0 0 Undefined 0 0 0 0 1  
690 0 0 0 Undefined 0 0 0 0 1  
691 0 0 0 Undefined 0 0 0 0 1  
692 0 0 0 Undefined 0 0 0 0 1  
693 0 0 0 Undefined 0 0 0 0 1  
694 0 0 0 Undefined 0 0 0 0 1  
695 0 0 0 Undefined 0 0 0 0 1  
696 9.95E-14 0 2.09731 0 -7.63E-13 0 -8.9946 
-6.29E-
10 1  
697 0 0 0 Undefined 0 0 0 0 1  
698 87.5209 0 0 0 -671.397 43.0157 
-
14.0853 2.77725 0.095612 neg 
699 0 0 0 Undefined 0 0 0 0 1  
700 0 0 0 Undefined 0 0 0 0 1  
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701 0 0 0 Undefined 0 0 0 0 1  
702 0 0 0 Undefined 0 0 0 0 1  
703 0 0 0 Undefined 0 0 0 0 1  
704 0 0 0 Undefined 0 0 0 0 1  
705 56.3168 0 0 0 -432.022 48.208 
-
48.0366 5.58464 0.018119 neg 
706 3.02023 0 0 0 -23.169 2.4443 
-
13.8171 0.840376 0.359289  
707 0 0 0 Undefined 0 0 0 0 1  
708 0 0 0 Undefined 0 0 0 0 1  
709 0 0 0 Undefined 0 0 0 0 1  
710 0 0 0 Undefined 0 0 0 0 1  
711 0 0 0 Undefined 0 0 0 0 1  
712 0 0 0 Undefined 0 0 0 0 1  
713 0 0 0 Undefined 0 0 0 0 1  
714 0 0 0 Undefined 0 0 0 0 1  
715 0 0 0 Undefined 0 0 0 0 1  
716 0 0 0 Undefined 0 0 0 0 1  
717 0 0 0 Undefined 0 0 0 0 1  
718 0 0 0 Undefined 0 0 0 0 1  
719 0 0 0 Undefined 0 0 0 0 1  
720 0 0 0 Undefined 0 0 0 0 1  
721 0 0 0 Undefined 0 0 0 0 1  
722 0 0 0 Undefined 0 0 0 0 1  
723 0 0 0 Undefined 0 0 0 0 1  
724 0 0 0 Undefined 0 0 0 0 1  
725 0 0 0 Undefined 0 0 0 0 1  
726 0 0 0 Undefined 0 0 0 0 1  
727 0 0 0 Undefined 0 0 0 0 1  
728 0 0 0 Undefined 0 0 0 0 1  
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729 0 0 0 Undefined 0 0 0 0 1  
730 0 0 0 Undefined 0 0 0 0 1  
731 60.0067 0 0 0 -460.328 43.1652 
-
44.7533 13.6476 0.000221 neg 
732 0 0 0 Undefined 0 0 0 0 1  
733 0 0 0 Undefined 0 0 0 0 1  
734 0 0 0 Undefined 0 0 0 0 1  
735 0 0 0 Undefined 0 0 0 0 1  
736 0 0 0 Undefined 0 0 0 0 1  
737 0 0 0 Undefined 0 0 0 0 1  
738 0 0 0 Undefined 0 0 0 0 1  
739 0 0 0 Undefined 0 0 0 0 1  
740 0 0 0 Undefined 0 0 0 0 1  
741 0 0 0 Undefined 0 0 0 0 1  
742 0 0 1.55385 Undefined 0 0 
-
13.5512 0 1  
743 0 0 0 Undefined 0 0 0 0 1  
744 2.49E-15 11.3316 0 4.55E+15 86.9276 2.72027 -13.515 2.83542 0.092207 pos 
745 4.68991 0 0 0 -35.9776 3.80262 
-
18.3985 1.24322 0.264852  
746 0 0 0 Undefined 0 0 0 0 1  
747 0 0 0 Undefined 0 0 0 0 1  
748 0 0 0 Undefined 0 0 0 0 1  
749 0 0 0 Undefined 0 0 0 0 1  
750 0 0 0 Undefined 0 0 0 0 1  
751 0 0 0 Undefined 0 0 0 0 1  
752 0 0 0 Undefined 0 0 0 0 1  
753 8.02995 0 0 0 -61.6 5.70321 
-
15.9398 1.29482 0.255162  
754 0 0 0 Undefined 0 0 0 0 1  
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755 0 0 0 Undefined 0 0 0 0 1  
756 3.43E-15 0 8.59449 0 -2.63E-14 2.94E-14 
-
9.30109 0 1  
757 0 0 0 Undefined 0 0 0 0 1  
758 0 0 0 Undefined 0 0 0 0 1  
759 0 0 0 Undefined 0 0 0 0 1  
760 0 0 0 Undefined 0 0 0 0 1  
761 1.50599 0 0 0 -11.5529 1.24171 
-
8.42782 0.384783 0.535054  
762 0 0 0 Undefined 0 0 0 0 1  
763 0 0 0 Undefined 0 0 0 0 1  
764 0 0 0 Undefined 0 0 0 0 1  
765 0 0 0 Undefined 0 0 0 0 1  
766 0 0 0 Undefined 0 0 0 0 1  
767 60.1152 0 0 0 -461.16 42.5502 
-
44.8425 14.2596 0.000159 neg 
768 0 0 0 Undefined 0 0 0 0 1  
769 0 0 0 Undefined 0 0 0 0 1  
770 0 0 0 Undefined 0 0 0 0 1  
771 0 0 0 Undefined 0 0 0 0 1  
772 0 0 0 Undefined 0 0 0 0 1  
773 0 0 1.61586 Undefined 0 0 
-
10.7604 1.78E-14 1  
774 0 0 0 Undefined 0 0 0 0 1  
775 0 0 0 Undefined 0 0 0 0 1  
776 0 0 0 Undefined 0 0 0 0 1  
777 0 0 0 Undefined 0 0 0 0 1  
778 0 0 0 Undefined 0 0 0 0 1  
779 0 0 0 Undefined 0 0 0 0 1  
780 0 0 0 Undefined 0 0 0 0 1  
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781 0 0 0 Undefined 0 0 0 0 1  
782 0 0 0 Undefined 0 0 0 0 1  
783 40.7954 0 0 0 -312.953 30.4637 
-
52.4914 10.2396 0.001375 neg 
784 0 0 0 Undefined 0 0 0 0 1  
785 0 0 0 Undefined 0 0 0 0 1  
786 0 0 0 Undefined 0 0 0 0 1  
787 0 0 0 Undefined 0 0 0 0 1  
788 0 0 0 Undefined 0 0 0 0 1  
789 0 0 0 Undefined 0 0 0 0 1  
790 0 0 0 Undefined 0 0 0 0 1  
791 0 0 0 Undefined 0 0 0 0 1  
792 0 0 0 Undefined 0 0 0 0 1  
793 0 0 0 Undefined 0 0 0 0 1  
794 0 0 0 Undefined 0 0 0 0 1  
795 0 0 0 Undefined 0 0 0 0 1  
796 0 0 0 Undefined 0 0 0 0 1  
797 0 0 0 Undefined 0 0 0 0 1  
798 1.49622 0 0 0 -11.4779 1.31558 
-
9.06032 0.256451 0.612569  
799 0 0 0 Undefined 0 0 0 0 1  
800 0 0 0 Undefined 0 0 0 0 1  
801 0 0 0 Undefined 0 0 0 0 1  
802 0 0 0 Undefined 0 0 0 0 1  
803 0 0 0 Undefined 0 0 0 0 1  
804 0 0 0 Undefined 0 0 0 0 1  
805 0 0 0 Undefined 0 0 0 0 1  
806 0 0 0 Undefined 0 0 0 0 1  
807 0 0 0 Undefined 0 0 0 0 1  
808 0 0 0 Undefined 0 0 0 0 1  
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809 0 0 0 Undefined 0 0 0 0 1  
810 5.91E-15 10.7143 0 1.81E+15 82.1927 2.68877 
-
9.54939 2.74967 0.097274 pos 
811 0 0 0 Undefined 0 0 0 0 1  
812 0 0 0 Undefined 0 0 0 0 1  
813 0 0 0 Undefined 0 0 0 0 1  
814 0 0 0 Undefined 0 0 0 0 1  
815 0 0 0 Undefined 0 0 0 0 1  
816 0 0 0 Undefined 0 0 0 0 1  
817 0 0 0 Undefined 0 0 0 0 1  
818 0 0 0 Undefined 0 0 0 0 1  
819 0 0 0 Undefined 0 0 0 0 1  
820 0 0 0 Undefined 0 0 0 0 1  
821 0 0 0 Undefined 0 0 0 0 1  
822 0 0 0 Undefined 0 0 0 0 1  
823 0 0 0 Undefined 0 0 0 0 1  
824 0 0 0 Undefined 0 0 0 0 1  
825 0 0 0 Undefined 0 0 0 0 1  
826 1.73E-14 0 0 0 -1.32E-13 0 
-
4.82203 0 1  
827 0 0 0 Undefined 0 0 0 0 1  
828 0 0 0 Undefined 0 0 0 0 1  
829 0 0 0 Undefined 0 0 0 0 1  
830 0 0 0 Undefined 0 0 0 0 1  
831 0 0 0 Undefined 0 0 0 0 1  
832 0 0 0 Undefined 0 0 0 0 1  
833 23.8183 22.7939 51.7577 0.957 -7.85829 23.2932 -71.988 0.000954 0.975356  
834 0 0 0 Undefined 0 0 0 0 1  
835 0 0 0 Undefined 0 0 0 0 1  
836 0 0 0 Undefined 0 0 0 0 1  
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837 0 0 0 Undefined 0 0 0 0 1  
838 0 0 0 Undefined 0 0 0 0 1  
839 0 0 0 Undefined 0 0 0 0 1  
840 0 0 0 Undefined 0 0 0 0 1  
841 0 0 0 Undefined 0 0 0 0 1  
842 0 0 0 Undefined 0 0 0 0 1  
843 0 0 0 Undefined 0 0 0 0 1  
844 0 0 0 Undefined 0 0 0 0 1  
845 0 0 0 Undefined 0 0 0 0 1  
846 0 0 0 Undefined 0 0 0 0 1  
847 0 0 0 Undefined 0 0 0 0 1  
848 0 0 0 Undefined 0 0 0 0 1  
849 0 0 0 Undefined 0 0 0 0 1  
850 0 0 0 Undefined 0 0 0 0 1  
851 0 0 0 Undefined 0 0 0 0 1  
852 0 0 0 Undefined 0 0 0 0 1  
853 0 0 0 Undefined 0 0 0 0 1  
854 0 0 0 Undefined 0 0 0 0 1  
855 0 0 0 Undefined 0 0 0 0 1  
856 0 0 0 Undefined 0 0 0 0 1  
857 0 0 0 Undefined 0 0 0 0 1  
858 0 0 0 Undefined 0 0 0 0 1  
859 0 0 0 Undefined 0 0 0 0 1  
860 0 0 0 Undefined 0 0 0 0 1  
861 0 0 0 Undefined 0 0 0 0 1  
862 0 0 0 Undefined 0 0 0 0 1  
863 0 0 0 Undefined 0 0 0 0 1  
864 0 0 0 Undefined 0 0 0 0 1  
865 0 0 0 Undefined 0 0 0 0 1  
866 0 0 0 Undefined 0 0 0 0 1  
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867 0 0 0 Undefined 0 0 0 0 1  
868 0 0 0 Undefined 0 0 0 0 1  
869 0 0 0 Undefined 0 0 0 0 1  
870 0 0 0 Undefined 0 0 0 0 1  
871 0 0 0 Undefined 0 0 0 0 1  
872 0 0 0 Undefined 0 0 0 0 1  
873 0 0 0 Undefined 0 0 0 0 1  
874 0 0 0 Undefined 0 0 0 0 1  
875 0 0 0 Undefined 0 0 0 0 1  
876 0 0 0 Undefined 0 0 0 0 1  
877 0 0 0 Undefined 0 0 0 0 1  
878 0 0 0 Undefined 0 0 0 0 1  
879 1.29E-14 0 2.70651 0 -9.86E-14 0 
-
11.6029 0 1  
880 0 0 0 Undefined 0 0 0 0 1  
881 0 0 0 Undefined 0 0 0 0 1  
882 0 0 0 Undefined 0 0 0 0 1  
883 0 0 0 Undefined 0 0 0 0 1  
884 0 0 0 Undefined 0 0 0 0 1  
885 0 0 0 Undefined 0 0 0 0 1  
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887 0 0 0 Undefined 0 0 0 0 1  
888 0 0 5.13202 Undefined 0 0 -9.2112 0 1  
889 0 0 0 Undefined 0 0 0 0 1  
890 0 0 0 Undefined 0 0 0 0 1  
891 0 0 0 Undefined 0 0 0 0 1  
892 0 0 0 Undefined 0 0 0 0 1  
893 0 0 0 Undefined 0 0 0 0 1  
894 0 0 0 Undefined 0 0 0 0 1  
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895 0 0 0 Undefined 0 0 0 0 1  
896 0 0 0 Undefined 0 0 0 0 1  
897 0 0 0 Undefined 0 0 0 0 1  
898 0 0 0 Undefined 0 0 0 0 1  
899 0 0 0 Undefined 0 0 0 0 1  
900 0 0 0 Undefined 0 0 0 0 1  
901 0 0 0 Undefined 0 0 0 0 1  
902 0 0 0 Undefined 0 0 0 0 1  
903 0 0 0 Undefined 0 0 0 0 1  
904 0 0 0 Undefined 0 0 0 0 1  
905 0 0 0 Undefined 0 0 0 0 1  
906 0 0 0 Undefined 0 0 0 0 1  
907 0 0 0 Undefined 0 0 0 0 1  
908 0 0 0 Undefined 0 0 0 0 1  
909 0 0 0 Undefined 0 0 0 0 1  
910 0 0 0 Undefined 0 0 0 0 1  
911 0 0 0 Undefined 0 0 0 0 1  
912 72.1109 0 0 0 -553.183 50.7773 
-
38.0359 10.6272 0.001114 neg 
913 0 0 0 Undefined 0 0 0 0 1  
914 1.44E-13 0 26.8222 0 -1.10E-12 5.11E-17 
-
29.7183 0 1  
915 0 0 0 Undefined 0 0 0 0 1  
916 0 0 0 Undefined 0 0 0 0 1  
917 0 0 0 Undefined 0 0 0 0 1  
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919 0 0 0 Undefined 0 0 0 0 1  
920 0 0 0 Undefined 0 0 0 0 1  
921 0 0 0 Undefined 0 0 0 0 1  
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922 0 0 0 Undefined 0 0 0 0 1  
923 0 0 0 Undefined 0 0 0 0 1  
924 0 0 0 Undefined 0 0 0 0 1  
925 0 0 0 Undefined 0 0 0 0 1  
926 0 0 0 Undefined 0 0 0 0 1  
927 0 0 0 Undefined 0 0 0 0 1  
928 0 0 0 Undefined 0 0 0 0 1  
929 0 0 0 Undefined 0 0 0 0 1  
930 0 0 0 Undefined 0 0 0 0 1  
931 0 0 0 Undefined 0 0 0 0 1  
932 72.1109 0 0 0 -553.183 55.4588 
-
37.4269 7.97401 0.004745 neg 
933 0 0 0 Undefined 0 0 0 0 1  
934 0 0 0 Undefined 0 0 0 0 1  
935 0 0 0 Undefined 0 0 0 0 1  
936 0 0 0 Undefined 0 0 0 0 1  
937 0 0 0 Undefined 0 0 0 0 1  
938 0 0 0 Undefined 0 0 0 0 1  
939 0 0 0 Undefined 0 0 0 0 1  
940 0 0 0 Undefined 0 0 0 0 1  
941 0 0 0 Undefined 0 0 0 0 1  
942 0 0 0 Undefined 0 0 0 0 1  
943 0 0 0 Undefined 0 0 0 0 1  
944 0 0 0 Undefined 0 0 0 0 1  
945 0 0 0 Undefined 0 0 0 0 1  
946 0 0 0 Undefined 0 0 0 0 1  
947 29.5221 0 0 0 -226.472 21.0296 
-
22.7156 3.33971 0.067627 neg 
948 60.9685 0 0 0 -467.707 45.918 
-
35.9719 8.75218 0.003092 neg 
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949 0 0 0 Undefined 0 0 0 0 1  
950 0 0 0 Undefined 0 0 0 0 1  
951 0 0 0 Undefined 0 0 0 0 1  
952 0 0 1.63546 Undefined 0 0 
-
10.7397 0 1  
953 0 0 0 Undefined 0 0 0 0 1  
954 0 0 0 Undefined 0 0 0 0 1  
955 0 0 0 Undefined 0 0 0 0 1  
956 0 0 0 Undefined 0 0 0 0 1  
957 0 0 0 Undefined 0 0 0 0 1  
958 0 0 0 Undefined 0 0 0 0 1  
959 0 0 0 Undefined 0 0 0 0 1  
960 0 0 0 Undefined 0 0 0 0 1  
961 0 0 0 Undefined 0 0 0 0 1  
962 0 0 0 Undefined 0 0 0 0 1  
963 0 0 0 Undefined 0 0 0 0 1  
964 0 0 0 Undefined 0 0 0 0 1  
965 0 0 0 Undefined 0 0 0 0 1  
966 0 0 0 Undefined 0 0 
-
4.35807 0 1  
967 0 0 0 Undefined 0 0 0 0 1  
968 0 0 0 Undefined 0 0 0 0 1  
969 0 0 0 Undefined 0 0 0 0 1  
970 0 0 0 Undefined 0 0 0 0 1  
971 0 0 0 Undefined 0 0 0 0 1  
972 0 0 0 Undefined 0 0 0 0 1  
973 0 0 0 Undefined 0 0 0 0 1  
974 0 0 0 Undefined 0 0 0 0 1  
975 0 0 0 Undefined 0 0 0 0 1  
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976 20.3234 0 0 0 -155.906 17.3523 
-
42.8294 3.23039 0.072284 neg 
977 0 0 0 Undefined 0 0 0 0 1  
978 0 0 0 Undefined 0 0 0 0 1  
979 0 0 0 Undefined 0 0 0 0 1  
980 0 0 0 Undefined 0 0 0 0 1  
981 0 0 0 Undefined 0 0 0 0 1  
982 0 0 0 Undefined 0 0 0 0 1  
983 0 0 0 Undefined 0 0 0 0 1  
984 0 0 0 Undefined 0 0 0 0 1  
985 0 0 0 Undefined 0 0 0 0 1  
986 0 0 0 Undefined 0 0 0 0 1  
987 0 0 0 Undefined 0 0 0 0 1  
988 0 0 0 Undefined 0 0 0 0 1  
989 0 0 0 Undefined 0 0 0 0 1  
990 0 0 0 Undefined 0 0 0 0 1  
991 0 0 0 Undefined 0 0 0 0 1  
992 0 0 0 Undefined 0 0 0 0 1  
993 0 0 0 Undefined 0 0 0 0 1  
994 0 0 0 Undefined 0 0 0 0 1  
995 0 0 0 Undefined 0 0 0 0 1  
996 0 0 0 Undefined 0 0 0 0 1  
997 4.00245 0 0 0 -30.7039 2.93134 
-
9.73968 0.604756 0.436769  
998 0 0 0 Undefined 0 0 0 0 1  
999 0 0 0 Undefined 0 0 0 0 1  
1000 0 0 0 Undefined 0 0 0 0 1  
1001 0 0 0 Undefined 0 0 0 0 1  
1002 0 0 0 Undefined 0 0 0 0 1  
1003 0 0 0 Undefined 0 0 0 0 1  
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1004 0 0 0 Undefined 0 0 0 0 1  
1005 2.03129 0 0 0 -15.5826 1.73644 
-
14.1088 0.312832 0.575947  
1006 0 0 0 Undefined 0 0 0 0 1  
1007 0 0 0 Undefined 0 0 0 0 1  
1008 0 0 0 Undefined 0 0 0 0 1  
1009 0 0 0 Undefined 0 0 0 0 1  
1010 0 0 0 Undefined 0 0 0 0 1  
1011 0 0 0 Undefined 0 0 0 0 1  
1012 0 0 0 Undefined 0 0 0 0 1  
1013 0 0 0 Undefined 0 0 0 0 1  
1014 0 0 0 Undefined 0 0 0 0 1  
1015 0 0 0 Undefined 0 0 0 0 1  
1016 0 0 0 Undefined 0 0 0 0 1  
1017 0 0 0 Undefined 0 0 0 0 1  
1018 0 0 0 Undefined 0 0 0 0 1  
1019 0 0 0 Undefined 0 0 0 0 1  
1020 8.62007 10.1592 44.1818 1.179 11.8073 9.99397 -97.429 0.002223 0.962396  
1021 29.309 0 0 0 -224.837 12.902 
-
11.1081 1.63397 0.201155  
1022 0 0 0 Undefined 0 0 0 0 1  
1023 0 0 0 Undefined 0 0 0 0 1  
1024 0 0 0 Undefined 0 0 0 0 1  
1025 0 0 0 Undefined 0 0 0 0 1  
1026 0 0 0 Undefined 0 0 0 0 1  
1027 0 0 0 Undefined 0 0 0 0 1  
1028 0 0 0 Undefined 0 0 0 0 1  
1029 0 0 0 Undefined 0 0 0 0 1  
1030 0 0 0 Undefined 0 0 0 0 1  
1031 0 0 0 Undefined 0 0 0 0 1  
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1032 0 0 0 Undefined 0 0 0 0 1  
1033 0 0 0 Undefined 0 0 0 0 1  
1034 0 0 0 Undefined 0 0 0 0 1  
1035 42.7123 0 0 0 -327.658 21.5325 
-
9.48404 1.35541 0.244334  
1036 0 0 0 Undefined 0 0 0 0 1  
1037 0 0 0 Undefined 0 0 0 0 1  
1038 0 0 0 Undefined 0 0 0 0 1  
1039 0 0 0 Undefined 0 0 0 0 1  
1040 0 0 0 Undefined 0 0 0 0 1  
1041 0 0 0 Undefined 0 0 0 0 1  
1042 0 0 0 Undefined 0 0 0 0 1  
1043 0 0 0 Undefined 0 0 0 0 1  
1044 0 0 0 Undefined 0 0 0 0 1  
1045 0 0 0 Undefined 0 0 0 0 1  
1046 0 0 0 Undefined 0 0 0 0 1  
1047 0 0 0 Undefined 0 0 0 0 1  
1048 0 0 0 Undefined 0 0 0 0 1  
1049 1.51325 0 0 0 -11.6086 1.30648 
-
9.92001 0.292709 0.58849  
1050 0 0 0 Undefined 0 0 0 0 1  
1051 0 0 0 Undefined 0 0 0 0 1  
1052 2.46E-14 0 5.26361 0 -1.89E-13 2.90E-15 
-
11.1906 0 1  
1053 0 0 0 Undefined 0 0 0 0 1  
1054 0 0 0 Undefined 0 0 0 0 1  
1055 0 0 0 Undefined 0 0 0 0 1  
1056 0 0 0 Undefined 0 0 0 0 1  
1057 0 0 0 Undefined 0 0 0 0 1  
1058 0 0 0 Undefined 0 0 0 0 1  
Appendix 4 Chapter 7 Analysis of Selective Pressure  
1059 12.9699 0 0 0 -99.4957 10.9005 
-
14.7641 0.924264 0.336358  
1060 2.35E-15 0 2.48718 0 -1.80E-14 0 
-
11.8416 0 1  
1061 0 0 0 Undefined 0 0 0 0 1  
1062 0 0 0 Undefined 0 0 0 0 1  
1063 0 0 0 Undefined 0 0 0 0 1  
1064 1.56426 0 0 0 -11.9999 1.47358 -8.7652 0.118655 0.730497  
1065 1.50599 0 0 0 -11.5529 1.30117 
-
8.30796 0.291415 0.589315  
1066 0 0 0 Undefined 0 0 0 0 1  
1067 0 0 0 Undefined 0 0 0 0 1  
1068 1.55855 0 0 0 -11.9561 1.4685 
-
10.2337 0.118234 0.730957  
1069 0 0 0 Undefined 0 0 0 0 1  
1070 0 0 0 Undefined 0 0 0 0 1  
1071 0 0 0 Undefined 0 0 0 0 1  
1072 0 0 0 Undefined 0 0 0 0 1  
1073 0 0 0 Undefined 0 0 0 0 1  
1074 0 0 0 Undefined 0 0 0 0 1  
1075 0 0 0 Undefined 0 0 0 0 1  
1076 0 0 0 Undefined 0 0 0 0 1  
1077 0 0 0 Undefined 0 0 0 0 1  
1078 2.67788 0 0 0 -20.5427 2.18803 
-
10.5218 0.401786 0.526168  
1079 0 0 0 Undefined 0 0 0 0 1  
1080 0 0 0 Undefined 0 0 0 0 1  
1081 0 0 0 Undefined 0 0 0 0 1  
1082 0 0 0 Undefined 0 0 
-
3.20361 0 1  
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1083 42.9121 0 2.31453 0 -329.19 13.599 
-
21.6601 4.62169 0.03157 neg 
1084 0 0 0 Undefined 0 0 0 0 1  
1085 0 0 0 Undefined 0 0 0 0 1  
1086 0 0 0 Undefined 0 0 0 0 1  
1087 0 0 0 Undefined 0 0 0 0 1  
1088 0 0 0 Undefined 0 0 0 0 1  
1089 4.61141 0 0 0 -35.3754 3.78711 
-
16.1061 1.16931 0.279543  
1090 0 0 0 Undefined 0 0 0 0 1  
1091 0 0 0 Undefined 0 0 0 0 1  
1092 0 0 0 Undefined 0 0 0 0 1  
1093 0 0 0 Undefined 0 0 0 0 1  
1094 0 0 0 Undefined 0 0 
-
3.57414 0 1  
1095 16.709 0 0 0 -128.18 13.2124 
-
61.5539 4.06435 0.043798 neg 
1096 0 0 0 Undefined 0 0 0 0 1  
1097 0 0 0 Undefined 0 0 0 0 1  
1098 0 0 0 Undefined 0 0 0 0 1  
1099 0 0 0 Undefined 0 0 0 0 1  
1100 0 0 0 Undefined 0 0 0 0 1  
1101 0 0 0 Undefined 0 0 0 0 1  
1102 0 0 0 Undefined 0 0 0 0 1  
1103 0 0 0 Undefined 0 0 0 0 1  
1104 0 0 0 Undefined 0 0 0 0 1  
1105 0 0 0 Undefined 0 0 0 0 1  
1106 0 0 0 Undefined 0 0 0 0 1  
1107 0 0 0 Undefined 0 0 0 0 1  
1108 0 0 0 Undefined 0 0 0 0 1  
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1109 0 0 0 Undefined 0 0 0 0 1  
1110 0 0 0 Undefined 0 0 0 0 1  
1111 0 0 0 Undefined 0 0 0 0 1  
1112 0 0 0 Undefined 0 0 0 0 1  
1113 0 0 0 Undefined 0 0 0 0 1  
1114 0 0 0 Undefined 0 0 0 0 1  
1115 0 0 0 Undefined 0 0 0 0 1  
1116 0 0 0 Undefined 0 0 0 0 1  
1117 10.0042 0 0 0 -76.7451 8.60068 -24.817 1.75702 0.184997 neg 
1118 0 0 0 Undefined 0 0 0 0 1  
1119 0 0 0 Undefined 0 0 0 0 1  
1120 0 0 0 Undefined 0 0 0 0 1  
1121 0 0 0 Undefined 0 0 0 0 1  
1122 0 0 0 Undefined 0 0 0 0 1  
1123 0 0 0 Undefined 0 0 0 0 1  
1124 0 0 0 Undefined 0 0 0 0 1  
1125 0 0 0 Undefined 0 0 0 0 1  
1126 0 0 0 Undefined 0 0 0 0 1  
1127 0 0 0 Undefined 0 0 0 0 1  
1128 0 0 0 Undefined 0 0 0 0 1  
1129 0 0 0 Undefined 0 0 0 0 1  
1130 0 0 0 Undefined 0 0 0 0 1  
1131 0 0 0 Undefined 0 0 0 0 1  
1132 0 0 0 Undefined 0 0 0 0 1  
1133 0 0 0 Undefined 0 0 0 0 1  
1134 0 0 0 Undefined 0 0 0 0 1  
1135 0 0 0 Undefined 0 0 0 0 1  
1136 19.1833 0 0 0 -147.16 15.0388 
-
38.4198 4.57583 0.032426 neg 
1137 0 0 0 Undefined 0 0 0 0 1  
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1138 0 0 0 Undefined 0 0 0 0 1  
1139 0 0 0 Undefined 0 0 0 0 1  
1140 0 0 0 Undefined 0 0 0 0 1  
1141 0 0 0 Undefined 0 0 0 0 1  
1142 0 0 0 Undefined 0 0 0 0 1  
1143 0 0 0 Undefined 0 0 0 0 1  
1144 0 0 0 Undefined 0 0 0 0 1  
1145 0 0 0 Undefined 0 0 0 0 1  
1146 0 0 0 Undefined 0 0 0 0 1  
1147 0 0 0 Undefined 0 0 0 0 1  
1148 0 0 0 Undefined 0 0 0 0 1  
1149 0 0 0 Undefined 0 0 0 0 1  
1150 0 0 0 Undefined 0 0 0 0 1  
1151 0 0 0 Undefined 0 0 0 0 1  
1152 0 0 0 Undefined 0 0 0 0 1  
1153 0 0 0 Undefined 0 0 0 0 1  
1154 0 0 0 Undefined 0 0 0 0 1  
1155 0 0 0 Undefined 0 0 0 0 1  
1156 0 0 0 Undefined 0 0 0 0 1  
1157 4.13687 0 0 0 -31.7351 3.54131 
-
9.27786 0.298568 0.584782  
1158 3.18E-14 10.0232 2.26749 3.15E+14 76.8909 7.01566 
-
15.8961 0.697068 0.403771  
1159 4.90E-15 0 2.30672 0 -3.76E-14 0 
-
11.1882 0 1  
1160 0 0 0 Undefined 0 0 0 0 1  
1161 0 0 0 Undefined 0 0 0 0 1  
1162 0 0 0 Undefined 0 0 0 0 1  
1163 0 0 0 Undefined 0 0 0 0 1  
1164 0 0 0 Undefined 0 0 0 0 1  
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1165 0 0 0 Undefined 0 0 0 0 1  
1166 0 0 0 Undefined 0 0 0 0 1  
1167 0 0 0 Undefined 0 0 0 0 1  
1168 0 0 0 Undefined 0 0 0 0 1  
1169 0 0 0 Undefined 0 0 0 0 1  
1170 0 0 0 Undefined 0 0 0 0 1  
1171 0 0 0 Undefined 0 0 0 0 1  
1172 0 0 0 Undefined 0 0 0 0 1  
1173 0 0 0 Undefined 0 0 0 0 1  
1174 0 0 0 Undefined 0 0 0 0 1  
1175 0 0 0 Undefined 0 0 0 0 1  
1176 0 0 0 Undefined 0 0 0 0 1  
1177 0 0 0 Undefined 0 0 0 0 1  
1178 0 0 0 Undefined 0 0 0 0 1  
1179 0 0 0 Undefined 0 0 0 0 1  
1180 0 0 0 Undefined 0 0 -3.2907 0 1  
1181 0 0 0 Undefined 0 0 
-
3.20361 0 1  
1182 0 0 0 Undefined 0 5.55E-17 
-
3.13851 0 1  
1183 5.96E-14 0 0 0 -4.57E-13 0 -4.4515 0 1  
1184 0.922886 0 0 0 -7.07971 0 
-
5.18039 0 1  
1185 0 0 0 Undefined 0 0 
-
4.37207 0 1  
1186 0 0 0 Undefined 0 0 
-
3.25838 0 1  
1187 0 0 0 Undefined 0 7.62E-16 
-
3.39368 0 1  
1188 5.55E-17 0 0 0 -4.26E-16 0 
-
4.67916 0 1  
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1189 0 0 0 Undefined 0 0 
-
4.73944 0 1  
1190 0 0 0 Undefined 0 0 
-
4.35807 0 1  
1191 0 0 0 Undefined 0 5.55E-17 
-
4.25509 0 1  
1192 0 0 0 Undefined 0 0 
-
3.25838 0 1  
1193 3.23E-13 20.62 20.2811 6.38E+13 158.181 14.2298 
-
62.6069 1.41063 0.234951  
1194 0 0 0 Undefined 0 0 
-
3.67712 0 1  
1195 5.93E-14 0 0 0 -4.55E-13 0 -4.4515 0 1  
1196 1.49789 0 0 0 -11.4907 1.21438 
-
10.8133 0.418175 0.517849  
1197 3.15261 0 0 0 -24.1845 2.76278 
-
13.2998 0.523479 0.469361  
1198 1.50186 0 0 0 -11.5212 1.31992 
-
15.7473 0.257353 0.611944  
1199 59.5757 0 1.73704 0 -457.022 41.1447 
-
52.9909 12.5635 0.000393 neg 
1200 0 0 0 Undefined 0 0 
-
3.57414 0 1  
1201 0 0 0 Undefined 0 0 
-
3.22561 0 1  
1202 3.40E-15 11.3713 2.66367 3.34E+15 87.2326 2.73761 
-
16.6177 2.8297 0.092535 pos 
1203 5.67E-14 0 0 0 -4.35E-13 0 
-
4.53859 0 1  
1204 0 0 0 Undefined 0 0 
-
3.25838 0 1  
1205 0 0 0 Undefined 0 0 
-
3.20361 0 1  
Appendix 4 Chapter 7 Analysis of Selective Pressure  
1206 1.00E-14 0 0 0 -7.68E-14 0 
-
4.25221 0 1  
1207 0 0 0 Undefined 0 0 
-
4.62274 0 1  
1208 5.09E-14 0 31.6958 0 -3.91E-13 9.00E-15 
-
30.1803 0 1  
1209 6.42752 0 0 0 -49.3073 3.97192 -10.731 0.966305 0.325603  
1210 6.61E-15 0 0 0 -5.07E-14 0 -4.3393 0 1  
1211 5.55E-17 0 0 0 -4.26E-16 0 -4.19 0 1  
1212 0 0 0 Undefined 0 0 
-
4.45466 0 1  
1213 1.58548 0 0 0 -12.1627 1.52147 
-
8.17587 0.081872 0.774776  
1214 0 0 0 Undefined 0 0 -3.2907 0 1  
1215 0 0 0 Undefined 0 0 
-
3.42645 0 1  
1216 0 0 0 Undefined 0 7.62E-16 
-
3.39368 0 1  
1217 0 0 0 Undefined 0 0 
-
4.15723 0 1  
1218 0 0 0 Undefined 0 0 
-
4.50575 0 1  
1219 0 0 0 Undefined 0 0 
-
3.67712 0 1  
1220 0 0 0 Undefined 0 0 
-
3.67712 0 1  
1221 3.6569 0 0 0 -28.0531 2.31647 -9.6741 0.893264 0.344594  
1222 0 0 0 Undefined 0 0 
-
3.57414 0 1  
1223 4.66299 0 0 0 -35.7711 3.78639 -16.322 1.23711 0.266029  
1224 5.55E-17 0 0 0 -4.26E-16 0 
-
4.67916 0 1  
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1225 0 0 0 Undefined 0 0 
-
3.22561 0 1  
1226 0 0 0 Undefined 0 0 
-
4.35807 0 1  
1227 4.56283 0 2.65428 0 -35.0027 4.00232 
-
27.8719 0.777069 0.378039  
1228 0 0 0 Undefined 0 0 
-
5.06052 0 1  
1229 0 0 0 Undefined 0 0 -3.2907 0 1  
1230 0 0 0 Undefined 0 5.55E-17 
-
4.07013 0 1  
1231 0 0 0 Undefined 0 5.55E-17 
-
4.25509 0 1  
1232 0 0 0 Undefined 0 0 
-
4.45466 0 1  
1233 0 0 0 Undefined 0 5.55E-17 
-
3.13851 0 1  
1234 5.96E-14 0 0 0 -4.57E-13 0 -4.4515 0 1  
1235 0 0 0 Undefined 0 0 
-
4.63646 0 1  
1236 0 0 0 Undefined 0 5.55E-17 
-
3.13851 0 1  
1237 5.96E-14 0 0 0 -4.57E-13 0 -4.4515 0 1  
1238 0 0 0 Undefined 0 0 
-
3.32347 0 1  
1239 0 0 0 Undefined 0 5.55E-17 
-
4.25509 0 1  
1240 0 0 0 Undefined 0 0 
-
4.17123 0 1  
1241 0 0 0 Undefined 0 0 
-
3.22561 0 1  
1242 9.80E-15 0 2.49744 0 -7.52E-14 0 
-
11.2486 0 1  
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1243 0 0 0 Undefined 0 0 
-
4.76626 0 1  
1244 0 0 0 Undefined 0 0 -4.3253 0 1  
1245 0 0 0 Undefined 0 5.55E-17 
-
3.83464 0 1  
1246 5.97E-15 0 0 0 -4.58E-14 0 
-
4.23632 0 1  
1247 0 0 0 Undefined 0 0 
-
3.67712 0 1  
1248 0 0 0 Undefined 0 0 
-
3.22561 0 1  
1249 0 0 0 Undefined 0 0 
-
3.32347 0 1  
1250 0 0 0 Undefined 0 5.55E-17 
-
3.74754 0 1  
1251 11.6916 0 0 0 -89.6895 7.39306 
-
16.1543 2.552 0.110154 neg 
1252 0 0 0 Undefined 0 0 
-
4.51976 0 1  
1253 6.61E-15 0 0 0 -5.07E-14 0 -4.3393 0 1  
1254 2.88E-14 0 0 0 -2.21E-13 0 
-
4.82203 0 1  
1255 0 0 0 Undefined 0 0 -3.2907 0 1  
1256 0 0 0 Undefined 0 0 
-
3.22561 0 1  
1257 0 0 0 Undefined 0 7.62E-16 
-
3.39368 0 1  
1258 6.61E-15 0 0 0 -5.07E-14 0 -4.3393 0 1  
1259 0 0 0 Undefined 0 0 
-
4.26909 0 1  
1260 0 0 0 Undefined 0 0 
-
4.50575 0 1  
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1261 0 0 0 Undefined 0 5.55E-17 
-
3.13851 0 1  
1262 0 0 0 Undefined 0 0 
-
3.57414 0 1  
1263 0 0 0 Undefined 0 0 -4.3253 0 1  
1264 3.21919 0 0 0 -24.6953 2.89058 
-
12.5159 0.427122 0.513404  
1265 5.96E-14 0 0 0 -4.57E-13 0 -4.4515 0 1  
1266 0.922886 0 0 0 -7.07971 0 
-
4.60369 0 1  
1267 0 0 0 Undefined 0 0 
-
4.63646 0 1  
1268 0 0 0 Undefined 0 0 
-
3.42645 0 1  
1269 0 0 0 Undefined 0 0 
-
3.57414 0 1  
1270 0 0 0 Undefined 0 0 
-
4.45466 0 1  
1271 0 0 0 Undefined 0 0 
-
4.45466 0 1  
1272 0 0 0 Undefined 0 0 
-
3.20361 0 1  
1273 0 0 0 Undefined 0 0 
-
3.20361 0 1  
1274 0 0 0 Undefined 0 0 
-
4.17123 0 1  
1275 5.55E-17 0 0 0 -4.26E-16 0 -4.2382 0 1  
1276 3.7345 0 0 0 -28.6484 2.38656 
-
9.81292 0.874692 0.34966  
1277 0 0 0 Undefined 0 0 
-
3.22561 0 1  
1278 5.96E-14 0 0 0 -4.57E-13 0 -4.4515 0 1  
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1279 0 0 0 Undefined 0 0 
-
3.42645 0 1  
1280 5.55E-17 0 0 0 -4.26E-16 0 -4.19 0 1  
1281 5.97E-15 0 0 0 -4.58E-14 0 
-
4.23632 0 1  
1282 0 0 0 Undefined 0 5.55E-17 
-
4.07013 0 1  
1283 0 0 0 Undefined 0 0 
-
3.57414 0 1  
1284 0 0 0 Undefined 0 0 
-
4.17123 0 1  
1285 5.96E-14 0 0 0 -4.57E-13 0 -4.4515 0 1  
1286 0 0 0 Undefined 0 0 
-
3.57414 0 1  
1287 5.55E-17 0 0 0 -4.26E-16 0 
-
4.67916 0 1  
1288 0 0 0 Undefined 0 0 
-
3.22561 0 1  
1289 0 0 0 Undefined 0 0 
-
3.25838 0 1  
1290 0 0 0 Undefined 0 7.62E-16 
-
3.39368 0 1  
1291 0 0 0 Undefined 0 0 
-
3.25838 0 1  
1292 5.55E-17 0 0 0 -4.26E-16 0 -4.19 0 1  
1293 0 0 0 Undefined 0 0 
-
4.15723 0 1  
1294 0 0 0 Undefined 0 0 
-
4.17123 0 1  
1295 0.922886 0 0 0 -7.07971 0 
-
5.18039 0 1  
1296 0 0 0 Undefined 0 0 -4.9901 0 1  
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1297 0.922886 0 0 0 -7.07971 0 
-
5.18039 0 1  
1298 5.55E-17 0 0 0 -4.26E-16 0 -4.19 0 1  
1299 0 0 0 Undefined 0 0 -3.2907 0 1  
1300 0.922886 0 0 0 -7.07971 0 
-
5.18039 0 1  
1301 0 0 0 Undefined 0 0 
-
3.57414 0 1  
1302 0 0 0 Undefined 0 5.55E-17 
-
3.74754 0 1  
1303 1.59372 0 0 0 -12.2259 1.30314 
-
9.88543 0.40106 0.526542  
1304 0 0 0 Undefined 0 0 -3.2907 0 1  
1305 0 0 0 Undefined 0 0 
-
3.30659 0 1  
1306 0 0 0 Undefined 0 0 
-
5.06052 0 1  
1307 0 0 0 Undefined 0 0 
-
3.57414 0 1  
1308 0 0 0 Undefined 0 0 
-
3.20361 0 1  
1309 5.55E-17 0 0 0 -4.26E-16 0 -4.2382 0 1  
1310 0 0 0 Undefined 0 0 
-
4.26909 0 1  
1311 0 0 0 Undefined 0 0 
-
3.30659 0 1  
1312 0 0 0 Undefined 0 0 
-
4.51976 0 1  
1313 0 0 2.54668 Undefined 0 0 
-
14.7254 0 1  
1314 1.23E-15 0 5.05499 0 -9.40E-15 0 
-
15.5467 0 1  
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1315 0 0 0 Undefined 0 5.55E-17 
-
4.25509 0 1  
1316 0 0 0 Undefined 0 5.55E-17 
-
4.25509 0 1  
1317 5.97E-15 0 0 0 -4.58E-14 0 
-
4.23632 0 1  
1318 0 0 0 Undefined 0 0 
-
4.88712 0 1  
1319 0 0 0 Undefined 0 0 
-
4.79902 0 1  
1320 0 0 0 Undefined 0 0 
-
4.79902 0 1  
1321 0 0 0 Undefined 0 7.62E-16 
-
3.39368 0 1  
1322 0 0 0 Undefined 0 5.55E-17 
-
3.74754 0 1  
1323 0 0 0 Undefined 0 0 
-
3.86741 0 1  
1324 5.55E-17 0 0 0 -4.26E-16 0 
-
4.67916 0 1  
1325 6.61E-15 0 0 0 -5.07E-14 0 -4.3393 0 1  
1326 0 0 0 Undefined 0 0 
-
4.15723 0 1  
1327 0 0 0 Undefined 0 0 
-
3.86741 0 1  
1328 0.922886 0 0 0 -7.07971 0 
-
4.60369 0 1  
1329 2.25E-14 0 0 0 -1.73E-13 0 
-
4.69316 0 1  
1330 0 0 0 Undefined 0 0 
-
4.17123 0 1  
1331 0 0 0 Undefined 0 0 
-
3.57414 0 1  
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1332 5.67E-14 0 0 0 -4.35E-13 0 
-
4.53859 0 1  
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1334 0 0 0 Undefined 0 0 
-
3.22561 0 1  
1335 2.78E-17 0 0 0 -2.13E-16 7.62E-16 
-
4.11807 0 1  
1336 0 0 0 Undefined 0 0 
-
3.86741 0 1  
1337 0 0 0 Undefined 0 0 
-
3.86741 0 1  
1338 4.11263 0 0 0 -31.5491 3.52322 
-
9.29226 0.296941 0.585807  
1339 2.85E-15 0 0 0 -2.19E-14 0 
-
4.78026 0 1  
1340 1.58545 0 0 0 -12.1624 1.42605 
-
8.20864 0.211086 0.645918  
1341 5.96E-14 0 0 0 -4.57E-13 0 -4.4515 0 1  
1342 6.46E-14 0 0 0 -4.95E-13 0 
-
4.08413 0 1  
1343 5.55E-17 0 0 0 -4.26E-16 0 -4.19 0 1  
1344 0 0 0 Undefined 0 5.55E-17 
-
4.07013 0 1  
1345 0 0 0 Undefined 0 0 
-
4.50575 0 1  
1346 5.64E-14 0 4.97015 0 -4.33E-13 5.28E-15 
-
12.0542 0 1  
1347 0 0 0 Undefined 0 0 -4.9901 0 1  
1348 0 0 0 Undefined 0 0 
-
3.50904 0 1  
1349 5.67E-14 0 0 0 -4.35E-13 0 
-
4.53859 0 1  
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1350 0 0 0 Undefined 0 0 
-
3.20361 0 1  
1351 0 0 0 Undefined 0 0 
-
3.50904 0 1  
1352 0 0 0 Undefined 0 0 
-
3.20361 0 1  




15 1  
1354 0 0 0 Undefined 0 5.55E-17 
-
4.44066 0 1  




























1 0.807465 0.120706 -0.68676 0.288485 0.53065 1.751998 14.76076 0.005146 0.761786 
 
2 0.529974 0.126212 -0.40376 0.301655 0.517326 1.735532 14.89597 0.005177 0.811586 
 
3 0.122572 0.108548 -0.01402 0.332057 0.457447 1.78676 14.49487 0.00733 0.934044 
 
4 0.299843 0.11225 -0.18759 0.294446 0.515641 1.766334 14.64803 0.005696 0.784095 
 
5 0.18002 0.118023 -0.062 0.313873 0.493976 1.750592 14.77207 0.005904 0.859495 
 
6 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
7 0.137765 0.117985 -0.01978 0.332467 0.466686 1.7598 14.69885 0.006601 0.935768 
 
8 0.129587 0.115995 -0.01359 0.336283 0.459012 1.767932 14.63574 0.006911 0.951954 
 
9 0.807465 0.120706 -0.68676 0.288485 0.53065 1.751998 14.76076 0.005146 0.761786 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
10 0.119634 0.099134 -0.0205 0.319105 0.465118 1.810768 14.32526 0.007655 0.880536 
 
11 0.149251 0.113574 -0.03568 0.319463 0.481552 1.764721 14.66049 0.006401 0.881986 
 
12 0.15418 0.121821 -0.03236 0.327492 0.477585 1.746698 14.8036 0.006151 0.914946 
 
13 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
14 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
15 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
16 0.428398 0.164376 -0.26402 0.329643 0.496732 1.687859 15.32582 0.00478 0.923913 
 
17 0.164863 0.135153 -0.02971 0.336501 0.474286 1.723748 14.9967 0.005791 0.952881 
 
18 0.125007 0.118057 -0.00695 0.342929 0.450893 1.767693 14.63757 0.007062 0.980584 
 
19 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
20 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
21 0.309108 0.12188 -0.18723 0.305363 0.509129 1.742188 14.84056 0.005453 0.825945 
 
22 0.185886 0.134268 -0.05162 0.329437 0.484296 1.720399 15.02596 0.005567 0.923051 
 
23 0.497805 0.333548 -0.16426 0.586395 0.345092 1.054014 91.85549 0.001792 2.66378 
 
24 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
25 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
26 0.315902 2.41528 2.09937 0.922437 0.051365 1.006011 458.7956 0.000417 22.3446 Pos 
27 0.328108 0.146951 -0.18116 0.325526 0.496689 1.701364 15.19783 0.005022 0.906805 
 
28 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
29 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
30 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
31 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
32 0.326897 0.144523 -0.18237 0.324112 0.497591 1.703953 15.17388 0.005051 0.900975 
 
33 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
34 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
35 0.529974 0.126212 -0.40376 0.301655 0.517326 1.735532 14.89597 0.005177 0.811586 
 
36 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
37 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
38 5.78187 0.250758 -5.53112 0.0072629 0.987908 1.007951 391.2684 3.61E-06 0.013746 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
39 0.119641 0.099155 -0.02049 0.319136 0.4651 1.81071 14.32566 0.007654 0.880661 
 
40 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
41 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
42 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
43 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
44 0.824662 0.126773 -0.69789 0.294472 0.527241 1.737637 14.87833 0.00501 0.784194 
 
45 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
46 0.302077 0.133991 -0.16809 0.317616 0.500973 1.718232 15.04505 0.005228 0.874514 
 
47 0.292216 0.105109 -0.18711 0.285488 0.52087 1.786794 14.49462 0.0059 0.750709 
 
48 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
49 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
50 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
51 0.251361 0.346811 0.095451 0.637318 0.293868 1.055437 89.87212 0.001786 3.30159 
 
52 0.328108 0.146951 -0.18116 0.325526 0.496689 1.701364 15.19783 0.005022 0.906805 
 
53 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
54 0.127754 0.133068 0.005314 0.355361 0.443261 1.747541 14.79674 0.006763 1.03573 
 
55 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
56 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
57 0.529974 0.126212 -0.40376 0.301655 0.517326 1.735532 14.89597 0.005177 0.811586 
 
58 0.206946 0.477519 0.270573 0.710147 0.227883 1.052508 94.05998 0.001461 4.60323 
 
59 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
60 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
61 0.384851 0.204461 -0.18039 0.210451 0.730596 1.010878 320.603 0.000815 0.5008 
 
62 0.152122 0.110475 -0.04165 0.313811 0.486534 1.771573 14.60793 0.006421 0.859247 
 
63 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
64 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
65 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
66 0.129011 0.144212 0.0152 0.36112 0.43966 1.739233 14.86503 0.006628 1.062 
 
67 0.529974 0.126212 -0.40376 0.301655 0.517326 1.735532 14.89597 0.005177 0.811586 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
68 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
69 0.122988 0.11119 -0.0118 0.335598 0.455053 1.781176 14.5359 0.007263 0.949034 
 
70 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
71 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
72 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
73 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
74 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
75 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
76 0.116455 0.093632 -0.02282 0.312109 0.467986 1.82727 14.21471 0.007927 0.852472 
 
77 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
78 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
79 0.325358 0.145127 -0.18023 0.32456 0.497239 1.703291 15.17999 0.005046 0.902822 
 
80 0.127754 0.133068 0.005314 0.355361 0.443261 1.747541 14.79674 0.006763 1.03573 
 
81 0.158917 0.115266 -0.04365 0.317525 0.486073 1.759208 14.70351 0.006211 0.874148 
 
82 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
83 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
84 0.807465 0.120706 -0.68676 0.288485 0.53065 1.751998 14.76076 0.005146 0.761786 
 
85 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
86 12.6497 0.259671 -12.39 1.91E-05 0.99981 0.999283 1165.564 7.49E-11 3.59E-05 
 
87 0.125007 0.118057 -0.00695 0.342929 0.450893 1.767693 14.63757 0.007062 0.980584 
 
88 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
89 0.307392 0.119978 -0.18742 0.303337 0.51035 1.746575 14.8046 0.005497 0.818081 
 
90 0.325358 0.145127 -0.18023 0.32456 0.497239 1.703291 15.17999 0.005046 0.902822 
 
91 0.159029 0.115569 -0.04346 0.31788 0.485857 1.758508 14.70901 0.006203 0.875578 
 
92 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
93 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
94 0.308365 0.695235 0.38687 0.79413 0.150119 1.005728 470.7183 0.002047 23.2941 
 
95 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
96 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
97 0.616562 0.574823 -0.04174 0.699495 0.245894 1.005998 459.3452 0.001385 4.37346 
 
98 0.867281 1.73923 0.871944 0.684875 0.259104 1.026219 166.8322 0.001101 4.0834 
 
99 0.328108 0.146951 -0.18116 0.325526 0.496689 1.701364 15.19783 0.005022 0.906805 
 
100 0.149251 0.113574 -0.03568 0.319463 0.481552 1.764721 14.66049 0.006401 0.881986 
 
101 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
102 0.309108 0.12188 -0.18723 0.305363 0.509129 1.742188 14.84056 0.005453 0.825945 
 
103 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
104 0.129011 0.144212 0.0152 0.36112 0.43966 1.739233 14.86503 0.006628 1.062 
 
105 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
106 0.251353 0.346811 0.095458 0.637322 0.293864 1.055438 89.87072 0.001786 3.30164 
 
107 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
108 0.211401 0.738874 0.527473 0.736243 0.20677 1.046239 104.6325 0.001239 5.24458 
 
109 0.12122 0.10854 -0.01268 0.333349 0.455484 1.787664 14.48829 0.007391 0.939493 
 
110 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
111 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
112 18.3513 0.242641 -18.1087 2.84E-07 0.999992 0.998964 1258.427 1.86E-14 5.34E-07 
 
113 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
114 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
115 0.185886 0.134268 -0.05162 0.329437 0.484296 1.720399 15.02596 0.005567 0.923051 
 
116 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
117 0.12122 0.10854 -0.01268 0.333349 0.455484 1.787664 14.48829 0.007391 0.939493 
 
118 0.12122 0.10854 -0.01268 0.333349 0.455484 1.787664 14.48829 0.007391 0.939493 
 
119 0.152122 0.110475 -0.04165 0.313811 0.486534 1.771573 14.60793 0.006421 0.859247 
 
120 0.529974 0.126212 -0.40376 0.301655 0.517326 1.735532 14.89597 0.005177 0.811586 
 
121 0.325358 0.145127 -0.18023 0.32456 0.497239 1.703291 15.17999 0.005046 0.902822 
 
122 0.307392 0.119978 -0.18742 0.303337 0.51035 1.746575 14.8046 0.005497 0.818081 
 
123 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
124 0.120741 0.106858 -0.01388 0.331193 0.45677 1.791543 14.46021 0.007445 0.930407 
 
125 0.281989 1.13767 0.855681 0.718604 0.225421 1.033697 136.0689 0.001159 4.79805 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
126 0.372688 0.1661 -0.20659 0.176455 0.766929 1.01504 255.6241 0.000693 0.402569 
 
127 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
128 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
129 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
130 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
131 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
132 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
133 0.20974 0.616558 0.406819 0.726755 0.214404 1.048032 101.353 0.001316 4.99722 
 
134 0.292216 0.105109 -0.18711 0.285488 0.52087 1.786794 14.49462 0.0059 0.750709 
 
135 0.25136 0.347049 0.09569 0.63743 0.293769 1.055386 89.94185 0.001785 3.3032 
 
136 0.121684 0.110224 -0.01146 0.335439 0.454234 1.783938 14.51553 0.007339 0.948357 
 
137 0.209729 0.616436 0.406707 0.726751 0.214406 1.048038 101.3427 0.001317 4.99713 
 
138 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
139 0.256226 0.416576 0.160349 0.659347 0.274941 1.045736 105.5942 0.001597 3.63659 
 
140 0.529974 0.126212 -0.40376 0.301655 0.517326 1.735532 14.89597 0.005177 0.811586 
 
141 0.304039 0.152278 -0.15176 0.329542 0.493117 1.696709 15.24136 0.005001 0.923491 
 
142 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
143 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
144 0.125007 0.118057 -0.00695 0.342929 0.450893 1.767693 14.63757 0.007062 0.980584 
 
145 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
146 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
147 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
148 0.807465 0.120706 -0.68676 0.288485 0.53065 1.751998 14.76076 0.005146 0.761786 
 
149 0.129587 0.115995 -0.01359 0.336283 0.459012 1.767932 14.63574 0.006911 0.951954 
 
150 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
151 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
152 0.299843 0.11225 -0.18759 0.294446 0.515641 1.766334 14.64803 0.005696 0.784095 
 
153 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
154 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
155 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
156 0.119634 0.099134 -0.0205 0.319105 0.465118 1.810768 14.32526 0.007655 0.880536 
 
157 0.299843 0.11225 -0.18759 0.294446 0.515641 1.766334 14.64803 0.005696 0.784095 
 
158 0.275629 0.736773 0.461144 0.6956 0.244592 1.036053 128.6971 0.001307 4.29346 
 
159 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
160 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
161 0.80757 0.120741 -0.68683 0.288522 0.530629 1.751909 14.76148 0.005146 0.761923 
 
162 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
163 0.119893 0.104002 -0.01589 0.327391 0.45903 1.798458 14.41088 0.00754 0.914528 
 
164 0.119634 0.099134 -0.0205 0.319105 0.465118 1.810768 14.32526 0.007655 0.880536 
 
165 0.119634 0.099134 -0.0205 0.319105 0.465118 1.810768 14.32526 0.007655 0.880536 
 
166 0.281258 1.08439 0.803129 0.71607 0.22752 1.033927 135.3078 0.001174 4.73847 
 
167 0.264738 0.39956 0.134822 0.650831 0.282775 1.046457 104.221 0.001633 3.50207 
 
168 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
169 0.137765 0.117985 -0.01978 0.332467 0.466686 1.7598 14.69885 0.006601 0.935768 
 
170 18.4243 0.263901 -18.1604 3.10E-07 0.999983 1.002459 673.3397 1.26E-13 5.82E-07 
 
171 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
172 0.149251 0.113574 -0.03568 0.319463 0.481552 1.764721 14.66049 0.006401 0.881986 
 
173 0.116455 0.093632 -0.02282 0.312109 0.467986 1.82727 14.21471 0.007927 0.852472 
 
174 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
175 0.325358 0.145127 -0.18023 0.32456 0.497239 1.703291 15.17999 0.005046 0.902822 
 
176 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
177 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
178 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
179 0.15418 0.121821 -0.03236 0.327492 0.477585 1.746698 14.8036 0.006151 0.914946 
 
180 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
181 0.384625 0.146753 -0.23787 0.323094 0.500021 1.701459 15.19696 0.004965 0.896795 
 
182 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
183 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
184 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
185 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
186 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
187 0.137765 0.117985 -0.01978 0.332467 0.466686 1.7598 14.69885 0.006601 0.935768 
 
188 0.326897 0.144523 -0.18237 0.324112 0.497591 1.703953 15.17388 0.005051 0.900975 
 
189 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
190 0.119893 0.104002 -0.01589 0.327391 0.45903 1.798458 14.41088 0.00754 0.914528 
 
191 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
192 0.325358 0.145127 -0.18023 0.32456 0.497239 1.703291 15.17999 0.005046 0.902822 
 
193 0.856184 0.256189 -0.6 0.185878 0.762613 1.004662 521.7442 0.000607 0.428975 
 
194 0.264912 0.402394 0.137481 0.651577 0.282132 1.04618 104.7444 0.001627 3.51359 
 
195 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
196 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
197 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
198 0.206409 0.552828 0.346419 0.722669 0.217424 1.050336 97.45181 0.001367 4.89591 
 
199 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
200 0.118142 0.098551 -0.01959 0.319587 0.463625 1.813023 14.30987 0.007737 0.88249 
 
201 0.269014 0.490008 0.220994 0.668974 0.267185 1.040899 115.915 0.001493 3.79699 
 
202 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
203 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
204 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
205 0.120741 0.106858 -0.01388 0.331193 0.45677 1.791543 14.46021 0.007445 0.930407 
 
206 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
207 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
208 3.39469 0.242904 -3.15178 0.00678787 0.986665 1.007398 408.3946 4.71E-06 0.012841 
 
209 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
210 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
211 18.6256 0.256147 -18.3694 0.00277887 0.996029 1.003516 590.8611 3.61E-07 0.005236 
 
212 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
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213 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
214 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
215 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
216 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
217 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
218 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
219 0.125007 0.118057 -0.00695 0.342929 0.450893 1.767693 14.63757 0.007062 0.980584 
 
220 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
221 0.152122 0.110475 -0.04165 0.313811 0.486534 1.771573 14.60793 0.006421 0.859247 
 
222 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
223 0.120741 0.106858 -0.01388 0.331193 0.45677 1.791543 14.46021 0.007445 0.930407 
 
224 0.164863 0.135153 -0.02971 0.336501 0.474286 1.723748 14.9967 0.005791 0.952881 
 
225 0.415956 0.191703 -0.22425 0.193127 0.750056 1.010457 329.1179 0.000735 0.449707 
 
226 0.129011 0.144212 0.0152 0.36112 0.43966 1.739233 14.86503 0.006628 1.062 
 
227 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
228 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
229 0.328108 0.146951 -0.18116 0.325526 0.496689 1.701364 15.19783 0.005022 0.906805 
 
230 0.326897 0.144523 -0.18237 0.324112 0.497591 1.703953 15.17388 0.005051 0.900975 
 
231 0.82788 0.20784 -0.62004 0.166886 0.783449 1.005905 463.2125 0.000553 0.376365 
 
232 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
233 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
234 0.15418 0.121821 -0.03236 0.327492 0.477585 1.746698 14.8036 0.006151 0.914946 
 
235 0.152122 0.110475 -0.04165 0.313811 0.486534 1.771573 14.60793 0.006421 0.859247 
 
236 0.129011 0.144212 0.0152 0.36112 0.43966 1.739233 14.86503 0.006628 1.062 
 
237 0.385983 0.182861 -0.20312 0.191657 0.750823 1.012354 293.9815 0.000746 0.445473 
 
238 0.121684 0.110224 -0.01146 0.335439 0.454234 1.783938 14.51553 0.007339 0.948357 
 
239 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
240 0.807465 0.120706 -0.68676 0.288485 0.53065 1.751998 14.76076 0.005146 0.761786 
 
241 0.125007 0.118057 -0.00695 0.342929 0.450893 1.767693 14.63757 0.007062 0.980584 
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242 0.256178 0.415767 0.159589 0.659166 0.275096 1.045799 105.4724 0.001599 3.63366 
 
243 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
244 0.129011 0.144212 0.0152 0.36112 0.43966 1.739233 14.86503 0.006628 1.062 
 
245 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
246 0.121684 0.110224 -0.01146 0.335439 0.454234 1.783938 14.51553 0.007339 0.948357 
 
247 0.428398 0.164376 -0.26402 0.329643 0.496732 1.687859 15.32582 0.00478 0.923913 
 
248 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
249 0.326897 0.144523 -0.18237 0.324112 0.497591 1.703953 15.17388 0.005051 0.900975 
 
250 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
251 0.15418 0.121821 -0.03236 0.327492 0.477585 1.746698 14.8036 0.006151 0.914946 
 
252 0.326897 0.144523 -0.18237 0.324112 0.497591 1.703953 15.17388 0.005051 0.900975 
 
253 0.824662 0.126773 -0.69789 0.294472 0.527241 1.737637 14.87833 0.00501 0.784194 
 
254 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
255 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
256 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
257 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
258 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
259 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
260 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
261 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
262 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
263 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
264 0.122572 0.108548 -0.01402 0.332057 0.457447 1.78676 14.49487 0.00733 0.934044 
 
265 0.116875 0.094828 -0.02205 0.313967 0.466907 1.823702 14.23821 0.00788 0.859867 
 
266 0.119634 0.099134 -0.0205 0.319105 0.465118 1.810768 14.32526 0.007655 0.880536 
 
267 7.50346 0.209324 -7.29414 0.0714607 0.904874 1.007935 391.7423 0.000128 0.144597 
 
268 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
269 0.175532 0.113282 -0.06225 0.308939 0.496493 1.762025 14.68144 0.006047 0.839944 
 
270 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
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271 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
272 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
273 0.149251 0.113574 -0.03568 0.319463 0.481552 1.764721 14.66049 0.006401 0.881986 
 
274 0.125007 0.118057 -0.00695 0.342929 0.450893 1.767693 14.63757 0.007062 0.980584 
 
275 0.380562 0.204121 -0.17644 0.211356 0.729496 1.011109 316.117 0.000821 0.503531 
 
276 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
277 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
278 0.807465 0.120706 -0.68676 0.288485 0.53065 1.751998 14.76076 0.005146 0.761786 
 
279 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
280 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
281 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
282 0.787887 0.205552 -0.58234 0.108057 0.855147 0.999569 1093.374 0.000366 0.22762 
 
283 0.121684 0.110224 -0.01146 0.335439 0.454234 1.783938 14.51553 0.007339 0.948357 
 
284 0.149251 0.113574 -0.03568 0.319463 0.481552 1.764721 14.66049 0.006401 0.881986 
 
285 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
286 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
287 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
288 16.1678 0.325552 -15.8423 0.000108173 0.999112 1.00652 438.8788 1.07E-08 0.000203 
 
289 0.15457 0.117245 -0.03733 0.321894 0.48162 1.755697 14.73125 0.006236 0.891882 
 
290 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
291 0.328108 0.146951 -0.18116 0.325526 0.496689 1.701364 15.19783 0.005022 0.906805 
 
292 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
293 27.2309 0.283157 -26.9478 1.09E-10 1 1.005047 502.0795 1.75E-20 2.05E-10 
 
294 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
295 0.122988 0.11119 -0.0118 0.335598 0.455053 1.781176 14.5359 0.007263 0.949034 
 
296 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
297 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
298 0.383267 0.180818 -0.20245 0.190291 0.752212 1.012684 288.643 0.000743 0.441553 
 
299 0.164863 0.135153 -0.02971 0.336501 0.474286 1.723748 14.9967 0.005791 0.952881 
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300 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
301 0.275633 0.741926 0.466293 0.696028 0.244229 1.036009 128.826 0.001304 4.30215 
 
302 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
303 0.122988 0.11119 -0.0118 0.335598 0.455053 1.781176 14.5359 0.007263 0.949034 
 
304 0.868084 1.74709 0.87901 0.685104 0.258902 1.026191 166.9758 0.0011 4.08774 
 
305 0.164863 0.135153 -0.02971 0.336501 0.474286 1.723748 14.9967 0.005791 0.952881 
 
306 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
307 0.384625 0.146753 -0.23787 0.323094 0.500021 1.701459 15.19696 0.004965 0.896795 
 
308 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
309 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
310 0.824662 0.126773 -0.69789 0.294472 0.527241 1.737637 14.87833 0.00501 0.784194 
 
311 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
312 0.201666 0.38521 0.183544 0.693941 0.240832 1.060752 83.22822 0.001638 4.26002 
 
313 0.379725 0.166832 -0.21289 0.175517 0.7682 1.014569 261.5873 0.000685 0.399973 
 
314 0.125007 0.118057 -0.00695 0.342929 0.450893 1.767693 14.63757 0.007062 0.980584 
 
315 0.309108 0.12188 -0.18723 0.305363 0.509129 1.742188 14.84056 0.005453 0.825945 
 
316 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
317 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
318 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
319 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
320 0.172132 0.101818 -0.07031 0.293328 0.506303 1.793985 14.44269 0.006371 0.779881 
 
321 0.15418 0.121821 -0.03236 0.327492 0.477585 1.746698 14.8036 0.006151 0.914946 
 
322 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
323 0.119634 0.099134 -0.0205 0.319105 0.465118 1.810768 14.32526 0.007655 0.880536 
 
324 0.129587 0.115995 -0.01359 0.336283 0.459012 1.767932 14.63574 0.006911 0.951954 
 
325 0.149251 0.113574 -0.03568 0.319463 0.481552 1.764721 14.66049 0.006401 0.881986 
 
326 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
327 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
328 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
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329 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
330 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
331 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
332 0.801261 0.20747 -0.59379 0.167913 0.782152 1.00597 460.515 0.00056 0.379147 
 
333 0.529974 0.126212 -0.40376 0.301655 0.517326 1.735532 14.89597 0.005177 0.811586 
 
334 0.119893 0.104002 -0.01589 0.327391 0.45903 1.798458 14.41088 0.00754 0.914528 
 
335 0.384625 0.146753 -0.23787 0.323094 0.500021 1.701459 15.19696 0.004965 0.896795 
 
336 0.254775 0.391436 0.136661 0.652909 0.280463 1.048138 101.1666 0.00165 3.53429 
 
337 0.529974 0.126212 -0.40376 0.301655 0.517326 1.735532 14.89597 0.005177 0.811586 
 
338 0.127754 0.133068 0.005314 0.355361 0.443261 1.747541 14.79674 0.006763 1.03573 
 
339 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
340 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
341 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
342 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
343 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
344 0.149251 0.113574 -0.03568 0.319463 0.481552 1.764721 14.66049 0.006401 0.881986 
 
345 0.299843 0.11225 -0.18759 0.294446 0.515641 1.766334 14.64803 0.005696 0.784095 
 
346 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
347 0.116875 0.094828 -0.02205 0.313967 0.466907 1.823702 14.23821 0.00788 0.859867 
 
348 0.122575 0.108557 -0.01402 0.332069 0.45744 1.786739 14.49502 0.00733 0.934093 
 
349 0.122921 0.109788 -0.01313 0.333607 0.456519 1.783977 14.51524 0.007292 0.940586 
 
350 0.299843 0.11225 -0.18759 0.294446 0.515641 1.766334 14.64803 0.005696 0.784095 
 
351 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
352 0.428398 0.164376 -0.26402 0.329643 0.496732 1.687859 15.32582 0.00478 0.923913 
 
353 0.118142 0.098551 -0.01959 0.319587 0.463625 1.813023 14.30987 0.007737 0.88249 
 
354 0.119634 0.099134 -0.0205 0.319105 0.465118 1.810768 14.32526 0.007655 0.880536 
 
355 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
356 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
357 0.428398 0.164376 -0.26402 0.329643 0.496732 1.687859 15.32582 0.00478 0.923913 
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358 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
359 0.325358 0.145127 -0.18023 0.32456 0.497239 1.703291 15.17999 0.005046 0.902822 
 
360 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
361 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
362 0.299843 0.11225 -0.18759 0.294446 0.515641 1.766334 14.64803 0.005696 0.784095 
 
363 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
364 0.175132 0.107575 -0.06756 0.301095 0.501698 1.777238 14.56521 0.006192 0.80943 
 
365 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
366 0.119634 0.099134 -0.0205 0.319105 0.465118 1.810768 14.32526 0.007655 0.880536 
 
367 0.428398 0.164376 -0.26402 0.329643 0.496732 1.687859 15.32582 0.00478 0.923913 
 
368 0.307392 0.119978 -0.18742 0.303337 0.51035 1.746575 14.8046 0.005497 0.818081 
 
369 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
370 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
371 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
372 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
373 0.299843 0.11225 -0.18759 0.294446 0.515641 1.766334 14.64803 0.005696 0.784095 
 
374 0.255565 0.403024 0.147459 0.655981 0.277832 1.046926 103.3489 0.001624 3.58263 
 
375 0.18002 0.118023 -0.062 0.313873 0.493976 1.750592 14.77207 0.005904 0.859495 
 
376 0.428398 0.164376 -0.26402 0.329643 0.496732 1.687859 15.32582 0.00478 0.923913 
 
377 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
378 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
379 0.428398 0.164376 -0.26402 0.329643 0.496732 1.687859 15.32582 0.00478 0.923913 
 
380 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
381 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
382 0.428398 0.164376 -0.26402 0.329643 0.496732 1.687859 15.32582 0.00478 0.923913 
 
383 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
384 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
385 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
386 0.299843 0.11225 -0.18759 0.294446 0.515641 1.766334 14.64803 0.005696 0.784095 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
387 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
388 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
389 0.129587 0.115995 -0.01359 0.336283 0.459012 1.767932 14.63574 0.006911 0.951954 
 
390 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
391 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
392 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
393 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
394 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
395 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
396 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
397 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
398 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
399 3.34101 0.224159 -3.11685 0.00601199 0.988974 1.00682 427.9529 3.77E-06 0.011364 
 
400 0.607195 0.725379 0.118184 0.649314 0.28962 1.032072 141.6973 0.001337 3.4788 
 
401 0.152122 0.110475 -0.04165 0.313811 0.486534 1.771573 14.60793 0.006421 0.859247 
 
402 0.149251 0.113574 -0.03568 0.319463 0.481552 1.764721 14.66049 0.006401 0.881986 
 
403 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
404 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
405 0.121684 0.110224 -0.01146 0.335439 0.454234 1.783938 14.51553 0.007339 0.948357 
 
406 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
407 0.122921 0.109788 -0.01313 0.333607 0.456519 1.783977 14.51524 0.007292 0.940586 
 
408 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
409 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
410 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
411 0.249772 0.33147 0.081697 0.630296 0.299902 1.059435 84.77204 0.001852 3.20319 
 
412 0.121684 0.110224 -0.01146 0.335439 0.454234 1.783938 14.51553 0.007339 0.948357 
 
413 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
414 0.149251 0.113574 -0.03568 0.319463 0.481552 1.764721 14.66049 0.006401 0.881986 
 
415 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
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416 0.299843 0.11225 -0.18759 0.294446 0.515641 1.766334 14.64803 0.005696 0.784095 
 
417 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
418 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
419 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
420 0.18002 0.118023 -0.062 0.313873 0.493976 1.750592 14.77207 0.005904 0.859495 
 
421 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
422 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
423 0.782417 0.176561 -0.60586 0.144578 0.808089 1.008516 375.2438 0.000475 0.317552 
 
424 0.336734 4.59085 4.25412 0.980721 0.007855 1.00337 600.9716 0.000106 95.5788 Pos 
425 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
426 0.164863 0.135153 -0.02971 0.336501 0.474286 1.723748 14.9967 0.005791 0.952881 
 
427 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
428 0.529974 0.126212 -0.40376 0.301655 0.517326 1.735532 14.89597 0.005177 0.811586 
 
429 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
430 0.292216 0.105109 -0.18711 0.285488 0.52087 1.786794 14.49462 0.0059 0.750709 
 
431 18.6588 0.499505 -18.1593 0.0061235 0.990351 0.999662 1071.653 2.11E-06 0.011576 
 
432 0.307392 0.119978 -0.18742 0.303337 0.51035 1.746575 14.8046 0.005497 0.818081 
 
433 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
434 0.286334 0.892768 0.606434 0.794189 0.159145 1.004995 504.6295 0.000986 7.25016 
 
435 0.844116 0.243356 -0.60076 0.12353 0.836324 0.999448 1122.789 0.000439 0.264806 
 
436 0.129011 0.144212 0.0152 0.36112 0.43966 1.739233 14.86503 0.006628 1.062 
 
437 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
438 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
439 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
440 0.299843 0.11225 -0.18759 0.294446 0.515641 1.766334 14.64803 0.005696 0.784095 
 
441 0.129587 0.115995 -0.01359 0.336283 0.459012 1.767932 14.63574 0.006911 0.951954 
 
442 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
443 0.149251 0.113574 -0.03568 0.319463 0.481552 1.764721 14.66049 0.006401 0.881986 
 
444 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
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445 27.2445 0.283151 -26.9614 9.96E-11 1 1.004882 510.3153 1.47E-20 1.87E-10 
 
446 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
447 0.299843 0.11225 -0.18759 0.294446 0.515641 1.766334 14.64803 0.005696 0.784095 
 
448 0.125007 0.118057 -0.00695 0.342929 0.450893 1.767693 14.63757 0.007062 0.980584 
 
449 0.292216 0.105109 -0.18711 0.285488 0.52087 1.786794 14.49462 0.0059 0.750709 
 
450 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
451 0.164863 0.135153 -0.02971 0.336501 0.474286 1.723748 14.9967 0.005791 0.952881 
 
452 0.807465 0.120706 -0.68676 0.288485 0.53065 1.751998 14.76076 0.005146 0.761786 
 
453 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
454 0.118142 0.098551 -0.01959 0.319587 0.463625 1.813023 14.30987 0.007737 0.88249 
 
455 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
456 0.116875 0.094828 -0.02205 0.313967 0.466907 1.823702 14.23821 0.00788 0.859867 
 
457 0.273023 0.619743 0.34672 0.685531 0.25308 1.037471 124.654 0.001375 4.09583 
 
458 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
459 0.164863 0.135153 -0.02971 0.336501 0.474286 1.723748 14.9967 0.005791 0.952881 
 
460 0.251383 0.34713 0.095747 0.637456 0.293748 1.055366 89.96911 0.001785 3.30357 
 
461 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
462 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
463 0.292216 0.105109 -0.18711 0.285488 0.52087 1.786794 14.49462 0.0059 0.750709 
 
464 0.529974 0.126212 -0.40376 0.301655 0.517326 1.735532 14.89597 0.005177 0.811586 
 
465 0.118142 0.098551 -0.01959 0.319587 0.463625 1.813023 14.30987 0.007737 0.88249 
 
466 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
467 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
468 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
469 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
470 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
471 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
472 0.118142 0.098551 -0.01959 0.319587 0.463625 1.813023 14.30987 0.007737 0.88249 
 
473 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
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474 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
475 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
476 0.116455 0.093632 -0.02282 0.312109 0.467986 1.82727 14.21471 0.007927 0.852472 
 
477 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
478 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
479 0.149251 0.113574 -0.03568 0.319463 0.481552 1.764721 14.66049 0.006401 0.881986 
 
480 6.56676 0.25351 -6.31325 0.0055774 0.990533 1.007899 392.8302 2.13E-06 0.010538 
 
481 0.15418 0.121821 -0.03236 0.327492 0.477585 1.746698 14.8036 0.006151 0.914946 
 
482 0.302501 0.394229 0.091727 0.635013 0.298233 1.044881 107.272 0.001646 3.26888 
 
483 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
484 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
485 0.249237 0.326999 0.077762 0.628041 0.301837 1.060829 83.13961 0.001874 3.17239 
 
486 0.835398 0.191839 -0.64356 0.155226 0.796506 1.006892 425.4337 0.000511 0.345238 
 
487 0.129011 0.144212 0.0152 0.36112 0.43966 1.739233 14.86503 0.006628 1.062 
 
488 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
489 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
490 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
491 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
492 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
493 0.328108 0.146951 -0.18116 0.325526 0.496689 1.701364 15.19783 0.005022 0.906805 
 
494 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
495 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
496 0.328108 0.146951 -0.18116 0.325526 0.496689 1.701364 15.19783 0.005022 0.906805 
 
497 0.125007 0.118057 -0.00695 0.342929 0.450893 1.767693 14.63757 0.007062 0.980584 
 
498 0.126877 0.127326 0.000449 0.351366 0.445734 1.753721 14.74698 0.006858 1.01778 
 
499 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
500 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
501 1.94458 0.316165 -1.62842 0.0534459 0.919364 1.001561 764.2951 0.000158 0.106087 
 
502 0.328108 0.146951 -0.18116 0.325526 0.496689 1.701364 15.19783 0.005022 0.906805 
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503 0.122921 0.109788 -0.01313 0.333607 0.456519 1.783977 14.51524 0.007292 0.940586 
 
504 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
505 0.152122 0.110475 -0.04165 0.313811 0.486534 1.771573 14.60793 0.006421 0.859247 
 
506 0.2498 0.331511 0.081711 0.630304 0.299897 1.05942 84.79009 0.001852 3.20331 
 
507 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
508 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
509 0.309838 1.88105 1.57122 0.903078 0.066255 1.005251 492.2152 0.000556 17.5064 Pos 
510 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
511 0.152137 0.110514 -0.04162 0.31386 0.486505 1.771475 14.60867 0.00642 0.859442 
 
512 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
513 0.428398 0.164376 -0.26402 0.329643 0.496732 1.687859 15.32582 0.00478 0.923913 
 
514 0.566236 0.411344 -0.15489 0.609202 0.325469 1.041134 115.363 0.001587 2.92889 
 
515 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
516 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
517 0.15418 0.121821 -0.03236 0.327492 0.477585 1.746698 14.8036 0.006151 0.914946 
 
518 0.18002 0.118023 -0.062 0.313873 0.493976 1.750592 14.77207 0.005904 0.859495 
 
519 0.129011 0.144212 0.0152 0.36112 0.43966 1.739233 14.86503 0.006628 1.062 
 
520 0.254776 0.391448 0.136672 0.652912 0.28046 1.048136 101.1689 0.00165 3.53434 
 
521 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
522 0.8751 1.72514 0.850036 0.684003 0.25992 1.02622 166.8248 0.001103 4.06694 
 
523 0.125007 0.118057 -0.00695 0.342929 0.450893 1.767693 14.63757 0.007062 0.980584 
 
524 0.299843 0.11225 -0.18759 0.294446 0.515641 1.766334 14.64803 0.005696 0.784095 
 
525 0.116455 0.093632 -0.02282 0.312109 0.467986 1.82727 14.21471 0.007927 0.852472 
 
526 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
527 0.309108 0.12188 -0.18723 0.305363 0.509129 1.742188 14.84056 0.005453 0.825945 
 
528 0.118142 0.098551 -0.01959 0.319587 0.463625 1.813023 14.30987 0.007737 0.88249 
 
529 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
530 0.202143 0.396171 0.194028 0.696834 0.238462 1.059405 84.80776 0.001609 4.31858 
 
531 0.292216 0.105109 -0.18711 0.285488 0.52087 1.786794 14.49462 0.0059 0.750709 
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532 0.118142 0.098551 -0.01959 0.319587 0.463625 1.813023 14.30987 0.007737 0.88249 
 
533 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
534 0.303438 0.406115 0.102677 0.638174 0.295467 1.043734 109.617 0.001622 3.31385 
 
535 0.824662 0.126773 -0.69789 0.294472 0.527241 1.737637 14.87833 0.00501 0.784194 
 
536 0.428398 0.164376 -0.26402 0.329643 0.496732 1.687859 15.32582 0.00478 0.923913 
 
537 0.127754 0.133068 0.005314 0.355361 0.443261 1.747541 14.79674 0.006763 1.03573 
 
538 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
539 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
540 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
541 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
542 0.302077 0.133991 -0.16809 0.317616 0.500973 1.718232 15.04505 0.005228 0.874514 
 
543 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
544 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
545 0.137765 0.117985 -0.01978 0.332467 0.466686 1.7598 14.69885 0.006601 0.935768 
 
546 0.708682 0.175443 -0.53324 0.147653 0.804069 1.008885 365.4892 0.000495 0.325476 
 
547 0.292216 0.105109 -0.18711 0.285488 0.52087 1.786794 14.49462 0.0059 0.750709 
 
548 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
549 0.428398 0.164376 -0.26402 0.329643 0.496732 1.687859 15.32582 0.00478 0.923913 
 
550 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
551 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
552 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
553 0.824662 0.126773 -0.69789 0.294472 0.527241 1.737637 14.87833 0.00501 0.784194 
 
554 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
555 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
556 0.15344 0.114024 -0.03942 0.318164 0.483895 1.762957 14.67418 0.006321 0.876728 
 
557 0.164863 0.135153 -0.02971 0.336501 0.474286 1.723748 14.9967 0.005791 0.952881 
 
558 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
559 0.299843 0.11225 -0.18759 0.294446 0.515641 1.766334 14.64803 0.005696 0.784095 
 
560 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
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561 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
562 0.120741 0.106858 -0.01388 0.331193 0.45677 1.791543 14.46021 0.007445 0.930407 
 
563 0.807465 0.120706 -0.68676 0.288485 0.53065 1.751998 14.76076 0.005146 0.761786 
 
564 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
565 0.326897 0.144523 -0.18237 0.324112 0.497591 1.703953 15.17388 0.005051 0.900975 
 
566 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
567 0.15418 0.121821 -0.03236 0.327492 0.477585 1.746698 14.8036 0.006151 0.914946 
 
568 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
569 0.807465 0.120706 -0.68676 0.288485 0.53065 1.751998 14.76076 0.005146 0.761786 
 
570 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
571 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
572 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
573 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
574 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
575 0.255466 0.402957 0.147491 0.656012 0.277799 1.046941 103.3214 0.001625 3.58313 
 
576 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
577 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
578 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
579 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
580 0.127754 0.133068 0.005314 0.355361 0.443261 1.747541 14.79674 0.006763 1.03573 
 
581 0.121684 0.110224 -0.01146 0.335439 0.454234 1.783938 14.51553 0.007339 0.948357 
 
582 0.281457 1.10015 0.81869 0.716827 0.226893 1.03386 135.5282 0.00117 4.75614 
 
583 0.164863 0.135153 -0.02971 0.336501 0.474286 1.723748 14.9967 0.005791 0.952881 
 
584 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
585 0.122921 0.109788 -0.01313 0.333607 0.456519 1.783977 14.51524 0.007292 0.940586 
 
586 0.116455 0.093632 -0.02282 0.312109 0.467986 1.82727 14.21471 0.007927 0.852472 
 
587 0.328108 0.146951 -0.18116 0.325526 0.496689 1.701364 15.19783 0.005022 0.906805 
 
588 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
589 0.428398 0.164376 -0.26402 0.329643 0.496732 1.687859 15.32582 0.00478 0.923913 
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590 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
591 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
592 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
593 0.127754 0.133068 0.005314 0.355361 0.443261 1.747541 14.79674 0.006763 1.03573 
 
594 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
595 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
596 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
597 0.120741 0.106858 -0.01388 0.331193 0.45677 1.791543 14.46021 0.007445 0.930407 
 
598 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
599 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
600 0.15418 0.121821 -0.03236 0.327492 0.477585 1.746698 14.8036 0.006151 0.914946 
 
601 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
602 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
603 0.122921 0.109788 -0.01313 0.333607 0.456519 1.783977 14.51524 0.007292 0.940586 
 
604 0.18002 0.118023 -0.062 0.313873 0.493976 1.750592 14.77207 0.005904 0.859495 
 
605 0.428398 0.164376 -0.26402 0.329643 0.496732 1.687859 15.32582 0.00478 0.923913 
 
606 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
607 0.118142 0.098551 -0.01959 0.319587 0.463625 1.813023 14.30987 0.007737 0.88249 
 
608 0.116875 0.094828 -0.02205 0.313967 0.466907 1.823702 14.23821 0.00788 0.859867 
 
609 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
610 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
611 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
612 0.175132 0.107575 -0.06756 0.301095 0.501698 1.777238 14.56521 0.006192 0.80943 
 
613 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
614 0.152122 0.110475 -0.04165 0.313811 0.486534 1.771573 14.60793 0.006421 0.859247 
 
615 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
616 2.82587 0.227867 -2.598 0.0533142 0.926553 1.001409 782.1863 0.000109 0.105811 
 
617 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
618 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
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619 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
620 0.122921 0.109788 -0.01313 0.333607 0.456519 1.783977 14.51524 0.007292 0.940586 
 
621 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
622 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
623 0.309108 0.12188 -0.18723 0.305363 0.509129 1.742188 14.84056 0.005453 0.825945 
 
624 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
625 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
626 0.304039 0.152278 -0.15176 0.329542 0.493117 1.696709 15.24136 0.005001 0.923491 
 
627 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
628 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
629 0.119893 0.104002 -0.01589 0.327391 0.45903 1.798458 14.41088 0.00754 0.914528 
 
630 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
631 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
632 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
633 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
634 19.672 0.260071 -19.4119 1.23E-06 0.999981 0.99914 1205.426 3.27E-13 2.31E-06 
 
635 0.125007 0.118057 -0.00695 0.342929 0.450893 1.767693 14.63757 0.007062 0.980584 
 
636 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
637 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
638 0.15418 0.121821 -0.03236 0.327492 0.477585 1.746698 14.8036 0.006151 0.914946 
 
639 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
640 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
641 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
642 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
643 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
644 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
645 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
646 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
647 0.129011 0.144212 0.0152 0.36112 0.43966 1.739233 14.86503 0.006628 1.062 
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648 0.125007 0.118057 -0.00695 0.342929 0.450893 1.767693 14.63757 0.007062 0.980584 
 
649 0.125007 0.118057 -0.00695 0.342929 0.450893 1.767693 14.63757 0.007062 0.980584 
 
650 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
651 0.603621 0.188241 -0.41538 0.166317 0.782349 1.008006 389.6434 0.000581 0.374824 
 
652 0.152122 0.110475 -0.04165 0.313811 0.486534 1.771573 14.60793 0.006421 0.859247 
 
653 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
654 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
655 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
656 0.164863 0.135153 -0.02971 0.336501 0.474286 1.723748 14.9967 0.005791 0.952881 
 
657 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
658 0.147819 0.099596 -0.04822 0.298903 0.495514 1.801951 14.3863 0.006764 0.801023 
 
659 0.154209 0.115509 -0.0387 0.3198 0.482991 1.759499 14.70122 0.006277 0.883355 
 
660 0.150111 0.104908 -0.0452 0.306345 0.491105 1.786502 14.49675 0.006588 0.829773 
 
661 0.121478 0.108764 -0.01271 0.333438 0.455605 1.787035 14.49286 0.007375 0.939871 
 
662 0.123243 0.111413 -0.01183 0.335678 0.455174 1.780575 14.54035 0.007248 0.949372 
 
663 0.162715 0.125894 -0.03682 0.328613 0.479323 1.737726 14.87758 0.005956 0.919611 
 
664 0.816685 0.234335 -0.58235 0.180697 0.768084 1.005046 502.1075 0.000599 0.414382 
 
665 0.431947 0.170151 -0.2618 0.331384 0.495622 1.685048 15.35312 0.004745 0.931212 
 
666 0.836554 1.17628 0.339731 0.663995 0.277801 1.028377 156.5377 0.0012 3.71289 
 
667 0.154828 0.117301 -0.03753 0.321849 0.481738 1.755526 14.73261 0.006231 0.891699 
 
668 0.431947 0.170151 -0.2618 0.331384 0.495622 1.685048 15.35312 0.004745 0.931212 
 
669 0.12194 0.110447 -0.01149 0.33552 0.454359 1.783326 14.52003 0.007323 0.9487 
 
670 0.122829 0.10877 -0.01406 0.332151 0.45756 1.786135 14.49943 0.007315 0.934438 
 
671 0.15357 0.11372 -0.03985 0.317688 0.484278 1.763634 14.66892 0.006326 0.874804 
 
672 0.154828 0.117301 -0.03753 0.321849 0.481738 1.755526 14.73261 0.006231 0.891699 
 
673 0.138024 0.118199 -0.01982 0.332553 0.46676 1.759287 14.70289 0.00659 0.936132 
 
674 0.155224 0.105521 -0.0497 0.305059 0.493676 1.784274 14.51306 0.006491 0.824764 
 
675 0.158902 0.131331 -0.02757 0.335482 0.47328 1.730233 14.94085 0.005927 0.94854 
 
676 0.165195 0.135372 -0.02982 0.336561 0.474333 1.723403 14.9997 0.005783 0.953139 
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677 0.154209 0.115509 -0.0387 0.3198 0.482991 1.759499 14.70122 0.006277 0.883355 
 
678 0.307436 0.120025 -0.18741 0.303389 0.510319 1.746464 14.80551 0.005496 0.81828 
 
679 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
680 0.428398 0.164376 -0.26402 0.329643 0.496732 1.687859 15.32582 0.00478 0.923913 
 
681 0.122572 0.108548 -0.01402 0.332057 0.457447 1.78676 14.49487 0.00733 0.934044 
 
682 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
683 27.2792 0.42696 -26.8523 6.33E-14 1 1.010677 324.6102 7.96E-27 1.19E-13 
 
684 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
685 0.121684 0.110224 -0.01146 0.335439 0.454234 1.783938 14.51553 0.007339 0.948357 
 
686 1.58135 0.383392 -1.19796 0.560018 0.377179 1.042317 112.6705 0.001554 2.39144 
 
687 0.251346 0.346813 0.095467 0.637325 0.29386 1.055439 89.86963 0.001786 3.3017 
 
688 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
689 0.125007 0.118057 -0.00695 0.342929 0.450893 1.767693 14.63757 0.007062 0.980584 
 
690 0.118142 0.098551 -0.01959 0.319587 0.463625 1.813023 14.30987 0.007737 0.88249 
 
691 0.152122 0.110475 -0.04165 0.313811 0.486534 1.771573 14.60793 0.006421 0.859247 
 
692 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
693 0.180791 0.119859 -0.06093 0.315904 0.492731 1.746496 14.80525 0.005859 0.867624 
 
694 0.304039 0.152278 -0.15176 0.329542 0.493117 1.696709 15.24136 0.005001 0.923491 
 
695 0.299843 0.11225 -0.18759 0.294446 0.515641 1.766334 14.64803 0.005696 0.784095 
 
696 1.43155 0.383289 -1.04826 0.565027 0.371718 1.042578 112.0944 0.001564 2.44062 
 
697 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
698 20.9686 0.372796 -20.5958 0.00228271 0.995836 1.00095 841.8304 2.89E-07 0.004299 
 
699 0.175532 0.113282 -0.06225 0.308939 0.496493 1.762025 14.68144 0.006047 0.839944 
 
700 0.304039 0.152278 -0.15176 0.329542 0.493117 1.696709 15.24136 0.005001 0.923491 
 
701 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
702 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
703 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
704 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
705 27.1658 0.295925 -26.8699 6.86E-10 1 1.003485 592.9576 8.19E-19 1.29E-09 
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706 0.780133 0.183815 -0.59632 0.0931219 0.873581 0.999677 1068.338 0.000293 0.192928 
 
707 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
708 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
709 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
710 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
711 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
712 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
713 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
714 0.12122 0.10854 -0.01268 0.333349 0.455484 1.787664 14.48829 0.007391 0.939493 
 
715 0.137765 0.117985 -0.01978 0.332467 0.466686 1.7598 14.69885 0.006601 0.935768 
 
716 0.325358 0.145127 -0.18023 0.32456 0.497239 1.703291 15.17999 0.005046 0.902822 
 
717 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
718 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
719 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
720 0.118142 0.098551 -0.01959 0.319587 0.463625 1.813023 14.30987 0.007737 0.88249 
 
721 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
722 0.149251 0.113574 -0.03568 0.319463 0.481552 1.764721 14.66049 0.006401 0.881986 
 
723 0.119634 0.099134 -0.0205 0.319105 0.465118 1.810768 14.32526 0.007655 0.880536 
 
724 0.309108 0.12188 -0.18723 0.305363 0.509129 1.742188 14.84056 0.005453 0.825945 
 
725 0.326897 0.144523 -0.18237 0.324112 0.497591 1.703953 15.17388 0.005051 0.900975 
 
726 0.127754 0.133068 0.005314 0.355361 0.443261 1.747541 14.79674 0.006763 1.03573 
 
727 0.122921 0.109788 -0.01313 0.333607 0.456519 1.783977 14.51524 0.007292 0.940586 
 
728 0.328108 0.146951 -0.18116 0.325526 0.496689 1.701364 15.19783 0.005022 0.906805 
 
729 0.149251 0.113574 -0.03568 0.319463 0.481552 1.764721 14.66049 0.006401 0.881986 
 
730 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
731 27.2676 0.239035 -27.0285 5.22E-17 1 1.01279 286.9666 5.78E-33 9.80E-17 
 
732 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
733 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
734 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
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735 0.116875 0.094828 -0.02205 0.313967 0.466907 1.823702 14.23821 0.00788 0.859867 
 
736 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
737 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
738 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
739 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
740 0.127754 0.133068 0.005314 0.355361 0.443261 1.747541 14.79674 0.006763 1.03573 
 
741 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
742 0.249358 0.327632 0.078275 0.628345 0.301579 1.060619 83.38089 0.001871 3.17652 
 
743 0.164863 0.135153 -0.02971 0.336501 0.474286 1.723748 14.9967 0.005791 0.952881 
 
744 0.256045 0.413709 0.157664 0.65869 0.275502 1.045972 105.1397 0.001603 3.62598 
 
745 1.86871 0.204658 -1.66405 0.0324043 0.952213 1.000923 845.6956 6.43E-05 0.062922 
 
746 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
747 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
748 0.119893 0.104002 -0.01589 0.327391 0.45903 1.798458 14.41088 0.00754 0.914528 
 
749 0.164863 0.135153 -0.02971 0.336501 0.474286 1.723748 14.9967 0.005791 0.952881 
 
750 0.18002 0.118023 -0.062 0.313873 0.493976 1.750592 14.77207 0.005904 0.859495 
 
751 0.119893 0.104002 -0.01589 0.327391 0.45903 1.798458 14.41088 0.00754 0.914528 
 
752 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
753 3.32296 0.230403 -3.09256 0.0474928 0.934395 1.00205 711.9292 8.81E-05 0.093681 
 
754 0.292216 0.105109 -0.18711 0.285488 0.52087 1.786794 14.49462 0.0059 0.750709 
 
755 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
756 0.833521 1.17451 0.340993 0.664062 0.277725 1.028399 156.4413 0.0012 3.71401 
 
757 0.807465 0.120706 -0.68676 0.288485 0.53065 1.751998 14.76076 0.005146 0.761786 
 
758 0.119893 0.104002 -0.01589 0.327391 0.45903 1.798458 14.41088 0.00754 0.914528 
 
759 0.149251 0.113574 -0.03568 0.319463 0.481552 1.764721 14.66049 0.006401 0.881986 
 
760 0.307392 0.119978 -0.18742 0.303337 0.51035 1.746575 14.8046 0.005497 0.818081 
 
761 0.374369 0.166208 -0.20816 0.176123 0.767355 1.014926 257.0322 0.000691 0.401649 
 
762 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
763 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
764 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
765 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
766 0.158917 0.115266 -0.04365 0.317525 0.486073 1.759208 14.70351 0.006211 0.874148 
 
767 27.2683 0.236885 -27.0314 2.17E-17 1 1.01284 286.1871 9.98E-34 4.08E-17 
 
768 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
769 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
770 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
771 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
772 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
773 0.249763 0.331456 0.081693 0.630293 0.299904 1.05944 84.76604 0.001852 3.20315 
 
774 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
775 0.164863 0.135153 -0.02971 0.336501 0.474286 1.723748 14.9967 0.005791 0.952881 
 
776 0.164863 0.135153 -0.02971 0.336501 0.474286 1.723748 14.9967 0.005791 0.952881 
 
777 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
778 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
779 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
780 0.15418 0.121821 -0.03236 0.327492 0.477585 1.746698 14.8036 0.006151 0.914946 
 
781 0.164863 0.135153 -0.02971 0.336501 0.474286 1.723748 14.9967 0.005791 0.952881 
 
782 0.529974 0.126212 -0.40376 0.301655 0.517326 1.735532 14.89597 0.005177 0.811586 
 
783 24.8709 0.236055 -24.6348 1.44E-14 1 1.016061 243.6041 2.73E-28 2.71E-14 
 
784 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
785 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
786 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
787 0.118142 0.098551 -0.01959 0.319587 0.463625 1.813023 14.30987 0.007737 0.88249 
 
788 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
789 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
790 0.18002 0.118023 -0.062 0.313873 0.493976 1.750592 14.77207 0.005904 0.859495 
 
791 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
792 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
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793 0.326897 0.144523 -0.18237 0.324112 0.497591 1.703953 15.17388 0.005051 0.900975 
 
794 0.125007 0.118057 -0.00695 0.342929 0.450893 1.767693 14.63757 0.007062 0.980584 
 
795 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
796 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
797 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
798 0.377431 0.183569 -0.19386 0.194586 0.747376 1.012709 288.2462 0.000763 0.453926 
 
799 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
800 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
801 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
802 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
803 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
804 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
805 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
806 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
807 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
808 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
809 0.125007 0.118057 -0.00695 0.342929 0.450893 1.767693 14.63757 0.007062 0.980584 
 
810 0.255702 0.403439 0.147737 0.656033 0.277794 1.046875 103.4422 0.001624 3.58345 
 
811 0.122921 0.109788 -0.01313 0.333607 0.456519 1.783977 14.51524 0.007292 0.940586 
 
812 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
813 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
814 0.119634 0.099134 -0.0205 0.319105 0.465118 1.810768 14.32526 0.007655 0.880536 
 
815 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
816 0.328108 0.146951 -0.18116 0.325526 0.496689 1.701364 15.19783 0.005022 0.906805 
 
817 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
818 0.326897 0.144523 -0.18237 0.324112 0.497591 1.703953 15.17388 0.005051 0.900975 
 
819 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
820 0.15418 0.121821 -0.03236 0.327492 0.477585 1.746698 14.8036 0.006151 0.914946 
 
821 0.129587 0.115995 -0.01359 0.336283 0.459012 1.767932 14.63574 0.006911 0.951954 
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822 0.119893 0.104002 -0.01589 0.327391 0.45903 1.798458 14.41088 0.00754 0.914528 
 
823 0.326897 0.144523 -0.18237 0.324112 0.497591 1.703953 15.17388 0.005051 0.900975 
 
824 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
825 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
826 0.331329 0.150704 -0.18063 0.327454 0.495504 1.697793 15.23117 0.00498 0.914792 
 
827 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
828 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
829 0.118142 0.098551 -0.01959 0.319587 0.463625 1.813023 14.30987 0.007737 0.88249 
 
830 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
831 0.529974 0.126212 -0.40376 0.301655 0.517326 1.735532 14.89597 0.005177 0.811586 
 
832 0.129011 0.144212 0.0152 0.36112 0.43966 1.739233 14.86503 0.006628 1.062 
 
833 8.25558 24.5559 16.3003 0.854527 0.02296 1.000163 968.8067 0.014248 11.0367 Pos 
834 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
835 0.116875 0.094828 -0.02205 0.313967 0.466907 1.823702 14.23821 0.00788 0.859867 
 
836 0.158917 0.115266 -0.04365 0.317525 0.486073 1.759208 14.70351 0.006211 0.874148 
 
837 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
838 0.120741 0.106858 -0.01388 0.331193 0.45677 1.791543 14.46021 0.007445 0.930407 
 
839 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
840 0.15418 0.121821 -0.03236 0.327492 0.477585 1.746698 14.8036 0.006151 0.914946 
 
841 0.119893 0.104002 -0.01589 0.327391 0.45903 1.798458 14.41088 0.00754 0.914528 
 
842 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
843 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
844 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
845 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
846 0.309108 0.12188 -0.18723 0.305363 0.509129 1.742188 14.84056 0.005453 0.825945 
 
847 0.152122 0.110475 -0.04165 0.313811 0.486534 1.771573 14.60793 0.006421 0.859247 
 
848 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
849 0.149251 0.113574 -0.03568 0.319463 0.481552 1.764721 14.66049 0.006401 0.881986 
 
850 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
851 0.179224 0.116188 -0.06304 0.31178 0.495255 1.754854 14.73794 0.005951 0.851165 
 
852 0.126877 0.127326 0.000449 0.351366 0.445734 1.753721 14.74698 0.006858 1.01778 
 
853 0.18002 0.118023 -0.062 0.313873 0.493976 1.750592 14.77207 0.005904 0.859495 
 
854 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
855 0.126877 0.127326 0.000449 0.351366 0.445734 1.753721 14.74698 0.006858 1.01778 
 
856 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
857 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
858 0.299843 0.11225 -0.18759 0.294446 0.515641 1.766334 14.64803 0.005696 0.784095 
 
859 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
860 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
861 0.122988 0.11119 -0.0118 0.335598 0.455053 1.781176 14.5359 0.007263 0.949034 
 
862 0.529974 0.126212 -0.40376 0.301655 0.517326 1.735532 14.89597 0.005177 0.811586 
 
863 0.292216 0.105109 -0.18711 0.285488 0.52087 1.786794 14.49462 0.0059 0.750709 
 
864 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
865 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
866 0.325358 0.145127 -0.18023 0.32456 0.497239 1.703291 15.17999 0.005046 0.902822 
 
867 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
868 0.127754 0.133068 0.005314 0.355361 0.443261 1.747541 14.79674 0.006763 1.03573 
 
869 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
870 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
871 0.149251 0.113574 -0.03568 0.319463 0.481552 1.764721 14.66049 0.006401 0.881986 
 
872 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
873 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
874 0.137765 0.117985 -0.01978 0.332467 0.466686 1.7598 14.69885 0.006601 0.935768 
 
875 0.428398 0.164376 -0.26402 0.329643 0.496732 1.687859 15.32582 0.00478 0.923913 
 
876 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
877 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
878 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
879 1.01869 0.427653 -0.59104 0.591217 0.34531 1.038853 120.966 0.001524 2.71736 
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880 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
881 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
882 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
883 0.164863 0.135153 -0.02971 0.336501 0.474286 1.723748 14.9967 0.005791 0.952881 
 
884 0.152122 0.110475 -0.04165 0.313811 0.486534 1.771573 14.60793 0.006421 0.859247 
 
885 0.164863 0.135153 -0.02971 0.336501 0.474286 1.723748 14.9967 0.005791 0.952881 
 
886 0.564726 0.399678 -0.16505 0.606236 0.328125 1.042205 112.9205 0.001607 2.89267 
 
887 0.152122 0.110475 -0.04165 0.313811 0.486534 1.771573 14.60793 0.006421 0.859247 
 
888 0.273093 0.623919 0.350826 0.685939 0.252734 1.037413 124.8154 0.001372 4.10359 
 
889 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
890 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
891 0.326897 0.144523 -0.18237 0.324112 0.497591 1.703953 15.17388 0.005051 0.900975 
 
892 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
893 0.149251 0.113574 -0.03568 0.319463 0.481552 1.764721 14.66049 0.006401 0.881986 
 
894 0.137765 0.117985 -0.01978 0.332467 0.466686 1.7598 14.69885 0.006601 0.935768 
 
895 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
896 0.127754 0.133068 0.005314 0.355361 0.443261 1.747541 14.79674 0.006763 1.03573 
 
897 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
898 0.12122 0.10854 -0.01268 0.333349 0.455484 1.787664 14.48829 0.007391 0.939493 
 
899 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
900 0.529974 0.126212 -0.40376 0.301655 0.517326 1.735532 14.89597 0.005177 0.811586 
 
901 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
902 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
903 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
904 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
905 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
906 0.807465 0.120706 -0.68676 0.288485 0.53065 1.751998 14.76076 0.005146 0.761786 
 
907 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
908 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
909 0.125007 0.118057 -0.00695 0.342929 0.450893 1.767693 14.63757 0.007062 0.980584 
 
910 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
911 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
912 27.2767 0.265743 -27.011 4.77E-13 1 1.014628 260.8242 2.83E-25 8.97E-13 
 
913 0.807465 0.120706 -0.68676 0.288485 0.53065 1.751998 14.76076 0.005146 0.761786 
 
914 1.31909 3.21583 1.89674 0.793018 0.118425 1.001361 788.0427 0.005895 23.1365 
 
915 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
916 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
917 0.292216 0.105109 -0.18711 0.285488 0.52087 1.786794 14.49462 0.0059 0.750709 
 
918 0.564726 0.399678 -0.16505 0.606236 0.328125 1.042205 112.9205 0.001607 2.89267 
 
919 0.299843 0.11225 -0.18759 0.294446 0.515641 1.766334 14.64803 0.005696 0.784095 
 
920 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
921 0.152122 0.110475 -0.04165 0.313811 0.486534 1.771573 14.60793 0.006421 0.859247 
 
922 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
923 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
924 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
925 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
926 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
927 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
928 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
929 0.18002 0.118023 -0.062 0.313873 0.493976 1.750592 14.77207 0.005904 0.859495 
 
930 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
931 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
932 27.2767 0.283138 -26.9935 7.80E-11 1 1.004602 524.952 9.31E-21 1.46E-10 
 
933 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
934 0.309108 0.12188 -0.18723 0.305363 0.509129 1.742188 14.84056 0.005453 0.825945 
 
935 0.15418 0.121821 -0.03236 0.327492 0.477585 1.746698 14.8036 0.006151 0.914946 
 
936 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
937 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
938 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
939 0.807465 0.120706 -0.68676 0.288485 0.53065 1.751998 14.76076 0.005146 0.761786 
 
940 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
941 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
942 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
943 0.807465 0.120706 -0.68676 0.288485 0.53065 1.751998 14.76076 0.005146 0.761786 
 
944 0.428398 0.164376 -0.26402 0.329643 0.496732 1.687859 15.32582 0.00478 0.923913 
 
945 0.120741 0.106858 -0.01388 0.331193 0.45677 1.791543 14.46021 0.007445 0.930407 
 
946 0.179224 0.116188 -0.06304 0.31178 0.495255 1.754854 14.73794 0.005951 0.851165 
 
947 18.7226 0.284806 -18.4378 3.88E-06 0.999916 1.004615 524.2655 1.78E-11 7.30E-06 
 
948 27.0762 0.267769 -26.8084 6.26E-12 1 1.014378 264.0892 5.67E-23 1.18E-11 
 
949 0.299843 0.11225 -0.18759 0.294446 0.515641 1.766334 14.64803 0.005696 0.784095 
 
950 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
951 0.149251 0.113574 -0.03568 0.319463 0.481552 1.764721 14.66049 0.006401 0.881986 
 
952 0.249908 0.332889 0.082981 0.63101 0.299287 1.059015 85.27845 0.001845 3.21303 
 
953 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
954 0.126877 0.127326 0.000449 0.351366 0.445734 1.753721 14.74698 0.006858 1.01778 
 
955 0.529974 0.126212 -0.40376 0.301655 0.517326 1.735532 14.89597 0.005177 0.811586 
 
956 0.307392 0.119978 -0.18742 0.303337 0.51035 1.746575 14.8046 0.005497 0.818081 
 
957 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
958 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
959 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
960 0.824662 0.126773 -0.69789 0.294472 0.527241 1.737637 14.87833 0.00501 0.784194 
 
961 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
962 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
963 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
964 0.15418 0.121821 -0.03236 0.327492 0.477585 1.746698 14.8036 0.006151 0.914946 
 
965 0.118142 0.098551 -0.01959 0.319587 0.463625 1.813023 14.30987 0.007737 0.88249 
 
966 0.118179 0.098654 -0.01952 0.319738 0.463539 1.812735 14.31183 0.007734 0.883101 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
967 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
968 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
969 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
970 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
971 0.292216 0.105109 -0.18711 0.285488 0.52087 1.786794 14.49462 0.0059 0.750709 
 
972 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
973 0.307392 0.119978 -0.18742 0.303337 0.51035 1.746575 14.8046 0.005497 0.818081 
 
974 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
975 0.164863 0.135153 -0.02971 0.336501 0.474286 1.723748 14.9967 0.005791 0.952881 
 
976 11.6726 0.266699 -11.4059 6.47E-07 0.999957 1.005924 462.4161 7.78E-13 1.21E-06 
 
977 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
978 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
979 0.302077 0.133991 -0.16809 0.317616 0.500973 1.718232 15.04505 0.005228 0.874514 
 
980 0.15418 0.121821 -0.03236 0.327492 0.477585 1.746698 14.8036 0.006151 0.914946 
 
981 0.129011 0.144212 0.0152 0.36112 0.43966 1.739233 14.86503 0.006628 1.062 
 
982 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
983 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
984 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
985 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
986 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
987 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
988 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
989 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
990 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
991 0.299843 0.11225 -0.18759 0.294446 0.515641 1.766334 14.64803 0.005696 0.784095 
 
992 0.326897 0.144523 -0.18237 0.324112 0.497591 1.703953 15.17388 0.005051 0.900975 
 
993 0.129011 0.144212 0.0152 0.36112 0.43966 1.739233 14.86503 0.006628 1.062 
 
994 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
995 0.328108 0.146951 -0.18116 0.325526 0.496689 1.701364 15.19783 0.005022 0.906805 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
996 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
997 0.812544 0.195892 -0.61665 0.159457 0.791635 1.006642 434.3883 0.000528 0.356432 
 
998 0.120741 0.106858 -0.01388 0.331193 0.45677 1.791543 14.46021 0.007445 0.930407 
 
999 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
1000 0.328108 0.146951 -0.18116 0.325526 0.496689 1.701364 15.19783 0.005022 0.906805 
 
1001 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
1002 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
1003 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
1004 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
1005 0.416294 0.191644 -0.22465 0.193007 0.750194 1.010451 329.2456 0.000734 0.449363 
 
1006 0.325358 0.145127 -0.18023 0.32456 0.497239 1.703291 15.17999 0.005046 0.902822 
 
1007 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
1008 0.807465 0.120706 -0.68676 0.288485 0.53065 1.751998 14.76076 0.005146 0.761786 
 
1009 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
1010 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
1011 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
1012 0.119634 0.099134 -0.0205 0.319105 0.465118 1.810768 14.32526 0.007655 0.880536 
 
1013 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
1014 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
1015 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
1016 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
1017 0.428398 0.164376 -0.26402 0.329643 0.496732 1.687859 15.32582 0.00478 0.923913 
 
1018 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
1019 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
1020 4.86204 19.1439 14.2819 0.830691 0.081001 1.003174 615.2267 0.011262 9.21833 Pos 
1021 7.04598 0.271038 -6.77494 0.0912481 0.881301 1.005432 483.8392 0.000178 0.188656 
 
1022 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
1023 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
1024 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
1025 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
1026 0.18002 0.118023 -0.062 0.313873 0.493976 1.750592 14.77207 0.005904 0.859495 
 
1027 0.129011 0.144212 0.0152 0.36112 0.43966 1.739233 14.86503 0.006628 1.062 
 
1028 0.129011 0.144212 0.0152 0.36112 0.43966 1.739233 14.86503 0.006628 1.062 
 
1029 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
1030 0.307392 0.119978 -0.18742 0.303337 0.51035 1.746575 14.8046 0.005497 0.818081 
 
1031 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
1032 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
1033 0.137765 0.117985 -0.01978 0.332467 0.466686 1.7598 14.69885 0.006601 0.935768 
 
1034 0.118142 0.098551 -0.01959 0.319587 0.463625 1.813023 14.30987 0.007737 0.88249 
 
1035 10.0235 0.332797 -9.69069 0.0755737 0.901605 1.005326 488.715 0.000124 0.1536 
 
1036 0.15418 0.121821 -0.03236 0.327492 0.477585 1.746698 14.8036 0.006151 0.914946 
 
1037 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
1038 0.126877 0.127326 0.000449 0.351366 0.445734 1.753721 14.74698 0.006858 1.01778 
 
1039 0.326897 0.144523 -0.18237 0.324112 0.497591 1.703953 15.17388 0.005051 0.900975 
 
1040 0.137765 0.117985 -0.01978 0.332467 0.466686 1.7598 14.69885 0.006601 0.935768 
 
1041 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
1042 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
1043 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
1044 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
1045 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
1046 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
1047 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
1048 0.118142 0.098551 -0.01959 0.319587 0.463625 1.813023 14.30987 0.007737 0.88249 
 
1049 0.378387 0.178609 -0.19978 0.189221 0.753214 1.013155 281.3576 0.000741 0.438492 
 
1050 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
1051 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
1052 0.599605 0.688312 0.088707 0.646611 0.291997 1.032483 140.2278 0.001354 3.43782 
 
1053 0.127754 0.133068 0.005314 0.355361 0.443261 1.747541 14.79674 0.006763 1.03573 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
1054 0.122988 0.11119 -0.0118 0.335598 0.455053 1.781176 14.5359 0.007263 0.949034 
 
1055 0.529974 0.126212 -0.40376 0.301655 0.517326 1.735532 14.89597 0.005177 0.811586 
 
1056 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
1057 0.152122 0.110475 -0.04165 0.313811 0.486534 1.771573 14.60793 0.006421 0.859247 
 
1058 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
1059 7.87484 0.314106 -7.56073 0.00565646 0.98843 1.002815 643.0403 2.59E-06 0.010688 
 
1060 0.255494 0.403602 0.148108 0.656183 0.277652 1.046879 103.4346 0.001623 3.58584 
 
1061 0.116875 0.094828 -0.02205 0.313967 0.466907 1.823702 14.23821 0.00788 0.859867 
 
1062 0.428398 0.164376 -0.26402 0.329643 0.496732 1.687859 15.32582 0.00478 0.923913 
 
1063 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
1064 0.390484 0.220433 -0.17005 0.218447 0.722322 1.010025 338.3571 0.000836 0.525148 
 
1065 0.37745 0.178554 -0.1989 0.189391 0.753001 1.013202 280.6483 0.000743 0.438977 
 
1066 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
1067 0.529974 0.126212 -0.40376 0.301655 0.517326 1.735532 14.89597 0.005177 0.811586 
 
1068 0.389798 0.220273 -0.16953 0.218572 0.722167 1.010059 337.607 0.000837 0.525532 
 
1069 0.384625 0.146753 -0.23787 0.323094 0.500021 1.701459 15.19696 0.004965 0.896795 
 
1070 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
1071 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
1072 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
1073 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
1074 0.152122 0.110475 -0.04165 0.313811 0.486534 1.771573 14.60793 0.006421 0.859247 
 
1075 0.149251 0.113574 -0.03568 0.319463 0.481552 1.764721 14.66049 0.006401 0.881986 
 
1076 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
1077 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
1078 0.48138 0.194537 -0.28684 0.184683 0.760535 1.008796 367.7932 0.000678 0.425591 
 
1079 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
1080 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
1081 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
1082 0.154043 0.115321 -0.03872 0.319627 0.483058 1.759945 14.69772 0.006284 0.882651 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
1083 18.1564 0.499977 -17.6564 0.00687322 0.989207 0.999856 1029.391 2.60E-06 0.013003 
 
1084 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
1085 0.329808 0.150676 -0.17913 0.327507 0.495418 1.697827 15.23085 0.004982 0.915011 
 
1086 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
1087 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
1088 0.152122 0.110475 -0.04165 0.313811 0.486534 1.771573 14.60793 0.006421 0.859247 
 
1089 1.82333 0.21088 -1.61245 0.0351007 0.94821 1.001013 833.2052 7.39E-05 0.068348 
 
1090 0.428398 0.164376 -0.26402 0.329643 0.496732 1.687859 15.32582 0.00478 0.923913 
 
1091 0.299843 0.11225 -0.18759 0.294446 0.515641 1.766334 14.64803 0.005696 0.784095 
 
1092 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
1093 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
1094 0.148239 0.100759 -0.04748 0.300614 0.494466 1.798474 14.41076 0.006726 0.807578 
 
1095 9.70093 0.237827 -9.4631 1.42E-07 0.999977 0.99843 1452.498 2.73E-14 2.66E-07 
 
1096 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
1097 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
1098 0.149251 0.113574 -0.03568 0.319463 0.481552 1.764721 14.66049 0.006401 0.881986 
 
1099 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
1100 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
1101 0.166084 0.141227 -0.02486 0.340456 0.471766 1.717107 15.05501 0.005706 0.969864 
 
1102 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
1103 0.12122 0.10854 -0.01268 0.333349 0.455484 1.787664 14.48829 0.007391 0.939493 
 
1104 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
1105 0.326897 0.144523 -0.18237 0.324112 0.497591 1.703953 15.17388 0.005051 0.900975 
 
1106 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
1107 0.12122 0.10854 -0.01268 0.333349 0.455484 1.787664 14.48829 0.007391 0.939493 
 
1108 0.328108 0.146951 -0.18116 0.325526 0.496689 1.701364 15.19783 0.005022 0.906805 
 
1109 0.307392 0.119978 -0.18742 0.303337 0.51035 1.746575 14.8046 0.005497 0.818081 
 
1110 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
1111 0.118142 0.098551 -0.01959 0.319587 0.463625 1.813023 14.30987 0.007737 0.88249 
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1112 0.328108 0.146951 -0.18116 0.325526 0.496689 1.701364 15.19783 0.005022 0.906805 
 
1113 0.152122 0.110475 -0.04165 0.313811 0.486534 1.771573 14.60793 0.006421 0.859247 
 
1114 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
1115 0.325358 0.145127 -0.18023 0.32456 0.497239 1.703291 15.17999 0.005046 0.902822 
 
1116 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
1117 5.79138 0.252555 -5.53882 0.000117349 0.998721 0.998571 1395.72 5.03E-09 0.000221 
 
1118 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
1119 0.433461 0.179443 -0.25402 0.333798 0.493983 1.681558 15.38735 0.004701 0.941393 
 
1120 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
1121 0.310773 0.123787 -0.18699 0.307328 0.507938 1.737971 14.87554 0.00541 0.833619 
 
1122 0.158917 0.115266 -0.04365 0.317525 0.486073 1.759208 14.70351 0.006211 0.874148 
 
1123 0.529974 0.126212 -0.40376 0.301655 0.517326 1.735532 14.89597 0.005177 0.811586 
 
1124 0.18002 0.118023 -0.062 0.313873 0.493976 1.750592 14.77207 0.005904 0.859495 
 
1125 0.118142 0.098551 -0.01959 0.319587 0.463625 1.813023 14.30987 0.007737 0.88249 
 
1126 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
1127 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
1128 0.309108 0.12188 -0.18723 0.305363 0.509129 1.742188 14.84056 0.005453 0.825945 
 
1129 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
1130 0.120741 0.106858 -0.01388 0.331193 0.45677 1.791543 14.46021 0.007445 0.930407 
 
1131 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
1132 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
1133 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
1134 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
1135 0.125007 0.118057 -0.00695 0.342929 0.450893 1.767693 14.63757 0.007062 0.980584 
 
1136 10.997 0.239944 -10.7571 4.45E-08 0.999991 1.001538 766.9288 3.59E-15 8.36E-08 
 
1137 0.807465 0.120706 -0.68676 0.288485 0.53065 1.751998 14.76076 0.005146 0.761786 
 
1138 0.158917 0.115266 -0.04365 0.317525 0.486073 1.759208 14.70351 0.006211 0.874148 
 
1139 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
1140 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
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1141 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
1142 0.125007 0.118057 -0.00695 0.342929 0.450893 1.767693 14.63757 0.007062 0.980584 
 
1143 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
1144 0.126877 0.127326 0.000449 0.351366 0.445734 1.753721 14.74698 0.006858 1.01778 
 
1145 0.129011 0.144212 0.0152 0.36112 0.43966 1.739233 14.86503 0.006628 1.062 
 
1146 0.122572 0.108548 -0.01402 0.332057 0.457447 1.78676 14.49487 0.00733 0.934044 
 
1147 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
1148 0.326897 0.144523 -0.18237 0.324112 0.497591 1.703953 15.17388 0.005051 0.900975 
 
1149 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
1150 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
1151 0.149788 0.10469 -0.0451 0.306159 0.491121 1.787141 14.49209 0.0066 0.829048 
 
1152 0.153254 0.113511 -0.03974 0.317547 0.48427 1.764172 14.66474 0.006335 0.874237 
 
1153 0.162378 0.125686 -0.03669 0.328519 0.479296 1.738143 14.87411 0.005964 0.919221 
 
1154 0.158595 0.131117 -0.02748 0.335415 0.473231 1.730611 14.93762 0.005934 0.948256 
 
1155 0.148097 0.100741 -0.04736 0.300654 0.494386 1.79854 14.4103 0.006729 0.807732 
 
1156 0.122921 0.109788 -0.01313 0.333607 0.456519 1.783977 14.51524 0.007292 0.940586 
 
1157 0.865275 0.234594 -0.63068 0.178481 0.770793 1.004946 507.0921 0.000586 0.408195 
 
1158 0.67158 0.896289 0.224708 0.738222 0.210438 1.005967 460.6345 0.001238 5.29843 
 
1159 0.254774 0.391407 0.136633 0.652901 0.280469 1.048141 101.1611 0.00165 3.53417 
 
1160 0.129011 0.144212 0.0152 0.36112 0.43966 1.739233 14.86503 0.006628 1.062 
 
1161 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
1162 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
1163 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
1164 0.15939 0.116558 -0.04283 0.319019 0.485161 1.75627 14.7267 0.006177 0.880187 
 
1165 0.529974 0.126212 -0.40376 0.301655 0.517326 1.735532 14.89597 0.005177 0.811586 
 
1166 0.120741 0.106858 -0.01388 0.331193 0.45677 1.791543 14.46021 0.007445 0.930407 
 
1167 0.147537 0.099473 -0.04806 0.298836 0.495458 1.802344 14.38355 0.006772 0.800766 
 
1168 0.153894 0.115301 -0.03859 0.319668 0.482978 1.760018 14.69714 0.006287 0.88282 
 
1169 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
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1170 0.124734 0.123341 -0.00139 0.349296 0.445847 1.760234 14.69545 0.006997 1.00857 
 
1171 0.125007 0.118057 -0.00695 0.342929 0.450893 1.767693 14.63757 0.007062 0.980584 
 
1172 0.154875 0.105304 -0.04957 0.30487 0.493701 1.784903 14.50844 0.006502 0.824028 
 
1173 0.158887 0.11802 -0.04087 0.321048 0.483584 1.753263 14.75064 0.006154 0.888431 
 
1174 0.430451 0.169834 -0.26062 0.331338 0.495618 1.685196 15.35168 0.004748 0.931016 
 
1175 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
1176 0.167841 0.152963 -0.01488 0.346185 0.46807 1.708173 15.13524 0.005587 0.994823 
 
1177 0.129011 0.144212 0.0152 0.36112 0.43966 1.739233 14.86503 0.006628 1.062 
 
1178 0.154513 0.117093 -0.03742 0.321725 0.48172 1.756027 14.72863 0.00624 0.891195 
 
1179 0.302077 0.133991 -0.16809 0.317616 0.500973 1.718232 15.04505 0.005228 0.874514 
 
1180 0.159266 0.118254 -0.04101 0.321189 0.483597 1.752709 14.75507 0.006144 0.889007 
 
1181 0.154251 0.115537 -0.03871 0.319818 0.482993 1.759429 14.70177 0.006276 0.883427 
 
1182 0.166458 0.141494 -0.02496 0.340508 0.471828 1.716754 15.05813 0.005699 0.970085 
 
1183 0.328291 0.144772 -0.18352 0.324203 0.497578 1.703674 15.17646 0.005046 0.901351 
 
1184 0.825252 0.126993 -0.69826 0.294678 0.527123 1.737151 14.8824 0.005005 0.784971 
 
1185 0.301212 0.112489 -0.18872 0.294675 0.51555 1.76571 14.65284 0.005688 0.784959 
 
1186 0.162759 0.125922 -0.03684 0.328625 0.479327 1.737671 14.87805 0.005955 0.919664 
 
1187 0.15487 0.117328 -0.03754 0.321865 0.48174 1.755459 14.73314 0.006229 0.891767 
 
1188 0.125017 0.123604 -0.00141 0.349323 0.446024 1.759662 14.69994 0.006982 1.00868 
 
1189 0.175614 0.107816 -0.0678 0.301321 0.501637 1.776561 14.57028 0.006182 0.810299 
 
1190 0.118442 0.098812 -0.01963 0.319751 0.46373 1.81219 14.31555 0.007718 0.883156 
 
1191 0.119933 0.099394 -0.02054 0.319271 0.465215 1.809944 14.3309 0.007635 0.881206 
 
1192 0.162759 0.125922 -0.03684 0.328625 0.479327 1.737671 14.87805 0.005955 0.919664 
 
1193 1.05059 11.8642 10.8136 0.968321 0.012109 1.001989 718.1025 0.000511 57.4303 Pos 
1194 0.147908 0.099728 -0.04818 0.299078 0.495423 1.801549 14.38912 0.006758 0.801693 
 
1195 0.329458 0.144879 -0.18458 0.324216 0.497609 1.703552 15.17758 0.005044 0.901406 
 
1196 0.371538 0.159201 -0.21234 0.16825 0.775886 1.016202 242.0288 0.00066 0.380063 
 
1197 0.826221 0.213464 -0.61276 0.110045 0.852765 0.999438 1125.402 0.000375 0.232325 
 
1198 0.378179 0.183894 -0.19428 0.194713 0.747262 1.012642 289.3123 0.000763 0.454296 
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1199 27.1121 0.430074 -26.682 5.71E-13 1 1.010613 325.9072 6.77E-25 1.07E-12 
 
1200 0.148467 0.100994 -0.04747 0.300888 0.494356 1.797762 14.4158 0.006716 0.808634 
 
1201 0.168213 0.153282 -0.01493 0.346212 0.468146 1.707873 15.13797 0.00558 0.994944 
 
1202 0.290039 1.05776 0.767723 0.807529 0.147953 1.00533 488.5402 0.000913 7.88291 Pos 
1203 0.329503 0.147207 -0.1823 0.325611 0.496679 1.7011 15.20029 0.005018 0.907157 
 
1204 0.162759 0.125922 -0.03684 0.328625 0.479327 1.737671 14.87805 0.005955 0.919664 
 
1205 0.154251 0.115537 -0.03871 0.319818 0.482993 1.759429 14.70177 0.006276 0.883427 
 
1206 0.308766 0.120207 -0.18856 0.303525 0.510282 1.746054 14.80885 0.00549 0.81881 
 
1207 0.293579 0.105359 -0.18822 0.285756 0.520759 1.786069 14.49991 0.005891 0.751695 
 
1208 1.11346 15.6647 14.5512 0.975819 0.008078 1.00036 933.5333 0.00025 75.8202 Pos 
1209 1.35242 0.199304 -1.15311 0.138784 0.81781 1.005723 470.9412 0.000414 0.302774 
 
1210 0.312148 0.124015 -0.18813 0.307498 0.50788 1.737496 14.87951 0.005403 0.834284 
 
1211 0.125292 0.118313 -0.00698 0.342985 0.451047 1.76708 14.64229 0.007046 0.980827 
 
1212 0.435162 0.17986 -0.2553 0.333842 0.493992 1.681413 15.38878 0.004698 0.94158 
 
1213 0.39466 0.241623 -0.15304 0.225872 0.714723 1.009425 352.1124 0.000852 0.548206 
 
1214 0.159266 0.118254 -0.04101 0.321189 0.483597 1.752709 14.75507 0.006144 0.889007 
 
1215 0.150154 0.104937 -0.04522 0.30637 0.491103 1.786416 14.49738 0.006587 0.829871 
 
1216 0.15487 0.117328 -0.03754 0.321865 0.48174 1.755459 14.73314 0.006229 0.891767 
 
1217 0.129286 0.144553 0.015266 0.361094 0.439858 1.738774 14.86885 0.006615 1.06188 
 
1218 0.117177 0.095094 -0.02208 0.314155 0.466999 1.822822 14.24405 0.00786 0.86062 
 
1219 0.147908 0.099728 -0.04818 0.299078 0.495423 1.801549 14.38912 0.006758 0.801693 
 
1220 0.147908 0.099728 -0.04818 0.299078 0.495423 1.801549 14.38912 0.006758 0.801693 
 
1221 0.712464 0.168273 -0.54419 0.140488 0.812123 1.009844 342.3844 0.000467 0.307102 
 
1222 0.148467 0.100994 -0.04747 0.300888 0.494356 1.797762 14.4158 0.006716 0.808634 
 
1223 1.85115 0.204901 -1.64625 0.0327806 0.951669 1.000883 851.2899 6.56E-05 0.063677 
 
1224 0.125017 0.123604 -0.00141 0.349323 0.446024 1.759662 14.69994 0.006982 1.00868 
 
1225 0.168213 0.153282 -0.01493 0.346212 0.468146 1.707873 15.13797 0.00558 0.994944 
 
1226 0.118442 0.098812 -0.01963 0.319751 0.46373 1.81219 14.31555 0.007718 0.883156 
 
1227 1.90468 0.510651 -1.39403 0.111714 0.828539 1.010106 336.5721 0.000793 0.236292 
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1228 0.186351 0.134504 -0.05185 0.329532 0.484307 1.720026 15.02924 0.00556 0.923449 
 
1229 0.159266 0.118254 -0.04101 0.321189 0.483597 1.752709 14.75507 0.006144 0.889007 
 
1230 0.128032 0.133356 0.005324 0.355359 0.443446 1.747036 14.80085 0.006749 1.03572 
 
1231 0.119933 0.099394 -0.02054 0.319271 0.465215 1.809944 14.3309 0.007635 0.881206 
 
1232 0.435162 0.17986 -0.2553 0.333842 0.493992 1.681413 15.38878 0.004698 0.94158 
 
1233 0.166458 0.141494 -0.02496 0.340508 0.471828 1.716754 15.05813 0.005699 0.970085 
 
1234 0.328291 0.144772 -0.18352 0.324203 0.497578 1.703674 15.17646 0.005046 0.901351 
 
1235 0.149585 0.113812 -0.03577 0.319615 0.481572 1.764109 14.66524 0.00639 0.882605 
 
1236 0.166458 0.141494 -0.02496 0.340508 0.471828 1.716754 15.05813 0.005699 0.970085 
 
1237 0.328291 0.144772 -0.18352 0.324203 0.497578 1.703674 15.17646 0.005046 0.901351 
 
1238 0.15527 0.10555 -0.04972 0.305085 0.493673 1.784189 14.51368 0.00649 0.824862 
 
1239 0.119933 0.099394 -0.02054 0.319271 0.465215 1.809944 14.3309 0.007635 0.881206 
 
1240 0.432147 0.170194 -0.26195 0.331391 0.495622 1.685028 15.35332 0.004744 0.931239 
 
1241 0.168213 0.153282 -0.01493 0.346212 0.468146 1.707873 15.13797 0.00558 0.994944 
 
1242 0.256081 0.404369 0.148288 0.656108 0.277749 1.046756 103.6626 0.001622 3.58464 
 
1243 0.127157 0.127595 0.000438 0.351382 0.44591 1.753182 14.75128 0.006844 1.01785 
 
1244 0.121975 0.110477 -0.0115 0.33553 0.454375 1.783243 14.52064 0.007321 0.948745 
 
1245 0.165239 0.135401 -0.02984 0.336569 0.474339 1.723357 15.0001 0.005782 0.953174 
 
1246 0.531675 0.126439 -0.40524 0.301833 0.51725 1.735064 14.89991 0.005172 0.812269 
 
1247 0.147908 0.099728 -0.04818 0.299078 0.495423 1.801549 14.38912 0.006758 0.801693 
 
1248 0.168213 0.153282 -0.01493 0.346212 0.468146 1.707873 15.13797 0.00558 0.994944 
 
1249 0.15527 0.10555 -0.04972 0.305085 0.493673 1.784189 14.51368 0.00649 0.824862 
 
1250 0.158942 0.13136 -0.02758 0.335491 0.473287 1.730182 14.94128 0.005926 0.948578 
 
1251 6.74137 0.229322 -6.51204 0.0046787 0.992554 1.007174 415.7523 1.53E-06 0.008832 
 
1252 0.138058 0.118228 -0.01983 0.332565 0.46677 1.759218 14.70343 0.006589 0.936181 
 
1253 0.312148 0.124015 -0.18813 0.307498 0.50788 1.737496 14.87951 0.005403 0.834284 
 
1254 0.331205 0.150945 -0.18026 0.327584 0.495413 1.697585 15.23313 0.004978 0.915328 
 
1255 0.159266 0.118254 -0.04101 0.321189 0.483597 1.752709 14.75507 0.006144 0.889007 
 
1256 0.168213 0.153282 -0.01493 0.346212 0.468146 1.707873 15.13797 0.00558 0.994944 
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1257 0.15487 0.117328 -0.03754 0.321865 0.48174 1.755459 14.73314 0.006229 0.891767 
 
1258 0.312148 0.124015 -0.18813 0.307498 0.50788 1.737496 14.87951 0.005403 0.834284 
 
1259 0.154517 0.122057 -0.03246 0.327606 0.477621 1.74618 14.80782 0.006141 0.915421 
 
1260 0.117177 0.095094 -0.02208 0.314155 0.466999 1.822822 14.24405 0.00786 0.86062 
 
1261 0.166458 0.141494 -0.02496 0.340508 0.471828 1.716754 15.05813 0.005699 0.970085 
 
1262 0.148467 0.100994 -0.04747 0.300888 0.494356 1.797762 14.4158 0.006716 0.808634 
 
1263 0.121975 0.110477 -0.0115 0.33553 0.454375 1.783243 14.52064 0.007321 0.948745 
 
1264 0.852185 0.226072 -0.62611 0.114983 0.846721 0.999393 1136.795 0.000398 0.244104 
 
1265 0.328291 0.144772 -0.18352 0.324203 0.497578 1.703674 15.17646 0.005046 0.901351 
 
1266 0.808133 0.120931 -0.6872 0.288718 0.530519 1.751435 14.76529 0.005141 0.762648 
 
1267 0.149585 0.113812 -0.03577 0.319615 0.481572 1.764109 14.66524 0.00639 0.882605 
 
1268 0.150154 0.104937 -0.04522 0.30637 0.491103 1.786416 14.49738 0.006587 0.829871 
 
1269 0.148467 0.100994 -0.04747 0.300888 0.494356 1.797762 14.4158 0.006716 0.808634 
 
1270 0.435162 0.17986 -0.2553 0.333842 0.493992 1.681413 15.38878 0.004698 0.94158 
 
1271 0.435162 0.17986 -0.2553 0.333842 0.493992 1.681413 15.38878 0.004698 0.94158 
 
1272 0.154251 0.115537 -0.03871 0.319818 0.482993 1.759429 14.70177 0.006276 0.883427 
 
1273 0.154251 0.115537 -0.03871 0.319818 0.482993 1.759429 14.70177 0.006276 0.883427 
 
1274 0.432147 0.170194 -0.26195 0.331391 0.495622 1.685028 15.35332 0.004744 0.931239 
 
1275 0.121034 0.107112 -0.01392 0.331304 0.456902 1.790811 14.46548 0.007426 0.930873 
 
1276 0.730565 0.170353 -0.56021 0.141545 0.811082 1.009488 350.6042 0.000469 0.309792 
 
1277 0.168213 0.153282 -0.01493 0.346212 0.468146 1.707873 15.13797 0.00558 0.994944 
 
1278 0.328291 0.144772 -0.18352 0.324203 0.497578 1.703674 15.17646 0.005046 0.901351 
 
1279 0.150154 0.104937 -0.04522 0.30637 0.491103 1.786416 14.49738 0.006587 0.829871 
 
1280 0.125292 0.118313 -0.00698 0.342985 0.451047 1.76708 14.64229 0.007046 0.980827 
 
1281 0.531675 0.126439 -0.40524 0.301833 0.51725 1.735064 14.89991 0.005172 0.812269 
 
1282 0.128032 0.133356 0.005324 0.355359 0.443446 1.747036 14.80085 0.006749 1.03572 
 
1283 0.148467 0.100994 -0.04747 0.300888 0.494356 1.797762 14.4158 0.006716 0.808634 
 
1284 0.432147 0.170194 -0.26195 0.331391 0.495622 1.685028 15.35332 0.004744 0.931239 
 
1285 0.328291 0.144772 -0.18352 0.324203 0.497578 1.703674 15.17646 0.005046 0.901351 
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1286 0.148467 0.100994 -0.04747 0.300888 0.494356 1.797762 14.4158 0.006716 0.808634 
 
1287 0.125017 0.123604 -0.00141 0.349323 0.446024 1.759662 14.69994 0.006982 1.00868 
 
1288 0.168213 0.153282 -0.01493 0.346212 0.468146 1.707873 15.13797 0.00558 0.994944 
 
1289 0.162759 0.125922 -0.03684 0.328625 0.479327 1.737671 14.87805 0.005955 0.919664 
 
1290 0.15487 0.117328 -0.03754 0.321865 0.48174 1.755459 14.73314 0.006229 0.891767 
 
1291 0.162759 0.125922 -0.03684 0.328625 0.479327 1.737671 14.87805 0.005955 0.919664 
 
1292 0.125292 0.118313 -0.00698 0.342985 0.451047 1.76708 14.64229 0.007046 0.980827 
 
1293 0.131325 0.147128 0.015803 0.360906 0.441309 1.735401 14.89707 0.006518 1.06102 
 
1294 0.432147 0.170194 -0.26195 0.331391 0.495622 1.685028 15.35332 0.004744 0.931239 
 
1295 0.825252 0.126993 -0.69826 0.294678 0.527123 1.737151 14.8824 0.005005 0.784971 
 
1296 0.172618 0.102069 -0.07055 0.293587 0.506224 1.793227 14.44811 0.00636 0.780858 
 
1297 0.825252 0.126993 -0.69826 0.294678 0.527123 1.737151 14.8824 0.005005 0.784971 
 
1298 0.125292 0.118313 -0.00698 0.342985 0.451047 1.76708 14.64229 0.007046 0.980827 
 
1299 0.159266 0.118254 -0.04101 0.321189 0.483597 1.752709 14.75507 0.006144 0.889007 
 
1300 0.825252 0.126993 -0.69826 0.294678 0.527123 1.737151 14.8824 0.005005 0.784971 
 
1301 0.148467 0.100994 -0.04747 0.300888 0.494356 1.797762 14.4158 0.006716 0.808634 
 
1302 0.158942 0.13136 -0.02758 0.335491 0.473287 1.730182 14.94128 0.005926 0.948578 
 
1303 0.384467 0.167389 -0.21708 0.175014 0.768907 1.014264 265.6087 0.00068 0.398583 
 
1304 0.159266 0.118254 -0.04101 0.321189 0.483597 1.752709 14.75507 0.006144 0.889007 
 
1305 0.153613 0.113748 -0.03986 0.317707 0.484279 1.763562 14.66948 0.006324 0.87488 
 
1306 0.186351 0.134504 -0.05185 0.329532 0.484307 1.720026 15.02924 0.00556 0.923449 
 
1307 0.148467 0.100994 -0.04747 0.300888 0.494356 1.797762 14.4158 0.006716 0.808634 
 
1308 0.154251 0.115537 -0.03871 0.319818 0.482993 1.759429 14.70177 0.006276 0.883427 
 
1309 0.121034 0.107112 -0.01392 0.331304 0.456902 1.790811 14.46548 0.007426 0.930873 
 
1310 0.154517 0.122057 -0.03246 0.327606 0.477621 1.74618 14.80782 0.006141 0.915421 
 
1311 0.153613 0.113748 -0.03986 0.317707 0.484279 1.763562 14.66948 0.006324 0.87488 
 
1312 0.138058 0.118228 -0.01983 0.332565 0.46677 1.759218 14.70343 0.006589 0.936181 
 
1313 0.205056 0.404903 0.199847 0.696153 0.239381 1.057396 87.29206 0.00159 4.3047 
 
1314 0.226111 0.967623 0.741512 0.83692 0.123769 1.004614 524.3093 0.000735 9.64224 Pos 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
1315 0.119933 0.099394 -0.02054 0.319271 0.465215 1.809944 14.3309 0.007635 0.881206 
 
1316 0.119933 0.099394 -0.02054 0.319271 0.465215 1.809944 14.3309 0.007635 0.881206 
 
1317 0.531675 0.126439 -0.40524 0.301833 0.51725 1.735064 14.89991 0.005172 0.812269 
 
1318 0.129873 0.116243 -0.01363 0.336368 0.459131 1.767312 14.6405 0.006896 0.952313 
 
1319 0.123211 0.110039 -0.01317 0.333706 0.45665 1.783281 14.52036 0.007274 0.941005 
 
1320 0.123211 0.110039 -0.01317 0.333706 0.45665 1.783281 14.52036 0.007274 0.941005 
 
1321 0.15487 0.117328 -0.03754 0.321865 0.48174 1.755459 14.73314 0.006229 0.891767 
 
1322 0.158942 0.13136 -0.02758 0.335491 0.473287 1.730182 14.94128 0.005926 0.948578 
 
1323 0.159777 0.116792 -0.04298 0.319169 0.485167 1.755701 14.73122 0.006166 0.880796 
 
1324 0.125017 0.123604 -0.00141 0.349323 0.446024 1.759662 14.69994 0.006982 1.00868 
 
1325 0.312148 0.124015 -0.18813 0.307498 0.50788 1.737496 14.87951 0.005403 0.834284 
 
1326 0.129286 0.144553 0.015266 0.361094 0.439858 1.738774 14.86885 0.006615 1.06188 
 
1327 0.159777 0.116792 -0.04298 0.319169 0.485167 1.755701 14.73122 0.006166 0.880796 
 
1328 0.808133 0.120931 -0.6872 0.288718 0.530519 1.751435 14.76529 0.005141 0.762648 
 
1329 0.326744 0.145378 -0.18137 0.32465 0.497227 1.703016 15.18253 0.005041 0.903191 
 
1330 0.432147 0.170194 -0.26195 0.331391 0.495622 1.685028 15.35332 0.004744 0.931239 
 
1331 0.148467 0.100994 -0.04747 0.300888 0.494356 1.797762 14.4158 0.006716 0.808634 
 
1332 0.329503 0.147207 -0.1823 0.325611 0.496679 1.7011 15.20029 0.005018 0.907157 
 
1333 0.265559 0.407821 0.142262 0.652845 0.281055 1.045642 105.775 0.001616 3.53329 
 
1334 0.168213 0.153282 -0.01493 0.346212 0.468146 1.707873 15.13797 0.00558 0.994944 
 
1335 0.152484 0.110714 -0.04177 0.313988 0.486535 1.770925 14.61286 0.00641 0.859951 
 
1336 0.159777 0.116792 -0.04298 0.319169 0.485167 1.755701 14.73122 0.006166 0.880796 
 
1337 0.159777 0.116792 -0.04298 0.319169 0.485167 1.755701 14.73122 0.006166 0.880796 
 
1338 0.86203 0.234898 -0.62713 0.178862 0.770344 1.004955 506.637 0.000588 0.409256 
 
1339 0.386233 0.147007 -0.23923 0.323183 0.500006 1.701192 15.19943 0.004961 0.897162 
 
1340 0.389836 0.196009 -0.19383 0.202645 0.739092 1.011145 315.4211 0.000784 0.477504 
 
1341 0.328291 0.144772 -0.18352 0.324203 0.497578 1.703674 15.17646 0.005046 0.901351 
 
1342 0.430091 0.164705 -0.26539 0.329703 0.496732 1.687675 15.3276 0.004777 0.924161 
 
1343 0.125292 0.118313 -0.00698 0.342985 0.451047 1.76708 14.64229 0.007046 0.980827 
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1344 0.128032 0.133356 0.005324 0.355359 0.443446 1.747036 14.80085 0.006749 1.03572 
 
1345 0.117177 0.095094 -0.02208 0.314155 0.466999 1.822822 14.24405 0.00786 0.86062 
 
1346 0.605499 0.680685 0.075186 0.645554 0.292996 1.032543 140.0153 0.001358 3.42196 
 
1347 0.172618 0.102069 -0.07055 0.293587 0.506224 1.793227 14.44811 0.00636 0.780858 
 
1348 0.159304 0.115501 -0.0438 0.317682 0.486076 1.758622 14.70811 0.0062 0.874781 
 
1349 0.329503 0.147207 -0.1823 0.325611 0.496679 1.7011 15.20029 0.005018 0.907157 
 
1350 0.154251 0.115537 -0.03871 0.319818 0.482993 1.759429 14.70177 0.006276 0.883427 
 
1351 0.159304 0.115501 -0.0438 0.317682 0.486076 1.758622 14.70811 0.0062 0.874781 
 
1352 0.154251 0.115537 -0.03871 0.319818 0.482993 1.759429 14.70177 0.006276 0.883427 
 
1353 0.986884 0.590725 -0.39616 0.348116 0.491822 1.654671 15.66383 0.003986 1.00334 
 





Codon alpha beta1 p1 beta2 p2 LRT p-value q-value Log(L) 
 
1 0 0 0 0 1 0 1 1 0 
 
2 0 0 0 0 1 0 1 1 0 
 
3 0 0 0 0 1 0 1 1 0 
 
4 0 0 0 0 1 0 1 1 0 
 
5 0 0 0 0 1 0 1 1 0 
 
6 0 0 0 0 1 0 1 1 0 
 
7 0 0 0 0 1 0 1 1 0 
 
8 0 0 0 0 1 0 1 1 0 
 
9 0 0 0 0 1 0 1 1 0 
 
10 0 0 0 0 1 0 1 1 0 
 
11 0 0 0 0 1 0 1 1 0 
 
12 0 0 0 0 1 0 1 1 0 
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13 0 0 0 0 1 0 1 1 0 
 
14 0 0 0 0 1 0 1 1 0 
 
15 0 0 0 0 1 0 1 1 0 
 
16 0 0 0 0 1 0 1 1 0 
 
17 0 0 0 0 1 0 1 1 0 
 
18 0 0 0 0 1 0 1 1 0 
 
19 0 0 0 0 1 0 1 1 0 
 
20 0 0 0 0 1 0 1 1 0 
 
21 0 0 0 0 1 0 1 1 0 
 
22 0 0 0 0 1 0 1 1 0 
 
23 0 0 1.00E-09 1.41298 1 0.561877 0.414977 1 -
9.45616 
 
24 0 0 0 0 1 0 1 1 0 
 
25 0 0 0 0 1 0 1 1 0 
 
26 0 0 1.00E-09 4.45712 1 1.88658 0.194605 1 -
20.7152 
 
27 0 0 0 0 1 0 1 1 0 
 
28 0 0 0 0 1 0 1 1 0 
 
29 0 0 0 0 1 0 1 1 0 
 
30 0 0 0 0 1 0 1 1 0 
 
31 0 0 0 0 1 0 1 1 0 
 
32 0 0 0 0 1 0 1 1 0 
 
33 0 0 0 0 1 0 1 1 0 
 
34 0 0 0 0 1 0 1 1 0 
 
35 0 0 0 0 1 0 1 1 0 
 
36 0 0 0 0 1 0 1 1 0 
 
37 0 0 0 0 1 0 1 1 0 
 
38 11.6463 0 0.051665 0 0.948335 0 0.67 1 -
17.0448 
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39 0 0 0.046825 0 0.953175 0 0.67 1 -
4.25509 
 
40 0 0 0 0 1 0 1 1 0 
 
41 0 0 0 0 1 0 1 1 0 
 
42 0 0 0 0 1 0 1 1 0 
 
43 0 0 0 0 1 0 1 1 0 
 
44 0 0 0 0 1 0 1 1 0 
 
45 0 0 0 0 1 0 1 1 0 
 
46 0 0 0 0 1 0 1 1 0 
 
47 0 0 0 0 1 0 1 1 0 
 
48 0 0 0 0 1 0 1 1 0 
 
49 0 0 0 0 1 0 1 1 0 
 
50 0 0 0 0 1 0 1 1 0 
 
51 0 0 0.258805 2.08501 0.741195 0.656908 0.391256 1 -
10.0213 
 
52 0 0 0 0 1 0 1 1 0 
 
53 0 0 0 0 1 0 1 1 0 
 
54 0 0 0 0 1 0 1 1 0 
 
55 0 0 0 0 1 0 1 1 0 
 
56 0 0 0 0 1 0 1 1 0 
 
57 0 0 0 0 1 0 1 1 0 
 
58 0 0 1.00E-09 1.90154 1 1.4352 0.249421 1 -
9.47732 
 
59 0 0 0 0 1 0 1 1 0 
 
60 0 0 0 0 1 0 1 1 0 
 
61 1.75359 0 0.047373 0 0.952627 0 0.67 1 -
12.9305 
 
62 0 0 0 0 1 0 1 1 0 
 
63 0 0 0 0 1 0 1 1 0 
 
64 0 0 0 0 1 0 1 1 0 
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65 0 0 0 0 1 0 1 1 0 
 
66 0 0 0 0 1 0 1 1 0 
 
67 0 0 0 0 1 0 1 1 0 
 
68 0 0 0 0 1 0 1 1 0 
 
69 0 0 0 0 1 0 1 1 0 
 
70 0 0 0 0 1 0 1 1 0 
 
71 0 0 0 0 1 0 1 1 0 
 
72 0 0 0 0 1 0 1 1 0 
 
73 0 0 0 0 1 0 1 1 0 
 
74 0 0 0 0 1 0 1 1 0 
 
75 0 0 0 0 1 0 1 1 0 
 
76 0 0 0 0 1 0 1 1 0 
 
77 0 0 0 0 1 0 1 1 0 
 
78 0 0 0 0 1 0 1 1 0 
 
79 0 0 0 0 1 0 1 1 0 
 
80 0 0 0 0 1 0 1 1 0 
 
81 0 0 0 0 1 0 1 1 0 
 
82 0 0 0 0 1 0 1 1 0 
 
83 0 0 0 0 1 0 1 1 0 
 
84 0 0 0 0 1 0 1 1 0 
 
85 0 0 0 0 1 0 1 1 0 
 
86 22.3087 0 0.048167 0 0.951833 0 0.67 1 -20.821 
 
87 0 0 0 0 1 0 1 1 0 
 
88 0 0 0 0 1 0 1 1 0 
 
89 0 0 0 0 1 0 1 1 0 
 
90 0 0 0 0 1 0 1 1 0 
 
91 0 0 0.046825 0 0.953175 0 0.67 1 -
3.50904 
 
92 0 0 0 0 1 0 1 1 0 
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93 0 0 0 0 1 0 1 1 0 
 
94 0 0 1.00E-09 2.79255 1 2.39139 0.148254 1 -
19.0526 
 
95 0 0 0 0 1 0 1 1 0 
 
96 0 0 0 0 1 0 1 1 0 
 
97 0 0 0.96217 174.445 0.03783 2.16783 0.167141 1 -
16.3611 
 
98 0 0 0.274814 3.7108 0.725186 0.675296 0.386885 1 -
12.4293 
 
99 0 0 0 0 1 0 1 1 0 
 
100 0 0 0 0 1 0 1 1 0 
 
101 0 0 0 0 1 0 1 1 0 
 
102 0 0 0 0 1 0 1 1 0 
 
103 0 0 0 0 1 0 1 1 0 
 
104 0 0 0 0 1 0 1 1 0 
 
105 0 0 0 0 1 0 1 1 0 
 
106 0 0 0.262568 2.09736 0.737432 0.658421 0.390894 1 -
10.3096 
 
107 0 0 0 0 1 0 1 1 0 
 
108 0 0 0.270738 2.22378 0.729262 1.27868 0.272267 1 -12.078 
 
109 0 0 0 0 1 0 1 1 0 
 
110 0 0 0 0 1 0 1 1 0 
 
111 0 0 0 0 1 0 1 1 0 
 
112 33.5912 0 0.047296 0 0.952704 0 0.67 1 -
23.4331 
 
113 0 0 0 0 1 0 1 1 0 
 
114 0 0 0 0 1 0 1 1 0 
 
115 0 0 0 0 1 0 1 1 0 
 
116 0 0 0 0 1 0 1 1 0 
 
117 0 0 0 0 1 0 1 1 0 
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118 0 0 0 0 1 0 1 1 0 
 
119 0 0 0 0 1 0 1 1 0 
 
120 0 0 0 0 1 0 1 1 0 
 
121 0 0 0 0 1 0 1 1 0 
 
122 0 0 0 0 1 0 1 1 0 
 
123 0 0 0 0 1 0 1 1 0 
 
124 0 0 0 0 1 0 1 1 0 
 
125 0 0 0.242406 2.06924 0.757594 0.582795 0.409583 1 -
10.9985 
 
126 1.71493 0 0.052546 0 0.947454 0 0.67 1 -
9.73579 
 
127 0 0 0 0 1 0 1 1 0 
 
128 0 0 0 0 1 0 1 1 0 
 
129 0 0 0 0 1 0 1 1 0 
 
130 0 0 0 0 1 0 1 1 0 
 
131 0 0 0 0 1 0 1 1 0 
 
132 0 0 0 0 1 0 1 1 0 
 
133 0 0 0.223004 1.60021 0.776996 1.03982 0.311921 1 -
10.3299 
 
134 0 0 0 0 1 0 1 1 0 
 
135 0 0 0.270069 2.12618 0.729931 0.66255 0.389908 1 -
11.4069 
 
136 0 0 0 0 1 0 1 1 0 
 
137 0 0 0.257555 1.68699 0.742445 1.05198 0.309745 1 -
14.2651 
 
138 0 0 0 0 1 0 1 1 0 
 
139 0 0 0.251897 1.81656 0.748103 0.587921 0.408277 1 -
9.87406 
 
140 0 0 0 0 1 0 1 1 0 
 
141 0 0 0 0 1 0 1 1 0 
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142 0 0 0 0 1 0 1 1 0 
 
143 0 0 0 0 1 0 1 1 0 
 
144 0 0 0 0 1 0 1 1 0 
 
145 0 0 0 0 1 0 1 1 0 
 
146 0 0 0 0 1 0 1 1 0 
 
147 0 0 0 0 1 0 1 1 0 
 
148 0 0 0 0 1 0 1 1 0 
 
149 0 0 0 0 1 0 1 1 0 
 
150 0 0 0 0 1 0 1 1 0 
 
151 0 0 0 0 1 0 1 1 0 
 
152 0 0 0 0 1 0 1 1 0 
 
153 0 0 0 0 1 0 1 1 0 
 
154 0 0 0 0 1 0 1 1 0 
 
155 0 0 0 0 1 0 1 1 0 
 
156 0 0 0 0 1 0 1 1 0 
 
157 0 0 0 0 1 0 1 1 0 
 
158 0 0 0.274376 2.24532 0.725624 0.608435 0.403109 1 -
12.8252 
 
159 0 0 0 0 1 0 1 1 0 
 
160 0 0 0 0 1 0 1 1 0 
 
161 0.844619 0 0.046586 0 0.953414 0 0.67 1 -
4.60369 
 
162 0 0 0 0 1 0 1 1 0 
 
163 0 0 0 0 1 0 1 1 0 
 
164 0 0 0 0 1 0 1 1 0 
 
165 0 0 0 0 1 0 1 1 0 
 
166 0 0 0.272195 2.13728 0.727805 0.585365 0.408928 1 -
13.6514 
 
167 0 0 0.210435 2.03505 0.789565 0.591895 0.407269 1 -
8.99293 
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168 0 0 0 0 1 0 1 1 0 
 
169 0 0 0 0 1 0 1 1 0 
 
170 32.0806 0 0.047288 0 0.952712 0 0.67 1 -
26.2728 
 
171 0 0 0 0 1 0 1 1 0 
 
172 0 0 0 0 1 0 1 1 0 
 
173 0 0 0 0 1 0 1 1 0 
 
174 0 0 0 0 1 0 1 1 0 
 
175 0 0 0 0 1 0 1 1 0 
 
176 0 0 0 0 1 0 1 1 0 
 
177 0 0 0 0 1 0 1 1 0 
 
178 0 0 0 0 1 0 1 1 0 
 
179 0 0 0 0 1 0 1 1 0 
 
180 0 0 0 0 1 0 1 1 0 
 
181 0 0 0 0 1 0 1 1 0 
 
182 0 0 0 0 1 0 1 1 0 
 
183 0 0 0 0 1 0 1 1 0 
 
184 0 0 0 0 1 0 1 1 0 
 
185 0 0 0 0 1 0 1 1 0 
 
186 0 0 0 0 1 0 1 1 0 
 
187 0 0 0 0 1 0 1 1 0 
 
188 0 0 0 0 1 0 1 1 0 
 
189 0 0 0 0 1 0 1 1 0 
 
190 0 0 0 0 1 0 1 1 0 
 
191 0 0 0 0 1 0 1 1 0 
 
192 0 0 0 0 1 0 1 1 0 
 
193 4.77392 0 0.047427 0 0.952573 0 0.67 1 -
9.23813 
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194 0 0 0.216593 2.06812 0.783407 0.597218 0.405923 1 -
9.14514 
 
195 0 0 0 0 1 0 1 1 0 
 
196 0 0 0 0 1 0 1 1 0 
 
197 0 0 0 0 1 0 1 1 0 
 
198 0 0 0.256394 1.82022 0.743606 1.16901 0.289697 1 -
11.6295 
 
199 0 0 0 0 1 0 1 1 0 
 
200 0 0 0 0 1 0 1 1 0 
 
201 0 0 0.26734 2.62352 0.73266 0.697825 0.38162 1 -
10.6864 
 
202 0 0 0 0 1 0 1 1 0 
 
203 0 0 0 0 1 0 1 1 0 
 
204 0 0 0 0 1 0 1 1 0 
 
205 0 0 0 0 1 0 1 1 0 
 
206 0 0 0 0 1 0 1 1 0 
 
207 0 0 0 0 1 0 1 1 0 
 
208 7.59143 0 0.047289 0 0.952711 0 0.67 1 -
20.7668 
 
209 0 0 0 0 1 0 1 1 0 
 
210 0 0 0 0 1 0 1 1 0 
 
211 9.2238 0 0.047296 0 0.952704 0 0.67 1 -
20.4975 
 
212 0 0 0 0 1 0 1 1 0 
 
213 0 0 0 0 1 0 1 1 0 
 
214 0 0 0 0 1 0 1 1 0 
 
215 0 0 0 0 1 0 1 1 0 
 
216 0 0 0 0 1 0 1 1 0 
 
217 0 0 0 0 1 0 1 1 0 
 
218 0 0 0 0 1 0 1 1 0 
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219 0 0 0 0 1 0 1 1 0 
 
220 0 0 0 0 1 0 1 1 0 
 
221 0 0 0 0 1 0 1 1 0 
 
222 0 0 0 0 1 0 1 1 0 
 
223 0 0 0 0 1 0 1 1 0 
 
224 0 0 0 0 1 0 1 1 0 
 
225 1.74032 0 0.047467 0 0.952533 0 0.67 1 -11.756 
 
226 0 0 0 0 1 0 1 1 0 
 
227 0 0 0 0 1 0 1 1 0 
 
228 0 0 0 0 1 0 1 1 0 
 
229 0 0 0 0 1 0 1 1 0 
 
230 0 0 0 0 1 0 1 1 0 
 
231 4.71531 0 0.04842 0 0.95158 0 0.67 1 -
9.83305 
 
232 0 0 0 0 1 0 1 1 0 
 
233 0 0 0 0 1 0 1 1 0 
 
234 0 0 0 0 1 0 1 1 0 
 
235 0 0 0 0 1 0 1 1 0 
 
236 0 0 0 0 1 0 1 1 0 
 
237 1.84367 0 0.048483 0 0.951518 0 0.67 1 -
8.81874 
 
238 0 0 0 0 1 0 1 1 0 
 
239 0 0 0 0 1 0 1 1 0 
 
240 0 0 0 0 1 0 1 1 0 
 
241 0 0 0 0 1 0 1 1 0 
 
242 0 0 0.254208 1.8204 0.745792 0.588398 0.408156 1 -
10.1185 
 
243 0 0 0 0 1 0 1 1 0 
 
244 0 0 0 0 1 0 1 1 0 
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245 0 0 0 0 1 0 1 1 0 
 
246 0 0 0 0 1 0 1 1 0 
 
247 0 0 0 0 1 0 1 1 0 
 
248 0 0 0 0 1 0 1 1 0 
 
249 0 0 0 0 1 0 1 1 0 
 
250 0 0 0 0 1 0 1 1 0 
 
251 0 0 0 0 1 0 1 1 0 
 
252 0 0 0 0 1 0 1 1 0 
 
253 0 0 0 0 1 0 1 1 0 
 
254 0 0 0 0 1 0 1 1 0 
 
255 0 0 0 0 1 0 1 1 0 
 
256 0 0 0 0 1 0 1 1 0 
 
257 0 0 0 0 1 0 1 1 0 
 
258 0 0 0 0 1 0 1 1 0 
 
259 0 0 0 0 1 0 1 1 0 
 
260 0 0 0 0 1 0 1 1 0 
 
261 0 0 0 0 1 0 1 1 0 
 
262 0 0 0 0 1 0 1 1 0 
 
263 0 0 0 0 1 0 1 1 0 
 
264 0 0 0 0 1 0 1 1 0 
 
265 0 0 0 0 1 0 1 1 0 
 
266 0 0 0 0 1 0 1 1 0 
 
267 4.70236 0 0.047296 0 0.952704 0 0.67 1 -
9.80181 
 
268 0 0 0 0 1 0 1 1 0 
 
269 0 0 0 0 1 0 1 1 0 
 
270 0 0 0 0 1 0 1 1 0 
 
271 0 0 0 0 1 0 1 1 0 
 
272 0 0 0 0 1 0 1 1 0 
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273 0 0 0 0 1 0 1 1 0 
 
274 0 0 0 0 1 0 1 1 0 
 
275 1.71644 0 0.065 0 0.935 0 0.67 1 -
10.3739 
 
276 0 0 0 0 1 0 1 1 0 
 
277 0 0 0 0 1 0 1 1 0 
 
278 0 0 0 0 1 0 1 1 0 
 
279 0 0 0 0 1 0 1 1 0 
 
280 0 0 0 0 1 0 1 1 0 
 
281 0 0 0 0 1 0 1 1 0 
 
282 3.47085 0 0.048522 0 0.951478 0 0.67 1 -
13.5314 
 
283 0 0 0 0 1 0 1 1 0 
 
284 0 0 0 0 1 0 1 1 0 
 
285 0 0 0.046825 0 0.953175 0 0.67 1 -
3.67712 
 
286 0 0 0 0 1 0 1 1 0 
 
287 0 0 0 0 1 0 1 1 0 
 
288 28.7895 0 0.047296 0 0.952704 0 0.67 1 -
23.8186 
 
289 0 0 0.046825 0 0.953175 0 0.67 1 -
3.39368 
 
290 0 0 0 0 1 0 1 1 0 
 
291 0 0 0 0 1 0 1 1 0 
 
292 0 0 0 0 1 0 1 1 0 
 
293 76.1002 0 0.047274 0 0.952726 0 0.67 1 -
38.7698 
 
294 0 0 0 0 1 0 1 1 0 
 
295 0 0 0 0 1 0 1 1 0 
 
296 0 0 0 0 1 0 1 1 0 
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297 0 0 0 0 1 0 1 1 0 
 
298 1.8207 0 0.048423 0 0.951577 0 0.67 1 -
10.6079 
 
299 0 0 0 0 1 0 1 1 0 
 
300 0 0 0 0 1 0 1 1 0 
 
301 0 0 1.00E-09 4.19187 1 1.79394 0.20468 1 -
24.0763 
 
302 0 0 0 0 1 0 1 1 0 
 
303 0 0 0 0 1 0 1 1 0 
 
304 0 0 0.275669 3.71648 0.724331 0.675256 0.386895 1 -
14.3002 
 
305 0 0 0 0 1 0 1 1 0 
 
306 0 0 0 0 1 0 1 1 0 
 
307 0 0 0 0 1 0 1 1 0 
 
308 0 0 0 0 1 0 1 1 0 
 
309 0 0 0 0 1 0 1 1 0 
 
310 0 0 0 0 1 0 1 1 0 
 
311 0 0 0 0 1 0 1 1 0 
 
312 0 0 0.401265 2.40256 0.598735 1.22518 0.280614 1 -
14.7278 
 
313 1.82034 0 0.048417 0 0.951583 0 0.67 1 -
10.8285 
 
314 0 0 0 0 1 0 1 1 0 
 
315 0 0 0 0 1 0 1 1 0 
 
316 0 0 0 0 1 0 1 1 0 
 
317 0 0 0 0 1 0 1 1 0 
 
318 0 0 0 0 1 0 1 1 0 
 
319 0 0 0 0 1 0 1 1 0 
 
320 0 0 0 0 1 0 1 1 0 
 
321 0 0 0 0 1 0 1 1 0 
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322 0 0 0 0 1 0 1 1 0 
 
323 0 0 0 0 1 0 1 1 0 
 
324 0 0 0 0 1 0 1 1 0 
 
325 0 0 0 0 1 0 1 1 0 
 
326 0 0 0 0 1 0 1 1 0 
 
327 0 0 0 0 1 0 1 1 0 
 
328 0 0 0 0 1 0 1 1 0 
 
329 0 0 0 0 1 0 1 1 0 
 
330 0 0 0 0 1 0 1 1 0 
 
331 0 0 0 0 1 0 1 1 0 
 
332 4.5983 0 0.04999 0 0.95001 0 0.67 1 -
7.31265 
 
333 0 0 0 0 1 0 1 1 0 
 
334 0 0 0 0 1 0 1 1 0 
 
335 0 0 0 0 1 0 1 1 0 
 
336 0 0 0.241789 1.87294 0.758211 0.608195 0.403169 1 -
11.2522 
 
337 0 0 0 0 1 0 1 1 0 
 
338 0 0 0 0 1 0 1 1 0 
 
339 0 0 0 0 1 0 1 1 0 
 
340 0 0 0 0 1 0 1 1 0 
 
341 0 0 0 0 1 0 1 1 0 
 
342 0 0 0 0 1 0 1 1 0 
 
343 0 0 0 0 1 0 1 1 0 
 
344 0 0 0 0 1 0 1 1 0 
 
345 0 0 0 0 1 0 1 1 0 
 
346 0 0 0 0 1 0 1 1 0 
 
347 0 0 0 0 1 0 1 1 0 
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348 0 0 0.046825 0 0.953175 0 0.67 1 -
4.44066 
 
349 0 0 0 0 1 0 1 1 0 
 
350 0 0 0 0 1 0 1 1 0 
 
351 0 0 0 0 1 0 1 1 0 
 
352 0 0 0 0 1 0 1 1 0 
 
353 0 0 0 0 1 0 1 1 0 
 
354 0 0 0 0 1 0 1 1 0 
 
355 0 0 0 0 1 0 1 1 0 
 
356 0 0 0 0 1 0 1 1 0 
 
357 0 0 0 0 1 0 1 1 0 
 
358 0 0 0 0 1 0 1 1 0 
 
359 0 0 0 0 1 0 1 1 0 
 
360 0 0 0 0 1 0 1 1 0 
 
361 0 0 0 0 1 0 1 1 0 
 
362 0 0 0 0 1 0 1 1 0 
 
363 0 0 0 0 1 0 1 1 0 
 
364 0 0 0 0 1 0 1 1 0 
 
365 0 0 0 0 1 0 1 1 0 
 
366 0 0 0 0 1 0 1 1 0 
 
367 0 0 0 0 1 0 1 1 0 
 
368 0 0 0 0 1 0 1 1 0 
 
369 0 0 0 0 1 0 1 1 0 
 
370 0 0 0 0 1 0 1 1 0 
 
371 0 0 0 0 1 0 1 1 0 
 
372 0 0 0 0 1 0 1 1 0 
 
373 0 0 0 0 1 0 1 1 0 
 
374 0 0 0.2387 1.95254 0.7613 0.63133 0.397449 1 -
11.1048 
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375 0 0 0 0 1 0 1 1 0 
 
376 0 0 0 0 1 0 1 1 0 
 
377 0 0 0 0 1 0 1 1 0 
 
378 0 0 0 0 1 0 1 1 0 
 
379 0 0 0 0 1 0 1 1 0 
 
380 0 0 0 0 1 0 1 1 0 
 
381 0 0 0 0 1 0 1 1 0 
 
382 0 0 0 0 1 0 1 1 0 
 
383 0 0 0 0 1 0 1 1 0 
 
384 0 0 0 0 1 0 1 1 0 
 
385 0 0 0 0 1 0 1 1 0 
 
386 0 0 0 0 1 0 1 1 0 
 
387 0 0 0 0 1 0 1 1 0 
 
388 0 0 0 0 1 0 1 1 0 
 
389 0 0 0 0 1 0 1 1 0 
 
390 0 0 0 0 1 0 1 1 0 
 
391 0 0 0 0 1 0 1 1 0 
 
392 0 0 0 0 1 0 1 1 0 
 
393 0 0 0 0 1 0 1 1 0 
 
394 0 0 0 0 1 0 1 1 0 
 
395 0 0 0 0 1 0 1 1 0 
 
396 0 0 0 0 1 0 1 1 0 
 
397 0 0 0 0 1 0 1 1 0 
 
398 0 0 0 0 1 0 1 1 0 
 
399 7.50349 0 0.047422 0 0.952578 0 0.67 1 -
22.7303 
 
400 0 0 0.242496 2.00475 0.757504 0.555473 0.416649 1 -
12.3859 
 
401 0 0 0 0 1 0 1 1 0 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
402 0 0 0 0 1 0 1 1 0 
 
403 0 0 0 0 1 0 1 1 0 
 
404 0 0 0 0 1 0 1 1 0 
 
405 0 0 0 0 1 0 1 1 0 
 
406 0 0 0 0 1 0 1 1 0 
 
407 0 0 0 0 1 0 1 1 0 
 
408 0 0 0 0 1 0 1 1 0 
 
409 0 0 0 0 1 0 1 1 0 
 
410 0 0 0 0 1 0 1 1 0 
 
411 0 0 0.266842 2.00845 0.733158 0.631653 0.39737 1 -
10.6121 
 
412 0 0 0 0 1 0 1 1 0 
 
413 0 0 0 0 1 0 1 1 0 
 
414 0 0 0 0 1 0 1 1 0 
 
415 0 0 0 0 1 0 1 1 0 
 
416 0 0 0 0 1 0 1 1 0 
 
417 0 0 0 0 1 0 1 1 0 
 
418 0 0 0 0 1 0 1 1 0 
 
419 0 0 0 0 1 0 1 1 0 
 
420 0 0 0 0 1 0 1 1 0 
 
421 0 0 0 0 1 0 1 1 0 
 
422 0 0 0 0 1 0 1 1 0 
 
423 4.5983 0 0.047296 0 0.952704 0 0.67 1 -
7.37775 
 
424 0 0 0.903824 102.493 0.096176 3.35864 0.088882 1 -
24.7851 
Pos 
425 0 0 0 0 1 0 1 1 0 
 
426 0 0 0 0 1 0 1 1 0 
 
427 0 0 0 0 1 0 1 1 0 
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428 0 0 0 0 1 0 1 1 0 
 
429 0 0 0 0 1 0 1 1 0 
 
430 0 0 0 0 1 0 1 1 0 
 
431 9.06315 0 0.987845 842.645 0.012155 0.679717 0.385844 1 -
23.0652 
 
432 0 0 0 0 1 0 1 1 0 
 
433 0 0 0 0 1 0 1 1 0 
 
434 0 0 1.00E-09 2.87771 1 1.23127 0.279648 1 -
15.9992 
 
435 3.72589 0 0.047296 0 0.952704 0 0.67 1 -
12.8452 
 
436 0 0 0 0 1 0 1 1 0 
 
437 0 0 0 0 1 0 1 1 0 
 
438 0 0 0 0 1 0 1 1 0 
 
439 0 0 0 0 1 0 1 1 0 
 
440 0 0 0 0 1 0 1 1 0 
 
441 0 0 0 0 1 0 1 1 0 
 
442 0 0 0 0 1 0 1 1 0 
 
443 0 0 0 0 1 0 1 1 0 
 
444 0 0 0 0 1 0 1 1 0 
 
445 77.078 0 0.047382 0 0.952618 0 0.67 1 -39.569 
 
446 0 0 0 0 1 0 1 1 0 
 
447 0 0 0 0 1 0 1 1 0 
 
448 0 0 0 0 1 0 1 1 0 
 
449 0 0 0 0 1 0 1 1 0 
 
450 0 0 0 0 1 0 1 1 0 
 
451 0 0 0 0 1 0 1 1 0 
 
452 0 0 0 0 1 0 1 1 0 
 
453 0 0 0 0 1 0 1 1 0 
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454 0 0 0 0 1 0 1 1 0 
 
455 0 0 0 0 1 0 1 1 0 
 
456 0 0 0 0 1 0 1 1 0 
 
457 0 0 0.25884 1.6851 0.74116 0.482422 0.436451 1 -
11.3202 
 
458 0 0 0 0 1 0 1 1 0 
 
459 0 0 0 0 1 0 1 1 0 
 
460 0 0 0.266496 2.11365 0.733504 0.659763 0.390573 1 -
10.3057 
 
461 0 0 0 0 1 0 1 1 0 
 
462 0 0 0 0 1 0 1 1 0 
 
463 0 0 0 0 1 0 1 1 0 
 
464 0 0 0 0 1 0 1 1 0 
 
465 0 0 0 0 1 0 1 1 0 
 
466 0 0 0 0 1 0 1 1 0 
 
467 0 0 0 0 1 0 1 1 0 
 
468 0 0 0 0 1 0 1 1 0 
 
469 0 0 0 0 1 0 1 1 0 
 
470 0 0 0 0 1 0 1 1 0 
 
471 0 0 0 0 1 0 1 1 0 
 
472 0 0 0 0 1 0 1 1 0 
 
473 0 0 0 0 1 0 1 1 0 
 
474 0 0 0 0 1 0 1 1 0 
 
475 0 0 0 0 1 0 1 1 0 
 
476 0 0 0 0 1 0 1 1 0 
 
477 0 0 0 0 1 0 1 1 0 
 
478 0 0 0 0 1 0 1 1 0 
 
479 0 0 0 0 1 0 1 1 0 
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480 12.4278 0 0.048516 0 0.951484 0 0.67 1 -
15.9772 
 
481 0 0 0 0 1 0 1 1 0 
 
482 0 0 0.252628 1.88475 0.747372 0.680563 0.385645 1 -10.916 
 
483 0 0 0 0 1 0 1 1 0 
 
484 0 0 0 0 1 0 1 1 0 
 
485 0 0 0.254246 1.88583 0.745754 0.606729 0.403535 1 -
10.4945 
 
486 4.79298 0 0.047506 0 0.952494 0 0.67 1 -
10.7607 
 
487 0 0 0 0 1 0 1 1 0 
 
488 0 0 0 0 1 0 1 1 0 
 
489 0 0 0 0 1 0 1 1 0 
 
490 0 0 0 0 1 0 1 1 0 
 
491 0 0 0 0 1 0 1 1 0 
 
492 0 0 0 0 1 0 1 1 0 
 
493 0 0 0 0 1 0 1 1 0 
 
494 0 0 0 0 1 0 1 1 0 
 
495 0 0 0 0 1 0 1 1 0 
 
496 0 0 0 0 1 0 1 1 0 
 
497 0 0 0 0 1 0 1 1 0 
 
498 0 0 0 0 1 0 1 1 0 
 
499 0 0 0 0 1 0 1 1 0 
 
500 0 0 0 0 1 0 1 1 0 
 
501 5.59311 0 0.047375 0 0.952625 0 0.67 1 -
17.2408 
 
502 0 0 0 0 1 0 1 1 0 
 
503 0 0 0.046825 0 0.953175 0 0.67 1 -
4.79902 
 
504 0 0 0 0 1 0 1 1 0 
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505 0 0 0 0 1 0 1 1 0 
 
506 0 0 0.245299 1.94635 0.754701 0.627345 0.398426 1 -9.9166 
 
507 0 0 0 0 1 0 1 1 0 
 
508 0 0 0 0 1 0 1 1 0 
 
509 0 0 0.219909 2.06123 0.780091 0.594379 0.40664 1 -
9.42558 
 
510 0 0 0 0 1 0 1 1 0 
 
511 0 0 0.046825 0 0.953175 0 0.67 1 -
4.11807 
 
512 0 0 0 0 1 0 1 1 0 
 
513 0 0 0 0 1 0 1 1 0 
 
514 0 0 0.265592 2.01806 0.734408 0.571742 0.412421 1 -
13.2352 
 
515 0 0 0 0 1 0 1 1 0 
 
516 0 0 0 0 1 0 1 1 0 
 
517 0 0 0 0 1 0 1 1 0 
 
518 0 0 0 0 1 0 1 1 0 
 
519 0 0 0 0 1 0 1 1 0 
 
520 0 0 0.241897 1.87322 0.758103 0.608247 0.403156 1 -
11.2591 
 
521 0 0 0 0 1 0 1 1 0 
 
522 0 0 0.223596 3.45117 0.776404 0.668331 0.388533 1 -
12.9902 
 
523 0 0 0 0 1 0 1 1 0 
 
524 0 0 0 0 1 0 1 1 0 
 
525 0 0 0 0 1 0 1 1 0 
 
526 0 0 0 0 1 0 1 1 0 
 
527 0 0 0 0 1 0 1 1 0 
 
528 0 0 0 0 1 0 1 1 0 
 
529 0 0 0 0 1 0 1 1 0 
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530 0 0 0.265845 2.01963 0.734155 1.25142 0.276484 1 -
13.4674 
 
531 0 0 0 0 1 0 1 1 0 
 
532 0 0 0 0 1 0 1 1 0 
 
533 0 0 0 0 1 0 1 1 0 
 
534 0 0 0.272981 2.03393 0.727019 0.713161 0.378091 1 -
12.2044 
 
535 0 0 0 0 1 0 1 1 0 
 
536 0 0 0 0 1 0 1 1 0 
 
537 0 0 0 0 1 0 1 1 0 
 
538 0 0 0 0 1 0 1 1 0 
 
539 0 0 0 0 1 0 1 1 0 
 
540 0 0 0 0 1 0 1 1 0 
 
541 0 0 0 0 1 0 1 1 0 
 
542 0 0 0 0 1 0 1 1 0 
 
543 0 0 0 0 1 0 1 1 0 
 
544 0 0 0 0 1 0 1 1 0 
 
545 0 0 0 0 1 0 1 1 0 
 
546 4.05049 0 0.065 0 0.935 0 0.67 1 -
8.89474 
 
547 0 0 0 0 1 0 1 1 0 
 
548 0 0 0 0 1 0 1 1 0 
 
549 0 0 0 0 1 0 1 1 0 
 
550 0 0 0 0 1 0 1 1 0 
 
551 0 0 0 0 1 0 1 1 0 
 
552 0 0 0 0 1 0 1 1 0 
 
553 0 0 0 0 1 0 1 1 0 
 
554 0 0 0 0 1 0 1 1 0 
 
555 0 0 0 0 1 0 1 1 0 
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556 0 0 0.046825 0 0.953175 0 0.67 1 -
3.30659 
 
557 0 0 0 0 1 0 1 1 0 
 
558 0 0 0 0 1 0 1 1 0 
 
559 0 0 0 0 1 0 1 1 0 
 
560 0 0 0 0 1 0 1 1 0 
 
561 0 0 0 0 1 0 1 1 0 
 
562 0 0 0 0 1 0 1 1 0 
 
563 0 0 0 0 1 0 1 1 0 
 
564 0 0 0 0 1 0 1 1 0 
 
565 0 0 0 0 1 0 1 1 0 
 
566 0 0 0 0 1 0 1 1 0 
 
567 0 0 0 0 1 0 1 1 0 
 
568 0 0 0 0 1 0 1 1 0 
 
569 0 0 0 0 1 0 1 1 0 
 
570 0 0 0 0 1 0 1 1 0 
 
571 0 0 0 0 1 0 1 1 0 
 
572 0 0 0 0 1 0 1 1 0 
 
573 0 0 0 0 1 0 1 1 0 
 
574 0 0 0 0 1 0 1 1 0 
 
575 0 0 0.265392 2.01524 0.734608 0.637117 0.396036 1 -13.679 
 
576 0 0 0 0 1 0 1 1 0 
 
577 0 0 0 0 1 0 1 1 0 
 
578 0 0 0 0 1 0 1 1 0 
 
579 0 0 0 0 1 0 1 1 0 
 
580 0 0 0 0 1 0 1 1 0 
 
581 0 0 0 0 1 0 1 1 0 
 
582 0 0 0.246631 2.06334 0.753369 0.580102 0.410272 1 -
11.4659 
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583 0 0 0 0 1 0 1 1 0 
 
584 0 0 0 0 1 0 1 1 0 
 
585 0 0 0 0 1 0 1 1 0 
 
586 0 0 0 0 1 0 1 1 0 
 
587 0 0 0 0 1 0 1 1 0 
 
588 0 0 0 0 1 0 1 1 0 
 
589 0 0 0 0 1 0 1 1 0 
 
590 0 0 0 0 1 0 1 1 0 
 
591 0 0 0 0 1 0 1 1 0 
 
592 0 0 0 0 1 0 1 1 0 
 
593 0 0 0 0 1 0 1 1 0 
 
594 0 0 0 0 1 0 1 1 0 
 
595 0 0 0 0 1 0 1 1 0 
 
596 0 0 0 0 1 0 1 1 0 
 
597 0 0 0 0 1 0 1 1 0 
 
598 0 0 0 0 1 0 1 1 0 
 
599 0 0 0 0 1 0 1 1 0 
 
600 0 0 0 0 1 0 1 1 0 
 
601 0 0 0 0 1 0 1 1 0 
 
602 0 0 0 0 1 0 1 1 0 
 
603 0 0 0 0 1 0 1 1 0 
 
604 0 0 0 0 1 0 1 1 0 
 
605 0 0 0 0 1 0 1 1 0 
 
606 0 0 0 0 1 0 1 1 0 
 
607 0 0 0 0 1 0 1 1 0 
 
608 0 0 0 0 1 0 1 1 0 
 
609 0 0 0 0 1 0 1 1 0 
 
610 0 0 0 0 1 0 1 1 0 
 
611 0 0 0 0 1 0 1 1 0 
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612 0 0 0 0 1 0 1 1 0 
 
613 0 0 0 0 1 0 1 1 0 
 
614 0 0 0 0 1 0 1 1 0 
 
615 0 0 0 0 1 0 1 1 0 
 
616 8.11241 0 0.04848 0 0.95152 0 0.67 1 -
11.2457 
 
617 0 0 0 0 1 0 1 1 0 
 
618 0 0 0 0 1 0 1 1 0 
 
619 0 0 0 0 1 0 1 1 0 
 
620 0 0 0 0 1 0 1 1 0 
 
621 0 0 0 0 1 0 1 1 0 
 
622 0 0 0 0 1 0 1 1 0 
 
623 0 0 0 0 1 0 1 1 0 
 
624 0 0 0 0 1 0 1 1 0 
 
625 0 0 0 0 1 0 1 1 0 
 
626 0 0 0 0 1 0 1 1 0 
 
627 0 0 0 0 1 0 1 1 0 
 
628 0 0 0 0 1 0 1 1 0 
 
629 0 0 0 0 1 0 1 1 0 
 
630 0 0 0 0 1 0 1 1 0 
 
631 0 0 0 0 1 0 1 1 0 
 
632 0 0 0 0 1 0 1 1 0 
 
633 0 0 0 0 1 0 1 1 0 
 
634 18.1118 0 0.047426 0 0.952574 0 0.67 1 -
23.5531 
 
635 0 0 0 0 1 0 1 1 0 
 
636 0 0 0 0 1 0 1 1 0 
 
637 0 0 0 0 1 0 1 1 0 
 
638 0 0 0 0 1 0 1 1 0 
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639 0 0 0 0 1 0 1 1 0 
 
640 0 0 0 0 1 0 1 1 0 
 
641 0 0 0 0 1 0 1 1 0 
 
642 0 0 0 0 1 0 1 1 0 
 
643 0 0 0 0 1 0 1 1 0 
 
644 0 0 0 0 1 0 1 1 0 
 
645 0 0 0 0 1 0 1 1 0 
 
646 0 0 0 0 1 0 1 1 0 
 
647 0 0 0 0 1 0 1 1 0 
 
648 0 0 0 0 1 0 1 1 0 
 
649 0 0 0 0 1 0 1 1 0 
 
650 0 0 0 0 1 0 1 1 0 
 
651 2.23401 0 0.047334 0 0.952666 0 0.67 1 -10.517 
 
652 0 0 0 0 1 0 1 1 0 
 
653 0 0 0 0 1 0 1 1 0 
 
654 0 0 0 0 1 0 1 1 0 
 
655 0 0 0 0 1 0 1 1 0 
 
656 0 0 0 0 1 0 1 1 0 
 
657 0 0 0 0 1 0 1 1 0 
 
658 0 0 0.046825 0 0.953175 0 0.67 1 -
3.67712 
 
659 0 0 0.046825 0 0.953175 0 0.67 1 -
3.20361 
 
660 0 0 0.046825 0 0.953175 0 0.67 1 -
3.42645 
 
661 0 0 0.046825 0 0.953175 0 0.67 1 -
4.13522 
 
662 0 0 0.046825 0 0.953175 0 0.67 1 -
4.22232 
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663 0 0 0.046825 0 0.953175 0 0.67 1 -
3.25838 
 
664 4.62569 0 0.06496 0 0.93504 0 0.67 1 -
7.18704 
 
665 0 0 0.046825 0 0.953175 0 0.67 1 -
4.17123 
 
666 0 0 1.00E-09 1.58552 1 0.420919 0.454281 1 -
8.87441 
 
667 0 0 0.046825 0 0.953175 0 0.67 1 -
3.39368 
 
668 0 0 0.046825 0 0.953175 0 0.67 1 -
4.17123 
 
669 0 0 0.046825 0 0.953175 0 0.67 1 -4.3253 
 
670 0 0 0.046825 0 0.953175 0 0.67 1 -
4.44066 
 
671 0 0 0.046825 0 0.953175 0 0.67 1 -
3.30659 
 
672 0 0 0.046825 0 0.953175 0 0.67 1 -
3.39368 
 
673 0 0 0.046825 0 0.953175 0 0.67 1 -
4.51976 
 
674 0 0 0.046825 0 0.953175 0 0.67 1 -
3.32347 
 
675 0 0 0.046825 0 0.953175 0 0.67 1 -
3.74754 
 
676 0 0 0.046825 0 0.953175 0 0.67 1 -
3.83464 
 
677 0 0 0.046825 0 0.953175 0 0.67 1 -
3.20361 
 
678 0 0 0.046825 0 0.953175 0 0.67 1 -
4.25221 
 
679 0 0 0 0 1 0 1 1 0 
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680 0 0 0 0 1 0 1 1 0 
 
681 0 0 0 0 1 0 1 1 0 
 
682 0 0 0 0 1 0 1 1 0 
 
683 73.539 0 0.979384 162.003 0.020616 0.09505 0.579889 1 -
47.4195 
 
684 0 0 0 0 1 0 1 1 0 
 
685 0 0 0 0 1 0 1 1 0 
 
686 10000 0 0.983762 142.767 0.016238 0 0.67 1 -12.186 
 
687 0 0 0.269893 2.12037 0.730107 0.659956 0.390527 1 -
10.6686 
 
688 0 0 0 0 1 0 1 1 0 
 
689 0 0 0 0 1 0 1 1 0 
 
690 0 0 0 0 1 0 1 1 0 
 
691 0 0 0 0 1 0 1 1 0 
 
692 0 0 0 0 1 0 1 1 0 
 
693 0 0 0 0 1 0 1 1 0 
 
694 0 0 0 0 1 0 1 1 0 
 
695 0 0 0 0 1 0 1 1 0 
 
696 0 0 1.00E-09 1.00684 1 0.013887 0.639168 1 -9.8783 
 
697 0 0 0 0 1 0 1 1 0 
 
698 14.0634 0 0.047297 0 0.952703 0 0.67 1 -
14.0903 
 
699 0 0 0 0 1 0 1 1 0 
 
700 0 0 0 0 1 0 1 1 0 
 
701 0 0 0 0 1 0 1 1 0 
 
702 0 0 0 0 1 0 1 1 0 
 
703 0 0 0 0 1 0 1 1 0 
 
704 0 0 0 0 1 0 1 1 0 
 
705 63.4624 0 0.050195 0 0.949805 0 0.67 1 -
48.6938 
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706 3.47085 0 0.047296 0 0.952704 0 0.67 1 -
13.9019 
 
707 0 0 0 0 1 0 1 1 0 
 
708 0 0 0 0 1 0 1 1 0 
 
709 0 0 0 0 1 0 1 1 0 
 
710 0 0 0 0 1 0 1 1 0 
 
711 0 0 0 0 1 0 1 1 0 
 
712 0 0 0 0 1 0 1 1 0 
 
713 0 0 0 0 1 0 1 1 0 
 
714 0 0 0 0 1 0 1 1 0 
 
715 0 0 0 0 1 0 1 1 0 
 
716 0 0 0 0 1 0 1 1 0 
 
717 0 0 0 0 1 0 1 1 0 
 
718 0 0 0 0 1 0 1 1 0 
 
719 0 0 0 0 1 0 1 1 0 
 
720 0 0 0 0 1 0 1 1 0 
 
721 0 0 0 0 1 0 1 1 0 
 
722 0 0 0 0 1 0 1 1 0 
 
723 0 0 0 0 1 0 1 1 0 
 
724 0 0 0 0 1 0 1 1 0 
 
725 0 0 0 0 1 0 1 1 0 
 
726 0 0 0 0 1 0 1 1 0 
 
727 0 0 0 0 1 0 1 1 0 
 
728 0 0 0 0 1 0 1 1 0 
 
729 0 0 0 0 1 0 1 1 0 
 
730 0 0 0 0 1 0 1 1 0 
 
731 67.7753 0 0.047388 0 0.952612 0 0.67 1 -
45.5206 
 
732 0 0 0 0 1 0 1 1 0 
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733 0 0 0 0 1 0 1 1 0 
 
734 0 0 0 0 1 0 1 1 0 
 
735 0 0 0 0 1 0 1 1 0 
 
736 0 0 0 0 1 0 1 1 0 
 
737 0 0 0 0 1 0 1 1 0 
 
738 0 0 0 0 1 0 1 1 0 
 
739 0 0 0 0 1 0 1 1 0 
 
740 0 0 0 0 1 0 1 1 0 
 
741 0 0 0 0 1 0 1 1 0 
 
742 0 0 0.259572 1.90846 0.740428 0.608942 0.402982 1 -
12.2187 
 
743 0 0 0 0 1 0 1 1 0 
 
744 0 0 0.37228 2.18329 0.62772 0.599121 0.405444 1 -
14.1982 
 
745 5.38664 0 0.051676 0 0.948324 0 0.67 1 -
18.4612 
 
746 0 0 0 0 1 0 1 1 0 
 
747 0 0 0 0 1 0 1 1 0 
 
748 0 0 0 0 1 0 1 1 0 
 
749 0 0 0 0 1 0 1 1 0 
 
750 0 0 0 0 1 0 1 1 0 
 
751 0 0 0 0 1 0 1 1 0 
 
752 0 0 0 0 1 0 1 1 0 
 
753 8.5798 0 0.047281 0 0.952719 0 0.67 1 -16.823 
 
754 0 0 0 0 1 0 1 1 0 
 
755 0 0 0 0 1 0 1 1 0 
 
756 0 0 0.002697 1.61611 0.997303 0.429314 0.451779 1 -
11.4855 
 
757 0 0 0 0 1 0 1 1 0 
 
758 0 0 0 0 1 0 1 1 0 
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759 0 0 0 0 1 0 1 1 0 
 
760 0 0 0 0 1 0 1 1 0 
 
761 1.73172 0 0.047343 0 0.952657 0 0.67 1 -
8.44006 
 
762 0 0 0 0 1 0 1 1 0 
 
763 0 0 0 0 1 0 1 1 0 
 
764 0 0 0 0 1 0 1 1 0 
 
765 0 0 0 0 1 0 1 1 0 
 
766 0 0 0 0 1 0 1 1 0 
 
767 67.9124 0 0.047325 0 0.952675 0 0.67 1 -
45.6082 
 
768 0 0 0 0 1 0 1 1 0 
 
769 0 0 0 0 1 0 1 1 0 
 
770 0 0 0 0 1 0 1 1 0 
 
771 0 0 0 0 1 0 1 1 0 
 
772 0 0 0 0 1 0 1 1 0 
 
773 0 0 0.270469 2.02001 0.729531 0.633165 0.397 1 -
11.0154 
 
774 0 0 0 0 1 0 1 1 0 
 
775 0 0 0 0 1 0 1 1 0 
 
776 0 0 0 0 1 0 1 1 0 
 
777 0 0 0 0 1 0 1 1 0 
 
778 0 0 0 0 1 0 1 1 0 
 
779 0 0 0 0 1 0 1 1 0 
 
780 0 0 0 0 1 0 1 1 0 
 
781 0 0 0 0 1 0 1 1 0 
 
782 0 0 0 0 1 0 1 1 0 
 
783 46.0401 0 0.049938 0 0.950062 0 0.67 1 -
53.3841 
 
784 0 0 0 0 1 0 1 1 0 
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785 0 0 0 0 1 0 1 1 0 
 
786 0 0 0 0 1 0 1 1 0 
 
787 0 0 0 0 1 0 1 1 0 
 
788 0 0 0 0 1 0 1 1 0 
 
789 0 0 0 0 1 0 1 1 0 
 
790 0 0 0 0 1 0 1 1 0 
 
791 0 0 0 0 1 0 1 1 0 
 
792 0 0 0 0 1 0 1 1 0 
 
793 0 0 0 0 1 0 1 1 0 
 
794 0 0 0 0 1 0 1 1 0 
 
795 0 0 0 0 1 0 1 1 0 
 
796 0 0 0 0 1 0 1 1 0 
 
797 0 0 0 0 1 0 1 1 0 
 
798 1.72052 0 0.052139 0 0.947861 0 0.67 1 -
9.07851 
 
799 0 0 0 0 1 0 1 1 0 
 
800 0 0 0 0 1 0 1 1 0 
 
801 0 0 0 0 1 0 1 1 0 
 
802 0 0 0 0 1 0 1 1 0 
 
803 0 0 0 0 1 0 1 1 0 
 
804 0 0 0 0 1 0 1 1 0 
 
805 0 0 0 0 1 0 1 1 0 
 
806 0 0 0 0 1 0 1 1 0 
 
807 0 0 0 0 1 0 1 1 0 
 
808 0 0 0 0 1 0 1 1 0 
 
809 0 0 0 0 1 0 1 1 0 
 
810 0 0 0.255099 1.97512 0.744901 0.628381 0.398172 1 -
9.69733 
 
811 0 0 0 0 1 0 1 1 0 
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812 0 0 0 0 1 0 1 1 0 
 
813 0 0 0 0 1 0 1 1 0 
 
814 0 0 0 0 1 0 1 1 0 
 
815 0 0 0 0 1 0 1 1 0 
 
816 0 0 0 0 1 0 1 1 0 
 
817 0 0 0 0 1 0 1 1 0 
 
818 0 0 0 0 1 0 1 1 0 
 
819 0 0 0 0 1 0 1 1 0 
 
820 0 0 0 0 1 0 1 1 0 
 
821 0 0 0 0 1 0 1 1 0 
 
822 0 0 0 0 1 0 1 1 0 
 
823 0 0 0 0 1 0 1 1 0 
 
824 0 0 0 0 1 0 1 1 0 
 
825 0 0 0 0 1 0 1 1 0 
 
826 0 0 0.046825 0 0.953175 0 0.67 1 -
4.82203 
 
827 0 0 0 0 1 0 1 1 0 
 
828 0 0 0 0 1 0 1 1 0 
 
829 0 0 0 0 1 0 1 1 0 
 
830 0 0 0 0 1 0 1 1 0 
 
831 0 0 0 0 1 0 1 1 0 
 
832 0 0 0 0 1 0 1 1 0 
 
833 4.5553 4.55527 1.00E-09 29.9989 1 5.15481 0.034985 1 -
56.7437 
pos 
834 0 0 0 0 1 0 1 1 0 
 
835 0 0 0 0 1 0 1 1 0 
 
836 0 0 0 0 1 0 1 1 0 
 
837 0 0 0 0 1 0 1 1 0 
 
838 0 0 0 0 1 0 1 1 0 
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839 0 0 0 0 1 0 1 1 0 
 
840 0 0 0 0 1 0 1 1 0 
 
841 0 0 0 0 1 0 1 1 0 
 
842 0 0 0 0 1 0 1 1 0 
 
843 0 0 0 0 1 0 1 1 0 
 
844 0 0 0 0 1 0 1 1 0 
 
845 0 0 0 0 1 0 1 1 0 
 
846 0 0 0 0 1 0 1 1 0 
 
847 0 0 0 0 1 0 1 1 0 
 
848 0 0 0 0 1 0 1 1 0 
 
849 0 0 0 0 1 0 1 1 0 
 
850 0 0 0 0 1 0 1 1 0 
 
851 0 0 0 0 1 0 1 1 0 
 
852 0 0 0 0 1 0 1 1 0 
 
853 0 0 0 0 1 0 1 1 0 
 
854 0 0 0 0 1 0 1 1 0 
 
855 0 0 0 0 1 0 1 1 0 
 
856 0 0 0 0 1 0 1 1 0 
 
857 0 0 0 0 1 0 1 1 0 
 
858 0 0 0 0 1 0 1 1 0 
 
859 0 0 0 0 1 0 1 1 0 
 
860 0 0 0 0 1 0 1 1 0 
 
861 0 0 0 0 1 0 1 1 0 
 
862 0 0 0 0 1 0 1 1 0 
 
863 0 0 0 0 1 0 1 1 0 
 
864 0 0 0 0 1 0 1 1 0 
 
865 0 0 0 0 1 0 1 1 0 
 
866 0 0 0 0 1 0 1 1 0 
 
867 0 0 0 0 1 0 1 1 0 
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868 0 0 0 0 1 0 1 1 0 
 
869 0 0 0 0 1 0 1 1 0 
 
870 0 0 0 0 1 0 1 1 0 
 
871 0 0 0 0 1 0 1 1 0 
 
872 0 0 0 0 1 0 1 1 0 
 
873 0 0 0 0 1 0 1 1 0 
 
874 0 0 0 0 1 0 1 1 0 
 
875 0 0 0 0 1 0 1 1 0 
 
876 0 0 0 0 1 0 1 1 0 
 
877 0 0 0 0 1 0 1 1 0 
 
878 0 0 0 0 1 0 1 1 0 
 
879 0 0 0.265937 1.5995 0.734063 0.172926 0.54225 1 -
12.5962 
 
880 0 0 0 0 1 0 1 1 0 
 
881 0 0 0 0 1 0 1 1 0 
 
882 0 0 0 0 1 0 1 1 0 
 
883 0 0 0 0 1 0 1 1 0 
 
884 0 0 0 0 1 0 1 1 0 
 
885 0 0 0 0 1 0 1 1 0 
 
886 0 0 1.00E-09 1.43174 1 0.553425 0.417185 1 -
11.5211 
 
887 0 0 0 0 1 0 1 1 0 
 
888 0 0 1.00E-09 1.26767 1 0.487089 0.435143 1 -
11.1205 
 
889 0 0 0 0 1 0 1 1 0 
 
890 0 0 0 0 1 0 1 1 0 
 
891 0 0 0 0 1 0 1 1 0 
 
892 0 0 0 0 1 0 1 1 0 
 
893 0 0 0 0 1 0 1 1 0 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
894 0 0 0 0 1 0 1 1 0 
 
895 0 0 0 0 1 0 1 1 0 
 
896 0 0 0 0 1 0 1 1 0 
 
897 0 0 0 0 1 0 1 1 0 
 
898 0 0 0 0 1 0 1 1 0 
 
899 0 0 0 0 1 0 1 1 0 
 
900 0 0 0 0 1 0 1 1 0 
 
901 0 0 0 0 1 0 1 1 0 
 
902 0 0 0 0 1 0 1 1 0 
 
903 0 0 0 0 1 0 1 1 0 
 
904 0 0 0 0 1 0 1 1 0 
 
905 0 0 0 0 1 0 1 1 0 
 
906 0 0 0 0 1 0 1 1 0 
 
907 0 0 0 0 1 0 1 1 0 
 
908 0 0 0 0 1 0 1 1 0 
 
909 0 0 0 0 1 0 1 1 0 
 
910 0 0 0 0 1 0 1 1 0 
 
911 0 0 0 0 1 0 1 1 0 
 
912 84.0894 0 0.054567 0 0.945433 0 0.67 1 -
38.1326 
 
913 0 0 0 0 1 0 1 1 0 
 
914 0 0 0.126285 15.624 0.873715 4.33271 0.0535 1 -
35.7088 
pos 
915 0 0 0 0 1 0 1 1 0 
 
916 0 0 0 0 1 0 1 1 0 
 
917 0 0 0 0 1 0 1 1 0 
 
918 0 0 1.00E-09 1.43174 1 0.553425 0.417185 1 -
11.5211 
 
919 0 0 0 0 1 0 1 1 0 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
920 0 0 0 0 1 0 1 1 0 
 
921 0 0 0 0 1 0 1 1 0 
 
922 0 0 0 0 1 0 1 1 0 
 
923 0 0 0 0 1 0 1 1 0 
 
924 0 0 0 0 1 0 1 1 0 
 
925 0 0 0 0 1 0 1 1 0 
 
926 0 0 0 0 1 0 1 1 0 
 
927 0 0 0 0 1 0 1 1 0 
 
928 0 0 0 0 1 0 1 1 0 
 
929 0 0 0 0 1 0 1 1 0 
 
930 0 0 0 0 1 0 1 1 0 
 
931 0 0 0 0 1 0 1 1 0 
 
932 84.0894 0 0.047388 0 0.952612 0 0.67 1 -
37.5235 
 
933 0 0 0 0 1 0 1 1 0 
 
934 0 0 0 0 1 0 1 1 0 
 
935 0 0 0 0 1 0 1 1 0 
 
936 0 0 0 0 1 0 1 1 0 
 
937 0 0 0 0 1 0 1 1 0 
 
938 0 0 0 0 1 0 1 1 0 
 
939 0 0 0 0 1 0 1 1 0 
 
940 0 0 0 0 1 0 1 1 0 
 
941 0 0 0 0 1 0 1 1 0 
 
942 0 0 0 0 1 0 1 1 0 
 
943 0 0 0 0 1 0 1 1 0 
 
944 0 0 0 0 1 0 1 1 0 
 
945 0 0 0 0 1 0 1 1 0 
 
946 0 0 0 0 1 0 1 1 0 
 
947 34.3223 0 0.047303 0 0.952697 0 0.67 1 -22.647 
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948 67.8127 0 0.047285 0 0.952715 0 0.67 1 -
36.7738 
 
949 0 0 0 0 1 0 1 1 0 
 
950 0 0 0 0 1 0 1 1 0 
 
951 0 0 0 0 1 0 1 1 0 
 
952 0 0 0.238829 1.94852 0.761171 0.631306 0.397455 1 -
11.3569 
 
953 0 0 0 0 1 0 1 1 0 
 
954 0 0 0 0 1 0 1 1 0 
 
955 0 0 0 0 1 0 1 1 0 
 
956 0 0 0 0 1 0 1 1 0 
 
957 0 0 0 0 1 0 1 1 0 
 
958 0 0 0 0 1 0 1 1 0 
 
959 0 0 0 0 1 0 1 1 0 
 
960 0 0 0 0 1 0 1 1 0 
 
961 0 0 0 0 1 0 1 1 0 
 
962 0 0 0 0 1 0 1 1 0 
 
963 0 0 0 0 1 0 1 1 0 
 
964 0 0 0 0 1 0 1 1 0 
 
965 0 0 0 0 1 0 1 1 0 
 
966 0 0 0.046825 0 0.953175 0 0.67 1 -
4.35807 
 
967 0 0 0 0 1 0 1 1 0 
 
968 0 0 0 0 1 0 1 1 0 
 
969 0 0 0 0 1 0 1 1 0 
 
970 0 0 0 0 1 0 1 1 0 
 
971 0 0 0 0 1 0 1 1 0 
 
972 0 0 0 0 1 0 1 1 0 
 
973 0 0 0 0 1 0 1 1 0 
 
Appendix 4 Chapter 7 Analysis of Selective Pressure  
974 0 0 0 0 1 0 1 1 0 
 
975 0 0 0 0 1 0 1 1 0 
 
976 22.8911 0 0.047422 0 0.952578 0 0.67 1 -
43.1241 
 
977 0 0 0 0 1 0 1 1 0 
 
978 0 0 0 0 1 0 1 1 0 
 
979 0 0 0 0 1 0 1 1 0 
 
980 0 0 0 0 1 0 1 1 0 
 
981 0 0 0 0 1 0 1 1 0 
 
982 0 0 0 0 1 0 1 1 0 
 
983 0 0 0 0 1 0 1 1 0 
 
984 0 0 0 0 1 0 1 1 0 
 
985 0 0 0 0 1 0 1 1 0 
 
986 0 0 0 0 1 0 1 1 0 
 
987 0 0 0 0 1 0 1 1 0 
 
988 0 0 0 0 1 0 1 1 0 
 
989 0 0 0 0 1 0 1 1 0 
 
990 0 0 0 0 1 0 1 1 0 
 
991 0 0 0 0 1 0 1 1 0 
 
992 0 0 0 0 1 0 1 1 0 
 
993 0 0 0 0 1 0 1 1 0 
 
994 0 0 0 0 1 0 1 1 0 
 
995 0 0 0 0 1 0 1 1 0 
 
996 0 0 0 0 1 0 1 1 0 
 
997 4.33559 0 0.04842 0 0.95158 0 0.67 1 -
9.64138 
 
998 0 0 0 0 1 0 1 1 0 
 
999 0 0 0 0 1 0 1 1 0 
 
1000 0 0 0 0 1 0 1 1 0 
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1001 0 0 0 0 1 0 1 1 0 
 
1002 0 0 0 0 1 0 1 1 0 
 
1003 0 0 0 0 1 0 1 1 0 
 
1004 0 0 0 0 1 0 1 1 0 
 
1005 1.74385 0 0.0528 0 0.9472 0 0.67 1 -
14.7774 
 
1006 0 0 0 0 1 0 1 1 0 
 
1007 0 0 0 0 1 0 1 1 0 
 
1008 0 0 0 0 1 0 1 1 0 
 
1009 0 0 0 0 1 0 1 1 0 
 
1010 0 0 0 0 1 0 1 1 0 
 
1011 0 0 0 0 1 0 1 1 0 
 
1012 0 0 0 0 1 0 1 1 0 
 
1013 0 0 0 0 1 0 1 1 0 
 
1014 0 0 0 0 1 0 1 1 0 
 
1015 0 0 0 0 1 0 1 1 0 
 
1016 0 0 0 0 1 0 1 1 0 
 
1017 0 0 0 0 1 0 1 1 0 
 
1018 0 0 0 0 1 0 1 1 0 
 
1019 0 0 0 0 1 0 1 1 0 
 
1020 0 0 0.85731 365.728 0.14269 32.163 4.25E-08 5.75E-05 -
75.6224 
pos 
1021 4.71023 0 0.047285 0 0.952715 0 0.67 1 -
11.1096 
 
1022 0 0 0 0 1 0 1 1 0 
 
1023 0 0 0 0 1 0 1 1 0 
 
1024 0 0 0 0 1 0 1 1 0 
 
1025 0 0 0 0 1 0 1 1 0 
 
1026 0 0 0 0 1 0 1 1 0 
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1027 0 0 0 0 1 0 1 1 0 
 
1028 0 0 0 0 1 0 1 1 0 
 
1029 0 0 0 0 1 0 1 1 0 
 
1030 0 0 0 0 1 0 1 1 0 
 
1031 0 0 0 0 1 0 1 1 0 
 
1032 0 0 0 0 1 0 1 1 0 
 
1033 0 0 0 0 1 0 1 1 0 
 
1034 0 0 0 0 1 0 1 1 0 
 
1035 6.86392 0 0.047296 0 0.952704 0 0.67 1 -
9.48378 
 
1036 0 0 0 0 1 0 1 1 0 
 
1037 0 0 0 0 1 0 1 1 0 
 
1038 0 0 0 0 1 0 1 1 0 
 
1039 0 0 0 0 1 0 1 1 0 
 
1040 0 0 0 0 1 0 1 1 0 
 
1041 0 0 0 0 1 0 1 1 0 
 
1042 0 0 0 0 1 0 1 1 0 
 
1043 0 0 0 0 1 0 1 1 0 
 
1044 0 0 0 0 1 0 1 1 0 
 
1045 0 0 0 0 1 0 1 1 0 
 
1046 0 0 0 0 1 0 1 1 0 
 
1047 0 0 0 0 1 0 1 1 0 
 
1048 0 0 0 0 1 0 1 1 0 
 
1049 1.7397 0 0.047349 0 0.952651 0 0.67 1 -
9.94007 
 
1050 0 0 0 0 1 0 1 1 0 
 
1051 0 0 0 0 1 0 1 1 0 
 
1052 0 0 0.256614 1.90226 0.743386 0.547362 0.41878 1 -
13.0274 
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1053 0 0 0 0 1 0 1 1 0 
 
1054 0 0 0 0 1 0 1 1 0 
 
1055 0 0 0 0 1 0 1 1 0 
 
1056 0 0 0 0 1 0 1 1 0 
 
1057 0 0 0 0 1 0 1 1 0 
 
1058 0 0 0 0 1 0 1 1 0 
 
1059 15.1728 0 0.054768 0 0.945232 0 0.67 1 -
14.7612 
 
1060 0 0 0.271425 2.03443 0.728575 0.636484 0.39619 1 -
12.8754 
 
1061 0 0 0 0 1 0 1 1 0 
 
1062 0 0 0 0 1 0 1 1 0 
 
1063 0 0 0 0 1 0 1 1 0 
 
1064 1.83115 0 0.065 0 0.935 0 0.67 1 -
8.76278 
 
1065 1.73172 0 0.037343 0 0.962657 0 0.67 1 -
8.32019 
 
1066 0 0 0 0 1 0 1 1 0 
 
1067 0 0 0 0 1 0 1 1 0 
 
1068 1.82442 0 0.04731 0 0.952691 0 0.67 1 -10.234 
 
1069 0 0 0 0 1 0 1 1 0 
 
1070 0 0 0 0 1 0 1 1 0 
 
1071 0 0 0 0 1 0 1 1 0 
 
1072 0 0 0 0 1 0 1 1 0 
 
1073 0 0 0 0 1 0 1 1 0 
 
1074 0 0 0 0 1 0 1 1 0 
 
1075 0 0 0 0 1 0 1 1 0 
 
1076 0 0 0 0 1 0 1 1 0 
 
1077 0 0 0 0 1 0 1 1 0 
 
1078 1.97871 0 0.051553 0 0.948447 0 0.67 1 -10.984 
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1079 0 0 0 0 1 0 1 1 0 
 
1080 0 0 0 0 1 0 1 1 0 
 
1081 0 0 0 0 1 0 1 1 0 
 
1082 0 0 0.046825 0 0.953175 0 0.67 1 -
3.20361 
 
1083 9.11065 1.42107 0.999995 1.42111 5.26E-06 0 0.67 1 -
22.6012 
 
1084 0 0 0 0 1 0 1 1 0 
 
1085 0 0 0 0 1 0 1 1 0 
 
1086 0 0 0 0 1 0 1 1 0 
 
1087 0 0 0 0 1 0 1 1 0 
 
1088 0 0 0 0 1 0 1 1 0 
 
1089 5.29873 0 0.065 0 0.935 0 0.67 1 -
16.1569 
 
1090 0 0 0 0 1 0 1 1 0 
 
1091 0 0 0 0 1 0 1 1 0 
 
1092 0 0 0 0 1 0 1 1 0 
 
1093 0 0 0 0 1 0 1 1 0 
 
1094 0 0 0.046825 0 0.953175 0 0.67 1 -
3.57414 
 
1095 19.0063 0 0.046631 0 0.953369 0 0.67 1 -
65.0878 
 
1096 0 0 0 0 1 0 1 1 0 
 
1097 0 0 0 0 1 0 1 1 0 
 
1098 0 0 0 0 1 0 1 1 0 
 
1099 0 0 0 0 1 0 1 1 0 
 
1100 0 0 0 0 1 0 1 1 0 
 
1101 0 0 0 0 1 0 1 1 0 
 
1102 0 0 0 0 1 0 1 1 0 
 
1103 0 0 0 0 1 0 1 1 0 
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1104 0 0 0 0 1 0 1 1 0 
 
1105 0 0 0 0 1 0 1 1 0 
 
1106 0 0 0 0 1 0 1 1 0 
 
1107 0 0 0 0 1 0 1 1 0 
 
1108 0 0 0 0 1 0 1 1 0 
 
1109 0 0 0 0 1 0 1 1 0 
 
1110 0 0 0 0 1 0 1 1 0 
 
1111 0 0 0 0 1 0 1 1 0 
 
1112 0 0 0 0 1 0 1 1 0 
 
1113 0 0 0 0 1 0 1 1 0 
 
1114 0 0 0 0 1 0 1 1 0 
 
1115 0 0 0 0 1 0 1 1 0 
 
1116 0 0 0 0 1 0 1 1 0 
 
1117 11.7065 0 0.047262 0 0.952738 0 0.67 1 -
24.8607 
 
1118 0 0 0 0 1 0 1 1 0 
 
1119 0 0 0 0 1 0 1 1 0 
 
1120 0 0 0 0 1 0 1 1 0 
 
1121 0 0 0 0 1 0 1 1 0 
 
1122 0 0 0 0 1 0 1 1 0 
 
1123 0 0 0 0 1 0 1 1 0 
 
1124 0 0 0 0 1 0 1 1 0 
 
1125 0 0 0 0 1 0 1 1 0 
 
1126 0 0 0 0 1 0 1 1 0 
 
1127 0 0 0 0 1 0 1 1 0 
 
1128 0 0 0 0 1 0 1 1 0 
 
1129 0 0 0 0 1 0 1 1 0 
 
1130 0 0 0 0 1 0 1 1 0 
 
1131 0 0 0 0 1 0 1 1 0 
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1132 0 0 0 0 1 0 1 1 0 
 
1133 0 0 0 0 1 0 1 1 0 
 
1134 0 0 0 0 1 0 1 1 0 
 
1135 0 0 0 0 1 0 1 1 0 
 
1136 22.4507 0 0.047274 0 0.952726 0 0.67 1 -
38.3385 
 
1137 0 0 0 0 1 0 1 1 0 
 
1138 0 0 0 0 1 0 1 1 0 
 
1139 0 0 0 0 1 0 1 1 0 
 
1140 0 0 0 0 1 0 1 1 0 
 
1141 0 0 0 0 1 0 1 1 0 
 
1142 0 0 0 0 1 0 1 1 0 
 
1143 0 0 0 0 1 0 1 1 0 
 
1144 0 0 0 0 1 0 1 1 0 
 
1145 0 0 0 0 1 0 1 1 0 
 
1146 0 0 0 0 1 0 1 1 0 
 
1147 0 0 0 0 1 0 1 1 0 
 
1148 0 0 0 0 1 0 1 1 0 
 
1149 0 0 0 0 1 0 1 1 0 
 
1150 0 0 0 0 1 0 1 1 0 
 
1151 0 0 0 0 1 0 1 1 0 
 
1152 0 0 0 0 1 0 1 1 0 
 
1153 0 0 0 0 1 0 1 1 0 
 
1154 0 0 0 0 1 0 1 1 0 
 
1155 0 0 0 0 1 0 1 1 0 
 
1156 0 0 0 0 1 0 1 1 0 
 
1157 4.84172 0 0.037361 0 0.962639 0 0.67 1 -
9.27817 
 
1158 0 0 0.270789 3.97652 0.729211 1.11405 0.298916 1 -17.632 
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1159 0 0 0.262557 1.92146 0.737443 0.611466 0.402353 1 -12.194 
 
1160 0 0 0 0 1 0 1 1 0 
 
1161 0 0 0 0 1 0 1 1 0 
 
1162 0 0 0 0 1 0 1 1 0 
 
1163 0 0 0 0 1 0 1 1 0 
 
1164 0 0 0 0 1 0 1 1 0 
 
1165 0 0 0 0 1 0 1 1 0 
 
1166 0 0 0 0 1 0 1 1 0 
 
1167 0 0 0 0 1 0 1 1 0 
 
1168 0 0 0 0 1 0 1 1 0 
 
1169 0 0 0 0 1 0 1 1 0 
 
1170 0 0 0 0 1 0 1 1 0 
 
1171 0 0 0 0 1 0 1 1 0 
 
1172 0 0 0 0 1 0 1 1 0 
 
1173 0 0 0 0 1 0 1 1 0 
 
1174 0 0 0 0 1 0 1 1 0 
 
1175 0 0 0 0 1 0 1 1 0 
 
1176 0 0 0 0 1 0 1 1 0 
 
1177 0 0 0 0 1 0 1 1 0 
 
1178 0 0 0 0 1 0 1 1 0 
 
1179 0 0 0 0 1 0 1 1 0 
 
1180 0 0 0.046825 0 0.953175 0 0.67 1 -3.2907 
 
1181 0 0 0.046825 0 0.953175 0 0.67 1 -
3.20361 
 
1182 0 0 0.046825 0 0.953175 0 0.67 1 -
3.13851 
 
1183 0 0 0.046825 0 0.953175 0 0.67 1 -4.4515 
 
1184 0.844619 0 0.046586 0 0.953414 0 0.67 1 -
5.18039 
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1185 0 0 0.046825 0 0.953175 0 0.67 1 -
4.37207 
 
1186 0 0 0.046825 0 0.953175 0 0.67 1 -
3.25838 
 
1187 0 0 0.046825 0 0.953175 0 0.67 1 -
3.39368 
 
1188 0 0 0.046825 0 0.953175 0 0.67 1 -
4.67916 
 
1189 0 0 0.046825 0 0.953175 0 0.67 1 -
4.73944 
 
1190 0 0 0.046825 0 0.953175 0 0.67 1 -
4.35807 
 
1191 0 0 0.046825 0 0.953175 0 0.67 1 -
4.25509 
 
1192 0 0 0.046825 0 0.953175 0 0.67 1 -
3.25838 
 
1193 0 0 0.875922 774.587 0.124078 14.9208 0.000246 0.166439 -
65.5342 
pos 
1194 0 0 0.046825 0 0.953175 0 0.67 1 -
3.67712 
 
1195 0 0 0.046825 0 0.953175 0 0.67 1 -4.4515 
 
1196 1.72258 0 0.048579 0 0.951421 0 0.67 1 -10.831 
 
1197 3.58152 0 0.049977 0 0.950023 0 0.67 1 -
13.3592 
 
1198 1.72604 0 0.048472 0 0.951528 0 0.67 1 -
14.1952 
 
1199 66.8251 0 0.977306 145.302 0.022694 0.056737 0.60293 1 -
52.2368 
 
1200 0 0 0.046825 0 0.953175 0 0.67 1 -
3.57414 
 
1201 0 0 0.046825 0 0.953175 0 0.67 1 -
3.22561 
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1202 0 0 0.976136 828.408 0.023864 5.18587 0.034429 1 -
16.3115 
pos 
1203 0 0 0.046825 0 0.953175 0 0.67 1 -
4.53859 
 
1204 0 0 0.046825 0 0.953175 0 0.67 1 -
3.25838 
 
1205 0 0 0.046825 0 0.953175 0 0.67 1 -
3.20361 
 
1206 0 0 0.046825 0 0.953175 0 0.67 1 -
4.25221 
 
1207 0 0 0.046825 0 0.953175 0 0.67 1 -
4.62274 
 
1208 0 0 1.00E-09 16.2058 1 4.91281 0.039634 1 -
37.3941 
pos 
1209 3.51598 0 0.048372 0 0.951628 0 0.67 1 -
9.50809 
 
1210 0 0 0.046825 0 0.953175 0 0.67 1 -4.3393 
 
1211 0 0 0.046825 0 0.953175 0 0.67 1 -4.19 
 
1212 0 0 0.046825 0 0.953175 0 0.67 1 -
4.45466 
 
1213 1.85612 0 0.041862 0 0.958138 0 0.67 1 -
8.17025 
 
1214 0 0 0.046825 0 0.953175 0 0.67 1 -3.2907 
 
1215 0 0 0.046825 0 0.953175 0 0.67 1 -
3.42645 
 
1216 0 0 0.046825 0 0.953175 0 0.67 1 -
3.39368 
 
1217 0 0 0.046825 0 0.953175 0 0.67 1 -
4.15723 
 
1218 0 0 0.046825 0 0.953175 0 0.67 1 -
4.50575 
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1219 0 0 0.046825 0 0.953175 0 0.67 1 -
3.67712 
 
1220 0 0 0.046825 0 0.953175 0 0.67 1 -
3.67712 
 
1221 4.09599 0 0.047262 0 0.952738 0 0.67 1 -
9.71559 
 
1222 0 0 0.046825 0 0.953175 0 0.67 1 -
3.57414 
 
1223 5.35617 0 0.047297 0 0.952703 0 0.67 1 -
16.4319 
 
1224 0 0 0.046825 0 0.953175 0 0.67 1 -
4.67916 
 
1225 0 0 0.046825 0 0.953175 0 0.67 1 -
3.22561 
 
1226 0 0 0.046825 0 0.953175 0 0.67 1 -
4.35807 
 
1227 3.56872 0 0.989828 10000 0.010172 2.94118 0.110712 1 -
26.9728 
 
1228 0 0 0.046825 0 0.953175 0 0.67 1 -
5.06052 
 
1229 0 0 0.046825 0 0.953175 0 0.67 1 -3.2907 
 
1230 0 0 0.046825 0 0.953175 0 0.67 1 -
4.07013 
 
1231 0 0 0.046825 0 0.953175 0 0.67 1 -
4.25509 
 
1232 0 0 0.046825 0 0.953175 0 0.67 1 -
4.45466 
 
1233 0 0 0.046825 0 0.953175 0 0.67 1 -
3.13851 
 
1234 0 0 0.046825 0 0.953175 0 0.67 1 -4.4515 
 
1235 0 0 0.046825 0 0.953175 0 0.67 1 -
4.63646 
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1236 0 0 0.046825 0 0.953175 0 0.67 1 -
3.13851 
 
1237 0 0 0.046825 0 0.953175 0 0.67 1 -4.4515 
 
1238 0 0 0.046825 0 0.953175 0 0.67 1 -
3.32347 
 
1239 0 0 0.046825 0 0.953175 0 0.67 1 -
4.25509 
 
1240 0 0 0.046825 0 0.953175 0 0.67 1 -
4.17123 
 
1241 0 0 0.046825 0 0.953175 0 0.67 1 -
3.22561 
 
1242 0 0 0.270138 2.0446 0.729862 0.635899 0.396333 1 -
12.2829 
 
1243 0 0 0.046825 0 0.953175 0 0.67 1 -
4.76626 
 
1244 0 0 0.046825 0 0.953175 0 0.67 1 -4.3253 
 
1245 0 0 0.046825 0 0.953175 0 0.67 1 -
3.83464 
 
1246 0 0 0.046825 0 0.953175 0 0.67 1 -
4.23632 
 
1247 0 0 0.046825 0 0.953175 0 0.67 1 -
3.67712 
 
1248 0 0 0.046825 0 0.953175 0 0.67 1 -
3.22561 
 
1249 0 0 0.046825 0 0.953175 0 0.67 1 -
3.32347 
 
1250 0 0 0.046825 0 0.953175 0 0.67 1 -
3.74754 
 
1251 12.9989 0 0.047904 0 0.952096 0 0.67 1 -
16.2903 
 
1252 0 0 0.046825 0 0.953175 0 0.67 1 -
4.51976 
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1253 0 0 0.046825 0 0.953175 0 0.67 1 -4.3393 
 
1254 0 0 0.046825 0 0.953175 0 0.67 1 -
4.82203 
 
1255 0 0 0.046825 0 0.953175 0 0.67 1 -3.2907 
 
1256 0 0 0.046825 0 0.953175 0 0.67 1 -
3.22561 
 
1257 0 0 0.046825 0 0.953175 0 0.67 1 -
3.39368 
 
1258 0 0 0.046825 0 0.953175 0 0.67 1 -4.3393 
 
1259 0 0 0.046825 0 0.953175 0 0.67 1 -
4.26909 
 
1260 0 0 0.046825 0 0.953175 0 0.67 1 -
4.50575 
 
1261 0 0 0.046825 0 0.953175 0 0.67 1 -
3.13851 
 
1262 0 0 0.046825 0 0.953175 0 0.67 1 -
3.57414 
 
1263 0 0 0.046825 0 0.953175 0 0.67 1 -4.3253 
 
1264 3.76714 0 0.037366 0 0.962634 0 0.67 1 -12.571 
 
1265 0 0 0.046825 0 0.953175 0 0.67 1 -4.4515 
 
1266 0.844619 0 0.046586 0 0.953414 0 0.67 1 -
4.60369 
 
1267 0 0 0.046825 0 0.953175 0 0.67 1 -
4.63646 
 
1268 0 0 0.046825 0 0.953175 0 0.67 1 -
3.42645 
 
1269 0 0 0.046825 0 0.953175 0 0.67 1 -
3.57414 
 
1270 0 0 0.046825 0 0.953175 0 0.67 1 -
4.45466 
 
1271 0 0 0.046825 0 0.953175 0 0.67 1 -
4.45466 
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1272 0 0 0.046825 0 0.953175 0 0.67 1 -
3.20361 
 
1273 0 0 0.046825 0 0.953175 0 0.67 1 -
3.20361 
 
1274 0 0 0.046825 0 0.953175 0 0.67 1 -
4.17123 
 
1275 0 0 0.046825 0 0.953175 0 0.67 1 -4.2382 
 
1276 4.17879 0 0.048929 0 0.951071 0 0.67 1 -
9.85492 
 
1277 0 0 0.046825 0 0.953175 0 0.67 1 -
3.22561 
 
1278 0 0 0.046825 0 0.953175 0 0.67 1 -4.4515 
 
1279 0 0 0.046825 0 0.953175 0 0.67 1 -
3.42645 
 
1280 0 0 0.046825 0 0.953175 0 0.67 1 -4.19 
 
1281 0 0 0.046825 0 0.953175 0 0.67 1 -
4.23632 
 
1282 0 0 0.046825 0 0.953175 0 0.67 1 -
4.07013 
 
1283 0 0 0.046825 0 0.953175 0 0.67 1 -
3.57414 
 
1284 0 0 0.046825 0 0.953175 0 0.67 1 -
4.17123 
 
1285 0 0 0.046825 0 0.953175 0 0.67 1 -4.4515 
 
1286 0 0 0.046825 0 0.953175 0 0.67 1 -
3.57414 
 
1287 0 0 0.046825 0 0.953175 0 0.67 1 -
4.67916 
 
1288 0 0 0.046825 0 0.953175 0 0.67 1 -
3.22561 
 
1289 0 0 0.046825 0 0.953175 0 0.67 1 -
3.25838 
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1290 0 0 0.046825 0 0.953175 0 0.67 1 -
3.39368 
 
1291 0 0 0.046825 0 0.953175 0 0.67 1 -
3.25838 
 
1292 0 0 0.046825 0 0.953175 0 0.67 1 -4.19 
 
1293 0 0 0.046825 0 0.953175 0 0.67 1 -
4.15723 
 
1294 0 0 0.046825 0 0.953175 0 0.67 1 -
4.17123 
 
1295 0.844619 0 0.046586 0 0.953414 0 0.67 1 -
5.18039 
 
1296 0 0 0.046825 0 0.953175 0 0.67 1 -4.9901 
 
1297 0.844619 0 0.046586 0 0.953414 0 0.67 1 -
5.18039 
 
1298 0 0 0.046825 0 0.953175 0 0.67 1 -4.19 
 
1299 0 0 0.046825 0 0.953175 0 0.67 1 -3.2907 
 
1300 0.844619 0 0.046586 0 0.953414 0 0.67 1 -
5.18039 
 
1301 0 0 0.046825 0 0.953175 0 0.67 1 -
3.57414 
 
1302 0 0 0.046825 0 0.953175 0 0.67 1 -
3.74754 
 
1303 1.86561 0 0.065 0 0.935 0 0.67 1 -
9.88754 
 
1304 0 0 0.046825 0 0.953175 0 0.67 1 -3.2907 
 
1305 0 0 0.046825 0 0.953175 0 0.67 1 -
3.30659 
 
1306 0 0 0.046825 0 0.953175 0 0.67 1 -
5.06052 
 
1307 0 0 0.046825 0 0.953175 0 0.67 1 -
3.57414 
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1308 0 0 0.046825 0 0.953175 0 0.67 1 -
3.20361 
 
1309 0 0 0.046825 0 0.953175 0 0.67 1 -4.2382 
 
1310 0 0 0.046825 0 0.953175 0 0.67 1 -
4.26909 
 
1311 0 0 0.046825 0 0.953175 0 0.67 1 -
3.30659 
 
1312 0 0 0.046825 0 0.953175 0 0.67 1 -
4.51976 
 
1313 0 0 0.266608 1.99088 0.733392 1.1761 0.288532 1 -13.866 
 
1314 0 0 0.497656 5.92708 0.502344 2.55311 0.135999 1 -
16.8752 
 
1315 0 0 0.046825 0 0.953175 0 0.67 1 -
4.25509 
 
1316 0 0 0.046825 0 0.953175 0 0.67 1 -
4.25509 
 
1317 0 0 0.046825 0 0.953175 0 0.67 1 -
4.23632 
 
1318 0 0 0.046825 0 0.953175 0 0.67 1 -
4.88712 
 
1319 0 0 0.046825 0 0.953175 0 0.67 1 -
4.79902 
 
1320 0 0 0.046825 0 0.953175 0 0.67 1 -
4.79902 
 
1321 0 0 0.046825 0 0.953175 0 0.67 1 -
3.39368 
 
1322 0 0 0.046825 0 0.953175 0 0.67 1 -
3.74754 
 
1323 0 0 0.046825 0 0.953175 0 0.67 1 -
3.86741 
 
1324 0 0 0.046825 0 0.953175 0 0.67 1 -
4.67916 
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1325 0 0 0.046825 0 0.953175 0 0.67 1 -4.3393 
 
1326 0 0 0.046825 0 0.953175 0 0.67 1 -
4.15723 
 
1327 0 0 0.046825 0 0.953175 0 0.67 1 -
3.86741 
 
1328 0.844619 0 0.046586 0 0.953414 0 0.67 1 -
4.60369 
 
1329 0 0 0.046825 0 0.953175 0 0.67 1 -
4.69316 
 
1330 0 0 0.046825 0 0.953175 0 0.67 1 -
4.17123 
 
1331 0 0 0.046825 0 0.953175 0 0.67 1 -
3.57414 
 
1332 0 0 0.046825 0 0.953175 0 0.67 1 -
4.53859 
 
1333 0 0 1.00E-09 1.44479 1 0.544075 0.419649 1 -
9.03294 
 
1334 0 0 0.046825 0 0.953175 0 0.67 1 -
3.22561 
 
1335 0 0 0.046825 0 0.953175 0 0.67 1 -
4.11807 
 
1336 0 0 0.046825 0 0.953175 0 0.67 1 -
3.86741 
 
1337 0 0 0.046825 0 0.953175 0 0.67 1 -
3.86741 
 
1338 4.81418 0 0.052644 0 0.947356 0 0.67 1 -
9.31265 
 
1339 0 0 0.046825 0 0.953175 0 0.67 1 -
4.78026 
 
1340 1.85612 0 0.050131 0 0.949869 0 0.67 1 -
8.20302 
 
1341 0 0 0.046825 0 0.953175 0 0.67 1 -4.4515 
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1342 0 0 0.046825 0 0.953175 0 0.67 1 -
4.08413 
 
1343 0 0 0.046825 0 0.953175 0 0.67 1 -4.19 
 
1344 0 0 0.046825 0 0.953175 0 0.67 1 -
4.07013 
 
1345 0 0 0.046825 0 0.953175 0 0.67 1 -
4.50575 
 
1346 0 0 0.266156 2.18914 0.733844 0.59139 0.407397 1 -
13.7069 
 
1347 0 0 0.046825 0 0.953175 0 0.67 1 -4.9901 
 
1348 0 0 0.046825 0 0.953175 0 0.67 1 -
3.50904 
 
1349 0 0 0.046825 0 0.953175 0 0.67 1 -
4.53859 
 
1350 0 0 0.046825 0 0.953175 0 0.67 1 -
3.20361 
 
1351 0 0 0.046825 0 0.953175 0 0.67 1 -
3.50904 
 
1352 0 0 0.046825 0 0.953175 0 0.67 1 -
3.20361 
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Acession ID Host species Virus Strain/Isolate Country of Origin 
AF086833.2 Homo sapiens EBOV Mayinga DRC 
AF272001.1 Guinea pig EBOV Mayinga Germany 
AF499101.1 Mouse EBOV Mayinga DRC 
AY058898.1 Homo sapiens EBOV Bouee-96_Zaire Gabon 
AY142960.1 Homo sapiens EBOV Mayinga DRC 
AY354458.1 Homo sapiens EBOV Zaire  DRC 
AY358025.2 Homo sapiens MARBV Ozolin SA 
DQ447651.1 Homo sapiens MARBV 05DRC99 DRC 
EU051630.1* Gorilla EBOV Zaire DRC 
EU224440.2 Guinea pig EBOV Mayinga Russia 
HQ849547.1 Homo sapiens EBOV Mayibout Gabon 
JQ352763.1 Homo sapiens EBOV Kikwit DRC 
KC242785.1 Homo sapiens EBOV Luebo DRC 
KC242786.1 Human EBOV Luebo DRC 
KC242787.1 Human EBOV Luebo DRC 
KC242788.1 Human EBOV Luebo DRC 
KC242789.1 Homo sapiens EBOV Luebo DRC 
KC242790.1 Human EBOV Luebo DRC 
KC242791.1 Human EBOV Bonduni DRC 
KC242792.1 Homo sapiens EBOV Zaire Gabon 
KC242794.1 Human EBOV Zaire DRC 
KC242795.1 Human EBOV Zaire Gabon 
KC242796.1 Homo sapiens EBOV 13625 Kikwit DRC 
KC242797.1 Human EBOV Zaire Gabon 
KC242798.1 Human EBOV Zaire Gabon 
KC242799.1 Human EBOV Zaire DRC 
KC242800.1 Homo sapiens EBOV Ilembe Gabon 
KC242801.1 Human EBOV Zaire DRC 
KC545388.1 Homo sapiens MARBV Mbg-423-2012 Uganda 
KF113528.1 Homo sapiens EBOV Kelle 1 DRC 
KJ660346.2 Homo sapiens EBOV Makona-Kissidougou-C15 Guinea 
KJ660346.2 Human EBOV Makona-Kissidougou-C15 Guinea 
KJ660347.2 Human EBOV Makona-Gueckedou-C07 Guinea 
KJ660348.2 Homo sapiens EBOV Makona-Gueckedou-C05 Guinea 
KM034549.1 Homo sapiens EBOV Makona-EM095B Sierra Leone 
KM034558.1 Homo sapiens EBOV Makona-G3679.1 Sierra Leone 
KM034563.1 Homo sapiens EBOV Makona-G3687.1 Sierra Leone 
KM233041.1 Human EBOV Makona-EM115 SierraLeone 
KM233052.1 Homo sapiens EBOV Makona-G3713.4 Sierra Leone 
KM233063.1 Human EBOV Makona-G3764 SierraLeone 
KM233073.1 Human EBOV Makona-G3786 SierraLeone 
KM233085.1 Human EBOV Makona-G3808 SierraLeone 
KM233096.1 Human EBOV Makona-G3822 SierraLeone 
KM233107.1 Human EBOV Makona-G3841 SierraLeone 
KM233113.1 Human EBOV Makona-G3856.1 SierraLeone 
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KM233118.1 Human EBOV Makona-NM042.3 SierraLeone 
KM655246.1 Human EBOV Yambuku-Ecran DRC 
KP096420.1 Homo sapiens EBOV WPG-C05 Guinea 
KP096421.1 Homo sapiens EBOV WPG-C07 Guinea 
KP096422.1 Homo sapiens EBOV WPG-C15 Guinea 
KP178538.1 Homo sapiens EBOV Makona-201403007 Liberia 
KP260799.1 Homo sapiens EBOV Makona-Mali-DPR1 Mali 
KP271020.1 Homo sapiens EBOV Lomela-Lokolia19 DRC 
KP728283.1 Homo sapiens EBOV Makona-GE1 Switzerland 
KP759622.1 Homo sapiens EBOV Makona-J0162 Sierra Leone 
KP759625.1 Homo sapiens EBOV Makona-J0170 Sierra Leone 
KP759645.1 Homo sapiens EBOV Makona-J0085 Sierra Leone 
KP759649.1 Homo sapiens EBOV Makona-J0090 Sierra Leone 
KP759654.1 Homo sapiens EBOV Makona-J0096 Sierra Leone 
KP759676.1 Homo sapiens EBOV Makona-J0127 Sierra Leone 
KP759684.1 Homo sapiens EBOV Makona-J0136 Sierra Leone 
KP759699.1 Homo sapiens EBOV Makona-J0157 Sierra Leone 
KP759703.1 Homo sapiens EBOV Makona-J0165 Sierra Leone 
KP759704.1 Homo sapiens EBOV Makona-J0166 Sierra Leone 
KP759731.1 Homo sapiens EBOV Makona-J0067 Sierra Leone 
KP759744.1 Homo sapiens EBOV Makona-J0076 Sierra Leone 
KP759761.1 Homo sapiens EBOV Makona-J0094 Sierra Leone 
KR006951.1 Homo sapiens EBOV Makona-LIBR0176 Liberia 
KR013754.3 Human EBOV Makona-G3864.1 SierraLeone 
KR025228.1 Homo sapiens EBOV Makona-Liberia-DQE3 UK 
KR074997.1 Homo sapiens EBOV Makona-Liberia-DQE5 Liberia 
KR074998.1 Human EBOV Makona-Liberia-DQE4 Liberia 
KR074999.1 Homo sapiens EBOV Makona-Liberia-DQE12 Liberia 
KR075001.1 Homo sapiens EBOV Makona-Liberia-DQE13 Liberia 
KR075002.1 Homo sapiens EBOV Makona-G3886.1 Liberia 
KR105246.1 Homo sapiens EBOV Makona-G4422.1 Sierra Leone 
KR105250.1 Homo sapiens EBOV Makona-G4748.1 Sierra Leone 
KR105270.1 Homo sapiens EBOV Makona-G4942.1 Sierra Leone 
KR105279.1 Homo sapiens EBOV Makona-G4956.1 Sierra Leone 
KR105282.1 Homo sapiens EBOV Makona-G4981.1 Sierra Leone 
KR105287.1 Homo sapiens EBOV Makona-G5012.3 Sierra Leone 
KR105292.1 Homo sapiens EBOV Makona-G5039.1 Sierra Leone 
KR105295.1 Homo sapiens EBOV Makona-G5119.1 Sierra Leone 
KR105300.1 Homo sapiens EBOV Makona-G5520.1 Sierra Leone 
KR105308.1 Homo sapiens EBOV Makona-G5571.1 Sierra Leone 
KR105311.1 Homo sapiens EBOV Makona-G5640.1 Sierra Leone 
KR105313.1 Homo sapiens EBOV Makona-G5647.1 Sierra Leone 
KR105315.1 Homo sapiens EBOV Makona-G5684.1 Sierra Leone 
KR105316.1 Homo sapiens EBOV Makona-G5853.1 Sierra Leone 
KR105329.1 Homo sapiens EBOV Makona-G5983.1 Sierra Leone 
KR105333.1 Homo sapiens EBOV Makona-G5986.1 Sierra Leone 
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KR105335.1 Homo sapiens EBOV Makona-G5988.1 Sierra Leone 
KR105336.1 Homo sapiens EBOV Makona-G5998.1 Sierra Leone 
KR105339.1 Homo sapiens EBOV Makona-G6069.1 Sierra Leone 
KR105344.1 Homo sapiens EBOV Makona-G6095.1 Sierra Leone 
KR105347.1 Homo sapiens EBOV Makona-G6104.1 Sierra Leone 
KR105349.1 Homo sapiens EBOV Makona-20141582 Sierra Leone 
KR653230.1 Homo sapiens EBOV Makona-20140489 Sierra Leone 
KR653235.1 Homo sapiens EBOV Makona-20143753 Sierra Leone 
KR653236.1 Homo sapiens EBOV Makona-20143648 Sierra Leone 
KR653253.1 Homo sapiens EBOV Makona-20143659 Sierra Leone 
KR653256.1 Homo sapiens EBOV Makona-20140161 Sierra Leone 
KR653265.1 Homo sapiens EBOV Makona-20143317 Sierra Leone 
KR653282.1 Homo sapiens EBOV Makona-20140872 Sierra Leone 
KR653297.1 Homo sapiens EBOV Makona-20141227 Sierra Leone 
KR653303.1 Homo sapiens EBOV Makona-20143466 Sierra Leone 
KR653304.1 Homo sapiens EBOV Makona-EM75043 Sierra Leone 
KR817068.1 Homo sapiens EBOV Makona-EM27 Guinea 
KR817074.1 Homo sapiens EBOV Makona-EM321 Guinea 
KR817087.1 Homo sapiens EBOV Makona-EM983 Guinea 
KR817089.1 Homo sapiens EBOV Makona-EM1102 Guinea 
KR817113.1 Homo sapiens EBOV Makona-EM74354 Guinea 
KR817114.1 Human EBOV Makona-EM_074391 Liberia 
KR817192.1 Human EBOV Makona-EM_079442 Guinea 
KR817235.1 Homo sapiens EBOV Makona-EM_080076 Guinea 
KR817241.1 Homo sapiens EBOV Makona-EM_080223 Liberia 
KR817242.1 Homo sapiens EBOV Makona-EM_080253 Guinea 
KR824525.1 Homo sapiens EBOV Makona-SL3864.1 Sierra Leone 
KR824526.1 Homo sapiens EBOV Zaire-199510621 DRC 
KR867676.1 Homo sapiens EBOV Kikwit-9510621 DRC 
KU182911.1 Homo sapiens EBOV Bundibugyo-200706291 Uganda 
KU220269.1 Human EBOV Makona-LIBR4748 Liberia 
KU220276.1 Human EBOV Makona-LIBR5307 Liberia 
KU220284.1 Human EBOV Makona-NIH-4731 Liberia 
U23069.1 Homo sapiens EBOV Maleo Sudan 
U23152.1 Homo sapiens EBOV Reston DRC 
U77384.1 Homo sapiens EBOV Gabon-94 Gabon 
KC242793.1 Homo sapiens EBOV 1Eko Gabon 
NC_016144.1 M.schreibersii LLOV Lloviu  Spain 
Complete dataset of 128 Ebola glycoproteins used in analysis with accession IDs, host species, strain as well as country and year of isolation. No
year of isolation is not recorded then either year of publication, or year of upload to GenBank us recorded with the earliest of these two dates taken
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Chapter 8 Filovirus Data Ebola Selection analysis 
List of sequences downloaded from GenBank database for use in the analysis as Dataset_2. This dataset was reduced to 46 sequences by selective removal of closely related sequences. Note in 
instances where the year of isolation is not recorded then either year of publication, or year of upload to GenBank was recorGHGZLWKWKHHDUOLHVWRIWKHVHWZRGDWHVWDNHQ6WUDLQGDWDLVUHFRUGHG³DV
LV´IURPWKH*HQ%DQN database , with the information recorded here as it is recorded in the database and is used only for entry identification. 
Accession ID Virus Strain Year of Isolate Host Country of Origin 
AY358025.2 Marburg Ozolin 1975 Human SA 
AF086833.2 Ebola Zaire 1976 Human DRC 
KC242801.1 Ebola Zaire 1976 Human DRC 
KM655246.1 Ebola Zaire 1976 Human DRC 
KC242791.1 Ebola Congo 1977 Human DRC 
U23152.1 Ebola Reston 1995 Human  
AY354458.1 Ebola Zaire 1995 Human DRC 
KC242799.1 Ebola Congo 1995 Human DRC 
U23069.1 Ebola Maleo 1995 Human Sudan 
KC242794.1 Ebola Congo 1996 Human DRC 
KC242795.1 Ebola Gabon 1996 Human Gabon 
KC242797.1 Ebola Gabon 1996 Human Gabon 
KC242798.1 Ebola Gabon 1996 Human Gabon 
DQ447651.1 Marburg 05DRC99 1999 Human DRC 
AF272001.1 Ebola Mayinga 1999 Guinea pig Germany 
EU051630.1 Ebola Zaire 2002 Gorilla DRC 
KC242785.1 Ebola Congo 2007 Human DRC 
KC242786.1 Ebola Congo 2007 Human DRC 
KC242787.1 Ebola Congo 2007 Human DRC 
KC242788.1 Ebola Congo 2007 Human DRC 
KC242790.1 Ebola Leubo 2007 Human DRC 
EU224440.2 Ebola Mayinga 2007 Guinea pig Russia 
KU182911.1 Ebola Zaire 2007 Human Uganda 
KC545388.1 Marburg Mbg-423 2012 Human Uganda 
KP271020.1 Ebola Zaire 2014 Human DRC 
KJ660346.2 Ebola Zaire 2014 Human Guinea 
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KJ660347.2 Ebola Zaire 2014 Human Guinea 
KJ660348.2 Ebola Zaire 2014 Human Guinea 
KR817192.1 Ebola Zaire 2014 Human Guinea 
KR817114.1 Ebola Zaire 2014 Human Liberia 
KR013754.3 Ebola Zaire 2014 Human SierraLeone 
KM034558.1 Ebola Zaire 2014 Human SierraLeone 
KM233041.1 Ebola Zaire 2014 Human SierraLeone 
KM233052.1 Ebola Zaire 2014 Human SierraLeone 
KM233063.1 Ebola Zaire 2014 Human SierraLeone 
KM233074.1 Ebola Zaire 2014 Human SierraLeone 
KM233085.1 Ebola Zaire 2014 Human SierraLeone 
KM233096.1 Ebola Zaire 2014 Human SierraLeone 
KM233107.1 Ebola Zaire 2014 Human SierraLeone 
KM233113.1 Ebola Zaire 2014 Human SierraLeone 
KM233118.1 Ebola Zaire 2014 Human SierraLeone 
KR074998.1 Ebola Zaire 2015 Human Liberia 
KU220269.1 Ebola Zaire 2015 Human Liberia 
KU220276.1 Ebola Zaire 2015 Human Liberia 
KU220284.1 Ebola Zaire 2015 Human Liberia 

























1 0 0 0 1.17514 0 0 0 0 0 0 0 0 
 






3.40933 4.73197 1.32263 0.61678 0.774481 0.557059 
 






8.8817 3.58264 -5.29906 0.939063 0.232772 -2.23183 
 






0 2.52129 2.52129 0.475334 0.524666 1.0619 
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2.53566 1.31916 -1.2165 0.882892 0.567314 -0.51236 
 






3.58758 2.23113 -1.35645 0.857905 0.556147 -0.5713 
 
7 3 1 0.41984 0.74670
8 
0.75 0.3599 7.14558 1.33921 -5.80636 0.983223 0.136136 -2.44549 
 






5.05916 0 -5.05916 1 0.202156 -2.13078 
 






1.97205 0 -1.97205 1 0.465863 -0.83058 
 






5.10576 0 -5.10576 1 0.111111 -2.15041 
 






6.63523 0 -6.63523 1 0.059788 -2.79459 
 




0 2.16507 2.16507 0.667716 0.332284 0.911872 
 
13 2.5 1.5 0.42312
7 
0.63208 0.625 0.40099 5.90839 2.37312 -3.53527 0.896902 0.353426 -1.48896 
 




8.91373 1.87161 -7.04212 0.981818 0.141597 -2.96596 
 




10.7432 4.28248 -6.46074 0.950704 0.172391 -2.7211 
 






5.92828 3.53994 -2.38834 0.834348 0.475205 -1.00591 
 






3.71285 1.69392 -2.01893 0.868144 0.454569 -0.85032 
 






9.45255 1.42395 -8.02861 0.992485 0.069876 -3.38144 
 




4.31541 1.88456 -2.43085 0.915154 0.447055 -1.02381 
 






0 1.0274 1.0274 0.764298 0.235702 0.432716 
 






4.66607 2.31386 -2.35222 0.890511 0.404151 -0.99069 
 
22 0 0 0 0.64301
3 
0 0 0 0 0 0 0 0 
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4.67152 2.31255 -2.35897 0.890848 0.403469 -0.99354 
 






11.1388 1.0708 -10.068 0.998347 0.02314 -4.24038 
 






0 0 0 0 0 0 
 




10.766 0 -10.766 1 0.007416 -4.53437 
 






-7.38085 0.993599 0.090626 -3.10862 
 






4.54714 1.13524 -3.4119 0.960087 0.359653 -1.437 
 




8.14886 4.71186 -3.437 0.870715 0.358582 -1.44758 
 




4.73963 4.59237 -0.14726 0.69409 0.63491 -0.06202 
 




12.7836 4.5849 -8.19868 0.957358 0.160856 -3.45307 
 






6.96064 2.32021 -4.64043 0.954733 0.209877 -1.95443 
 




9.35703 2.20716 -7.14987 0.957697 0.24439 -3.01134 
 






9.28086 0 -9.28086 1 0.012346 -3.90886 
 
35 4.5 1.5 0.55445
9 
0.71389 0.75 0.43715 8.11602 2.10116 -6.01486 0.966064 0.147662 -2.5333 
 




0.583333 0.34032 8.05076 2.96662 -5.08414 0.936598 0.220334 -2.14131 
 




10.0255 3.367 -6.65854 0.96714 0.138402 -2.8044 
 
38 2.5 2.5 0.41401
3 
0.87897 0.5 0.3202 6.03845 2.84424 -3.19422 0.885047 0.351859 -1.34532 
 






8.55572 3.18356 -5.37216 0.950095 0.20432 -2.26261 
 






-10.6656 0.998417 0.026998 -4.49208 
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8.95862 1.86962 -7.089 0.982077 0.140359 -2.9857 
 




7.09623 2.29826 -4.79797 0.957803 0.200532 -2.02078 
 






8.10304 0 -8.10304 1 0.035912 -3.41279 
 






8.35895 2.2723 -6.08665 0.967204 0.202249 -2.56354 
 






4.64024 3.48039 -1.15985 0.790103 0.539121 -0.4885 
 






1.37955 5.97094 4.59139 0.297818 0.863412 1.93377 
 
47 0 4.96978 0.26915 1.00369 0 0.21145
5 
0 4.95149 4.95149 0.307078 0.692922 2.08544 
 






5.74281 3.17554 -2.56728 0.875037 0.407945 -1.08127 
 




7.79547 0 -7.79547 1 0.039372 -3.28325 
 






8.6186 3.31753 -5.30107 0.938793 0.27137 -2.23267 
 






9.39874 0 -9.39874 1 0.024779 -3.9585 
 






6.96064 0 -6.96064 1 0.037037 -2.93164 
 




1 0.21577 15.702 0 -15.702 1 0.002168 -6.61327 
 








0.645247 0.654751 0.052632 
 




10.3117 1.43193 -8.87974 0.98797 0.092691 -3.73992 
 




2.18369 3.48006 1.29637 0.64068 0.55977 0.545998 
 






6.1293 0 -6.1293 1 0.054244 -2.5815 
 




4.70583 4.20186 -0.50398 0.727841 0.61513 -0.21226 
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9.44596 2.69304 -6.75292 0.973577 0.132219 -2.84415 
 






6.96064 0 -6.96064 1 0.037037 -2.93164 
 




3.8173 4.86374 1.04644 0.647799 0.743847 0.440732 
 






7.15858 2.48175 -4.67684 0.944933 0.274323 -1.96976 
 




5.00054 1.46992 -3.53062 0.951778 0.266951 -1.48701 
 






4.08345 3.03682 -1.04663 0.821268 0.587632 -0.44081 
 






7.94716 3.67098 -4.27619 0.896501 0.304941 -1.80102 
 




6.0631 1.70328 -4.35982 0.945481 0.240227 -1.83624 
 






6.96064 0 -6.96064 1 0.038178 -2.93164 
 






7.0214 1.38258 -5.63882 0.983395 0.122015 -2.37492 
 




5.52235 1.46864 -4.05371 0.938437 0.310479 -1.70732 
 






6.09248 0 -6.09248 1 0.055234 -2.56599 
 






17.8688 2.85135 -15.0175 0.996877 0.023915 -6.32497 
 






4.64043 0 -4.64043 1 0.112603 -1.95443 
 




7.58925 4.90214 -2.68711 0.84269 0.437884 -1.13174 
 




0 3.7386 3.7386 0.281805 0.718195 1.5746 
 




4.7344 2.29741 -2.43699 0.894682 0.395646 -1.0264 
 






6.96064 1.17616 -5.78448 0.987195 0.113851 -2.43627 
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7.07238 2.30203 -4.77035 0.957282 0.202137 -2.00915 
 




10.9956 1.96056 -9.03509 0.99176 0.066731 -3.80535 
 






7.10896 3.44439 -3.66457 0.906588 0.305953 -1.54342 
 






3.43321 1.76008 -1.67313 0.84717 0.488907 -0.70468 
 






7.05875 3.99285 -3.0659 0.869923 0.375837 -1.29128 
 






6.96064 4.64043 -2.32021 0.826703 0.429355 -0.97721 
 






6.96064 1.16015 -5.80049 0.987653 0.111119 -2.44302 
 






7.40606 0 -7.40606 1 0.048199 -3.11924 
 






6.5119 0 -6.5119 1 0.057064 -2.74264 
 
86 0 0 0 0.70749
3 
0 0 0 0 0 0 0 0 
 






6.96064 1.22354 -5.7371 0.985789 0.122004 -2.41632 
 
88 1 0 0.22427 1.06871 1 0.17345
1 
4.45892 0 -4.45892 1 0.173451 -1.87798 
 






11.8148 0 -11.8148 1 0.006714 -4.97609 
 






6.96064 2.39416 -4.56648 0.95118 0.220367 -1.92328 
 






0 0 0 0 0 0 
 






9.28086 0 -9.28086 1 0.012346 -3.90886 
 






4.64043 0 -4.64043 1 0.111111 -1.95443 
 






4.64043 0 -4.64043 1 0.111111 -1.95443 
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11.1689 1.06838 -10.1005 0.997528 0.036931 -4.25409 
 








3.06928 2.28339 0.451529 0.696591 0.961705 
 






4.64043 0 -4.64043 1 0.111111 -1.95443 
 




5.09993 3.61216 -1.48777 0.812106 0.55551 -0.62661 
 




7.47609 0 -7.47609 1 0.056096 -3.14873 
 




4.58515 1.98262 -2.60253 0.916432 0.444115 -1.09612 
 




0.625 0.32662 5.9335 1.72681 -4.20669 0.941693 0.250353 -1.77175 
 




1 0.34623 6.96064 0 -6.96064 1 0.041504 -2.93164 
 




13.5411 0 -13.5411 1 0.005932 -5.70318 
 




108.755 2.77443 -105.981 0.999528 0.03731 -44.6364 
 






4.64043 0 -4.64043 1 0.111111 -1.95443 
 








0.829734 0.170266 0.414663 
 




10.289 1.42858 -8.86044 0.987974 0.092671 -3.73179 
 






0 0 0 0 0 0 
 






4.60435 0 -4.60435 1 0.201252 -1.93923 
 






-3.75648 0.999845 0.207974 -1.58213 
 




0.625 0.43492 4.44568 2.053 -2.39268 0.871245 0.402931 -1.00773 
 




5.2359 3.78791 -1.44799 0.806631 0.562436 -0.60985 
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5.65853 1.06436 -4.59417 0.979573 0.183322 -1.93495 
 






7.24494 1.04522 -6.19972 0.988772 0.127973 -2.61116 
 




4.50914 1.9782 -2.53093 0.914558 0.448419 -1.06596 
 






6.96064 2.39407 -4.56658 0.951185 0.220353 -1.92332 
 




8.58246 1.88693 -6.69553 0.979747 0.151232 -2.81998 
 






-6.95171 0.999966 0.038498 -2.92788 
 




7.83001 1.9327 -5.89731 0.973574 0.177686 -2.48379 
 






6.51263 2.5087 -4.00393 0.907501 0.363476 -1.68635 
 






4.15727 2.20634 -1.95093 0.88651 0.506419 -0.82168 
 






5.05184 0 -5.05184 1 0.102937 -2.1277 
 






9.1884 2.34582 -6.84258 0.980983 0.104824 -2.88192 
 






3.68025 5.12854 1.4483 0.547858 0.757404 0.609984 
 






6.96064 1.16011 -5.80054 0.987654 0.111111 -2.44303 
 






11.6011 0 -11.6011 1 0.004115 -4.88607 
 




4.08877 2.88334 -1.20543 0.833878 0.570221 -0.5077 
 






4.74287 2.29543 -2.44745 0.895185 0.394609 -1.0308 
 






7.13689 2.29192 -4.84497 0.958673 0.197834 -2.04058 
 






9.57608 0 -9.57608 1 0.01859 -4.0332 
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2.37132 1.15918 -1.21214 0.892198 0.548863 -0.51052 
 






-7.78488 0.99435 0.083865 -3.27879 
 






4.64043 0 -4.64043 1 0.111111 -1.95443 
 




8.60549 1.2231 -7.38239 0.993744 0.061274 -3.10927 
 




4.45892 0 -4.45892 1 0.196295 -1.87798 
 






5.62563 2.95567 -2.66996 0.861216 0.393709 -1.12452 
 






0 2.32015 2.32015 0.568701 0.431299 0.977185 
 






4.66605 1.15693 -3.50912 0.96357 0.256822 -1.47795 
 




4.55267 0 -4.55267 1 0.169879 -1.91747 
 




9.09344 1.97467 -7.11877 0.980324 0.148591 -2.99824 
 






4.67283 2.3122 -2.36063 0.890933 0.403299 -0.99424 
 




0.333333 0.26513 3.42347 2.47027 -0.9532 0.826393 0.603145 -0.40146 
 






2.32021 0 -2.32021 1 0.351298 -0.97721 
 






7.12037 2.31952 -4.80086 0.957198 0.202395 -2.022 
 




5.53312 3.09624 -2.43688 0.850293 0.420951 -1.02635 
 






11.6011 0 -11.6011 1 0.004115 -4.88607 
 






7.74335 2.14925 -5.5941 0.965664 0.207853 -2.35609 
 






6.96064 2.32021 -4.64043 0.954733 0.209877 -1.95443 
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7.55099 3.57085 -3.98014 0.911534 0.295622 -1.67633 
 




5.92298 2.40449 -3.51849 0.899937 0.378178 -1.4819 
 






6.71068 4.31415 -2.39653 0.841101 0.449975 -1.00936 
 






6.96064 0 -6.96064 1 0.037037 -2.93164 
 






-3.29344 0.966719 0.331582 -1.38711 
 




13.2145 0 -13.2145 1 0.005413 -5.56559 
 




11.811 2.18576 -9.62523 0.985924 0.087068 -4.0539 
 








0.718392 0.690682 0.094061 
 






6.96064 0 -6.96064 1 0.040172 -2.93164 
 






2.32021 0 -2.32021 1 0.333333 -0.97721 
 




13.2507 0 -13.2507 1 0.005369 -5.58086 
 




0 0 0 0 0 0 
 






4.98153 0 -4.98153 1 0.103649 -2.09809 
 






0 0 0 0 0 0 
 




7.55923 0 -7.55923 1 0.041872 -3.18375 
 






7.57049 0 -7.57049 1 0.044753 -3.18849 
 




5.89121 2.18042 -3.71078 0.916768 0.288362 -1.56289 
 






6.96064 0 -6.96064 1 0.037037 -2.93164 
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4.64043 0 -4.64043 1 0.148239 -1.95443 
 






4.64043 0 -4.64043 1 0.111111 -1.95443 
 






7.06367 3.45513 -3.60854 0.904594 0.310049 -1.51982 
 






5.58993 1.06929 -4.52064 0.978812 0.187335 -1.90397 
 




1 0.20607 4.46956 0 -4.46956 1 0.20607 -1.88246 
 




1.80619 0 -1.80619 1 0.502739 -0.76072 
 






8.49125 1.80392 -6.68733 0.975837 0.125688 -2.81653 
 






7.17519 4.5864 -2.58879 0.840663 0.407973 -1.09033 
 






4.93692 3.37886 -1.55806 0.818864 0.498995 -0.65621 
 




7.59011 0 -7.59011 1 0.041532 -3.19676 
 








0.735015 0.709375 0.018945 
 




4.49751 0 -4.49751 1 0.181676 -1.89423 
 






4.64043 0 -4.64043 1 0.111111 -1.95443 
 






4.74274 2.29546 -2.44728 0.895177 0.394626 -1.03073 
 






12.3616 2.25097 -10.1107 0.995199 0.034508 -4.25834 
 






4.64043 0 -4.64043 1 0.111111 -1.95443 
 




11.3167 1.94574 -9.37094 0.992614 0.061853 -3.9468 
 






3.67897 1.49388 -2.18509 0.909989 0.422518 -0.9203 
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11.3764 0 -11.3764 1 0.008483 -4.79146 
 






4.99731 1.47462 -3.52269 0.951383 0.268291 -1.48367 
 




0.428571 0.33262 7.07253 4.69991 -2.37263 0.827797 0.427712 -0.99929 
 






13.4749 3.05787 -10.417 0.98724 0.081276 -4.38737 
 






6.96064 2.32021 -4.64043 0.954733 0.209877 -1.95443 
 






3.46039 2.11908 -1.3413 0.860911 0.551276 -0.56492 
 






3.62918 3.13743 -0.49175 0.781787 0.636829 -0.20711 
 




9.49284 4.39697 -5.09587 0.903884 0.29611 -2.14625 
 




8.17157 1.908 -6.26357 0.976721 0.164582 -2.63805 
 




0.333333 0.20938 7.73949 4.09929 -3.64019 0.889259 0.367681 -1.53315 
 






8.30632 6.73793 -1.56839 0.761131 0.536939 -0.66057 
 






6.96064 1.44456 -5.51608 0.978324 0.160941 -2.32323 
 






7.48182 4.48454 -2.99728 0.860455 0.376009 -1.26238 
 






7.12037 1.15979 -5.96058 0.98839 0.106645 -2.51044 
 




10.8122 5.02211 -5.79011 0.932729 0.20228 -2.43864 
 






4.8322 5.35878 0.52658 0.642658 0.680553 0.221782 
 






7.17956 1.05453 -6.12503 0.988294 0.131254 -2.5797 
 




4.14964 3.7703 -0.37934 0.71552 0.61303 -0.15977 
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6.96064 4.64043 -2.32021 0.826703 0.429355 -0.97721 
 
204 3 1 0.25524
8 
1.03774 0.75 0.19741 11.7533 0.96363
6 
-10.7896 0.998481 0.026217 -4.54432 
 






5.14387 6.72466 1.58079 0.555999 0.736417 0.665786 
 




0.5 0.32774 5.89958 2.87616 -3.02342 0.877888 0.36483 -1.27338 
 




7.31261 5.15399 -2.15862 0.816062 0.47733 -0.90915 
 




3.85197 2.9031 -0.94887 0.817998 0.591998 -0.39964 
 






6.96064 3.51662 -3.44402 0.897566 0.324186 -1.45053 
 




11.6011 2.76752 -8.83356 0.987063 0.072902 -3.72046 
 






-11.6929 0.998865 0.021333 -4.92476 
 






4.03758 5.75333 1.71576 0.601952 0.777872 0.722632 
 






21.2681 1.15985 -20.1083 0.999903 0.002225 -8.46907 
 




6.4375 8.84523 2.40773 0.508609 0.768523 1.01407 
 






4.64043 1.16015 -3.48028 0.96296 0.259271 -1.4658 
 




0.1875 0.30597 3.79157 7.2434 3.45183 0.390154 0.851244 1.45382 
 






3.19987 5.40402 2.20416 0.48528 0.816487 0.928333 
 






6.97621 4.68784 -2.28837 0.823981 0.433423 -0.9638 
 






3.08945 7.57759 4.48814 0.343926 0.909567 1.89029 
 




11.0923 2.61017 -8.48209 0.972974 0.135868 -3.57244 
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10.32 3.28501 -7.03497 0.96673 0.156151 -2.96295 
 




0.388889 0.29593 9.14717 6.04162 -3.10555 0.822507 0.393677 -1.30797 
 




0.21875 0.22334 6.19962 6.36712 0.16750
2 
0.666847 0.639193 0.070548 
 






10.1888 3.00438 -7.18441 0.972965 0.13582 -3.02589 
 
225 0 2 0.28106
9 
1.01191 0 0.21738 0 1.97645 1.97645 0.612494 0.387506 0.83243 
 






9.28086 0 -9.28086 1 0.012854 -3.90886 
 




7.11338 4.62777 -2.48561 0.83491 0.416894 -1.04687 
 




7.63458 3.98554 -3.64903 0.892343 0.361816 -1.53688 
 






9.66616 6.63474 -3.03142 0.808375 0.437771 -1.27676 
 






7.29037 4.53781 -2.75256 0.849068 0.394649 -1.1593 
 






2.04743 3.80134 1.75391 0.597228 0.609774 0.738703 
 






5.6872 3.733 -1.9542 0.831061 0.480799 -0.82306 
 




3.99322 0 -3.99322 1 0.153048 -1.68184 
 
234 2.52869 4.50273 0.25613
3 
1.02807 0.359627 0.19945 9.87255 4.3798 -5.49274 0.912114 0.278542 -2.3134 
 






15.0541 3.17311 -11.881 0.992863 0.045703 -5.00398 
 




7.31118 3.43484 -3.87635 0.912835 0.29286 -1.63262 
 
237 2 2.02446 0.22478 1.0682 0.496962 0.17384
6 
8.89759 1.8952 -7.00239 0.981299 0.143654 -2.94922 
 




10.951 2.94405 -8.00693 0.979114 0.114011 -3.37231 
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0.444444 0.30156 10.3613 5.59205 -4.76928 0.899268 0.273918 -2.0087 
 




0.5 0.3293 5.88398 2.88891 -2.99506 0.876378 0.367521 -1.26144 
 






7.549 2.23285 -5.31615 0.96057 0.225624 -2.23902 
 






7.11956 2.31965 -4.79991 0.95718 0.202451 -2.0216 
 






1.84908 4.05721 2.20812 0.546643 0.663998 0.930004 
 




4.10644 2.49334 -1.6131 0.84543 0.486104 -0.6794 
 




8.68504 1.92915 -6.75589 0.979258 0.153445 -2.84541 
 






8.40192 4.10078 -4.30114 0.909228 0.278691 -1.81153 
 






8.59142 2.90059 -5.69083 0.948332 0.191887 -2.39683 
 




0 3.7266 3.7266 0.479041 0.520959 1.56955 
 






7.00158 1.15673 -5.84485 0.987941 0.109386 -2.4617 
 






9.28086 0 -9.28086 1 0.012346 -3.90886 
 




6.91944 2.5201 -4.39934 0.939127 0.29066 -1.85289 
 




10.7082 2.10692 -8.60124 0.98363 0.096667 -3.62262 
 




6.42276 1.21211 -5.21066 0.982923 0.137729 -2.19459 
 




2.52717 4.4579 1.93073 0.515834 0.839053 0.813173 
 




6.91944 2.51184 -4.4076 0.939529 0.289555 -1.85637 
 






4.01377 3.77501 -0.23876 0.70751 0.637315 -0.10056 
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7.1412 2.96174 -4.17946 0.928533 0.297034 -1.76028 
 






10.5179 4.22062 -6.2973 0.945394 0.205874 -2.65226 
 






9.41762 2.31148 -7.10614 0.983153 0.09616 -2.99292 
 






5.70015 2.12295 -3.5772 0.936333 0.298245 -1.50662 
 






0 4.85076 4.85076 0.309824 0.690176 2.04301 
 






7.11715 6.94733 -0.16982 0.663391 0.60958 -0.07152 
 




5.52235 3.42684 -2.09552 0.825286 0.48796 -0.88258 
 




4 6.24781 2.24781 0.491028 0.792243 0.946721 
 




10.3762 5.42854 -4.94763 0.895755 0.265543 -2.08381 
 






9.28863 2.70207 -6.58655 0.975074 0.11807 -2.77408 
 




-7.89357 0.994627 0.081289 -3.32456 
 




9.0479 0.93289 -8.11501 0.995003 0.077687 -3.41783 
 






4.88835 2.26283 -2.62552 0.903345 0.377373 -1.1058 
 






9.28086 0 -9.28086 1 0.012346 -3.90886 
 






4.65286 2.39489 -2.25797 0.883049 0.418919 -0.951 
 




0 2.24641 2.24641 0.626081 0.373919 0.946129 
 




3.47521 0 -3.47521 1 0.245566 -1.46367 
 






2.6756 2.17572 -0.49988 0.79764 0.640664 -0.21054 
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0 4.14644 4.14644 0.961545 0.038455 1.74637 
 






8.34525 1.09908 -7.24617 0.993567 0.071561 -3.0519 
 






6.01481 4.06725 -1.94756 0.816046 0.46276 -0.82026 
 




7.59011 1.94272 -5.64739 0.971319 0.186653 -2.37853 
 






4.64043 1.16011 -3.48032 0.962963 0.259259 -1.46582 
 
280 0.5 4.5 0.24779 1.00414 0.1 0.19792
7 
2.01783 4.48145 2.46362 0.536734 0.668052 1.03761 
 




0.6 0.28402 8.1692 2.16041 -6.00879 0.974857 0.142592 -2.53075 
 




3.85361 1.95143 -1.90218 0.894035 0.491906 -0.80115 
 






0 0 0 0 0 0 
 






0 0 0 0 0 0 
 






0 0 0 0 0 0 
 






0 0 0 0 0 0 
 






0 0 0 0 0 0 
 






0 0 0 0 0 0 
 






0 0 0 0 0 0 
 






0 0 0 0 0 0 
 






6.96064 3.51413 -3.44652 0.897724 0.323872 -1.45158 
 






6.25809 5.13676 -1.12133 0.762255 0.547985 -0.47228 
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9.71538 4.53893 -5.17645 0.92648 0.228823 -2.18019 
 






6.96064 0 -6.96064 1 0.037187 -2.93164 
 




1 0.21691 11.3008 0 -11.3008 1 0.010206 -4.7596 
 




0 2.81388 2.81388 0.964774 0.035227 1.18513 
 






3.56018 1.72679 -1.83339 0.857407 0.472498 -0.77218 
 




4.2388 2.83804 -1.40076 0.845522 0.553276 -0.58996 
 




91.3293 5.57912 -85.7501 0.997805 0.072982 -36.1157 
 




4.58515 1.98262 -2.60253 0.916432 0.444115 -1.09612 
 
301 0 2 0.38709
4 
0.90589 0 0.29938 0 2.20777 2.20777 0.490868 0.509132 0.929857 
 




6.87725 2.46386 -4.41339 0.917168 0.343755 -1.8588 
 




0 1.9579 1.9579 0.686596 0.313404 0.824616 
 
304 2.5 2.5 0.23588 1.05709 0.5 0.18243
2 
10.5986 2.36498 -8.23363 0.974978 0.136252 -3.46779 
 






3.33535 3.02065 -0.31471 0.768458 0.651892 -0.13255 
 






9.28086 1.16011 -8.12075 0.995885 0.045268 -3.42025 
 




0.248456 0.19441 4.25157 3.10355 -1.14802 0.825802 0.581088 -0.48352 
 






2.13349 3.85012 1.71664 0.605531 0.600469 0.723004 
 




4.37723 3.5882 -0.78903 0.759565 0.578057 -0.33232 
 








0.599136 0.713182 0.373582 
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1.34371 4.01611 2.6724 0.447129 0.758824 1.12554 
 






0 2.00103 2.00103 0.673802 0.326198 0.84278 
 






0.666221 0.736533 0.324515 
 






3.53923 1.49614 -2.04308 0.903846 0.437343 -0.86049 
 






0.616511 0.786027 0.420603 
 
316 0 3 0.25108
5 
1.0419 0 0.19419 0 2.87936 2.87936 0.523235 0.476765 1.21271 
 




0.2 0.22493 3.59601 4.17433 0.57831
6 
0.685573 0.720291 0.243571 
 






2.45227 6.77814 4.32587 0.297803 0.929509 1.82194 
 




0.333333 0.3973 2.07646 2.73761 0.66114
4 
0.651884 0.781071 0.278457 
 




0.5 0.38412 4.64043 2.8942 -1.74623 0.838607 0.49719 -0.73547 
 






0 7.07482 7.07482 0.168236 0.831764 2.97973 Pos 




3.5665 7.97874 4.41224 0.382252 0.891306 1.85832 
 






6.461 8.62067 2.15967 0.495361 0.750187 0.909598 
 






3.79501 5.02766 1.23266 0.632116 0.755918 0.519163 
 




0 7.96845 7.96845 0.173155 0.826845 3.3561 Pos 






6.85455 6.00457 -0.84998 0.711657 0.560885 -0.35799 
 








0.656676 0.649004 0.131881 
 








0.683233 0.722301 0.243044 
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3.10961 4.97095 1.86133 0.558182 0.813829 0.783944 
 




5.28456 4.49617 -0.78839 0.738867 0.586214 -0.33205 
 




1.18563 5.32582 4.14019 0.296883 0.867921 1.74374 
 






2.40908 4.73871 2.32963 0.468204 0.864633 0.981179 
 




3.45309 7.02741 3.57432 0.369297 0.866168 1.50541 
 






2.36328 2.29927 -0.06401 0.748802 0.695531 -0.02696 
 






7.1068 4.6561 -2.45069 0.832577 0.420467 -1.03217 
 




0.25 0.25867 4.9022 5.13152 0.22932 0.665051 0.660264 0.096583 
 






8.0746 3.40405 -4.67055 0.932231 0.249335 -1.96711 
 






4.75218 6.99263 2.24045 0.491795 0.785158 0.94362 
 




9.18636 8.2994 -0.88696 0.688402 0.54938 -0.37356 
 




0.25 0.29375 2.63287 3.28526 0.65239
5 
0.662707 0.75121 0.274772 
 




0 4.78722 4.78722 0.389444 0.610556 2.01625 
 






7.83461 7.66 -0.17461 0.661929 0.608233 -0.07354 
 




9.43775 4.60218 -4.83557 0.917614 0.247395 -2.03661 
 






3.70563 7.33119 3.62556 0.373698 0.860493 1.52699 
 






6.079 8.66182 2.58281 0.487945 0.783292 1.08781 
 




4.34796 1.90005 -2.44791 0.915067 0.447255 -1.031 
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347 1.5 4.5 0.23588 1.02807 0.25 0.18662
2 
6.35916 4.37715 -1.98202 0.802536 0.511111 -0.83477 
 






8.63667 3.60154 -5.03513 0.933973 0.245181 -2.12066 
 
349 0.5 4.5 0.25894
3 
1.02543 0.1 0.20161 1.93093 4.38839 2.45746 0.529189 0.675603 1.03502 
 






0.659361 0.685609 0.090598 
 






4.64024 3.48039 -1.15985 0.790103 0.539121 -0.4885 
 








0.72977 0.714476 0.036413 
 








0.672514 0.731344 0.298118 
 






0.701386 0.706367 0.166224 
 






0 2.32021 2.32021 0.444444 0.555556 0.977214 
 






2.37127 3.44326 1.07199 0.60535 0.793825 0.451493 
 






3.55699 6.52529 2.96829 0.416718 0.839222 1.25017 
 




4.10019 2.9888 -1.11139 0.812972 0.32716 -0.46809 
 






0.740752 0.703692 -3.76E-05 
 






0 5.40637 5.40637 0.214429 0.785571 2.27702 
 






1.10861 3.02133 1.91273 0.492783 0.728883 0.805591 
 






12.0879 4.59919 -7.48872 0.947711 0.177246 -3.15405 
 




8.38223 6.41654 -1.9657 0.780794 0.474082 -0.8279 
 






3.77076 6.36786 2.5971 0.454981 0.815787 1.09383 
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3.59178 5.36813 1.77635 0.581656 0.79178 0.748152 
 






0 0 0 0 0 0 
 






3.22575 4.22755 1.00179 0.579826 0.741166 0.421928 
 






8.39543 4.00929 -4.38615 0.909823 0.326834 -1.84733 
 






5.13069 7.58477 2.45408 0.508679 0.773526 1.0336 
 






1.26895 5.05273 3.78378 0.337291 0.839847 1.59363 
 






1.26734 5.09093 3.82359 0.334301 0.842001 1.6104 
 






1.97579 5.03027 3.05448 0.398714 0.872274 1.28647 
 




0.4 0.31577 4.89854 3.39099 -1.50755 0.815441 0.503969 -0.63494 
 






0 0 0 0 0 0 
 




0 0 0 0 0 0 
 




6.96083 1.89122 -5.06962 0.959335 0.240228 -2.13519 
 






10.0029 4.47878 -5.52415 0.934514 0.211262 -2.32663 
 








0.610273 0.703651 0.325149 
 






2.29262 8.31286 6.02024 0.182451 0.964531 2.53557 Pos 








0.717108 0.691893 0.099306 
 






2.00667 4.81886 2.81219 0.422247 0.859307 1.18442 
 




0.194444 0.3106 2.94988 5.50599 2.5561 0.452043 0.844276 1.07656 
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4.75503 3.48032 -1.2747 0.798057 0.528388 -0.53687 
 






6.96064 4.65591 -2.30474 0.825564 0.431061 -0.9707 
 




0 0 0 0 0 0 
 




2.66329 4.36267 1.69938 0.547775 0.82026 0.715735 
 




8.81325 7.16658 -1.64667 0.748115 0.490344 -0.69354 
 






0.670433 0.725561 0.348762 
 






9.28544 4.64272 -4.64272 0.912056 0.25865 -1.95539 
 






7.04178 6.62131 -0.42047 0.706624 0.603963 -0.17709 
 




0.1 0.29992 1.30114 5.01678 3.71564 0.348276 0.831834 1.56493 
 






7.73596 3.31658 -4.41938 0.929471 0.255827 -1.86133 
 






11.7825 4.30789 -7.47458 0.963619 0.139795 -3.1481 
 






6.30303 2.9514 -3.35163 0.901287 0.381792 -1.41162 
 






7.82428 4.23971 -3.58457 0.879605 0.399598 -1.50973 
 






3.77858 7.39025 3.61167 0.379082 0.857496 1.52114 
 






0.67685 0.62925 0.007825 
 




0.25 0.29297 5.29921 6.58747 1.28826 0.596355 0.719796 0.54258 
 






3.41614 1.47485 -1.94129 0.909071 0.512159 -0.81762 
 






11.2302 4.67821 -6.55194 0.917084 0.277254 -2.75951 
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17.3359 11.1599 -6.17595 0.841379 0.353268 -2.60115 
 




4.89614 6.73337 1.83723 0.616785 0.767276 0.773793 
 






3.86212 3.40758 -0.45454 0.776255 0.665906 -0.19144 
 






8.75662 5.08752 -3.6691 0.858927 0.345838 -1.54533 
 




9.49383 6.93546 -2.55838 0.798639 0.424839 -1.07752 
 




0.214286 0.19605 7.88552 7.05084 -0.83468 0.723154 0.597658 -0.35155 
 






2.50837 5.85346 3.34509 0.520466 0.684224 1.40886 
 






8.83596 4.91121 -3.92475 0.857199 0.386008 -1.653 
 






1.84946 5.74082 3.89136 0.415582 0.774942 1.63894 
 






13.2149 5.46674 -7.74816 0.957856 0.13791 -3.26332 
 




7.29037 3.42877 -3.8616 0.912622 0.293315 -1.62641 
 




5.35724 6.6971 1.33985 0.588796 0.71647 0.564311 
 




8.81608 5.45575 -3.36033 0.838264 0.399769 -1.41528 
 








0.597316 0.66719 0.290451 
 








0.674996 0.741192 0.249868 
 






5.86943 7.69059 1.82117 0.555119 0.743617 0.767027 
 






3.96672 8.64097 4.67425 0.405108 0.885609 1.96867 
 






9.56239 5.18599 -4.3764 0.871686 0.363637 -1.84323 
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10.587 7.33963 -3.24738 0.817059 0.432363 -1.36771 
 






5.77963 3.7576 -2.02202 0.851836 0.543707 -0.85162 
 




10.3794 5.38456 -4.9948 0.893656 0.359293 -2.10368 
 






5.04401 6.76745 1.72343 0.564157 0.745136 0.725865 
 








0.627579 0.695839 0.213613 
 




4.42061 3.75927 -0.66134 0.786887 0.618571 -0.27854 
 




0 6.1424 6.1424 0.219838 0.780162 2.58702 
 






2.85745 6.72826 3.87081 0.369197 0.901471 1.63028 
 






7.50374 3.36922 -4.13452 0.921402 0.273959 -1.74135 
 






4.80854 3.47191 -1.33663 0.796321 0.522849 -0.56295 
 






0 8.16379 8.16379 0.121981 0.878019 3.43838 Pos 






2.70487 5.5244 2.81953 0.438782 0.871275 1.18751 
 




7.46736 6.88151 -0.58585 0.715724 0.588816 -0.24675 
 






7.71443 4.42997 -3.28447 0.872649 0.355163 -1.38333 
 






9.42431 3.45555 -5.96875 0.957536 0.165737 -2.51388 
 






13.1945 6.70779 -6.48675 0.924485 0.205005 -2.73205 
 






7.52755 4.5551 -2.97245 0.857224 0.380681 -1.25192 
 






7.43359 8.14845 0.71486 0.596648 0.6678 0.30108 
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0.63776 0.770463 0.354275 
 








0.607208 0.65808 0.24137 
 




9.66645 4.6934 -4.97304 0.918543 0.245484 -2.09452 
 






3.87921 0 -3.87921 1 0.333333 -1.63382 
 




0 0.28013 0 0 0 0 0 0 
 






0 0 0 0 0 0 
 




0 0 0 0 0 0 
 




0 0 0 0 0 0 
 






0 0 0 0 0 0 
 
446 0 0 0 0.34649
9 
0 0 0 0 0 0 0 0 
 
447 2 7 0.28132 0.95857
9 
0.222222 0.22689 7.10933 7.30247 0.19313
8 
0.665207 0.640724 0.081345 
 






6.96397 2.35086 -4.61312 0.953617 0.212503 -1.94292 
 








0.602213 0.607663 0.086906 
 






2.29256 4.91813 2.62557 0.547985 0.65663 1.10582 
 






4.71333 5.75602 1.04269 0.582525 0.72701 0.439154 
 






7.29974 4.69382 -2.60592 0.83874 0.410972 -1.09755 
 
453 0.333333 4.66667 0.25196 1.02968 0.066667 0.19659
2 
1.32296 4.53216 3.2092 0.471227 0.665282 1.35163 
 






5.73257 7.45811 1.72553 0.542029 0.74727 0.726749 
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4.99964 2.23976 -2.75988 0.909031 0.364887 -1.16239 
 




9.73757 2.26705 -7.47052 0.985722 0.085417 -3.14639 
 




0.4 0.24803 13.7408 6.79841 -6.94238 0.924153 0.219542 -2.92395 
 






0 0 0 0 0 0 
 






0 0 0 0 0 0 
 






0 0 0 0 0 0 
 






0 0 0 0 0 0 
 






0 0 0 0 0 0 
 




0 0 0 0 0 0 
 




0 0 0 0 0 0 
 




0 0 0 0 0 0 
 






0 0 0 0 0 0 
 






0 0 0 0 0 0 
 






0 0 0 0 0 0 
 






0 0 0 0 0 0 
 
470 0 0 0 0.04334
6 
0 0 0 0 0 0 0 0 
 




8.33519 6.99331 -1.34189 0.75558 0.543507 -0.56517 
 






3.80451 6.1406 2.3361 0.475904 0.8023 0.983903 
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0.383333 0.32246 9.3431 7.15328 -2.18982 0.771981 0.455015 -0.92229 
 






0.641878 0.675402 0.179156 
 






5.07949 6.73104 1.65156 0.535586 0.757104 0.695593 
 




0.285714 0.35004 4.41895 5.94964 1.53069 0.532191 0.76627 0.644685 
 






10.4999 5.60411 -4.89578 0.889751 0.277218 -2.06198 
 






7.71384 6.63664 -1.07721 0.72786 0.539264 -0.45369 
 






9.08314 4.69149 -4.39165 0.904421 0.273671 -1.84965 
 




7.09639 3.44735 -3.64904 0.90604 0.307083 -1.53688 
 






11.4161 4.8116 -6.60453 0.944237 0.170698 -2.78166 
 






1.20659 5.39525 4.18867 0.29839 0.866914 1.76416 
 






10.1628 4.44745 -5.71535 0.938536 0.202177 -2.40715 
 






0 0 0 0 0 0 
 






0 0 0 0 0 0 
 






6.96064 1.16011 -5.80054 0.987654 0.111111 -2.44303 
 








0.627491 0.681365 0.39135 
 




7.6295 4.44556 -3.18394 0.868572 0.362275 -1.34099 
 






4.98594 9.27617 4.29022 0.39229 0.845529 1.80693 
 
490 2 5 0.26681
2 
1.01822 0.285714 0.20763 7.49592 4.91052 -2.5854 0.838595 0.444179 -1.0889 
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7.0935 4.65088 -2.44261 0.832327 0.42085 -1.02876 
 






9.2329 7.22948 -2.00342 0.757128 0.474659 -0.84379 
 








0.646518 0.629001 0.026562 
 




0.375 0.32806 7.07253 5.75501 -1.31752 0.752066 0.518766 -0.55491 
 








0.601865 0.715305 0.383918 
 




5.90247 3.38604 -2.51643 0.843411 0.462057 -1.05985 
 
497 2.5 4.5 0.26722 1.02576 0.357143 0.20666
9 
9.35559 4.38698 -4.96862 0.901497 0.300627 -2.09265 
 






7.46198 2.24481 -5.21718 0.964888 0.177849 -2.19734 
 




3.12096 6.40118 3.28022 0.402156 0.866689 1.38154 
 






8.52949 5.31201 -3.21748 0.853493 0.376965 -1.35512 
 




1.76035 4.86813 3.10778 0.463126 0.738077 1.30891 
 
502 3 5 0.25976 1.02281 0.375 0.20253
1 
11.5491 4.88851 -6.66061 0.941366 0.208683 -2.80528 
 






4.94554 2.25078 -2.69476 0.906324 0.370883 -1.13496 
 






9.9283 5.71984 -4.20847 0.881095 0.306493 -1.7725 
 






0 3.62951 3.62951 0.698928 0.301072 1.52866 
 






2.50938 4.16383 1.65445 0.633979 0.576724 0.696809 
 




0 0.51247 0 0 0 0 0 0 
 






0 0 0 0 0 0 
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14.6101 3.24502 -11.3651 0.96697 0.330453 -4.78668 
 






0 0 0 0 0 0 
 






1.95104 4.71764 2.7666 0.50864 0.695729 1.16522 
 




3.96877 5.88458 1.91581 0.581807 0.786871 0.806889 
 






6.37181 7.29318 0.92137 0.582195 0.683047 0.388057 
 






5.00518 6.71593 1.71075 0.528856 0.762151 0.720525 
 




7.18206 5.90764 -1.27442 0.738024 0.531431 -0.53675 
 








0.677104 0.641636 0.010788 
 






7.89182 10.0522 2.16038 0.556283 0.740709 0.909895 
 






0 4.92859 4.92859 0.43374 0.56626 2.07579 
 






9.45371 7.28872 -2.16499 0.772291 0.505157 -0.91184 
 




5.89344 1.8202 -4.07324 0.934848 0.267959 -1.71554 
 






8.83475 2.86366 -5.9711 0.965298 0.149843 -2.51487 
 






8.35217 3.21269 -5.13947 0.945778 0.21573 -2.16461 
 






6.44666 4.96632 -1.48033 0.76204 0.506381 -0.62348 
 






12.2763 4.40274 -7.87357 0.957437 0.150106 -3.31614 
 






9.43004 3.4802 -5.94984 0.956741 0.167899 -2.50592 
 






3.81579 6.1121 2.29631 0.479419 0.799986 0.967146 
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0.25 0.31104 3.74374 5.07048 1.32673 0.560121 0.748207 0.558785 
 




0.291667 0.31993 5.72075 6.53589 0.81513
7 
0.590394 0.687543 0.343314 
 






7.37615 4.51331 -2.86284 0.854312 0.386153 -1.20575 
 






2.35746 5.75508 3.39762 0.36165 0.907964 1.43099 
 






9.24846 6.09849 -3.14997 0.823097 0.392829 -1.32668 
 






4.83879 8.62838 3.78959 0.342125 0.857893 1.59608 
 




4.13951 6.6677 2.52818 0.419222 0.821398 1.0648 
 






2.54285 4.59732 2.05447 0.505123 0.845051 0.865289 
 




0.166667 0.32848 2.37151 5.80025 3.42873 0.360821 0.908304 1.44409 
 








0.638409 0.643066 0.069461 
 






5.62903 2.26607 -3.36295 0.925778 0.325488 -1.41639 
 




8.30748 4.55961 -3.74787 0.884586 0.333966 -1.5785 
 






6.69084 5.13635 -1.5545 0.787037 0.516772 -0.65471 
 






9.12307 4.07612 -5.04695 0.927308 0.24001 -2.12564 
 




7.50245 2.43612 -5.06632 0.957534 0.201362 -2.1338 
 




0.199079 0.20836 4.01041 4.24658 0.23617
3 
0.717566 0.690654 0.09947 
 






5.19614 3.7963 -1.39984 0.798638 0.527593 -0.58958 
 
544 2.16667 3.83333 0.35388 0.80645
7 
0.361111 0.30498 6.1226 4.7533 -1.3693 0.766777 0.536264 -0.57671 
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545 1.5 4.5 0.39538 0.76176 0.25 0.34168
7 
3.79382 5.90737 2.11355 0.499328 0.791866 0.890174 
 








0.691966 0.714736 0.228461 
 






5.10576 2.55288 -2.55288 0.888889 0.407407 -1.07521 
 






6.27776 3.82067 -2.45709 0.851634 0.44826 -1.03486 
 






6.38634 4.6405 -1.74584 0.803638 0.504738 -0.7353 
 






0 0 0 0 0 0 
 






8.82033 0 -8.82033 1 0.039175 -3.71489 
 






-7.79094 0.994439 0.083041 -3.28134 
 






6.96064 1.16011 -5.80054 0.987654 0.111111 -2.44303 
 
554 3 3 0.25901 1.03097 0.5 0.20078
6 
11.5826 2.90987 -8.67271 0.982798 0.099848 -3.65272 
 








-7.12257 0.999953 0.046568 -2.99984 
 




10.6785 3.39442 -7.2841 0.952927 0.194641 -3.06787 
 




11.5216 2.31209 -9.20954 0.988324 0.084847 -3.87882 
 
558 0 0 0 0.70749
3 
0 0 0 0 0 0 0 0 
 






7.11381 1.14775 -5.96605 0.988684 0.104835 -2.51275 
 






4.64043 2.32021 -2.32021 0.888889 0.407407 -0.97721 
 






9.64476 2.92165 -6.72311 0.951093 0.208115 -2.8316 
 




0 1.97164 1.97164 0.629444 0.370556 0.830402 
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9.06095 2.03729 -7.02366 0.978663 0.156105 -2.95818 
 






7.5788 3.34395 -4.23484 0.924544 0.267155 -1.78361 
 






4.82506 4.55331 -0.27175 0.705323 0.623163 -0.11445 
 






4.64043 0 -4.64043 1 0.111111 -1.95443 
 






7.36708 3.3869 -3.98019 0.917029 0.283837 -1.67635 
 






6.96064 0 -6.96064 1 0.041365 -2.93164 
 






6.20465 4.05982 -2.14483 0.826933 0.446394 -0.90335 
 






4.71469 2.30208 -2.41261 0.893501 0.398074 -1.01613 
 
571 0 0 0 0.70749
3 
0 0 0 0 0 0 0 0 
 




7.53738 0 -7.53738 1 0.042115 -3.17455 
 






9.28086 0 -9.28086 1 0.012346 -3.90886 
 






7.7441 1.15102 -6.59309 0.987968 0.13346 -2.77684 
 




8.73087 0 -8.73087 1 0.031388 -3.67721 
 






4.64043 0 -4.64043 1 0.118346 -1.95443 
 






9.27973 1.16018 -8.11955 0.995882 0.045288 -3.41974 
 








0.738386 0.706049 0.007777 
 




0.5 0.3315 4.66609 2.31385 -2.35224 0.890512 0.404149 -0.9907 
 




13.5515 0 -13.5515 1 0.005918 -5.70753 
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4.64043 0 -4.64043 1 0.12006 -1.95443 
 




8.72272 1.05368 -7.66904 0.994994 0.060263 -3.23 
 






8.84115 0 -8.84115 1 0.043214 -3.72366 
 






9.47782 8.03724 -1.44058 0.72816 0.507526 -0.60674 
 






12.7215 2.62665 -10.0949 0.985821 0.078233 -4.2517 
 






4.64043 0 -4.64043 1 0.111111 -1.95443 
 






5.66917 2.64202 -3.02715 0.903882 0.337383 -1.27496 
 








0.987831 0.012169 0.329751 
 
589 1 2 0.22389 1.06634 0.333333 0.17352
8 
4.46649 1.87558 -2.5909 0.920115 0.435472 -1.09122 
 




19.4316 0 -19.4316 1 0.000312 -8.18408 
 






4.56803 0 -4.56803 1 0.203486 -1.92394 
 




3.67963 2.93767 -0.74196 0.803362 0.610864 -0.3125 
 






5.50084 4.2204 -1.28044 0.762163 0.528645 -0.53929 
 




0.75 0.42198 6.00837 1.46213 -4.54624 0.968292 0.20544 -1.91476 
 






10.543 2.18918 -8.3538 0.99014 0.065376 -3.5184 
 






8.51577 0 -8.51577 1 0.041293 -3.58662 
 






4.63045 1.17792 -3.45253 0.961656 0.264442 -1.45411 
 






5.51629 1.45216 -4.06413 0.962087 0.229939 -1.7117 
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6.9289 1.17912 -5.74978 0.986952 0.115282 -2.42166 
 






5.26582 1.874 -3.39182 0.905704 0.384667 -1.42855 
 






3.26627 0 -3.26627 1 0.224269 -1.37567 
 






4.64266 1.15983 -3.48283 0.963016 0.259046 -1.46688 
 




7.50316 0 -7.50316 1 0.0425 -3.16013 
 




9.03516 1.00395 -8.03121 0.993989 0.087158 -3.38254 
 






6.96064 0 -6.96064 1 0.037037 -2.93164 
 






6.96064 1.16011 -5.80054 0.987654 0.111111 -2.44303 
 






4.56803 1.15794 -3.41009 0.959104 0.363558 -1.43624 
 






6.96064 1.16011 -5.80054 0.987654 0.111111 -2.44303 
 






10.236 0 -10.236 1 0.008837 -4.31111 
 






8.61913 1.17619 -7.44293 0.990143 0.1182 -3.13477 
 






10.6531 1.44457 -9.20853 0.996343 0.035118 -3.87839 
 






-7.52809 0.993834 0.088541 -3.17063 
 




0.857143 0.47166 10.4508 1.55495 -8.89587 0.994807 0.045911 -3.74671 
 




13.7533 0 -13.7533 1 0.001553 -5.79252 
 






4.64043 1.16011 -3.48032 0.962963 0.259259 -1.46582 
 






4.64043 0 -4.64043 1 0.111111 -1.95443 
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9.28086 0 -9.28086 1 0.012346 -3.90886 
 






7.33775 0 -7.33775 1 0.049599 -3.09047 
 






4.8246 3.03938 -1.78521 0.829685 0.473487 -0.75188 
 






12.9339 0 -12.9339 1 0.00257 -5.44741 
 






6.96064 0 -6.96064 1 0.037037 -2.93164 
 






12.6402 1.06248 -11.5777 0.998355 0.027735 -4.87624 
 






9.28086 1.37154 -7.90932 0.992922 0.066942 -3.3312 
 






6.73693 2.02163 -4.7153 0.959327 0.229798 -1.98596 
 






4.55391 2.36112 -2.19279 0.881545 0.42183 -0.92355 
 




7.72551 0 -7.72551 1 0.040089 -3.25378 
 






6.78062 0 -6.78062 1 0.048414 -2.85582 
 




8.42405 2.00934 -6.41471 0.975555 0.169522 -2.70171 
 






6.96064 0 -6.96064 1 0.037037 -2.93164 
 




5.86854 0 -5.86854 1 0.069473 -2.47167 
 
631 3 0 0.23587
9 
1.0571 1 0.18243 12.7184 0 -12.7184 1 0.006071 -5.35665 
 




7.79547 0 -7.79547 1 0.039372 -3.28325 
 




10.0021 0 -10.0021 1 0.00939 -4.21263 
 






6.81744 0 -6.81744 1 0.042405 -2.87133 
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0.703604 0.716483 0.159761 
 




1 0.50659 5.3689 0 -5.3689 1 0.130008 -2.26124 
 
637 0 0 0 0 0 0 0 0 0 0 0 0 
 
638 0 0 0 0 0 0 0 0 0 0 0 0 
 
639 0 0 0 0 0 0 0 0 0 0 0 0 
 
640 0 0 0 0 0 0 0 0 0 0 0 0 
 
641 0 0 0 0 0 0 0 0 0 0 0 0 
 
642 0 0 0 0 0 0 0 0 0 0 0 0 
 
643 0 0 0 0 0 0 0 0 0 0 0 0 
 
644 0 0 0 0 0 0 0 0 0 0 0 0 
 
645 0 0 0 0 0 0 0 0 0 0 0 0 
 
646 0 0 0 0 0 0 0 0 0 0 0 0 
 






0 2.82325 2.82325 0.998229 0.001771 1.18908 
 






6.96064 0 -6.96064 1 0.041459 -2.93164 
 




1 0.34373 6.96064 0 -6.96064 1 0.040612 -2.93164 
 






4.64043 0 -4.64043 1 0.111111 -1.95443 
 




8.55833 0 -8.55833 1 0.040987 -3.60455 
 
652 0 0 0 0 0 0 0 0 0 0 0 0 
 
653 0 0 0 0 0 0 0 0 0 0 0 0 
 
654 0 0 0 0 0 0 0 0 0 0 0 0 
 






9.8498 3.73898 -6.11082 0.953149 0.177493 -2.57372 
 






3.9814 1.63714 -2.34426 0.885015 0.424703 -0.98734 
 






8.48689 0 -8.48689 1 0.023779 -3.57446 
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2.32021 0 -2.32021 1 0.349888 -0.97721 
 






4.64043 0 -4.64043 1 0.111111 -1.95443 
 




3.50296 1.99798 -1.50498 0.874132 0.52891 -0.63386 
 






3.95573 0 -3.95573 1 0.214563 -1.66605 
 




4.19077 0 -4.19077 1 0.205624 -1.76504 
 




1 0.28149 11.1004 0 -11.1004 1 0.006478 -4.67518 
 






6.98015 1.06684 -5.91331 0.987168 0.138766 -2.49053 
 






2.36962 2.29628 -0.07334 0.749958 0.694341 -0.03089 
 
666 1 2 0.27189
8 
1.01806 0.333333 0.21078 3.67786 1.96452 -1.71333 0.885444 0.508421 -0.72161 
 




3.67963 0 -3.67963 1 0.210185 -1.54977 
 




0 1.4195 1.4195 0.966218 0.033782 0.597855 
 




6.96291 2.31984 -4.64308 0.954786 0.209716 -1.95554 
 






10.9595 1.04394 -9.9156 0.99756 0.036593 -4.17619 
 




8.82033 0 -8.82033 1 0.030754 -3.71489 
 






5.80814 0 -5.80814 1 0.070925 -2.44624 
 






6.96064 1.1727 -5.78795 0.987294 0.113259 -2.43773 
 




-11.7943 0.998891 0.020988 -4.96747 
 
675 1 2 0.20997 1.01262 0.333333 0.17174
3 
4.76258 1.97508 -2.7875 0.921645 0.431807 -1.17402 
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5.73875 0 -5.73875 1 0.072651 -2.41701 
 
677 3 1 0.25524
8 
1.03774 0.75 0.19741 11.7533 0.96363
6 
-10.7896 0.998481 0.026217 -4.54432 
 






9.06545 0 -9.06545 1 0.042054 -3.81813 
 






8.17807 0 -8.17807 1 0.022837 -3.44439 
 




0.5 0.26243 8.89589 3.16519 -5.7307 0.955461 0.189577 -2.41362 
 




3.66395 1.966 -1.69796 0.884689 0.509831 -0.71514 
 




7.51587 0 -7.51587 1 0.042356 -3.16549 
 






8.57387 0 -8.57387 1 0.039403 -3.61109 
 




2.95622 1.19492 -1.76129 0.91714 0.492848 -0.74181 
 






8.59354 1.06111 -7.53243 0.992232 0.102131 -3.17246 
 
686 1 3 0.21807
6 
1.02992 0.25 0.17474 4.58556 2.91284 -1.67272 0.856682 0.536166 -0.70451 
 






5.93363 2.89937 -3.03426 0.877403 0.365697 -1.27795 
 




5.26057 2.88155 -2.37903 0.867729 0.408795 -1.00198 
 






7.05923 2.31219 -4.74704 0.956623 0.204156 -1.99933 
 




10.3049 4.27237 -6.03254 0.923305 0.257474 -2.54075 
 








0.678795 0.647348 0.021056 
 






6.2643 4.08219 -2.18211 0.812833 0.453035 -0.91905 
 
693 0 0 0 0.04334
6 
0 0 0 0 0 0 0 0 
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0 0 0 0 0 0 
 




8.86021 3.4626 -5.3976 0.927122 0.255948 -2.27333 
 




0 1.97642 1.97642 0.612511 0.387489 0.832418 
 
697 1 3 0.2791 1.01388 0.25 0.21585
7 
3.58295 2.95892 -0.62403 0.794383 0.621923 -0.26282 
 








0.789664 0.210336 0.413376 
 






13.2611 2.15813 -11.103 0.971986 0.208574 -4.6763 
 
700 0 0 0 0.70749
3 
0 0 0 0 0 0 0 0 
 






4.64043 0 -4.64043 1 0.111111 -1.95443 
 




6.9612 2.36975 -4.59145 0.952374 0.216878 -1.9338 
 






0 0 0 0 0 0 
 
704 0 0 0 0.70749
3 
0 0 0 0 0 0 0 0 
 






3.94236 1.74511 -2.19724 0.873223 0.445808 -0.92542 
 






10.7256 2.93356 -7.79209 0.96065 0.181552 -3.28182 
 






35.3812 3.26701 -32.1142 0.973652 0.075147 -13.5257 
 






8.28033 2.14897 -6.13137 0.976086 0.137901 -2.58237 
 






7.11381 2.2955 -4.8183 0.958182 0.19936 -2.02934 
 






6.86697 2.34668 -4.52029 0.951932 0.218173 -1.90383 
 




1 0.34623 9.28086 0 -9.28086 1 0.01437 -3.90886 
 
Chapter 8 Filovirus Data Ebola Selection analysis 






8.80056 0 -8.80056 1 0.018325 -3.70657 
 






6.8923 2.37376 -4.51854 0.951027 0.220811 -1.90309 
 






7.76846 3.30831 -4.46015 0.93058 0.253233 -1.8785 
 






6.94767 4.64477 -2.3029 0.825746 0.43079 -0.96992 
 




0.714286 0.35082 11.5002 2.48591 -9.01431 0.990874 0.056155 -3.79659 
 




4.76633 5.72492 0.95859 0.590929 0.720071 0.403733 
 




4.07139 0 -4.07139 1 0.189961 -1.71476 
 






2.72592 2.15951 -0.56641 0.804183 0.632512 -0.23856 
 






4.64043 1.16011 -3.48032 0.962963 0.259259 -1.46582 
 






5.23775 3.30639 -1.93135 0.841922 0.463929 -0.81344 
 




14.6003 0 -14.6003 1 0.002016 -6.14928 
 






4.64043 0 -4.64043 1 0.111111 -1.95443 
 






5.09899 0 -5.09899 1 0.09936 -2.14756 
 




7.05909 3.45622 -3.60287 0.90439 0.310466 -1.51744 
 






3.77608 0 -3.77608 1 0.221937 -1.59039 
 






-9.43775 0.997553 0.036664 -3.97494 
 






8.82033 0 -8.82033 1 0.039175 -3.71489 
 






0 0 0 0 0 0 
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0 0 0 0 0 0 
 






0 0 0 0 0 0 
 






0 0 0 0 0 0 
 




0 0 0 0 0 0 
 




0 2.95182 2.95182 0.499005 0.500995 1.24323 
 






4.41168 2.38197 -2.02972 0.872929 0.438113 -0.85486 
 



















2 0.890205 0 0 0 -0.37493 0 -4.14326 0 1 
 
3 4.47809 4.34487 0 0.97 -0.05611 4.39495 -19.4419 0.000707 0.97878 
 
4 7.72771 3.32993 0 0.431 -1.8522 4.77314 -23.1701 0.661475 0.41604 
 
5 0 0 0.69457 Undefined 0 0 -10.3835 0 1 
 
6 0.645302 0 0.332203 0 -0.27178 0.357253 -10.9253 1.20331 0.272662 
 
7 6.68355 0 0.6133 0 -2.81489 0.799463 -19.4744 4.96845 0.025814 
 
8 2.69558 0 0.311501 0 -1.13529 1.05584 -13.6316 3.03618 0.081427 
 
9 1.81512 0 0 0 -0.76447 0.379217 -6.48618 2.5365 0.111241 
 
10 0.404137 0 0 0 -0.17021 0.251524 -8.0399 0.886637 0.34639 
 
11 0.920421 0 0 0 -0.38765 0.453532 -7.89359 2.51077 0.113071 
 
12 2.31819 0 0 0 -0.97634 0.913935 -10.7791 4.33368 0.037365 
 
13 4.06E-16 0.095515 0.516554 2.35E+14 0.040228 0 -11.886 0.015307 0.901537 
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14 2.00393 0 0.468215 0 -0.84399 0.803156 -14.4127 2.47794 0.115453 
 
15 1.7587 0.379852 0 0.216 -0.58072 0.589644 -12.5993 1.25083 0.263394 
 
16 3.04708 0.77383 0.466332 0.254 -0.95742 1.85383 -28.326 0.686629 0.407313 
 
17 1.34594 0.58195 0.251261 0.432 -0.32177 0.825568 -21.3191 0.323064 0.569772 
 
18 1.1313 0 0.324822 0 -0.47647 0.164657 -14.2665 4.29221 0.038288 
 
19 3.00979 0.28513 0 0.095 -1.14754 1.05478 -15.928 3.68813 0.054801 
 
20 0.407666 0.156859 0.235797 0.385 -0.10563 0.218215 -17.5225 0.312156 0.57636 
 
21 0 0 0.254914 Undefined 0 5.55E-17 -9.301 3.55E-15 1 
 
22 0.637846 0.499406 0 0.783 -0.05831 0.561731 -15.5579 0.040589 0.840334 
 
23 0.915689 0 0 0 -0.38566 0 -4.95231 0 1 
 
24 0.712642 0.714775 0 1.003 0.000898 0.713592 -16.1855 5.36E-06 0.998153 
 
25 3.22236 0.196124 0 0.061 -1.27455 0.731081 -15.9565 4.55277 0.032866 
 
26 0 0 0 Undefined 0 0 0 0 1 
 
27 3.57455 0 0 0 -1.50548 0.973132 -14.5301 10.738 0.00105 
 
28 1.3493 0.212344 0 0.157 -0.47885 0.496087 -11.8008 1.9169 0.166199 
 
29 1.55864 0 0.256359 0 -0.65645 0.130369 -10.9057 3.76328 0.05239 
 
30 1.10166 0.213396 1.73616 0.194 -0.37411 0.465393 -27.7183 1.24382 0.264736 
 
31 1.69585 1.58033 0 0.932 -0.04865 1.61795 -18.0516 0.003761 0.951099 
 
32 3.90642 0.712066 0.598057 0.182 -1.34535 1.2506 -32.6397 2.09597 0.147688 
 
33 0.948128 0.269822 0.257873 0.285 -0.28568 0.611744 -22.9201 0.849724 0.35663 
 
34 2.4849 0.482737 0 0.194 -0.84325 0.70581 -16.2788 1.0213 0.31221 
 
35 2.71269 0 0 0 -1.14249 0.673876 -14.1224 10.8271 0.001 
 
36 3.49604 0.219069 0 0.063 -1.38015 0.146253 -16.7981 6.70506 0.009614 
 
37 2.63483 0.800701 0 0.304 -0.77247 1.32807 -17.8616 1.09093 0.296265 
 
38 3.33125 0.313273 0.654903 0.094 -1.27107 1.30529 -26.2775 3.78079 0.051844 
 
39 1.46295 0.46988 0 0.321 -0.41825 0.773667 -15.4258 0.78744 0.374875 
 
40 2.71022 0.958601 0 0.354 -0.73772 1.13248 -19.8051 0.329851 0.565747 
 
41 4.12183 0.161425 0 0.039 -1.66799 0.680812 -13.2798 5.80611 0.015971 
 
42 3.76323 0.166814 0.231186 0.044 -1.51469 0.452553 -16.5244 3.82313 0.05055 
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43 1.93661 0.468665 0 0.242 -0.61825 0.765897 -17.9923 0.920927 0.337232 
 
44 3.67568 0 0 0 -1.54807 1.27492 -10.8956 4.92649 0.026448 
 
45 4.97202 0 0.637493 0 -2.09405 0.579162 -17.1216 8.41492 0.003722 
 
46 0.731099 0.548985 0.30064 0.751 -0.0767 0.618618 -17.3245 0.053475 0.817124 
 
47 0 0.975067 1.80976 Infinite 0.410666 0.652805 -32.8019 1.0076 0.315478 
 
48 1.09726 0.936252 0 0.853 -0.06781 0.96822 -23.3462 0.00963 0.921826 
 
49 1.61963 0.730597 0 0.451 -0.37443 1.11604 -17.8604 0.415027 0.519429 
 
50 1.57031 0 0 0 -0.66136 0.27061 -7.23623 6.1493 0.013146 
 
51 1.19569 0.77814 0 0.651 -0.17586 0.903253 -15.3323 0.136874 0.711409 
 
52 2.79009 0 0 0 -1.1751 1.42281 -15.5143 4.89666 0.026909 
 
53 1.55811 0 0 0 -0.65623 0.475564 -10.6722 6.82752 0.008976 
 
54 3.86249 0 0 0 -1.62675 0.495792 -12.1533 9.89345 0.001659 
 
55 0.789975 0.651638 0.52458 0.825 -0.05826 0.709874 -20.6989 0.023329 0.878605 
 
56 1.80535 0.214139 0 0.119 -0.67017 0.616618 -11.082 2.59731 0.107045 
 
57 0.739959 0.258192 0.519719 0.349 -0.20291 0.355745 -16.3881 0.221514 0.637889 
 
58 1.12764 0 0 0 -0.47492 0.368975 -12.7014 5.76787 0.016322 
 
59 0.639237 0.540345 0.387329 0.845 -0.04165 0.586694 -17.8038 0.020727 0.885526 
 
60 5.10845 0.66375 0 0.13 -1.87196 1.21411 -22.246 3.02569 0.081955 
 
61 2.35048 0 0 0 -0.98994 0.431011 -14.6564 7.93349 0.004853 
 
62 0.789961 0.628193 0.728279 0.795 -0.06813 0.684899 -17.8386 0.025668 0.872714 
 
63 7.16185 0.480797 0 0.067 -2.81384 0.899997 -15.3837 3.29836 0.069349 
 
64 1.16447 0.299097 0 0.257 -0.36447 0.682457 -16.014 1.09557 0.295241 
 
65 1.29252 0.657144 0 0.508 -0.2676 0.787806 -14.142 0.256783 0.612339 
 
66 1.47645 0.294134 0.332451 0.199 -0.49795 0.727698 -23.473 1.77183 0.183156 
 
67 2.17358 0.197753 0 0.091 -0.83215 0.672905 -13.1751 3.52722 0.060369 
 
68 1.30708 0 0 0 -0.5505 0.419581 -10.7237 5.75339 0.016457 
 
69 2.66996 0.187394 0 0.07 -1.04557 0.831211 -16.5728 5.07258 0.024307 
 
70 1.0889 0.220852 0 0.203 -0.36559 0.468275 -10.8197 1.10133 0.293975 
 
71 1.14211 0 0 0 -0.48102 0.387415 -12.5305 5.557 0.018407 
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72 9.38559 0.487075 0 0.052 -3.74776 1.48983 -15.289 7.51351 0.006124 
 
73 0.951326 0 0 0 -0.40067 0.25084 -11.1319 4.00091 0.045476 
 
74 3.34824 0.411466 0.90904 0.123 -1.23687 0.748602 -31.8744 1.98775 0.158576 
 
75 0 0.416297 0.328998 Infinite 0.175331 0.232158 -17.1466 2.20639 0.13744 
 
76 1.99459 0 0.652935 0 -0.84006 0.273943 -22.3035 5.63123 0.017643 
 
77 1.5706 0 0.308092 0 -0.66149 0.474629 -14.9676 7.09698 0.007721 
 
78 2.64251 0.430185 0 0.163 -0.93176 0.887961 -17.9499 2.52011 0.112403 
 
79 2.50034 0.521133 0 0.208 -0.83357 0.845669 -16.8487 1.3284 0.24909 
 
80 1.41088 0.546207 0.296458 0.387 -0.36417 0.792641 -17.8457 0.639359 0.423943 
 
81 0.341631 0.306011 0 0.896 -0.015 0.32326 -10.944 0.004861 0.944413 
 
82 1.95835 0.807194 0.302832 0.412 -0.48483 1.31185 -20.1646 0.550854 0.457969 
 
83 1.57777 1.73051 0.314112 1.097 0.064328 1.64237 -37.0428 0.006262 0.936925 
 
84 1.48163 0.242751 0 0.164 -0.52178 0.67028 -14.4547 2.06142 0.151069 
 
85 2.33973 0 0 0 -0.98542 0.296393 -7.46701 7.36008 0.006669 
 
86 2.03207 0 0 0 -0.85584 0.478495 -12.5248 6.04356 0.013957 
 
87 0 0 0 Undefined 0 0 0 0 1 
 
88 1.14781 0.291446 0 0.254 -0.36067 0.644419 -13.6709 1.16068 0.281325 
 
89 0.565291 0 0 0 -0.23808 0.10244 -7.43982 2.73351 0.098263 
 
90 3.16447 0 0 0 -1.33277 1.01571 -13.1498 10.073 0.001505 
 
91 1.44995 0.261002 0.308746 0.18 -0.50075 0.791196 -18.5347 1.90297 0.167746 
 
92 0 0 0 Undefined 0 0 0 0 1 
 
93 2.42871 0 0 0 -1.02289 0.605009 -17.4605 8.41234 0.003727 
 
94 2.44864 0 0 0 -1.03129 0.218624 -15.218 6.34072 0.0118 
 
95 0.808651 0 0 0 -0.34058 0.19847 -11.7164 4.14062 0.041866 
 
96 4.75027 0 0.253974 0 -2.00066 0.517099 -15.6514 10.9336 0.000944 
 
97 0 0.781468 0 Infinite 0.329128 0.455978 -10.7199 1.84179 0.174742 
 
98 0.543872 0 0 0 -0.22906 0.216298 -10.0095 3.29364 0.069549 
 
99 1.14251 0.750943 0 0.657 -0.16492 0.822306 -14.5141 0.078581 0.77923 
 
100 5.353 0 0 0 -2.25451 0.280612 -11.0955 7.60573 0.005818 
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101 0.777078 0.396932 0 0.511 -0.16011 0.465129 -12.4559 0.193906 0.659686 
 
102 1.35917 0.229161 0 0.169 -0.47592 0.587461 -12.4824 1.79761 0.180002 
 
103 1.2291 0 0 0 -0.51766 0.371171 -10.9328 5.40636 0.020064 
 
104 9.14396 0 0 0 -3.85113 0.497327 -10.2569 11.8432 0.000579 
 
105 1.81828 0.645415 0 0.355 -0.49397 0.794851 -10.5679 0.363558 0.546537 
 
106 0.612436 0 0 0 -0.25794 0.220291 -9.23699 3.72962 0.053456 
 
107 0 0.16081 0 Infinite 0.067728 0.122744 -6.34096 0.517969 0.471709 
 
108 1.39451 0.208683 0 0.15 -0.49943 0.501529 -10.9153 1.66431 0.197022 
 
109 0 0 0 Undefined 0 0 0 0 1 
 
110 0.440489 0 0 0 -0.18552 0.122902 -13.5767 2.20441 0.137617 
 
111 0.458549 0 0 0 -0.19313 0.108375 -6.78824 2.44568 0.117849 
 
112 1.58053 0.209299 0 0.132 -0.57752 0.567887 -15.1205 2.11011 0.146329 
 
113 1.7159 0.61619 0.19896 0.359 -0.46316 0.895426 -15.6482 0.453595 0.500633 
 
114 0.631691 0.185544 0 0.294 -0.1879 0.352565 -11.1637 0.843196 0.358484 
 
115 1.74097 0.18423 0 0.106 -0.65565 0.49309 -11.0721 2.67016 0.102246 
 
116 1.5389 0.360276 0 0.234 -0.4964 0.509448 -11.0232 1.0231 0.311784 
 
117 1.5629 0 0.645488 0 -0.65824 0.4623 -17.7936 7.05385 0.00791 
 
118 0.895414 0.501108 0 0.56 -0.16607 0.625551 -12.7135 0.227952 0.633046 
 
119 1.39599 0 0 0 -0.58794 0.411274 -10.9484 5.79601 0.016063 
 
120 1.66522 0.368839 0 0.221 -0.54599 0.635325 -11.5456 1.59092 0.207195 
 
121 1.30362 0.676582 0 0.519 -0.26409 0.80746 -13.3195 0.190687 0.662345 
 
122 0.798674 0.481167 0 0.602 -0.13372 0.544366 -13.5145 0.114961 0.734565 
 
123 0.695031 0 0 0 -0.29272 0.318537 -12.0497 3.93897 0.04718 
 
124 3.16279 0.204368 0 0.065 -1.24599 0.944987 -15.777 5.00323 0.0253 
 
125 0.609005 1.73326 0.771529 2.846 0.4735 0.614667 -21.243 0.096831 0.755666 
 
126 2.06775 0.184133 0 0.089 -0.79332 0.901327 -17.5119 3.34152 0.067552 
 
127 3.12506 0 0 0 -1.31617 0.723384 -12.4113 11.6486 0.000643 
 
128 0.714288 0.439173 0.229141 0.615 -0.11587 0.476657 -15.7263 0.082505 0.773931 
 
129 0.671951 0.415049 0 0.618 -0.1082 0.508368 -13.3698 0.163627 0.685839 
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130 1.59595 0.880447 0 0.552 -0.30135 1.17463 -18.1979 0.249553 0.61739 
 
131 3.10549 0 0 0 -1.30793 0.903106 -17.4135 9.22871 0.002383 
 
132 0.238064 0.193947 0 0.815 -0.01858 0.213146 -10.7654 0.018154 0.892819 
 
133 0.902102 0.214027 0 0.237 -0.2898 0.417424 -11.1171 1.15186 0.28316 
 
134 0.986755 0 0 0 -0.41559 0.220217 -10.1748 4.92098 0.026533 
 
135 2.08661 0.214526 0 0.103 -0.78846 0.943056 -15.0207 3.56073 0.059162 
 
136 0.565291 0 0 0 -0.23808 0.119793 -7.62164 2.42264 0.119593 
 
137 1.57977 0.323699 0 0.205 -0.52902 0.746467 -15.0068 0.970251 0.324618 
 
138 0 0.563801 0 Infinite 0.237454 0.293213 -8.76924 2.66416 0.102632 
 
139 1.31601 0.200577 0 0.152 -0.46979 0.466897 -13.0004 1.89163 0.169018 
 
140 0.350189 0 0 0 -0.14749 0.09949 -5.98209 2.40905 0.120635 
 
141 5.14753 0.369451 0 0.072 -2.01237 0.769313 -12.7635 4.12208 0.042327 
 
142 1.04765 0.197566 0.292902 0.189 -0.35803 0.418462 -15.3352 1.40288 0.236242 
 
143 0.60456 0.551885 0 0.913 -0.02218 0.571 -17.5581 0.003 0.95632 
 
144 0.330033 0 0 0 -0.139 0.130058 -7.32141 1.94536 0.163088 
 
145 2.84933 0.451449 0 0.158 -1.00991 0.865461 -18.0453 2.34836 0.125415 
 
146 1.9092 0.482039 0 0.252 -0.60107 0.865628 -14.4356 1.41377 0.234432 
 
147 3.00855 0 0 0 -1.2671 0.656152 -14.1933 11.1054 0.000861 
 
148 1.43448 0.392076 0 0.273 -0.43903 0.613517 -12.1788 1.1863 0.276076 
 
149 1.55485 0.696394 0 0.448 -0.36155 1.1162 -17.6987 0.47928 0.488749 
 
150 3.09577 0.697635 0.243494 0.225 -1.01002 1.84077 -19.6083 0.850901 0.356298 
 
151 1.34179 0.246417 0.243149 0.184 -0.46133 0.551795 -15.3907 1.04176 0.307412 
 
152 0.987766 0.245785 1.17126 0.249 -0.3125 0.523886 -20.2818 0.886056 0.346548 
 
153 0.711607 0 0 0 -0.29971 0.24325 -8.851 4.18568 0.040767 
 
154 0.370562 0.159988 0 0.432 -0.08869 0.216622 -10.2783 0.264431 0.607092 
 
155 3.65995 0 0 0 -1.54145 0.355974 -11.6571 9.1029 0.002552 
 
156 2.84315 0.524782 0 0.185 -0.97642 0.946239 -14.8065 1.90621 0.167385 
 
157 2.40426 1.07836 0.327761 0.449 -0.55843 1.23652 -19.0253 0.240002 0.624204 
 
158 1.70731 0 0 0 -0.71906 0.485198 -10.7293 6.88573 0.008689 
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159 0.320131 0 0 0 -0.13483 0.115551 -7.06155 2.11929 0.145454 
 
160 4.24648 0 0 0 -1.78848 0.366987 -10.8542 9.173 0.002456 
 
161 0 0 0 Undefined 0 0 0 0 1 
 
162 1.0737 0 0 0 -0.45221 0.356428 -15.0771 4.67174 0.030663 
 
163 0 0 0 Undefined 0 0 0 0 1 
 
164 3.26359 0 0 0 -1.37451 0.244891 -11.8164 6.08541 0.01363 
 
165 1.17528 0 0 0 -0.49499 0.476573 -12.3239 4.73561 0.029544 
 
166 3.58376 0.225218 0 0.063 -1.41451 0.845077 -22.4337 3.6177 0.057168 
 
167 1.18126 0 0 0 -0.49751 0.355022 -9.98051 5.77985 0.016211 
 
168 0.593699 0 0 0 -0.25005 0.231732 -9.53178 3.44395 0.063484 
 
169 0.956554 0 0 0 -0.40287 0.124445 -9.61692 3.33 0.068027 
 
170 1.26274 0.486293 0.250134 0.385 -0.32702 0.874056 -16.4595 0.589557 0.442591 
 
171 2.91666 0.163678 0 0.056 -1.15946 0.416856 -14.9637 2.93343 0.086763 
 
172 0.547527 0 0 0 -0.2306 0.125487 -7.32096 2.34505 0.125682 
 
173 0.161757 0 0 0 -0.06813 0.105502 -8.46141 0.820843 0.364934 
 
174 2.90464 0 0.326265 0 -1.22334 0.626756 -18.3097 8.22074 0.004141 
 
175 1.87645 0.372493 0.832904 0.199 -0.63342 1.14135 -21.8542 0.90599 0.341181 
 
176 0.596713 0.403016 0.274817 0.675 -0.08158 0.477265 -16.8761 0.114666 0.734893 
 
177 1.03444 0 0 0 -0.43567 0.225535 -7.7432 5.11179 0.023764 
 
178 0.274117 0.187888 0.305728 0.685 -0.03632 0.223022 -16.4038 0.058643 0.808654 
 
179 0.966871 0 0 0 -0.40721 0.124821 -6.41892 3.39867 0.065249 
 
180 0.906455 0 0 0 -0.38177 0.273745 -10.5252 4.30326 0.038039 
 
181 0.951292 0.523676 0 0.55 -0.1801 0.63165 -13.6794 0.224104 0.63593 
 
182 6.1021 0.196331 0.293611 0.032 -2.48732 1.5635 -27.4793 8.70602 0.003172 
 
183 1.86155 0 0 0 -0.78402 0.28983 -10.3107 6.5908 0.010251 
 
184 3.17925 0.469287 0 0.148 -1.14134 0.908889 -16.141 2.59488 0.107209 
 
185 0.772895 0.198974 0 0.257 -0.24172 0.425169 -13.6094 1.04549 0.306548 
 
186 2.24148 0 0 0 -0.94404 0.494787 -9.25697 8.7566 0.003085 
 
187 1.03636 0.293303 0 0.283 -0.31295 0.644751 -16.0018 1.003 0.316585 
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188 0.935258 0.585333 0.555249 0.626 -0.14738 0.74508 -19.986 0.16712 0.682684 
 
189 5.41763 0.336373 0.339983 0.062 -2.14006 1.06316 -22.0709 3.68669 0.054848 
 
190 1.18639 0.923954 0 0.779 -0.11053 1.08148 -17.5162 0.038224 0.844995 
 
191 0.441465 0.477138 0 1.081 0.015024 0.465823 -11.8338 0.003231 0.954672 
 
192 0.929921 0.389963 0.256421 0.419 -0.22741 0.50836 -15.0206 0.403514 0.52528 
 
193 5.62203 0.422972 0.944852 0.075 -2.18967 1.0552 -25.9378 3.7273 0.05353 
 
194 2.33126 0.378949 0 0.163 -0.82225 0.729251 -12.7032 2.23118 0.13525 
 
195 0.811553 0.232994 0.905496 0.287 -0.24367 0.403762 -20.6422 0.705772 0.400851 
 
196 1.85759 1.61775 0.325138 0.871 -0.10101 1.67699 -21.1725 0.011635 0.914103 
 
197 1.47575 0 0.362868 0 -0.62154 0.443414 -15.5856 5.6407 0.017548 
 
198 1.18862 0.995875 0.277407 0.838 -0.08118 1.06524 -20.7394 0.014428 0.904391 
 
199 2.85087 0.186259 0 0.065 -1.12225 0.558963 -18.3386 3.75078 0.052783 
 
200 3.25047 1.25616 0.957807 0.386 -0.83994 2.09 -26.9228 0.66932 0.413289 
 
201 6.59108 0.304697 0.525616 0.046 -2.64762 1.88221 -25.6791 4.99408 0.025434 
 
202 1.64681 0.194611 0 0.118 -0.61162 0.49393 -11.1329 2.50788 0.113278 
 
203 0.738077 0.470727 0.304811 0.638 -0.1126 0.576531 -18.0732 0.133683 0.714643 
 
204 1.23707 1.0354 0.405417 0.837 -0.08494 1.11431 -19.8925 0.024659 0.875219 
 
205 1.04478 0.165956 0 0.159 -0.37013 0.295257 -10.2622 1.30623 0.253078 
 
206 0.672877 0.532915 2.35729 0.792 -0.05895 0.565027 -21.6978 0.011799 0.913503 
 
207 1.83935 0.513006 0 0.279 -0.55861 1.0426 -21.6567 1.09336 0.295727 
 
208 1.22275 0.91427 0.983356 0.748 -0.12992 1.03668 -21.0965 0.050622 0.821984 
 
209 0.754911 0.405977 0.254456 0.538 -0.14696 0.479098 -14.4306 0.177427 0.673594 
 
210 1.51395 0.191113 0.5058 0.126 -0.55714 0.649521 -18.774 2.8876 0.089264 
 
211 5.57098 0.272501 0.34675 0.049 -2.23154 1.42952 -25.3253 5.48138 0.01922 
 
212 1.55229 0.164492 0 0.106 -0.5845 0.459346 -10.2906 2.78761 0.094996 
 
213 0.551513 1.58429 0.328072 2.873 0.434969 1.3363 -29.8046 0.538267 0.463152 
 
214 8.71523 0 0.297368 0 -3.67057 0.803395 -22.9582 13.8102 0.000202 
 
215 1.84949 0.644288 4.46594 0.348 -0.50759 0.954733 -28.3765 0.453728 0.50057 
 
216 1.60274 0.200323 0 0.125 -0.59065 0.531393 -15.731 1.93967 0.163704 
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217 0.432049 0.832656 1.991 1.927 0.168722 0.45256 -22.4677 0.06865 0.793312 
 
218 0 0.808355 1.65851 Infinite 0.340452 0.439628 -21.2783 0.846908 0.357429 
 
219 2.00464 0.939743 0 0.469 -0.4485 1.28026 -18.0303 0.595778 0.440194 
 
220 0.345669 0.216574 2.66984 0.627 -0.05437 0.223401 -24.7948 0.023205 0.878924 
 
221 3.3002 0.617633 0 0.187 -1.12981 1.14381 -14.8401 1.90055 0.168016 
 
222 2.46347 0.625325 0.310846 0.254 -0.77416 2.50601 -24.55 -0.31143 1 
 
223 2.59086 1.22109 1.23744 0.471 -0.5769 1.81137 -34.9616 0.240401 0.623917 
 
224 0.639137 0.271379 2.47081 0.425 -0.15489 0.483268 -21.0551 0.207291 0.648899 
 
225 5.32099 0.715997 0 0.135 -1.93947 1.1203 -23.7422 1.64982 0.198984 
 
226 0 0.457789 0 Infinite 0.192805 0.256708 -8.76831 2.35036 0.125254 
 
227 2.53678 0 0 0 -1.06841 0.630411 -17.2568 8.27082 0.004029 
 
228 1.4902 1.03906 0.645475 0.697 -0.19001 1.2216 -24.0727 0.11912 0.72999 
 
229 2.04929 0.623197 0.559738 0.304 -0.60063 0.739317 -20.4163 0.308615 0.578531 
 
230 2.93284 0.257155 2.66196 0.088 -1.12691 1.11224 -28.8828 2.53883 0.111077 
 
231 2.62288 3.40502 1.88336 1.298 0.329412 2.92068 -34.8395 0.034227 0.853225 
 
232 2.92E-16 0 2.44414 0 -1.23E-16 1.23E-15 -15.4429 0 1 
 
233 4.5297 2.95197 0 0.652 -0.66449 3.14737 -18.9818 0.066229 0.796909 
 
234 0.864818 0 0 0 -0.36423 0.222803 -12.8134 3.80981 0.050953 
 
235 2.21334 0.573194 0.475852 0.259 -0.69078 0.909141 -26.5865 1.28889 0.256253 
 
236 7.28081 0.372875 0.245756 0.051 -2.90939 2.14627 -19.6576 3.28734 0.069816 
 
237 2.21345 0.765281 0.30242 0.346 -0.60992 1.19016 -18.9953 1.00368 0.316421 
 
238 3.4407 0.163339 0.246165 0.047 -1.38032 0.444541 -14.2525 4.21529 0.040061 
 
239 2.20145 0.785448 0.140794 0.357 -0.59637 1.42809 -18.5337 0.236285 0.626902 
 
240 2.19827 1.45 0.395007 0.66 -0.31515 1.83021 -22.7734 0.072247 0.788092 
 
241 1.7244 0.208049 0.260759 0.121 -0.63864 0.737371 -22.7124 2.75592 0.096895 
 
242 3.30135 0.242145 0.331301 0.073 -1.28843 0.582575 -16.8985 2.8068 0.093866 
 
243 1.93333 0.689917 0 0.357 -0.52368 1.04224 -15.9575 0.947378 0.330388 
 
244 0.164077 0.425483 0.525527 2.593 0.110096 0.38906 -16.6716 0.123096 0.725701 
 
245 1.15398 0.500012 0 0.433 -0.27543 0.675308 -16.3226 0.47951 0.488645 
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246 0.803078 0.454955 0 0.567 -0.14662 0.5523 -13.1606 0.165129 0.684478 
 
247 2.48412 0.232038 3.71917 0.093 -0.9485 2.15518 -30.7335 2.27501 0.131474 
 
248 0.735331 3.29955 0.390319 4.487 1.07997 1.90992 -27.7161 0.966386 0.325583 
 
249 0 1.19387 0 Infinite 0.502819 0.70251 -15.1385 3.08655 0.078942 
 
250 2.83959 0.42879 0 0.151 -1.01535 0.965447 -20.3942 2.21116 0.137015 
 
251 2.43912 0 0 0 -1.02728 0.586412 -12.2054 10.0138 0.001554 
 
252 0.97873 0.809566 0 0.827 -0.07125 0.868928 -16.1906 0.027034 0.869401 
 
253 1.3027 0.374422 0 0.287 -0.39096 0.585558 -12.2959 1.00494 0.316119 
 
254 1.50216 0.205856 0 0.137 -0.54596 0.615834 -21.3098 2.29183 0.130057 
 
255 0.220021 0.203264 1.18818 0.924 -0.00706 0.211816 -19.0282 0.002378 0.961103 
 
256 0.980428 0.45318 0 0.462 -0.22206 0.623174 -12.2768 0.405368 0.52433 
 
257 1.15028 0.79159 0 0.688 -0.15107 0.908314 -19.1542 0.105876 0.744889 
 
258 0.59217 0.405753 0.252979 0.685 -0.07851 0.46048 -19.8976 0.079363 0.778163 
 
259 3.2086 1.02214 0.311311 0.319 -0.92087 1.42058 -21.7918 0.796249 0.372217 
 
260 4.21783 0.439667 0 0.104 -1.59124 0.965701 -17.76 3.22498 0.072523 
 
261 3.32233 0 0.583686 0 -1.39926 0.261236 -24.0212 6.32924 0.011876 
 
262 0 0.951182 0.382218 Infinite 0.400607 0.633616 -18.5674 1.96725 0.16074 
 
263 1.46163 2.08198 1.82691 1.424 0.26127 1.75174 -28.091 0.061153 0.804683 
 
264 0.94568 0.587497 0.26758 0.621 -0.15086 0.726162 -17.3816 0.107051 0.743527 
 
265 1.1455 0.307875 1.72486 0.269 -0.35278 0.592048 -20.5133 0.549531 0.458509 
 
266 6.07219 0.992725 0.388631 0.163 -2.1393 2.13914 -24.3679 1.7061 0.191492 
 
267 3.31061 0.526256 0 0.159 -1.17268 1.78634 -20.9409 2.24432 0.134106 
 
268 0.645925 0.219794 0 0.34 -0.17947 0.342278 -12.4332 0.522294 0.469865 
 
269 1.01344 0.16047 0 0.158 -0.35924 0.360518 -13.9475 1.68061 0.194844 
 
270 0.718286 0.183603 0.306887 0.256 -0.22519 0.347487 -16.9388 0.90265 0.342072 
 
271 2.72293 0 0 0 -1.14681 0.739733 -11.6819 10.0457 0.001527 
 
272 0.569422 1.37996 0 2.423 0.341373 0.921955 -19.7939 0.588021 0.443185 
 
273 0 0 0.572574 Undefined 0 0 -10.1327 1.78E-14 1 
 
274 0.887416 0 0 0 -0.37375 0.47899 -10.0291 1.85663 0.173014 
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275 0.237549 0.198024 0.264128 0.834 -0.01665 0.216766 -12.6913 0.014517 0.904097 
 
276 1.59536 0.775677 0 0.486 -0.34523 0.82247 -10.8685 0.072411 0.787859 
 
277 2.17935 0.193383 0 0.089 -0.83642 0.73958 -17.988 2.70418 0.100086 
 
278 1.50375 0.827842 0 0.551 -0.28467 1.07794 -18.3624 0.312369 0.57623 
 
279 0.986777 0.4414 0 0.447 -0.2297 0.639794 -15.6501 0.31791 0.572866 
 
280 0.717548 0 0.291355 0 -0.30221 0.232351 -13.4119 4.60074 0.031958 
 
281 1.18099 0.421781 0.683637 0.357 -0.31976 0.499136 -19.1531 0.233338 0.629059 
 
282 1.06003 0.238536 0.259052 0.225 -0.34599 0.692179 -17.3772 0.977408 0.322839 
 
283 1.31092 0 0.53267 0 -0.55212 0.115811 -12.6845 3.517 0.060742 
 
284 1.31E-15 0 0 0 -5.50E-16 5.55E-17 -3.76561 0 1 
 
285 2.47E-15 0 0 0 -1.04E-15 5.55E-17 -4.03126 0 1 
 
286 11.2046 0 0 0 -4.71901 3.02303 -4.76552 2.24738 0.133841 
 
287 0 0 0 Undefined 0 5.55E-17 -4.30138 0 1 
 








290 0 0 0 Undefined 0 0 -4.32392 0 1 
 
291 0 0 0 Undefined 0 5.55E-17 -4.07853 0 1 
 
292 2.97908 0.338588 0.534271 0.114 -1.11209 1.0982 -21.4293 2.95018 0.085868 
 
293 1.2008 2.44063 0 2.033 0.522174 1.84037 -18.8682 0.282907 0.594802 
 
294 2.14187 0.786889 0.382461 0.367 -0.57068 1.19835 -20.5237 0.772362 0.379487 
 
295 2.93685 0 0 0 -1.2369 0.465265 -12.7263 7.37996 0.006595 
 
296 2.28301 0 0 0 -0.96153 0.352759 -7.23809 7.86929 0.005028 
 
297 0 0.48534 0 Infinite 0.204409 0.391951 -9.08075 0.903313 0.341895 
 
298 0.48768 0.27238 0 0.559 -0.09068 0.359436 -11.352 0.141608 0.706688 
 
299 0.34667 0.344767 0.243702 0.995 -0.0008 0.345288 -18.7193 1.38E-05 0.997032 
 
300 10.9356 1.31133 0 0.12 -4.05343 1.86981 -23.101 1.8825 0.170051 
 
301 0.777078 0.396932 0 0.511 -0.16011 0.465129 -12.4559 0.193906 0.659686 
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302 0 0 0.594935 Undefined 0 0 -9.7991 0 1 
 
303 1.46248 0.619755 0 0.424 -0.35493 0.761256 -13.9222 0.297503 0.585452 
 
304 2.42E-15 0.349403 0 1.44E+14 0.147157 0.304805 -8.90933 0.378737 0.53828 
 
305 3.2895 0.431503 0 0.131 -1.20369 0.791858 -13.8177 2.21952 0.136276 
 
306 0.266907 0.412947 0.358556 1.547 0.061507 0.345769 -16.9292 0.085904 0.76945 
 
307 2.54514 0.323211 0 0.127 -0.9358 1.10919 -23.584 1.67778 0.19522 
 
308 0.512653 0.195433 0.543414 0.381 -0.1336 0.306806 -16.1243 0.328382 0.566614 
 
309 0 0.176435 1.17222 Infinite 0.074309 0.148055 -22.6503 0.32537 0.568398 
 
310 0.771857 1.18122 0 1.53 0.17241 1.01953 -17.079 0.116693 0.732649 
 
311 0.933287 0.925982 1.36081 0.992 -0.00308 0.929758 -25.5071 2.16E-05 0.996288 Pos 
312 0 1.48693 0 Infinite 0.626247 1.17556 -15.5971 3.09655 0.078459 
 
313 0 0.563001 0 Infinite 0.237118 0.345058 -9.52306 2.02929 0.154293 
 
314 0.442661 0.456173 0.580618 1.031 0.005691 0.451449 -16.3306 0.000428 0.98349 
 
315 0.621044 0.193853 0 0.312 -0.17992 0.376726 -12.9883 0.791301 0.373707 
 
316 0.328693 0.185845 0.592672 0.565 -0.06016 0.244205 -16.2108 0.14562 0.702757 
 
317 0 0.348566 0.246736 Infinite 0.146805 0.207795 -13.2043 1.99903 0.1574 
 
318 0.391808 0 1.835 0 -0.16502 0.133952 -16.4701 2.35258 0.125076 Pos 
319 0.16634 3.02182 0.524803 18.167 1.20263 0.588672 -23.0085 3.36597 0.066556 
 
320 0.259473 0.575474 0 2.218 0.133089 0.410582 -14.3563 0.376051 0.539724 
 
321 0.785285 0.226371 0.329937 0.288 -0.2354 0.434336 -17.7614 0.819706 0.365266 
 
322 0 0.473756 1.91799 Infinite 0.19953 0.295166 -19.5566 1.47493 0.22457 Pos 
323 3.43E-16 4.14384 2.09585 1.21E+16 1.74525 1.47697 -29.6479 3.4007 0.065169 
 
324 3.98E-16 2.61279 3.07678 6.56E+15 1.10042 2.42584 -28.3749 2.1252 0.144894 
 
325 0.605748 0.202878 1.27371 0.335 -0.16968 0.321403 -18.9107 0.4428 0.505774 Pos 
326 0 1.69794 1.32749 Infinite 0.715118 0.933429 -24.0038 2.99895 0.083319 Pos 
327 2.63E-16 3.0526 1.5913 1.16E+16 1.28565 0.976248 -24.7759 5.53727 0.018616 
 
328 2.13025 0.734714 1.68808 0.345 -0.58775 1.12337 -22.4328 0.585948 0.44399 
 
329 0.761103 2.56246 0 3.367 0.758673 1.82067 -18.6108 0.8502 0.356496 
 
330 0.350716 0.557468 0.747285 1.59 0.087077 0.466349 -17.0411 0.112105 0.737761 
 
Chapter 8 Filovirus Data Ebola Selection analysis 
331 1.57109 0.175035 1.18808 0.111 -0.58797 0.377962 -19.5001 1.42863 0.231988 
 
332 0 0.871992 0.558941 Infinite 0.367254 0.430595 -16.8835 1.32998 0.248809 
 
333 0.259082 0.195471 1.20335 0.754 -0.02679 0.225899 -16.9251 0.033048 0.855747 
 
334 0.293761 5.34377 0.616812 18.191 2.1269 0.87679 -22.592 1.42131 0.233188 
 
335 0.292658 0.430943 0 1.473 0.058241 0.372987 -13.3056 0.082778 0.773567 
 
336 2.23534 0 1.97844 0 -0.94145 1.10711 -25.9528 6.22215 0.012616 
 
337 1.00E-06 0.981029 1.83361 981029 0.413177 0.925036 -22.1334 0.395142 0.529609 
 
338 3.377 2.25975 0 0.669 -0.47055 2.48923 -21.5545 0.07737 0.780894 
 
339 0.587474 1.09349 2.15905 1.861 0.213115 0.666064 -22.349 0.024811 0.874839 
 
340 2.54528 8.95307 0.445449 3.518 2.69875 5.85236 -35.2925 0.907876 0.340679 
 
341 0.245009 0 1.26281 0 -0.10319 0.098311 -18.4151 1.73899 0.187266 
 
342 0 0.666877 0.43372 Infinite 0.280866 0.428325 -21.1137 2.13003 0.144438 
 
343 1.81394 2.11488 0.581284 1.166 0.126748 1.98982 -25.5045 0.017054 0.896101 
 
344 3.53762 0.669536 0.635937 0.189 -1.20794 1.56627 -24.9916 1.32462 0.249765 Pos 
345 0.226956 4.75712 0.455837 20.961 1.90795 2.53777 -25.5229 3.39622 0.065346 
 
346 1.70865 0.852803 2.87367 0.499 -0.36045 1.18917 -30.5634 0.181382 0.670188 
 
347 4.77164 0.163304 0.248828 0.034 -1.94088 0.253883 -18.0141 1.57353 0.209696 
 
348 0.871 0.551874 0.442693 0.634 -0.13441 0.639357 -17.888 0.089681 0.764584 
 
349 1.65824 2.158 0 1.301 0.210482 1.93936 -20.3472 0.0502 0.822716 
 
350 2.11E-15 1.45139 0.272302 6.89E+14 0.611279 0.81574 -18.1255 2.08942 0.148322 
 
351 0.534111 1.00324 0 1.878 0.197581 0.747557 -19.9589 0.32372 0.569381 
 
352 0.650027 0.902212 0 1.388 0.106212 0.791238 -18.5435 0.075854 0.782997 
 
353 3.39E-16 1.83703 0 5.43E+15 0.773696 0.502111 -15.4256 1.66523 0.196899 
 
354 0.499529 0.54835 1.06618 1.098 0.020562 0.530847 -22.3544 0.003837 0.950608 
 
355 0.266639 0.887716 0.274217 3.329 0.261577 0.589228 -19.9081 0.900995 0.342515 
 
356 0 0 0.570864 Undefined 0 0 -12.6058 0 1 
 
357 0.230196 0.494956 0.236116 2.15 0.111508 0.344126 -16.3552 0.292889 0.588375 
 
358 0.440739 0.882205 1.91716 2.002 0.185931 0.646319 -21.5391 0.19333 0.66016 
 
359 0.461204 0.433219 0.367867 0.939 -0.01179 0.445224 -15.0673 0.000583 0.980737 
 
Chapter 8 Filovirus Data Ebola Selection analysis 
360 0.267787 0.409645 0 1.53 0.059746 0.350041 -12.291 0.105426 0.745413 Pos 
361 0 1.5954 0 Infinite 0.671931 0.750157 -16.0478 5.84202 0.015648 
 
362 0.158359 0.315956 0.329294 1.995 0.066374 0.26188 -14.5707 0.057547 0.810416 
 
363 5.18566 0.45196 0.676529 0.087 -1.99368 1.08742 -28.6126 3.18148 0.074477 
 
364 2.8098 2.53099 1.00656 0.901 -0.11742 2.65977 -26.5555 0.008959 0.92459 
 
365 0.43777 1.16997 0.804918 2.673 0.308378 0.724127 -20.8118 0.432043 0.510988 
 
366 0.602872 0.657189 1.05389 1.09 0.022876 0.640954 -19.7056 0.003448 0.953177 
 
367 0 0 0 Undefined 0 0 -3.69669 0 1 
 
368 0.431472 0.931756 0.353773 2.159 0.210703 0.692691 -17.9095 0.219328 0.639552 
 
369 1.39199 0.189451 0.841506 0.136 -0.50647 0.524977 -22.1146 1.26159 0.26135 
 
370 1.4 3.74876 1.2747 2.678 0.989221 2.18016 -25.7954 0.539243 0.462747 
 
371 0 0.744422 0.829452 Infinite 0.313526 0.386789 -15.5373 1.95532 0.162014 
 
372 0 1.00571 0.444074 Infinite 0.42357 0.527954 -19.7322 1.30645 0.253038 
 
373 0 1.30978 0.403484 Infinite 0.551638 0.609881 -16.4991 2.43774 0.118447 
 
374 0.757222 0.594306 0.440768 0.785 -0.06862 0.696012 -20.6172 0.029171 0.864384 
 








377 1.21624 0 0.559793 0 -0.51224 0.44827 -18.779 5.67696 0.017189 
 
378 2.35128 0.90131 0.635036 0.383 -0.61068 1.76058 -26.5141 0.347239 0.55568 
 
379 0.463629 0.222752 3.27262 0.48 -0.10145 0.320158 -24.677 0.166718 0.683045 
 
380 0.285817 0.22511 4.94653 0.788 -0.02557 0.252078 -34.5971 0.021596 0.883166 
 
381 0.579938 1.33692 0 2.305 0.318815 1.092 -16.5576 0.441338 0.506478 
 
382 3.47E-15 0.461023 1.29724 1.33E+14 0.194168 0.354788 -18.2085 0.652423 0.419248 
 
383 0 1.09607 2.47147 Infinite 0.46163 0.434196 -26.6412 1.83287 0.175789 
 
384 0.408054 0.318247 0.785497 0.78 -0.03782 0.360133 -20.7605 0.01952 0.888886 
 
385 1.59129 0 1.6752 0 -0.6702 0.835991 -18.7606 5.59599 0.018002 
 




Chapter 8 Filovirus Data Ebola Selection analysis 
387 0.35581 0.23107 1.10943 0.649 -0.05254 0.282664 -18.0435 0.058202 0.809362 
 
388 4.59697 5.79851 0.472934 1.261 0.506048 5.30271 -35.871 0.048474 0.82574 
 
389 1.17187 5.24252 0 4.474 1.71442 4.03345 -25.9628 1.13326 0.287081 
 
390 2.49596 1.02201 0.266126 0.409 -0.62078 1.71249 -31.1434 0.596981 0.439732 
 
391 5.71649 2.53373 1.84957 0.443 -1.34047 3.8779 -34.9838 0.451544 0.501603 
 
392 0 1.00201 0.616134 Infinite 0.422013 0.456909 -21.8431 2.61723 0.105709 
 
393 3.46879 0.194239 0.285561 0.056 -1.37913 2.83187 -21.7539 1.69881 0.192443 
 
394 2.09711 0.66453 0.841688 0.317 -0.60335 0.777185 -20.3589 0.157117 0.691825 
 
395 1.37392 0.205567 0.367494 0.15 -0.49207 0.79222 -19.0974 1.46477 0.226173 
 
396 1.96081 0.29848 0.818882 0.152 -0.70012 0.684952 -16.2738 1.21074 0.271186 
 
397 0.362815 4.31967 0.594828 11.906 1.6665 1.18763 -25.3674 1.10761 0.292603 
 
398 3.2964 0.216499 2.45521 0.066 -1.29715 1.29915 -22.6409 2.53316 0.111476 
 
399 0.582125 2.05603 0 3.532 0.620759 1.6887 -18.3016 0.720272 0.396055 
 
400 0.302272 0.195763 0 0.648 -0.04486 0.236169 -12.7607 0.070792 0.790187 
 
401 3.02844 0.297214 2.08393 0.098 -1.1503 0.623786 -33.9324 0.638179 0.424371 
 
402 6.83645 2.02306 6.55464 0.296 -2.02724 3.56625 -47.6439 0.911061 0.339833 
 
403 0.65167 0.816018 1.1838 1.252 0.069218 0.762593 -17.6876 0.014107 0.905457 
 
404 1.05876 0 1.06485 0 -0.44592 0.65057 -11.6856 0.872039 0.350391 
 
405 1.48609 0 1.27457 0 -0.62589 0.858548 -23.5164 4.1121 0.042578 
 
406 3.70392 0.901246 2.07331 0.243 -1.18039 2.08261 -26.2423 1.17789 0.277786 
 
407 1.11328 1.48629 4.22554 1.335 0.157099 1.31445 -22.3845 0.027862 0.867434 
 
408 0.30445 0.293874 1.35533 0.965 -0.00445 0.297096 -22.0444 0.000152 0.990168 
 
409 1.1465 0 2.45044 0 -0.48287 0.227549 -17.2206 3.98527 0.0459 
 
410 0.175385 1.36364 0.576433 7.775 0.500453 0.861053 -20.3381 0.71442 0.397981 
 
411 8.26099 0.813903 0.616273 0.099 -3.13647 2.46549 -38.832 4.45581 0.034783 
 
412 1.06783 0.267429 0.687398 0.25 -0.3371 0.673938 -19.7521 1.20217 0.272889 
 
413 0.229055 3.27517 0.560015 14.299 1.28292 0.19919 -22.5607 -0.16462 1 
 
414 1.12677 0.691547 4.75149 0.614 -0.1833 0.872637 -30.5515 0.098811 0.753262 
 
415 2.65605 1.09612 2.97168 0.413 -0.65699 2.27663 -29.6844 0.137292 0.710988 
 
Chapter 8 Filovirus Data Ebola Selection analysis 
416 0.239037 0.635494 0.345064 2.659 0.166975 0.415205 -16.2235 0.292903 0.588366 
 
417 0.885754 0.581577 3.92026 0.657 -0.12811 0.710061 -21.9996 0.061189 0.804627 
 
418 1.00E-06 1.61594 5.02807 1615940 0.68058 0.617982 -29.2208 1.25297 0.262986 
 
419 2.19355 0.192767 1.23791 0.088 -0.84266 0.543466 -19.1796 2.66079 0.10285 
 
420 1.05385 0.55199 2.28276 0.524 -0.21137 0.695751 -19.4519 0.145383 0.702987 
 
421 0.468423 0.731447 0.1251 1.562 0.110777 0.635756 -18.9985 0.057491 0.810506 
 
422 2.61749 0.519338 1.01897 0.198 -0.88367 1.33767 -20.2282 1.32701 0.249339 
 
423 3.28847 0.588059 3.15157 0.179 -1.13732 1.20587 -26.2017 0.983698 0.321287 
 
424 0.929995 1.41292 0.369528 1.519 0.203391 1.12084 -25.4504 0.116237 0.733152 
 
425 0.613651 0.418942 0.562535 0.683 -0.082 0.469584 -18.1712 0.060372 0.805909 
 
426 1.77E-16 0.236702 2.21796 1.33E+15 0.099691 0.112085 -19.9298 1.04821 0.30592 
 
427 0.448077 2.23222 0.628111 4.982 0.751423 1.75552 -28.2703 1.23463 0.266508 
 
428 1.85341 0.248296 0.586351 0.134 -0.67602 1.34456 -21.5802 1.26825 0.260095 
 
429 0.584571 0 1.16779 0 -0.2462 0.236553 -18.1299 3.50131 0.06132 
 
430 4.02372 0.579768 0 0.144 -1.45048 1.42497 -19.8871 1.49175 0.221945 Pos 
431 0 3.31558 0.413349 Infinite 1.39641 1.00282 -20.9828 5.94625 0.014749 
 
432 1.30937 0.798234 2.0552 0.61 -0.21527 0.905175 -27.8916 0.069542 0.792005 
 
433 1.2755 0.23324 1.44219 0.183 -0.43896 0.830985 -25.8437 1.05118 0.305236 
 
434 2.39081 0.416005 0.422765 0.174 -0.83172 1.14976 -26.6512 1.16692 0.280035 
 
435 7.44042 2.42041 1.82247 0.325 -2.11426 4.59876 -46.6897 1.0258 0.311148 
 
436 1.1281 0.585377 1.25602 0.519 -0.22858 0.854114 -21.9836 0.229962 0.631552 
 
437 1.7382 0.905235 2.56391 0.521 -0.35082 1.30852 -29.6126 0.265853 0.606127 
 
438 0.211745 0.464518 0.305342 2.194 0.106459 0.33072 -15.6154 0.343698 0.557703 
 
439 1.30764 1.34206 2.15106 1.026 0.014497 1.32364 -25.7061 0.000211 0.988422 
 
440 2.36294 0.197086 1.22502 0.083 -0.91218 1.36003 -22.6877 3.49301 0.061628 
 




442 0.999959 0.818197 0.814952 0.818 -0.07655 1.00786 -3.8776 6.22E-15 1 
 
443 0.926157 1.08152 0.99921 1.168 0.065434 1.07719 -4.2486 0 1 
 
Chapter 8 Filovirus Data Ebola Selection analysis 
444 1.02058 1.02084 0.809803 1 0.000108 1.02236 -4.10771 3.55E-15 1 
 
445 0.926417 0.999236 1.05985 1.079 0.030669 1 -4.32392 3.55E-15 1 
 
446 1.04237 1.01755 0.831726 0.976 -0.01045 1.04527 -4.03126 1.78E-15 1 
 




448 1.06572 0.260599 2.86701 0.245 -0.33909 0.496042 -21.2952 0.526134 0.468237 
 
449 1.31604 0.165801 0.255545 0.126 -0.48444 0.547922 -21.9562 2.67928 0.101662 
 
450 3.01063 8.05053 7.95314 2.674 2.12264 5.22793 -52.6629 0.577397 0.447334 
 
451 0 1.05982 0.305036 Infinite 0.446362 0.650789 -18.2688 1.35087 0.245126 
 
452 0.579443 0.226104 2.54744 0.39 -0.14882 0.378473 -21.1683 0.259624 0.610379 
 
453 1.64926 1.87133 0.809 1.135 0.093528 1.72458 -24.1524 0.007754 0.929831 
 
454 0 0 1.78286 Undefined 0 0 -16.7501 1.42E-14 1 
 
455 1.92E-15 4.4501 2.43798 2.32E+15 1.87424 2.40819 -28.7176 2.2799 0.13106 
 
456 0.926041 0.18845 0.304291 0.204 -0.31065 0.38322 -20.6016 0.996592 0.318137 
 
457 3.67202 0 0.683609 0 -1.54653 1.04905 -21.8684 9.19055 0.002433 
 
458 9.72778 0.703345 2.13906 0.072 -3.80079 3.85147 -31.6806 3.08241 0.079143 
 
459 5.84E-16 0 0 0 -2.46E-16 0 -4.17027 0 1 
 
460 0 0 0 Undefined 0 5.55E-17 -4.36394 0 1 
 
461 4.91E-16 5.55303 0 1.13E+16 2.33875 3.05568 -5.9393 1.0762 0.29955 
 
462 1.18E-15 0 0 0 -4.98E-16 5.55E-17 -4.31116 0 1 
 




464 8.80603 0 0 0 -3.70881 3.09421 -5.72786 1.91189 0.166754 
 
465 0 5.74168 0 Infinite 2.41821 3.2459 -6.43537 1.03208 0.309671 
 
466 1.19E-15 0 0 0 -5.02E-16 0 -3.61736 0 1 
 
467 0 0 0 Undefined 0 0 -4.4792 0 1 
 




469 0 0 0 Undefined 0 0 -3.81503 0 1 
 
470 0 0 0 Undefined 0 5.55E-17 -4.30138 0 1 
 
Chapter 8 Filovirus Data Ebola Selection analysis 
471 0.921587 5.55E-17 0 0 -0.38814 0 -4.95231 1.78E-15 1 
 
472 0.893329 0.217963 2.52905 0.244 -0.28444 0.300274 -26.6454 0.448162 0.503209 
 
473 0.465307 2.69802 0 5.798 0.940346 2.61188 -27.3058 1.0159 0.313494 
 
474 2.86721 2.10405 1.04402 0.734 -0.32142 2.51819 -31.7129 0.067255 0.795377 
 
475 3.24983 2.19728 0 0.676 -0.4433 2.25878 -25.0408 0.052247 0.819198 
 
476 1.08589 2.97835 1.11983 2.743 0.797042 1.98885 -32.1537 0.318857 0.572296 
 
477 1.57638 0.220588 2.20189 0.14 -0.57101 0.906147 -26.1985 1.5717 0.20996 
 
478 0.772378 1.20067 2.06652 1.555 0.180384 1.04144 -23.3263 0.077191 0.781141 
 
479 1.05204 0.991329 0.918454 0.942 -0.02557 1.01876 -25.19 0.00216 0.962931 
 
480 2.01475 0.611418 0.774426 0.303 -0.59104 1.15802 -23.2079 1.0397 0.307892 
 
481 2.2318 0.912926 0 0.409 -0.55547 1.23211 -18.1403 0.645778 0.421626 
 
482 3.3128 0.592875 0.797852 0.179 -1.14554 1.3661 -25.6819 2.40106 0.121253 
 
483 0 0.541899 1.55202 Infinite 0.22823 0.298753 -18.5066 2.09201 0.148071 
 
484 4.16561 0.575763 0.912226 0.138 -1.51193 1.60882 -29.4432 1.08917 0.296654 
 
485 0.644285 0.559957 0 0.869 -0.03552 0.60514 -7.79568 0.004221 0.948201 
 
486 0 1.19025 0 Infinite 0.501295 7.15E-16 -7.4243 1.03756 0.308389 
 
487 1.08437 0 0.255141 0 -0.4567 0.246971 -14.0844 5.31094 0.021192 
 
488 1.5581 2.74736 1.46516 1.763 0.500875 2.24149 -26.5531 0.141405 0.706888 
 
489 1.25433 0.846137 0.285631 0.675 -0.17192 0.98364 -18.6895 0.092646 0.76084 
 
490 1.54411 3.60128 0.598309 2.332 0.866411 2.76808 -32.1043 0.495832 0.481337 
 
491 1.12608 0.455881 1.43155 0.405 -0.28227 0.688471 -20.7193 0.407287 0.52335 
 
492 1.97741 1.80385 0.398485 0.912 -0.0731 1.8846 -22.9097 0.00536 0.941636 
 
493 2.18655 0.857441 1.70282 0.392 -0.55978 1.54252 -25.2854 0.338179 0.560882 
 
494 1.07966 0.403258 1.70785 0.374 -0.28488 0.827324 -21.446 0.285225 0.593297 
 
495 1.26264 2.01277 0.369703 1.594 0.31593 1.66847 -22.5453 0.162624 0.686752 
 
496 0.291168 0.337071 1.47024 1.158 0.019333 0.314965 -19.2917 0.003679 0.951632 
 
497 1.81522 0.168216 0.652239 0.093 -0.69366 0.339087 -25.7712 2.01362 0.155893 
 
498 4.14944 0.321264 1.21696 0.077 -1.6123 1.37694 -23.2887 2.06299 0.150914 
 
499 1.63205 0.181293 0.32076 0.111 -0.61101 0.537731 -17.6654 2.85197 0.091262 
 
Chapter 8 Filovirus Data Ebola Selection analysis 
500 2.60E-15 2.29776 0.385368 8.85E+14 0.967742 1.30928 -20.7453 1.41269 0.23461 
 
501 0.900583 0.345279 2.67518 0.383 -0.23388 0.66124 -22.8069 0.249646 0.617325 
 
502 1.00E-06 0.242629 2.40156 242629 0.102187 0.227695 -21.31 0.130732 0.717675 
 
503 2.74582 0.923394 0.777961 0.336 -0.76754 1.33464 -24.5089 0.777632 0.377866 
 
504 0.476309 0.245764 0.295804 0.516 -0.0971 0.366829 -16.8505 0.253409 0.614685 
 
505 1.28316 0.270995 3.09557 0.211 -0.42629 0.542164 -21.9081 0.633085 0.426226 
 
506 1.25664 1.13725 1.1294 0.905 -0.05028 1.17122 -14.2122 0.002042 0.96396 
 
507 1.08685 0.294143 2.38168 0.271 -0.33386 5.43E-16 -12.3611 -0.20963 1 
 
508 1.01975 1.73412 0 1.701 0.300869 1.45342 -9.08161 0.06902 0.792769 
 
509 7.52721 0.308145 0 0.041 -3.04043 2.90333 -9.68203 2.86821 0.090345 
 
510 39.4176 18.9498 18.3192 0.481 -8.62036 40.6587 -14.407 0.010231 0.919433 
 
511 0.747126 1.46679 0 1.963 0.303098 1.21707 -8.72387 0.114855 0.734683 
 
512 0 0 2.3077 Undefined 0 0 -16.6843 0 1 
 
513 0.660146 0.197349 2.6185 0.299 -0.19492 0.214622 -32.7992 0.12357 0.725194 
 
514 1.64875 1.5882 1.13848 0.963 -0.0255 1.61445 -22.9156 0.000801 0.977417 
 
515 0.384689 0.833994 2.7892 2.168 0.189233 0.587864 -25.7768 0.291064 0.589539 
 
516 3.72588 1.94596 0.701089 0.522 -0.74964 2.69701 -26.6771 0.230095 0.631453 
 
517 1.21416 1.11613 1.87382 0.919 -0.04129 1.15362 -23.754 0.003487 0.952913 
 
518 1.19935 2.25226 1.66197 1.878 0.443449 1.63662 -21.1077 0.171009 0.679217 
 
519 0 0.218369 0.875111 Infinite 0.09197 0.16213 -13.2466 0.446978 0.503774 
 
520 1.20234 0.313543 1.53339 0.261 -0.37433 0.852991 -25.2788 0.567613 0.451209 
 
521 1.59856 0.206349 0 0.129 -0.58635 0.631723 -12.9078 2.80245 0.094121 
 
522 5.76186 0 0.688899 0 -2.4267 0.841347 -29.1615 9.60991 0.001935 
 
523 2.49966 0.184904 0.594733 0.074 -0.9749 0.805166 -22.4114 3.96327 0.046503 
 
524 1.12139 0.525353 0.628948 0.468 -0.25103 0.738999 -24.6458 0.379039 0.538118 
 
525 3.52135 0.56536 0.760204 0.161 -1.24497 1.25393 -22.036 2.52439 0.112098 
 
526 1.41585 0.572598 0.265915 0.404 -0.35515 0.859764 -24.5858 0.653602 0.418828 
 
527 1.13613 0.372138 1.84719 0.328 -0.32177 0.917178 -27.2302 0.134967 0.713337 
 
528 6.45E-16 0.648503 4.36187 1E+15 0.273128 1.20874 -22.3452 1.13634 0.286427 
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529 1.65726 0.917972 0.871611 0.554 -0.31136 1.20247 -22.7918 0.242125 0.622675 
 
530 3.17346 0.503382 0.734976 0.159 -1.12455 1.94777 -24.2881 2.01534 0.155717 
 
531 0.452716 0.807014 0.919546 1.783 0.149219 0.744924 -22.4126 0.082152 0.774403 
 
532 3.97568 0.121405 2.2402 0.031 -1.62329 1.39634 -29.715 4.35574 0.036884 
 
533 0.846698 0.968473 1.85977 1.144 0.051288 0.919693 -22.5104 0.009809 0.921107 
 
534 1.43336 1.35994 0 0.949 -0.03092 1.38949 -25.2882 0.001905 0.965183 
 
535 0 1.33454 0.782691 Infinite 0.562064 0.350477 -19.3127 0.805542 0.369441 
 
536 0.251659 1.35835 0.43698 5.398 0.466104 0.686215 -20.4596 1.68744 0.193938 
 
537 1.43066 1.57928 2.63873 1.104 0.062595 1.50075 -24.8725 0.005313 0.941892 
 
538 1.17328 0.201512 0.275471 0.172 -0.40928 0.413231 -19.8648 1.60536 0.205146 
 
539 4.34662 0.427168 0.30803 0.098 -1.65074 1.13244 -20.567 4.86391 0.027424 
 
540 0.923874 1.06462 1.24822 1.152 0.059279 0.950922 -26.4458 0.004302 0.947704 
 
541 2.07626 0.489366 0.33413 0.236 -0.66835 1.03501 -21.843 1.54977 0.21317 
 
542 2.83347 0.415617 0 0.147 -1.01832 0.923957 -15.4572 3.06353 0.080068 
 
543 1.31012 0.204939 1.27335 0.156 -0.46547 0.437434 -20.1449 1.30329 0.253614 
 
544 1.36346 1.00574 0.66322 0.738 -0.15066 1.24319 -22.3202 0.033159 0.855507 
 
545 1.70262 0.710541 1.77797 0.417 -0.41783 1.34607 -17.2763 0.14072 0.707566 
 
546 1.58929 0.486222 3.20632 0.306 -0.46458 1.4397 -18.4472 0.066231 0.796906 
 
547 1.44437 0 1.37056 0 -0.60832 0.789665 -15.6141 0.657806 0.417336 
 
548 1.34129 0.145314 0.543442 0.108 -0.50371 0.803432 -13.6328 0.734397 0.391462 
 
549 2.69602 1.24825 0.499463 0.463 -0.60975 1.73735 -16.4641 0.289575 0.590493 
 
550 0.642885 1.63401 1.24727 2.542 0.41743 0.836981 -16.6668 0.32286 0.569894 
 
551 0 0 0 Undefined 0 0 -3.61736 0 1 
 
552 1.02549 0 0 0 -0.4319 0.250433 -7.82372 4.67818 0.030548 
 
553 0.922862 0.160891 0 0.174 -0.32092 0.362339 -9.4168 1.65522 0.19825 
 
554 4.32115 0.233886 0 0.054 -1.72142 0.78542 -19.3113 4.5709 0.03252 
 
555 3.95817 0.38059 0.24915 0.096 -1.50676 0.973746 -18.4138 3.97566 0.046162 
 
556 3.27299 0 0 0 -1.37847 0.641155 -16.3939 8.76353 0.003073 
 
557 4.70817 0.210266 0.233992 0.045 -1.89437 0.909186 -17.6093 4.11962 0.042389 
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558 3.1126 0.658139 0 0.211 -1.03374 1.11426 -19.5264 1.82688 0.176496 
 
559 0 0 0 Undefined 0 0 0 0 1 
 
560 1.89866 0.251552 0 0.132 -0.69371 0.734422 -13.9953 2.45528 0.11713 
 
561 1.03941 0.474041 0 0.456 -0.23811 0.653167 -15.3188 0.407609 0.523186 
 
562 2.96264 0 0.839773 0 -1.24777 0.333747 -16.7642 7.59311 0.005859 
 
563 0 0.177179 0.257015 Infinite 0.074622 0.148477 -12.4897 0.343615 0.55775 
 
564 4.67719 0.178308 0.288889 0.038 -1.89478 0.55695 -15.6833 5.32682 0.021 
 
565 2.26816 0.221013 0.798135 0.097 -0.86219 0.621316 -19.7961 2.5474 0.110476 
 
566 0.963317 0.580746 0.674551 0.603 -0.16113 0.717322 -19.6942 0.157583 0.691391 
 
567 1.44489 0 0 0 -0.60854 0.249362 -10.0656 5.1404 0.023375 
 
568 1.53407 0.471794 0.418583 0.308 -0.4474 0.913903 -18.0865 1.12866 0.288062 
 
569 1.3829 0 0 0 -0.58243 0.415831 -10.9419 5.79047 0.016113 
 
570 2.99799 0 0.386906 0 -1.26265 0.773112 -21.105 8.44345 0.003664 
 
571 0.514525 0.51873 0 1.008 0.001771 0.516827 -13.3144 5.22E-05 0.994237 
 
572 0 0 0 Undefined 0 0 0 0 1 
 
573 1.60775 0 0 0 -0.67713 0.267407 -8.69431 6.44385 0.011134 
 
574 2.91619 0 0 0 -1.2282 0.480765 -12.7395 9.60897 0.001936 
 
575 1.49144 0.238617 0 0.16 -0.52765 0.534853 -11.4951 1.84255 0.174652 
 
576 0.923237 0 0 0 -0.38884 0.221171 -7.5146 4.98898 0.025509 
 
577 0.799584 0 0 0 -0.33676 0.269724 -9.44576 4.07411 0.043545 
 
578 1.90448 0 0.24243 0 -0.8021 0.439146 -20.8979 8.52431 0.003504 
 
579 0.277403 0.278156 0.387533 1.003 0.000317 0.277815 -16.416 3.23E-06 0.998567 
 
580 0.596587 0.403854 0 0.677 -0.08117 0.480754 -12.5475 0.111664 0.738258 
 
581 13.2907 0 0 0 -5.59761 0.520021 -15.3475 15.3302 9.03E-05 
 
582 0.500913 0 0 0 -0.21097 0.15814 -9.18816 2.48832 0.114694 
 
583 2.29402 0.195249 0 0.085 -0.88393 0.661041 -18.4803 3.71171 0.054032 
 
584 1.09449 0 0 0 -0.46097 0.266844 -7.53992 4.64473 0.031149 
 
585 4.64328 0 15.0942 0 -1.95559 2.40059 -58.0249 7.50602 0.006149 
 
586 7.32151 0.212093 0.255264 0.029 -2.99425 1.13096 -26.3232 6.68411 0.009728 
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587 1.27579 0 0 0 -0.53732 0.285573 -10.7572 4.93294 0.026349 
 
588 1.04268 0 0.799312 0 -0.43914 0.413317 -22.5793 4.3255 0.037545 
 
589 1.2997 0.146893 0 0.113 -0.48552 0.144992 -8.1665 0.248962 0.617807 
 
590 0.790021 0.342057 0 0.433 -0.18867 0.406599 -11.4837 0.281408 0.59578 
 
591 6.89248 0 0 0 -2.90288 0.810583 -10.503 14.4226 0.000146 
 
592 1.35631 0 0 0 -0.57123 0.12977 -6.99099 3.54321 0.05979 
 
593 0.330378 0.170783 0.605724 0.517 -0.06722 0.229394 -26.8262 0.173034 0.67743 
 
594 2.18042 0.471627 0.376272 0.216 -0.71969 0.904004 -18.9368 1.81719 0.177648 
 
595 1.79669 0 0 0 -0.75671 0.650971 -13.1599 6.97602 0.008261 
 
596 1.52082 0.188792 0.27572 0.124 -0.56101 0.598733 -20.4083 2.90443 0.088336 
 
597 1.57326 0 0 0 -0.66261 0.290545 -8.10275 6.00046 0.014302 
 
598 0.624445 0.202185 0 0.324 -0.17784 0.366463 -15.3425 0.781404 0.376712 
 
599 1.44413 0 0 0 -0.60822 0.539174 -13.0137 6.06576 0.013783 
 
600 4.10896 0 0 0 -1.73056 0.760868 -16.6951 10.9998 0.000911 
 
601 1.13737 0.248302 0 0.218 -0.37445 0.469682 -11.8168 1.13591 0.286519 
 
602 0.548659 0 0 0 -0.23108 0.213262 -11.9226 2.88379 0.089475 
 
603 0.875567 0 0.273909 0 -0.36876 0.223612 -18.5709 4.13685 0.041959 
 
604 3.71115 0 0 0 -1.56301 0.23916 -10.4599 6.91491 0.008548 
 
605 5.72795 0.213714 0 0.037 -2.32242 0.577447 -13.7068 4.8273 0.028012 
 
606 1.4051 0 0 0 -0.59178 0.369878 -10.3496 6.78319 0.009202 
 
607 1.02261 0.18095 0 0.177 -0.35448 0.486901 -13.7134 1.93383 0.16434 
 
608 1.44346 0.176362 0 0.122 -0.53366 0.287658 -9.87094 1.1937 0.274584 
 
609 0.976017 0.237851 0 0.244 -0.31089 0.56284 -16.5875 1.2119 0.270957 
 
610 2.80632 0 0 0 -1.18193 0.867268 -15.7504 9.47655 0.002081 
 
611 2.50789 0.21645 0 0.086 -0.96508 0.632104 -11.1185 3.37559 0.066169 
 
612 3.25973 0 0.327086 0 -1.37289 1.28246 -27.4827 10.8486 0.000989 
 
613 2.70416 0.178508 0 0.066 -1.06372 0.408749 -16.4963 3.10411 0.078095 
 
614 2.39126 0 0.349004 0 -1.00712 0.974397 -31.27 8.91821 0.002823 
 
615 5.21966 0 0 0 -2.19835 1.26421 -14.3151 12.2249 0.000472 
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616 0.617407 0.191045 0 0.309 -0.17957 0.32766 -15.5041 0.660508 0.416381 
 
617 0.846364 0 0 0 -0.35646 0.218726 -9.77411 4.19803 0.040471 
 
618 2.75817 0 0 0 -1.16165 0.758589 -15.0119 10.0139 0.001554 
 
619 2.16474 0 0 0 -0.91172 0.309155 -7.64542 7.02741 0.008027 
 
620 0.984348 0.714085 0 0.725 -0.11383 0.823911 -21.2244 0.09625 0.756377 
 
621 7.0556 0 0 0 -2.97159 1.5972 -23.8442 14.1012 0.000173 
 
622 1.38123 0 0 0 -0.58173 0.45784 -9.84332 7.15652 0.007469 
 
623 1.53512 0.218828 0 0.143 -0.55438 0.645493 -14.9638 1.75186 0.185643 
 
624 3.2685 0 0.352917 0 -1.37658 0.662135 -17.9244 9.32848 0.002256 
 
625 1.78819 0.222905 0.268498 0.125 -0.65925 0.62037 -17.5891 2.40036 0.121308 
 
626 1.99002 0.203821 0 0.102 -0.75229 0.685258 -15.6547 3.65222 0.055995 
 
627 1.59428 0 0 0 -0.67146 0.277733 -7.16009 6.57188 0.01036 
 
628 2.28616 0 0 0 -0.96285 0.539779 -12.3612 7.78233 0.005276 
 
629 2.32195 0.379051 0 0.163 -0.81829 0.750991 -12.2918 2.3447 0.125709 
 
630 2.38279 0 0 0 -1.00355 0.418445 -11.4907 7.70126 0.005518 
 
631 1.46179 0 0 0 -0.61566 0.257488 -9.1955 5.68572 0.017104 
 
632 3.52072 0 0 0 -1.48281 0.362361 -9.89233 8.67108 0.003233 
 
633 1.57028 0 0 0 -0.66135 0.254012 -7.97545 6.33347 0.011848 
 
634 2.97741 0 0 0 -1.25399 0.925444 -16.3292 10.0021 0.001564 
 
635 2.19277 0 0 0 -0.92352 0.630298 -19.844 8.8333 0.002958 
 
636 0.473604 0.44936 0.291072 0.949 -0.01021 0.456416 -15.454 0.001189 0.972492 
 
637 0.639999 0 0 0 -0.26955 0.350754 -11.0241 3.29258 0.069594 
 
638 0.968435 1.09657 0.705361 1.132 0.053967 1.24613 3.11E-15 2.66E-15 1 
 
639 0.968435 1.09657 0.705361 1.132 0.053967 1.24613 3.11E-15 2.66E-15 1 
 
640 0.968435 1.09657 0.705361 1.132 0.053967 1.24613 3.11E-15 2.66E-15 1 
 
641 0.968435 1.09657 0.705361 1.132 0.053967 1.24613 3.11E-15 2.66E-15 1 
 
642 0.968435 1.09657 0.705361 1.132 0.053967 1.24613 3.11E-15 2.66E-15 1 
 
643 0.968435 1.09657 0.705361 1.132 0.053967 1.24613 3.11E-15 2.66E-15 1 
 
644 0.968435 1.09657 0.705361 1.132 0.053967 1.24613 3.11E-15 2.66E-15 1 
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645 0.968435 1.09657 0.705361 1.132 0.053967 1.24613 3.11E-15 2.66E-15 1 
 
646 0.968435 1.09657 0.705361 1.132 0.053967 1.24613 3.11E-15 2.66E-15 1 
 
647 0.968435 1.09657 0.705361 1.132 0.053967 1.24613 3.11E-15 2.66E-15 1 
 
648 1.19E-14 0.514376 0 4.32E+13 0.216638 0.484537 -24.5314 0.078756 0.778991 
 
649 2.89538 0 0 0 -1.21944 0.466793 -13.3204 8.05161 0.004546 
 
650 1.82028 0 0 0 -0.76664 0.521629 -11.0278 7.26 0.007051 
 
651 1.04381 0 0 0 -0.43962 0.221511 -9.92859 4.42992 0.035314 
 
652 1.10091 0 0 0 -0.46367 0.200976 -7.83134 4.40678 0.035796 
 
653 0.968435 1.09657 0.705361 1.132 0.053967 1.24613 3.11E-15 2.66E-15 1 
 
654 0.968435 1.09657 0.705361 1.132 0.053967 1.24613 3.11E-15 2.66E-15 1 
 
655 0.968435 1.09657 0.705361 1.132 0.053967 1.24613 3.11E-15 2.66E-15 1 
 
656 7.05193 0.515094 0 0.073 -2.7531 1.45484 -20.2101 4.47073 0.03448 
 
657 0.862544 0.220643 0 0.256 -0.27035 0.403122 -11.8141 0.800349 0.370989 
 
658 2.60326 0 0 0 -1.09641 1.02019 -17.0886 9.23479 0.002375 
 
659 0.254206 0 0 0 -0.10706 0.11191 -8.17643 1.55712 0.212087 
 
660 0.787052 0 0 0 -0.33148 0.236753 -9.57274 4.80356 0.028401 
 
661 0.428436 0 0.638793 0 -0.18044 0.112231 -14.3964 2.31341 0.128262 
 
662 1.02529 0 0 0 -0.43182 0.140758 -7.89017 3.46134 0.062819 
 
663 1.03588 0 0 0 -0.43628 0.143068 -7.82852 3.55804 0.059258 
 
664 5.30344 0 0 0 -2.23363 0.537693 -19.028 9.47947 0.002078 
 
665 0.988478 0.195792 0 0.198 -0.33385 0.432997 -10.605 1.45274 0.228089 
 
666 0.275431 0.386917 0 1.405 0.046954 0.342427 -12.2087 0.067606 0.794855 
 
667 0.837144 0.431787 0 0.516 -0.17072 0.51133 -15.9784 0.205741 0.650127 
 
668 0.334874 0 0 0 -0.14104 0.107784 -5.61534 2.18162 0.139668 
 
669 0 0.267066 0 Infinite 0.11248 0.204933 -8.53708 0.537503 0.46347 
 
670 2.19343 0.24601 0.261729 0.112 -0.82019 0.717383 -25.7987 2.79197 0.094738 
 
671 2.78659 0.182429 0 0.065 -1.09679 0.594086 -12.3855 4.17255 0.041084 
 
672 1.02549 0 0 0 -0.4319 0.229054 -6.82099 5.11432 0.023729 
 
673 1.736 0 0 0 -0.73114 0.249206 -9.21528 5.71097 0.016859 
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674 2.38992 0.25667 0 0.107 -0.89846 0.762911 -18.7929 2.72899 0.098542 
 
675 3.90373 0.17513 0 0.045 -1.57037 0.563542 -11.8243 4.89045 0.027006 
 
676 1.38497 0.177988 0.238879 0.129 -0.50834 0.308675 -14.8687 1.2581 0.262012 
 
677 1.51491 0 0 0 -0.63803 0.246796 -9.37177 5.47506 0.01929 
 
678 1.04478 0.256426 0 0.245 -0.33203 0.41773 -12.2738 0.809153 0.368371 
 
679 5.17961 0 0 0 -2.18148 0.290313 -13.5667 8.64784 0.003275 
 
680 0.91181 0 0 0 -0.38402 0.255295 -8.44607 4.8626 0.027445 
 
681 3.44746 0.287799 0.324501 0.083 -1.33074 0.979951 -19.5219 3.48521 0.06192 
 
682 0.778449 0.365889 0 0.47 -0.17376 0.446319 -13.6965 0.259959 0.610148 
 
683 3.11691 0 0 0 -1.31274 0.26876 -8.62088 6.98488 0.00822 
 
684 1.86399 0 0 0 -0.78505 0.585256 -7.04799 3.73694 0.053222 
 
685 0.48287 0.590252 0 1.222 0.045226 0.533861 -9.17374 0.017616 0.894412 
 
686 1.24153 0 0.260642 0 -0.52289 0.383002 -14.4148 2.41456 0.120211 
 
687 6.53279 0.492439 0 0.075 -2.54399 0.843898 -19.9028 2.5166 0.112654 
 
688 0.998914 0.498908 0 0.499 -0.21059 0.703072 -15.1995 0.349449 0.554425 
 
689 3.88432 0.586615 0 0.151 -1.38888 0.873308 -24.1715 1.68884 0.193754 
 
690 1.24987 0.514017 0 0.411 -0.30992 0.773617 -14.9897 0.688925 0.40653 
 
691 1.87912 0.391748 0.356342 0.208 -0.62643 0.900434 -23.7111 1.39468 0.237616 
 
692 1.89963 0.538451 0.561524 0.283 -0.57328 0.851689 -24.7174 0.920702 0.337291 
 
693 1.51165 0 1.43783 0 -0.63666 0.425914 -17.8262 5.66623 0.017295 
 
694 0.921587 5.55E-17 0 0 -0.38814 0 -4.95231 1.78E-15 1 
 
695 0 0 0 Undefined 0 0 -4.1411 0 1 
 
696 2.7247 0.708248 0.259582 0.26 -0.84926 1.08719 -18.6777 1.20694 0.271938 
 
697 1.00E-06 0.456145 0 456145 0.192113 0.249569 -9.83215 2.25648 0.133056 
 
698 0.674751 0.195052 0.765735 0.289 -0.20203 0.305151 -18.2717 0.567894 0.451097 
 
699 0 0.163423 0 Infinite 0.068828 0.131466 -7.65113 0.373123 0.541307 
 
700 2585.47 0 0.360261 0 -1088.91 0.251135 -11.1691 9.38432 0.002189 
 
701 0 0 0 Undefined 0 0 0 0 1 
 
702 0.678816 0 0 0 -0.2859 0.213065 -13.8384 3.91976 0.047722 
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703 1.69112 0.760621 0 0.45 -0.3919 1.09556 -16.0926 0.614208 0.433208 
 
704 3.41E-15 0 0 0 -1.44E-15 0 -3.70304 0 1 
 
705 0 0 0 Undefined 0 0 0 0 1 
 
706 0.952849 0.241647 0 0.254 -0.29954 0.447048 -11.8182 0.894984 0.34413 
 
707 5.06827 0.672126 0 0.133 -1.85151 1.14759 -19.1012 2.3869 0.122356 
 
708 2.8273 0.402776 0 0.142 -1.02113 0.743619 -11.2492 0.553492 0.456894 
 
709 1.36308 0.183193 0.260106 0.134 -0.49693 0.578149 -15.4137 1.9885 0.158498 
 
710 2.25099 0.447065 0 0.199 -0.75975 0.830569 -15.5595 1.83379 0.175681 
 
711 1.69796 0.522633 0 0.308 -0.49501 0.88941 -15.3614 1.17071 0.279255 
 
712 2.81274 0 0 0 -1.18463 0.653127 -16.8964 8.8796 0.002884 
 
713 3.26432 0 0 0 -1.37483 0.475617 -12.3178 9.51324 0.00204 
 
714 2.16315 0.762183 0 0.352 -0.59004 1.18146 -18.1652 0.943648 0.331341 
 
715 1.37726 0.515885 0.287929 0.375 -0.36278 0.879977 -27.76 0.725397 0.394379 
 
716 1.53826 0.460526 0.634774 0.299 -0.45391 0.803913 -26.4173 1.09229 0.295964 
 
717 7.23044 0.75515 0 0.104 -2.72718 2.13621 -25.5784 5.44657 0.019607 
 
718 0.63629 0.566181 1.15742 0.89 -0.02953 0.59632 -30.4756 0.009622 0.921859 
 
719 0.540516 0 0 0 -0.22765 0.11475 -7.72715 2.9524 0.08575 
 
720 0.276655 0.389049 0 1.406 0.047337 0.346686 -10.928 0.06394 0.800374 
 
721 0.762132 0.190353 0 0.25 -0.24081 0.382131 -12.0091 1.06451 0.302189 
 
722 1.45135 0.668654 0 0.461 -0.32965 0.987 -16.5543 0.389292 0.532672 
 
723 3.13817 0 0 0 -1.32169 0.766916 -14.6994 10.9859 0.000918 
 
724 1.11647 0 0 0 -0.47022 0.246124 -9.95819 4.86226 0.02745 
 
725 1.94792 0 0 0 -0.8204 0.388226 -12.9471 6.10928 0.013447 
 
726 1.2367 0.607471 0 0.491 -0.26501 0.786699 -16.8935 0.389517 0.532554 
 
727 0.41814 0 0 0 -0.17611 0.116014 -7.47413 2.20769 0.137324 
 
728 2.19564 0 0.257191 0 -0.92473 0.511186 -12.6275 8.5674 0.003422 
 
729 1.02549 0 0 0 -0.4319 0.250433 -7.82372 4.67818 0.030548 
 
730 0 0 0 Undefined 0 0 -4.54576 0 1 
 
731 0 0 0 Undefined 0 0 -3.81503 0 1 
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733 6.34732 0 0 0 -2.67328 2.54845 -5.2162 1.66887 0.19641 
 
734 0 0 0 Undefined 0 0 0 0 1 
 
735 0 0.237225 0.564618 Infinite 0.099911 0.15024 -15.6637 0.937135 0.333016 
 
736 0.70083 0.534625 0 0.763 -0.07 0.599054 -18.0416 0.043018 0.835691 
 
737 6.04185 0.883444 0.81997 0.146 -2.17255 1.89592 -32.5212 3.17164 0.074927 
 
 
FUBAR Results  




























1 0.930187 0.03884 -0.89135 0.01974 0.966722 0.999806 1039.88 3.38E-05 0.066293 Neg 
2 0.845348 0.347587 -0.49776 0.27118 0.661067 1.020565 202.0362 0.002272 1.22491 
 
3 1.51366 0.250971 -1.26269 0.048981 0.926887 1.022421 188.8808 0.000166 0.169554 Neg 
4 0.217326 0.222832 0.005506 0.529889 0.411749 1.006713 431.8082 0.002 3.71066 
 
5 0.438908 0.152091 -0.28682 0.129067 0.833134 1.022901 185.7608 0.0005 0.48786 Neg 
6 1.09742 0.174882 -0.92254 0.051541 0.929021 1.002997 628.6479 0.000109 0.178896 Neg 
7 0.794606 0.140348 -0.65426 0.045962 0.938336 1.002796 644.6351 7.54E-05 0.158599 Neg 
8 0.731461 0.053302 -0.67816 0.012247 0.981911 1.009697 345.7394 6.30E-06 0.040817 Neg 
9 0.394645 0.081033 -0.31361 0.072092 0.903421 1.00873 369.5221 0.000185 0.255769 Neg 
10 0.569352 0.048977 -0.52038 0.009792 0.98479 1.006391 443.7636 5.12E-06 0.032554 Neg 
11 0.866176 0.055894 -0.81028 0.005331 0.992243 1.0256 170.0523 1.23E-06 0.017645 Neg 
12 0.477496 0.182368 -0.29513 0.229862 0.727053 1.012356 293.9552 0.000867 0.98257 
 
13 0.719405 0.162632 -0.55677 0.078835 0.895588 1.004224 546.1523 0.00022 0.281741 Neg 
14 0.721826 0.113767 -0.60806 0.029032 0.958838 1.004042 556.9361 3.55E-05 0.098431 Neg 
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15 0.880157 0.228329 -0.65183 0.081208 0.887742 1.01765 227.0478 0.000369 0.29097 Neg 
16 0.564764 0.189213 -0.37555 0.132657 0.829321 1.012694 288.4946 0.000525 0.503507 Neg 
17 0.611124 0.096743 -0.51438 0.031308 0.956343 1.022974 185.2968 4.10E-05 0.106397 Neg 
18 0.950129 0.101778 -0.84835 0.00567 0.991086 1.016294 241.0183 2.00E-06 0.018772 Neg 
19 0.508544 0.117563 -0.39098 0.078969 0.893388 1.012088 298.4408 0.000263 0.282259 Neg 
20 0.331648 0.093241 -0.23841 0.198366 0.747365 1.000634 888.528 0.001934 0.814626 
 
21 0.437806 0.146498 -0.29131 0.105322 0.85926 1.020047 206.0536 0.000419 0.387541 Neg 
22 0.927001 0.071444 -0.85556 0.049711 0.932557 1.007286 412.0131 7.58E-05 0.172211 Neg 
23 0.44647 0.17326 -0.27321 0.142299 0.816222 1.02084 199.9656 0.000643 0.546174 Neg 
24 0.89546 0.086166 -0.8093 0.003721 0.993969 1.02973 150.7374 8.91E-07 0.012296 Neg 
25 0.169069 0.03227 -0.1368 0.143683 0.724975 1.000587 896.0279 0.003683 0.552377 
 
26 1.03985 0.034722 -1.00512 0.000315 0.999484 1.072095 72.1125 8.53E-09 0.001038 Neg 
27 0.673811 0.089147 -0.58466 0.01364 0.979078 1.020295 204.1104 1.03E-05 0.045525 Neg 
28 0.695221 0.086928 -0.60829 0.02165 0.967837 1.016488 238.9114 2.56E-05 0.072852 Neg 
29 0.519996 0.278851 -0.24115 0.230486 0.704626 1.015687 247.861 0.001695 0.98604 
 
30 0.582472 0.217891 -0.36458 0.147307 0.806309 1.014647 260.5772 0.000771 0.568717 Neg 
31 1.03677 0.243057 -0.79371 0.071543 0.895904 1.025083 172.8403 0.000382 0.253672 Neg 
32 0.559598 0.143843 -0.41576 0.062584 0.912409 1.013136 281.6503 0.000168 0.219786 Neg 
33 0.702058 0.124952 -0.57711 0.042867 0.940887 1.001381 785.6415 6.95E-05 0.14744 Neg 
34 0.979878 0.024591 -0.95529 8.00E-05 0.999848 1.050192 97.68503 5.80E-10 0.000263 Neg 
35 1.01456 0.098026 -0.91653 0.019649 0.977135 1.078838 66.93175 1.49E-05 0.065982 Neg 
36 0.868336 0.163129 -0.70521 0.032209 0.952383 1.004824 513.2495 6.12E-05 0.109561 Neg 
37 0.950372 0.188058 -0.76231 0.029847 0.954059 1.014365 264.264 6.71E-05 0.101282 Neg 
38 0.662548 0.136194 -0.52636 0.046568 0.935914 1.006748 430.5176 8.38E-05 0.160792 Neg 
39 0.66541 0.196034 -0.46938 0.116433 0.846481 1.00702 420.9812 0.000456 0.433814 Neg 
40 1.0172 0.078533 -0.93866 0.001907 0.996847 1.05133 95.86696 2.66E-07 0.00629 Neg 
41 0.895986 0.106841 -0.78915 0.014614 0.978422 1.004021 558.2544 1.01E-05 0.048823 Neg 
42 0.673239 0.130118 -0.54312 0.040481 0.942815 1.004656 522.0562 6.67E-05 0.138888 Neg 
43 0.978223 0.063562 -0.91466 0.01706 0.979804 1.055642 89.59426 8.13E-06 0.057136 Neg 
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44 1.0061 0.123331 -0.88276 0.015514 0.977242 1.002935 633.4797 1.12E-05 0.051879 Neg 
45 0.455409 0.194414 -0.261 0.171614 0.779873 1.016915 234.4049 0.0009 0.682001 
 
46 0.360625 0.349408 -0.01122 0.563419 0.375507 1.009626 347.3674 0.002209 4.24846 
 
47 0.465099 0.198786 -0.26631 0.241617 0.712529 1.016512 238.6583 0.001042 1.04883 
 
48 0.630157 0.166403 -0.46375 0.06729 0.906744 1.011338 311.7857 0.000186 0.237503 Neg 
49 0.751648 0.027974 -0.72367 0.001526 0.997291 1.008175 384.7748 1.61E-07 0.005031 Neg 
50 0.556072 0.185408 -0.37066 0.115405 0.846743 1.016233 241.6935 0.00048 0.429485 Neg 
51 0.980417 0.059885 -0.92053 0.00183 0.996973 1.033703 136.0475 2.56E-07 0.006036 Neg 
52 0.766068 0.034812 -0.73126 0.001395 0.997647 1.009015 362.1753 1.13E-07 0.004599 Neg 
53 1.0247 0.031804 -0.9929 0.000336 0.999402 1.039482 119.3642 8.47E-09 0.001107 Neg 
54 0.45674 0.227947 -0.22879 0.2321 0.712035 1.015349 251.8511 0.001363 0.995031 
 
55 0.769866 0.090874 -0.67899 0.01021 0.984662 1.025807 168.9618 5.48E-06 0.033957 Neg 
56 0.450905 0.193166 -0.25774 0.237433 0.716809 1.017526 228.255 0.001037 1.02501 
 
57 0.641927 0.033028 -0.6089 0.001978 0.996582 1.003673 580.3031 2.56E-07 0.006524 Neg 
58 0.402518 0.221273 -0.18125 0.243158 0.696028 1.01436 264.3224 0.001519 1.05767 
 
59 1.00802 0.146504 -0.86152 0.018612 0.972124 1.004319 540.63 1.97E-05 0.062432 Neg 
60 0.863412 0.028513 -0.8349 0.000657 0.998841 1.021234 197.0794 2.85E-08 0.002163 Neg 
61 0.440295 0.261566 -0.17873 0.311627 0.619531 1.012717 288.1239 0.002158 1.49031 
 
62 1.12612 0.124564 -1.00155 0.015948 0.976612 1.001068 825.7123 1.20E-05 0.053353 Neg 
63 0.561358 0.114854 -0.4465 0.037846 0.946231 1.020154 205.2111 6.44E-05 0.12949 Neg 
64 0.576202 0.163443 -0.41276 0.100178 0.868915 1.014659 260.4279 0.00032 0.366508 Neg 
65 0.623977 0.160079 -0.4639 0.060368 0.915095 1.011356 311.454 0.000166 0.211503 Neg 
66 0.846115 0.091074 -0.75504 0.006266 0.990255 1.025033 173.1151 2.23E-06 0.020756 Neg 
67 0.708914 0.037427 -0.67149 0.002355 0.996088 1.005913 462.8563 3.18E-07 0.007773 Neg 
68 0.894135 0.08646 -0.80768 0.002791 0.995399 1.029797 150.4636 5.28E-07 0.009215 Neg 
69 0.617257 0.094496 -0.52276 0.028033 0.960247 1.022368 189.2292 3.71E-05 0.094946 Neg 
70 0.590082 0.035819 -0.55426 0.003432 0.994215 1.00439 536.6419 7.78E-07 0.011338 Neg 
71 1.8838 0.126944 -1.75686 0.001413 0.997593 1.026167 167.0955 1.76E-07 0.004657 Neg 
72 0.666733 0.037269 -0.62946 0.004732 0.992158 1.005394 485.5682 1.34E-06 0.015652 Neg 
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73 0.776221 0.246208 -0.53001 0.1354 0.818609 1.020678 201.1789 0.000812 0.515547 Neg 
74 0.171251 0.199947 0.028696 0.591364 0.350912 1.006297 447.4067 0.002458 4.76413 
 
75 0.70495 0.138251 -0.5667 0.046817 0.93556 1.000672 882.6856 7.88E-05 0.161695 Neg 
76 0.712745 0.096155 -0.61659 0.012205 0.981407 1.020713 200.9202 7.61E-06 0.040676 Neg 
77 0.83588 0.117546 -0.71833 0.013393 0.979541 1.000196 962.5627 9.19E-06 0.044688 Neg 
78 0.782087 0.132837 -0.64925 0.028446 0.958604 1.000381 929.8735 3.78E-05 0.096387 Neg 
79 0.574648 0.186335 -0.38831 0.097867 0.866148 1.014165 266.9448 0.000401 0.357133 Neg 
80 0.330784 0.106075 -0.22471 0.107133 0.855913 1.015336 252.0108 0.000563 0.395005 Neg 
81 0.658804 0.2201 -0.4387 0.111987 0.846205 1.013082 282.4669 0.000586 0.415158 Neg 
82 0.628906 0.249791 -0.37912 0.146488 0.799932 1.014193 266.5624 0.000935 0.565011 
 
83 0.701716 0.093781 -0.60794 0.011712 0.982055 1.020333 203.8164 7.24E-06 0.039014 Neg 
84 0.8321 0.02824 -0.80386 0.001177 0.997941 1.016342 240.4936 9.24E-08 0.003879 Neg 
85 0.81404 0.037129 -0.77691 0.002764 0.995806 1.02037 203.5262 3.66E-07 0.009124 Neg 
86 0.928636 0.04361 -0.88503 0.023593 0.962342 1.001112 819.7426 3.88E-05 0.079546 Neg 
87 0.608997 0.108056 -0.50094 0.026357 0.961507 1.018553 218.6362 3.33E-05 0.089119 Neg 
88 0.605814 0.025954 -0.57986 0.005088 0.990021 1.003086 621.8202 2.87E-06 0.016835 Neg 
89 1.01429 0.034708 -0.97958 0.000436 0.999307 1.070332 73.62005 1.48E-08 0.001437 Neg 
90 0.62273 0.150475 -0.47226 0.049626 0.929155 1.012764 287.3779 0.000112 0.171903 Neg 
91 0.156416 0.040582 -0.11583 0.172902 0.701431 1.000662 884.255 0.003833 0.68819 
 
92 0.89346 0.033903 -0.85956 0.000621 0.998934 1.027827 159.0343 2.53E-08 0.002047 Neg 
93 0.803387 0.024981 -0.77841 0.001172 0.99775 1.013361 278.291 1.20E-07 0.003864 Neg 
94 0.676706 0.025388 -0.65132 0.002575 0.995036 1.00534 488.0516 6.18E-07 0.008499 Neg 
95 1.04432 0.084001 -0.96032 0.002732 0.995648 1.044655 107.7262 4.89E-07 0.009019 Neg 
96 0.264915 0.180248 -0.08467 0.349659 0.594891 1.016489 238.8998 0.001928 1.76998 
 
97 0.501402 0.037045 -0.46436 0.010367 0.982793 1.004106 553.0756 7.62E-06 0.034487 Neg 
98 0.559547 0.177158 -0.38239 0.126614 0.837065 1.014729 259.533 0.000489 0.477244 Neg 
99 0.99272 0.034957 -0.95776 0.001576 0.997365 1.028267 157.0294 1.59E-07 0.005197 Neg 
100 0.622511 0.122521 -0.49999 0.060269 0.917693 1.007498 405.1689 0.000145 0.211131 Neg 
101 0.657548 0.0978 -0.55975 0.018568 0.972436 1.021809 193.0129 1.72E-05 0.062283 Neg 
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102 0.69314 0.037497 -0.65564 0.002963 0.9951 1.005624 475.2438 5.00E-07 0.009782 Neg 
103 1.29557 0.028188 -1.26739 0.000226 0.999598 1.050401 97.34534 4.10E-09 0.000745 Neg 
104 0.830161 0.169667 -0.66049 0.104914 0.864971 1.008005 389.6747 0.000317 0.385864 Neg 
105 0.486423 0.033128 -0.4533 0.007143 0.987678 1.005434 483.7594 3.99E-06 0.023685 Neg 
106 0.380313 0.088352 -0.29196 0.143579 0.811326 1.001529 768.0012 0.001201 0.551913 Neg 
107 0.681853 0.090843 -0.59101 0.018663 0.972991 1.025032 173.1208 1.70E-05 0.062607 Neg 
108 0.310084 0.034913 -0.27517 0.082306 0.849091 0.99936 1145.222 0.000991 0.295255 Neg 
109 0.654889 0.036891 -0.618 0.011139 0.981354 1.004446 533.5096 8.99E-06 0.037082 Neg 
110 0.583559 0.027681 -0.55588 0.007137 0.986729 1.003323 604.3735 5.00E-06 0.023664 Neg 
111 0.734393 0.094299 -0.6401 0.012678 0.981014 1.022172 190.5413 8.29E-06 0.042273 Neg 
112 0.65249 0.183736 -0.46876 0.10999 0.857079 1.011328 311.9766 0.000396 0.40684 Neg 
113 0.497413 0.092878 -0.40454 0.034659 0.948918 1.016643 237.2537 6.79E-05 0.118194 Neg 
114 0.724178 0.088269 -0.63591 0.012154 0.981491 1.022594 187.7425 7.92E-06 0.040503 Neg 
115 0.675067 0.115469 -0.5596 0.038233 0.946532 1.005489 481.2606 6.00E-05 0.130868 Neg 
116 0.672738 0.12792 -0.54482 0.032974 0.952608 1.006369 444.6238 4.67E-05 0.112252 Neg 
117 0.547079 0.13693 -0.41015 0.064038 0.911665 1.015983 244.4827 0.000169 0.225241 Neg 
118 0.73489 0.03708 -0.69781 0.002224 0.996299 1.00746 406.3766 2.84E-07 0.007339 Neg 
119 0.716679 0.110138 -0.60654 0.019748 0.97074 1.004718 518.7913 1.87E-05 0.066319 Neg 
120 0.601816 0.155105 -0.44671 0.087816 0.885023 1.010556 327.0776 0.000247 0.316927 Neg 
121 0.532148 0.14404 -0.38811 0.095582 0.874365 1.014542 261.9328 0.000307 0.347916 Neg 
122 0.486818 0.042175 -0.44464 0.010139 0.984127 1.005949 461.381 6.29E-06 0.033721 Neg 
123 0.985543 0.084466 -0.90108 0.001887 0.996927 1.041971 113.4448 2.70E-07 0.006224 Neg 
124 0.378228 0.330901 -0.04733 0.447403 0.472986 1.010329 331.7982 0.002978 2.66536 
 
125 0.820438 0.087419 -0.73302 0.005948 0.990704 1.034188 134.4585 1.98E-06 0.019698 Neg 
126 0.992242 0.024614 -0.96763 7.41E-05 0.999858 1.056111 88.96632 5.28E-10 0.000244 Neg 
127 0.472261 0.168352 -0.30391 0.152188 0.807155 1.020145 205.2786 0.000665 0.590945 Neg 
128 0.510247 0.134671 -0.37558 0.071188 0.902384 1.016926 234.2986 0.00021 0.252317 Neg 
129 0.645181 0.15705 -0.48813 0.056581 0.920234 1.008262 382.2751 0.000138 0.197438 Neg 
130 0.988544 0.035393 -0.95315 0.000473 0.999212 1.057397 87.29038 1.77E-08 0.001558 Neg 
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131 0.365111 0.103271 -0.26184 0.110126 0.84701 1.012012 299.7393 0.000607 0.407404 Neg 
132 0.603162 0.090933 -0.51223 0.020947 0.968352 1.017317 230.3249 2.51E-05 0.070434 Neg 
133 0.576252 0.025934 -0.55032 0.002487 0.995234 1.00428 542.8648 5.74E-07 0.008206 Neg 
134 0.837142 0.093465 -0.74368 0.006533 0.990021 1.024016 178.9146 2.35E-06 0.02165 Neg 
135 0.600686 0.033529 -0.56716 0.00847 0.98511 1.003981 560.6793 6.03E-06 0.028121 Neg 
136 0.719433 0.106301 -0.61313 0.024067 0.966013 1.023519 181.9023 2.64E-05 0.081182 Neg 
137 0.214113 0.167413 -0.0467 0.461302 0.479212 1.005383 486.0692 0.002491 2.81907 
 
138 0.638431 0.095843 -0.54259 0.02094 0.968852 1.018929 215.3282 2.21E-05 0.070408 Neg 
139 0.453935 0.022695 -0.43124 0.007304 0.984928 1.002996 628.6884 7.39E-06 0.024221 Neg 
140 1.04341 0.10873 -0.93468 0.008771 0.986748 1.009957 339.8564 3.93E-06 0.029131 Neg 
141 0.537307 0.137832 -0.39948 0.068185 0.906434 1.01688 234.7749 0.000185 0.240893 Neg 
142 0.489681 0.166422 -0.32326 0.156807 0.804082 1.012451 292.3942 0.000593 0.612216 Neg 
143 0.334747 0.042132 -0.29262 0.031897 0.949757 1.00659 436.2896 7.38E-05 0.108466 Neg 
144 0.866422 0.119191 -0.74723 0.013958 0.978876 1.00027 949.2962 9.78E-06 0.046601 Neg 
145 0.771877 0.132605 -0.63927 0.026809 0.961254 1.000143 972.5005 3.32E-05 0.090688 Neg 
146 0.980177 0.024624 -0.95555 9.23E-05 0.999824 1.048803 100.0103 7.79E-10 0.000304 Neg 
147 0.662774 0.122358 -0.54042 0.031621 0.954304 1.007953 391.2207 4.60E-05 0.107498 Neg 
148 0.656984 0.131715 -0.52527 0.032289 0.953013 1.009446 351.6075 4.78E-05 0.109843 Neg 
149 0.801699 0.189268 -0.61243 0.069566 0.904641 1.00894 364.082 0.000213 0.246139 Neg 
150 0.606239 0.136253 -0.46999 0.065137 0.912779 1.009837 342.544 0.00015 0.229376 Neg 
151 0.475775 0.260629 -0.21515 0.261618 0.669602 1.012844 286.1334 0.001923 1.16641 
 
152 0.472281 0.033376 -0.43891 0.005974 0.989693 1.007844 394.4621 2.81E-06 0.019784 Neg 
153 0.49062 0.084371 -0.40625 0.043027 0.934709 1.012441 292.5552 0.000129 0.148014 Neg 
154 0.950317 0.021988 -0.92833 0.000225 0.999556 1.025548 170.3256 4.63E-09 0.000742 Neg 
155 0.852973 0.126879 -0.72609 0.019337 0.971474 0.999425 1128.602 1.80E-05 0.064914 Neg 
156 0.629138 0.269281 -0.35986 0.245511 0.69506 1.017065 232.8714 0.001654 1.07123 
 
157 0.778011 0.036601 -0.74141 0.00155 0.997409 1.010989 318.4315 1.37E-07 0.005111 Neg 
158 0.322302 0.034242 -0.28806 0.021979 0.96187 1.006271 448.4164 4.69E-05 0.073983 Neg 
159 0.969134 0.025699 -0.94344 0.000349 0.999356 1.02761 160.0391 9.71E-09 0.001148 Neg 
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160 0.313362 0.026188 -0.28717 0.061683 0.868629 0.999118 1211.837 0.000842 0.216411 Neg 
161 0.604809 0.041236 -0.56357 0.006402 0.98983 1.004086 554.2757 2.28E-06 0.021213 Neg 
162 0.284306 0.0396 -0.24471 0.102054 0.823364 0.999762 1049.488 0.001255 0.374149 Neg 
163 0.847587 0.028415 -0.81917 0.00161 0.997146 1.015304 252.3955 1.87E-07 0.00531 Neg 
164 0.637648 0.042334 -0.59531 0.005998 0.991008 1.005173 495.9514 1.72E-06 0.019865 Neg 
165 0.934143 0.098227 -0.83592 0.006713 0.989639 1.019394 211.3684 2.62E-06 0.022248 Neg 
166 0.64418 0.032047 -0.61213 0.002283 0.996074 1.003432 596.6744 3.41E-07 0.007533 Neg 
167 0.480454 0.041846 -0.43861 0.01267 0.9802 1.006404 443.2862 9.72E-06 0.042245 Neg 
168 0.588366 0.029906 -0.55846 0.00592 0.989315 1.004005 559.225 2.95E-06 0.019606 Neg 
169 0.56337 0.17549 -0.38788 0.082457 0.885426 1.017584 227.6926 0.000302 0.295847 Neg 
170 0.766294 0.082412 -0.68388 0.008803 0.985927 1.022301 189.6764 4.85E-06 0.029239 Neg 
171 0.606871 0.037018 -0.56985 0.010541 0.982356 1.004423 534.7882 7.97E-06 0.035071 Neg 
172 0.229971 0.064078 -0.16589 0.124306 0.828286 1.00186 731.3785 0.000793 0.467309 Neg 
173 0.912015 0.097452 -0.81456 0.007994 0.988056 1.023048 184.8268 3.46E-06 0.02653 Neg 
174 0.620603 0.244217 -0.37639 0.154026 0.794985 1.015495 250.1116 0.00095 0.599379 
 
175 0.449387 0.173574 -0.27581 0.140268 0.81697 1.0188 216.4486 0.000667 0.537108 Neg 
176 0.668282 0.027206 -0.64108 0.0023 0.995841 1.004407 535.6335 4.13E-07 0.007588 Neg 
177 0.361455 0.15014 -0.21132 0.193486 0.757231 1.014581 261.43 0.001038 0.789774 
 
178 0.672701 0.028559 -0.64414 0.004614 0.991567 1.004308 541.2525 1.82E-06 0.015261 Neg 
179 0.617858 0.037348 -0.58051 0.004546 0.992622 1.004922 508.2786 1.19E-06 0.015034 Neg 
180 0.511991 0.143969 -0.36802 0.079013 0.892382 1.019939 206.9133 0.000247 0.282432 Neg 
181 1.38072 0.120641 -1.26008 0.001235 0.997803 1.036877 126.3136 1.53E-07 0.004071 Neg 
182 0.763801 0.03113 -0.73267 0.001773 0.996937 1.010289 332.652 1.95E-07 0.005849 Neg 
183 0.901429 0.121842 -0.77959 0.013398 0.979749 1.000827 859.3904 9.40E-06 0.044705 Neg 
184 0.461364 0.107657 -0.35371 0.047681 0.932663 1.024655 175.2251 0.00011 0.164827 Neg 
185 0.865989 0.027798 -0.83819 0.00051 0.999109 1.022299 189.6891 1.71E-08 0.00168 Neg 
186 0.509813 0.116432 -0.39338 0.043983 0.937882 1.023553 181.6932 8.99E-05 0.151454 Neg 
187 0.455392 0.228955 -0.22644 0.197366 0.742596 1.015507 249.979 0.001332 0.809505 
 
188 1.12247 0.157908 -0.96457 0.025263 0.963003 1.005795 467.8517 3.40E-05 0.085321 Neg 
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189 0.551139 0.162888 -0.38825 0.076924 0.893852 1.019476 210.6833 0.000242 0.274341 Neg 
190 0.424279 0.141198 -0.28308 0.133035 0.828377 1.018037 223.3682 0.000588 0.505162 Neg 
191 0.502023 0.168182 -0.33384 0.131169 0.831379 1.019791 208.1048 0.000524 0.497005 Neg 
192 1.24064 0.242723 -0.99791 0.075844 0.894323 1.024833 174.2289 0.000347 0.270172 Neg 
193 0.823951 0.11059 -0.71336 0.014389 0.978561 1.002142 702.8931 9.95E-06 0.048059 Neg 
194 0.530232 0.226927 -0.30331 0.208992 0.737518 1.011143 315.4561 0.001156 0.869789 
 
195 0.576662 0.325214 -0.25145 0.339853 0.585918 1.018568 218.5073 0.002971 1.69479 
 
196 0.665026 0.112139 -0.55289 0.027046 0.960844 1.015609 248.7708 3.30E-05 0.091511 Neg 
197 0.628698 0.217873 -0.41083 0.155339 0.800956 1.008652 371.5937 0.000776 0.605429 Neg 
198 0.851622 0.081689 -0.76993 0.004131 0.993245 1.032144 141.4386 1.14E-06 0.013655 Neg 
199 0.950325 0.321161 -0.62916 0.120471 0.824029 1.028899 154.244 0.001284 0.450919 Neg 
200 1.37767 0.184304 -1.19336 0.043314 0.94207 1.017552 227.9989 9.10E-05 0.149047 Neg 
201 0.700486 0.090233 -0.61025 0.013711 0.979242 1.020703 200.9896 9.94E-06 0.045766 Neg 
202 0.409242 0.185037 -0.22421 0.170154 0.782752 1.025864 168.6626 0.000908 0.67501 
 
203 0.499327 0.256739 -0.24259 0.217084 0.715932 1.013664 273.8968 0.00173 0.912808 
 
204 0.62574 0.083358 -0.54238 0.019979 0.969234 1.018327 220.6867 2.47E-05 0.067112 Neg 
205 0.494173 0.350276 -0.1439 0.404242 0.521324 1.01573 247.3671 0.002962 2.23377 
 
206 0.749014 0.126267 -0.62275 0.025263 0.963483 1.001605 759.2504 2.81E-05 0.085324 Neg 
207 0.460303 0.312111 -0.14819 0.340929 0.574763 1.012603 289.9367 0.003083 1.70294 
 
208 0.48191 0.166937 -0.31497 0.133841 0.827807 1.021668 193.9978 0.000565 0.508696 Neg 
209 0.655818 0.150914 -0.5049 0.044498 0.935888 1.009631 347.2454 9.32E-05 0.15331 Neg 
210 1.24913 0.141342 -1.10778 0.005942 0.990044 1.020386 203.4055 3.18E-06 0.019677 Neg 
211 0.726465 0.081337 -0.64513 0.008295 0.986875 1.028313 156.8247 4.30E-06 0.027536 Neg 
212 0.415753 0.311764 -0.10399 0.433627 0.487042 1.009997 338.9711 0.002994 2.52046 
 
213 1.55719 0.091391 -1.4658 0.000825 0.998584 1.032604 139.8012 5.56E-08 0.002719 Neg 
214 0.602116 0.727674 0.125558 0.584468 0.308351 1.008802 367.6305 0.007262 4.63043 
 
215 0.692188 0.092157 -0.60003 0.017523 0.974072 1.022601 187.697 1.44E-05 0.058714 Neg 
216 0.348451 0.390186 0.041735 0.582602 0.329911 1.010726 323.6158 0.003883 4.59502 
 
217 0.343262 0.297715 -0.04555 0.465009 0.471796 1.010268 333.0829 0.002155 2.86142 
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218 0.608442 0.209384 -0.39906 0.151383 0.808316 1.012969 284.1895 0.000706 0.587259 Neg 
219 0.425806 0.380165 -0.04564 0.490063 0.420994 1.012966 284.231 0.003931 3.16374 
 
220 0.91922 0.140538 -0.77868 0.021108 0.968945 1.00172 746.404 2.31E-05 0.070987 Neg 
221 0.805386 0.194014 -0.61137 0.077077 0.893173 1.008627 372.2523 0.000271 0.274932 Neg 
222 0.735757 0.352574 -0.38318 0.222891 0.70014 1.022931 185.5714 0.002575 0.94423 
 
223 0.33258 0.401508 0.068928 0.582795 0.336115 1.010243 333.6245 0.003251 4.59867 
 
224 0.883039 0.16148 -0.72156 0.046144 0.935071 1.002347 683.4987 9.52E-05 0.159255 Neg 
225 0.216392 0.144134 -0.07226 0.411185 0.526306 1.002941 633.0384 0.002831 2.29892 
 
226 0.923873 0.035666 -0.88821 0.000592 0.998982 1.031584 143.4848 2.35E-08 0.00195 Neg 
227 0.578494 0.274707 -0.30379 0.199329 0.729605 1.014781 258.8621 0.001838 0.819564 
 
228 0.591886 0.230331 -0.36156 0.197793 0.750321 1.013869 271.0082 0.001113 0.811692 
 
229 0.73936 0.406576 -0.33278 0.292251 0.617725 1.021313 196.5065 0.003752 1.35939 
 
230 0.718135 0.316581 -0.40155 0.182906 0.752035 1.016949 234.0597 0.001404 0.736921 
 
231 0.465004 0.299645 -0.16536 0.417953 0.520072 1.009999 338.9317 0.001979 2.36393 
 
232 0.830406 0.292498 -0.53791 0.208799 0.728956 1.015918 245.2148 0.001501 0.868773 
 
233 0.619264 0.034134 -0.58513 0.00541 0.991026 1.004002 559.402 1.83E-06 0.017907 Neg 
234 0.744543 0.217945 -0.5266 0.105416 0.857008 1.016859 234.9909 0.000512 0.387929 Neg 
235 1.30856 0.147319 -1.16124 0.010164 0.984252 1.01415 267.1397 6.90E-06 0.033804 Neg 
236 0.73306 0.207327 -0.52573 0.077764 0.889762 1.012594 290.0759 0.000325 0.277588 Neg 
237 0.878262 0.109051 -0.76921 0.014126 0.97909 1.003659 581.1988 9.36E-06 0.047171 Neg 
238 0.69974 0.174795 -0.52495 0.071939 0.901125 1.007871 393.6635 0.000213 0.255183 Neg 
239 0.702054 0.303803 -0.39825 0.196525 0.74303 1.020581 201.9124 0.001729 0.805213 
 
240 0.703445 0.129163 -0.57428 0.028119 0.959179 1.005746 469.9233 3.63E-05 0.095246 Neg 
241 0.823339 0.141089 -0.68225 0.040146 0.9443 0.998559 1400.446 6.28E-05 0.13769 Neg 
242 0.724475 0.149252 -0.57522 0.036416 0.947079 1.003666 580.7485 6.40E-05 0.124415 Neg 
243 0.411759 0.202316 -0.20944 0.289693 0.660235 1.015922 245.163 0.001357 1.34264 
 
244 0.548579 0.143091 -0.40549 0.066256 0.908606 1.018852 215.9926 0.00018 0.233593 Neg 
245 0.52255 0.140767 -0.38178 0.096306 0.874577 1.017153 231.9691 0.000293 0.350832 Neg 
246 0.895297 0.243971 -0.65133 0.089931 0.874585 1.016052 243.6977 0.000437 0.325311 Neg 
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247 0.964242 0.137827 -0.82642 0.027205 0.961938 1.009901 341.0944 3.51E-05 0.092064 Neg 
248 0.265685 0.247459 -0.01823 0.527132 0.41494 1.008407 378.2267 0.002031 3.66982 
 
249 0.865571 0.097096 -0.76848 0.008526 0.986928 1.015865 245.8137 3.78E-06 0.02831 Neg 
250 0.921067 0.024648 -0.89642 0.000156 0.999706 1.034005 135.0545 1.97E-09 0.000515 Neg 
251 0.524876 0.147755 -0.37712 0.082333 0.888873 1.017867 224.9715 0.000257 0.295362 Neg 
252 0.642485 0.116072 -0.52641 0.032893 0.953614 1.010932 319.5438 4.67E-05 0.111968 Neg 
253 0.694666 0.094454 -0.60021 0.01089 0.983068 1.018926 215.349 6.46E-06 0.036245 Neg 
254 0.27881 0.250674 -0.02814 0.465406 0.46438 1.007434 407.2306 0.002553 2.86599 
 
255 0.541498 0.135035 -0.40646 0.063446 0.91278 1.017543 228.0871 0.000166 0.223017 Neg 
256 0.459487 0.183031 -0.27646 0.139195 0.816902 1.021844 192.7753 0.000671 0.532335 Neg 
257 0.502685 0.165703 -0.33698 0.135925 0.824994 1.014668 260.3029 0.000577 0.51786 Neg 
258 0.78764 0.232884 -0.55476 0.111091 0.848493 1.017837 225.2501 0.000591 0.411423 Neg 
259 0.968472 0.117111 -0.85136 0.008404 0.986877 1.005202 494.5441 4.15E-06 0.027902 Neg 
260 0.755398 0.126075 -0.62932 0.040204 0.944556 0.999255 1173.318 5.91E-05 0.137898 Neg 
261 0.33026 0.267194 -0.06307 0.487628 0.450974 1.009089 360.3199 0.002055 3.13306 
 
262 0.504509 0.479585 -0.02492 0.440263 0.469452 1.014504 262.4273 0.004311 2.58937 
 
263 0.508566 0.191847 -0.31672 0.160033 0.797301 1.016226 241.7665 0.00071 0.627211 
 
264 0.461213 0.306621 -0.15459 0.364933 0.557153 1.012598 290.0153 0.002875 1.89173 
 
265 1.57059 0.243256 -1.32733 0.052142 0.925918 1.028115 157.7158 0.000211 0.181095 Neg 
266 0.974175 0.141173 -0.833 0.02202 0.969602 1.029205 152.9327 2.60E-05 0.074123 Neg 
267 0.588784 0.088817 -0.49997 0.029465 0.955546 1.01223 296.0484 5.13E-05 0.099945 Neg 
268 0.746111 0.080581 -0.66553 0.011718 0.981397 1.019333 211.8805 9.08E-06 0.039034 Neg 
269 0.466953 0.13899 -0.32796 0.091113 0.878309 1.021463 195.4369 0.000302 0.330016 Neg 
270 0.950627 0.02812 -0.92251 0.000217 0.999612 1.04438 108.2831 3.62E-09 0.000715 Neg 
271 0.379207 0.180376 -0.19883 0.1908 0.758556 1.021254 196.9371 0.000999 0.776227 
 
272 0.320288 0.205001 -0.11529 0.381141 0.564408 1.013129 281.7525 0.001632 2.0275 
 
273 0.558225 0.070125 -0.4881 0.028494 0.960311 1.007157 416.3297 3.02E-05 0.096555 Neg 
274 0.269207 0.148805 -0.1204 0.243867 0.694749 1.011859 302.3861 0.001729 1.06175 
 
275 0.742424 0.193651 -0.54877 0.199873 0.760047 1.012789 286.9871 0.000773 0.822359 
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276 0.812791 0.095726 -0.71707 0.012513 0.981497 1.023319 183.1317 7.43E-06 0.041715 Neg 
277 0.563926 0.205188 -0.35874 0.135538 0.821796 1.013789 272.1238 0.000642 0.516157 Neg 
278 0.582585 0.140345 -0.44224 0.07049 0.905116 1.011156 315.2085 0.000177 0.249653 Neg 
279 0.447139 0.089477 -0.35766 0.02884 0.956237 1.021322 196.4444 5.29E-05 0.097762 Neg 
280 0.532027 0.233059 -0.29897 0.254507 0.692786 1.013248 279.9683 0.001241 1.12389 
 
281 0.561107 0.148143 -0.41296 0.072176 0.901235 1.015403 251.2043 0.000202 0.256091 Neg 
282 0.599621 0.126632 -0.47299 0.067027 0.910865 1.009094 360.196 0.00015 0.236508 Neg 
283 0.655196 0.175667 -0.47953 0.192081 0.770783 1.006763 429.9876 0.000477 0.782679 
 
284 0.638962 0.176745 -0.46222 0.192023 0.770866 1.006752 430.3757 0.000476 0.782386 
 
285 1.70259 0.162753 -1.53984 0.055 0.927594 1.017297 230.5235 8.48E-05 0.191601 Neg 
286 0.531301 0.17453 -0.35677 0.208341 0.752152 1.006769 429.7856 0.000548 0.86637 
 
287 0.572706 0.176902 -0.3958 0.201358 0.760162 1.006745 430.6255 0.000516 0.830009 
 
288 0.572706 0.176902 -0.3958 0.201358 0.760162 1.006745 430.6255 0.000516 0.830009 
 
289 0.544303 0.17894 -0.36536 0.211091 0.749216 1.006763 429.9853 0.000555 0.880865 
 
290 0.542453 0.18295 -0.3595 0.215443 0.744477 1.006732 431.1028 0.000568 0.904012 
 
291 0.860105 0.176561 -0.68354 0.039459 0.942363 1.008045 388.5192 8.63E-05 0.135237 Neg 
292 0.573613 0.251505 -0.32211 0.196706 0.747472 1.014727 259.5583 0.001296 0.806138 
 
293 0.698538 0.224326 -0.47421 0.097539 0.861952 1.015847 246.0266 0.000531 0.355808 Neg 
294 0.882167 0.035378 -0.84679 0.001086 0.998195 1.024578 175.6604 6.99E-08 0.003579 Neg 
295 0.839598 0.028821 -0.81078 0.000895 0.998435 1.017574 227.7919 5.12E-08 0.002948 Neg 
296 0.447898 0.158861 -0.28904 0.235044 0.721126 1.013729 272.9734 0.001044 1.01153 
 
297 0.429015 0.107724 -0.32129 0.074702 0.898139 1.018236 221.5156 0.000258 0.265775 Neg 
298 0.427205 0.157961 -0.26924 0.163822 0.793521 1.020528 202.316 0.000813 0.64497 
 
299 2.15201 0.243847 -1.90817 0.100967 0.866919 1.021903 192.3675 0.000441 0.369716 Neg 
300 0.622511 0.122521 -0.49999 0.060269 0.917693 1.007498 405.1689 0.000145 0.211131 Neg 
301 0.161482 0.161323 -0.00016 0.53023 0.403803 1.001489 772.7325 0.002979 3.71574 
 
302 0.709837 0.141535 -0.5683 0.061874 0.917166 1.003965 561.6652 0.000134 0.217126 Neg 
303 0.400867 0.122639 -0.27823 0.167603 0.791992 1.009228 356.8735 0.000871 0.662854 
 
304 0.873584 0.11605 -0.75753 0.016018 0.976558 1.002391 679.4918 1.22E-05 0.053591 Neg 
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305 0.329829 0.193388 -0.13644 0.291715 0.649765 1.017598 227.5576 0.001725 1.35586 
 
306 0.819132 0.107086 -0.71205 0.013782 0.979214 1.011869 302.2209 9.65E-06 0.046005 Neg 
307 0.391654 0.195328 -0.19633 0.23985 0.708589 1.019653 209.2259 0.0012 1.03874 
 
308 0.472644 0.21077 -0.26187 0.292555 0.660508 1.011539 308.0898 0.001195 1.36138 
 
309 0.43231 0.216815 -0.2155 0.203634 0.741007 1.020177 205.031 0.00123 0.841787 
 
310 0.397362 0.350278 -0.04708 0.438448 0.469778 1.010828 321.5741 0.003776 2.57036 
 
311 0.402747 0.256784 -0.14596 0.432895 0.515196 1.00866 371.37 0.001807 2.51296 
 
312 0.279102 0.161705 -0.1174 0.358726 0.586044 1.009547 349.2154 0.00198 1.84155 
 
313 0.342626 0.231103 -0.11152 0.341429 0.594142 1.013284 279.4308 0.002032 1.70673 
 
314 0.392925 0.10867 -0.28426 0.062897 0.912041 1.022688 187.1313 0.000197 0.220957 Neg 
315 0.287685 0.195762 -0.09192 0.316212 0.621987 1.014355 264.3885 0.00191 1.52238 
 
316 0.207193 0.173198 -0.034 0.492821 0.449542 1.006967 422.8134 0.002682 3.19886 
 
317 0.276779 0.309082 0.032302 0.553591 0.375798 1.006781 429.3407 0.002569 4.08245 
 
318 0.22469 0.389123 0.164433 0.75015 0.186877 1.005405 485.0662 0.002072 9.88405 
 
319 0.266201 0.198939 -0.06726 0.373107 0.568564 1.012188 296.7489 0.00195 1.95932 
 
320 0.516258 0.150394 -0.36586 0.091609 0.876964 1.015917 245.2259 0.000306 0.331994 Neg 
321 0.263806 0.369941 0.106136 0.699197 0.239314 1.007064 419.4515 0.002148 7.65215 
 
322 0.272654 0.811966 0.539313 0.813132 0.130419 1.012561 290.6155 0.001985 14.3249 Pos 
323 0.29029 0.819112 0.528822 0.802515 0.140862 1.011167 314.9981 0.002355 13.3778 Pos 
324 0.507281 0.267422 -0.23986 0.30556 0.631578 1.01166 305.9191 0.001854 1.44853 
 
325 0.278578 0.446506 0.167928 0.723279 0.212778 1.011357 311.4415 0.002299 8.60456 
 
326 0.17786 0.700146 0.522287 0.908787 0.058375 1.017483 228.6776 0.000709 32.7998 Pos 
327 0.664672 0.352052 -0.31262 0.293681 0.628351 1.022174 190.5276 0.003172 1.3688 
 
328 0.433884 0.238259 -0.19563 0.264062 0.675042 1.014836 258.1706 0.001565 1.18122 
 
329 0.286836 0.25544 -0.0314 0.444934 0.483445 1.007951 391.265 0.002632 2.63886 
 
330 0.581389 0.244081 -0.33731 0.225953 0.720623 1.012252 295.6727 0.001271 0.960986 
 
331 0.223887 0.256815 0.032928 0.566223 0.372476 1.007011 421.2743 0.002333 4.29722 
 
332 0.235025 0.277022 0.041997 0.560391 0.370688 1.003941 563.124 0.002515 4.19654 
 
333 0.331144 0.428676 0.097532 0.57583 0.345809 1.009983 339.2766 0.003072 4.4691 
 
Chapter 8 Filovirus Data Ebola Selection analysis 
334 0.342524 0.137196 -0.20533 0.163711 0.788358 1.016388 239.9956 0.000955 0.644446 
 
335 0.682753 0.27082 -0.41193 0.169063 0.771347 1.017693 226.6345 0.001349 0.669802 
 
336 0.472828 0.302241 -0.17059 0.370445 0.569135 1.013159 281.3049 0.002008 1.93712 
 
337 0.747242 0.195493 -0.55175 0.091367 0.877305 1.008701 370.298 0.000326 0.331029 Neg 
338 0.363444 0.424946 0.061502 0.568895 0.34527 1.012409 293.0904 0.003823 4.34424 
 
339 0.785851 2.21245 1.4266 0.714542 0.166426 0.997696 1844.504 0.008751 8.24047 
 
340 0.313543 0.231526 -0.08202 0.387697 0.545392 1.008086 387.3318 0.002039 2.08445 
 
341 0.266038 0.248144 -0.01789 0.528042 0.413305 1.008689 370.6085 0.00214 3.68325 
 
342 0.601075 0.326348 -0.27473 0.268178 0.649157 1.01865 217.7747 0.002966 1.20638 
 
343 0.889918 0.234727 -0.65519 0.077972 0.887433 1.019024 214.501 0.000386 0.278393 Neg 
344 0.312677 0.514978 0.202301 0.680808 0.243564 1.010366 331.009 0.002794 7.02163 
 
345 0.508166 0.610945 0.102779 0.544785 0.364052 1.01422 266.1939 0.005309 3.9398 
 
346 0.748921 0.116789 -0.63213 0.049254 0.932697 1.000767 868.2197 9.11E-05 0.170547 Neg 
347 0.498813 0.209225 -0.28959 0.190417 0.760278 1.015514 249.8874 0.000999 0.774301 
 
348 0.62948 0.271221 -0.35826 0.192407 0.749182 1.014123 267.5027 0.00136 0.784321 
 
349 0.304623 0.265631 -0.03899 0.477066 0.45945 1.009263 356.022 0.002162 3.00329 
 
350 0.356036 0.21553 -0.14051 0.285239 0.651443 1.014078 268.12 0.0018 1.31375 
 
351 0.435723 0.19693 -0.23879 0.175662 0.774004 1.019689 208.9289 0.00098 0.701518 
 
352 0.275325 0.168861 -0.10646 0.286389 0.653831 1.012047 299.1427 0.00173 1.32118 
 
353 0.397071 0.27219 -0.12488 0.382319 0.547993 1.010045 337.9056 0.002289 2.03764 
 
354 0.290171 0.242856 -0.04732 0.430318 0.500269 1.007887 393.169 0.002505 2.4867 
 
355 0.126436 0.172037 0.0456 0.646507 0.292083 1.002301 687.7349 0.002798 6.02086 
 
356 0.257659 0.190196 -0.06746 0.350915 0.582945 1.010222 334.0684 0.00227 1.77978 
 
357 0.330547 0.370784 0.040237 0.5538 0.362095 1.009062 360.985 0.003424 4.08591 
 
358 0.414487 0.18244 -0.23205 0.23159 0.72244 1.020811 200.1808 0.001095 0.992186 
 
359 0.319967 0.143144 -0.17682 0.192212 0.754826 1.014881 257.6081 0.001225 0.783338 
 
360 0.17261 0.29721 0.1246 0.748542 0.204392 1.003421 597.4156 0.001434 9.7998 
 
361 0.266466 0.173569 -0.0929 0.325936 0.61915 1.01663 237.3972 0.001802 1.59183 
 
362 1.03389 0.213396 -0.82049 0.065301 0.908394 1.017131 232.1922 0.000238 0.229992 Neg 
Chapter 8 Filovirus Data Ebola Selection analysis 
363 0.775452 0.395805 -0.37965 0.248062 0.658175 1.022295 189.7164 0.003706 1.08604 
 
364 0.381702 0.312056 -0.06965 0.464521 0.460744 1.009279 355.6223 0.002771 2.8558 
 
365 0.39488 0.286496 -0.10839 0.384119 0.5395 1.010326 331.8617 0.00269 2.05322 
 
366 0.544156 0.178202 -0.36595 0.209037 0.751481 1.006786 429.1636 0.000547 0.870025 
 
367 0.327305 0.238581 -0.08872 0.360867 0.578593 1.018433 219.7223 0.002016 1.85875 
 
368 0.642334 0.235711 -0.40662 0.200955 0.747196 1.013913 270.3987 0.001091 0.827931 
 
369 0.486797 0.649145 0.162349 0.566091 0.327222 1.012008 299.8063 0.006322 4.2949 
 
370 0.214323 0.282724 0.068401 0.642208 0.299826 1.004613 524.3637 0.002063 5.90896 
 
371 0.256367 0.26776 0.011393 0.525573 0.409498 1.008656 371.4982 0.002363 3.64695 
 
372 0.225306 0.275986 0.05068 0.596683 0.341076 1.005522 479.7496 0.002328 4.87038 
 
373 0.418722 0.216148 -0.20257 0.214603 0.727498 1.017337 230.1253 0.001246 0.899525 
 
374 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
375 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
376 0.601347 0.119992 -0.48136 0.037478 0.946426 1.016047 243.7625 6.06E-05 0.128182 Neg 
377 0.732507 0.250042 -0.48247 0.11952 0.833903 1.017153 231.9715 0.000736 0.446876 Neg 
378 0.345263 0.40073 0.055468 0.511171 0.411867 1.009337 354.2083 0.002888 3.4425 
 
379 0.250401 0.931875 0.681474 0.860023 0.093205 1.008424 377.759 0.001279 20.2265 Pos 
380 0.398096 0.246806 -0.15129 0.324714 0.612563 1.013659 273.9743 0.001867 1.583 
 
381 0.318951 0.256415 -0.06254 0.444294 0.492813 1.009839 342.4863 0.002134 2.63203 
 
382 0.293079 0.368485 0.075406 0.611194 0.32388 1.007116 417.6838 0.002274 5.17501 
 
383 0.362621 0.233066 -0.12956 0.316655 0.624235 1.016167 242.423 0.001585 1.5255 
 
384 0.607449 0.241534 -0.36592 0.155591 0.79362 1.013981 269.4537 0.000953 0.606594 
 
385 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
386 0.337481 0.24813 -0.08935 0.383482 0.548488 1.010597 326.2239 0.002206 2.0477 
 
387 1.1895 0.699408 -0.49009 0.273099 0.582059 1.008743 369.18 0.006687 1.23683 
 
388 0.452234 0.37605 -0.07618 0.43355 0.491002 1.011876 302.0956 0.002527 2.51966 
 
389 0.825177 0.20294 -0.62224 0.047854 0.927455 1.015062 255.3511 0.00016 0.165455 Neg 
390 1.14003 0.455429 -0.6846 0.218443 0.690742 1.018659 217.697 0.002825 0.920116 
 
391 0.215729 0.278194 0.062466 0.629338 0.312856 1.005064 501.2497 0.002059 5.58949 
 
Chapter 8 Filovirus Data Ebola Selection analysis 
392 0.887263 0.136903 -0.75036 0.034881 0.952885 1.008445 377.2053 4.92E-05 0.118979 Neg 
393 0.467773 0.292815 -0.17496 0.426714 0.519075 1.01157 307.5298 0.002003 2.45037 
 
394 0.594388 0.159246 -0.43514 0.084061 0.88819 1.009449 351.527 0.000222 0.302132 Neg 
395 0.653928 0.211002 -0.44293 0.150872 0.807816 1.00429 542.2959 0.000655 0.584927 Neg 
396 0.378578 0.392297 0.013719 0.511699 0.399579 1.010872 320.7116 0.003716 3.44979 
 
397 0.796035 0.352186 -0.44385 0.253591 0.666585 1.022905 185.7363 0.003063 1.11846 
 
398 0.38869 0.335451 -0.05324 0.479544 0.447728 1.010018 338.5141 0.002592 3.03326 
 
399 0.442488 0.115021 -0.32747 0.107007 0.859196 1.014822 258.3513 0.000374 0.394483 Neg 
400 0.70686 0.275771 -0.43109 0.214086 0.730527 1.011847 302.5964 0.001299 0.896764 
 
401 2.5143 1.29038 -1.22391 0.245055 0.557834 0.998856 1293.544 0.009176 1.0686 
 
402 0.388283 0.311683 -0.0766 0.436509 0.483796 1.009739 344.773 0.00295 2.55018 
 
403 0.475233 0.269868 -0.20537 0.296333 0.643607 1.011392 310.7808 0.001516 1.38637 
 
404 0.663447 0.235426 -0.42802 0.146065 0.809344 1.012634 289.4427 0.000795 0.563101 Neg 
405 1.04321 0.374135 -0.66908 0.139858 0.787092 1.027892 158.7327 0.001911 0.53528 
 
406 0.449691 0.625988 0.176297 0.564725 0.350487 1.010059 337.6057 0.003835 4.27109 
 
407 0.389833 0.269282 -0.12055 0.397675 0.542375 1.010911 319.9503 0.001819 2.17351 
 
408 0.465237 0.288358 -0.17688 0.304056 0.628759 1.012924 284.8831 0.001865 1.43828 
 
409 0.353187 0.301586 -0.0516 0.476561 0.448087 1.008123 386.2438 0.002794 2.99722 
 
410 1.87834 0.256819 -1.62152 0.016162 0.971441 1.029506 151.6667 3.35E-05 0.05408 Neg 
411 0.482011 0.214731 -0.26728 0.154217 0.793984 1.018703 217.3007 0.000909 0.600259 
 
412 0.414291 0.407572 -0.00672 0.530625 0.38602 1.012861 285.8619 0.003584 3.72163 
 
413 0.478801 0.484985 0.006184 0.442343 0.473914 1.012985 283.9449 0.003462 2.6113 
 
414 0.733863 0.581666 -0.1522 0.400059 0.476513 1.012277 295.2662 0.0078 2.19524 
 
415 0.301429 0.218715 -0.08271 0.373559 0.565575 1.012808 286.6949 0.001943 1.96311 
 
416 0.405813 0.432342 0.026529 0.503224 0.414401 1.012769 287.3031 0.003466 3.33477 
 
417 0.319927 1.00104 0.681113 0.81105 0.126152 1.005842 465.8424 0.002204 14.1308 Pos 
418 0.693508 0.255084 -0.43842 0.177395 0.769858 1.01701 233.4326 0.001179 0.70993 
 
419 0.651384 0.337278 -0.31411 0.330173 0.601424 1.019553 210.0468 0.002653 1.62273 
 
420 0.532495 0.200097 -0.3324 0.206336 0.746486 1.009796 343.4744 0.00091 0.855861 
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421 0.739064 0.247492 -0.49157 0.131359 0.821482 1.01665 237.1879 0.000807 0.497836 Neg 
422 0.678485 0.313273 -0.36521 0.27073 0.666244 1.016952 234.0252 0.001808 1.22212 
 
423 0.456743 0.25738 -0.19936 0.25723 0.673772 1.012927 284.8406 0.001825 1.14008 
 
424 0.465353 0.216623 -0.24873 0.231155 0.71508 1.01559 249.0013 0.001216 0.989763 
 
425 0.160106 0.410606 0.2505 0.852289 0.110396 1.006654 433.9307 0.00087 18.9951 Pos 
426 0.437423 0.396172 -0.04125 0.53474 0.380578 1.012029 299.4478 0.003505 3.78367 
 
427 0.693192 0.192705 -0.50049 0.077551 0.891762 1.008698 370.3783 0.000269 0.276764 Neg 
428 0.402324 0.238033 -0.16429 0.285371 0.653564 1.01194 300.9839 0.001577 1.3146 
 
429 0.303601 0.957172 0.653571 0.807557 0.137035 1.006815 428.1496 0.002371 13.8146 Pos 
430 0.881668 3.53132 2.64965 0.82109 0.067433 0.996773 2793.844 0.009098 15.1085 Pos 
431 0.512224 0.399235 -0.11299 0.433294 0.482206 1.017151 231.9912 0.003942 2.51705 
 
432 0.539106 0.274602 -0.26451 0.235883 0.692482 1.013126 281.7967 0.00195 1.01626 
 
433 0.767829 0.179579 -0.58825 0.058939 0.917553 1.006952 423.3135 0.000167 0.206181 Neg 
434 2.13129 0.469424 -1.66187 0.046814 0.892548 1.020135 205.3644 0.000367 0.161684 Neg 
435 0.488486 0.270268 -0.21822 0.240891 0.691098 1.013602 274.7765 0.001758 1.04468 
 
436 0.60271 0.416239 -0.18647 0.3273 0.569 1.01718 231.7003 0.00436 1.60173 
 
437 0.247305 0.198983 -0.04832 0.398701 0.533151 1.007944 391.4987 0.002507 2.18284 
 
438 0.482863 0.451227 -0.03164 0.450134 0.457501 1.014121 267.5368 0.004158 2.69496 
 
439 0.787112 0.241129 -0.54598 0.082261 0.878777 1.018062 223.1325 0.000471 0.295081 Neg 
440 1.14795 0.211601 -0.93635 0.060041 0.924522 1.013346 278.5056 6.49E-05 0.210285 Neg 
441 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
442 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
443 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
444 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
445 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
446 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
447 0.416803 0.411779 -0.00502 0.517267 0.398073 1.013763 272.4932 0.003752 3.52755 
 
448 0.626638 0.117085 -0.50955 0.026407 0.961152 1.013441 277.1122 3.29E-05 0.089291 Neg 
449 0.252325 0.472327 0.220001 0.726998 0.213074 1.009785 343.7103 0.00191 8.76664 
 
Chapter 8 Filovirus Data Ebola Selection analysis 
450 0.326997 0.248493 -0.0785 0.430436 0.508452 1.011706 305.0938 0.002089 2.4879 
 
451 0.36827 0.388335 0.020066 0.528415 0.392319 1.011213 314.1247 0.003187 3.68877 
 
452 0.606552 0.327741 -0.27881 0.250574 0.676421 1.016384 240.0413 0.002276 1.10071 
 
453 0.406669 0.290886 -0.11578 0.451848 0.48492 1.009257 356.1548 0.002113 2.71367 
 
454 0.45013 0.362243 -0.08789 0.415434 0.498224 1.01338 278.0077 0.003497 2.33956 
 
455 0.646135 0.138546 -0.50759 0.071746 0.904213 1.001219 805.8902 0.000162 0.254446 Neg 
456 0.956713 0.128268 -0.82845 0.015057 0.977511 1.009213 357.2478 1.22E-05 0.050325 Neg 
457 2.7917 0.355422 -2.43628 0.04433 0.92379 1.029541 151.5186 0.000225 0.152706 Neg 
458 0.656226 0.168034 -0.48819 0.186219 0.777207 1.006802 428.6056 0.00046 0.753324 
 
459 0.549722 0.173671 -0.37605 0.201825 0.759533 1.006722 431.4603 0.000521 0.832419 
 
460 0.564802 0.47839 -0.08641 0.414631 0.527684 1.008646 371.7428 0.001413 2.33183 
 
461 0.655297 0.181854 -0.47344 0.19741 0.764946 1.006732 431.0966 0.000493 0.809733 
 
462 0.673025 0.168176 -0.50485 0.18524 0.77836 1.006808 428.3872 0.000455 0.748466 
 
463 1.36778 0.166305 -1.20148 0.060687 0.920481 1.017027 233.2514 0.000101 0.212693 Neg 
464 0.528423 0.507033 -0.02139 0.425204 0.516873 1.008664 371.2742 0.00143 2.43528 
 
465 0.725594 0.170439 -0.55516 0.179615 0.784878 1.00689 425.4861 0.000431 0.720762 
 
466 0.497841 0.201838 -0.296 0.235898 0.722147 1.006801 428.6488 0.000635 1.01634 
 
467 0.655479 0.171869 -0.48361 0.189822 0.773245 1.006773 429.6535 0.000471 0.771313 
 
468 0.573832 0.176963 -0.39687 0.204173 0.757009 1.006746 430.5893 0.000527 0.84459 
 
469 0.531301 0.17453 -0.35677 0.208341 0.752152 1.006769 429.7856 0.000548 0.86637 
 
470 0.936932 0.182807 -0.75413 0.177316 0.788026 1.007232 413.8076 0.000411 0.709548 
 
471 0.36936 0.429018 0.059659 0.595706 0.323266 1.012301 294.8638 0.00342 4.85066 
 
472 0.579775 0.332466 -0.24731 0.392534 0.534854 1.01507 255.2547 0.002644 2.12726 
 
473 0.870252 0.388655 -0.4816 0.181823 0.736398 1.025378 171.2392 0.002532 0.731591 
 
474 0.594136 0.268557 -0.32558 0.265294 0.66946 1.014272 265.4953 0.001816 1.18872 
 
475 0.455464 0.4956 0.040136 0.494393 0.416584 1.013417 277.4722 0.004162 3.21903 
 
476 0.515848 0.263401 -0.25245 0.226827 0.71008 1.015813 246.4108 0.001576 0.965793 
 
477 0.499406 0.391192 -0.10821 0.452573 0.463282 1.016486 238.935 0.003956 2.72162 
 
478 0.463885 0.320443 -0.14344 0.336433 0.580747 1.013724 273.0383 0.003063 1.66909 
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479 0.662517 0.249629 -0.41289 0.126187 0.82188 1.016687 236.7906 0.000918 0.475404 Neg 
480 0.723619 0.167751 -0.55587 0.049266 0.929183 1.007177 415.6417 0.000118 0.17059 Neg 
481 0.91693 0.233505 -0.68343 0.063 0.906952 1.022357 189.3044 0.000299 0.221344 Neg 
482 0.234827 0.293802 0.058975 0.633599 0.311847 1.005067 501.1016 0.001909 5.69278 
 
483 0.920335 0.250859 -0.66948 0.115031 0.845896 1.018275 221.162 0.000562 0.427912 Neg 
484 0.654625 0.213232 -0.44139 0.198184 0.758571 1.007962 390.9598 0.000686 0.813692 
 
485 0.39926 0.302274 -0.09699 0.468521 0.475385 1.008233 383.112 0.001575 2.90207 
 
486 0.60007 0.084504 -0.51557 0.01495 0.976733 1.022444 188.7253 1.34E-05 0.049964 Neg 
487 0.55753 0.55591 -0.00162 0.503816 0.405163 1.014587 261.3566 0.00514 3.34268 
 
488 0.571932 0.229497 -0.34244 0.17022 0.779562 1.015008 256.0116 0.000972 0.675326 
 
489 0.449125 0.5415 0.092375 0.579716 0.32502 1.014734 259.4636 0.004895 4.54087 
 
490 0.495994 0.294718 -0.20128 0.306176 0.61725 1.013548 275.5658 0.002519 1.45274 
 
491 0.672986 0.258419 -0.41457 0.158282 0.790504 1.014563 261.663 0.000999 0.619055 
 
492 0.656012 0.355496 -0.30052 0.272374 0.636895 1.02056 202.0749 0.003651 1.23232 
 
493 0.482935 0.340755 -0.14218 0.35955 0.555737 1.014915 257.1738 0.00342 1.84816 
 
494 0.477741 0.346932 -0.13081 0.335529 0.583083 1.013919 270.3126 0.002875 1.66234 
 
495 0.372389 0.275003 -0.09739 0.418593 0.518501 1.009616 347.6102 0.002085 2.37016 
 
496 0.677248 0.175338 -0.50191 0.098969 0.871935 1.00556 478.0583 0.000294 0.361599 Neg 
497 0.863373 0.25672 -0.60665 0.140378 0.815334 1.019841 207.7032 0.000854 0.537599 Neg 
498 0.678311 0.129657 -0.54865 0.036874 0.948335 1.005622 475.3107 5.35E-05 0.126038 Neg 
499 0.390261 0.343846 -0.04641 0.506574 0.420234 1.010955 319.0866 0.002877 3.37976 
 
500 0.531822 0.375261 -0.15656 0.385369 0.525358 1.016521 238.5632 0.00394 2.06408 
 
501 0.530517 0.312804 -0.21771 0.378001 0.554371 1.013215 280.463 0.002231 2.00064 
 
502 0.765338 0.281467 -0.48387 0.162805 0.776893 1.020644 201.4355 0.001448 0.640189 
 
503 0.35463 0.155162 -0.19947 0.152459 0.801188 1.018431 219.7365 0.0008 0.592186 Neg 
504 0.50587 0.400015 -0.10586 0.410562 0.502208 1.016453 239.2863 0.003931 2.29302 
 
505 0.604537 0.351794 -0.25274 0.354829 0.577192 1.012316 294.6179 0.00202 1.81055 
 
506 0.589934 0.363962 -0.22597 0.377277 0.558989 1.012208 296.4131 0.001878 1.99449 
 
507 0.611693 0.344857 -0.26684 0.321919 0.617006 1.01097 318.7833 0.001627 1.5629 
 
Chapter 8 Filovirus Data Ebola Selection analysis 
508 1.42564 0.173336 -1.2523 0.044692 0.938947 1.008692 370.5242 6.78E-05 0.154011 Neg 
509 6.10652 6.71997 0.613453 0.44055 0.405245 0.999788 1043.848 0.007329 2.59239 
 
510 0.619706 0.304609 -0.3151 0.307722 0.632538 1.010142 335.8091 0.001471 1.46334 
 
511 0.410653 0.314567 -0.09609 0.475245 0.458732 1.009616 347.6077 0.002216 2.98145 
 
512 0.414299 0.403208 -0.01109 0.516687 0.404878 1.011832 302.8628 0.003021 3.51937 
 
513 0.564451 0.385731 -0.17872 0.362835 0.54401 1.017383 229.6636 0.004144 1.87466 
 
514 0.321382 0.379132 0.057751 0.561805 0.352689 1.008146 385.5882 0.003477 4.22069 
 
515 0.889851 0.329078 -0.56077 0.206206 0.728833 1.026913 163.3696 0.0022 0.855183 
 
516 0.470501 0.358447 -0.11205 0.397804 0.513972 1.013705 273.3102 0.00349 2.17469 
 
517 0.463666 0.504295 0.040629 0.503541 0.400846 1.013934 270.1055 0.004704 3.33901 
 
518 0.327513 0.233118 -0.09439 0.401441 0.539302 1.013379 278.0245 0.001823 2.20791 
 
519 0.52841 0.252881 -0.27553 0.208361 0.72988 1.014012 269.029 0.001435 0.866471 
 
520 0.714511 0.095538 -0.61897 0.01173 0.982198 1.02069 201.0921 7.22E-06 0.039074 Neg 
521 1.15288 0.142807 -1.01008 0.015438 0.976887 1.011556 307.7781 1.46E-05 0.051619 Neg 
522 0.787348 0.165021 -0.62233 0.043059 0.938133 1.00435 538.896 9.00E-05 0.148131 Neg 
523 0.485721 0.233418 -0.2523 0.195179 0.747323 1.015994 244.3581 0.001263 0.798362 
 
524 0.942228 0.232946 -0.70928 0.069329 0.900122 1.022086 191.1214 0.000326 0.245236 Neg 
525 0.599101 0.182744 -0.41636 0.086791 0.880535 1.014392 263.9076 0.000316 0.312873 Neg 
526 0.431239 0.349377 -0.08186 0.4096 0.506751 1.01216 297.2266 0.003226 2.28391 
 
527 0.396343 0.356346 -0.04 0.491809 0.439788 1.011676 305.6182 0.002573 3.18593 
 
528 0.606754 0.299675 -0.30708 0.22702 0.701569 1.019237 212.6877 0.002236 0.966854 
 
529 0.884841 0.22558 -0.65926 0.06376 0.90703 1.019738 208.537 0.000275 0.224194 Neg 
530 0.380225 0.297008 -0.08322 0.42246 0.503406 1.009453 351.4291 0.002588 2.40807 
 
531 1.18815 0.316656 -0.87149 0.109684 0.844947 1.031845 142.5226 0.000869 0.405568 Neg 
532 0.397116 0.395045 -0.00207 0.503522 0.404586 1.013161 281.2678 0.00429 3.33876 
 
533 0.579708 0.232467 -0.34724 0.149209 0.801037 1.016184 242.2286 0.000897 0.577347 Neg 
534 0.336622 0.278267 -0.05835 0.467689 0.469487 1.007759 397.0497 0.002146 2.89239 
 
535 0.267186 0.313162 0.045977 0.590326 0.335598 1.004408 535.58 0.002741 4.74372 
 
536 0.541707 0.51095 -0.03076 0.419853 0.481893 1.01377 272.3867 0.005137 2.38246 
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537 0.615327 0.130721 -0.48461 0.046553 0.934465 1.010724 323.6602 9.06E-05 0.160738 Neg 
538 1.09736 0.165845 -0.93152 0.02639 0.962891 1.018435 219.7044 3.97E-05 0.089233 Neg 
539 0.440113 0.325994 -0.11412 0.365751 0.551651 1.012353 294.0121 0.00293 1.89842 
 
540 0.752552 0.184536 -0.56802 0.05917 0.915479 1.008476 376.3517 0.00019 0.207041 Neg 
541 0.899737 0.118264 -0.78147 0.010985 0.983242 1.002769 646.8138 6.33E-06 0.036564 Neg 
542 0.540989 0.259392 -0.2816 0.24487 0.693436 1.013775 272.322 0.001542 1.06753 
 
543 0.538784 0.270957 -0.26783 0.218587 0.718188 1.013307 279.0934 0.001492 0.920893 
 
544 0.604811 0.3431 -0.26171 0.292199 0.633039 1.016801 235.5959 0.00251 1.35904 
 
545 0.501686 0.464001 -0.03769 0.435757 0.479843 1.014442 263.2407 0.003564 2.5424 
 
546 0.495831 0.290365 -0.20547 0.325649 0.603285 1.012949 284.4987 0.002249 1.58975 
 
547 0.58819 0.182698 -0.40549 0.110237 0.853549 1.009933 340.3797 0.000411 0.407867 Neg 
548 0.797494 0.276457 -0.52104 0.180406 0.766173 1.016871 234.8589 0.001181 0.724634 
 
549 0.353406 0.358444 0.005038 0.502761 0.410154 1.00958 348.4389 0.003468 3.3286 
 
550 0.457189 0.052539 -0.40465 0.064881 0.901427 1.000441 919.8156 0.000264 0.228412 Neg 
551 0.660069 0.033497 -0.62657 0.003415 0.994096 1.004547 527.9406 8.04E-07 0.011282 Neg 
552 0.614776 0.082294 -0.53248 0.014876 0.97668 1.019246 212.6108 1.43E-05 0.049711 Neg 
553 0.983894 0.084595 -0.8993 0.003143 0.994942 1.036832 126.4411 6.46E-07 0.01038 Neg 
554 1.02236 0.144325 -0.87803 0.014173 0.978316 1.008623 372.3736 1.21E-05 0.047329 Neg 
555 0.946751 0.037958 -0.90879 0.001342 0.997924 1.045757 105.5537 1.03E-07 0.004425 Neg 
556 1.0384 0.123099 -0.9153 0.016598 0.97656 1.019183 213.1464 1.37E-05 0.055562 Neg 
557 0.911626 0.142426 -0.7692 0.021567 0.967808 1.000506 909.0569 2.48E-05 0.072565 Neg 
558 0.928636 0.04361 -0.88503 0.023593 0.962342 1.001112 819.7426 3.88E-05 0.079546 Neg 
559 0.752007 0.093098 -0.65891 0.010366 0.984192 1.020927 199.3205 5.62E-06 0.034484 Neg 
560 0.519932 0.147459 -0.37247 0.080881 0.890313 1.019225 212.7893 0.000248 0.289696 Neg 
561 0.844266 0.138987 -0.70528 0.034628 0.952049 1.000047 990.7743 4.83E-05 0.118085 Neg 
562 0.442102 0.131034 -0.31107 0.158885 0.804132 1.011142 315.4829 0.00067 0.621862 Neg 
563 1.00844 0.117396 -0.89104 0.012883 0.980948 1.004753 516.9679 7.77E-06 0.042966 Neg 
564 0.76132 0.191445 -0.56988 0.0764 0.896791 1.008961 363.5328 0.000244 0.272317 Neg 
565 0.430321 0.248738 -0.18158 0.253659 0.680815 1.015333 252.0518 0.001759 1.11887 
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566 0.700851 0.03156 -0.66929 0.002795 0.995176 1.006053 457.0899 5.06E-07 0.009227 Neg 
567 0.607981 0.193077 -0.4149 0.086398 0.878454 1.013701 273.3763 0.00036 0.311324 Neg 
568 0.707073 0.037514 -0.66956 0.0026 0.995698 1.005987 459.7883 3.87E-07 0.008581 Neg 
569 0.982048 0.107623 -0.87443 0.012646 0.982154 1.032891 138.7997 9.25E-06 0.042163 Neg 
570 0.411049 0.145437 -0.26561 0.11909 0.841907 1.017094 232.5672 0.000538 0.445049 Neg 
571 0.928636 0.04361 -0.88503 0.023593 0.962342 1.001112 819.7426 3.88E-05 0.079546 Neg 
572 0.756809 0.027253 -0.72956 0.001326 0.997623 1.008102 386.8637 1.20E-07 0.004372 Neg 
573 0.922412 0.024694 -0.89772 0.00023 0.99957 1.034141 134.6093 4.27E-09 0.000758 Neg 
574 0.698634 0.099983 -0.59865 0.019059 0.971816 1.016128 242.8561 1.74E-05 0.063962 Neg 
575 0.63862 0.026647 -0.61197 0.002289 0.995778 1.003807 571.5662 4.35E-07 0.007553 Neg 
576 0.501746 0.039333 -0.46241 0.007695 0.98758 1.007826 395.0301 3.84E-06 0.025527 Neg 
577 0.799981 0.079082 -0.7209 0.003262 0.994561 1.039987 118.1096 7.23E-07 0.010774 Neg 
578 0.354441 0.171581 -0.18286 0.244554 0.704118 1.015336 252.012 0.001236 1.06571 
 
579 0.448257 0.132028 -0.31623 0.08187 0.888192 1.019559 209.9939 0.000288 0.293554 Neg 
580 1.90914 0.028282 -1.88086 8.42E-05 0.999846 1.062172 81.63066 6.70E-10 0.000277 Neg 
581 0.500583 0.039818 -0.46077 0.014327 0.976722 1.005326 488.6923 1.39E-05 0.047851 Neg 
582 0.814931 0.087726 -0.72721 0.006235 0.990153 1.025424 170.9923 2.26E-06 0.020654 Neg 
583 0.673955 0.03657 -0.63739 0.004156 0.993086 1.005186 495.3095 1.05E-06 0.013738 Neg 
584 1.56144 2.69496 1.13352 0.546684 0.237929 0.997777 1791.115 0.021561 3.9701 
 
585 1.26545 0.12272 -1.14273 0.005299 0.991637 1.022167 190.5714 1.94E-06 0.017538 Neg 
586 0.683474 0.036801 -0.64667 0.00346 0.994245 1.005679 472.8476 6.98E-07 0.011429 Neg 
587 0.549901 0.170425 -0.37948 0.10732 0.858023 1.010062 337.5471 0.000386 0.395777 Neg 
588 0.746452 0.073723 -0.67273 0.027455 0.959673 1.016318 240.7586 6.74E-05 0.092936 Neg 
589 0.596226 0.107522 -0.4887 0.043811 0.937936 1.00764 400.71 9.33E-05 0.150835 Neg 
590 1.28681 0.025407 -1.2614 3.69E-05 0.999931 1.079013 66.80861 1.52E-10 0.000122 Neg 
591 0.707198 0.029682 -0.67752 0.004254 0.992263 1.005437 483.5881 1.54E-06 0.014064 Neg 
592 0.34951 0.186468 -0.16304 0.264606 0.681472 1.016351 240.3966 0.001398 1.18453 
 
593 0.762248 0.181474 -0.58077 0.056353 0.920591 1.008629 372.1951 0.000156 0.196595 Neg 
594 0.807588 0.041888 -0.7657 0.003922 0.994418 1.01979 208.1122 6.51E-07 0.012963 Neg 
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595 0.680851 0.125774 -0.55508 0.026087 0.961205 1.007391 408.5948 3.36E-05 0.08818 Neg 
596 0.753271 0.032862 -0.72041 0.00189 0.996712 1.008281 381.753 2.32E-07 0.006234 Neg 
597 0.449762 0.101992 -0.34777 0.043681 0.935949 1.019621 209.4876 0.000107 0.150368 Neg 
598 0.70162 0.04371 -0.65791 0.005107 0.992502 1.007853 394.1983 1.13E-06 0.0169 Neg 
599 1.05881 0.033201 -1.0256 0.000629 0.999066 1.07348 70.97569 2.58E-08 0.002072 Neg 
600 0.608934 0.100561 -0.50837 0.029371 0.958278 1.021119 197.9142 4.00E-05 0.099618 Neg 
601 0.470651 0.040298 -0.43035 0.014317 0.976785 1.005594 476.5405 1.43E-05 0.047816 Neg 
602 0.559307 0.094557 -0.46475 0.029741 0.956252 1.018618 218.0556 4.53E-05 0.100909 Neg 
603 0.900606 0.026103 -0.8745 0.001064 0.998051 1.021565 194.7194 9.03E-08 0.003507 Neg 
604 1.04563 0.087154 -0.95847 0.005445 0.991565 1.02847 156.1255 1.70E-06 0.018024 Neg 
605 0.727278 0.029111 -0.69817 0.001209 0.997886 1.005672 473.1465 8.94E-08 0.003985 Neg 
606 0.601458 0.089257 -0.5122 0.014311 0.977637 1.020867 199.769 1.24E-05 0.047795 Neg 
607 0.686162 0.087992 -0.59817 0.023501 0.965032 1.014175 266.8062 3.04E-05 0.079227 Neg 
608 0.585268 0.104148 -0.48112 0.025953 0.961513 1.018251 221.384 3.45E-05 0.087715 Neg 
609 0.974218 0.033983 -0.94024 0.000328 0.999436 1.04957 98.7113 8.69E-09 0.001079 Neg 
610 0.842662 0.090311 -0.75235 0.008278 0.987322 1.022117 190.9132 3.63E-06 0.027477 Neg 
611 1.03438 0.093882 -0.9405 0.002364 0.99625 1.045497 106.0571 4.91E-07 0.0078 Neg 
612 0.8343 0.08286 -0.75144 0.007062 0.988729 1.023147 184.2057 3.16E-06 0.023414 Neg 
613 0.919724 0.100414 -0.81931 0.003963 0.993356 1.016166 242.4289 1.25E-06 0.013098 Neg 
614 1.17689 0.033829 -1.14306 0.000137 0.999775 1.088646 60.73022 1.84E-09 0.000452 Neg 
615 0.532533 0.094339 -0.43819 0.036883 0.945521 1.014213 266.2865 7.60E-05 0.126068 Neg 
616 0.611169 0.02983 -0.58134 0.003707 0.993439 1.003809 571.4355 1.01E-06 0.01225 Neg 
617 0.966654 0.028082 -0.93857 0.000182 0.999674 1.048208 101.0427 2.62E-09 0.0006 Neg 
618 0.80385 0.029651 -0.7742 0.001437 0.997526 1.013994 269.2761 1.32E-07 0.004736 Neg 
619 0.515424 0.171031 -0.34439 0.10352 0.859734 1.016006 244.2235 0.000422 0.380147 Neg 
620 1.37154 0.035357 -1.33618 4.06E-05 0.999924 1.071619 72.51302 2.12E-10 0.000134 Neg 
621 0.688817 0.029413 -0.6594 0.001149 0.997993 1.003357 601.9257 8.46E-08 0.003785 Neg 
622 0.700313 0.10544 -0.59487 0.02454 0.964873 1.01696 233.9463 2.57E-05 0.082821 Neg 
623 0.944073 0.096684 -0.84739 0.005231 0.991783 1.02175 193.4217 1.67E-06 0.017311 Neg 
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624 0.690252 0.133255 -0.557 0.038168 0.946285 1.003384 600.026 5.72E-05 0.130637 Neg 
625 0.737174 0.096742 -0.64043 0.025863 0.966132 1.027552 160.3129 2.49E-05 0.087404 Neg 
626 0.761592 0.025946 -0.73565 0.001114 0.99797 1.008542 374.5399 9.03E-08 0.00367 Neg 
627 0.867765 0.034613 -0.83315 0.001191 0.998072 1.027962 158.411 7.86E-08 0.003926 Neg 
628 0.796986 0.113725 -0.68326 0.01688 0.975099 1.001371 786.8606 1.31E-05 0.056523 Neg 
629 0.848222 0.030717 -0.81751 0.000888 0.998459 1.019625 209.4551 5.02E-08 0.002926 Neg 
630 0.688136 0.029975 -0.65816 0.002578 0.995526 1.005471 482.0472 4.45E-07 0.00851 Neg 
631 0.942573 0.026867 -0.91571 0.000483 0.999122 1.027895 158.7179 1.71E-08 0.001591 Neg 
632 0.752035 0.026818 -0.72522 0.001324 0.99759 1.008065 387.9249 1.31E-07 0.004365 Neg 
633 0.96835 0.034103 -0.93425 0.000361 0.999388 1.05182 95.10664 9.54E-09 0.001189 Neg 
634 0.84831 0.031941 -0.81637 0.00053 0.999065 1.017918 224.4828 1.84E-08 0.001746 Neg 
635 0.430982 0.185346 -0.24564 0.199523 0.752862 1.019448 210.9151 0.000992 0.820559 
 
636 0.44055 0.051833 -0.38872 0.021724 0.969359 1.008371 379.2474 2.36E-05 0.073103 Neg 
637 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
638 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
639 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
640 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
641 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
642 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
643 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
644 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
645 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
646 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
647 0.855529 0.153852 -0.70168 0.143119 0.826101 1.007176 415.6759 0.000429 0.549849 Neg 
648 0.914649 0.035766 -0.87888 0.001007 0.998324 1.032849 138.9438 6.28E-08 0.003318 Neg 
649 0.801874 0.036303 -0.76557 0.001309 0.997812 1.014075 268.1658 9.79E-08 0.004315 Neg 
650 0.643842 0.029617 -0.61423 0.003172 0.994382 1.004131 551.6298 7.24E-07 0.010474 Neg 
651 0.665989 0.033409 -0.63258 0.003995 0.993046 1.005067 501.0614 1.12E-06 0.013205 Neg 
652 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
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653 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
654 0.998328 0.634217 -0.36411 0.231924 0.729792 1.007252 413.1572 0.000486 0.994046 
 
655 1.37869 0.148795 -1.2299 0.020096 0.971374 1.015278 252.7145 2.31E-05 0.067514 Neg 
656 0.542212 0.097826 -0.44439 0.038767 0.945107 1.019386 211.4291 7.46E-05 0.132768 Neg 
657 0.975797 0.037026 -0.93877 0.000406 0.999305 1.049724 98.45596 1.32E-08 0.001336 Neg 
658 0.398085 0.041458 -0.35663 0.029734 0.951705 1.004309 541.2214 6.91E-05 0.100884 Neg 
659 0.5381 0.02614 -0.51196 0.002765 0.994788 1.005145 497.2976 6.99E-07 0.009126 Neg 
660 0.476566 0.143758 -0.33281 0.131687 0.832662 1.013398 277.746 0.000478 0.499268 Neg 
661 0.644757 0.0338 -0.61096 0.005779 0.989967 1.004851 511.879 2.49E-06 0.019136 Neg 
662 0.646264 0.033577 -0.61269 0.005402 0.990562 1.004816 513.6847 2.19E-06 0.017879 Neg 
663 0.973014 0.028912 -0.9441 0.000399 0.999294 1.029871 150.158 1.14E-08 0.001313 Neg 
664 0.589882 0.093995 -0.49589 0.023826 0.964537 1.018693 217.3953 3.03E-05 0.080351 Neg 
665 0.382527 0.125068 -0.25746 0.133893 0.822591 1.012756 287.5127 0.00074 0.508924 Neg 
666 0.677703 0.117231 -0.56047 0.050244 0.930403 1.004242 545.0691 0.000107 0.174157 Neg 
667 0.431404 0.030657 -0.40075 0.014329 0.974679 1.004226 546.0372 1.95E-05 0.047859 Neg 
668 0.412336 0.126843 -0.28549 0.182574 0.776735 1.011794 303.528 0.000831 0.735287 
 
669 0.762907 0.128664 -0.63424 0.025792 0.962371 0.999731 1056.198 2.96E-05 0.087157 Neg 
670 0.865056 0.084992 -0.78007 0.005442 0.991399 1.030336 148.2823 1.74E-06 0.018015 Neg 
671 0.664447 0.025788 -0.63866 0.00194 0.996398 1.004037 557.261 3.05E-07 0.006398 Neg 
672 0.732079 0.029359 -0.70272 0.002307 0.995962 1.007718 398.3086 3.65E-07 0.007614 Neg 
673 0.794973 0.093881 -0.70109 0.009244 0.985765 1.018546 218.703 4.54E-06 0.030717 Neg 
674 0.943172 0.082046 -0.86113 0.003651 0.994121 1.036271 128.058 8.47E-07 0.012063 Neg 
675 0.737604 0.122018 -0.61559 0.048724 0.933412 1.002836 641.3443 8.82E-05 0.168617 Neg 
676 0.693355 0.029947 -0.66341 0.002713 0.995282 1.005831 466.3073 5.00E-07 0.008955 Neg 
677 0.606205 0.105624 -0.50058 0.03994 0.943892 1.014416 263.5857 6.63E-05 0.136955 Neg 
678 1.00154 0.029113 -0.97242 0.00068 0.998774 1.030359 148.1925 3.58E-08 0.002241 Neg 
679 0.565749 0.030951 -0.5348 0.003592 0.993677 1.004882 510.3189 9.65E-07 0.011868 Neg 
680 0.899214 0.146798 -0.75242 0.030384 0.956875 1.003447 595.6153 4.42E-05 0.103161 Neg 
681 0.650289 0.111859 -0.53843 0.046143 0.935535 1.004325 540.2769 9.43E-05 0.159253 Neg 
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682 0.869408 0.027982 -0.84143 0.001147 0.997967 1.020572 201.9787 9.42E-08 0.003779 Neg 
683 0.792345 0.048283 -0.74406 0.005029 0.99229 1.013602 274.7858 1.16E-06 0.01664 Neg 
684 0.408557 0.143565 -0.26499 0.138829 0.82186 1.020198 204.8661 0.000571 0.530711 Neg 
685 0.639714 0.121401 -0.51831 0.052447 0.928887 1.011803 303.3669 9.36E-05 0.182215 Neg 
686 1.01575 0.133661 -0.88209 0.033977 0.953056 0.999117 1212.214 4.36E-05 0.115786 Neg 
687 0.544063 0.130495 -0.41357 0.049844 0.929786 1.021781 193.2102 0.000114 0.172695 Neg 
688 0.793283 0.14391 -0.64937 0.040386 0.94296 0.999097 1217.958 6.92E-05 0.13855 Neg 
689 0.61514 0.125938 -0.4892 0.031267 0.953966 1.014314 264.9336 4.90E-05 0.106254 Neg 
690 0.707519 0.171031 -0.53649 0.061729 0.914416 1.007155 416.3987 0.000166 0.216585 Neg 
691 0.613797 0.226909 -0.38689 0.156096 0.797045 1.015387 251.3971 0.000875 0.608926 
 
692 0.618386 0.223715 -0.39467 0.145663 0.80992 1.011784 303.7062 0.00075 0.561287 Neg 
693 0.936932 0.182807 -0.75413 0.177316 0.788026 1.007232 413.8076 0.000411 0.709548 
 
694 0.558632 0.182398 -0.37623 0.208955 0.751793 1.006687 432.7325 0.000541 0.869593 
 
695 0.77438 0.191531 -0.58285 0.069904 0.902743 1.009938 340.2714 0.000235 0.247423 Neg 
696 0.216025 0.159981 -0.05604 0.441891 0.497596 1.004574 526.4823 0.002544 2.60652 
 
697 0.444221 0.192509 -0.25171 0.190844 0.761315 1.02013 205.399 0.000916 0.776446 
 
698 0.350145 0.089332 -0.26081 0.149255 0.803432 1.001391 784.358 0.001251 0.577558 Neg 
699 2.20418 0.110468 -2.09371 0.014589 0.980019 1.012853 285.995 8.42E-06 0.048737 Neg 
700 0.928636 0.04361 -0.88503 0.023593 0.962342 1.001112 819.7426 3.88E-05 0.079546 Neg 
701 0.597014 0.029964 -0.56705 0.004424 0.992158 1.003525 590.218 1.49E-06 0.014627 Neg 
702 0.667691 0.161532 -0.50616 0.051257 0.926373 1.008363 379.4563 0.000125 0.177857 Neg 
703 0.673151 0.170235 -0.50292 0.186197 0.777317 1.006804 428.5394 0.000458 0.753214 
 
704 0.928636 0.04361 -0.88503 0.023593 0.962342 1.001112 819.7426 3.88E-05 0.079546 Neg 
705 0.548749 0.102345 -0.4464 0.038342 0.946259 1.023073 184.6714 6.84E-05 0.131257 Neg 
706 1.13527 0.141971 -0.99329 0.019972 0.970889 1.002177 699.5124 2.02E-05 0.06709 Neg 
707 0.854103 0.140103 -0.714 0.081579 0.898676 1.006554 437.6193 0.000163 0.292415 Neg 
708 0.645754 0.125038 -0.52072 0.035852 0.948609 1.007454 406.5696 5.64E-05 0.122416 Neg 
709 0.832614 0.11349 -0.71912 0.012049 0.981718 1.0021 706.9745 7.47E-06 0.040149 Neg 
710 0.706673 0.135946 -0.57073 0.030779 0.955043 1.003903 565.5196 4.48E-05 0.104543 Neg 
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711 0.946745 0.035314 -0.91143 0.000536 0.999088 1.037495 124.5898 1.95E-08 0.001767 Neg 
712 0.937938 0.028604 -0.90933 0.000472 0.999173 1.036486 127.4343 1.59E-08 0.001556 Neg 
713 0.763829 0.161485 -0.60234 0.042693 0.938229 1.00334 603.133 8.94E-05 0.146815 Neg 
714 0.582892 0.186295 -0.3966 0.092057 0.872599 1.014456 263.0568 0.00037 0.333781 Neg 
715 0.569333 0.222703 -0.34663 0.140145 0.81322 1.01674 236.2378 0.000757 0.536562 Neg 
716 1.67674 0.158881 -1.51786 0.002097 0.996215 1.021329 196.397 4.95E-07 0.006918 Neg 
717 0.366683 0.29953 -0.06715 0.409598 0.50614 1.008616 372.5473 0.003184 2.28389 
 
718 0.54559 0.027309 -0.51828 0.006526 0.987802 1.003332 603.7085 4.15E-06 0.021624 Neg 
719 0.344962 0.134369 -0.21059 0.16182 0.790415 1.016593 237.7873 0.000967 0.635568 
 
720 0.533808 0.094354 -0.43945 0.029813 0.955749 1.017436 229.1419 4.88E-05 0.101162 Neg 
721 0.626649 0.164271 -0.46238 0.074914 0.898314 1.010081 337.125 0.000215 0.266591 Neg 
722 0.99348 0.027543 -0.96594 0.000144 0.999742 1.055512 89.77054 1.76E-09 0.000474 Neg 
723 0.619099 0.032171 -0.58693 0.003789 0.993451 1.004113 552.65 9.80E-07 0.012521 Neg 
724 0.760926 0.038081 -0.72285 0.002986 0.995168 1.011261 313.2262 4.82E-07 0.009861 Neg 
725 0.619483 0.154384 -0.4651 0.060883 0.914638 1.010176 335.0605 0.000161 0.213423 Neg 
726 0.540639 0.034866 -0.50577 0.011709 0.979776 1.003973 561.1623 1.15E-05 0.039002 Neg 
727 0.83162 0.085391 -0.74623 0.005196 0.991837 1.034453 133.6057 1.58E-06 0.017195 Neg 
728 0.660069 0.033497 -0.62657 0.003415 0.994096 1.004547 527.9407 8.04E-07 0.011282 Neg 
729 0.548652 0.173913 -0.37474 0.202697 0.758561 1.006712 431.8445 0.000524 0.836933 
 
730 0.573832 0.176963 -0.39687 0.204173 0.757009 1.006746 430.5893 0.000527 0.84459 
 
731 0.655164 0.172773 -0.48239 0.190967 0.771982 1.006763 430.008 0.000475 0.777068 
 
732 1.23151 0.156496 -1.07501 0.06142 0.91911 1.015608 248.7833 0.000108 0.21543 Neg 
733 0.394293 0.027924 -0.36637 0.043311 0.911193 0.998678 1355.487 0.000351 0.149035 Neg 
734 0.322179 0.19401 -0.12817 0.38692 0.561256 1.012389 293.4159 0.001802 2.07764 
 
735 0.496666 0.141816 -0.35485 0.088468 0.880564 1.015137 254.4205 0.000294 0.319506 Neg 
736 1.55465 0.292694 -1.26196 0.046302 0.926419 1.033104 138.0667 0.000266 0.15983 Neg 
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MEME Results 
Codon alpha beta1 p1 beta2 p2 LRT p-value q-value Log(L) Sele 
1 0.844619 0 0.046586 0 0.953414 0 0.67 0.70245 -4.14326 
 
2 3.32397 0.562096 1 0.562253 3.81E-09 0 0.67 0.696497 -20.8219 
 
3 6.01993 0.306182 0.895154 5.62793 0.104846 0 0.67 0.718834 -26.0345 
 
4 0 0 1.00E-09 0.284922 1 1.69371 0.216222 1 -10.854 
 
5 0.345083 0.112046 0.999999 0.112047 1.47E-06 0 0.67 0.73931 -11.0875 
 
6 6.40142 0.244052 1 0.244187 1.00E-09 0 0.67 0.741534 -20.5217 
 
7 1.79814 0.129083 1 0.129072 1.00E-09 0 0.67 0.738204 -13.8212 
 
8 1.15862 0 0.0501 0 0.9499 0 0.67 0.736 -6.42766 
 
9 0.243399 0 0.065 0 0.935 0 0.67 0.7371 -7.98132 
 
10 0.590334 0 0.048373 0 0.951627 0 0.67 0.742651 -7.98658 
 
11 1.43472 0 0.04842 0 0.95158 0 0.67 0.748285 -10.6583 
 
12 0 0 1.00E-09 0.19966 1 0.483988 0.436011 1 -11.4074 
 
13 1.94604 0.132673 1 0.132711 1.74E-09 0 0.67 0.749422 -14.54 
 
14 1.02285 0.147774 0.550618 0 0.449382 0 0.67 0.747152 -12.9111 
 
15 1.86473 0 0.638952 2.19781 0.361048 0.0127 0.640615 1 -26.9093 
 
16 0.831925 0.244576 1 0.243717 1.00E-09 0 0.67 0.743771 -21.3511 
 
17 0.762614 0.311175 0.317484 0 0.682516 0 0.67 0.744894 -14.7155 
 
18 2.00824 0.06855 1 0.06852 1.00E-09 0 0.67 0.72305 -16.0918 
 
19 0.303845 0.099014 1 0.099036 1.00E-09 0 0.67 0.724112 -18.089 
 
20 0 0 0.697374 0.239277 0.302626 0.732134 0.373785 1 -9.99073 
 
21 0.321292 0.117378 1 0.117488 1.00E-09 0 0.67 0.719883 -16.2394 
 
22 0.844619 0 0.046586 0 0.953414 0 0.67 0.720936 -4.95231 
 
23 0.440569 0.254411 0.744254 0 0.255746 0 0.67 0.726244 -17.7577 
 
24 2.48558 0.058653 1 0.058657 1.00E-09 0 0.67 0.731632 -16.8211 
 
25 0 0 0 0 1 0 1 1 0 
 
26 2.47457 0 0.049947 0 0.950053 0 0.67 0.727316 -14.2593 
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27 1.01311 0.050816 1 0.050821 1.00E-09 0 0.67 0.730548 -11.8523 
 
28 1.12256 0.23788 0.352161 0 0.647839 0 0.67 0.73381 -11.8412 
 
29 0.807966 0.31504 0.986176 255.567 0.013824 1.45381 0.246851 1 -28.5836 
 
30 1.26563 0.289075 1 0.289072 1.00E-09 0 0.67 0.970709 -18.5169 
 
31 3.14249 0.715545 0.52807 0 0.47193 0 0.67 0.972623 -32.1581 
 
32 0.635854 0.14451 1 0.144353 1.00E-09 0 0.67 0.974545 -22.853 
 
33 2.25898 0.1169 1 0.116835 1.00E-09 0 0.67 0.968802 -17.0853 
 
34 1.66977 0 0.047321 0 0.952679 0 0.67 0.963125 -14.0169 
 
35 2.20135 0.070058 1 0.070154 1.00E-09 0 0.67 0.96501 -16.982 
 
36 2.08028 0.530521 0.247387 0 0.752613 0 0.67 0.966902 -17.9901 
 
37 2.42177 0.243155 1 0.243235 1.00E-09 0 0.67 0.976475 -26.5766 
 
38 0.996782 0.116512 1 0.116244 1.00E-09 0 0.67 0.98624 -16.048 
 
39 2.48574 0.053257 0.902509 6.52188 0.097491 0.437358 0.449402 1 -19.5052 
 
40 3.72275 0.046323 1 0.046333 1.00E-09 0 0.67 0.992193 -13.4958 
 
41 3.31381 0.095629 1 0.0955 1.00E-09 0 0.67 0.990201 -16.2907 
 
42 2.32359 0.186715 1 0.186862 1.00E-09 0 0.67 0.984271 -19.6648 
 
43 2.76024 0 0.05 0 0.95 0 0.67 0.978413 -10.7124 
 
44 3.54212 0 0.456439 0.334847 0.543561 0 0.67 0.980358 -18.5495 
 
45 0.461902 0.21224 0.924952 0.21224 0.075048 0 0.67 0.961248 -17.0363 
 
46 0 0 0.821542 20.653 0.178458 9.37053 0.004066 0.748175 -28.9379 Pos 
47 0.200334 0.200334 0.187507 0.213272 0.812493 0.000337 0.665524 1 -24.3296 
 
48 1.06711 0.180913 1 0.18058 1.00E-09 0 0.67 0.942868 -19.4177 
 
49 1.17869 0 0.048385 0 0.951615 0 0.67 0.944674 -7.11063 
 
50 0.580846 0.243628 0.999995 0.243628 5.26E-06 0 0.67 0.933939 -17.0522 
 
51 1.97045 0 0.04842 0 0.95158 0 0.67 0.935712 -15.3928 
 
52 0.881863 0 0.048465 0 0.951535 0 0.67 0.946488 -10.3077 
 
53 3.39876 0 0.048418 0 0.951583 0 0.67 0.957515 -12.1618 
 
54 0.435095 0.298462 0.777175 0.298462 0.222825 0 0.67 0.95381 -20.2141 
 
55 1.28336 0.05226 1 0.052276 1.00E-09 0 0.67 0.950135 -11.2245 
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56 0 0 0.5646 0.751037 0.4354 0.515344 0.427354 1 -16.0742 
 
57 0.586953 0 0.047288 0 0.952712 0 0.67 1 -12.1493 
 
58 0.375748 0.271043 0.430351 0.271046 0.569649 0 0.67 1 -17.5388 
 
59 4.48057 0 0.750348 0.578952 0.249652 0 0.67 1 -22.3831 
 
60 1.80927 0 0.05 0 0.95 0 0.67 1 -14.513 
 
61 0.496885 0.341064 1 0.340596 1.00E-09 0 0.67 1 -17.2925 
 
62 5.1332 0.210111 0.508659 0 0.491341 0 0.67 1 -15.9699 
 
63 0.630013 0.070488 1 0.070445 1.00E-09 0 0.67 0.932174 -16.1032 
 
64 0.830001 0.190138 1 0.190011 3.81E-09 0 0.67 0.862098 -15.4147 
 
65 0.818597 0.166931 1 0.166909 1.00E-09 0 0.67 0.863608 -23.603 
 
66 1.19614 0.052589 1 0.052616 1.00E-09 0 0.67 0.859094 -13.1734 
 
67 0.751755 0 0.04842 0 0.95158 0 0.67 0.874326 -10.4619 
 
68 1.62554 0.056689 1 0.056714 1.00E-09 0 0.67 0.875879 -16.8731 
 
69 0.699203 0.062789 1 0.0628 1.00E-09 0 0.67 0.853149 -11.3788 
 
70 0.810526 0 0.048408 0 0.951592 0 0.67 0.831568 -12.2593 
 
71 7.02129 0.230457 0.414235 0 0.585765 0 0.67 0.844384 -15.8182 
 
72 0.684179 0 0.047296 0 0.952704 0 0.67 0.911497 -11.0546 
 
73 3.02019 0.185002 0.980483 151.998 0.019517 6.48106 0.017712 1 -26.013 Pos 
74 0 0 1.00E-09 0.173289 1 1.94154 0.18888 1 -16.9924 
 
75 1.09258 0 0.67737 0.90029 0.32263 0 0.67 0.90814 -23.9132 
 
76 1.15237 0.280408 0.329461 0 0.670539 0 0.67 0.925178 -15.4831 
 
77 2.21713 0.126492 0.775844 0.150741 0.224156 0 0.67 0.926917 -18.9983 
 
78 2.50434 0.488565 0.240977 0 0.759023 0 0.67 0.923446 -17.3511 
 
79 0.845791 0.211115 1 0.211274 1.00E-09 0 0.67 0.92 -17.3561 
 
80 0.202599 0.081968 1 0.081961 2.21E-07 0 0.67 0.92172 -11.1304 
 
81 1.14154 0.489318 0.58993 0 0.41007 0 0.67 0.886906 -19.1355 
 
82 0.406446 0.041762 0.920871 94.6333 0.079129 5.84365 0.024552 1 -33.7255 Pos 
83 0.821174 0.065401 1 0.065371 1.00E-09 0 0.67 0.888505 -14.1095 
 
84 1.33536 0 0.04842 0 0.95158 0 0.67 0.899854 -7.33949 
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85 1.69673 0 0.050087 0 0.949913 0 0.67 0.828773 -12.336 
 
86 0 0 0 0 1 0 1 1 0 
 
87 1.08185 0.061045 1 0.061173 1.00E-09 0 0.67 0.766905 -14.0737 
 
88 0.535375 0 0.065 0 0.935 0 0.67 0.779021 -7.41194 
 
89 2.40551 0 0.048716 0 0.951284 0 0.67 1 -13.0561 
 
90 0.987415 0.153258 1 0.153165 1.00E-09 0 0.67 1 -17.4889 
 
91 0 0 0 0 1 0 1 1 0 
 
92 1.85996 0 0.047296 0 0.952704 0 0.67 1 -17.4324 
 
93 1.68472 0 0.048417 0 0.951583 0 0.67 1 -14.8821 
 
94 2.03523 0 0.05015 0 0.94985 0 0.67 1 -11.9009 
 
95 3.15713 0 0.642469 0.213619 0.357531 0 0.67 1 -17.064 
 
96 0 0 0.769837 0.583916 0.230163 2.37003 0.149957 1 -10.7809 
 
97 0.311106 0 0.04842 0 0.95158 0 0.67 1 -9.51169 
 
98 0.827356 0.190184 1 0.190154 4.99E-08 0 0.67 1 -15.3493 
 
99 4.86015 0 0.04739 0 0.95261 0 0.67 0.777792 -11.0686 
 
100 0.569606 0.223822 0.430449 0 0.569551 0 0.67 0.776567 -13.5484 
 
101 0.843366 0.065891 0.999996 0.065891 4.07E-06 0 0.67 0.775346 -13.1721 
 
102 0.669675 0 0.047296 0 0.952704 0 0.67 0.774129 -10.6673 
 
103 6.38736 0 0.047558 0 0.952442 0 0.67 0.7705 -10.2335 
 
104 0.759584 0.300362 0.37767 0 0.62233 0 0.67 0.771706 -11.0605 
 
105 0.3096 0 0.049947 0 0.950053 0 0.67 0.772915 -9.00232 
 
106 0 0 1.00E-09 0.048386 1 0.365743 0.471333 1 -6.5202 
 
107 0.917101 0.061731 1 0.061734 1.00E-09 0 0.67 0.785223 -11.4421 
 
108 0 0 0 0 1 0 1 1 0 
 
109 0.317851 0 0.065 0 0.935 0 0.67 0.786475 -13.9701 
 
110 0.365364 0 0.04842 0 0.95158 0 0.67 0.787732 -6.81886 
 
111 0.832092 0.066224 1 0.066218 1.00E-09 0 0.67 0.783975 -15.2059 
 
112 1.18782 0.198533 1 0.19855 1.00E-09 0 0.67 0.780253 -15.3702 
 
113 0.527661 0.050569 1 0.050584 1.00E-09 0 0.67 0.78149 -11.476 
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114 1.00922 0.059062 0.999995 0.059062 5.26E-06 0 0.67 0.78273 -11.7903 
 
115 0.861149 0.10366 1 0.103759 1.00E-09 0 0.67 0.769298 -11.3642 
 
116 0.890374 0 0.500637 0.452777 0.499363 0 0.67 0.756319 -18.8461 
 
117 0.550303 0.427554 0.262847 0 0.737153 0 0.67 0.757481 -13.1718 
 
118 0.75271 0 0.048422 0 0.951578 0 0.67 0.758646 -10.6964 
 
119 1.22324 0.149183 0.545749 0 0.454251 0 0.67 0.755161 -12.0967 
 
120 0.882692 0 0.797124 0.694858 0.202876 0 0.67 0.752855 -13.3606 
 
121 0.584089 0.178573 0.511449 0 0.488551 0 0.67 0.754006 -13.979 
 
122 0.460902 0 0.04842 0 0.95158 0 0.67 0.759815 -12.2378 
 
123 2.35317 0.062911 1 0.062918 1.00E-09 0 0.67 0.765714 -15.8521 
 
124 0.376326 0.376326 1.00E-06 0.742767 0.999999 0.213971 0.525179 1 -21.0036 
 
125 1.1503 1.1503 0.160636 0 0.839364 0 0.67 0.7681 -16.6955 
 
126 2.24486 0 0.048404 0 0.951596 0 0.67 0.764527 -12.3186 
 
127 0.46383 0.184998 0.002346 0.184997 0.997654 0 0.67 0.760988 -15.4341 
 
128 0.341348 0.105615 0.999995 0.105615 5.26E-06 0 0.67 0.762164 -13.8348 
 
129 1.19049 0 0.639485 0.755247 0.360515 0 0.67 0.763344 -18.4786 
 
130 2.38866 0 0.047345 0 0.952655 0 0.67 0.788992 -17.3093 
 
131 0.162738 0.050473 1 0.050492 1.00E-09 0 0.67 0.815074 -11.4485 
 
132 0.582796 0.051471 1 0.051513 1.00E-09 0 0.67 0.816424 -11.1981 
 
133 0.784175 0 0.04842 0 0.95158 0 0.67 0.817778 -10.1749 
 
134 1.41067 0.054142 1 0.054136 1.00E-09 0 0.67 0.813729 -15.2228 
 
135 0.535375 0 0.050005 0 0.949995 0 0.67 0.809721 -7.59376 
 
136 1.13496 0.063052 1 0.063017 1.00E-09 0 0.67 0.811053 -14.9365 
 
137 0 0 0.648622 0.343289 0.351378 2.2294 0.161698 1 -9.45044 
 
138 0.681981 0.053372 1 0.053432 1.00E-09 0 0.67 0.812389 -12.9614 
 
139 0.206629 0 0.06496 0 0.93504 0 0.67 0.819136 -5.78118 
 
140 3.96824 0.184455 0.511196 0 0.488804 0 0.67 0.825997 -13.588 
 
141 0.797857 0.114318 1 0.114313 1.00E-09 0 0.67 0.827383 -15.4735 
 
142 0.41608 0 0.907436 6.15149 0.092564 1.91474 0.191649 1 -14.8263 
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143 0.163683 0 0.05256 0 0.94744 0 0.67 0.824615 -6.88599 
 
144 2.01272 0.421083 0.301529 0 0.698471 0 0.67 0.820499 -18.9722 
 
145 1.14752 0.113696 0.870733 0.118265 0.129267 0 0.67 0.821867 -14.7939 
 
146 1.85633 0 0.048625 0 0.951375 0 0.67 0.823239 -14.0808 
 
147 1.06609 0.103791 1 0.103902 1.98E-09 0 0.67 0.808393 -12.9547 
 
148 0.870281 0.147701 1 0.14768 1.00E-09 0 0.67 0.794074 -18.1109 
 
149 2.0725 0.205365 1 0.20538 1.00E-09 0 0.67 0.795355 -19.2199 
 
150 0.73043 0.116691 1 0.116649 7.94E-09 0 0.67 0.79664 -14.9269 
 
151 0.703049 0.366566 1 0.366547 1.00E-09 0 0.67 0.792797 -20.5792 
 
152 0.471504 0 0.048463 0 0.951537 0 0.67 0.790256 -8.92834 
 
153 0.261911 0.0472 1 0.047201 1.00E-09 0 0.67 0.791525 -10.7794 
 
154 3.34207 0 0.04738 0 0.95262 0 0.67 0.797929 -11.6739 
 
155 2.23013 0.506113 0.24861 0 0.75139 0 0.67 0.804437 -15.5284 
 
156 0.998411 0.345189 1 0.345217 9.54E-08 0 0.67 0.805752 -18.5103 
 
157 1.04253 0 0.048418 0 0.951583 0 0.67 0.80707 -10.4303 
 
158 0.15028 0 0.04842 0 0.95158 0 0.67 0.803127 -6.66801 
 
159 3.91697 0 0.065 0 0.935 0 0.67 0.799222 -10.849 
 
160 0 0 0 0 1 0 1 1 0 
 
161 0.868101 0 0.05251 0 0.94749 0 0.67 0.800519 -15.3507 
 
162 0 0 0 0 1 0 1 1 0 
 
163 3.10879 0 0.047405 0 0.952595 0 0.67 0.801821 -11.8428 
 
164 0.829213 0 0.047296 0 0.952704 0 0.67 0.751707 -12.0593 
 
165 2.53427 0.070905 1 0.0709 1.00E-09 0 0.67 0.715704 -23.041 
 
166 0.836175 0 0.047281 0 0.952719 0 0.67 0.710548 -9.88521 
 
167 0.456911 0 0.047373 0 0.952627 0 0.67 0.705465 -9.84462 
 
168 0.385449 0 0.048474 0 0.951526 0 0.67 0.704457 -9.16466 
 
169 0.916197 0.185583 1 0.185463 1.49E-09 0 0.67 0.706476 -16.2141 
 
170 3.36372 0.045842 1 0.045843 1.00E-09 0 0.67 0.709525 -15.038 
 
171 0.517362 0 0.065 0 0.935 0 0.67 0.708506 -7.3215 
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172 0.100492 0 0.037361 0 0.962639 0 0.67 0.707489 -8.87524 
 
173 2.32276 0 0.686988 0.272004 0.313012 0 0.67 0.716744 -18.9923 
 
174 1.24432 0.419813 1 0.419252 3.81E-09 0 0.67 0.717787 -21.5264 
 
175 0.320951 0.19428 1 0.194327 1.00E-09 0 0.67 0.714667 -16.5351 
 
176 0.727764 0 0.065 0 0.935 0 0.67 0.711573 -7.67849 
 
177 0.129909 0.125701 0.999994 0.125699 6.10E-06 0 0.67 0.712601 -15.6807 
 
178 0.621556 0 0.048417 0 0.951583 0 0.67 0.713632 -6.38049 
 
179 0.399678 0 0.052838 0 0.947162 0 0.67 0.703452 -9.98368 
 
180 0.804726 0.22992 0.444367 0 0.555633 0 0.67 0.690644 -14.2031 
 
181 4.632 0.113802 1 0.113863 1.00E-09 0 0.67 0.691613 -27.1181 
 
182 1.1339 0 0.04842 0 0.95158 0 0.67 0.684889 -10.0285 
 
183 2.80505 0.263581 0.352518 0 0.647482 0 0.67 0.683939 -16.7356 
 
184 0.414627 0.056189 1 0.056198 1.00E-09 0 0.67 0.682992 -14.0971 
 
185 1.62299 0 0.047365 0 0.952636 0 0.67 0.692584 -9.10865 
 
186 0.525057 0.071027 1 0.071052 1.00E-09 0 0.67 0.695515 -15.944 
 
187 0.677796 0.37287 0.999999 0.372871 7.22E-07 0 0.67 0.694535 -19.144 
 
188 3.73965 0.176073 1 0.175876 1.00E-09 0 0.67 0.693558 -21.8721 
 
189 0.723471 0.22085 1 0.222356 1.49E-09 0 0.67 0.681105 -18.3592 
 
190 0.215195 0.113881 1 0.113703 1.00E-09 0 0.67 0.682047 -12.598 
 
191 0.480536 0.187839 1 0.187756 1.21E-09 0 0.67 0.689678 -14.6696 
 
192 4.48824 0.319354 0.879669 0.962623 0.120331 0 0.67 0.680166 -26.1238 
 
193 1.54628 0.146741 0.551404 0 0.448596 0 0.67 0.688715 -13.061 
 
194 0.660771 0.286971 0.799939 0.295363 0.200061 0 0.67 0.687755 -20.5409 
 
195 1.36072 0.615106 0.914382 0.61511 0.085618 0 0.67 0.69847 -22.0694 
 
196 0.838894 0 0.724158 0.440956 0.275842 0 0.67 0.697482 -15.8672 
 
197 1.56289 0.354618 1 0.353898 1.00E-09 0 0.67 0.699461 -21.4428 
 
198 2.61105 0.066039 1 0.06598 1.00E-09 0 0.67 0.941069 -18.9878 
 
199 2.23389 0.55777 1 0.55803 1.00E-09 0 0.67 0.885314 -26.2853 
 
200 6.05361 0.204076 1 0.204065 1.00E-09 0 0.67 0.894955 -25.259 
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201 0.962063 0.051001 1 0.051013 1.00E-09 0 0.67 0.893333 -11.4247 
 
202 0.335157 0.250899 0.551243 0.250868 0.448757 0 0.67 0.891718 -17.206 
 
203 0.76337 0.346934 1 0.346554 1.00E-09 0 0.67 0.896582 -19.5316 
 
204 0.70862 0.053518 1 0.053416 1.00E-09 0 0.67 0.901499 -10.845 
 
205 0.78834 0.78834 1.00E-09 0.870205 1 0.002005 0.658864 1 -22.1105 
 
206 0.991865 0.146723 0.999995 0.146723 5.26E-06 0 0.67 0.898215 -23.1858 
 
207 0.662384 0.528241 1 0.52827 4.22E-07 0 0.67 0.890108 -20.7246 
 
208 0.52128 0.184166 1 0.184225 1.49E-09 0 0.67 0.882147 -14.2621 
 
209 0.926713 0.179554 0.986452 0.262096 0.013548 0 0.67 0.880571 -18.859 
 
210 4.0144 0.157495 1 0.157173 1.00E-09 0 0.67 0.879002 -24.5892 
 
211 1.16267 0.044459 1 0.044454 1.00E-09 0 0.67 0.883728 -10.4394 
 
212 0.44039 0 0.642096 2.24066 0.357904 0.500245 0.43149 1 -29.9592 
 
213 3.44296 0 0.988794 950.2 0.011207 2.42253 0.145806 1 -20.9504 
 
214 1.29594 1.29413 1.03E-09 1.29933 1 3.40E-06 0.669556 1 -28.9157 
 
215 1.18553 0.568144 0.226366 0 0.773634 0 0.67 0.90315 -15.6408 
 
216 0.314568 0.314568 1.00E-09 0.8076 1 0.549656 0.418176 1 -21.6167 
 
217 0 0 0.655 3.32928 0.345 4.04621 0.06208 1 -20.1111 Pos 
218 1.13383 0.278813 1 0.279224 1.00E-09 0 0.67 0.918287 -19.895 
 
219 0.625557 0.625552 1.00E-09 0.772237 1 0.020062 0.632362 1 -26.5434 
 
220 2.36407 0.486796 0.273915 0 0.726085 0 0.67 0.928663 -15.1497 
 
221 2.25843 0.211955 1 0.211496 1.00E-09 0 0.67 0.930415 -24.2598 
 
222 1.7044 0.236077 0.940789 94.5417 0.059211 2.91708 0.11213 1 -33.1352 
 
223 0.262161 0.262161 1.00E-09 1.15534 1 0.667816 0.388655 1 -21.2081 
 
224 4.36738 0.059964 0.842624 1.26428 0.157376 0 0.67 0.91658 -25.0807 
 
225 0 0 0.590438 0.21805 0.409562 1.71735 0.213437 1 -9.42723 
 
226 1.80635 0 0.050004 0 0.949996 0 0.67 0.906471 -17.0985 
 
227 1.12352 0.436513 1 0.436585 1.00E-09 0 0.67 0.904807 -23.4732 
 
228 2.92625 0.697946 0.438326 0 0.561674 0 0.67 0.909815 -19.9009 
 
229 2.00975 0.8923 1 0.891019 1.00E-09 0 0.67 0.914879 -30.5411 
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230 2.78109 2.78109 0.484552 0 0.515448 0 0.67 0.913185 -33.1714 
 
231 0 0 1.00E-09 0.628619 1 0.903411 0.337639 1 -15.2748 
 
232 4.90598 0.662057 1 0.662174 6.48E-08 0 0.67 0.877438 -20.6927 
 
233 0.565394 0 0.037361 0 0.962639 0 0.67 0.845832 -12.6648 
 
234 1.27861 0 0.809332 9.43886 0.190668 1.5454 0.234626 1 -24.8255 
 
235 5.11907 0.15842 0.91224 0.169357 0.08776 0 0.67 0.84294 -19.5749 
 
236 1.29916 0.242779 1 0.242628 3.81E-09 0 0.67 0.847285 -18.2117 
 
237 3.00379 0.099667 1 0.099693 1.00E-09 0 0.67 0.851675 -13.9525 
 
238 2.14426 0.349128 0.653728 0 0.346272 0 0.67 0.850207 -18.9677 
 
239 1.36388 0.560867 1 0.561514 1.00E-09 0 0.67 0.848744 -22.4212 
 
240 1.08921 0.146494 1 0.146553 1.00E-09 0 0.67 0.841502 -23.3142 
 
241 3.00454 0.134614 1 0.134631 1.00E-09 0 0.67 0.834382 -16.2909 
 
242 1.24879 0.465488 0.269116 0 0.730884 0 0.67 0.832973 -16.0159 
 
243 0 0 0.422964 0.517379 0.577036 0.977229 0.323415 1 -15.6939 
 
244 0.568668 0.231912 0.487545 0 0.512455 0 0.67 0.835797 -16.2865 
 
245 0.494882 0.13413 1 0.134087 1.36E-08 0 0.67 0.840068 -14.5278 
 
246 2.41247 0 0.606561 2.35532 0.393439 0 0.67 0.838639 -30.3646 
 
247 3.86115 0.14106 1 0.14097 2.59E-09 0 0.67 0.837216 -20.7266 
 
248 0 0 0.769065 2.86291 0.230935 3.51944 0.081703 1 -15.9262 Pos 
249 2.03208 2.03208 0.126238 0 0.873762 0 0.67 0.8697 -19.2588 
 
250 1.51882 0 0.047296 0 0.952704 0 0.67 0.868169 -12.145 
 
251 0.462689 0.142017 1 0.142324 1.00E-09 0 0.67 0.866643 -16.683 
 
252 0.836029 0.168418 0.504384 0 0.495616 0 0.67 0.871237 -12.9086 
 
253 0.702645 0 0.915725 7.34955 0.084275 1.47198 0.244371 1 -21.7108 
 
254 0.151505 0.151505 1.00E-09 0.321159 1 0.324207 0.484936 1 -18.7997 
 
255 0.490821 0 0.669078 0.36925 0.330922 0 0.67 0.872779 -13.1092 
 
256 0.630167 0.22616 1 0.225495 1.00E-09 0 0.67 0.865123 -20.0956 
 
257 0.286804 0.180758 0.999995 0.180763 4.96E-06 0 0.67 0.8576 -20.2119 
 
258 2.10084 0.320036 1 0.319258 1.00E-09 0 0.67 0.856111 -22.1186 
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259 3.40044 0.251268 0.437247 0 0.562753 0 0.67 0.854627 -18.2613 
 
260 3.01939 0.045515 0.980154 148.631 0.019846 1.48469 0.242651 1 -24.5597 
 
261 0 0 1.00E-09 0.402487 1 1.71962 0.213172 1 -18.1551 
 
262 0.907058 0.907058 0.002852 1.30121 0.997148 0.055522 0.603747 1 -27.1688 
 
263 0.586711 0.261475 0.065108 0.261472 0.934892 0 0.67 0.860593 -17.7286 
 
264 0.358456 0.084209 0.623167 1.58756 0.376833 0.304261 0.491735 1 -20.4975 
 
265 4.62424 0.365604 1 0.365473 3.81E-09 0 0.67 1 -24.1087 
 
266 2.36448 0.142055 7.03E-06 0.142056 0.999993 0 0.67 1 -21.3552 
 
267 0.285603 0.052622 1 0.052717 1.00E-09 0 0.67 1 -12.7991 
 
268 0.638694 0.04721 1 0.047264 1.00E-09 0 0.67 1 -14.3656 
 
269 0.59957 0.126017 1 0.125905 1.00E-09 0 0.67 1 -16.2595 
 
270 1.62578 0 0.048519 0 0.951481 0 0.67 1 -11.8111 
 
271 0.273128 0.049213 0.920009 8.98204 0.079991 5.04753 0.036973 1 -17.6001 Pos 
272 0 0 1.00E-09 0.271563 1 1.10247 0.300902 1 -10.8228 
 
273 0.56714 0 0.04867 0 0.95133 0 0.67 1 -9.79188 
 
274 0.129965 0.128569 0.999521 0.128569 0.000479 0 0.67 0.998219 -12.9476 
 
275 0.782238 0.441184 0.283445 0 0.716555 0 0.67 0.996202 -11.1935 
 
276 1.5252 0 0.850108 1.34166 0.149892 0 0.67 1 -18.2427 
 
277 1.12156 0.2335 1 0.233348 1.00E-09 0 0.67 1 -19.0083 
 
278 0.715191 0 0.760216 1.82215 0.239784 0.290313 0.496602 1 -15.4963 
 
279 0.3897 0 0.65697 0.265653 0.34303 0 0.67 1 -13.9144 
 
280 0.311007 0 0.381504 0.751619 0.618496 0.261219 0.50708 1 -18.769 
 
281 0.663357 0.124753 1 0.124717 1.00E-09 0 0.67 1 -17.2514 
 
282 0.914663 0 0.403769 0.244128 0.596231 0 0.67 1 -14.506 
 
283 0 0 0.046825 0 0.953175 0 0.67 1 -3.76561 
 
284 0 0 0.046825 0 0.953175 0 0.67 1 -4.03126 
 
285 9.82746 0 0.048506 0 0.951495 0 0.67 1 -4.75781 
 
286 0 0 0.046825 0 0.953175 0 0.67 1 -4.30138 
 
287 0 0 0.046825 0 0.953175 0 0.67 1 -3.69269 
 
Chapter 8 Filovirus Data Ebola Selection analysis 
288 0 0 0.046825 0 0.953175 0 0.67 1 -3.69269 
 
289 0 0 0.046825 0 0.953175 0 0.67 1 -4.32392 
 
290 0 0 0.046825 0 0.953175 0 0.67 1 -4.07853 
 
291 2.20716 0.252624 1 0.252516 1.00E-09 0 0.67 1 -20.9061 
 
292 0.719564 0 0.764867 2.89539 0.235133 0.832727 0.351992 1 -19.0243 
 
293 2.0701 0.296582 1 0.296631 1.00E-09 0 0.67 1 -20.1741 
 
294 1.82857 0 0.04842 0 0.95158 0 0.67 1 -12.693 
 
295 1.28686 0 0.048428 0 0.951573 0 0.67 1 -7.09923 
 
296 0 0 0.383909 0.168732 0.616091 0.737568 0.372563 1 -9.97647 
 
297 0.397082 0.071974 1 0.071876 1.00E-09 0 0.67 0.994194 -12.0945 
 
298 0.231087 0.159353 1 0.159358 1.00E-09 0 0.67 0.951969 -19.1239 
 
299 9.54193 0.187514 0.98523 299.919 0.01477 1.17807 0.288208 1 -24.0077 
 
300 0.569606 0.223822 0.430449 0 0.569551 0 0.67 0.948308 -13.5484 
 
301 0 0 0.408596 0.33638 0.591404 2.28768 0.156718 1 -12.3732 
 
302 2.55693 0.641548 0.214361 0 0.785639 0 0.67 0.959377 -14.3922 
 
303 0 0 0.312088 0.129576 0.687912 0.488727 0.434686 1 -9.06352 
 
304 2.39705 0.275089 0.362892 0 0.637108 0 0.67 0.955659 -14.322 
 
305 0.176838 0.176837 1.00E-09 0.203622 1 0.009193 0.645281 1 -16.9833 
 
306 2.20323 2.20323 0.12553 0 0.87447 0 0.67 0.93749 -22.3716 
 
307 0.226741 0 0.24285 0.367936 0.75715 0.10781 0.573071 1 -16.1106 
 
308 0 0 0.723132 4.70897 0.276868 8.05294 0.007943 1 -21.458 Pos 
309 0.386124 0.258999 0.982288 0.259004 0.017712 0 0.67 0.939276 -18.7802 
 
310 0.491684 0.303377 0.785831 2.97443 0.214169 0.154043 0.550635 1 -25.4748 
 
311 0 0 0.630226 0.989911 0.369774 2.63926 0.129908 1 -16.4775 
 
312 0 0 0.743501 0.470981 0.256499 2.57037 0.134755 1 -9.90188 
 
313 0.175817 0.171075 0.218943 0.313416 0.781057 0.11817 0.567763 1 -15.7851 
 
314 0.33458 0.056077 1 0.056104 1.00E-09 0 0.67 0.982311 -13.8864 
 
315 0.134247 0.069284 0.822722 1.47907 0.177278 1.29306 0.270072 1 -16.0353 
 
316 0 0 1.00E-09 0.164379 1 1.80191 0.203791 1 -12.7357 
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317 0.007814 0.007813 1.00E-09 0.822797 1 1.67868 0.218013 1 -18.0791 
 
318 0.110903 0.110903 1.00E-09 0.845797 1 3.11851 0.100831 1 -23.3631 
 
319 0.110578 0.110578 1.00E-09 0.197085 1 0.101441 0.576433 1 -15.0807 
 
320 0.528764 0.147418 1 0.147477 1.00E-09 0 0.67 0.988216 -17.8795 
 
321 0 0 1.00E-09 0.918917 1 2.4088 0.14688 1 -20.1448 
 
322 0 0 1.00E-09 2.32133 1 2.30998 0.154857 1 -30.086 
 
323 0 0 1.00E-09 1.95689 1 2.74055 0.123108 1 -27.2673 
 
324 0.348215 0.348215 1.00E-09 0.574754 1 0.043912 0.611954 1 -19.6913 
 
325 0 0 0.594579 4.67919 0.405421 2.03213 0.179835 1 -24.5403 
 
326 0 0 1.00E-09 1.29727 1 5.50217 0.029258 1 -24.6641 Pos 
327 1.43088 0.255117 0.740588 2.49801 0.259412 0.075127 0.591294 1 -21.8004 
 
328 0.510353 0.15295 0.613689 0.826039 0.386311 0.027735 0.625047 1 -20.2181 
 
329 0 0 0.698768 1.6674 0.301232 1.05576 0.309073 1 -16.2724 
 
330 1.23064 0.112474 0.555393 0.707822 0.444607 0 0.67 0.830168 -20.0122 
 
331 0 0 1.00E-09 0.484131 1 2.64262 0.129676 1 -16.2754 
 
332 0.098516 0.098516 0.270904 0.591851 0.729096 1.38086 0.257098 1 -17.3848 
 
333 0.34744 0.34744 0.615251 2.59957 0.384749 0.498043 0.432098 1 -23.2326 
 
334 0.276704 0.276704 0.405436 0 0.594564 0 0.67 0.72839 -15.0178 
 
335 1.84037 0.792491 0.703215 0 0.296785 0 0.67 0.729467 -28.2473 
 
336 0 0 0.624622 3.78438 0.375378 1.11971 0.29795 1 -21.6671 
 
337 2.81326 1.18965 0.444652 0 0.555348 0 0.67 0.732719 -22.3586 
 
338 0.123254 0.123254 1.00E-09 1.23862 1 0.887748 0.340755 1 -21.7514 
 
339 1.86074 1.86074 1.00E-09 4.22543 1 0.453654 0.444648 1 -36.3637 
 
340 0.250936 0 0.255003 0.580898 0.744997 0.419023 0.45485 1 -21.4682 
 
341 0 0 1.00E-09 0.32373 1 1.41161 0.252722 1 -20.7723 
 
342 1.42832 0.86135 1 0.860306 4.70E-08 0 0.67 0.721991 -26.4981 
 
343 2.88151 0.462143 1 0.462213 1.00E-09 0 0.67 0.725176 -24.8475 
 
344 0.198236 0.198236 1.00E-09 1.69961 1 1.63184 0.223699 1 -27.6768 
 
345 1.08279 0.76082 0.877615 11.4454 0.122385 0.440388 0.448512 1 -30.3623 
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346 4.04481 0 0.394805 0.247302 0.605195 0 0.67 0.734903 -17.9031 
 
347 0.650409 0.335863 0.999995 0.335863 5.26E-06 0 0.67 0.746021 -17.5733 
 
348 0.909966 0.167062 0.905345 7.93009 0.094655 1.1885 0.286506 1 -20.5841 
 
349 0.081135 0.081135 0.193258 0.572503 0.806742 0.557782 0.416045 1 -18.8838 
 
350 0.228288 0.228287 1.00E-09 0.263234 1 0.015415 0.63738 1 -22.0754 
 
351 0.333062 0.216462 0.967921 0.216476 0.032079 0 0.67 0.750563 -20.2383 
 
352 0.160072 0 0.656021 0.973315 0.343979 1.0848 0.303962 1 -16.2207 
 
353 0.281328 0.271783 0.891773 3.85911 0.108227 0.289756 0.496798 1 -23.2676 
 
354 0.151514 0 0.323731 0.507421 0.676269 0.48138 0.436744 1 -20.1779 
 
355 0 0 0.637702 0.732569 0.362298 3.02652 0.105838 1 -13.5586 
 
356 0.119823 0.119823 1.00E-09 0.245853 1 0.33316 0.481942 1 -15.9482 
 
357 0.305911 0.305911 1.00E-09 0.809181 1 0.650202 0.392867 1 -20.5866 
 
358 0.189408 0.189407 1.00E-09 0.205138 1 0.001959 0.658997 1 -14.6072 
 
359 0.206076 0.112367 1 0.112278 1.00E-09 0 0.67 0.74042 -13.9059 
 
360 0 0 1.00E-09 0.500048 1 4.22652 0.056529 1 -17.7058 Pos 
361 0.042877 0.042877 1.00E-09 0.157817 1 0.178245 0.539954 1 -13.814 
 
362 4.42808 0.32729 1 0.326958 1.49E-09 0 0.67 0.686797 -28.0188 
 
363 2.3279 0.990905 1 0.992404 1.00E-09 0 0.67 0.685841 -26.5019 
 
364 0.313569 0.313569 1.00E-06 0.677285 0.999999 0.265371 0.505556 1 -20.5515 
 
365 0.454375 0.406174 1 0.405859 1.00E-09 0 0.67 0.700455 -19.2216 
 
366 0 0 0.046825 0 0.953175 0 0.67 0.701451 -3.69669 
 
367 0.162741 0 0.138913 0.368027 0.861087 0.101753 0.576266 1 -17.6652 
 
368 0.546837 0 0.235438 0.58115 0.764562 0.0012 0.661446 1 -22.6861 
 
369 0.84648 0.84646 1.00E-09 1.9239 1 0.423199 0.453599 1 -25.9455 
 
370 0 0 1.00E-09 0.525167 1 2.29773 0.155876 1 -15.5862 
 
371 0.023294 0.023294 1.00E-09 0.370623 1 0.827258 0.353134 1 -19.8934 
 
372 0 0 1.00E-09 0.453408 1 2.30067 0.155631 1 -16.0766 
 
373 0.512457 0 0.700144 1.71905 0.299856 0.663243 0.389743 1 -19.7586 
 
374 0.925958 0.289319 0.778647 1.95557 0.221353 3.55E-15 0.67 1 -4.10371 
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375 1.85714 0.135594 0.721483 3.23673 0.278517 5.33E-15 0.67 1 -4.1411 
 
376 0.717199 0.349535 0.36679 0 0.63321 0 0.67 1 -19.6117 
 
377 1.86571 0.4379 0.93424 4.95825 0.06576 0.039883 0.615 1 -27.0574 
 
378 0 0 1.00E-09 1.92572 1 2.2522 0.15973 1 -25.4614 
 
379 0 0 0.548265 7.77136 0.451735 6.18346 0.020626 1 -34.7098 Pos 
380 0.476179 0.358824 0.999995 0.358823 5.26E-06 0 0.67 1 -19.0629 
 
381 0 0 0.658541 1.38269 0.341459 2.34508 0.151972 1 -16.9403 
 
382 0.111052 0.111052 0.879758 13.4171 0.120242 3.76014 0.072051 1 -25.9056 Pos 
383 0.358968 0 0.323058 0.653744 0.676942 0.123435 0.565134 1 -20.3963 
 
384 1.10994 1.10994 0.381754 0 0.618246 0 0.67 1 -19.3764 
 
385 0.999253 0.219557 0.75 1.49858 0.25 -1.78E-15 0.67 1 -4.44227 
 
386 0.211432 0.040494 0.09847 0.454993 0.90153 0.231948 0.518119 1 -18.7851 
 
387 4.47732 4.47732 0.473344 0.431607 0.526656 0 0.67 1 -37.5818 
 
388 0.90621 0 0.569379 3.67656 0.430621 0.86368 0.345614 1 -26.9153 
 
389 1.94099 0.151988 0.865888 13.7475 0.134112 1.57792 0.230448 1 -30.9956 
 
390 5.0427 1.61113 1 1.60696 1.00E-09 0 0.67 1 -34.484 
 
391 0 0 0.557648 1.54043 0.442352 2.66321 0.128265 1 -22.0328 
 
392 2.16175 0 0.691517 1.4687 0.308483 0 0.67 1 -21.5927 
 
393 1.34285 0.486825 1 0.486112 1.00E-09 0 0.67 1 -19.8812 
 
394 0.647721 0 0.662013 1.35268 0.337987 0.075707 0.590947 1 -19.0369 
 
395 1.13657 0.272905 1 0.273235 1.00E-09 0 0.67 1 -16.5677 
 
396 0.341039 0.341039 1.00E-06 1.17507 0.999999 0.938831 0.33072 1 -25.6767 
 
397 3.13178 0.799064 0.2171 0.799079 0.7829 0 0.67 1 -23.1547 
 
398 0.387154 0.387154 1.00E-09 0.939498 1 0.167039 0.544824 1 -19.328 
 
399 0.266083 0 0.722039 0.474258 0.277961 0.05312 0.605384 1 -13.0253 
 
400 0.51573 0.193455 0.987343 950.099 0.012657 6.80315 0.015022 1 -29.5247 Pos 
401 6.19069 0 0.784222 30.4436 0.215778 1.45727 0.246376 1 -44.5129 
 
402 0.6053 0.563514 0.999999 0.563516 1.47E-06 0 0.67 1 -17.0204 
 
403 0.492808 0.492808 1.00E-06 0.721462 0.999999 0.03779 0.616631 1 -11.8931 
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404 0.804508 0 0.818863 5.8497 0.181137 1.31482 0.266789 1 -21.7922 
 
405 2.24709 0.895961 1 0.895868 1.00E-09 0 0.67 1 -25.9795 
 
406 0.562876 0.562876 1.00E-09 1.74562 1 0.449447 0.445868 1 -21.885 
 
407 0.083825 0.083823 1.00E-09 0.839849 1 0.383213 0.465816 1 -23.9582 
 
408 0.62697 0.62697 1.00E-09 0.834294 1 0.033043 0.620472 1 -19.3401 
 
409 0.133133 0.133132 1.00E-09 0.510045 1 0.654784 0.391765 1 -19.2775 
 
410 7.76956 0.226059 0.89722 16.0449 0.10278 0.272002 0.503143 1 -37.7756 
 
411 0.638358 0.072339 0.85539 2.58599 0.14461 0.881355 0.342038 1 -18.6364 
 
412 0.634235 0.634235 1.00E-06 0.924881 0.999999 0.040618 0.614435 1 -22.7323 
 
413 0.731178 0 0.695988 7.77121 0.304012 2.11565 0.171905 1 -29.3534 
 
414 1.68485 1.53339 1 1.53321 1.00E-09 0 0.67 1 -29.5086 
 
415 0.140965 0.140965 0.14853 0.466293 0.85147 0.355715 0.474552 1 -16.7133 
 
416 0.067926 0.067926 1.00E-06 1.28924 0.999999 0.430685 0.451372 1 -22.0284 
 
417 0 0 0.446604 4.35673 0.553396 2.78625 0.120163 1 -29.1539 
 
418 1.40818 0.961152 0.365423 0.161889 0.634577 0 0.67 1 -20.229 
 
419 0.832076 0.832076 0.003537 0.955546 0.996463 0.004436 0.653172 1 -19.279 
 
420 2.11812 0.350212 0.999995 0.350212 5.26E-06 0 0.67 1 -19.7038 
 
421 2.27929 0.538392 1 0.537993 1.00E-09 0 0.67 1 -20.409 
 
422 2.95281 0.849196 0.781551 0.850253 0.218449 0 0.67 1 -26.1231 
 
423 0.574397 0.464011 0.822282 0.459235 0.177718 0 0.67 1 -25.5663 
 
424 0.531207 0.313059 1 0.31301 1.00E-09 0 0.67 1 -18.0021 
 
425 0 0 1.00E-09 1.05491 1 6.25426 0.019892 1 -20.1279 Pos 
426 3.05842 1.11567 1 1.11434 1.00E-09 0 0.67 1 -29.7693 
 
427 1.17401 0.513871 0.730584 0 0.269416 0 0.67 1 -20.8924 
 
428 0.456187 0 0.656001 1.29744 0.343999 0.531071 0.42311 1 -19.7526 
 
429 0.020233 0.020233 0.692932 6.27791 0.307068 2.3486 0.151686 1 -27.3473 Pos 
430 0 0 0.417115 2.1851 0.582885 3.88707 0.067439 1 -22.3755 Pos 
431 1.18163 0.704575 0.984106 83.335 0.015894 0.323551 0.485157 1 -28.4194 
 
432 0.924613 0.696829 1 0.695848 1.00E-09 0 0.67 1 -26.3195 
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433 1.24133 0.064343 0.81905 7.75274 0.18095 1.22335 0.280904 1 -25.3844 
 
434 7.00065 1.61202 1 1.61549 1.00E-09 0 0.67 1 -45.4811 
 
435 0.725974 0.627955 1 0.62787 6.48E-08 0 0.67 1 -21.3012 
 
436 1.18902 0.125925 0.389654 2.52652 0.610346 0.217596 0.523737 1 -30.0799 
 
437 0.124926 0 0.18434 0.310462 0.81566 0.349589 0.476539 1 -15.0133 
 
438 0.904645 0.904645 1.00E-06 1.33212 0.999999 0.073319 0.592385 1 -25.7055 
 
439 1.86979 0.449731 1 0.447865 1.00E-09 0 0.67 1 -23.3486 
 
440 17.5658 0 0.999005 0 0.000995 0 0.67 1 -4.99112 
 
441 0.765256 0.189473 0.778572 0.319388 0.221428 0 0.67 1 -3.8776 
 
442 1 0.214308 0.719979 1.94041 0.280021 -1.78E-15 0.67 1 -4.2486 
 
443 0.999147 0.168516 0.749688 1.93888 0.250312 0 0.67 1 -4.10771 
 
444 1 0.228291 0.721305 1.94129 0.278695 -5.33E-15 0.67 1 -4.32392 
 
445 0.538462 0.189505 0.750274 0.807692 0.249726 -3.55E-15 0.67 1 -4.03126 
 
446 0.633987 0.214031 0.721487 1.47273 0.278513 5.33E-15 0.67 1 -4.14326 
 
447 0.450445 0.450445 1.00E-09 0.891633 1 0.147311 0.553721 1 -21.719 
 
448 0.962317 0.045168 0.920424 12.5058 0.079576 0.610623 0.402563 1 -21.8014 
 
449 2.5231 0.316799 0.715132 31.652 0.284868 4.52462 0.048438 1 -51.3588 Pos 
450 0.039883 0.039883 1.00E-09 0.497195 1 0.725546 0.375273 1 -20.0152 
 
451 0.809122 0.809121 1.00E-09 0.941397 1 0.006409 0.649584 1 -22.1435 
 
452 0.81011 0.80951 1.00E-09 0.834897 1 0.000536 0.664331 1 -23.2067 
 
453 0 0 0.727129 1.73322 0.272871 6.3368 0.019069 1 -16.8854 Pos 
454 9.68E-17 8.83E-17 1.00E-09 2.59078 1 2.1324 0.170361 1 -28.4993 
 
455 2.59512 0 0.551042 0.580689 0.448958 0 0.67 1 -20.4239 
 
456 2.15364 0 0.476825 0.41954 0.523175 0 0.67 1 -22.9394 
 
457 9.33278 1.47166 0.545226 0 0.454774 0 0.67 1 -30.7885 
 
458 0 0 0.046825 0 0.953175 0 0.67 1 -4.17027 
 
459 0 0 0.046825 0 0.953175 0 0.67 1 -4.36394 
 
460 0 0 1.00E-09 1.9025 1 0.525283 0.424665 1 -6.1566 
 
461 0 0 0.046825 0 0.953175 0 0.67 1 -4.31116 
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462 0 0 0.046825 0 0.953175 0 0.67 1 -4.44227 
 
463 6.84154 0 0.065025 0 0.934975 0 0.67 1 -5.55396 
 
464 0 0 1.00E-09 1.92469 1 0.584417 0.40917 1 -6.68997 
 
465 0 0 0.046825 0 0.953175 0 0.67 1 -3.61736 
 
466 0 0 0.046825 0 0.953175 0 0.67 1 -4.4792 
 
467 0 0 0.046825 0 0.953175 0 0.67 1 -4.05942 
 
468 0 0 0.046825 0 0.953175 0 0.67 1 -3.81503 
 
469 0 0 0.046825 0 0.953175 0 0.67 1 -4.30138 
 
470 0.844619 0 0.046586 0 0.953414 0 0.67 1 -4.95231 
 
471 0.020245 0.020245 1.00E-09 1.03233 1 0.408747 0.457951 1 -28.031 
 
472 3.73378 0.320181 0.77987 4.30112 0.22013 0.003663 0.654774 1 -30.9229 
 
473 1.97607 1.06816 0.995652 12.6127 0.004348 0.001044 0.662036 1 -31.7914 
 
474 3.02163 0.560348 0.884251 0.562792 0.115749 0 0.67 1 -26.8321 
 
475 0 0 0.650657 10.5802 0.349343 4.01557 0.063076 1 -30.8093 Pos 
476 0.929185 0.436493 1 0.436828 1.00E-09 0 0.67 1 -26.8765 
 
477 0.508001 0.508001 1.00E-06 0.981507 0.999999 0.17159 0.542832 1 -22.4969 
 
478 1.20924 1.20924 0.505408 0.293208 0.494592 0 0.67 1 -25.7043 
 
479 1.53796 0.356718 1 0.356652 1.00E-09 0 0.67 1 -22.3754 
 
480 2.2442 0.39347 0.652402 0 0.347598 0 0.67 1 -20.1564 
 
481 2.10614 0.345765 1 0.346162 1.04E-08 0 0.67 1 -24.8335 
 
482 0 0 1.00E-09 0.490144 1 2.80688 0.118858 1 -18.5326 
 
483 3.49977 0.293308 0.93825 10.2767 0.06175 0.098893 0.5778 1 -28.8818 
 
484 0.381429 0.150907 1 0.151213 1.00E-09 0 0.67 1 -7.64265 
 
485 0 0 1.00E-09 0.449654 1 1.97244 0.185741 1 -7.47457 
 
486 0.743051 0 0.658182 0.268456 0.341818 0 0.67 1 -14.9929 
 
487 0.860352 0.860352 1.00E-09 1.57769 1 0.152465 0.551354 1 -26.9502 
 
488 1.42657 0.338667 1 0.338227 1.00E-09 0 0.67 1 -19.1303 
 
489 0.940071 0.940071 0.105861 1.2465 0.894139 0.027281 0.625454 1 -33.4426 
 
490 0.936348 0.936348 0.566783 0 0.433217 0 0.67 1 -20.0152 
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491 1.09917 1.01116 0.61317 0 0.38683 0 0.67 1 -22.4807 
 
492 1.91427 1.1117 1 1.10948 1.00E-09 0 0.67 1 -25.6081 
 
493 0.510312 0.510311 1.00E-09 0.84638 1 0.14459 0.554983 1 -21.0526 
 
494 0.761669 0.761587 1.00E-09 0.800098 1 0.00137 0.660845 1 -22.4569 
 
495 0.184681 0 0.228776 0.876979 0.771224 0.791621 0.360694 1 -19.2481 
 
496 1.64776 0.110456 0.985707 421.68 0.014293 2.84659 0.116386 1 -24.4854 
 
497 2.99002 0.437552 1 0.437644 1.00E-09 0 0.67 1 -22.7106 
 
498 1.26315 0.129707 1 0.129815 1.00E-09 0 0.67 1 -17.1664 
 
499 0 0 1.00E-09 0.998288 1 1.65036 0.221432 1 -21.1406 
 
500 0.823236 0.823236 1.00E-09 0.943725 1 0.008928 0.645663 1 -22.3915 
 
501 0 0 0.214373 0.942293 0.785627 0.412482 0.45682 1 -21.0606 
 
502 2.4286 0.513526 1 0.513465 4.70E-08 0 0.67 1 -24.4563 
 
503 0.287373 0.14687 1 0.146852 9.54E-08 0 0.67 1 -15.9383 
 
504 1.03028 0.859413 1 0.85834 1.00E-09 0 0.67 1 -22.4093 
 
505 0.519958 0.519945 1.00E-09 0.53881 1 0.000228 0.666322 1 -13.8769 
 
506 0.731925 0.731925 1.00E-06 0.789925 0.999999 0.000908 0.662584 1 -12.5253 
 
507 0.532524 0.532524 1.00E-06 0.624593 0.999999 0.004651 0.65275 1 -8.93245 
 
508 5.39 0.122816 1 0.123006 1.00E-09 0 0.67 1 -9.64636 
 
509 37.4149 16.1637 1 16.1627 1.00E-09 0 0.67 1 -14.3249 
 
510 0.342085 0.342085 1.00E-09 0.54656 1 0.051785 0.606307 1 -8.67823 
 
511 0 0 0.551109 1.5499 0.448891 3.98943 0.06394 1 -18.9066 Pos 
512 0.304271 0.304271 0.966234 236.506 0.033766 4.99635 0.037962 1 -32.4213 Pos 
513 1.2778 0.753971 0.717902 0.753971 0.282098 0 0.67 1 -22.0564 
 
514 0.337613 0.337613 1.00E-06 0.774851 0.999999 0.471229 0.439612 1 -25.7973 
 
515 3.46088 0.609896 0.676845 0.609894 0.323155 0 0.67 1 -27.0392 
 
516 1.04457 1.04449 1.00E-09 1.08451 1 0.001019 0.662134 1 -23.4292 
 
517 0.682339 0.682339 1.00E-09 1.17688 1 0.167246 0.544733 1 -20.794 
 
518 0 0 1.00E-09 0.283357 1 1.04688 0.310657 1 -13.3035 
 
519 1.27438 0.453662 1 0.453465 1.00E-09 0 0.67 1 -25.5754 
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520 1.27046 0.051544 0.999985 0.051545 1.47E-05 0 0.67 1 -13.0688 
 
521 4.36806 0 0.697198 1.33907 0.302802 0 0.67 1 -30.8078 
 
522 1.8726 0.209428 1 0.209469 1.00E-09 0 0.67 1 -23.6358 
 
523 0.752148 0.33135 1 0.331217 1.00E-09 0 0.67 1 -24.3008 
 
524 2.64488 2.64488 0.239094 0 0.760906 0 0.67 1 -20.6603 
 
525 0.965193 0.153588 0.983887 287.623 0.016113 2.00059 0.18293 1 -22.6829 
 
526 0.259264 0.111478 0.507773 2.82353 0.492227 0.807075 0.35739 1 -27.371 
 
527 0 0 1.00E-09 0.959339 1 0.662137 0.390006 1 -21.7096 
 
528 0.932362 0.456521 0.988805 0.947454 0.011195 -5.71E-05 0.67 1 -23.1657 
 
529 2.48212 0.36142 1 0.361927 1.00E-09 0 0.67 1 -25.2651 
 
530 0.246613 0.246613 1.00E-06 0.480957 0.999999 0.141764 0.556304 1 -21.8788 
 
531 3.37062 1.09865 0.568729 0.132369 0.431271 0 0.67 1 -30.9812 
 
532 0.465903 0.465903 1.00E-06 0.846901 0.999999 0.206017 0.528378 1 -21.9541 
 
533 0.951822 0.350163 0.999999 0.350168 7.93E-07 0 0.67 1 -28.0869 
 
534 0.126934 0.126934 1.00E-09 0.486283 1 0.451725 0.445207 1 -18.53 
 
535 0.164405 0.164405 1.00E-09 0.463136 1 0.681294 0.385474 1 -20.0032 
 
536 0.913252 0.913252 1.00E-09 1.20477 1 0.057957 0.602116 1 -24.3191 
 
537 0.939021 0.109102 1 0.109113 1.00E-09 0 0.67 1 -19.5219 
 
538 3.39695 0.176336 0.999995 0.176336 5.26E-06 0 0.67 1 -20.0003 
 
539 0.607263 0.076984 0.651281 3.82285 0.348719 1.78689 0.20547 1 -25.5738 
 
540 1.64816 0.190945 1 0.190918 1.00E-09 0 0.67 1 -21.4769 
 
541 2.19854 0.16402 0.569521 0 0.430479 0 0.67 1 -16.1341 
 
542 0.486927 0.115765 0.819814 3.05821 0.180186 0.650429 0.392812 1 -19.7409 
 
543 0.891931 0.113744 0.815437 10.0109 0.184563 1.89472 0.193745 1 -21.9538 
 
544 1.29008 0.934658 1 0.930925 1.00E-09 0 0.67 1 -17.1639 
 
545 1.33177 1.1073 1 1.10748 2.68E-08 0 0.67 1 -18.1543 
 
546 0.769187 0.511349 1 0.511312 1.00E-09 0 0.67 1 -15.5147 
 
547 0.930323 0.24844 1 0.248188 1.00E-09 0 0.67 1 -13.236 
 
548 2.47815 2.47815 0.293199 0.111715 0.706801 0 0.67 1 -15.7823 
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549 0.404178 0.404178 1.00E-09 0.91681 1 0.445789 0.446932 1 -16.1686 
 
550 0 0 0.046825 0 0.953175 0 0.67 1 -3.61736 
 
551 0.681442 0 0.050373 0 0.949627 0 0.67 1 -7.69487 
 
552 0.588333 0.047249 1 0.047208 6.79E-09 0 0.67 1 -9.48725 
 
553 3.88048 0.065659 1 0.065646 1.00E-09 0 0.67 1 -19.5686 
 
554 3.12723 0.165703 1 0.165625 1.00E-09 0 0.67 1 -18.008 
 
555 2.39755 0 0.047314 0 0.952686 0 0.67 1 -16.2947 
 
556 3.62688 0.121389 1 0.121328 1.00E-09 0 0.67 1 -16.9672 
 
557 2.71459 0 0.685504 0.393764 0.314496 0 0.67 1 -20.0357 
 
558 0 0 0 0 1 0 1 1 0 
 
559 1.20984 0.06412 1 0.063998 1.00E-09 0 0.67 1 -13.9179 
 
560 0.745073 0.151219 1 0.151307 1.00E-09 0 0.67 1 -16.0431 
 
561 1.21335 0 0.903623 4.51579 0.096377 0.623082 0.399475 1 -14.458 
 
562 0 0 1.00E-09 0.099326 1 0.365519 0.471404 1 -11.9423 
 
563 3.53405 0.110871 1 0.110989 1.00E-09 0 0.67 1 -15.4742 
 
564 1.22438 1.22438 0.172366 0.071933 0.827634 0 0.67 1 -19.2601 
 
565 0.405262 0.349874 0.98786 0.349893 0.01214 0 0.67 1 -19.0747 
 
566 1.15674 0 0.048516 0 0.951484 0 0.67 1 -9.96386 
 
567 1.06859 0.247481 1 0.247325 1.49E-09 0 0.67 1 -17.8246 
 
568 0.750062 0 0.047268 0 0.952732 0 0.67 1 -10.6651 
 
569 1.46312 0.531578 0.254229 0 0.745771 0 0.67 1 -21.9633 
 
570 0.349052 0.228847 0.456122 0 0.543878 0 0.67 1 -13.8628 
 
571 0 0 0 0 1 0 1 1 0 
 
572 1.11288 0 0.047296 0 0.952704 0 0.67 1 -8.4727 
 
573 2.01113 0 0.047288 0 0.952712 0 0.67 1 -12.516 
 
574 1.14328 0.058769 1 0.058746 1.00E-09 0 0.67 1 -11.5503 
 
575 0.589378 0 0.037323 0 0.962677 0 0.67 1 -7.38021 
 
576 0.421192 0 0.05006 0 0.94994 0 0.67 1 -9.14573 
 
577 1.23463 0 0.985436 352.57 0.014564 5.05919 0.036752 1 -18.1908 Pos 
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578 0.151849 0.148048 4.44E-05 0.148046 0.999956 0 0.67 1 -15.7319 
 
579 0.467351 0.11499 1 0.115051 1.00E-09 0 0.67 1 -13.5686 
 
580 9.40629 0 0.047343 0 0.952657 0 0.67 1 -15.351 
 
581 0.401298 0 0.048497 0 0.951503 0 0.67 1 -9.44615 
 
582 1.8949 0.058514 0.648945 0.058514 0.351055 0 0.67 1 -19.4767 
 
583 0.725696 0 0.04842 0 0.95158 0 0.67 1 -7.42568 
 
584 3.7996 0.038664 0.884473 191.171 0.115527 19.6044 2.33E-05 0.01712 -55.4822 Pos 
585 4.19058 0.127515 1 0.127611 1.00E-09 0 0.67 1 -26.424 
 
586 0.643304 0 0.047296 0 0.952704 0 0.67 1 -10.4698 
 
587 0.831173 0.4458 0.549974 0 0.450026 0 0.67 1 -24.2414 
 
588 0.637904 0.038429 1 0.038386 1.00E-09 0 0.67 1 -8.24603 
 
589 0.770664 0.109755 0.623644 0.117353 0.376356 0 0.67 1 -12.4154 
 
590 6.22724 0 0.047445 0 0.952555 0 0.67 1 -10.4688 
 
591 0.857565 0 0.048377 0 0.951624 0 0.67 1 -6.90879 
 
592 0.198485 0.049022 0.963782 154.61 0.036218 7.93286 0.008443 1 -23.0069 Pos 
593 1.24714 0.188482 1 0.188508 1.00E-09 0 0.67 1 -18.1379 
 
594 1.22438 0 0.05251 0 0.94749 0 0.67 1 -12.9405 
 
595 1.29545 0.110524 1 0.110439 1.00E-09 0 0.67 1 -20.3512 
 
596 1.17734 0 0.050031 0 0.949969 0 0.67 1 -7.97386 
 
597 0.315135 0.050033 1 0.04998 1.00E-09 0 0.67 1 -16.1828 
 
598 0.902632 0 0.065 0 0.935 0 0.67 1 -12.8413 
 
599 3.23166 0 0.047851 0 0.952149 0 0.67 1 -16.4007 
 
600 0.567905 0.067914 1 0.067947 1.00E-09 0 0.67 1 -11.7094 
 
601 0.376875 0 0.047244 0 0.952756 0 0.67 1 -11.6215 
 
602 1.07421 0 0.97293 75.5947 0.02707 3.56274 0.079874 1 -17.4819 Pos 
603 3.32013 0 0.052963 0 0.947037 0 0.67 1 -10.4504 
 
604 3.91119 0.054243 1 0.054225 1.00E-09 0 0.67 1 -13.8578 
 
605 0.658011 0 0.047296 0 0.952704 0 0.67 1 -10.0315 
 
606 0.732679 0.055885 1 0.055894 1.00E-09 0 0.67 1 -14.6568 
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607 0.876418 0.060769 1 0.060749 1.00E-09 0 0.67 1 -10.4521 
 
608 0.607213 0.063951 1 0.064005 1.00E-09 0 0.67 1 -17.1874 
 
609 1.81295 0 0.047284 0 0.952716 0 0.67 1 -15.6874 
 
610 1.41415 0.05953 1 0.059532 1.00E-09 0 0.67 1 -11.0795 
 
611 2.14039 0 0.974705 108.937 0.025295 3.38744 0.08755 1 -25.0122 Pos 
612 2.39389 0.04925 1 0.049236 1.00E-09 0 0.67 1 -17.0767 
 
613 1.08067 0 0.988338 950.202 0.011663 11.0915 0.0017 0.417102 -25.4946 Pos 
614 4.36958 0 0.047296 0 0.952704 0 0.67 1 -14.0536 
 
615 0.512817 0.054817 1 0.054826 1.00E-09 0 0.67 1 -16.3232 
 
616 0.751681 0 0.04842 0 0.95158 0 0.67 1 -9.848 
 
617 1.97834 0 0.047296 0 0.952704 0 0.67 1 -14.9933 
 
618 1.24704 0 0.04842 0 0.95158 0 0.67 1 -7.50148 
 
619 0.659259 0.407338 0.34531 0 0.65469 0 0.67 1 -22.5096 
 
620 6.41037 0 0.047984 0 0.952016 0 0.67 1 -23.5099 
 
621 0.900065 0 0.065 0 0.935 0 0.67 1 -9.6358 
 
622 1.39435 1.39435 0.130203 0 0.869797 0 0.67 1 -13.9999 
 
623 2.46317 0 0.654015 0.282873 0.345985 0 0.67 1 -18.5906 
 
624 1.34794 0.136421 1 0.136376 1.00E-09 0 0.67 1 -17.8147 
 
625 1.44452 0.066667 1 0.06665 1.00E-09 0 0.67 1 -15.8606 
 
626 1.17658 0 0.04842 0 0.95158 0 0.67 1 -7.02693 
 
627 1.53357 0 0.047296 0 0.952704 0 0.67 1 -12.1467 
 
628 1.40401 0.112142 0.871119 0.124998 0.128882 0 0.67 1 -13.0088 
 
629 2.08163 0 0.04842 0 0.95158 0 0.67 1 -11.5626 
 
630 1.04816 0 0.037398 0 0.962602 0 0.67 1 -9.06551 
 
631 3.24406 0 0.047326 0 0.952674 0 0.67 1 -9.89579 
 
632 1.17869 0 0.04842 0 0.95158 0 0.67 1 -7.84986 
 
633 1.96499 0 0.073912 0 0.926088 0 0.67 1 -16.2918 
 
634 1.37281 0 0.049947 0 0.950053 0 0.67 1 -19.809 
 
635 0.311481 0.246334 1 0.246374 1.00E-09 0 0.67 1 -15.3104 
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636 0.392081 0 0.05005 0 0.94995 0 0.67 1 -11.1256 
 
637 0.999984 0.258898 0.778263 1.50141 0.221737 2.22E-15 0.67 1 2.22E-15 
 
638 0.999984 0.258898 0.778263 1.50141 0.221737 2.22E-15 0.67 1 2.22E-15 
 
639 0.999984 0.258898 0.778263 1.50141 0.221737 2.22E-15 0.67 1 2.22E-15 
 
640 0.999984 0.258898 0.778263 1.50141 0.221737 2.22E-15 0.67 1 2.22E-15 
 
641 0.999984 0.258898 0.778263 1.50141 0.221737 2.22E-15 0.67 1 2.22E-15 
 
642 0.999984 0.258898 0.778263 1.50141 0.221737 2.22E-15 0.67 1 2.22E-15 
 
643 0.999984 0.258898 0.778263 1.50141 0.221737 2.22E-15 0.67 1 2.22E-15 
 
644 0.999984 0.258898 0.778263 1.50141 0.221737 2.22E-15 0.67 1 2.22E-15 
 
645 0.999984 0.258898 0.778263 1.50141 0.221737 2.22E-15 0.67 1 2.22E-15 
 
646 0.999984 0.258898 0.778263 1.50141 0.221737 2.22E-15 0.67 1 2.22E-15 
 
647 0 0 0.958428 128.358 0.041572 13.1335 0.000606 0.222893 -19.7217 Pos 
648 2.22422 0 0.050061 0 0.949939 0 0.67 1 -13.2853 
 
649 1.23562 0 0.047296 0 0.952704 0 0.67 1 -10.6677 
 
650 0.888358 0 0.048417 0 0.951583 0 0.67 1 -9.85687 
 
651 0.729186 0 0.047296 0 0.952704 0 0.67 1 -7.6859 
 
652 0.999984 0.258898 0.778263 1.50141 0.221737 2.22E-15 0.67 1 2.22E-15 
 
653 0.999984 0.258898 0.778263 1.50141 0.221737 2.22E-15 0.67 1 2.22E-15 
 
654 0.999984 0.258898 0.778263 1.50141 0.221737 2.22E-15 0.67 1 2.22E-15 
 
655 5.57427 0.142741 0.999995 0.142741 5.26E-06 0 0.67 1 -20.7978 
 
656 0.547399 0.055056 1 0.055003 1.00E-09 0 0.67 1 -11.7406 
 
657 1.58431 0 0.047353 0 0.952648 0 0.67 1 -17.1567 
 
658 0.149581 0 0.047382 0 0.952618 0 0.67 1 -8.67848 
 
659 0.412224 0 0.048556 0 0.951444 0 0.67 1 -9.25353 
 
660 0.376545 0 0.886918 2.48893 0.113083 0.877089 0.342897 1 -13.8153 
 
661 0.709535 0 0.048372 0 0.951628 0 0.67 1 -7.75311 
 
662 0.709498 0 0.065 0 0.935 0 0.67 1 -7.68551 
 
663 6.12898 0 0.047532 0 0.952468 0 0.67 1 -19.1299 
 
664 0.499555 0.050988 1 0.050979 1.00E-09 0 0.67 1 -10.8566 
 
Chapter 8 Filovirus Data Ebola Selection analysis 
665 0.168113 0.131101 1 0.131113 2.44E-07 0 0.67 1 -13.6322 
 
666 4.24375 0.214947 0.440193 0 0.559807 0 0.67 1 -16.1036 
 
667 0.198295 0 0.025557 0 0.974443 0 0.67 1 -5.41076 
 
668 0 0 1.00E-09 0.061552 1 0.304693 0.491586 1 -8.78234 
 
669 1.92435 0.142252 1 0.142207 1.00E-09 0 0.67 1 -25.6909 
 
670 1.81908 0.050532 1 0.050573 1.00E-09 0 0.67 1 -12.5533 
 
671 0.681442 0 0.047321 0 0.952679 0 0.67 1 -6.69214 
 
672 1.32104 0 0.049937 0 0.950063 0 0.67 1 -9.07503 
 
673 2.13048 0.066967 1 0.066943 1.00E-09 0 0.67 1 -18.8085 
 
674 3.14413 0.048449 1 0.048454 1.00E-09 0 0.67 1 -11.981 
 
675 3.63083 0.12434 1 0.124217 1.00E-09 0 0.67 1 -14.8115 
 
676 1.06838 0 0.049943 0 0.950057 0 0.67 1 -9.20397 
 
677 0.695141 0 0.874862 1.70183 0.125138 0.178732 0.539746 1 -11.923 
 
678 3.54347 0 0.050081 0 0.949919 0 0.67 1 -13.5784 
 
679 0.63463 0 0.050978 0 0.949022 0 0.67 1 -8.36015 
 
680 2.53987 0.151033 1 0.150943 1.00E-09 0 0.67 1 -18.8304 
 
681 0.497077 0.19559 0.475981 0 0.524019 0 0.67 1 -14.4192 
 
682 2.82482 0 0.048517 0 0.951483 0 0.67 1 -8.58854 
 
683 1.37462 0 0.049962 0 0.950038 0 0.67 1 -6.94445 
 
684 0.297531 0.107117 1 0.106735 1.00E-09 0 0.67 1 -10.3297 
 
685 0.817039 0 0.963199 44.6207 0.036801 2.94144 0.110696 1 -12.5701 
 
686 4.71722 0.133898 1 0.133905 1.00E-09 0 0.67 1 -20.4753 
 
687 0.678251 0.15628 0.999995 0.15628 5.26E-06 0 0.67 1 -16.8722 
 
688 2.78381 0.426188 0.3172 0 0.6828 0 0.67 1 -24.2815 
 
689 0.817522 0.422081 0.299379 0 0.700621 0 0.67 1 -15.4813 
 
690 1.1746 0.187296 1 0.187275 1.00E-09 0 0.67 1 -23.595 
 
691 0.96077 0.354756 0.599333 0.354791 0.400668 0 0.67 1 -24.2121 
 
692 0.687721 0 0.66318 1.16237 0.33682 0.121288 0.566201 1 -19.2669 
 
693 0.844619 0 0.046586 0 0.953414 0 0.67 1 -4.95231 
 
Chapter 8 Filovirus Data Ebola Selection analysis 
694 0 0 0.046825 0 0.953175 0 0.67 1 -4.1411 
 
695 2.15133 0.228903 1 0.22865 1.00E-09 0 0.67 1 -18.0399 
 
696 0 0 1.00E-09 0.122475 1 1.31921 0.266131 1 -10.579 
 
697 0.468452 0.056494 0.878422 2.62188 0.121578 1.13536 0.2953 1 -17.106 
 
698 0 0 1.00E-09 0.047917 1 0.268597 0.504379 1 -7.64519 
 
699 950.217 0 0.748708 0.415011 0.251292 0 0.67 1 -11.9305 
 
700 0 0 0 0 1 0 1 1 0 
 
701 0.452861 0 0.079686 0 0.920314 0 0.67 1 -13.6998 
 
702 1.06282 0.517227 0.249764 0 0.750236 0 0.67 1 -16.0625 
 
703 0 0 0.046825 0 0.953175 0 0.67 1 -3.70304 
 
704 0 0 0 0 1 0 1 1 0 
 
705 0.618179 0.054255 1 0.054309 1.00E-09 0 0.67 1 -11.6345 
 
706 3.35525 0.456895 0.282158 0 0.717842 0 0.67 1 -19.2951 
 
707 1.78446 0.071203 1 0.071107 1.00E-09 0 0.67 1 -11.2786 
 
708 1.02676 0.114967 1 0.114965 1.00E-09 0 0.67 1 -15.2577 
 
709 1.13128 0.468045 0.278424 0 0.721576 0 0.67 1 -15.9372 
 
710 1.17172 0.261074 0.41871 0 0.581291 0 0.67 1 -15.681 
 
711 1.93503 0 0.047886 0 0.952114 0 0.67 1 -16.4238 
 
712 2.48268 0 0.047297 0 0.952703 0 0.67 1 -12.4066 
 
713 1.76484 0.540465 0.245837 0 0.754163 0 0.67 1 -18.4083 
 
714 0.932239 0.228295 1 0.228007 1.00E-09 0 0.67 1 -28.7883 
 
715 0.853376 0.329643 0.999998 0.329645 1.63E-06 0 0.67 1 -26.0536 
 
716 5.79588 0.489966 0.259001 0 0.740999 0 0.67 1 -25.4303 
 
717 0.321413 0.321405 1.00E-09 0.40685 1 0.050546 0.607171 1 -30.7163 
 
718 0.299083 0 0.047439 0 0.952561 0 0.67 1 -7.44039 
 
719 0.148314 0.108136 1 0.107985 1.00E-09 0 0.67 1 -11.9022 
 
720 0.467993 0.054586 1 0.054608 1.00E-09 0 0.67 1 -12.144 
 
721 0.824752 0.160467 1 0.160624 1.00E-09 0 0.67 1 -17.1278 
 
722 2.68877 0 0.050103 0 0.949897 0 0.67 1 -14.603 
 
Chapter 8 Filovirus Data Ebola Selection analysis 
723 0.82271 0 0.047296 0 0.952704 0 0.67 1 -9.955 
 
724 1.25976 0 0.047296 0 0.952704 0 0.67 1 -12.6271 
 
725 0.898399 0.175758 1 0.175802 1.00E-09 0 0.67 1 -18.0735 
 
726 0.307347 0 0.04842 0 0.95158 0 0.67 1 -7.49801 
 
727 1.49661 0.139325 0.45339 0 0.54661 0 0.67 1 -13.36 
 
728 0.681442 0 0.047296 0 0.952704 0 0.67 1 -7.69487 
 
729 0 0 0.046825 0 0.953175 0 0.67 1 -4.54576 
 
730 0 0 0.046825 0 0.953175 0 0.67 1 -3.81503 
 
731 0 0 0.046825 0 0.953175 0 0.67 1 -4.50483 
 
732 5.17872 0 0.04842 0 0.95158 0 0.67 1 -5.2736 
 
733 0 0 0 0 1 0 1 1 0 
 
734 0 0 1.00E-09 0.176753 1 1.35877 0.260294 1 -15.3297 
 
735 0.802037 0.143995 1 0.143966 1.00E-09 0 0.67 1 -19.7264 
 
736 4.95396 0.422981 1 0.423028 1.00E-09 0 0.67 1 -32.5857 
 
 
